

Compilation of abstract titles from ASCO Annual Meeting 2021 (oral, poster discussion, posters, mains track by cancer types only)

Table of Content

I. ORAL PRESENTATIONS.....	4
Plenary Session	4
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology.....	7
Lung Cancer—Non-Small Cell Metastatic.....	10
Sarcoma.....	13
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant.....	15
Pediatric Oncology I	18
Melanoma/Skin Cancers	21
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers.....	25
Breast Cancer—Local/Regional/Adjuvant	28
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary	32
Breast Cancer—Metastatic.....	35
Central Nervous System Tumors	39
Genitourinary Cancer—Kidney and Bladder	42
Gynecologic Cancer.....	45
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.....	49
Gastrointestinal Cancer—Colorectal and Anal	52
Head and Neck Cancer	56
Developmental Therapeutics—Immunotherapy.....	59

Genitourinary Cancer—Prostate, Testicular, and Penile	62
Hematologic Malignancies—Plasma Cell Dyscrasia.....	65
 II. POSTER DISCUSSION PRESENTATIONS	69
Central Nervous System Tumors	69
Developmental Therapeutics—Immunotherapy.....	72
Gastrointestinal Cancer—Colorectal and Anal	76
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary	79
Genitourinary Cancer—Kidney and Bladder	83
Genitourinary Cancer—Prostate, Testicular, and Penile	86
Gynecologic Cancer.....	90
Head and Neck Cancer	94
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant.....	97
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.....	100
Hematologic Malignancies—Plasma Cell Dyscrasia.....	103
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers.....	107
Lung Cancer—Non-Small Cell Metastatic.....	110
Melanoma/Skin Cancers	114
Pediatric Oncology	117
Sarcoma.....	120
Pediatric Oncology II	124
 III. POSTER PRESENTATIONS.....	127
Breast Cancer—Local/Regional/Adjuvant	127
Breast Cancer—Metastatic.....	145
Central Nervous System Tumors	166
Developmental Therapeutics—Immunotherapy.....	176
Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology.....	212
Gastrointestinal Cancer—Colorectal and Anal	242
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary	265
Genitourinary Cancer—Kidney and Bladder	301
Genitourinary Cancer—Prostate, Testicular, and Penile	320

Gynecologic Cancer.....	338
Head and Neck Cancer.....	357
Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allotransplant.....	375
Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia.....	383
Hematologic Malignancies—Plasma Cell Dyscrasia.....	396
Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers.....	405
Lung Cancer—Non-Small Cell Metastatic.....	421
Melanoma/Skin Cancers	446
Pediatric Oncology	463
Sarcoma.....	469

I. ORAL PRESENTATIONS

Plenary Session

Sunday, June 6, 7:00 PM - 10:00 PM CEST

Back to Program

Showing 17 Presentations

<https://meetinglibrary.asco.org/session/13668>

Chair

CHAIR

Norah Lynn Henry, MD, PhD, FASCO, FACP | University of Michigan

Chair

CHAIR

Lori J. Pierce, MD, FASTRO, FASCO | University of Michigan

OlympiA: A phase III, multicenter, randomized, placebo-controlled trial of adjuvant olaparib after (neo)adjuvant chemotherapy in patients with germline *BRCA1/2* mutations and high-risk HER2-negative early breast cancer.

AUTHOR(S)

Andrew Tutt, Judy E. Garber, Bella Kaufman, Giuseppe Viale, Debora Fumagalli, Priya Rastogi, Richard D. Gelber, Evandro de Azambuja, Anitra Fielding, Judith Balmana Gelpi, Karen A. Gelmon, Nigel Baker, Amal Arahmani, Elzbieta Senkus-Konefka, Eleanor Mc Fadden, Vassiliki Karantza, Sunil R. Lakhani, Greg Yothers, Christine Campbell, Charles E. Geyer Jr.

ABSTRACT

LBA1

Discussion

DISCUSSANT

Nadine M. Tung, MD | Beth Israel Deaconess Medical Center

Panel Question and Answer with Drs. Pierce, Henry, Tutt and Tung

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

JUPITER-02: Randomized, double-blind, phase 3 study of toripalimab or placebo plus gemcitabine and cisplatin as first-line treatment for recurrent or metastatic nasopharyngeal carcinoma (NPC).

AUTHOR(S)

Rui-hua Xu, Hai-Qiang Mai, Qiu-Yan Chen, Dongping Chen, Chaosu Hu, Kunyu Yang, Jiyu Wen, Jin-Gao Li, Yingrui Shi, Feng Jin, Ruilian Xu, Jianji Pan, Shenhong Qu, Ping Li, Chunhong Hu, Yi-Chun Liu, Yi Jiang, Xia He, Hung-Ming Wang, Wan-Teck Lim

ABSTRACT

LBA2

Discussion

DISCUSSANT

Anthony T. C. Chan, MD | The Chinese University of Hong Kong, Prince of Wales Hospital

Panel Question and Answer with Drs. Pierce, Henry, Xu, and Chan

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Adjuvant chemotherapy following chemoradiation as primary treatment for locally advanced cervical cancer compared to chemoradiation alone: The randomized phase III OUTBACK Trial (ANZGOG 0902, RTOG 1174, NRG 0274).

AUTHOR(S)

Linda R. Mileshtkin, Kathleen N. Moore, Elizabeth Barnes, Val Gebiski, Kailash Narayan, Nathan Bradshaw, Yeh Chen Lee, Katrina Diamante, Anthony W. Fyles, William Small Jr., David K. Gaffney, Pearly Khaw, Susan Brooks, Warner K. Huh, Matthew Carlson, Cara A. Mathews, Danny Rischin, Martin R. Stockler, Bradley J. Monk

ABSTRACT

LBA3

Discussion

DISCUSSANT

Kunle Odunsi, MD, PhD | The University of Chicago

Panel Question and Answer with Drs. Pierce, Henry, Mileshtkin, and Odunsi

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Phase III study of lutetium-177-PSMA-617 in patients with metastatic castration-resistant prostate cancer (VISION).

AUTHOR(S)

Michael J. Morris, Johann S. De Bono, Kim N. Chi, Karim Fizazi, Ken Herrmann, Kambiz Rahbar, Scott T. Tagawa, Luke T. Nordquist, Nitin Vaishampayan, Ghassan El-Haddad, Chandler H. Park, Tomasz M. Beer, Wendy J. Pérez-Contreras, Michelle Desilvio, Euloge E. Kpamegan, Gerold Gericke, Richard A. Messmann, Bernd J. Krause, A. O. Sartor

ABSTRACT

LBA4

Discussion

DISCUSSANT

Mary-Ellen Taplin, MD, FASCO | Lank Center for Genitourinary Oncology, Dana-Farber Cancer Institute

Panel Question and Answer with Drs. Pierce, Henry, Morris, and Taplin

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Pembrolizumab versus placebo as post-nephrectomy adjuvant therapy for patients with renal cell carcinoma: Randomized, double-blind, phase III KEYNOTE-564 study.

AUTHOR(S)

Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Yen-Hwa Chang, Jaroslav Hajek, Stefan N. Symeonides, Jae-Lyun Lee, Naveed Sarwar, Antoine Thiery-Vuillemin, Marine Gross-Goupil, Mauricio Mahave, Naomi B. Haas, Piotr Sawrycki, Eric (Pingye) Zhang, Jaqueline Willemann Rogerio, Kentaro Imai, David I. Quinn, Thomas Powles

ABSTRACT

LBA5

Discussion

DISCUSSANT

Rana R. McKay, MD | University of California San Diego, Moores Cancer Center

Panel Question and Answer with Drs. Pierce, Henry, Choueiri, and McKay

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

Friday, June 4, 5:00 PM - 8:00 PM CEST

Back to Program

Showing 17 Presentations

<https://meetinglibrary.asco.org/session/13619>

Chair

CHAIR

Lisa A. Kachnic, FASTRO, MD | Boston Medical Center

Chair

CHAIR

Gregory Michael Cote, MD, PhD | Massachusetts General Hospital

A first-in-human phase 1 study of a novel PARP7 inhibitor RBN-2397 in patients with advanced solid tumors.

AUTHOR(S)

Gerald S. Falchook, Manish R. Patel, Timothy A. Yap, Kristen McEachern, Kristy Kuplast-Barr, Luke Utley, Lisa Cleary, Erika Manyak, Viviana Bozon, Sudha Parasuraman, Melissa L. Johnson

ABSTRACT

3000

First-in-human biomarker-driven phase I trial of the potent and selective glutaminase-1 (GLS1) inhibitor IACS-6274 (IPN60090) in patients (pts) with molecularly selected advanced solid tumors.

AUTHOR(S)

Timothy A. Yap, Ecaterina E. Dumbrava, Jordi Rodon Ahnert, David S. Hong, Shubham Pant, Daniel D. Karp, Sarina Anne A. Piha-Paul, Vivek Subbiah, Apostolia M. Tsimberidou, Siqing Fu, Filip Janku, Sandra Montez, Majd T. Ahmad-Taha, Darlene Guerrero, Natalya N. Nazarenko, Yan Moore, Michael Soth, Jeff Kovacs, Timothy P. Heffernan, Philip Jones

ABSTRACT

3001

Phase 2 study of DRD2 antagonist/ClpP agonist ONC201 in neuroendocrine tumors.

AUTHOR(S)

Peter M. Anderson, Janette Gortz

ABSTRACT

3002

New Directions in Targeting Metabolism and Stress Response

DISCUSSANT

Dwight Hall Owen, MD | Division of Medical Oncology, Department of Internal Medicine, Ohio State University

Panel Question and Answer with Drs. Kachnic, Cote, Falchook, Yap, Anderson and Owen

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Efficacy and safety of zenocutuzumab in advanced pancreas cancer and other solid tumors harboring NRG1 fusions.

AUTHOR(S)

Alison M. Schram, Eileen M. O'Reilly, Grainne M. O'Kane, Koichi Goto, Dong-Wan Kim, Cindy Neuzillet, Patricia Martin-Romano, Michaël Duruisseaux, Misako Nagasaka, Jordi Rodon, Benjamin A. Weinberg, Kumiko Umemoto, Sai-Hong I. Ou, Teresa Macarulla, Christelle De La Fouchardiere, Andrew K. Joe, Ernesto Wasserman, Viktoriya Stalbovskaya, Jim Ford

ABSTRACT

3003

MyPathway HER2 basket study: Pertuzumab (P) + trastuzumab (H) treatment of a large, tissue-agnostic cohort of patients with HER2-positive advanced solid tumors.

AUTHOR(S)

Funda Meric-Bernstam, John Hainsworth, Ron Bose, Howard A. Burris III, Claire F. Friedman, Razelle Kurzrock, Charles Swanton, Yong Wang, Jonathan Levy, Katja Schulze, Richard Price, Arisha Patel, Christopher Sweeney

ABSTRACT

3004

Initial results from a dose finding study of TNO155, a SHP2 inhibitor, in adults with advanced solid tumors.

AUTHOR(S)

Irene Brana, Geoffrey Shapiro, Melissa L. Johnson, Helena A. Yu, Debbie Robbrecht, Daniel S. Tan, Lillian L. Siu, Hironobu Minami, Neeltje Steeghs, Thomas Hengelage, Eugene Tan, Kelly Biette, Kun Xu, Susan E. Moody, Maria Jove

ABSTRACT

3005

HER2: A SHP(2) That Hasn't Sailed

DISCUSSANT

Ignacio Garrido-Laguna, MD, PhD | Huntsman Cancer Institute, University of Utah

Panel Question and Answer with Drs. Kachnic, Cote, Schram, Meric-Bernstam, Brana, and Garrido-Laguna

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

First-in-human phase I/II study of CYT-0851, a first-in-class inhibitor of RAD51-mediated homologous recombination in patients with advanced solid and hematologic cancers.

AUTHOR(S)

Ryan Lynch, Johanna C. Bendell, Ranjana H. Advani, Gerald S. Falchook, Pamela N. Munster, Manish R. Patel, Martin Gutierrez, Monika L. Burness, Neil Palmisiano, Mehdi Hamadani, William D. Bradley, Thomas J. O'Shea, Susan Doleman, Markus F. Renschler, Judson M. Englert, Timothy A. Yap

ABSTRACT

3006

A phase Ib trial of belvarafenib in combination with cobimetinib in patients with advanced solid tumors: Interim results of dose-escalation and patients with NRAS-mutant melanoma of dose-expansion.

AUTHOR(S)

Sang Joon Shin, Jeeyun Lee, Tae Min Kim, Jin-Soo Kim, Yu Jung Kim, Yong Sang Hong, Sun Young Kim, Jeong Eun Kim, Dae Ho Lee, Yoon-hee Hong, Young Su Noh, Song Kim, Eunhye Baek, Sujin Jung, Paul Rhee, Jinjoo Kim, Jennifer Eng-Wong, Vikram Malhi, Sharareh Monemi, Tae Won Kim

ABSTRACT

3007

BOS172738, a highly potent and selective RET inhibitor, for the treatment of *RET*-altered tumors including *RET*-fusion+ NSCLC and *RET*-mutant MTC: Phase 1 study results.

AUTHOR(S)

Patrick Schoffski, Byoung Chul Cho, Antoine Italiano, Herbert H. Loong, Christophe Massard, Laura Medina Rodriguez, Jin-Yuan Shih, Vivek Subbiah, Loic Verlingue, Karen Andreas, Craig T. Basson, Alicia Clawson, Peter T. Ho, Shelley Knight, Anita Scheuber, Mitchell Keegan

ABSTRACT

3008

New Twists on Old Targets

DISCUSSANT

Ulka N. Vaishampayan, MD | University of Michigan Cancer Center

Panel Question and Answer with Drs. Kachnic, Cote, Lynch, Shin, Schoffski, and Vaishampayan

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Lung Cancer—Non-Small Cell Metastatic

Friday, June 4, 7:00 PM - 10:00 PM CEST

Back to Program

Showing 17 Presentations

<https://meetinglibrary.asco.org/session/13658>

Chair

CHAIR

Christine L. Hann, MD, PhD | Johns Hopkins University School of Medicine, Sidney Kimmel Comprehensive Cancer Center

Chair

CHAIR

Raymond U. Osarogiagbon, FACP, MBBS | Baptist Cancer Center, Multidisciplinary Thoracic Oncology Department

First-line nivolumab (NIVO) plus ipilimumab (IPI) plus two cycles of chemotherapy (chemo) versus chemo alone (4 cycles) in patients with advanced non-small cell lung cancer (NSCLC): Two-year update from CheckMate 9LA.

AUTHOR(S)

Martin Reck, Tudor-Eliade Ciuleanu, Manuel Cobo, Michael Schenker, Bogdan Zurawski, Juliana Janoski de Menezes, Eduardo Richardet, Jaafar Bennouna, Enriqueta Felip, Oscar Juan-Vidal, Aurella Alexandru, Hiroshi Sakai, Arnaud Scherpereel, Shun Lu, Luis G. Paz-Ares, David P. Carbone, Arteid Memaj, Sathiya Marimuthu, Phuong Tran, Tom John

ABSTRACT

9000

Outcomes of anti-PD-(L1) therapy in combination with chemotherapy versus immunotherapy (IO) alone for first-line (1L) treatment of advanced non-small cell lung cancer (NSCLC) with PD-L1 score 1-49%: FDA pooled analysis.

AUTHOR(S)

Oladimeji Akinboro, Jonathon J. Vallejo, Pallavi S. Mishra-Kalyani, Erin A. Larkins, Nicole L. Drezner, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Harpreet Singh

ABSTRACT

9001

Pooled analyses of immune-related adverse events (irAEs) and efficacy from the phase 3 trials IMpower130, IMpower132, and IMpower150.

AUTHOR(S)

Mark A. Socinski, Robert M. Jotte, Federico Cappuzzo, Makoto Nishio, Tony S. Mok, Martin Reck, Gene G. Finley, Wei Yu, Hina Patel, Nindhana Paranthaman, Ilze Bara, Howard West

ABSTRACT

9002

Optimizing Effective and Safe Deployment of Immune Checkpoint Inhibitors for Patients With NSCLC

DISCUSSANT

Mary Weber Redman, PhD | SWOG Statistical Center, Fred Hutchinson Cancer Research Center

Panel Question and Answer with Drs. Hann, Osarogiagbon, Reck, Akinboro, Socinski, and Redman

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Overall survival and exploratory subgroup analyses from the phase 2 CodeBreakK 100 trial evaluating sotorasib in pretreated *KRAS* p.G12C mutated non-small cell lung cancer.

AUTHOR(S)

Ferdinand Skoulidis, Bob T. Li, Ramaswamy Govindan, Grace K. Dy, Geoffrey Shapiro, Joshua Bauml, Martin H. Schuler, Alfredo Addeo, Terufumi Kato, Benjamin Besse, Abraham Anderson, Agnes Ang, Gatara Ngarmchamnanrith, Qui Tran, Vamsidhar Velcheti

ABSTRACT

9003

Biomarker tissue journey among patients (pts) with untreated metastatic non-small cell lung cancer (mNSCLC) in the U.S. Oncology Network community practices.

AUTHOR(S)

Nicholas J. Robert, Esmond D. Nwokeji, Janet L. Espirito, Liwei Chen, Mandar Karhade, Makenzi C. Evangelist, Alexander I. Spira, Marcus A. Neubauer, Susie A. Bullock, Robert L. Coleman

ABSTRACT

9004

Racial disparities in biomarker testing and clinical trial enrollment in non-small cell lung cancer (NSCLC).

AUTHOR(S)

Debora S. Bruno, Lisa M. Hess, Xiaohong Li, Eric W. Su, Yajun E. Zhu, Monaliben Patel

ABSTRACT

9005

Biomarker Testing for Lung Cancer in 2021: Further Precision but Still Not Meeting the Mark for Equitable Distribution

DISCUSSANT

Christine M. Lovly, MD, PhD | Vanderbilt-Ingram Cancer Center, Vanderbilt University Medical Center

Panel Question and Answer with Drs. Hann, Osarogiagbon, Skoulidis, Robert, Bruno, and Lovly

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Amivantamab in combination with lazertinib for the treatment of osimertinib-relapsed, chemotherapy-naïve EGFR mutant (EGFRm) non-small cell lung cancer (NSCLC) and potential biomarkers for response.

AUTHOR(S)

Joshua Bauml, Byoung Chul Cho, Keunchil Park, Ki Hyeong Lee, EUN KYUNG CHO, Dong-Wan Kim, Sang-We Kim, Eric B. Haura, Joshua K. Sabari, Rachel E. Sanborn, Misako Nagasaka, Sai-Hong I. Ou, Anna R. Minchom, Jorge E. Gomez, Joshua C. Curtin, Grace Gao, Amy Roshak, Meena Thayu, Roland E. Knoblauch, Alexander I. Spira

ABSTRACT

9006

Efficacy and safety of patritumab deruxtecan (HER3-DXd) in EGFR inhibitor-resistant, *EGFR*-mutated (*EGFRm*) non-small cell lung cancer (NSCLC).

AUTHOR(S)

Pasi A. Janne, Christina S. Baik, Wu-Chou Su, Melissa L. Johnson, Hidetoshi Hayashi, Makoto Nishio, Dong-Wan Kim, Marianna Koczywas, Kathryn A. Gold, Conor E. Steuer, Haruyasu Murakami, James Chih-Hsin Yang, Sang-We Kim, Michele Vigliotti, Zhenhao Qi, Yang Qiu, Lihui Zhao, David W. Sternberg, Channing Yu, Helena A. Yu

ABSTRACT

9007

Preliminary safety and efficacy results from phase 1 studies of DZD9008 in NSCLC patients with EGFR Exon20 insertion mutations.

AUTHOR(S)

James Chih-Hsin Yang, Mengzhao Wang, Paul Mitchell, Jian Fang, Weiqi Nian, Chao-Hua Chiu, Jianying Zhou, Yanqiu Zhao, Wu-Chou Su, D. R. Camidge, Tsung-Ying Yang, Viola W. Zhu, Michael Millward, Yun Fan, Wen Tsung Huang, Ying Cheng, Liyan Jiang, Li Zheng, Xiuhui Ye, Pasi A. Janne

ABSTRACT

9008

New Drugs and Novel Combinations to Combat EGFR TKI Resistance

DISCUSSANT

Nicolas Girard, MD, PhD | Institut Curie

Panel Question and Answer with Drs. Hann, Osarogiagbon, Bauml, Janne, Yang, and Girard

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Sarcoma

Friday, June 4, 7:30 PM - 10:30 PM CEST

Back to Program

Showing 17 Presentations

<https://meetinglibrary.asco.org/session/13679>

Chair

CHAIR

Katherine Anne Thornton, MD | Memorial Sloan Kettering Cancer Center

Chair

CHAIR

Anthony Paul Conley, MD | The University of Texas MD Anderson Cancer Center

TK216 for relapsed/refractory Ewing sarcoma: Interim phase 1/2 results.

AUTHOR(S)

Joseph A. Ludwig, Noah C. Federman, Peter M. Anderson, Margaret E. Macy, Richard F. Riedel, Lara E. Davis, Najat C. Daw, Jade Wulff, AeRang Kim, Ravin Ratan, Edwina S. Baskin-Bey, Jeffrey A. Toretsky, James B. Breitmeyer, Paul A. Meyers

ABSTRACT

11500

Efficacy of dose intensification in induction therapy for localized Ewing sarcoma: Italian Sarcoma Group (ISG) and Associazione Italiana Ematologia ed Oncologia Pediatrica (AIEOP) ISG/AIEOP EW-1 study.

AUTHOR(S)

Roberto Luksch, Giuseppe M. Milano, Francesco Barretta, Alessandra Longhi, Emanuela Palmerini, Nadia Puma, Sebastian D. Asaftei, Marta G. Podda, Giovanni Grignani, Gianni Bisogno, Rossella Bertulli, Luca Coccoli, Angela Tamburini, Carla Manzitti, Virginia Ferraresi, Maurizio Mascarin, Marco Rabusin, Stefano Ferrari, Piero Picci, Franca Fagioli

ABSTRACT

11501

Association of treatment delays with an unfavorable outcome in patients with localized Ewing sarcoma: A retrospective analysis of data from the GPOH Euro-E.W.I.N.G.99 trial.

AUTHOR(S)

Uta Dirksen, Andreas Ranft, Daniel Baumhoer, Henk van den Berg, Bénédicte Brichard, Hans-Theodor Eich, Hans Gelderblom, Jendrik Harges, Wolfgang Hartmann, Heribert Juergens, Attila Kollar, Jarmila Kruseova, Thomas Kuehne, Ruth L. Ladenstein, Andreas Leithner, Arne Streitbuerger, Beate Timmermann, Per-Ulf Tunn, Dimosthenis Andreou

ABSTRACT

11502

Something Old, Something New: Improving Outcomes for Ewing Sarcoma

DISCUSSANT

Steven G. DuBois, MD | Dana-Farber/Boston Children's Cancer and Blood Disorders Center and Harvard Medical School

Panel Question and Answer with Drs. Thornton, Conley, Ludwig, Luksch, Dirksen, and DuBois

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

P10015/SARC033: A phase 2 trial of trametinib in patients with advanced epithelioid hemangioendothelioma (EHE).

AUTHOR(S)

Scott Schuetze, Karla V. Ballman, Kristen N. Ganjoo, Elizabeth J. Davis, Jeffrey A. Morgan, Gabriel Tinoco, Melissa A. Burgess, Brian A. Van Tine, Edwin Choy, Dale R. Shepard, Ciara M. Kelly, Richard F. Riedel, Margaret von Mehren, Brittany L. Siontis, Steven Attia, Gary K. Schwartz, Hari A. Deshpande, Erin Kozlowski, Helen X. Chen, Brian Rubin

ABSTRACT

11503

SPEARHEAD-1: A phase 2 trial of afamitresgene autoleucel (Formerly ADP-A2M4) in patients with advanced synovial sarcoma or myxoid/round cell liposarcoma.

AUTHOR(S)

Sandra P. D'Angelo, Brian A. Van Tine, Steven Attia, Jean-Yves Blay, Sandra J. Strauss, Claudia M. Valverde Morales, Albiruni R. Abdul Razak, Erin Van Winkle, Trupti Trivedi, Swethajit Biswas, Dennis Williams, Elliot Norry, Dejka M. Araujo

ABSTRACT

11504

A phase III study (APROMISS) of AL3818 (Catequentinib, Anlotinib) hydrochloride monotherapy in subjects with metastatic or advanced synovial sarcoma.

AUTHOR(S)

Brian A. Van Tine, Sant P. Chawla, Jonathan C. Trent, Breelyn A. Wilky, Rashmi Chugh, Bartosz Chmielowski, Shivaani Kummar, Atrayee Basu Mallick, Neeta Somaiah, Lee D. Cranmer, Mark Agulnik, Vicki L. Keedy, Silvia Stacchiotti, Bruno Vincenzi, Giuseppe Badalamenti, Brittany L. Siontis, Steven Attia

ABSTRACT

11505

Later-Phase Studies in Rare Sarcoma Subtypes Are Possible

DISCUSSANT

Robin Lewis Jones, MD, MBBS, MRCP, BSc | Royal Marsden Hospital and Institute of Cancer Research

Panel Question and Answer with Drs. Thornton, Conley, Schuetze, D'Angelo, Van Tine, and Jones

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

NCI protocol 10250: A phase II study of temozolomide and olaparib for the treatment of advanced uterine leiomyosarcoma.

AUTHOR(S)

Matthew Ingham, Jacob B. Allred, Katherine Gano, Suzanne George, Steven Attia, Melissa A. Burgess, Mahesh Seetharam, Sosipatros A. Boikos, Nam Bui, James L. Chen, Julia L. Close, Gregory M. Cote, Premal H. Thaker, S. P. Ivy, Biswajit Das, Geoffrey Shapiro, Bose Kochupurakkal, Jane B. Trepel, Yves Pommier, Gary K. Schwartz

ABSTRACT

11506

PD1 inhibition in soft-tissue sarcomas with tertiary lymphoid structures: A multicenter phase II trial.

AUTHOR(S)

Antoine Italiano, Alban Bessede, Emmanuelle Bompas, Sophie Piperno-Neumann, Christine Chevreau, Nicolas Penel, Francois Bertucci, Maud Toulmonde, Carine A. Bellera, Jean-Philippe Guegan, Catherine Sautes-Fridman, Antoine Bougoüin, Coralie Cantarel, Francois Le Loarer, Jean-Yves Blay, Wolf-Herman Fridman

ABSTRACT

11507

Phase II trial of pegylated arginine deiminase in combination with gemcitabine and docetaxel for the treatment of soft tissue sarcoma.

AUTHOR(S)

Brian A. Van Tine, Angela C. Hirbe, Jingqin Luo, Peter J. Oppelt, Mia C. Weiss, Vanessa A. Eulo, Jacqui Toeniskoetter, Sasha Haarberg, Sarah Abaricia, Tyler Ruff, John S. Bomalaski, Amanda Johnston, Chih-Ling Kuo, Chiung-Fang Shiu, Matthew Ingham, Nam Bui, Sant P. Chawla, Gary K. Schwartz, Kristen N. Ganjoo

ABSTRACT

11508

From Bench to Clinic: Novel Mechanisms, Novel Targets

DISCUSSANT

Breelyn A. Wilky, MD | University of Colorado

Panel Question and Answer with Drs. Thornton, Conley, Ingham, Italiano, Van Tine, and Wilky

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft Transplantation

Friday, June 4, 8:30 PM - 11:30 PM CEST

Back to Program

Showing 17 Presentations

<https://meetinglibrary.asco.org/session/13643>

Chair

CHAIR

Patrick William Burke, MD | Univ of Michigan

Chair

CHAIR

Milos Miljkovic, MD, MSc | Center for Cancer Research, National Cancer Institute

OPTIC primary analysis: A dose-optimization study of 3 starting doses of ponatinib (PON).

AUTHOR(S)

Jorge E. Cortes, Jane Apperley, Elza Lomaia, Beatriz Moiraghi, Maria Undurraga Sutton, Carolina Pavlovsky, Charles Chuah, Tomasz Sacha, Jeffrey H. Lipton, Charles Schiffer, James K. McCloskey, Andreas Hochhaus, Philippe H. Rousselot, Gianantonio Rosti, Hugues De Lavallade, Michael J. Mauro, Tracey Hall, Vickie Lu, Shouryadeep Srivastava, Michael W. Deininger

ABSTRACT

7000

Combination of ponatinib and blinatumomab in Philadelphia chromosome-positive acute lymphoblastic leukemia: Early results from a phase II study.

AUTHOR(S)

Nicholas J. Short, Hagop M. Kantarjian, Marina Konopleva, Nitin Jain, Xuelin Huang, Farhad Ravandi, William G. Wierda, Gautam Borthakur, Koji Sasaki, Ghayas C. Issa, Yesid Alvarado, Naveen Pemmaraju, Guillermo Garcia-Manero, Jennifer Thankachan, Rebecca Garriss, Elias Jabbour

ABSTRACT

7001

Phase 2 results of the ZUMA-3 study evaluating KTE-X19, an anti-CD19 chimeric antigen receptor (CAR) T-cell therapy, in adult patients (pts) with relapsed/refractory B-cell acute lymphoblastic leukemia (R/R B-ALL).

AUTHOR(S)

Bijal D. Shah, Armin Ghobadi, Olalekan O. Oluwole, Aaron Logan, Nicolas Boissel, Ryan D. Cassaday, Edouard Forcade, Michael R. Bishop, Max S. Topp, Dimitrios Tzachanis, Kristen M. O'Dwyer, Martha L. Arellano, Yi Lin, Maria R. Baer, Gary J. Schiller, Jinghui Dong, Tong Shen, Francesca Milletti, Behzad Kharabi Masouleh, Roch Houot

ABSTRACT

7002

Targeting BCR/ABL and Beyond

DISCUSSANT

Matthew Joseph Wieduwilt, MD, PhD | University of California, San Diego

Panel Question and Answer with Drs. Burke, Miljkovic, Cortes, Short, Shah and Wieduwilt

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

The results of multicenter phase II, double-blind placebo-controlled trial of maintenance ixazomib after allogeneic hematopoietic cell transplantation (alloHCT) for high-risk multiple myeloma (MM) from the Blood and Marrow Transplant Clinical Trials Network (BMT CTN 1302).

AUTHOR(S)

Taiga Nishihori, Qaiser Bashir, Marcelo C. Pasquini, Michael Martens, Juan Wu, Melissa Alsina, Yvonne A. Efebera, Cristina Gasparetto, Nancy Geller, Sergio Giral, John Koreth, Philip L. McCarthy, Emma C. Scott, Edward A. Stadtmauer, David H. Vesole, Parameswaran Hari

ABSTRACT

7003

Letermovir prophylaxis and cytomegalovirus reactivation in adult allogeneic hematopoietic cell transplant recipients with graft versus host disease.

AUTHOR(S)

Delaney Wolfe, Qihong Zhao, Emma G. Siegel, Marcin M. Puto, Yvonne A. Efebera, Justin C. Tossey

ABSTRACT

7004

Prospective longitudinal evaluation of microbiome diversity in patients with hematological malignancy undergoing allogeneic hematopoietic stem cell transplantation (HSCT).

AUTHOR(S)

Emily Walsh, Anastasia Tsakmaklis, Liyang Diao, Jessica Bryant, Mary-Jane Lombardo, Barbara McGovern, Lisa von Moltke, Matthew R. Henn, Christopher B. Ford, Maria J. Vehreschild

ABSTRACT

7005

Allografting: Tackling Disease, Bugs, and Microbiome

DISCUSSANT

Miguel-Angel Perales, MD | Memorial Sloan Kettering Cancer Center

Panel Question and Answer with Drs. Burke, Miljkovic, Nishihori, Wolfe, Walsh, and Perales

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Effect of olutasidenib (FT-2102) on complete remissions in patients with relapsed/refractory (R/R) *mIDH1* acute myeloid leukemia (AML): Results from a planned interim analysis of a phase 2 clinical trial.

AUTHOR(S)

Stéphane De Botton, Karen W. Yee, Christian Recher, Andrew Wei, Pau Montesinos, David Taussig, Arnaud Pigneux, Thorsten Braun, Antonio Curti, Jordi Esteve, Carolyn Grove, Brian A. Jonas, Asim Khwaja, Ollivier Legrand, Pierre Peterlin, Olga Polyanskaya, Jennifer Sweeney, Hesham Mohamed, Jorge E. Cortes, Pierre Fenau

ABSTRACT

7006

Efficacy and safety of aspacytarabine (BST-236) as a single-agent, first-line therapy for patients with acute myeloid leukemia unfit for standard chemotherapy.

AUTHOR(S)

Jessica K. Altman, Jamie Koprivnikar, James K. McCloskey, Vamsi Kota, Olga Frankfurt, Ashkan Emadi, Dale Bixby, Micah Burch, Moshe Y. Levy, Selina Luger, Tsila Zuckerman, Bhavana Bhatnagar, Ofir Wolach, Chezi Ganzel, Itai Levi, Anna Gourevitch, Ruth Ben Yakar, Shoshi Tessler, Liat Flaishon, Jacob Rowe

ABSTRACT

7007

Phase 1 first-in-human study of irreversible FLT3 inhibitor FF-10101-01 in relapsed or refractory acute myeloid leukemia.

AUTHOR(S)

Mark J. Levis, Catherine C. Smith, Alexander E. Perl, Gary J. Schiller, Amir T. Fathi, Gail J. Roboz, Eunice S. Wang, Jessica K. Altman, Makoto Ando, Takeaki Suzuki, Ruth A. Subach, Gary Maier, Timothy Madden, Mary Johansen, Kin Cheung, Michael R. Kurman

ABSTRACT

7008

New Versions of Approved Antileukemia Agents: Do They Advance Patient Care?

DISCUSSANT

Guru Subramanian Guru Murthy, MD | Medical College of Wisconsin

Panel Question and Answer with Drs. Burke, Miljkovic, De Botton, Altman, Levis, and Murthy

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Pediatric Oncology I

Saturday, June 5, 4:00 PM - 7:00 PM CEST

Back to Program

Showing 17 Presentations

<https://meetinglibrary.asco.org/session/13666>

Chair

CHAIR

Shannon L. Maude, MD, PhD | Cancer Immunotherapy Program, Children's Hospital of Philadelphia

Chair

CHAIR

Martha Boeri Donoghue, MD | U.S. Food and Drug Administration

The efficacy and safety of anti-CLL1 based CAR-T cells in children with relapsed or refractory acute myeloid leukemia: A multicenter interim analysis.

AUTHOR(S)

Hui Zhang, Chaoke Bu, Zhiyong Peng, min luo, Chunfu Li

ABSTRACT

10000

Donor-derived CD7 CAR T cells for T-cell acute lymphoblastic leukemia.

AUTHOR(S)

Jing Pan, Biping Deng, Zhuojun Ling, Weiliang Song, Jinlong Xu, Jiajia Duan, Zelin Wang, Alex Chang, Xiaoming Feng

ABSTRACT

10001

Driving Progress in Leukemia With New CARs

DISCUSSANT

Rayne H. Rouce, MD | Texas Children's Hospital

Panel Question and Answer with Drs. Donoghue, Maude, Zhang, Pan, and Rouce

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Targeted gene expression classifier identifies pediatric T-cell acute lymphoblastic leukemia (T-ALL) patients at high risk for end induction minimal residual disease positivity.

AUTHOR(S)

Lauren K. Meyer, Ritu Roy, Benjamin J. Huang, Cristina Delgado-Martin, Tiffaney L. Vincent, Brent L. Wood, Yu Liu, Jinghui Zhang, Charles G. Mullighan, Terzah M. Horton, Mignon L. Loh, Meenakshi Devidas, Elizabeth A. Raetz, Robert J. Hayashi, Stuart S. Winter, Kimberly P. Dunsmore, Stephen Hunger, David T. Teachey, Adam B. Olshen, Michelle L. Hermiston

ABSTRACT

10002

Prognostic Impact of CNS-2 status in T-ALL: A report from the Children's Oncology Group.

AUTHOR(S)

Nathan Gossai, Stuart S. Winter, Meenakshi Devidas, Zhiguo Chen, Brent L. Wood, Patrick A. Zweidler-McKay, Karen R. Rabin, Naomi J. Winick, Michael Burke, William L. Carroll, Natia Esiashvili, Nyla A. Heerema, Andrew J. Carroll, Mignon L. Loh, Elizabeth A. Raetz, Stephen Hunger, Kimberly P. Dunsmore, David T. Teachey

ABSTRACT

10003

Minimal residual disease at end of induction and consolidation remain important prognostic indicators for newly diagnosed children and young adults with very high-risk (VHR) B-lymphoblastic leukemia (B-ALL): Children's Oncology Group AALL1131.

AUTHOR(S)

Wanda L. Salzer, Michael J. Burke, Meenakshi Devidas, Yunfeng Dai, Nyla A. Heerema, Andrew J. Carroll, Lia Gore, Joanne M. Hilden, Eric Larsen, Elizabeth A. Raetz, Naomi J. Winick, William L. Carroll, Stephen Hunger, Mignon L. Loh, Brent L. Wood, Michael J. Borowitz

ABSTRACT

10004

Refining Risk-Adapted Therapy in Pediatric Leukemia

DISCUSSANT

Rob Pieters, MD | Princess Maxima Center for Pediatric Oncology

Panel Question and Answer with Drs. Donoghue, Maude, Meyer, Gossai, Salzer, and Pieters

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Clinical impact of molecular tumor profiling in pediatric, adolescent, and young adult patients with extra-cranial solid malignancies: An interim report from the GAIN/iCat2 study.

AUTHOR(S)

Alanna J. Church, Laura Corson, Pei-Chi Kao, Alma Imamovic-Tuco, Wenjun Kang, Navin R. Pinto, Luke Maese, Theodore W. Laetsch, AeRang Kim, Susan Colace, Margaret E. Macy, Mark A. Applebaum, Rochelle Bagatell, Amit J. Sabnis, Daniel Weiser, Julia L. Glade Bender, Samuel L. Volchenboum, Steven G. DuBois, Wendy B. London, Katherine A. Janeway

ABSTRACT

10005

Integrated whole-exome and transcriptome analysis of 250 treatment-refractory or relapsed (R/R) childhood solid tumors.

AUTHOR(S)

Sara A. Byron, William P. Hendricks, Abhinav B. Nagulapally, Karl Dykema, Jeffrey Bond, Hsien-Chao Chou, Jun S. Wei, Xinyu Wen, Hue V. Reardon, Sara Nasser, Tyler Izatt, Daniel Enriquez, Apurva M. Hegde, Szabolcs Szelinger, Jonathan J. Keats, Rebecca F. Halperin, Javed Khan, Giselle L. Saulnier Sholler, Jeffrey M. Trent

ABSTRACT

10006

Factors impacting enrollment on NCI-COG Pediatric MATCH trial treatment protocols.

AUTHOR(S)

Donald W. Parsons, Katherine A. Janeway, David R. Patton, Jennifer Lee, Brent Coffey, Paul M. Williams, Sinchita Roy-Chowdhuri, Gregory J. Tsongalis, Mark Routbort, Nilsa C. Ramirez, Lauren Saguilig, Jin Piao, Todd A. Alonzo, Stacey L. Berg, Elizabeth Fox, Douglas S. Hawkins, Margaret M. Mooney, Naoko Takebe, James V. Tricoli, Nita Seibel

ABSTRACT

10007

Selumetinib in patients with tumors with MAPK pathway alterations: Results from Arm E of the NCI-COG pediatric MATCH trial.

AUTHOR(S)

Carl E. Allen, Olive Eckstein, Paul M. Williams, Sinchita Roy-Chowdhuri, David R. Patton, Brent Coffey, Joel M. Reid, Jin Piao, Lauren Saguilig, Todd A. Alonzo, Stacey L. Berg, Alok Jaju, Elizabeth Fox, Douglas S. Hawkins, Margaret M. Mooney, Naoko Takebe, James V. Tricoli, Katherine A. Janeway, Nita Seibel, Donald W. Parsons

ABSTRACT

10008

Precision Oncology: Moving From Discovery to Implementation

DISCUSSANT

Birgit Geoerger, MD, PhD | Gustave Roussy Cancer Center, Department of Pediatric and Adolescent Oncology, Université Paris-Saclay

Panel Question and Answer with Drs. Church, Byron, Parsons, Allen, and Geoerger

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Melanoma/Skin Cancers

Sunday, June 6, 2:00 PM - 5:00 PM CEST

Back to Program

Showing 17 Presentations

<https://meetinglibrary.asco.org/session/13661>

Chair

CHAIR

Grant A. McArthur, MBBS, PhD, FRACP | Melanoma and Skin Service and Cancer Therapeutics Program, Peter MacCallum Cancer Centre

Chair

CHAIR

Georgia Beasley, MD | Duke University

Crossover and rechallenge with pembrolizumab in recurrent patients from the EORTC 1325-MG/Keynote-054 phase 3 trial, pembrolizumab versus placebo after complete resection of high-risk stage III melanoma.

AUTHOR(S)

Alexander M. Eggermont, Andrey Meshcheryakov, Victoria Atkinson, Christian U. Blank, Mario Mandalà, Georgina V. Long, Catherine Barrow, Anna M. Di Giacomo, Rosalie Stephens, Shahneen K. Sandhu, Ragini R. Kudchadkar, Pablo L. Ortiz-Romero, Inge M. Svane, Alexander C. Van Akkooi, Clemens Krepler, Nageatte Ibrahim, Sandrine Marreaud, Michal Kicinski, Stefan Suciu, Caroline Robert

ABSTRACT

9500

Final analysis of overall survival (OS) and relapse-free-survival (RFS) in the intergroup S1404 phase III randomized trial comparing either high-dose interferon (HDI) or ipilimumab to pembrolizumab in patients with high-risk resected melanoma.

AUTHOR(S)

Kenneth F. Grossmann, Megan Othus, Sapna P. Patel, Ahmad A. Tarhini, Vernon K. Sondak, Teresa M. Petrella, Thach-Giao Truong, Nikhil I. Khushalani, Justine V. Cohen, Elizabeth I. Buchbinder, Kari L. Kendra, Pauline Funchain, Karl D. Lewis, Bartosz Chmielowski, Hongli Li, James Moon, Krishna S. Gunturu, Zeynep Eroglu, John M. Kirkwood, Antoni Ribas

ABSTRACT

9501

Neoadjuvant and adjuvant nivolumab (nivo) with anti-LAG3 antibody relatlimab (rela) for patients (pts) with resectable clinical stage III melanoma.

AUTHOR(S)

Rodabe N. Amaria, Michael A. Postow, Michael T. Tetzlaff, Merrick I. Ross, Isabella C. Glitza, Jennifer L. McQuade, Michael K. Wong, Jeffrey E. Gershenwald, Ryan Goepfert, Emily Z. Keung, Sarah B. Fisher, Denai R. Milton, Sapna P. Patel, Adi Diab, Lauren Simpson, Michael A. Davies, Jennifer A. Wargo, Elizabeth M. Burton, Charlotte E. Ariyan, Hussein A. Tawbi

ABSTRACT

9502

The Evolving Role of Systemic Therapy in Stage III Melanoma

DISCUSSANT

Alexander M. Menzies, MBBS, FRACP, PhD | Melanoma Institute Australia, The University of Sydney, and Royal North Shore and Mater Hospitals

Panel Question and Answer with Drs. Beasley, McArthur, Eggermont, Grossmann, Amaria, and Menzies

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Relatlimab (RELA) plus nivolumab (NIVO) versus NIVO in first-line advanced melanoma: Primary phase III results from RELATIVITY-047 (CA224-047).

AUTHOR(S)

Evan J. Lipson, Hussein A. Tawbi, Dirk Schadendorf, Paolo A. Ascierto, Luis Matamala, Erika C. Gutiérrez, Piotr Rutkowski, Helen Gogas, Christopher D. Lao, Juliana Janoski de Menezes, Stéphane Dalle, Ana M. Arance, Jean-Jacques Grob, Shivani Srivastava, Mena Abaskharoun, Katy L. Simonsen, Bin Li, Georgina V. Long, F. S. Hodi

ABSTRACT

9503

Lenvatinib (len) plus pembrolizumab (pembro) for patients (pts) with advanced melanoma and confirmed progression on a PD-1 or PD-L1 inhibitor: Updated findings of LEAP-004.

AUTHOR(S)

Ana M. Arance, Luis de la Cruz-Merino, Teresa M. Petrella, Rahima Jamal, Lars Ny, Ana Carneiro, Alfonso Berrocal, Ivan Marquez-Rodas, Anna Spreafico, Victoria Atkinson, Fernanda C. Svedman, Andrew Mant, Alan D. Smith, Ke Chen, Scott J. Diede, Clemens Krepler, Georgina V. Long

ABSTRACT

9504

Lifileucel (LN-144), a cryopreserved autologous tumor infiltrating lymphocyte (TIL) therapy in patients with advanced melanoma: Evaluation of impact of prior anti-PD-1 therapy.

AUTHOR(S)

James Larkin, Amod Sarnaik, Jason A. Chesney, Nikhil I. Khushalani, John M. Kirkwood, Jeffrey S. Weber, Karl D. Lewis, Theresa M. Medina, Harriet M. Kluger, Sajeve S. Thomas, Evidio Domingo-Musibay, Judit Olah, Eric D. Whitman, Salvador Martin-Algarra, Philippa G. Corrie, Jose Lutzky, Wen Shi, Renee X. Wu, Maria Fardis, Omid Hamid

ABSTRACT

9505

Novel Therapeutic Strategies as the Next Step for Advanced Melanoma

DISCUSSANT

Jason J. Luke, MD, FACP | UPMC Hillman Cancer Center

Panel Question and Answer with Drs. Beasley, McArthur, Lipson, Arance, Larkin, and Luke

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

CheckMate 067: 6.5-year outcomes in patients (pts) with advanced melanoma.

AUTHOR(S)

Jedd D. Wolchok, Vanna Chiarion-Sileni, Rene Gonzalez, Jean-Jacques Grob, Piotr Rutkowski, Christopher D. Lao, Charles L. Cowey, Dirk Schadendorf, John Wagstaff, Reinhard Dummer, Pier Francesco Ferrucci, Michael Smylie, Marcus O. Butler, Andrew G. Hill, Ivan Marquez-Rodas, John B. Haanen, Tuba Bas, Wim van Dijck, James Larkin, F. S. Hodi

ABSTRACT

9506

Five-year overall survival (OS) in COLUMBUS: A randomized phase 3 trial of encorafenib plus binimetinib versus vemurafenib or encorafenib in patients (pts) with *BRAF* V600-mutant melanoma.

AUTHOR(S)

Reinhard Dummer, Keith Flaherty, Caroline Robert, Ana M. Arance, Jan Willem de Groot, Claus Garbe, Helen Gogas, Ralf Gutzmer, Ivana Krajsová, Gabriella Liskay, Carmen Loquai, Mario Mandalà, Dirk Schadendorf, Naoya Yamazaki, Michael D. Pickard, Fabian Zohren, Michelle L. Edwards, Paolo A. Ascierto

ABSTRACT

9507

Five-year overall survival from the anti-PD1 brain collaboration (ABC Study): Randomized phase 2 study of nivolumab (nivo) or nivo+ipilimumab (ipi) in patients (pts) with melanoma brain metastases (mets).

AUTHOR(S)

Georgina V. Long, Victoria Atkinson, Serigne Lo, Alexander D. Guminiski, Shahneen K. Sandhu, Michael P. Brown, Maria Gonzalez, Richard A. Scolyer, Louise Emmett, Grant A. McArthur, Alexander M. Menzies

ABSTRACT

9508

Informing Clinical Practice: Long-Term Updates of Pivotal Trials

DISCUSSANT

Sunandana Chandra, MD | Division of Hematology Oncology, Northwestern University Feinberg School of Medicine

Panel Question and Answer with Drs. Beasley, McArthur, Wolchok, Dummer, Long, and Chandra

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

Sunday, June 6, 2:00 PM - 5:00 PM CEST

Back to Program

Showing 17 Presentations

<https://meetinglibrary.asco.org/session/13655>

Chair

CHAIR

Chandra Prakash Belani, MD | Penn State Cancer Institute

Chair

CHAIR

Estelamari Rodriguez, MD, MPH | Sylvester Comprehensive Cancer Center, University of Miami

IMpower010: Primary results of a phase III global study of atezolizumab versus best supportive care after adjuvant chemotherapy in resected stage IB-IIIA non-small cell lung cancer (NSCLC).

AUTHOR(S)

Heather A. Wakelee, Nasser K. Altorki, Caicun Zhou, Tibor Csösz, Ihor O. Vynnychenko, Oleksandr Goloborodko, Alexander Luft, Andrey Akopov, Alex Martinez-Marti, Hirotugu Kenmotsu, Yuh-Min Chen, Antonio Chella, Shunichi Sugawara, Barbara J. Gitlitz, Elizabeth Bennett, Fan Wu, Jing Yi, Yu Deng, Mark McClelland, Enriqueta Felip

ABSTRACT

8500

Adjuvant gefitinib versus cisplatin/vinorelbine in Japanese patients with completely resected, EGFR-mutated, stage II-III non-small cell lung cancer (IMPACT, WJOG6410L): A randomized phase 3 trial.

AUTHOR(S)

Hirohito Tada, Tetsuya Mitsudomi, Takeharu Yamanaka, Kenji Sugio, Masahiro Tsuboi, Isamu Okamoto, Yasuo Iwamoto, Noriaki Sakakura, Shunichi Sugawara, Shinji Atagi, Toshiaki Takahashi, Hidetoshi Hayashi, Morihito Okada, Hiroshige Yoshioka, Hidetoshi Inokawa, Kazuhisa Takahashi, Masahiko Higashiyama, Ichiro Yoshino, Kazuhiko Nakagawa

ABSTRACT

8501

CTONG1103: Final overall survival analysis of the randomized phase 2 trial of erlotinib versus gemcitabine plus cisplatin as neoadjuvant treatment of stage IIIA-N2 EGFR-mutant non-small cell lung cancer.

AUTHOR(S)

Yi-Long Wu, Wenzhao Zhong, Ke-Neng Chen, Chun Chen, Fan Yang, Xue-Ning Yang, Chundong Gu, Weimin Mao, Qun Wang, Gui-Bin Qiao, Ying Cheng, Lin Xu, Changli Wang, Mingwei Chen, Hong-Hong Yan, Ri-qiang Liao, Xuchao Zhang, Jinji Yang, Si-yang Liu, Qing Zhou

ABSTRACT

8502

Role of Targeted Therapy and Immunotherapy in Resected Non-Small Cell Lung Cancer

DISCUSSANT

Zofia Piotrowska, MD | Massachusetts General Hospital Cancer Center

Panel Question and Answer with Drs. Belani, Rodriguez, Wakelee, Tada, Wu, and Piotrowska

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Surgical outcomes from the phase 3 CheckMate 816 trial: Nivolumab (NIVO) + platinum-doublet chemotherapy (chemo) vs chemo alone as neoadjuvant treatment for patients with resectable non-small cell lung cancer (NSCLC).

AUTHOR(S)

Jonathan Spicer, Changli Wang, Fumihito Tanaka, Gene B. Saylor, Ke-Neng Chen, Moishe Liberman, Everett E. Vokes, Nicolas Girard, Shun Lu, Mariano Provencio, Tetsuya Mitsudomi, Mark M. Awad, Enriqueta Felip, Patrick M. Forde, Scott Swanson, Julie R. Brahmer, Keith Kerr, Cécile Dorange, Junliang Cai, Stephen Broderick

ABSTRACT

8503

Video-assisted thoracoscopic versus open lobectomy in patients with early-stage lung cancer: One-year results from a randomized controlled trial (VIOLET).

AUTHOR(S)

Eric K. Lim, Tim J. Batchelor, Joel Dunning, Michael Shackcloth, Vladimir Anikin, Babu Naidu, Elizabeth Belcher, Mahmoud Loubani, Vipin Zamvar, Rosie A. Harris, Lucy Dabner, Holly E. Mckee, Sangeetha Paramasivan, Alba Realpe, Daisy Elliot, Paulo De Sousa, Jane M. Blazeby, Chris A. Rogers

ABSTRACT

8504

Assessing Surgical Outcomes in Resectable Non-Small Cell Lung Cancer

DISCUSSANT

Valerie W. Rusch, MD | Memorial Sloan Kettering Cancer Center

Panel Question and Answer with Drs. Belani, Rodriguez, Spicer, Lim, and Rusch

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Phase 3 comparison of high-dose once-daily (QD) thoracic radiotherapy (TRT) with standard twice-daily (BID) TRT in limited stage small cell lung cancer (LSCLC): CALGB 30610 (Alliance)/RTOG 0538.

AUTHOR(S)

Jeffrey A. Bogart, Xiaofei F. Wang, Gregory A. Masters, Junheng Gao, Ritsuko Komaki, Charles S. Kuzma, John Heymach, William J. Petty, Laurie E. Gaspar, Saiama N. Waqar, Tom Stinchcombe, Jeffrey D. Bradley, Everett E. Vokes

ABSTRACT

8505

Stereotactic ablative radiotherapy in operable stage I NSCLC patients: Long-term results of the expanded STARS clinical trial.

AUTHOR(S)

Joe Y. Chang, Reza J. Mehran, Lei Feng, Peter Balter, Stephen McRae, Donald A. Berry, Jack A. Roth

ABSTRACT

8506

Emerging Trends in Radiation for Localized Lung Cancers

DISCUSSANT

Ramesh Rengan, MD, PhD | Department of Radiation Oncology, University of Washington

A randomized phase II trial of oral vinorelbine as second-line therapy for patients with malignant pleural mesothelioma.

AUTHOR(S)

Dean A. Fennell, Angela C. Casbard, Catharine Porter, Robin Rudd, Jason F. Lester, Marianne Nicolson, Bruno Morgan, Jeremy P. Steele, Liz Darlison, Georgina M. Gardner, Lisette S. Nixon, Terri Kitson, Ann White, Gareth O. Griffiths, Charlotte Poile, Aarti Gaba, Sara Busacca, Catherine J. Richards

ABSTRACT

8507

Salvage Therapy in Mesothelioma

DISCUSSANT

Anna K. Nowak, PhD, MBBS, FRACP | Sir Charles Gairdner Hospital

Panel Question and Answer with Drs. Belani, Rodriguez, Bogart, Chang, Rengan, Fennell, and Nowak

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Breast Cancer—Local/Regional/Adjuvant

Sunday, June 6, 2:00 PM - 5:00 PM CEST

Back to Program

Showing 17 Presentations

<https://meetinglibrary.asco.org/session/13604>

Chair

CHAIR

Frederique Madeleine Penault-Llorca, MD, PhD | Centre Jean Perrin

Chair

CHAIR

Richard C. Zellars, MD | Department of Radiation Oncology, Indiana University School of Medicine

Outcome of patients with an ultralow risk 70-gene signature in the MINDACT trial.

AUTHOR(S)

Josephine Lopes Cardozo, Caroline Drukker, Marjanka Schmidt, Laura van 't Veer, Annuska Glas, Anke Witteveen, Fatima Cardoso, Martine J. Piccart-Gebhart, Coralie Poncet, Emiel J. Rutgers

ABSTRACT

500

Breast Cancer Index (BCI) and prediction of benefit from extended aromatase inhibitor (AI) therapy (tx) in HR+ breast cancer: NRG oncology/NSABP B-42.

AUTHOR(S)

Eleftherios P. Mamounas, Hanna Bandos, Priya Rastogi, Yi Zhang, Kai Treuner, Peter C. Lucas, Charles E. Geyer Jr., Louis Fehrenbacher, Mark Graham, Stephen K. Chia, Adam Brufsky, Janice M. Walshe, Gamini S. Soori, Shaker R. Dakhil, Soonmyung Paik, Sandra M. Swain, Dennis Sgroi, Catherine A. Schnabel, Norman Wolmark

ABSTRACT

501

Utility of the 70-gene MammaPrint assay for prediction of benefit from extended letrozole therapy (ELT) in the NRG Oncology/NSABP B-42 trial.

AUTHOR(S)

Priya Rastogi, Hanna Bandos, Peter C. Lucas, Laura van 't Veer, Jia-Perng J. Wei, Charles E. Geyer Jr., Louis Fehrenbacher, Mark Graham, Stephen K. Chia, Adam Brufsky, Janice M. Walshe, Gamini S. Soori, Shaker R. Dakhil, Soonmyung Paik, Sandra M. Swain, Andrea Menicucci, Shiyu Wang, M. W. Audeh, Norman Wolmark, Eleftherios P. Mamounas

ABSTRACT

502

How Much, How Long: Optimizing Adjuvant Therapy Through Genomics

DISCUSSANT

Fabrice Andre, MD, PhD | Gustave Roussy

Panel Question and Answer with Drs. Zellars, Penault-Llorca, Cardozo, Mamounas, Rastogi, and Andre

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

De-escalated neoadjuvant pertuzumab+trastuzumab with or without paclitaxel weekly in HR-/HER2+ early breast cancer: ADAPT-HR-/HER2+ biomarker and survival results.

AUTHOR(S)

Nadia Harbeck, Oleg Gluz, Matthias Christgen, Sherko Kuemmel, Eva-Maria Grischke, Michael Braun, Jochem Potenberg, Katja Krauss, Claudia Schumacher, Helmut Forstbauer, Toralf Reimer, Andrea Stefek, Hans Holger Fischer, Enrico Pelz, Monika Graeser, Christine zu Eulenburg, Ronald E. Kates, Rachel Wuerstlein, Hans H. Kreipe, Ulrike Nitz

ABSTRACT

503

Prognostic impact of recurrence score, endocrine response and clinical-pathological factors in high-risk luminal breast cancer: Results from the WSG-ADAPT HR+/HER2- chemotherapy trial.

AUTHOR(S)

Oleg Gluz, Ulrike Nitz, Matthias Christgen, Michael Braun, Kerstin Luedtke-Heckenkamp, Maren Darsow, Helmut Forstbauer, Jochem Potenberg, Christoph Uleer, Eva-Maria Grischke, Bahriye Aktas, Claudia Schumacher, Christine zu Eulenburg, Katarzyna Jozwiak, Ronald E. Kates, Monika Graeser, Rachel Wuerstlein, Hans H. Kreipe, Sherko Kuemmel, Nadia Harbeck

ABSTRACT

504

Neoadjuvant talazoparib in patients with germline *BRCA1/2* (g*BRCA1/2*) mutation-positive, early HER2-negative breast cancer (BC): Results of a phase 2 study.

AUTHOR(S)

Jennifer K. Litton, Joseph T. Beck, Jason M. Jones, Jay Andersen, Joanne L. Blum, Lida A. Mina, Raymond Brig, Michael A. Danso, Yuan Yuan, Antonello Abbattista, Kay Noonan, Jayeta Chakrabarti, Akos Czibere, William F. Symmans, Melinda L. Telli

ABSTRACT

505

Subtype-Directed De-escalation

DISCUSSANT

Lisa A. Carey, MD, FASCO | University of North Carolina

Panel Question and Answer with Drs. Zellars, Penault-Llorca, Harbeck, Gluz, Litton, and Carey

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Durvalumab improves long-term outcome in TNBC: results from the phase II randomized GeparNUEVO study investigating neoadjuvant durvalumab in addition to an anthracycline/taxane based neoadjuvant chemotherapy in early triple-negative breast cancer (TNBC).

AUTHOR(S)

Sibylle Loibl, Andreas Schneeweiss, Jens B. Huober, Michael Braun, Julia Rey, Jens U. Blohmer, Jenny Furlanetto, Dirk M. Zahm, Claus Hanusch, Jörg Thomalla, Christian Jackisch, Peter Staib, Theresa Link, Kerstin Rhiem, Christine Solbach, Peter A. Fasching, Nicole Burchardi, Carsten Denkert, Michael Untch

ABSTRACT

506

Evaluation of intra-tumoral (IT) SD-101 and pembrolizumab (Pb) in combination with paclitaxel (P) followed by AC in high-risk HER2-negative (HER2-) stage II/III breast cancer: Results from the I-SPY 2 trial.

AUTHOR(S)

Amy J. Chien, Hatem H. Soliman, Cheryl A. Ewing, Judy C. Boughey, Michael J. Campbell, Hope S. Rugo, Anne M. Wallace, Kathy S. Albain, Erica M. Stringer-Reasor, An L. Church, Kevin Kalinsky, Anthony D. Elias, Zahi I. Mitri, Amy S. Clark, Rita Nanda, Alexandra Thomas, Christina Yau, I-SPY 2 Consortium, Donald A. Berry, Laura Esserman

ABSTRACT

508

A randomized phase III post-operative trial of platinum-based chemotherapy (P) versus capecitabine (C) in patients (pts) with residual triple-negative breast cancer (TNBC) following neoadjuvant chemotherapy (NAC): ECOG-ACRIN EA1131

AUTHOR(S)

Ingrid A. Mayer, Fengmin Zhao, Carlos L. Arteaga, William F. Symmans, Ben H. Park, Brian L. Burnette, Amye J. Tevaarwerk, Sofia F. Garcia, Karen L. Smith, Erica L. Mayer, William M. Sikov, Eve T. Rodler, Lynne I. Wagner, Angela DeMichele, Joseph A. Sparano, Antonio C. Wolff, Kathy Miller

ABSTRACT

605

New Opportunities in High-Risk Early-Stage Disease

DISCUSSANT

Melinda L. Telli, MD | Stanford University School of Medicine

Panel Question and Answer with Drs. Zellars, Penault-Llorca, Lloibl, Chien, Mayer, and Telli

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

Saturday, June 5, 7:45 PM - 10:45 PM CEST

Back to Program

Showing 17 Presentations

<https://meetinglibrary.asco.org/session/13625>

Chair

CHAIR

Steven Ades, MD, MSCE, FRCPC | Fletcher Allen Health Care/UVM

Chair

CHAIR

Marcus Smith Noel, MD | Georgetown Lombardi Cancer Center

ESCORT-1st: A randomized, double-blind, placebo-controlled, phase 3 trial of camrelizumab plus chemotherapy versus chemotherapy in patients with untreated advanced or metastatic esophageal squamous cell carcinoma (ESCC).

AUTHOR(S)

Rui-hua Xu, Huiyan Luo, Jin Lu, Yuxian Bai, Teng Mao, Jun Wang, Qingxia Fan, Yiping Zhang, Kuaile Zhao, Zhendong Chen, Shengan Gao, Jiancheng Li, Zhichao Fu, Kangsheng Gu, Zhihua Liu, Lin Wu, Xiaodong Zhang, Yi Zhu, Qing Yang, Jianjun Zou

ABSTRACT

4000

Nivolumab (NIVO) plus ipilimumab (IPI) or NIVO plus chemotherapy (chemo) versus chemo as first-line (1L) treatment for advanced esophageal squamous cell carcinoma (ESCC): First results of the CheckMate 648 study.

AUTHOR(S)

Ian Chau, Yuichiro Doki, Jaffer A. Ajani, Jianming Xu, Lucjan Wyrwicz, Satoru Motoyama, Takashi Ogata, Hisato Kawakami, Chih-Hung Hsu, Antoine Adenis, Farid El Hajbi, Maria Di Bartolomeo, Maria Ignez F. Braghiroli, Eva Holtved, Ioannis Xynos, Xuan Liu, Ming Lei, Kaoru Kondo, Ken Kato, Yuko Kitagawa

ABSTRACT

LBA4001

First-line (1L) nivolumab (NIVO) plus chemotherapy (chemo) versus chemo in advanced gastric cancer/gastroesophageal junction cancer/esophageal

adenocarcinoma (GC/GEJC/EAC): Expanded efficacy and safety data from CheckMate 649.

AUTHOR(S)

Markus H. Moehler, Kohei Shitara, Marcelo Garrido, Pamela Salman, Lin Shen, Lucjan Wyrwicz, Kensei Yamaguchi, Tomasz Skoczylas, Arinilda S. Campos Bragagnoli, Tianshu Liu, Michael Schenker, Patricio E. Yanez, Mustapha Tehfe, Mingshun Li, Dana Cullen, Arteid Memaj, Ming Lei, Hong Xiao, Yelena Y. Janjigian, Jaffer A. Ajani

ABSTRACT

4002

Finding First-Line Chemoimmunotherapy for Gastroesophageal Cancer

DISCUSSANT

David Cunningham, MD | The Royal Marsden NHS Foundation Trust

Panel Question and Answer with Drs. Noel, Ades, Xu, Chau, Moehler, and Cunningham

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Adjuvant nivolumab (NIVO) in resected esophageal or gastroesophageal junction cancer (EC/GEJC) following neoadjuvant chemoradiotherapy (CRT): Expanded efficacy and safety analyses from CheckMate 577.

AUTHOR(S)

Ronan J. Kelly, Jaffer A. Ajani, Jaroslaw Kuzdzal, Thomas Zander, Eric Van Cutsem, Guillaume Piessen, Guillermo Mendez, Josephine L. Feliciano, Satoru Motoyama, Astrid Lièvre, Hope E. Uronis, Elena Elimova, Cecile Grootscholten, Karen P. Geboes, Jenny Zhang, Samira Soleymani, Ming Lei, Prianka Singh, James M. Cleary, Markus H. Moehler

ABSTRACT

4003

Neo-AEGIS (Neoadjuvant trial in Adenocarcinoma of the Esophagus and Esophago-Gastric Junction International Study): Preliminary results of phase III RCT of CROSS versus perioperative chemotherapy (Modified MAGIC or FLOT protocol). (NCT01726452).

AUTHOR(S)

John V. Reynolds, Shaun R. Preston, Brian O'Neill, Maeve A. Lowery, Lene Baeksgaard, Thomas Crosby, Moya Cunningham, Sinead Cuffe, Gareth O. Griffiths, Rajarshi Roy, Stephen Falk, George Hanna, Frederick R. Bartlett, Imelda Parker, Alberto Alvarez-Iglesias, Magnus Nilsson, Guillaume Piessen, Signe Risum, Narayanasamy Ravi, Raymond S. McDermott

ABSTRACT

4004

Multicenter, randomized phase II study of neoadjuvant pembrolizumab plus chemotherapy and chemoradiotherapy in esophageal adenocarcinoma (EAC).

AUTHOR(S)

Manish A. Shah, Khaldoun Almhanna, Syma Iqbal, Prashant Thakkar, Bryan J. Schneider, Rhonda Yantiss, Yiru Wu, Emma Futamura, Jeffrey L. Port, Cathy Spinelli, Sandipto Sarkar, Paul J. Christos, Gagandeep Brar, Doron Betel, Nicholas J. Sanfilippo, Nasser K. Altorki

ABSTRACT

4005

Perioperative Treatment of Gastroesophageal Cancer: 2021 and Beyond

DISCUSSANT

Manisha Palta, MD | Duke University Medical Center, Department of Radiation Oncology

Panel Question and Answer with Drs. Noel, Ades, Kelly, Reynolds, Shah, and Palta

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Liposomal irinotecan (nal-IRI) in combination with fluorouracil (5-FU) and leucovorin (LV) for patients with metastatic biliary tract cancer (BTC) after progression on gemcitabine plus cisplatin (GemCis): Multicenter comparative randomized phase 2b study (NIFTY).

AUTHOR(S)

Changhoon Yoo, Kyu-Pyo Kim, Ilhwan Kim, Myoung Joo Kang, Jaekyung Cheon, Byung Woog Kang, Hyewon Ryu, Jae Ho Jeong, Ji Sung Lee, Kyung Won Kim, Baek-Yeol Ryoo

ABSTRACT

4006

Hepatic arterial infusion chemotherapy of oxaliplatin plus fluorouracil versus sorafenib in advanced hepatocellular carcinoma: A biomolecular exploratory, randomized, phase 3 trial (The FOHAIC-1 study).

AUTHOR(S)

Ning Lyu, Ming Zhao

ABSTRACT

4007

Neoadjuvant transarterial infusion chemotherapy with FOLFOX could improve outcomes of resectable BCLC stage A/B hepatocellular carcinoma patients beyond

Milan criteria: An interim analysis of a multi-center, phase 3, randomized, controlled clinical trial.

AUTHOR(S)

Shaohua Li, Chong Zhong, Qiang Li, Jingwen Zou, Qiaoxuan Wang, Changzhen Shang, Yuan Cheng, Mingrong Cao, Huakun Huang, Jie Mei, Lianghe Lu, Rongce Zhao, Wenping Lin, Yuhua Wen, Zhixing Guo, Yihong Ling, Lie Zheng, Wei Wei, Rongping Guo

ABSTRACT

4008

Beyond Traditional Therapy for Liver Cancer

DISCUSSANT

Mark Yarchoan, MD | Hospital of the University of Pennsylvania

Panel Question and Answer with Drs. Noel, Ades, Yoo, Lyu, Li, and Yarchoan

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Breast Cancer—Metastatic

Saturday, June 5, 7:30 PM - 10:30 PM CEST

Back to Program

Showing 17 Presentations

<https://meetinglibrary.asco.org/session/13607>

Chair

CHAIR

Olwen Mary Hahn, MD | University of Chicago Medical Center

Chair

CHAIR

Adam Brufsky, MD, PhD | NSABP/NRG Oncology, and the UPMC Hillman Cancer Center

Overall survival (OS) with palbociclib (PAL) + fulvestrant (FUL) in women with hormone receptor-positive (HR+), human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): Updated analyses from PALOMA-3.

AUTHOR(S)

Massimo Cristofanilli, Hope S. Rugo, Seock-Ah Im, Dennis J. Slamon, Nadia Harbeck, Igor Bondarenko, Norikazu Masuda, Marco Colleoni, Angela DeMichele, Sherene Loi, Hiroji Iwata, Ben O'Leary, Eustratios Bananis, Yuan Liu, Xin Huang, Sindy Kim, Mariajose Lechuga, Nicholas C. Turner

ABSTRACT

1000

Updated overall survival (OS) results from the phase III MONALEESA-3 trial of postmenopausal patients (pts) with HR+/HER2- advanced breast cancer (ABC) treated with fulvestrant (FUL) ± ribociclib (RIB).

AUTHOR(S)

Dennis J. Slamon, Patrick Neven, Stephen K. Chia, Guy H. Jerusalem, Michelino De Laurentiis, Seock-Ah Im, Katarina Petrakova, Giulia V. Bianchi, Miguel Martin, Arnd Nusch, Gabe S. Sonke, Luis de la Cruz-Merino, J. T. Beck, Craig Wang, Uday Deore, Arunava Chakravartty, Juan Pablo Zarate, Tetiana Taran, Peter A. Fasching

ABSTRACT

1001

Dalpiciclib versus placebo plus fulvestrant in HR+/HER2- advanced breast cancer that relapsed or progressed on previous endocrine therapy (DAWNA-1): A multicenter, randomized, phase 3 study.

AUTHOR(S)

Binghe Xu, Qingyuan Zhang, Pin Zhang, Xichun Hu, Wei Li, Zhongsheng Tong, Tao Sun, Yuee Teng, Xinhong Wu, Quchang Ouyang, Xi Yan, Jing Cheng, Qiang Liu, Jifeng Feng, Xiaojia Wang, Xiaoyu Zhu, Fei Wu, Xiao Zhang, Jianjun Zou

ABSTRACT

1002

Solidifying CDK4/6 Inhibitors in Advanced Breast Cancer

DISCUSSANT

Otto Metzger, MD | Dana-Farber Cancer Institute

Panel Question and Answer with Drs. Brufsky, Hahn, Cristofanilli, Slamon, Xu, and Metzger

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Trastuzumab plus endocrine therapy or chemotherapy as first-line treatment for metastatic breast cancer with hormone receptor-positive and HER2-positive: The sysucc-002 randomized clinical trial.

AUTHOR(S)

Zhongyu Yuan, Jia-Jia Huang, Xin Hua, Jian-Li Zhao, Ying Lin, Yuan-Qi Zhang, Zhiyong Wu, Lehong Zhang, XiWen Bi, Wen Xia, Yong-yi Zhong, Shu-Sen Wang, Fei Xu, Ruoxi Hong, Kuikui Jiang, Yanxia Shi, Cong Xue, Xin An

ABSTRACT

1003

Results from VERONICA: A randomized, phase II study of second-/third-line venetoclax (VEN) + fulvestrant (F) versus F alone in estrogen receptor (ER)-positive, HER2-negative, locally advanced, or metastatic breast cancer (LA/MBC).

AUTHOR(S)

Geoffrey J. Lindeman, Rebecca Bowen, Katarzyna J. Jerzak, Xinni Song, Thomas Decker, Frances M. Boyle, Steven L. McCune, Anne Armstrong, Catherine M. Shannon, Gianfilippo Bertelli, Tharu M. Fernando, Rupal Desai, Kushagra Gupta, Jerry Y. Hsu, Aulde Flechais, Aditya Bardia

ABSTRACT

1004

Treatment-related side effects and views about dosage assessment to sustain quality of life: Results of an advocate-led survey of patients with metastatic breast cancer (MBC).

AUTHOR(S)

Anne L. Loeser, Jeffrey M. Peppercorn, Mark E. Burkard, Kevin Kalinsky, Hope S. Rugo, Aditya Bardia

ABSTRACT

1005

Leveraging Oral Therapy in Advanced Breast Cancer

DISCUSSANT

William John Gradishar, FACP, FASCO, MD | Robert H. Lurie Comprehensive Cancer Center of Northwestern University

Panel Question and Answer with Drs. Brufsky, Hahn, Yuan, Lindeman, Gradishar, and Ms. Loeser

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

The tumor microenvironment (TME) and atezolizumab + *nab*-paclitaxel (A+nP) activity in metastatic triple-negative breast cancer (mTNBC): IMpassion130.

AUTHOR(S)

Leisha A. Emens, Leonard D. Goldstein, Peter Schmid, Hope S. Rugo, Sylvia Adams, Carlos H. Barrios, Andreas Schneeweiss, Veronique Dieras, Hiroji Iwata, Ching-Wei Chang, Hartmut Koeppen, Stephen Y. Chui, Sherene Loi, Luciana Molinero

ABSTRACT

1006

Combination of famitinib with camrelizumab plus nab-paclitaxel as first-line treatment for patients with immunomodulatory advanced triple-negative breast cancer (FUTURE-C-PLUS): A prospective, single-arm, phase 2 study.

AUTHOR(S)

Li Chen, Shao Zhimin, Zhonghua Wang, Wentao Yang, Yizhou Jiang, Jianjun Zou, Jiong Wu, Genhong Di, Guangyu Liu, Keda Yu, Lei Fan, Junjie Li, Yifeng Hou, Zhen Hu, Canming Chen, Xiaoyan Huang, Ayong Cao, Xin Hu, Songyang Wu, Shen Zhao

ABSTRACT

1007

Randomized multicenter trial of 3 weekly cabazitaxel versus weekly paclitaxel chemotherapy in the first-line treatment of HER2 negative metastatic breast cancer (MBC).

AUTHOR(S)

Amit Bahl, Jeremy Braybrooke, Alicia Bravo, Emily Foulstone, Jessica Ball, Mark Churn, Sidharth Dubey, Saiqa Spensley, Rebecca Bowen, Simon Waters, Pippa Riddle, Duncan Wheatley, Peter Stephens, Janine Mansi, Pavel Bezecny, Srinivasan Madhusudan, Mark Verrill, Alison Markham, Sylvia Pearson, William Wilson

ABSTRACT

1008

Refining Treatment Options for Triple-Negative Breast Cancer

DISCUSSANT

Marleen Kok, MD | Netherlands Cancer Institute

Panel Question and Answer with Drs. Brufsky, Hahn, Emens, Chen, Bahl, and Kok

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Central Nervous System Tumors

Monday, June 7, 2:00 PM - 5:00 PM CEST

Back to Program

Showing 17 Presentations

<https://meetinglibrary.asco.org/session/13613>

Chair

CHAIR

Evanthia Galanis, MD | Mayo Clinic

Chair

CHAIR

E. Antonio Chiocca, MD, PhD | Brigham and Women's Hospital

Alliance A071601: Phase II trial of BRAF/MEK inhibition in newly diagnosed papillary craniopharyngiomas.

AUTHOR(S)

Priscilla K. Brastianos, Erin Twohy, Susan M. Geyer, Elizabeth R. Gerstner, Timothy J. Kaufmann, Michael Ruff, Daniela A. Bota, David A. Reardon, Adam L. Cohen, Macarena I. De La Fuente, Glenn J. Lesser, Jian L. Campian, Pankaj Agarwalla, Priya Kumthekar, Daniel P. Cahill, Helen A. Shih, Paul D. Brown, Sandro Santagata, Frederick G. Barker II, Evanthia Galanis

ABSTRACT

2000

ALK inhibitors for treatment of adult-onset neuroblastoma.

AUTHOR(S)

Jessica Stiefel, Brian H. Kushner, Ellen M. Basu, Stephen S. Roberts, Shakeel Modak

ABSTRACT

2001

Efficacy and safety of larotrectinib in adult and pediatric patients with tropomyosin receptor kinase (TRK) fusion-positive primary central nervous system tumors.

AUTHOR(S)

Sébastien Perreault, Cornelis M. van Tilburg, Birgit Geoerger, Karsten Nysom, Ingrid Ora, Igor T. Gavrilovic, Ricarda Norenberg, Laura Dima, Esther A. De La Cuesta, Alexander E. Drilon, Francois P. Doz

ABSTRACT

2002

Targeting Common Mutations in Rare CNS Tumors

DISCUSSANT

Jaishri O'Neill Blakeley, MD | Johns Hopkins School of Medicine

Panel Question and Answer with Drs. Galanis, Chiocca, Brastianos, Steifel, Perreault, and Blakeley

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

The 1994 National Cancer Institute's strategy to fund multi-institutional, multidisciplinary consortia to design and conduct early phase clinical trials in patients with high grade gliomas.

AUTHOR(S)

Stuart A. Grossman, Louis B. Nabors, Joy D. Fisher, Patrick Y. Wen, William C. Timmer, Frederick G. Barker II, David M. Peereboom, Benjamin M. Ellingson, Jeffrey G. Supko, Michelle A. Rudek, Ingo K. Mellinghoff, Tom Mikkelsen, Timothy F. Cloughesy, Michael Prados, Glenn J. Lesser, E. Antonio Chiocca, Tracy Batchelor, Susan M. Chang, Frank S. Lieberman, Xiaobu Ye

ABSTRACT

2003

EORTC 1709/CCTG CE.8: A phase III trial of marizomib in combination with temozolomide-based radiochemotherapy versus temozolomide-based radiochemotherapy alone in patients with newly diagnosed glioblastoma.

AUTHOR(S)

Patrick Roth, Thierry Gorlia, Jaap C. Reijneveld, Filip Y. De Vos, Ahmed Idbaih, Jean-Sebastien Frenel, Emilie Le Rhun, José M. Sepulveda Sánchez, James R. Perry, Laura Masucci, Pierre Freres, Hal W. Hirte, Clemens Seidel, Anna Maria E. Walenkamp, Frederic Dhermain, Martin J. Van Den Bent, Christopher J. O'Callaghan, Maureen Vanlancker, Warren P. Mason, Michael Weller

ABSTRACT

2004

A Phase 0 'trigger' trial of CDK4/6 plus ERK1/2 inhibitors in recurrent glioblastoma.

AUTHOR(S)

Nader Sanai, Yu-Wei Chang, Tigran Margaryan, Anita DeSantis, Mackenna Elliott, Chelsea Pennington-Krygier, Garry Hook, Wonsuk Yoo, An-Chi Tien, Artak Tovmasyan, Shwetal Mehta

ABSTRACT

2005

Evaluating the benefit of adaptive randomization in the CC-115 arm of the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGHt): A phase II randomized Bayesian adaptive platform trial in newly diagnosed MGMT unmethylated glioblastoma.

AUTHOR(S)

Rifaquat Rahman, Lorenzo Trippa, Geoffrey Fell, Eudocia Q. Lee, Isabel Arrillaga-Romany, Mehdi Touat, Jan Drappatz, Evanthia Galanis, Manmeet S. Ahluwalia, Howard Colman, Louis B. Nabors, Jaroslaw T. Hepel, David Schiff, Mary R. Welch, David M. Meredith, E. Antonio Chiocca, David A. Reardon, Keith L. Ligon, Brian M. Alexander, Patrick Y. Wen

ABSTRACT

2006

Reassessment of Drug Evaluation in GBM

DISCUSSANT

Mark R. Gilbert, MD | National Cancer Institute at the National Institutes of Health

Panel Question and Answer Drs. Galanis, Chiocca, Grossman, Roth, Sanai, Rahman, and Gilbert

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Olaparib in recurrent IDH-mutant high-grade glioma (OLAGLI).

AUTHOR(S)

Francois Ducray, Marc Sanson, Olivier L. Chinot, Maxime Fontanilles, Romain Rivoirard, Laure Thomas-Maisonneuve, Stephanie Cartalat, Emeline Tabouret, Alice Bonneville-Levard, Amelie Darlix, Roxana Ameli, David Meyronet, Francois Gueyffier, Laurent Remontet, Delphine Maucourt-Boulch, Caroline Dehais, Jérôme Honnorat

ABSTRACT

2007

Impact of mutant IDH (mIDH) inhibition on DNA hydroxymethylation, tumor cell function, and tumor immune microenvironment (TIME) in resected mIDH1 lower-grade glioma (LGG).

AUTHOR(S)

Min Lu, Timothy F. Cloughesy, Patrick Y. Wen, Ania Tassinari, Sung Choe, Dongwei Zhu, Islam Hassan, Lori Steelman, Shuchi S. Pandya, Bin Wu, Ingo K. Mellinghoff

ABSTRACT

2008

Developing Targeted Treatments for IDH-Mutant Glioma

DISCUSSANT

Howard Colman, MD, PhD | Huntsman Cancer Institute, University of Utah

Panel Question and Answer with Drs. Galanis, Chiocca, Ducray, Lu, and Colman

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Genitourinary Cancer—Kidney and Bladder

Monday, June 7, 2:00 PM - 5:00 PM CEST

Back to Program

Showing 17 Presentations

<https://meetinglibrary.asco.org/session/13628>

Chair

CHAIR

Daniel M. Geynisman, MD | Fox Chase Cancer Center, Department of Hematology and Oncology

Chair

CHAIR

Cristina Suarez Rodriguez, MD | Medical Oncology, Vall d'Hebron Institute of Oncology (VHIO), Hospital Universitari Vall d'Hebron, Vall d'Hebron Barcelona Hospital Campus

Pembrolizumab (pembro) plus axitinib (axi) versus sunitinib as first-line therapy for advanced clear cell renal cell carcinoma (ccRCC): Results from 42-month follow-up of KEYNOTE-426

AUTHOR(S)

Brian I. Rini, Elizabeth R. Plimack, Viktor Stus, Tom Waddell, Rustem Gafanov, Frédéric Pouliot, Dmitry Nosov, Bohuslav Melichar, Denis Soulieres, Delphine Borchiellini, Ihor O. Vynnychenko, Raymond S. McDermott, Sergio J. Azevedo, Satoshi Tamada, Anna Kryzhanivska, Chenxiang Li, Joseph E. Burgents, L. Rhoda Molife, Jens Bedke, Thomas Powles

ABSTRACT

4500

CANTATA: Primary analysis of a global, randomized, placebo (Pbo)-controlled, double-blind trial of telaglenastat (CB-839) + cabozantinib versus Pbo + cabozantinib in advanced/metastatic renal cell carcinoma (mRCC) patients (pts) who progressed on immune checkpoint inhibitor (ICI) or anti-angiogenic therapies.

AUTHOR(S)

Nizar M. Tannir, Neeraj Agarwal, Camillo Porta, Nicola J. Lawrence, Robert J. Motzer, Richard J. Lee, Rohit K. Jain, Nancy B. Davis, Leonard J. Appleman, Oscar B. Goodman Jr., Walter M. Stadler, Sunil G. Gandhi, Daniel M. Geynisman, Roberto Iacovelli, Begona Mellado, Robert A. Figlin, Thomas Powles, Lalith V. Akella, Keith W. Orford, Bernard Escudier

ABSTRACT

4501

Health-related quality-of-life (HRQoL) analysis from the phase 3 CLEAR trial of lenvatinib (LEN) plus pembrolizumab (PEMBRO) or everolimus (EVE) versus sunitinib (SUN) for patients (pts) with advanced renal cell carcinoma (aRCC).

AUTHOR(S)

Robert J. Motzer, Camillo Porta, Boris Alekseev, Sun Y. Rha, Toni K. Choueiri, Maria Jose Mendez-Vidal, Sung-Hoo Hong, Anil Kapoor, Jeffrey C. Goh, Masatoshi Eto, Jinyi Wang, Janice Pan, Alemseged Ayele Asfaw, Cixin S. He, Kalgi Mody, David Cella

ABSTRACT

4502

Expanding VEGF Blockade Combination Therapeutic Options in Advanced Renal Cell Carcinoma

DISCUSSANT

Andrea B. Apolo, MD | National Cancer Institute, National Institutes of Health

Panel Question and Answer with Drs. Rodriguez, Geynisman, Rini, Tannir, Motzer, and Apolo

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Phase 2 trial of gemcitabine, cisplatin, plus nivolumab with selective bladder sparing in patients with muscle- invasive bladder cancer (MIBC): HCRN GU 16-257.

AUTHOR(S)

Matt D. Galsky, Siamak Daneshmand, Kevin G. Chan, Tanya B. Dorff, Jeremy P. Cetnar, Brock O Neil, Anishka D'souza, Ronac Mamtani, Christos Kyriakopoulos, Philip Garcia, Sudeh Izadmehr, Menggang Yu, Qianqian Zhao, Reza Mehrazin, Sara C. Lewis, John Sfakianos, Sumanta K. Pal

ABSTRACT

4503

Pembrolizumab (pembro) in combination with gemcitabine (Gem) and concurrent hypofractionated radiation therapy (RT) as bladder sparing treatment for muscle-invasive urothelial cancer of the bladder (MIBC): A multicenter phase 2 trial.

AUTHOR(S)

Arjun V. Balar, Matthew I. Milowsky, Peter H. O'Donnell, Ajjai S. Alva, Marisa Kollmeier, Tracy L. Rose, Sean Pitroda, Samuel D. Kaffenberger, Jonathan E. Rosenberg, Kaitlyn Francese, Tsivia Hochman, Judith D. Goldberg, Sarah Griglund, Dayna Leis, Gary D. Steinberg, James Wysock, Peter B. Schiff, Nicholas J. Sanfilippo, Samir Taneja, William C. Huang

ABSTRACT

4504

Phase II trial of durvalumab plus tremelimumab with concurrent radiotherapy (RT) in patients (pts) with localized muscle invasive bladder cancer (MIBC) treated with a selective bladder preservation approach: IMMUNOPRESERVE-SOGUG trial.

AUTHOR(S)

Xavier Garcia del Muro, Begoña P. Valderrama, Ana Medina, M. Andres Cuellar, Olatz Etxaniz, Regina Gironés Sarrió, María Jose Juan-Fita, Ferran Ferrer, Isabel Miras Rodríguez, Guillermo Lendínez-Cano, Roberto de Haro Piedra, Arturo Candal Gomez, Venancio Chantada Abal, Oscar Buisán, Salvador Villà, José Luis Pontones, Erica Collado, José L. Domínguez-Escrig, Yashmina Murria, Francesc Vigués

ABSTRACT

4505

Steps Toward a Bladder-Intact Cure for Muscle-Invasive Bladder Cancer

DISCUSSANT

Andrea Necchi, MD | Fondazione IRCCS Istituto Nazionale dei Tumori

Panel Question and Answer with Drs. Rodriguez, Geynisman, Galsky, Balar, Garcia del Muro, and Necchi

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

A randomized phase II study comparing cisplatin and gemcitabine with or without berzosertib in patients with advanced urothelial carcinoma.

AUTHOR(S)

Sumanta K. Pal, Amir Mortazavi, Matthew I. Milowsky, Ulka N. Vaishampayan, Mamta Parikh, Yung Lyou, Peng Wang, Rahul A. Parikh, Benjamin A. Teplý, Robert Dreicer, Hamid Enamekhoo, M. Dror Michaelson, Christopher J. Hoimes, Tian Zhang, Sandy Srinivas, William Y. Kim, Glenn Liu, Paul H. Frankel, Yuijie Cui, Primo "Lucky" N. Lara Jr.

ABSTRACT

4507

First-line pembrolizumab (pembro) in cisplatin-ineligible patients with advanced urothelial cancer (UC): Response and survival results up to five years from the KEYNOTE-052 phase 2 study.

AUTHOR(S)

Peter H. O'Donnell, Arjun V. Balar, Jacqueline Vuky, Daniel Castellano, Joaquim Bellmunt, Thomas Powles, Dean F. Bajorin, Petros Grivas, Noah M. Hahn, Elizabeth R. Plimack, Jin Zhi Xu, James L. Godwin, Blanca Homet Moreno, Ronald De Wit

ABSTRACT

4508

Inducible T-cell co-stimulatory (ICOS) receptor agonist, feladilimab (fela), alone and in combination (combo) with pembrolizumab (P): Results from INDUCE-1 urothelial carcinoma (UC) expansion cohorts (ECs).

AUTHOR(S)

Arjun V. Balar, Victor Moreno, Eric Angevin, Hui K. Gan, Maria Vieito, Antoine Italiano, Riccardo Danielli, Erminia Massarelli, Frans Opdam, Michael J. Chisamore, Debra Rogan, Xiao Ji, Courtney Henry, Catherine E. Ellis, Marc S. Ballas, Axel Hoos, Francesco Ricci

ABSTRACT

4519

Conundrums in First-Line Urothelial Carcinoma: Is More Always Better?

DISCUSSANT

Shilpa Gupta, MD | Cleveland Clinic Taussig Cancer Institute

Panel Question and Answer with Drs. Rodriguez, Geynisman, Pal, O'Donnell, Balar, and Gupta

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Gynecologic Cancer

Monday, June 7, 2:00 PM - 5:00 PM CEST

Back to Program

Showing 17 Presentations

<https://meetinglibrary.asco.org/session/13634>

Chair

CHAIR

Kathleen N. Moore, MD | Stephenson Cancer Center

Chair

CHAIR

Rachel N. Grisham, MD | Memorial Sloan Kettering Cancer Center and Weill Cornell Medical College

Efficacy and safety results from neopembrov study, a randomized phase II trial of neoadjuvant chemotherapy (CT) with or without pembrolizumab (P) followed by interval debulking surgery and standard systemic therapy $\pm$ P for advanced high-grade serous carcinoma (HGSC): A GINECO study.

AUTHOR(S)

Isabelle L. Ray-Coquard, Aude Marie Savoye, Marie-ange Mouret-Reynier, Sylvie Chabaud, Olfa Derbel, Elsa Kalbacher, Marianne Leheurteur, Alejandra Martinez, Corina Cornila, Mathilde Martinez, Leila Bengrine, Frank Priou, Nicolas Cloarec, Laurence Venat-Bouvet, Frederic Selle, Dominique Berton, Olivier Collard, Florence Joly, Olivier Tredan

ABSTRACT

5500

Optimal treatment duration of bevacizumab (BEV) combined with carboplatin and paclitaxel in patients (pts) with primary epithelial ovarian (EOC), fallopian tube (FTC) or peritoneal cancer (PPC): A multicenter open-label randomized 2-arm phase 3 ENGOT/GCIG trial of the AGO Study Group, GINECO, and NSGO (AGO-OVAR 17/BOOST, GINECO OV118, ENGOT Ov-15, NCT01462890).

AUTHOR(S)

Jacobus Pfisterer, Florence Joly, Gunnar Kristensen, Joern Rau, Sven Mahner, Patricia Pautier, Ahmed El-Balat, Jean Emmanuel Kurtz, Ulrich Canzler, Jalid Sehouli, Martin L. Heubner, Andreas D. Hartkopf, Klaus Baumann, Annette Hasenburg, Lars C. Haker, Antje Belau, Barbara Schmalfeldt, Dominik Denschlag, Tjoung-Won Park-Simon, Philipp Harter

ABSTRACT

5501

Maintenance vigil immunotherapy in newly diagnosed advanced ovarian cancer: Efficacy assessment of homologous recombination proficient (HRP) patients in the phase IIb VITAL trial.

AUTHOR(S)

Rodney P. Rocconi, Sharad A. Ghamande, Minal A. Barve, Erin E. Stevens, Phylicia Aaron, Laura Stanbery, Ernest Bogner, Luisa Manning, John J. Nemunaitis, David M. O'Malley, Thomas J. Herzog, Bradley J. Monk, Robert L. Coleman

ABSTRACT

5502

First Impressions Are Lasting: Optimizing Upfront Therapy of Ovarian Cancer

DISCUSSANT

Carol Aghajanian, MD | Memorial Sloan Kettering Cancer Center

Panel Question and Answer with Drs. Moore, Grisham, Ray-Coquard, Pfisterer, Rocconi, and Aghajanian

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Phase 3, randomized, single-dose, open-label study to investigate the safety and efficacy of pafolacianine sodium injection (OTL38) for intraoperative imaging of folate receptor positive ovarian cancer.

AUTHOR(S)

Janos L. Tanyi, Hye Sook Chon, Mark A. Morgan, Setsuko K. Chambers, Kristina A. Butler, Carrie L. Langstraat, Matthew A. Powell, Leslie M. Randall, Alexander L. Vahrmeijer, Ira S. Winer, Robert M. Wenham

ABSTRACT

5503

Mirvetuximab soravtansine, a folate receptor alpha (FR α)-targeting antibody-drug conjugate (ADC), in combination with bevacizumab in patients (pts) with platinum-agnostic ovarian cancer: Final analysis.

AUTHOR(S)

David M. O'Malley, Ana Oaknin, Ursula A. Matulonis, Gina Mantia-Smaldone, Peter C. Lim, Cesar M. Castro, Diane M. Provencher, Sanaz Memarzadeh, Patrick A. Zweidler-McKay, Jiuzhou Wang, Brooke Esteves, Kathleen N. Moore, Lucy Gilbert

ABSTRACT

5504

EFFORT: EFFicacy Of adavosertib in parp ResisTance: A randomized two-arm non-comparative phase II study of adavosertib with or without olaparib in women with PARP-resistant ovarian cancer.

AUTHOR(S)

Shannon N. Westin, Robert L. Coleman, Bryan M. Fellman, Ying Yuan, Anil K. Sood, Pamela T. Soliman, Alexi A. Wright, Neil S. Horowitz, Susana M. Campos, Panagiotis A. Konstantinopoulos, Charles F. Levenback, David M. Gershenson, Karen H. Lu, Virginia Bayer, Sobiya Tukdi, Alexis Rabbit, Lone Ottesen, Robert Godin, Gordon B. Mills, Joyce F. Liu

ABSTRACT

5505

Expanding the Landscape of Novel Targets in Recurrent Ovarian Cancer

DISCUSSANT

Amit M. Oza, MD | Princess Margaret Cancer Centre, University of Toronto

Panel Question and Answer with Drs. Moore, Grisham, Tanyi, O'Malley, Westin, and Oza

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Intensive versus minimalist follow-up in patients treated for endometrial cancer: A multicentric randomized controlled trial (The TOTEM study—NCT00916708).

AUTHOR(S)

Paolo Zola, Giovannino Ciccone, Elisa Piovano, Luca Fuso, Elena Peirano, Daniela Di Cuonzo, Anna M. Perrone, Vincenzo D. Mandato, Laura Zavallone, Francesca Chiudinelli, Roberto Berretta, Serena Loda, Mario Valenzano Menada, Stefano Greggi, Marco Adorni, Enrico Busato, Marco Marinaccio, Giuseppe Commerci, Massimiliano Fambrini, Annamaria Ferrero

ABSTRACT

5506

Victoria: A multicentric, randomized, open-label, phase I/II of mTOR inhibitor (VISTUSERIB) combined with anastrozole in patients with hormone receptor-positive advanced/metastatic endometrial cancer—A CLIPP program INCA in collaboration with GINECO group.

AUTHOR(S)

Pierre-Etienne Heudel, Jean-Sebastien Frenel, Cécile Dalban, Fernando Bazan, Florence Joly, Antoine Arnaud, Cyril Abdeddaim, Annick Chevalier, Paule Augereau, Patricia Pautier, Camille Chakiba, Benoit You, Laurence Lancry Lecomte, Gwenaëlle Garin, Virginie MARcel, Jean-Jacques Diaz, Isabelle Treilleux, David Pérol, Michel Fabbro, Isabelle L. Ray-Coquard

ABSTRACT

5507

Pertuzumab plus trastuzumab (P+T) in patients (Pts) with uterine cancer (UC) with *ERBB2* or *ERBB3* amplification, overexpression or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

AUTHOR(S)

Hussein M. Ali-Ahmad, Michael Roth, Pam K. Mangat, Liz Garrett-Mayer, Eugene Ahn, John Chan, Michael L. Maitland, Ani S. Balmanoukian, Sapna R. Patel, Zachary Reese, Charles W. Drescher, Charles A. Leath III, Rui Li, Apostolia M. Tsimberidou, Richard L. Schilsky

ABSTRACT

5508

Fine-Tuning the Diagnosis and Treatment of Recurrent Endometrial Cancer

DISCUSSANT

TBD | TBD

Panel Question and Answer with Drs. Moore, Grisham, Zola, Heudel, Ali-Ahmad

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

Monday, June 7, 5:30 PM - 8:30 PM CEST

Back to Program

Showing 17 Presentations

<https://meetinglibrary.asco.org/session/13648>

Chair

CHAIR

Mary Jo Lechowicz, MD | Emory University, Winship Cancer Institute

Chair

CHAIR

Leslie Popplewell, MD | City of Hope

First results of a head-to-head trial of acalabrutinib versus ibrutinib in previously treated chronic lymphocytic leukemia.

AUTHOR(S)

John C. Byrd, Peter Hillmen, Paolo Ghia, Arnon P. Kater, Asher Alban A. Chanan-Khan, Richard R. Furman, Susan M. O'Brien, Mustafa N. Yenerel, Árpád Illés, Neil E. Kay, Jose A. Garcia Marco, Anthony R. Mato, John F. Seymour, Stephane Leprêtre, Stephan Stilgenbauer, Tadeusz Robak, Priti Patel, Kara Higgins, Sophia Sohoni, Wojciech Jurczak

ABSTRACT

7500

Fixed-duration (FD) first-line treatment (tx) with ibrutinib (I) plus venetoclax (V) for chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): Primary analysis of the FD cohort of the phase 2 captivate study.

AUTHOR(S)

Paolo Ghia, John N. Allan, Tanya Siddiqi, Thomas J. Kipps, Ryan Jacobs, Stephen Opat, Paul M. Barr, Alessandra Tedeschi, Livio Trentin, Rajat Bannerji, Sharon R. Jackson, Byrone Kuss, Carol Moreno, Edith Szafer-Glusman, Kristin Russell, Cathy Zhou, Joi S. Ninomoto, James P. Dean, William G. Wierda, Constantine S. Tam

ABSTRACT

7501

First-in-human study of lisaftoclax (APG-2575), a novel BCL-2 inhibitor (BCL-2i), in patients (pts) with relapsed/refractory (R/R) CLL and other hematologic malignancies (HMs).

AUTHOR(S)

Sikander Ailawadhi, Asher Alban A. Chanan-Khan, Zi Chen, Bo Huang, Marina Konopleva, Danielle M. Brander, David Rizzieri, Masa Lasica, Constantine S. Tam, Costas K. Yannakou, H. M. Prince, Matthew S. Davids, Zhicong He, Ming Lu, Mohammad Ahmad, Mingyu Li, Zhiyan Liang, Boyd Mudenda, Dajun Yang, Yifan Zhai

ABSTRACT

7502

On Target: Optimizing CLL Therapy

DISCUSSANT

Jacqueline Claudia Barrientos, MD, MS | Hofstra Northwell School of Medicine

Panel Question and Answer with Drs. Popplewell, Lechowicz, Byrd, Ghia, Ailawadhi, and Barrientos

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

ECOG-ACRIN E1411 randomized phase 2 trial of bendamustine-rituximab (BR)-based induction followed by rituximab (R) ± lenalidomide (L) consolidation for Mantle cell lymphoma: Effect of adding bortezomib to front-line BR induction on PFS.

AUTHOR(S)

Mitchell R. Smith, Opeyemi Jegede, Peter Martin, Brian G. Till, Samir S. Parekh, David T. Yang, Lale Kostakoglu, Carla Casulo, Nancy L. Bartlett, Paolo F. Caimi, Tareq Al Baghdadi, Kami J. Maddocks, Mark D. Romer, David J. Inwards, Rachel E. Lerner, Lynne I. Wagner, Richard F. Little, Jonathan W. Friedberg, John P. Leonard, Brad S. Kahl

ABSTRACT

7503

Real-world (RW) treatment (tx) patterns and outcomes of 3,455 previously untreated mantle cell lymphoma (MCL) patients (pts) in U.S. routine clinical practice.

AUTHOR(S)

Peter Martin, Michael Wang, Anita Kumar, Keqin Qi, Katherine Daly, Lori Parisi, Angeline Zhu, Gilles A. Salles

ABSTRACT

7504

The combination of venetoclax, lenalidomide, and rituximab in patients with newly diagnosed mantle cell lymphoma induces high response rates and MRD undetectability.

AUTHOR(S)

Tyrel Phillips, Alexey V. Danilov, David A. Bond, Alex F. Herrera, Kami J. Maddocks, Sumana Devata, Yasmin Karimi, Shannon Carty, Ryan A. Wilcox, Mark S. Kaminski, Sami N. Malek, Moshe Talpaz, Leslie Popplewell

ABSTRACT

7505

Upfront Therapy for Mantle Cell Lymphoma: Can We Do Better?

DISCUSSANT

Brian K. Link, MD | University of Iowa Carver College of Medicine

Panel Question and Answer with Drs. Popplewell, Lechowicz, Smith, Martin, Phillips, and Link

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Myeloablative versus non-myeloablative consolidative chemotherapy for newly diagnosed primary central nervous system lymphoma: Results of CALGB 51101 (Alliance).

AUTHOR(S)

Tracy Batchelor, Sharmila Giri, Amy S. Ruppert, Nancy L. Bartlett, Eric D. Hsi, Bruce D. Cheson, Lakshmi Nayak, John P. Leonard, James L. Rubenstein

ABSTRACT

7506

CALGB 50801 (Alliance): PET adapted therapy in bulky stage I/II classic Hodgkin lymphoma (cHL).

AUTHOR(S)

Ann S. LaCasce, Travis Dockter, Amy S. Ruppert, Lale Kostakoglu, Heiko Schöder, Eric D. Hsi, Jeffrey A. Bogart, Bruce D. Cheson, Nina D. Wagner-Johnston, Jeremy S. Abramson, Kami J. Maddocks, John P. Leonard, Nancy L. Bartlett

ABSTRACT

7507

Efficacy and safety of tisagenlecleucel (Tisa-cel) in adult patients (Pts) with relapsed/refractory follicular lymphoma (r/r FL): Primary analysis of the phase 2 Elara trial.

AUTHOR(S)

Stephen J. Schuster, Michael J. Dickinson, Martin H. Dreyling, Joaquín Martínez, Arne Kolstad, Jason P. Butler, Monalisa Ghosh, Leslie Popplewell, Julio C. Chavez, Emmanuel Bachy, Koji Kato, Hideo Harigae, Marie J. Kersten, Charalambos Andreadis, Peter A. Riedell, Ahmed M. Abdelhady, Aiesha Zia, Mony Chenda Morisse, Nathan H. Fowler, Catherine Thieblemont

ABSTRACT

7508

Fine-Tuning Intensity in Lymphoma Treatment

DISCUSSANT

Sonali M. Smith, MD, FASCO | The University of Chicago

Panel Question and Answer with Drs. Popplewell, Lechowicz, Batchelor, LaCasce, Schuster, and Smith

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Gastrointestinal Cancer—Colorectal and Anal

Monday, June 7, 7:15 PM - 10:15 PM CEST

Back to Program

Showing 16 Presentations

<https://meetinglibrary.asco.org/session/13622>

Chair

CHAIR

Tanios S. Bekaii-Saab, MD, FACP | Division of Hematology/Oncology, Mayo Clinic

Chair

CHAIR

Cathy Eng, MD, FACP, FASCO | The University of Texas MD Anderson Cancer Center

Final overall survival for the phase III KN177 study: Pembrolizumab versus chemotherapy in microsatellite instability-high/mismatch repair deficient (MSI-H/dMMR) metastatic colorectal cancer (mCRC).

AUTHOR(S)

Thierry Andre, Kai-Keen Shiu, Tae Won Kim, Benny V. Jensen, Lars Henrik Jensen, Cornelis J. Punt, Denis M. Smith, Rocio Garcia-Carbonero, Julia Alcaide, Peter Gibbs, Christelle De La Fouchardiere, Fernando Rivera, Elena Elez, Johanna C. Bendell, Dung T. Le, Takayuki Yoshino, Wen Yan Zhong, David R. Fogelman, Patricia Marinello, Luis A. Diaz Jr.

ABSTRACT

3500

The randomized phase II study of FOLFOXIRI plus cetuximab versus FOLFOXIRI plus bevacizumab as the first-line treatment in metastatic colorectal cancer with *RAS* wild-type tumors: The DEEPER trial (JACCRO CC-13).

AUTHOR(S)

Akihito Tsuji, Hisatsugu Otori, Tatsuro Yamaguchi, Masato Matsuura, Atsujiro Nishioka, Akitaka Makiyama, Shingo Noura, Mitsugu Kochi, Tamotsu Sagawa, Masahito Kotaka, Yutaro Kubota, Yu Sunakawa, Takashi Sekikawa, Masato Nakamura, Masahiro Takeuchi, Wataru Ichikawa, Masashi Fujii

ABSTRACT

3501

Randomized study to investigate FOLFOXIRI plus either bevacizumab or cetuximab as first-line treatment of BRAF V600E-mutant mCRC: The phase-II FIRE-4.5 study (AIO KRK-0116).

AUTHOR(S)

Sebastian Stintzing, Kathrin Heinrich, David Tougeron, Dominik P. Modest, Ingo Schwaner, Jan Euker, Rudolf Pihusch, Martina Stauch, Florian Kaiser, Christoph Kahl, Meinolf Karthaus, Christian Mueller, Christof Burkart, Anke Reinacher-Schick, Stefan Kasper, Ludwig Fischer von Weikersthal, Beate Krammer-Steiner, Gerald W. Prager, Julien Taieb, Volker Heinemann

ABSTRACT

3502

Personalizing First-Line Therapy for Every Patient

DISCUSSANT

Nilofer Saba Azad, MD | Department of Oncology, Johns Hopkins Sidney Kimmel Cancer Center

Panel Question and Answer with Drs. Bekaii-Saab, Eng, Andre, Tsuji, Stintzing, and Azad

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Maintenance therapy with 5-fluoruracil/leucovorin (5FU/LV) plus panitumumab (pmab) or 5FU/LV alone in RAS wildtype (WT) metastatic colorectal cancer (mCRC) - the PANAMA trial (AIO KRK 0212).

AUTHOR(S)

Dominik P. Modest, Meinolf Karthaus, Stefan Fröhlich, Ullrich Graeven, Lothar Müller, Alexander Koenig, Ludwig F. Von Weikersthal, Karel Caca, Albrecht Kretschmar, Eray Goekkurt, Siegfried Haas, Annika Kurreck, Arndt Stahler, Volker Heinemann, Swantje Held, Armin Jarosch, David Horst, Stefan Kasper, Sebastian Stintzing, Tanja Trarbach

ABSTRACT

3503

Oral maintenance capecitabine versus active monitoring for patients with metastatic colorectal cancer (mCRC) who are stable or responding after 16 weeks of first-line treatment: Results from the randomized FOCUS4-N trial.

AUTHOR(S)

Richard Adams, David Fisher, Janet Graham, Jenny F. Seligmann, Matthew Seymour, Richard S. Kaplan, Emma Yates, Susan D. Richman, Philip Quirke, Rachel Butler, Ewan Brown, Stephen Falk, Fiona J. Collinson, Richard H. Wilson, Louise C. Brown, Tim Maughan

ABSTRACT

3504

When Less Is More: Maintenance Strategies

DISCUSSANT

Wen Wee Ma, MBBS | Division of Medical Oncology, Mayo Clinic

Panel Question and Answer with Drs. Bekaii-Saab, Eng, Modest, Adams, and Ma

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients (pts) with HER2-expressing metastatic colorectal cancer (mCRC): Final results from a phase 2, multicenter, open-label study (DESTINY-CRC01).

AUTHOR(S)

Takayuki Yoshino, Maria Di Bartolomeo, Kanwal P. Raghav, Toshiki Masuishi, Fotios Loupakis, Hisato Kawakami, Kensei Yamaguchi, Tomohiro Nishina, Zev A. Wainberg, Elena Elez, Javier Rodriguez, Marwan Fakih, Fortunato Ciardiello, Kapil Saxena, Kojiro Kobayashi, Emarjola Bako, Yasuyuki Okuda, Gerold Meinhardt, Axel Grothey, Salvatore Siena

ABSTRACT

3505

Phase II study of anti-EGFR rechallenge therapy with panitumumab driven by circulating tumor DNA molecular selection in metastatic colorectal cancer: The CHRONOS trial.

AUTHOR(S)

Andrea Sartore-Bianchi, Filippo Pietrantonio, Sara Lonardi, Benedetta Mussolin, Francesco Rua, Elisabetta Fenocchio, Alessio Amatu, Salvatore Corallo, Chiara Manai, Federica Tosi, Paolo Manca, Francesca Daniel, Valter Torri, Angelo Vanzulli, Giovanni Cappello, Caterina Marchiò, Anna Sapino, Silvia Marsoni, Salvatore Siena, Alberto Bardelli

ABSTRACT

3506

The TRUSTY study: A randomized phase 2/3 study of trifluridine/tipiracil plus bevacizumab versus irinotecan and fluoropyrimidine plus bevacizumab as second-line treatment in patients with metastatic colorectal cancer.

AUTHOR(S)

Yasutoshi Kuboki, Tetsuji Terazawa, Toshiki Masuishi, Masato Nakamura, Jun Watanabe, Hitoshi Ojima, Yudai Shinohara, Masahito Kotaka, Hiroki Hara, Takashi Ohta, Eiji Oki, Yu Sunakawa, Soichiro Ishihara, Hiroya Taniguchi, Takako E. Nakajima, Satoshi Morita, Kuniaki Shirao, Takayuki Yoshino

ABSTRACT

3507

Expanding Therapeutic Strategies in Second Line and Beyond: More to Learn

DISCUSSANT

Guillem Argiles, MD | Vall d'Hebron University Hospital

Panel Question and Answer with Drs. Bekaii-Saab, Eng, Yoshino, Sartore-Bianchi, Kuboki, and Argiles

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Head and Neck Cancer

Monday, June 7, 8:45 PM - 11:45 PM CEST

Back to Program

Showing 16 Presentations

<https://meetinglibrary.asco.org/session/13637>

Chair

CHAIR

Roselle B. De Guzman, MD | Manila Central University-FDTMF Hospital

Chair

CHAIR

Jochen H. Lorch, MD | Dana-Farber Cancer Institute

Camrelizumab versus placebo combined with gemcitabine and cisplatin for recurrent or metastatic nasopharyngeal carcinoma: A randomized, double-blind, phase 3 trial.

AUTHOR(S)

Li Zhang, Yunpeng Yang, Song Qu, Jin-Gao Li, Chaosu Hu, Mingjun Xu, Weidong Li, Ting Zhou, Liangfang Shen, Hui Wu, Jin Yi Lang, Guangyuan Hu, Zhanxiong Luo, Zhichao Fu, Shenhong Qu, Ben Zhang, Qing Yang, Xiaojing Zhang, Jianjun Zou, Wenfeng Fang

ABSTRACT

6000

Cabozantinib versus placebo in patients with radioiodine-refractory differentiated thyroid cancer who have progressed after prior VEGFR-targeted therapy: Results from the phase 3 COSMIC-311 trial.

AUTHOR(S)

Marcia S. Brose, Bruce Robinson, Steven I. Sherman, Barbara Jarzab, Chia-Chi Lin, Fernanda Vaisman, Ana Hoff, Erika Hitre, Daniel W. Bowles, Leonardo Faoro, Kamalika Banerjee, Jennifer Oliver, Bhumsuk Keam, Jaume Capdevila

ABSTRACT

6001

A phase II trial cohort of nivolumab plus ipilimumab in patients (Pts) with recurrent/metastatic salivary gland cancers (R/M SGCs).

AUTHOR(S)

Bharat Burman, Eric J. Sherman, Lara Dunn, James V. Fettes, Loren S. Michel, Luc G. Morris, Irina Ostrovnaya, Sofia Haque, David G. Pfister, Alan L. Ho

ABSTRACT

6002

Targeted Therapy for Recurrent/Metastatic Head and Neck Cancers

DISCUSSANT

Nicole Grace Chau, MD | BC Cancer Agency

Panel Question and Answer with Drs. Lorch, De Guzman, Zhang, Brose, Burman, and Chau

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Metronomic capecitabine as adjuvant therapy in locoregionally advanced nasopharyngeal carcinoma: A phase 3, multicenter, randomized controlled trial.

AUTHOR(S)

Jun Ma, Yu-Pei Chen, Ying Sun, Qin Zhou, Kun-Yu Yang, Feng Jin, Xiao-Dong Zhu, Mei Shi, Guoqing Hu, Yan Sun, Hong-Fen Wu, Hui Wu, Qin Lin, Hui Wang, Ye Tian, Ning Zhang, Xicheng Wang, Liangfang Shen, Fangyun Xie, Xu Liu

ABSTRACT

6003

Adjuvant capecitabine in locoregionally advanced nasopharyngeal carcinoma: A multicenter randomized controlled phase III trial.

AUTHOR(S)

Jingjing Miao, Lin Wang, Sze Huey Tan, Jin-Gao Li, Junlin Yi, Ye Zhang, Xiaochang Gong, Xiang Yanqun, Qiu-Yan Chen, Mingyuan Chen, Xing Lv, Weixiong Xia, Lin-Quan Tang, Xiao-Wu Deng, Xiang Guo, Hai-Qiang Mai, Fei Han, Melvin L. Chua, Chong Zhao

ABSTRACT

6005

Induction or Adjuvant Therapy for Nasopharyngeal Carcinoma

DISCUSSANT

Herbert H. F. Loong, MBBS | The Chinese University of Hong Kong

Panel Question and Answer with Drs. Lorch, De Guzman, Ma, Miao, and Loong

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Association of pathological response to neoadjuvant pembrolizumab with tumor PD-L1 expression and high disease-free survival (DFS) in patients with resectable, local-regionally advanced, head and neck squamous cell carcinoma (HNSCC).

AUTHOR(S)

Trisha M. Wise-Draper, Vinita Takiar, Michelle L. Mierzwa, Keith Casper, Sarah Palackdharry, Francis P. Worden, Matthew O. Old, Neal E. Dunlap, John M. Kaczmar, Yash Patil, Muhammad Kashif K. Riaz, Aubrey Hamilton, Ann M. Gillenwater, Benjamin H. Hinrichs, Diana Bell, Casey Allen, Sheena M. Lanverman, Li Zhang, J. Jack Lee, Maura L. Gillison

ABSTRACT

6006

Primary results of the phase II CheckRad-CD8 trial: First-line treatment of locally advanced head and neck squamous cell carcinoma (HNSCC) with double checkpoint blockade and radiotherapy dependent on intratumoral CD8+ T-cell infiltration.

AUTHOR(S)

Markus Hecht, Markus Eckstein, Sandra Rutzner, Jens von der Grün, Thomas Illmer, Gunther Klautke, Simon Laban, Matthias G. Hautmann, Thomas Brunner, Balint Tamaskovics, Axel Hinke, Benjamin Frey, Sabine Semrau, Arndt Hartmann, Panagiotis Balcermpas, Wilfried Budach, Udo S. Gaipl, Heinrich Iro, Antoniu-Oreste Gostian, Rainer Fietkau

ABSTRACT

6007

Enhanced pathologic tumor response with two cycles of neoadjuvant pembrolizumab in surgically resectable, locally advanced HPV-negative head and neck squamous cell carcinoma (HNSCC).

AUTHOR(S)

Ravindra Uppaluri, Rebecca Chernock, Mena Mansour, Ryan Jackson, Jason Rich, Patrik Pipkorn, Randal C. Paniello, Sidharth Puram, Jose P. Zevallos, Donald J. Annino Jr., Laura A. Goguen, Luc Morris, Robert I. Haddad, Glenn J. Hanna, Peter J. Oppelt, Lara Dunn, Jessica C. Ley, Dorina Kallogjeri, Ann Marie Egloff, Douglas Adkins

ABSTRACT

6008

Pathologic Responses As Predictors of Clinical Benefit

DISCUSSANT

Lisa Rooper | John Hopkins University

Panel Question and Answer with Drs. Lorch, De Guzman, Wise-Draper, Hecht, Uppaluri, and Rooper

PANEL SPEAKER

Developmental Therapeutics—Immunotherapy

Monday, June 7, 9:00 PM - 12:00 AM CEST

Back to Program

Showing 16 Presentations

<https://meetinglibrary.asco.org/session/13616>

Chair

CHAIR

Amita Patnaik, MD | START

Chair

CHAIR

Gerald Steven Falchook, MD | Sarah Cannon Research Institute

Clinical activity of systemic VSV-IFN β -NIS oncolytic virotherapy in patients with relapsed refractory T-cell lymphoma.

AUTHOR(S)

Joselle Cook, Kah W. Peng, Susan M. Geyer, Brenda F. Ginos, Amylou C. Dueck, Nandakumar Packiriswamy, Lianwen Zhang, Beth Brunton, Baskar Balakrishnan, Thomas E. Witzig, Stephen M. Broski, Mrinal Patnaik, Francis Buadi, Angela Dispenzieri, Morie A. Gertz, Leif P. Bergsagel, S. V. Rajkumar, Shaji Kumar, Stephen J. Russell, Martha Lacy

ABSTRACT

2500

Phase II evaluation of the triple combination of PDS0101, M9241, and bintrafusp alfa in patients with HPV 16 positive malignancies.

AUTHOR(S)

Julius Strauss, Charalampos S. Floudas, Houssein Abdul Sater, Michell Manu, Elizabeth Lamping, Deneise C. Francis, Lisa M. Cordes, Jenn Marte, Renee N. Donahue, Caroline Jochems, Jason Redman, Ravi A. Madan, Marijo Bilusic, Fatima Karzai, Scott Norberg, Christian S. Hinrichs, Lauren V. Wood, Frank K. Bedu-Addo, Jeffrey Schlom, James L. Gulley

ABSTRACT

2501

First report of the safety/tolerability and preliminary antitumor activity of HB-201 and HB-202, an arenavirus-based cancer immunotherapy, in patients with HPV16+ cancers.

AUTHOR(S)

Alan L. Ho, Marshall R. Posner, Jiaxin Niu, Siqing Fu, Rom S. Leidner, Alexander T. Pearson, Ki Y. Chung, Debra L. Richardson, Ding Wang, Agustin Pimentel, Jorge J. Nieva, Ari Rosenberg, Bharat Burman, Corinne Iacobucci, Xiaoping Qing, Andy Hwang, Kia Katchar, Katia Schlienger, Igor Matushansky, David G. Pfister

ABSTRACT

2502

Going Viral: Virus Targeted Immunotherapy

DISCUSSANT

John Robert Hyngstrom, FACS, MD | The Univ of Utah

Panel Question and Answer with Drs. Falchook, Patnaik, Cook, Strauss, Ho, and Hyngstrom

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Phase 1 study of SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF- β , in patients with advanced solid tumors.

AUTHOR(S)

Dan Liu, Jifang Gong, Tianshu Liu, KunYan Li, Xianli Yin, Yunpeng Liu, Yongsheng Wang, Linna Wang, Wenliang Wang, Yanyan Zhang, Lin Shen

ABSTRACT

2503

COM701 with or without nivolumab: Results of an ongoing phase 1 study of safety, tolerability and preliminary antitumor activity in patients with advanced solid malignancies (NCT03667716).

AUTHOR(S)

Daniel A. Vaena, Gini F. Fleming, Bartosz Chmielowski, Manish Sharma, Erika P. Hamilton, Ryan J. Sullivan, Dale R. Shepard, Kyriakos P. Papadopoulos, Amita Patnaik, Adam ElNaggar, Adeboye H. Adewoye, Robina Smith, Emerson A. Lim, Ecaterina E. Dumbrava, Drew W. Rasco

ABSTRACT

2504

Preliminary clinical and biologic results of GB1275, a first-in-class oral CD11b modulator, alone and with pembrolizumab, in advanced solid tumors (KEYNOTE A36).

AUTHOR(S)

Haeseong Park, Johanna C. Bendell, Wells A. Messersmith, Drew W. Rasco, Johann S. De Bono, John H. Strickler, Lei Zhou, Laura L. Carter, Jean-Marie Bruey, Jack Li, Kartik Raghupathi, Jakob Dupont, Marya F. Chaney, Wungki Park

ABSTRACT

2505

Preliminary results of a phase II study of alrizomadlin (APG-115), a novel, small-molecule MDM2 inhibitor, in combination with pembrolizumab in patients (pts) with unresectable or metastatic melanoma or advanced solid tumors that have failed immuno-oncologic (I-O) drugs.

AUTHOR(S)

Anthony W. Tolcher, James A. Reeves Jr., Meredith McKean, Bartosz Chmielowski, Joseph T. Beck, Montaser F. Shaheen, Neeta Somaiah, Melissa Wilson, Alexander I. Spira, Joseph J. Drabick, Yuefen Tang, Robert Winkler, Mingyu Li, Mohammad Ahmad, Ming Lu, Zhiyan Liang, Dajun Yang, Yifan Zhai

ABSTRACT

2506

Panel Question and Answer with Drs. Falchook, Patnaik, Liu, Vaena, Park, and Tolcher

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Safety and efficacy of a novel anti-CD20/CD19 bi-specific CAR T-cell therapy (C-CAR039) in relapsed or refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL).

AUTHOR(S)

Aibin Liang, Lili Zhou, Ping Li, Wenjuan Yu, Min Yang, Yangyang Xu, Shiguang Ye, Judy Zhu, Jiaqi Huang, Yan Zhang, Lanfang Li, Jing Zhao, Jing Li, Chengxiao Zheng, Kevin Zhu, Liping Lan, Huilai Zhang, Daobin Zhou, Yihong Yao, Jie Jin

ABSTRACT

2507

Safety and efficacy of a novel anti-CD20 chimeric antigen receptor (CAR)-T cell therapy in relapsed/refractory (r/r) B-cell non-Hodgkin lymphoma (B-NHL) patients after failing CD19 CAR-T therapy.

AUTHOR(S)

Aibin Liang, Shiguang Ye, Ping Li, Jiaqi Huang, Shigui Zhu, Xin Yao, Lili Zhou, Yangyang Xu, Judy Zhu, Chengxiao Zheng, Shiyi Chen, Liping Lan, Xiaoteng Lv, Yutian Wei, Michael Humphries, Yihong Yao

ABSTRACT

2508

CD20-Directed CAR T

DISCUSSANT

Tara K. Gregory, MD | Rocky Mtn Blood and Marrow Transplant Prog

Panel Question and Answer with Drs. Falchook, Patnaik, Liang, and Gregory

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Genitourinary Cancer—Prostate, Testicular, and Penile

Tuesday, June 8, 2:00 PM - 5:00 PM CEST

Back to Program

Showing 16 Presentations

<https://meetinglibrary.asco.org/session/13631>

Chair

CHAIR

Joaquin Mateo, MD, PhD | Vall d'Hebron Institute of Oncology and Vall d'Hebron University Hospital

Chair

CHAIR

Eugene Shenderov, MD, PhD | Johns Hopkins University School of Medicine

A phase 3 trial with a 2x2 factorial design of abiraterone acetate plus prednisone and/or local radiotherapy in men with *de novo* metastatic castration-sensitive prostate cancer (mCSPC): First results of PEACE-1.

AUTHOR(S)

Karim Fizazi, Xavier Maldonado, Stéphanie Foulon, Guilhem Roubaud, Raymond S. McDermott, Aude Flechon, Bertrand F. TOMBAL, Stephane Supiot, Dominik R. Berthold, Philippe Ronchin, Gabriel Kacso, Gwenaëlle Gravis, Fabio Calabro, Jean F. Berdah, Ali Hasbini, Marlon Silva, Antoine Thiery-Vuillemin, Isabelle Rieger, Marie Laure Tanguy, Alberto Bossi

ABSTRACT

5000

SWOG S1216: A phase III randomized trial comparing androgen deprivation therapy (ADT) plus TAK-700 with ADT plus bicalutamide in patients (pts) with newly diagnosed metastatic hormone-sensitive prostate cancer (mHSPC) (NCT01809691).

AUTHOR(S)

Neeraj Agarwal, Catherine Tangen, Maha H. Hussain, Shilpa Gupta, Melissa Plets, Primo "Lucky" N. Lara Jr., Andrea Harzstark, Przemyslaw Twardowski, Channing J. Paller, Dylan M. Zylla, Matthew R. Zibelman, Ellis G. Levine, Bruce J. Roth, Amir Goldkorn, Daniel A. Vaena, Manish Kohli, Tony Crispino, Nicholas J. Vogelzang, Ian M. Thompson Jr., David I. Quinn

ABSTRACT

5001

Decreased fracture rate by mandating bone protecting agents in the EORTC 1333/PEACEIII trial combining Ra223 with enzalutamide versus enzalutamide alone: An updated safety analysis.

AUTHOR(S)

Silke Gillesen, Ananya Choudhury, Alejo Rodriguez-Vida, Franco Nole, Enrique Gallardo Diaz, Thierry A. Roumeguere, Gedske Daugaard, Yohann Lorient, Fred Saad, Raymond S. McDermott, Anouk Neven, Beatrice Fournier, Bertrand F. TOMBAL

ABSTRACT

5002

Can We Define the Standard of Therapy for First-Line Metastatic Hormone-Sensitive Prostate Cancer?

DISCUSSANT

Lisa Horvath, PhD, MBBS, FRACP | Sydney Cancer Centre

Panel Question and Answer with Drs. Shenderov, Mateo, Fizazi, Agarwal, Gillesen, and Horvath

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Ancestral characterization of the genomic landscape, comprehensive genomic profiling utilization, and treatment patterns may inform disparities in advanced prostate cancer: A large-scale analysis.

AUTHOR(S)

Smruthy Sivakumar, Jessica K. Lee, Jay A. Moore, Julia Hopkins, Justin Newberg, Alexa B. Schrock, Randy Vince, Idalid I. Franco, Crystal S. Seldon, JENNIFER MILLS, Jeffrey M. Venstrom, Brandon A. Mahal

ABSTRACT

5003

Association of increased intensity of prostate-specific antigen screening in younger African American men with improved prostate cancer outcomes.

AUTHOR(S)

Edmund M. Qiao, Nikhil V. Kotha, Vinit Nalawade, Alexander S. Qian, Rohith S. Voora, Tyler J. Nelson, Tyler F. Stewart, John K. Parsons, Brent S. Rose

ABSTRACT

5004

A prospective ValiDation of the genomic classifier defines high-metastasis risk in a subset of African American men with early localized prostate cancer: VanDAAM study.

AUTHOR(S)

Kosj Yamoah, Jasreman Dhillon, Peter A. Johnstone, Julio M. Pow-Sang, Elai Davicioni, Angelina Fink, Amanda C. DeRenzis, G. Daniel Grass, Roger Li, Brandon J. Manley, Kenneth L. Gage, Evangelia Katsoulakis, Ryan J. Burri, Andrew Leone, Cesar E. Ercole, Joshua D. Palmer, Neha Vapiwala, Curtiland Deville, Timothy Rebbeck, Adam P. Dicker

ABSTRACT

5005

Disparities in Prostate Cancer: Are We Making Progress?

DISCUSSANT

Peter C. Black, MD | Vancouver Prostate Centre, University of British Columbia

Panel Question and Answer with Drs. Shenderov, Mateo, Sivakumar, Qiao, Yamoah, and Black

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Testicular cancer in the cisplatin era: Causes of death and mortality rates in a population-based cohort.

AUTHOR(S)

Ragnhild Hellesnes, Tor Åge Myklebust, Sophie D. Fossa, Roy M. Bremnes, Asa Karlsdottir, Oivind Kvammen, Torgrim Tandstad, Tom Wilsaard, Helene F. Negaard, Hege Sagstuen S. Haugnes

ABSTRACT

5006

Late relapse of germ cell tumors: Detection and treatment outcomes.

AUTHOR(S)

Noah H. Richardson, Sandra K. Althouse, Ryan Ashkar, Clint Cary, Timothy A. Masterson, Richard Foster, Nasser H. Hanna, Lawrence H. Einhorn, Nabil Adra

ABSTRACT

5007

Late Relapses and Toxicities in Testicular Cancer: Good and Bad News?

DISCUSSANT

Siamak Daneshmand, MD | USC Norris Comprehensive Cancer Center

Panel Question and Answer with Drs. Shenderov, Mateo, Hellesnes, Richardson, and Daneshmand

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Hematologic Malignancies—Plasma Cell Dyscrasia

Tuesday, June 8, 2:00 PM - 5:00 PM CEST

Back to Program

Showing 17 Presentations

<https://meetinglibrary.asco.org/session/13649>

Chair

CHAIR

Philip L. McCarthy, MD | Roswell Park Cancer Institute

Chair

CHAIR

Suzanne Lentzsch, MD, PhD | Columbia University

Upfront autologous stem cell transplantation (ASCT) versus carfilzomib-cyclophosphamide-dexamethasone (KCd) consolidation with K maintenance in transplant-eligible, newly diagnosed (NDTE) multiple myeloma (MM).

AUTHOR(S)

Kwee Yong, Marquita Camilleri, William Wilson, Karthink Ramasamy, Matthew J. Streetly, Jonathan Sive, Ceri Bygrave, Michael A. Chapman, Ruth De Tute, Selina J. Chavda, Elizabeth Phillips, Maria Cuadrado, Gavin Pang, Richard Jenner, Tushhar Dadaga, Sumaiya Kamora, James D. Cavenagh, Laura Clifton-Hadley, Roger G. Owen, Rakesh Popat

ABSTRACT

8000

Depth of response and minimal residual disease status in ultra high-risk multiple myeloma and plasma cell leukemia treated with daratumumab, bortezomib, lenalidomide, cyclophosphamide and dexamethasone (Dara-CVRd): Results of the UK optimum/MUKnine trial.

AUTHOR(S)

Martin F. Kaiser, Andrew Hall, Katrina Walker, Ruth De Tute, Sadie Roberts, Emma Ingleson, Kristian Bowles, Mamta Garg, Anand Lokare, Christina Messiou, Graham H. Jackson, Guy Pratt, Gordon Cook, Mark Drayson, Roger G. Owen, Sarah R. Brown, Matthew Jenner

ABSTRACT

8001

Carfilzomib-based induction/consolidation with or without autologous transplant (ASCT) followed by lenalidomide (R) or carfilzomib-lenalidomide (KR) maintenance: Efficacy in high-risk patients.

AUTHOR(S)

Francesca Gay, Roberto Mina, Delia Rota-Scalabrini, Monica Galli, Angelo Belotti, Elena Zamagni, Luca Bertamini, Renato Zambello, Barbara Gamberi, Giovanni De Sabbata, Giuseppe Pietrantuono, Andrea Capra, Anna Pascarella, Anna Marina Liberati, Salvatore Palmieri, Angela Cuoghi, Massimo Offidani, Michele Cavo, Pellegrino Musto, Mario Boccadoro

ABSTRACT

8002

Evolution of Modern Total Therapy in Myeloma

DISCUSSANT

Gordon Cook | St James's Institute of Oncology, Leeds Teaching Hospitals NHS Trust and University of Leeds

Panel Question and Answer with Drs. McCarthy, Lentzsch, Yong, Kaiser, Gay, and Cook

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Subcutaneous daratumumab + bortezomib, cyclophosphamide, and dexamethasone (VCd) in patients with newly diagnosed light chain (AL) amyloidosis: Updated results from the phase 3 ANDROMEDA study.

AUTHOR(S)

Efstathios Kastritis, Vaishali Santhorawala, Giampaolo Merlini

ABSTRACT

8003

Daratumumab (DARA) maintenance or observation (OBS) after treatment with bortezomib, thalidomide and dexamethasone (VTd) with or without DARA and autologous stem cell transplant (ASCT) in patients (pts) with newly diagnosed multiple myeloma (NDMM): CASSIOPEIA Part 2.

AUTHOR(S)

Philippe Moreau, Pieter Sonneveld

ABSTRACT

8004

What More Can Anti-CD38 Monoclonal Antibodies Offer?

DISCUSSANT

Caitlin Costello, MD | Department of Medicine, Division of Blood and Marrow Transplantation, Moores Cancer Center, University of California San Diego

Panel Question and Answer with Drs. McCarthy, Lentzsch, Kastritis, Moreau, and Costello

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

Ciltacabtagene autoleucel, a B-cell maturation antigen (BCMA)-directed chimeric antigen receptor T-cell (CAR-T) therapy, in relapsed/refractory multiple myeloma (R/R MM): Updated results from CARTITUDE-1.

AUTHOR(S)

Saad Z. Usmani, Jesus G. Berdeja, Deepu Madduri, Andrzej J. Jakubowiak, Mounzer Agha, Adam D. Cohen, Parameswaran Hari, Tzu-Min Yeh, Yungsi Olyslager, Arnob Banerjee, Carolyn C. Jackson, Alicia J. Allred, Enrique Zudaire, William Deraedt, Xiaoling Wu, Marlene Carrasco-Alfonso, Muhammad Akram, Yi Lin, Thomas G. Martin, Sundar Jagannath

ABSTRACT

8005

Efficacy and safety of elranatamab (PF-06863135), a B-cell maturation antigen (BCMA)-CD3 bispecific antibody, in patients with relapsed or refractory multiple myeloma (MM).

AUTHOR(S)

Nizar J. Bahlis, Noopur S. Raje, Caitlin Costello, Bhagirathbhai R. Dholaria, Melhem M. Solh, Moshe Y. Levy, Michael H. Tomasson, Harman Dube, Feng Liu, Kai H. Liao, Cynthia Basu, Athanasia Skoura, Edward M. Chan, Suzanne Trudel, Andrzej J. Jakubowiak, Michael P. Chu, Cristina Gasparetto, Andrew Dalovisio, Michael Sebag, Alexander M. Lesokhin

ABSTRACT

8006

Updated phase 1 results of teclistamab, a B-cell maturation antigen (BCMA) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

AUTHOR(S)

Amrita Y. Krishnan, Alfred L. Garfall, Maria-Victoria Mateos, Niels W. van de Donk, Hareth Nahi, Jesús F. San-Miguel, Albert Oriol, Laura Rosiñol, Ajai Chari, Manisha Bhutani, Lionel Karlin, Lotfi Benboubker, Lixia Pei, Raluca Verona, Suzette Girgis, Tara Stephenson, Jenna D. Goldberg, Arnob Banerjee, Saad Z. Usmani

ABSTRACT

8007

Updated results of a phase 1, first-in-human study of talquetamab, a G protein-coupled receptor family C group 5 member D (GPRC5D) × CD3 bispecific antibody, in relapsed/refractory multiple myeloma (MM).

AUTHOR(S)

Jesus G. Berdeja, Amrita Y. Krishnan, Albert Oriol, Niels W. van de Donk, Paula Rodríguez-Otero, Elham Askari, Maria-Victoria Mateos, Monique C. Minnema, Luciano J. Costa, Raluca Verona, Suzette Girgis, Thomas Prior, Brandi W. Hilder, Jeffery S. Russell, Jenna D. Goldberg, Ajai Chari

ABSTRACT

8008

Let's Take a T-Cell-fy...

DISCUSSANT

Surbhi Sidana, MD | Cleveland Clinic Foundation

Panel Question and Answer with Drs. McCarthy, Lentzsch, Usmani, Bahlis, Krishnan, Berdeja, and Sidana

PANEL SPEAKER

Panel Discussion | American Society of Clinical Oncology

II. POSTER DISCUSSION PRESENTATIONS

Central Nervous System Tumors

[Back to Program](#)

Showing 16 Presentations

<https://meetinglibrary.asco.org/session/13614>

Long-term results of the GEINO 1401 TRIAL: Randomizing patients to stop or to continue temozolomide until 12 cycles.

AUTHOR(S)

Marta Domenech, Carles Fabregat-Franco, Carlos Mesia, Anna Esteve, Sonia D. Berron, Estela Pineda, Regina Gironés Sarrió, Ramon De las peñas, Jose Fuster, Miriam Alonso, Clara Olier, Pedro Perez, Alfonso Berrocal, Marta Covela Rúa, Ainhoa Hernandez Gonzalez, Cristina Carrato, Carolina Sanz, José M. Sepulveda Sánchez, Carmen Balana

ABSTRACT

2013

Preliminary results of the abemaciclib arm in the Individualized Screening Trial of Innovative Glioblastoma Therapy (INSIGhT): A phase II platform trial using Bayesian adaptive randomization.

AUTHOR(S)

Eudocia Q. Lee, Lorenzo Trippa, Geoffrey Fell, Rifaquat Rahman, Isabel Arrillaga-Romany, Mehdi Touat, Jan Drappatz, Mary R. Welch, Evanthia Galanis, Manmeet S. Ahluwalia, Howard Colman, Louis B. Nabors, Jaroslaw T. Hepel, David Schiff, David M. Meredith, E. Antonio Chiocca, David A. Reardon, Keith L. Ligon, Brian M. Alexander, Patrick Y. Wen

ABSTRACT

2014

Randomized phase 2 study of nivolumab (nivo) plus either standard or reduced dose bevacizumab (bev) in recurrent glioblastoma (rGBM).

AUTHOR(S)

Manmeet S. Ahluwalia, Yasmeen Rauf, Hong Li, Patrick Y. Wen, David M. Peereboom, David A. Reardon

ABSTRACT

2015

Digital measurement of functional status of patients with glioblastoma.

AUTHOR(S)

Yasaman Demastani, Minesh P. Mehta, Howard Colman, Kevin A. Camphausen, Michael Weller, Evanthia Galanis, Martin J. Van Den Bent, John F. De Groot, Andrew B. Lassman, Andreas F. Hottinger, Louis B. Nabors, J Paul Duic, Kai Li, Yang Liu, Shijie Tang, Sharon Tamir, Eran Shacham, Jatin J. Shah, Sharon Shacham, Patrick Y. Wen

ABSTRACT

2016

Superior overall survival (OS) and disease-free survival (DFS) predictions for patients with glioblastoma multiforme (GBM) using Cellworks Singula: myCare-022-03.

AUTHOR(S)

Patrick Y. Wen, Michael Castro, Drew Watson, Shweta Kapoor, Ashish Agrawal, Aftab Alam, Kunal G. Roy, Swaminathan Rajagopalan, Kabya Basu, Deepak A. Lala, Nirjhar Mundkur, Jim Christie, Anusha Pampana, Sayani Basu, Diwyanshu Sahu, Yugandhara Narvekar, Divya Singh, Prashant Nair, Manmeet S. Ahluwalia

ABSTRACT

2017

Refining GBM Treatment

DISCUSSANT

Susan Marina Chang, MD | University of California, San Francisco

A multisite clinical trial of spectroscopic MRI-guided radiation dose escalation for newly-diagnosed glioblastomas.

AUTHOR(S)

Hui-Kuo G. Shu, Eric A. Mellon, Lawrence Kleinberg, Saumya S. Gurbani, Karthik K. Ramesh, Mohammed Goryawala, Sulaiman A. Sheriff, Vicki Huang, Peter B. Barker, Andrew Maudsley, Eduard Schreibmann, Brent D. Weinberg, Hyunsuk Shim

ABSTRACT

2018

Gene expression signature to predict radiation response in lower-grade gliomas.

AUTHOR(S)

David C. Qian, Joseph A. Marascio, Stewart G. Neill, Kimberly B. Hoang, Jeffrey J. Olson, Bree R. Eaton, Hui-Kuo G. Shu, Jim Zhong

ABSTRACT

2019

Optimizing Radiation Therapy for Glioma

DISCUSSANT

Jann Nagina Sarkaria, MD | Mayo Clinic

Comparison of immune microenvironment between primary lung tumors and paired brain metastatic tumors.

AUTHOR(S)

Likun Chen, Lihong Wu, Meichen Li, Huan Chen, Lijia Wu, Pei Hao, Ji He

ABSTRACT

2020

Profiling of immune checkpoint biomarkers by multiplex immunofluorescence in breast cancer brain metastases.

AUTHOR(S)

Gaia Griguolo, Anna Tosi, Valentina Guarneri, Maria Vittoria Dieci, Susan Fineberg, Annavera Ventura, Luc Bauchet, Jack Jacob, Valerie Rigau, William Jacot, Antonio Rosato, Amelie Darlix, Pierfranco Conte

ABSTRACT

2021

Phase 1, 2 trial of concurrent anti-PD1 and stereotactic radiosurgery for melanoma and non-small cell lung cancer brain metastases (NCT02858869).

AUTHOR(S)

Mohammad K. Khan, Tahseen Nasti, Troy Kleber, David H. Lawson, Melinda L. Yushak, Jeffrey M. Switchenko, David Wallington, Taofeek K. Owonikoko, Suresh S. Ramalingam, Khadija Kirmani, Rafi Ahmed

ABSTRACT

2022

A phase II trial combining nivolumab and stereotactic brain radiosurgery for treatment of brain metastases in patients with NSCLC.

AUTHOR(S)

Philip Wong, Marie Florescu, Marc-Emile Plourde, Valerie Panet-Raymond, Michel Pavic, Scott P. Owen, Laurence Masson-Cote, Cynthia Menard, Bertrand Routy, Mustapha Tehfe, Normand Blais, David Roberge, Laura Masucci

ABSTRACT

2023

Immune Checkpoint Inhibitors and SRS: Triggering Synergy?

DISCUSSANT

Jing Li, MD, PhD | The University of Texas MD Anderson Cancer Center

Multi-center, single arm phase II study of the dual mTORC1/mTORC2 inhibitor vistusertib for patients with recurrent or progressive grade II-III meningiomas.

AUTHOR(S)

Scott R. Plotkin, Priya Kumthekar, Patrick Y. Wen, Frederick G. Barker II, Anat Stemmer-Rachamimov, Roberta L. Beauchamp, Justin T. Jordan, Alona Muzikansky, Vijaya Ramesh

ABSTRACT

2024

Targeted Treatment for Meningioma

DISCUSSANT

Warren P. Mason, MD | Princess Margaret Cancer Centre, University Health Network

Developmental Therapeutics—Immunotherapy

Back to Program

Showing 16 Presentations

<https://meetinglibrary.asco.org/session/13617>

Phase Ib study of the anti-TGF- β monoclonal antibody (mAb) NIS793 combined with spartalizumab (PDR001), a PD-1 inhibitor, in patients (pts) with advanced solid tumors.

AUTHOR(S)

Todd M. Bauer, Chia-Chi Lin, Richard Greil, Maria-Elisabeth Goebeler, Marie Luise Huetter-Kroenke, Ignacio Garrido-Laguna, Armando Santoro, Antonella Perotti, Anna Spreafico, Thomas Yau, Markus Joerger, Viviana Cremasco, Mirek Dostalek, Marc Pelletier, Louise Barys, Darlene Lu, Vicky Katsanou, Claire Fabre, Toshihiko Doi

ABSTRACT

2509

Safety, pharmacokinetic and pharmacodynamic results from dose escalation of SAR439459, a TGF β inhibitor, as monotherapy or in combination with cemiplimab in a phase 1/1b study.

AUTHOR(S)

Stephen K. Williamson, F. S. Hodi, Melissa L. Johnson, Minal A. Barve, Dejan Juric, Joaquina C. Baranda, Reva E. Schneider, Todd M. Bauer, Tun Tun Lin, Rui Wang, Amele Amrate, Helene Guillemin-Paveau, Ryan J. Sullivan

ABSTRACT

2510

Preliminary safety, pharmacokinetics (PK), pharmacodynamics (PD) and clinical efficacy of uliledlimab (TJ004309), a differentiated CD73 antibody, in combination with atezolizumab in patients with advanced cancer.

AUTHOR(S)

Francisco Robert, Ecaterina E. Dumbrava, Yan Xing, Elizabeth Mills, James L. Freddo, Charles P. Theuer, Bonne J. Adams, James Lawrence, Alicia A. Trigeiro, Claire Xu, Yuan Meng, Linda Lee, Yonggang Zhao, Jerry Wang, Huaqiong J. Shen, Michael S. Gordon

ABSTRACT

2511

Overcoming Resistance by Targeting Tumor Microenvironment

DISCUSSANT

Maria De Miguel, MD, PhD | START Madrid-CIOCC, Centro Integral Oncológico Clara Campal, Hospital Universitario HM Sanchinarro

BDB001, an intravenously administered toll-like receptor 7 and 8 (TLR7/8) agonist, in combination with pembrolizumab in advanced solid tumors: Phase 1 safety and efficacy results.

AUTHOR(S)

Manish R. Patel, Anthony W. Tolcher, Drew W. Rasco, Melissa L. Johnson, Angela T. Alistar, Lixin Li, Alexander H. Chung, Robert H. Andtbacka

ABSTRACT

2512

ARTISTRY-1: Nemvaleukin alfa monotherapy and in combination with pembrolizumab in patients (pts) with advanced solid tumors.

AUTHOR(S)

Valentina Boni, Ira S. Winer, Lucy Gilbert, Ulka N. Vaishampayan, Seth D. Rosen, Jameel Muzaffar, Anna Spreafico, David F. McDermott, Quincy S. Chu, Olivier Dumas, Aman Chauhan, Arvind Chaudhry, Piotr Tomczak, MD, Debora S. Bruno, Yangchun Du, Ilda Bidollari, Jessica M. Rege, Marc S. Ernstoff, James F. Strauss, Vamsidhar Velcheti

ABSTRACT

2513

Preliminary results of a phase 1b study of fruquintinib plus sintilimab in advanced colorectal cancer.

AUTHOR(S)

Ye Guo, Weijie Zhang, Jieer Ying, Yanqiao Zhang, Yueyin Pan, Wensheng Qiu, Weiguo Su, Panfeng Tan, Hongyan Yin, Yan Wang, Yang Luo, Hui Zhou, Jin Li

ABSTRACT

2514

Safety and efficacy of AK112, an anti-PD-1/VEGF-A bispecific antibody, in patients with advanced solid tumors in a phase I dose escalation study.

AUTHOR(S)

Jermaine Coward, Anna R. Mislang, Sophia Frentzas, Charlotte R. Lemech, Adnan Nagrial, Xiaoping Jin, Baiyong Li, Zhongmin M. Wang, Kon Yew Kwek, Yu Xia

ABSTRACT

2515

Retooling the Tumor Microenvironment: Old Drugs, New Tricks

DISCUSSANT

Bartosz Chmielowski, MD, PhD | Division of Hematology-Oncology, David Geffen School of Medicine at UCLA

A first-in-human study of AO-176, a highly differentiated anti-CD47 antibody, in patients with advanced solid tumors.

AUTHOR(S)

Howard A. Burris III, Alexander I. Spira, Matthew H. Taylor, Oladapo O. Yeku, Joyce F. Liu, Pamela N. Munster, Erika P. Hamilton, Jacob S. Thomas, Frances Gatlin, Richard T. Penson, Thomas A. Abrams, Mallika S. Dhawan, Jacqueline M. Walling, John W. Frye, Kevin Romanko, Victoria Sung, Carrie Brachmann, Anthony B. El-Khoueiry

ABSTRACT

2516

First-in-human phase 1 dose escalation study of HX009, a novel recombinant humanized anti-PD-1 and CD47 bispecific antibody, in patients with advanced malignancies.

AUTHOR(S)

Aflah Roohullah, Vinod Ganju, Faming Zhang, Lei Zhang, Ting Yu, Kate Wilkinson, Adam Cooper, Paul de Souza

ABSTRACT

2517

Phase I INSIGHT platform trial: Advanced safety and efficacy data from stratum D evaluating feasibility and safety of eftilagimod alpha (soluble LAG-3 protein) combined with avelumab in advanced solid tumors.

AUTHOR(S)

Thorsten O. Goetze, Daniel W. Mueller, Mohammad-Reza Rafiyan, Dragan Kiselicki, Timursah Habibzade, Marina Schaaf, Regina Eickhoff, Elke Jäger, Salah-Eddin Al-Batran

ABSTRACT

2518

Bridging the Divide Between Innate and Adaptive Immunity

DISCUSSANT

Matthew R. Zibelman, MD | Fox Chase Cancer Center

Pan cancer analysis of the intra-tumoral microbiome's correlation with racial disparities.

AUTHOR(S)

Wei Tse Li, Matthew Uzelac, Jaideep Chakladar, Lindsay M. Wong, Aditi Gnanasekar, Abby C. Lee, Daniel John, Jay P. Lopez, Weg M. Ongkeko

ABSTRACT

2519

Safety and efficacy of neoadjuvant pembrolizumab in mismatch repair deficient localized/locally advanced solid tumors.

AUTHOR(S)

Kaysia Ludford, Kanwal P. Raghav, Mariela A. Blum Murphy, Nicole D. Fleming, Douglas A. Nelson, Michael S. Lee, Brandon G. Smaglo, Y. Nancy You, Matthew M. Tillman, Carlos Kamiya-Matsuoka, Selvi Thirumurthi, Craig Messick, Benny Johnson, Eduardo Vilar Sanchez, Arvind Dasari, Jane V. Thomas, Wai C. Foo, Wei Qiao, Scott Kopetz, Michael J. Overman

ABSTRACT

2520

Microbiome Racial Disparities and Neoadjuvant Strategies

DISCUSSANT

Jarushka Naidoo, MBBCh, MHS | Johns Hopkins Kimmel Comprehensive Cancer Center and Bloomberg-Kimmel Institute for Cancer Immunotherapy

Gastrointestinal Cancer—Colorectal and Anal

[Back to Program](#)

Showing 16 Presentations

<https://meetinglibrary.asco.org/session/13623>

CCTG CO.28 primary endpoint analysis: Neoadjuvant chemotherapy, excision and observation for early rectal cancer, the NEO trial.

AUTHOR(S)

Hagen F. Kennecke, Carl J. Brown, Jonathan M. Loree, Husein Moloo, Derek J. Jonker, Manoj Raval, Reilly Musselman, Grace Ma, Antonio Caycedo-Marulanda, Val Simianu, Sunil Patel, Lacey D. Pitre, Ramzi Helewa, Vallerie L. Gordon, Katerina Neumann, Max Sherry, Dongsheng Tu, Christopher J. O'Callaghan

ABSTRACT

3508

Survival and organ preservation according to clinical response after total neoadjuvant therapy in locally advanced rectal cancer patients: A secondary analysis from the organ preservation in rectal adenocarcinoma (OPRA) trial.

AUTHOR(S)

Hannah Thompson, Jin K. Kim, Jonathan B. Yuval, Floris Verheij, Sujata Patil, Marc J. Gollub, Abraham J. Wu, Meghan Lee, Aram F. Hezel, Jorge Marcet, Peter Cataldo, Blase N. Polite, Daniel Herzig, David Liska, Samuel Oommen, Charles Friel, Charles A. Ternent, Andrew L. Covelev, Steven R. Hunt, Julio Garcia-Aguilar

ABSTRACT

3509

Moving Toward Organ Preservation in Rectal Cancer

DISCUSSANT

Karyn Beth Stitzenberg, MD, MPH | The University of North Carolina at Chapel Hill

A multicenter, randomized, phase III trial of short-term radiotherapy plus chemotherapy versus long-term chemoradiotherapy in locally advanced rectal cancer (STELLAR): The final reports.

AUTHOR(S)

Jing Jin, Yuan Tang, Chen Hu, Yong Cai, Yuan Zhu, Guanghui Cheng, Hongyan Zhang, Xin Wang, Suyu Zhu, Jun Wang, Gaofeng Li, Jialin Yang, Kuan Zhang, Yihebal Chi, Haitao Zhou, Lichun Wei, Wenling Wang, Shixin Liu, Yuanhong Gao, Ye-Xiong Li

ABSTRACT

3510

Phase II study of preoperative (PREOP) chemoradiotherapy (CTRT) plus avelumab (AVE) in patients (PTS) with locally advanced rectal cancer (LARC): The AVANA study.

AUTHOR(S)

Lisa Salvatore, Maria Bensi, Salvatore Corallo, Francesca Bergamo, Ilaria Pellegrini, Cosimo Rasola, Beatrice Borelli, Emiliano Tamburini, Giovanni Randon, Sara Galuppo, Alessandra Boccaccino, Massimo Giuseppe Viola, Alessandra Auriemma, Elena Fea, Cecilia Barbara, Sara Bustreo, Valeria Smioldo, Brunella Barbaro, Maria Antonietta Gambacorta, Giampaolo Tortora

ABSTRACT

3511

Phase II trial of neoadjuvant mFOLFOX 6 with panitumumab (P) in T3 rectal cancer with clear mesorectal fascia (MRF) and *KRAS*, *NRAS*, *BRAF*, *PI3KCA* wild type (4WT). GEMCAD 1601 PIER trial.

AUTHOR(S)

Carlos Fernandez-Martos, Carles Pericay, Joan Maurel, Ana Virgili, Jaume Capdevila, Javier Gallego, Ruth Vera, Nuria Rodriguez-Salas, Ferran Losa, Manuel Valladares, Ana Vivancos, Juan Ayuso, Monique Maas, Fernando Martínez, Marcos Melian, Xabier García de Albéniz

ABSTRACT

3512

Optimizing Neoadjuvant Therapy for Locally Advanced Rectal Cancer

DISCUSSANT

A. William Blackstock, MD, FASCO | Wake Forest School of Medicine

Molecular correlates of clinical benefit in previously treated patients (pts) with *BRAF* V600E-mutant metastatic colorectal cancer (mCRC) from the BEACON study.

AUTHOR(S)

Scott Kopetz, Danielle A. Murphy, Jie Pu, Fortunato Ciardiello, Jayesh Desai, Axel Grothey, Eric Van Cutsem, Harpreet S. Wasan, Rona Yaeger, Takayuki Yoshino, Amber C. Donahue, Adele Golden, Ashwin Gollerkeri, Zhou Zhu, Josep Tabernero

ABSTRACT

3513

Rarity of acquired mutations (MTs) after first-line therapy with anti-EGFR therapy (EGFRi).

AUTHOR(S)

Christine M. Parseghian, Ryan Sun, Stefania Napolitano, Van K. Morris II, Jason Henry, Jason Willis, Eduardo Vilar Sanchez, Kanwal P. Raghav, Agnes Ang, Scott Kopetz

ABSTRACT

3514

Immune signatures to affect overall survival (OS) and response to bevacizumab (Bev) or cetuximab (Cet) in patients (pts) with metastatic colorectal cancer (mCRC) of CALGB/SWOG 80405 (Alliance).

AUTHOR(S)

Federico Innocenti, Akram Yazdani, Xueping Qu, Fang-Shu Ou, Scott Van Buren, Omar Kabbarah, Charles D. Blanke, Alan P. Venook, Heinz-Josef Lenz, Benjamin G. Vincent

ABSTRACT

3515

Examination of the tumor immune microenvironment (TIME) with multispectral immunofluorescence (m-IF): Association of markers with prognosis and bevacizumab (bev) benefit in NRG Oncology/NSABP C-08.

AUTHOR(S)

Katherine L. Pogue-Geile, Marion Joy, Ying Wang, Nan Song, Rim S. Kim, Greg Yothers, Carmen J. Allegra, Ashok Srinivasan, Melanie Finnigan, Samuel A. Jacobs, Soonmyung Paik, Jennifer Marie M. Suga, Judith O. Hopkins, Nicholas J. DiBella, Naoyuki G. Saito, Peter C. Lucas, Norman Wolmark

ABSTRACT

3516

Molecular Determinants of Resistance and Sensitivity for Targeted Therapy

DISCUSSANT

James M. Cleary, MD | Dana Farber Cancer Institute

Early-onset stage II/III colorectal adenocarcinoma in the IDEA database: Treatment adherence, toxicities, and outcomes from adjuvant fluoropyrimidine and oxaliplatin.

AUTHOR(S)

Elisa Fontana, Jeffrey P. Meyers, Alberto F. Sobrero, Timothy Iveson, Anthony F. Shields, Julien Taieb, Takayuki Yoshino, Ioannis Souglakos, Elizabeth C. Smyth, Florian Lordick, Markus H. Moehler, Andrea Harkin, Roberto Labianca, Jeffrey A. Meyerhardt, Thierry Andre, Takeharu Yamanaka, Ioannis Boukovinas, Axel Grothey, Irit Ben-Aharon, Qian Shi

ABSTRACT

3517

Prevalence of fertility discussions between young adult colorectal cancer survivors and their providers.

AUTHOR(S)

Julia Stal, Serena Yi, Sally Cohen-Cutler, Phuong Gallagher, Afsaneh Barzi, Joel Milam, David R. Freyer, Heinz-Josef Lenz, Kimberly A. Miller

ABSTRACT

3518

Microbiome signature, global methylation and immune landscape in early onset colorectal cancer.

AUTHOR(S)

Ning Jin, Xiaokui Mo, Rebecca Hoyd, Ayse Selen Yilmaz, YunZhou Liu, Malvenderjit Jagjit Singh, Mitchell Muniak, Heather Hampel, Daniel Spakowicz

ABSTRACT

3519

Unraveling the Complexities in the Care of Patients With Early-Onset Colorectal Cancer

DISCUSSANT

Andrea Cercek, MD | Memorial Sloan Kettering Cancer Center

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

[Back to Program](#)

Showing 16 Presentations

<https://meetinglibrary.asco.org/session/13626>

RATIONALE 302: Randomized, phase 3 study of tislelizumab versus chemotherapy as second-line treatment for advanced unresectable/metastatic esophageal squamous cell carcinoma.

AUTHOR(S)

Lin Shen, Ken Kato, Sung-Bae Kim, Jaffer A. Ajani, Kuaile Zhao, Zhiyong He, Xinmin Yu, Yongqian Shu, Qi Luo, Jufeng Wang, Zhendong Chen, Zuoxing Niu, Jong M. Sun, Chen-Yuan Lin, Hiroki Hara, Roberto Pazo-Cid, Christophe Borg, Liyun Li, Aiyang Tao, Eric Van Cutsem

ABSTRACT

4012

Pembrolizumab plus trastuzumab and chemotherapy for HER2+ metastatic gastric or gastroesophageal junction (G/GEJ) cancer: Initial findings of the global phase 3 KEYNOTE-811 study.

AUTHOR(S)

Yelena Y. Janjigian, Akihito Kawazoe, Patricio E. Yanez, Suxia Luo, Sara Lonardi, Oleksii Kolesnik, Olga Barajas, Yuxian Bai, Lin Shen, Yong Tang, Lucjan Wyrwicz, Kohei Shitara, Shukui Qin, Eric Van Cutsem, Josep Tabernero, Lie Li, Chie-Schin Shih, Pooja Bhagia, Hyun Cheol C. Chung

ABSTRACT

4013

Phase III trial comparing XELOX regimen (oxaliplatin plus capecitabine) versus EOX regimen (epirubicin, oxaliplatin and capecitabine) as first-line treatment for advanced gastric cancer: EXELOX trial.

AUTHOR(S)

Weijian Guo, Xiaodong Zhu, Mingzhu Huang, Yusheng Wang, Zhiyu Chen, Wanjing Feng, Yifu He, Xiaowei Zhang, Xin Liu, Chenchen Wang, Wen Zhang, Jieer Ying, Jun Wu, Lei Yang, Yanru Qin, Xiaoying Zhao, Wenhua Li, Zhe Zhang, Lixin Qiu, XiaoFeng Wang

ABSTRACT

4014

Maintenance durvalumab after first-line platinum-based chemotherapy in advanced oesophago-gastric (OG) adenocarcinoma: Results from the PLATFORM trial.

AUTHOR(S)

Caroline Fong, Bijal Patel, Clare Peckitt, Elli Bourmpaki, Katharina von Loga, Ruwaida Begum, Michael Davidson, Gayathri Anandappa, Catherine Cafferkey, David J. Watkins, Sheela Rao, Tom Waddell, Jonathan Wadsley, Fareeda Coxon, Tom Roques, Carys Morgan, Charlotte Rees, Naureen Starling, Ian Chau, David Cunningham

ABSTRACT

4015

Systemic Options for Gastroesophageal Cancer

DISCUSSANT

Nataliya Volodymyrivna Uboha, MD, PhD | UW Carbone Cancer Center

Preoperative chemoradiotherapy to improve overall survival in pancreatic cancer: Long-term results of the multicenter randomized phase III PREOPANC trial.

AUTHOR(S)

Casper H. Van Eijck, Eva Versteijne, Mustafa Suker, Karin Groothuis, Marc G. Besselink, Olivier R. Busch, Bert A. Bonsing, Bas Groot Koerkamp, Ignace H. de Hingh, Sebastiaan Festen, Gijs A. Patijn, Judith de Vos-Geelen, Aeilko H. Zwinderman, Cornelis J. Punt, Geertjan van Tienhoven

ABSTRACT

4016

Randomized phase II study of modified FOLFIRINOX versus gemcitabine plus nab-paclitaxel combination therapy for locally advanced pancreatic cancer (JCOG1407).

AUTHOR(S)

Masato Ozaka, Makoto Ueno, Hiroshi Ishii, Junki Mizusawa, Hiroshi Katayama, Tomoko Kataoka, Takuji Okusaka, Masafumi Ikeda, Haruo Miwa, Shuichi Kaneko, Tomohiro Maesono, Nobumasa Mizuno, Tomohisa Yamamoto, Yasuyuki Kawamoto, Akiko Todaka, Ken Kamata, Terumasa Hisano, Nao Fujimori, Junji Furuse

ABSTRACT

4017

Shifting the Dial for Localized Pancreatic Cancer

DISCUSSANT

Naureen Starling, BSc, FRCP, MD | The Royal Marsden Hospital NHS Foundation Trust

Masitinib plus gemcitabine as first-line treatment of pancreatic cancer with pain: Results from phase 3 study AB12005.

AUTHOR(S)

Joel Ezenfis, Olivier Hermine

ABSTRACT

4018

Gemcitabine (Gem) and nab-paclitaxel (NP) ± nivolumab (nivo) ± CD40 agonistic monoclonal antibody APX005M (Sotigalimab), in patients (Pts) with untreated metastatic pancreatic adenocarcinoma (mPDAC): Phase (Ph) 2 final results.

AUTHOR(S)

Mark H. O'Hara, Eileen M. O'Reilly, Robert A. Wolff, Zev A. Wainberg, Andrew H. Ko, Osama E. Rahma, George A. Fisher Jr., Jaclyn P. Lyman, Christopher R. Cabanski, Joyson J. Karakunnel, Pier F. Gherardini, Lacey J. Kitch, Samantha Bucktrout, Elizabeth Christopher, Rosemarie Mick, Richard Chen, Ovidiu C. Trifan, Lisa Salvador, Jill O'Donnell-Tormey, Robert H. Vonderheide

ABSTRACT

4019

KG 4/2015: A randomized, controlled, multicenter, open-label phase III clinical trial of GV1001 with gemcitabine/capecitabine in previous untreated, eotaxin-high patients with advanced pancreatic ductal adenocarcinoma.

AUTHOR(S)

Jung Hyun Jo, Yong-Tae Kim, Ho Soon Choi, Ho Gak Kim, Hong Sik Lee, Young Woo Choi, Dong Uk Kim, Kwang Hyuck Lee, Eui Joo Kim, Jeong Ho Han, Seung Ok Lee, Chang-Hwan Park, Eun Kwang Choi, Kyong Joo Lee, Jae Yong Cho, Woo Jin Lee, Si Young Song

ABSTRACT

4020

Novel Systemic Approaches for Metastatic Pancreatic Cancer

DISCUSSANT

Benjamin Adam Weinberg, MD | Georgetown University Hospital

High CXCR4 expression in pancreatic ductal adenocarcinoma as characterized by an inflammatory tumor phenotype with potential implications for an immunotherapeutic approach.

AUTHOR(S)

Andreas Seeber, Florian Kocher, Andreas Pircher, Alberto Puccini, Yasmine Baca, Joanne Xiu, Kai Zimmer, Johannes Haybaeck, Gilbert Spizzo, Richard M. Goldberg, Axel Grothey, Anthony F. Shields, Mohamed E. Salem, John Marshall, Michael J. Hall, Wolfgang M. Korn, Chadi Nabhan, Francesca Battaglin, Heinz-Josef Lenz, Dominik G. Wolf

ABSTRACT

4021

Identification and prognostic impact of *PBRM1* mutations in biliary tract cancers: Results of a comprehensive molecular profiling study.

AUTHOR(S)

Kai Zimmer, Florian Kocher, Gerold Untergasser, Alberto Puccini, Joanne Xiu, Dominik Wolf, Gilbert Spizzo, Richard M. Goldberg, Axel Grothey, Anthony F. Shields, John Marshall, Michael J. Hall, Wolfgang M. Korn, Chadi Nabhan, Francesca Battaglin, Heinz-Josef Lenz, Wafik S. El-Deiry, Arno Amann, David Hsiehchen, Andreas Seeber

ABSTRACT

4022

Multimodal profiling of biliary tract cancers detects potentially actionable biomarkers and differences in immune signatures between subtypes.

AUTHOR(S)

Kabir Mody, Nilofer S. Azad, Prerna Jain, Sherif El-Refai, Rachna T. Shroff, Robin Kate Kelley, Anthony B. El-Khoueiry, Denise Lau, Gregory B. Lesinski, Mark Yarchoan

ABSTRACT

4023

How Can We Use Multi-omic Profiling of Pancreatobiliary Cancers?

DISCUSSANT

Sumera Ilyas, MBBS, BA | Mayo Clinic

Genitourinary Cancer—Kidney and Bladder

[Back to Program](#)

Showing 15 Presentations

<https://meetinglibrary.asco.org/session/13629>

Nivolumab plus cabozantinib in patients with non-clear cell renal cell carcinoma: Results of a phase 2 trial.

AUTHOR(S)

Chung-Han Lee, Martin H. Voss, Maria I. Carlo, Ying-Bei Chen, Eduard Reznik, Andrea Knezevic, Robert A. Lefkowitz, Natalie Shapnik, Diana Tassone, Chloe Dadoun, Neil J. Shah, Colette N. Owens, Deaglan J. McHugh, David H. Aggen, Andrew L. Laccetti, Ritesh Kotecha, Darren R. Feldman, Robert J. Motzer

ABSTRACT

4509

Phase II study of nivolumab and salvage nivolumab + ipilimumab in treatment-naïve patients (pts) with advanced non-clear cell renal cell carcinoma (nccRCC) (HCRN GU16-260-Cohort B).

AUTHOR(S)

Michael B. Atkins, Opeyemi Jegede, Naomi B. Haas, David F. McDermott, Mehmet A. Bilen, Jessica Hawley, Jeffrey A. Sosman, Robert S. Alter, Elizabeth R. Plimack, Moshe C. Ornstein, Michael E. Hurwitz, David J. Peace, Sabina Signoretti, Catherine J. Wu, Paul J. Catalano, Hans J. Hammers

ABSTRACT

4510

Clinical activity of durvalumab and savolitinib in MET-driven, metastatic papillary renal cancer.

AUTHOR(S)

Cristina Suarez Rodriguez, James Larkin, Poulam M. Patel, Begoña P. Valderrama, Alejo Rodriguez-Vida, Hilary Glen, Fiona Thistlethwaite, Christy Ralph, Gopalakrishnan Srinivasan, Maria Jose Mendez-Vidal, Abigail Carter, Charlotte Tyson, Aaron Prendergast, Kelly Mousa, Thomas Powles

ABSTRACT

4511

Making Strides in the Treatment of Non-Clear Cell Carcinoma: Are We Ready for Adaptive and Biomarker-Driven Strategies?

DISCUSSANT

Deepak Kilari, MD | Medical College of Wisconsin

Vorolanib, everolimus, and the combination in patients with pretreated metastatic renal cell carcinoma (CONCEPT study): A randomized, phase 3, double-blind, multicenter trial.

AUTHOR(S)

Xinan Sheng, Dingwei Ye, Ai-Ping Zhou, Xin Yao, Hong Luo, Zhisong He, Zengjun Wang, Yingchao Zhao, Zhigang Ji, Qing Zou, Chaohong He, Jianming Guo, Xinhua Tu, Ziling Liu, Benkang Shi, Ben Liu, Peng Chen, Qiang Wei, Fang-Jian Zhou, Jun Guo

ABSTRACT

4512

First results of a randomized phase IB study comparing nivolumab/ipilimumab with or without CBM-588 in patients with metastatic renal cell carcinoma.

AUTHOR(S)

Luis A. Meza, Nazli Dizman, Paulo G. Bergerot, Tanya B. Dorff, Yung Lyou, Paul H. Frankel, Valerie Mira, Marian Llamas, Joann Hsu, Zeynep B. Zengin, Nicholas Salgia, Sabrina Salgia, Jasnoor Malhotra, Neal S. Chawla, Alex Chehrizi-Raffle, John D. Gillece, Lauren J. Reining, Jeffrey M. Trent, Sarah K. Highlander, Sumanta K. Pal

ABSTRACT

4513

Novel Strategies to Improve Outcomes in Advanced Renal Cell Carcinoma

DISCUSSANT

Guillermo de Velasco, MD, PhD | Department of Oncology, Hospital 12 de Octubre

Outcomes of patients who progressed while receiving avelumab + axitinib (A + Ax) and received subsequent treatment (Tx) in JAVELIN Renal 101.

AUTHOR(S)

Laurence Albiges, Martin H. Voss, Brian I. Rini, Gwenaëlle Gravis, Marc-Oliver Grimm, Paul D. Nathan, Georg A. Bjarnason, Yoshihiko Tomita, Konstantin Penkov, Bradley McGregor, Bo Huang, Despina Thomaidou, Mariangela Mariani, Alessandra Di Pietro, Toni K. Choueiri

ABSTRACT

4514

Safety and efficacy outcomes with nivolumab plus ipilimumab in patients with advanced renal cell carcinoma and brain metastases: results from the CheckMate 920 trial.

AUTHOR(S)

Hamid Emamekhoo, Mark R. Olsen, Bradley C. Carthon, Alexandra Drakaki, Ivor J. Percent, Ana M. Molina, Daniel C. Cho, Johanna C. Bendell, Lucio N. Gordan, Arash Rezazadeh Kalebasty, Daniel J. George, Thomas E. Hutson, Edward Arrowsmith, Joshua Zhang, Jesus Zoco, Jennifer L. Johansen, David Leung, Scott S. Tykodi

ABSTRACT

4515

Survival benefit of nephrectomy prior to immunotherapy-based combinations in patients with metastatic renal cell carcinoma: An FDA pooled analysis.

AUTHOR(S)

Jaleh Fallah, Haley Gittleman, Chana Weinstock, Erik Bloomquist, Elaine Chang, Daniel L. Suzman, Sundeep Agrawal, Amna Ibrahim, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani

ABSTRACT

4516

Unanswered Questions in the Management of Advanced Renal Cell Carcinoma

DISCUSSANT

Anil Kapoor, MD | Juravinski Cancer Centre, McMaster University

Neoadjuvant atezolizumab (A) with gemcitabine and cisplatin (GC) in patients (pts) with muscle-invasive bladder cancer (MIBC): A multicenter, single-arm, phase 2 trial.

AUTHOR(S)

Samuel A. Funt, Michael Lattanzi, Karissa Whiting, Hikmat A. Al-Ahmadie, Colleen Quinlan, Min Yuen Teo, Jeffrey Kamradt, Maged F. Khalil, Irina Ostrovnaya, Asia S. McCoy, Grace Hettich, Marwah Jihad, Edmund Folefac, William C. Huang, Dean F. Bajorin, Gopa Iyer, Bernard H. Bochner, Arjun V. Balar, Amir Mortazavi, Jonathan E. Rosenberg

ABSTRACT

4517

PrE0807: A phase Ib feasibility trial of neoadjuvant nivolumab (N) without or with lirilumab (L) in cisplatin-ineligible patients (pts) with muscle-invasive bladder cancer (MIBC).

AUTHOR(S)

Petros Grivas, Jun Yin, Vadim S. Koshkin, Suzanne Cole, Rohit K. Jain, Robert Dreicer, Jeremy P. Cetnar, Debasish Sundi, Benjamin A. Gartrell, Matt D. Galsky, Colin M. Sievers, Noah M. Hahn, Michael A. Carducci

ABSTRACT

4518

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC): Analysis of clinical and genomic subgroups from the JAVELIN Bladder 100 trial.

AUTHOR(S)

Thomas Powles, Daniel P. Petrylak, Se Hoon Park, Srikala S. Sridhar, Claudia Caserta, Antoine Thiery Vuillemin, Hyo Jin Lee, Joaquim Bellmunt, Yoshiaki Yamamoto, Jeanny B. Aragon-Ching, Bo Huang, Keith A. Ching, Craig B. Davis, Alessandra Di Pietro, Yohann Loriot, Petros Grivas

ABSTRACT

4520

Novel Immunotherapy Approaches Across the Spectrum of Urothelial Cancer Stages

DISCUSSANT

Bishoy Morris Faltas, MD | Weill Cornell Medicine

Genitourinary Cancer—Prostate, Testicular, and Penile
[Back to Program](#)

Showing 16 Presentations

<https://meetinglibrary.asco.org/session/13632>

The CADMUS trial: A paired cohort, blinded study comparing multiparametric ultrasound targeted biopsies with multiparametric MRI targeted biopsies in the detection of clinically significant prostate cancer.

AUTHOR(S)

Alistair Grey, Rebecca Scott, Bina Shah, Peter Acher, Sidath Liyanage, Menelaos Pavlou, Rumana Omar, Frank Chinegwundoh, Prasad Patki, Diane Campbell, Taimur T. Shah, Sami Hamid, Chris Brew-Graves, Nim Arumainayagam, Alex Chapman, David Eldred-Evans, Alex Freeman, Mathias Winkler, Mark Emberton, Hashim U. Ahmed

ABSTRACT

5008

MRI and targeted biopsies compared to transperineal mapping biopsies for targeted ablation in recurrent prostate cancer after radiotherapy: Primary outcomes of the FORECAST trial.

AUTHOR(S)

Taimur T. Shah, Abi Kanthabalan, Menelaos Pavlou, Sola Adeleke, Francesco Giganti, Chris Brew-Graves, Athar Haroon, Harbir Sidhu, Alex Freeman, Ashok Nikapota, Tim Dudderidge, Richard G. Hindley, Mani Arya, Heather A. Payne, Anita Mitra, Gail Horan, Caroline Moore, Mark Emberton, Shonit Punwani, Hashim U. Ahmed

ABSTRACT

5009

Validation of the decipher genomic classifier (GC) in SAKK 09/10: A phase III randomized trial of dose-escalated salvage radiotherapy (SRT) after radical prostatectomy (RP).

AUTHOR(S)

Alan Dal Pra, Pirus Ghadjar, Stefanie Hayoz, Daniel E. Spratt, Vinnie Y. Liu, Tamara Todorovic, Elai Davicioni, Huei-Chung Huang, Philipp Gut, Ludwig Plasswilm, Tobias Hölscher, Bülent Polat, Guido Hildebrandt, Arndt-Christian Mueller, George N. Thalmann, Daniel R. Zwahlen, Daniel M. Aebersold

ABSTRACT

5010

Have We Optimized the Detection and Risk Stratification in Men With Localized Prostate Cancer?

DISCUSSANT

Samir Taneja, MD | NYU Langone Health

Radiation and androgen deprivation therapy with or without docetaxel in the management of non-metastatic unfavorable-risk prostate cancer: A prospective randomized trial.

AUTHOR(S)

Anthony V. D'Amico, Wanling Xie, Elizabeth McMahon, Marian Loffredo, Shana Medeiros, David J. Joseph, James W. Denham, David S. Lamb, Parvesh Kumar, Glenn Bubley, Molly A. Sullivan, Richard Hellwig, Juan Carlos Vera, Rolf Freter, W. J. Baker, Jeffrey Y. Wong, Andrew A. Renshaw, Philip W. Kantoff

ABSTRACT

5011

Interim results of aasur: A single arm, multi-center phase 2 trial of apalutamide (A) + abiraterone acetate + prednisone (AA+P) + leuprolide with stereotactic ultra-hypofractionated radiation (UHRT) in very high risk (VHR), node negative (N0) prostate cancer (PCa).

AUTHOR(S)

Sean M. McBride, Daniel E. Spratt, Marisa Kollmeier, Wassim Abida, Han Xiao, Susan F. Slovin, Channing J. Paller, Curtiland Deville, Robert B. Den, Jason W. Hearn, Howard I. Scher, Michael J. Zelefsky, Dana E. Rathkopf

ABSTRACT

5012

Is There a Role for Systemic Therapy Intensification With Radiotherapy in Locally Advanced Prostate Cancer?

DISCUSSANT

Neha Vapiwala, MD, FACR | University of Pennsylvania

Results of an ongoing phase 1/2a dose escalation study of HPN424, a tri-specific half-life extended PSMA-targeting T-cell engager, in patients with metastatic castration-resistant prostate cancer (mCRPC).

AUTHOR(S)

Johann S. De Bono, Lawrence Fong, Tomasz M. Beer, Xin Gao, Daniel M. Geynisman, Howard A. Burris III, James F. Strauss, Kevin D. Courtney, David I. Quinn, David J. VanderWeele, Yifan Yaron, Che-Leung Law, Mark N. Stein

ABSTRACT

5013

COMBAT-CRPC: COncurrent adMinistration of Bipolar Androgen Therapy (BAT) and nivolumab in men with metastatic castration-resistant prostate cancer (mCRPC).

AUTHOR(S)

Mark C. Markowski, Mary-Ellen Taplin, Rahul R. Aggarwal, Hao Wang, Aliya Lalji, Channing J. Paller, Catherine H. Marshall, Michael A. Carducci, Mario A. Eisenberger, Angelo M. De Marzo, Samuel R. Denmeade, Emmanuel S. Antonarakis

ABSTRACT

5014

Phase I study of ^{225}Ac -J591 for men with metastatic castration-resistant prostate cancer (mCRPC).

AUTHOR(S)

Scott T. Tagawa, Michael Sun, A. O. Sartor, Charlene Thomas, Sharon Singh, Mahelia Bissassar, Escarleth Fernandez, Muhammad Junaid Niaz, Benedict Ho, Shankar Vallabhajosula, John Babich, Ana M. Molina, Cora N. Sternberg, David M. Nanus, Joseph Osborne, Neil H. Bander

ABSTRACT

5015

Novel Approaches to Metastatic Prostate Cancer: Are We Making Progress?

DISCUSSANT

Julie N Graff, MD | OHSU Knight Cancer Institute

Hearing loss after cisplatin-based chemotherapy: Patient-reported outcomes versus audiometric assessments.

AUTHOR(S)

Shirin Ardeshirrouhanifard, Sophie Fosså, Robert A. Huddart, Patrick O. Monahan, Chunkit Fung, Yiqing Song, M. Eileen Dolan, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Neil E. Martin, Christian K. Kollmannsberger, Paul C. Dinh Jr., Lifang Hou, Yinan Zheng, Lawrence Einhorn, Robert D. Frisina, Lois B. Travis

ABSTRACT

5016

Immunity to childhood vaccines following high dose chemotherapy (HDCT) and autologous stem cell transplantation (ASCT) for germ cell tumors (GCT) with comparison to Hodgkin lymphoma (HL).

AUTHOR(S)

Darren R. Feldman, Akeem R. Lewis, Andrea Knezevic, David Ali, Maria Bromberg, Julia Aronson, Samuel A. Funt, Deaglan J. McHugh, Robert J. Motzer, Dean F. Bajorin, Sujata Patil, Gunjan L. Shah, Monika Shah, Susan Seo, Mini Kamboj, Miguel-Angel Perales, Genofeva Papanicolaou

ABSTRACT

5017

Surveillance after complete response in patients with metastatic non-seminomatous germ-cell tumor (NSGCT).

AUTHOR(S)

Jennifer King, Sandra K. Althouse, Clint Cary, Timothy A. Masterson, Richard Foster, Ryan Ashkar, Nasser H. Hanna, Lawrence H. Einhorn, Nabil Adra

ABSTRACT

5018

Effect of pretreatment central adiposity on the cardiometabolic risk of male germ cell tumor survivors after cisplatin-based chemotherapy.

AUTHOR(S)

Andreas G. Wibmer, Darren R. Feldman, Carol Chen, Maria Bromberg, Paul C. Dinh Jr., Junting Zheng, Marinela Capanu, Lois B. Travis, Hebert A. Vargas

ABSTRACT

5019

Survivorship Challenges in Testicular Cancer: Are There Factors We Can Modify?

DISCUSSANT

Timothy D. Gilligan, FASCO, MD, MS | Cleveland Clinic Taussig Cancer Institute

Gynecologic Cancer

Back to Program

Showing 16 Presentations

<https://meetinglibrary.asco.org/session/13635>

Evaluation of a RAD51 functional assay in advanced ovarian cancer, a GINECO/GINEGEPS study.

AUTHOR(S)

Felix Blanc-Durand, Elisa Yaniz, Catherine Genestie, Etienne Rouleau, Dominique Berton, Alain Lortholary, Nathalie Dohollou, Christophe Desauw, Michel Fabbro, Emmanuelle Malaurie, Nathalie Bonichon-Lamichhane, Coraline Dubot, Jean-Emmanuel Kurtz, Gaetan De Rauglaudre, Nadia Raban, Cyril Abdeddaim, Gwenael Ferron, Marie-Christine Kaminsky, Alba Llop-Guevara, Alexandra Leary

ABSTRACT

5513

Progression-free survival (PFS) and second PFS (PFS2) by disease stage in patients (pts) with homologous recombination deficiency (HRD)-positive newly diagnosed advanced ovarian cancer receiving bevacizumab (bev) with olaparib/placebo maintenance in the phase III PAOLA-1/ENGOT-ov25 trial.

AUTHOR(S)

Patricia Pautier, Philipp Harter, Carmela Pisano, Claire Cropet, Susana Hernando Polo, Regina Berger, Takashi Matsumoto, Ignace Vergote, Nicoletta Colombo, Trine J. Noettrup, Georges Garnier, Peter Hillemanns, Claudio Zamagni, Antonio Gonzalez Martin, Claudia Lefeuvre-Plesse, Dominik Denschlag, Alain Lortholary, Jalid Sehouli, Frederic Selle, Isabelle L. Ray-Coquard

ABSTRACT

5514

Olaparib treatment (Tx) in patients (pts) with platinum-sensitive relapsed ovarian cancer (PSR OC) by BRCA mutation (BRCAm) and homologous recombination deficiency (HRD) status: Overall survival (OS) results from the phase II LIGHT study.

AUTHOR(S)

Cara A. Mathews, Fiona Simpkins, Karen A. Cadoo, Ying L. Liu, Diane M. Provencher, Colleen McCormick, Adam ElNaggar, Alon D. Altman, Lucy Gilbert, Destin Black, Nashwa Kabil, James Bennett, Jiefen Munley, Judy Yu, Carol Aghajanian

ABSTRACT

5515

Choosing Wisely: Selecting the Right Population at the Right Time for DNA-Damaging Therapy

DISCUSSANT

Elizabeth M. Swisher, MD | University of Washington School of Medicine

Combination of PARP and ATR inhibitors (olaparib and ceralasertib) shows clinical activity in acquired PARP inhibitor-resistant recurrent ovarian cancer.

AUTHOR(S)

Stephanie L. Wethington, Payal D. Shah, Lainie P. Martin, Janos L. Tanyi, Nawar A. Latif, Mark A. Morgan, Drew A. Torigian, Cheyenne Pagan, Diego Rodriguez, Susan M. Domchek, Ronny Drapkin, Ie-Ming Shih, Simon Smith, Emma Dean, Deborah K. Armstrong, Stephanie Gaillard, Fiona Simpkins

ABSTRACT

5516

Subgroup analysis of rucaparib versus chemotherapy as treatment for BRCA-mutated, advanced, relapsed ovarian carcinoma: Effect of platinum sensitivity in the randomized, phase 3 study ARIEL4.

AUTHOR(S)

Amit M. Oza, Alla S. Lisyanskaya, Alexander A. Fedenko, Mikhail Dvorkin, Andreia C. de Melo, Yaroslav V. Shparyk, Irina Rakhmatullina, Igor Bondarenko, Nicoletta Colombo, Valentyn Svintsitskiy, David Cibula, Róbert Póka, Ana Oaknin, Tamar Safra, Beata Mackowiak-Matejczyk, Ling Ma, Karen R. McLachlan, Sandra Goble, Rebecca S. Kristeleit

ABSTRACT

5517

Niraparib efficacy and safety in patients with *BRCA* mutated (*BRCAm*) ovarian cancer: Results from three phase 3 niraparib trials.

AUTHOR(S)

Antonio Gonzalez Martin, Ursula A. Matulonis, Jacob Korach, Mansoor R. Mirza, Kathleen N. Moore, Divya Gupta, Stanislav Lechpammer, Bradley J. Monk

ABSTRACT

5518

A Tale of Three PARP Inhibitors

DISCUSSANT

Debra L. Richardson, MD | Stephenson Cancer Center at the University of Oklahoma Health Sciences Center

Molecular results and potential biomarkers identified from MILO/ENGOT-ov11 phase 3 study of binimetinib versus physicians choice of chemotherapy (PCC) in recurrent low-grade serous ovarian cancer (LGSOC).

AUTHOR(S)

Rachel N. Grisham, Ignace Vergote, Susana N. Banerjee, Esther N. Drill, Michel Fabbro, Mansoor R. Mirza, Ignacio Romero, Robert L. Coleman, Amit M. Oza, Felix Hilpert, Kathleen N. Moore, Anneke M. Westermann, Carol Aghajanian, Giovanni Scambia, Adam P. Boyd, Jean Cantey-Kiser, David M. O'Malley, John H. Farley, Nicoletta Colombo, Bradley J. Monk

ABSTRACT

5519

An umbrella study of biomarker-driven targeted therapy in patients with platinum-resistant recurrent ovarian cancer (KGOG 3045, AMBITION).

AUTHOR(S)

Jung-Yun Lee, Byoung-Gie Kim, Jae-Weon Kim, Jung Bok Lee, Eunhyang Park, Sung Hoon Kim, Chel Hun Choi, Hee Seung Kim

ABSTRACT

5520

Dendritic cell vaccine (DCVAC) combined with chemotherapy (CMT) in patients with newly diagnosed epithelial ovarian carcinoma (EOC) after primary debulking surgery (PDS): Biomarker exploratory analysis of a phase 2, open-label, randomized, multicenter trial.

AUTHOR(S)

Lukas Rob, David Cibula, Pawel Knapp, Peter Mallmann, Jaroslav Klat, Lubos Minar, Pavel Bartos, Josef Chovanec, Petr Valha, Marek Pluta, Zdenek Novotny, Jiri Spacek, Bohuslav Melichar, Dariusz Kieszko, Jitka Fucikova, Tereza Hrnčiarova, Roman P. Korolkiewicz, Marek Hraska, Jirina Bartunkova, Radek Spisek

ABSTRACT

5521

Using Biomarkers to Improve Outcomes in Ovarian Cancer

DISCUSSANT

Rebecca Christian Arend, MD | University of Alabama at Birmingham

Pembrolizumab in combination with bevacizumab and pegylated liposomal doxorubicin in patients with platinum-resistant epithelial ovarian cancer.

AUTHOR(S)

Judith Michels, François Ghiringhelli, Jean-Sebastien Frenel, Caroline Brard, Benoit You, Anne Floquet, Lauriane Eberst, Rastilav Bahleda, Catherine Genestie, Corinne Balleyguier, Sophie Broutin, Patricia Pautier, Emeline Colomba, Fanny Pommeret, Christophe Massard, Aurelien Marabelle, Alexandra Leary

ABSTRACT

5522

A phase II evaluation of pembrolizumab in recurrent microsatellite instability-high (MSI-H) endometrial cancer patients with Lynch-like versus *MLH-1* methylated characteristics (NCT02899793).

AUTHOR(S)

Dana M. Roque, Stefania Bellone, Eric R. Siegel, Natalia Buza, Elena Bonazzoli, Adele Guglielmi, Luca Zammataro, Nupur Nagarkatti, Samir Zaidi, Jungsoo Lee, Peter E. Schwartz, Elena Ratner, Ludmil B. Alexandrov, Akiko Iwasaki, Yong Kong, Eric Song, Weilai Dong, Julia A. Elvin, Jungmin Choi, Alessandro Santin

ABSTRACT

5523

Anlotinib plus sintilimab in patients with recurrent advanced cervical cancer: A prospective, multicenter, single-arm, phase II clinical trial.

AUTHOR(S)

Qin Xu, Chuanben Chen, Yang Sun, Zhangzhou Huang, Yibin Lin, Jing Liu, Li Li, Zirong Li, Junping Pan, Ying Chen

ABSTRACT

5524

Checkpoint Inhibitors Across the Spectrum of Gynecologic Cancers

DISCUSSANT

Oladapo O. Yeku, MD, PhD, FACP | Memorial Sloan Kettering Cancer Center

Head and Neck Cancer

[Back to Program](#)

Showing 13 Presentations

<https://meetinglibrary.asco.org/session/13638>

Updated report of a phase II randomized trial of transoral surgical resection followed by low-dose or standard postoperative therapy in resectable p16+ locally advanced oropharynx cancer: A trial of the ECOG-ACRIN cancer research group (E3311).

AUTHOR(S)

Robert L. Ferris, Yael Flamand, Gregory S. Weinstein, Shuli Li, Harry Quon, Ranee Mehra, Joaquin J. Garcia, Jolie Ringash, Jan S. Lewin, Umamaheswar Duvvuri, Bert W. O'Malley, Enver Ozer, Giovana R. Thomas, Wayne Koch, Michael E. Kupferman, Richard B. Bell, Nabil F. Saba, Miriam Lango, Lynne I. Wagner, Barbara Burtress

ABSTRACT

6010

Nivolumab, nabpaclitaxel, and carboplatin followed by risk/response adaptive de-escalated locoregional therapy for HPV-associated oropharyngeal cancer: OPTIMA II trial.

AUTHOR(S)

Ari Rosenberg, Nishant Agrawal, Alexander T. Pearson, Tanguy Y. Seiwert, Zhen Gooi, Elizabeth A. Blair, Daniel Ginat, Adam Howard, Jeffrey Chin, Sara Kochanny, Evgeny Izumchenko, Aditya Juloori, Daniel J. Haraf, Everett E. Vokes

ABSTRACT

6011

De-intensification Approaches for HPV-Positive Head and Neck Cancers

DISCUSSANT

Anthony C. Nichols, MD | Western University and London Health Sciences Centre

Randomized trial of radiotherapy with weekly cisplatin or cetuximab in low risk HPV associated oropharyngeal cancer (TROG 12.01): A Trans-Tasman Radiation Oncology Group study.

AUTHOR(S)

Danny Rischin, Madeleine T. King, Lizbeth M. Kenny, Sandro Porceddu, Christopher Wratten, Andrew Macann, James E. Jackson, Mathias Bressel, Alan Herschtal, Fisher Richard, Tsien Fua, Charles Lin, Chen-Shin Liu, Brett G. Hughes, Margie McGrath, Lachlan McDowell, June Corry

ABSTRACT

6012

TRYHARD, a randomized phase II trial (RTOG Foundation 3501) of concurrent accelerated radiation plus cisplatin (cis) with or without lapatinib (Lap) for stage III- IV Non-HPV head and neck carcinoma (HNC).

AUTHOR(S)

Stuart J. Wong, Pedro A. Torres-Saavedra, Nabil F. Saba, George Shenouda, Jeffrey Bumpous, Robert E. Wallace, Christine H. Chung, Adel K. El-Naggar, Clement K. Gwede, Barbara Burtness, Paul Tennant, Neal E. Dunlap, Loren K. Mell, Sharon Spencer, William A. Stokes, Min Yao, Darrion L. Mitchell, Jonathan Harris, Walter J. Curran, Quynh-Thu Le

ABSTRACT

6014

Lessons Learned From Negative Trials

DISCUSSANT

Douglas Adkins, MD | Washington University School of Medicine

Randomized phase II trial of ficlatuzumab with or without cetuximab in pan-refractory, advanced head and neck squamous cell carcinoma (HNSCC).

AUTHOR(S)

Julie E. Bauman, Nabil F. Saba, Denise Roe, Jessica R. Bauman, John M. Kaczmar, Aarti K. Bhatia, Jameel Muzaffar, Ricklie A. Julian, Steven Wang, Shethal Bearely, Audrey Baker, Conor E. Steuer, Anshu Giri, Barbara Burtness, Sara Centuori, Carlos Caulin, Kathylynn Saboda, Stefanie Obara, Christine H. Chung

ABSTRACT

6015

Phase II trial of soluble EphB4-albumin in combination with PD-1 antibody (pembrolizumab) in relapsed/refractory head neck squamous cell carcinoma.

AUTHOR(S)

Alexandra Jackovich, Barbara J. Gitlitz, Justin Wayne W. Tiu-lim, Vinay Duddalwar, Kevin G. King, Anthony B. El-Khoueiry, Jacob S. Thomas, Denice Tsao-Wei, David I. Quinn, Parkash S. Gill, Jorge J. Nieva

ABSTRACT

6016

Efficacy of concurrent cetuximab (CTX) and nivolumab (NIVO) in previously untreated recurrent and/or metastatic (R/M) head and neck squamous cell carcinoma (HNSCC).

AUTHOR(S)

Christine H. Chung, Nabil F. Saba, Conor E. Steuer, Jiannong Li, Priyanka Bhateja, Matthew Johnson, Jude Masannat, Maria Poole, Dirk Hoening, Feifei Song, Juan C. Hernandez-Prera, Helen Molina, Bruce Wenig, Joaquim Farinhas, Julie A. Kish, Jameel Muzaffar, Kedar Kirtane, James W. Rocco, Michael J. Schell, Marcelo R. Bonomi

ABSTRACT

6017

Novel Combinations in Recurrent/Metastatic Head and Neck Cancers

DISCUSSANT

Hyunseok Kang, FACP, MD, MPH | University of California, San Francisco

A randomized phase II trial of diffusion-weighted MR imaging-guided radiotherapy plus chemotherapy versus standard chemoradiotherapy in locoregional advanced nasopharyngeal carcinoma.

AUTHOR(S)

Feng Liu, Shengnan Fu, Yanzhu Chen, Ouying Yan, Lili He, Cuihong Jiang, Xiangwei Wu, Yaqian Han, Hui Wang

ABSTRACT

6018

The 30 ROC trial: Precision intra-treatment imaging guiding major radiation reduction in human papillomavirus related oropharyngeal cancer.

AUTHOR(S)

Nancy Y. Lee, Eric J. Sherman, Heiko Schöder, Sean M. McBride, Yao Yu, Jung Kang, C. Jillian Tsai, Daphna Y. Gelblum, Jay Boyle, Bhuvanesh Singh, Marc Cohen, Jennifer R. Cracchiolo, Ian Ganly, Lara Dunn, Anuja Kriplani, James V. Fettes, Loren S. Michel, Richard J. Wong, David G. Pfister, Nadeem Riaz

ABSTRACT

6019

Image-Based Risk-Adapted Radiotherapy: It's Not Just Black and White!

DISCUSSANT

Quynh-Thu Le, MD | Stanford University

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft

[Back to Program](#)

Showing 14 Presentations

<https://meetinglibrary.asco.org/session/13644>

Second-line bosutinib (BOS) for patients (pts) with chronic phase (CP) chronic myeloid leukemia (CML): Final 10-year results of a phase 1/2 study.

AUTHOR(S)

Carlo Gambacorti-Passerini, Tim H. Brümmendorf, Dong-Wook Kim, Yeow Tee Goh, Irina S. Dyagil, Katia Pagnano, Arpad Batai, Anna G. Turkina, Eric Leip, Simon Purcell, Jocelyn M. Leone, Andrea Viqueira, Jorge E. Cortes

ABSTRACT

7009

Phase II study of the IDH2-inhibitor enasidenib in patients with high-risk IDH2-mutated myelodysplastic syndromes (MDS).

AUTHOR(S)

Sangeetha Venugopal, Courtney D. Dinardo, Koichi Takahashi, Marina Konopleva, Sanam Loghavi, Gautam Borthakur, Amy E. Dezern, Lucia Masarova, Naval G. Daver, Nicholas J. Short, Yesid Alvarado, Farhad Ravandi, Guillermo Montalban-Bravo, Koji Sasaki, Ricardo Delumpa, Mikkael A. Sekeres, Bhumika J. Patel, Gail J. Roboz, Hagop M. Kantarjian, Guillermo Garcia-Manero

ABSTRACT

7010

Venetoclax and azacitidine combination in chemotherapy ineligible untreated patients with therapy-related myeloid neoplasms, antecedent myelodysplastic syndromes, or myelodysplastic/myeloproliferative neoplasms.

AUTHOR(S)

Vinod Pullarkat, Keith Pratz, Hartmut Dohner, Christian Recher, Michael J. Thirman, Courtney D. Dinardo, Pierre Fenau, Andre C. Schuh, Andrew H. Wei, Arnaud Pigneux, Jun Ho Jang, Gunnar Juliusson, Kazuhito Miyazaki, Dominik Selleslag, Martha L. Arellano, Kiran Naqvi, Jun Yu, Jean Ridgeway, Jalaja Potluri, Marina Konopleva

ABSTRACT

7011

Beyond Dose Intensity: Targeted Therapy of Myeloid Malignancies

DISCUSSANT

Ami B. Patel, MD | Huntsman Cancer Institute, University of Utah

A phase Ib/II study of ivosidenib with venetoclax +/- azacitidine in IDH1-mutated myeloid malignancies.

AUTHOR(S)

Curtis A. Lachowicz, Gautam Borthakur, Sanam Loghavi, Zhihong Zeng, Tapan M. Kadia, Lucia Masarova, Koichi Takahashi, George D. Tippet, Samantha Smith, Jacqueline S. Garcia, Prithviraj Bose, Elias Jabbour, Farhad Ravandi, Naval G. Daver, Guillermo Garcia-Manero, Bilyana Stoilova, Paresh Vyas, Hagop M. Kantarjian, Marina Konopleva, Courtney D. Dinardo

ABSTRACT

7012

Follow-up of patients with *FLT3*-mutated R/R AML in the phase 3 ADMIRAL trial.

AUTHOR(S)

Alexander E. Perl, Richard A. Larson, Nikolai A. Podoltsev, Stephen Strickland, Eunice S. Wang, Gary J. Schiller, Giovanni Martinelli, Andreas Neubauer, Jorge Sierra, Pau Montesinos, Christian Recher, Sung-Soo Yoon, Naoko Hosono, Masahiro Onozawa, Shigeru Chiba, Hee-Je Kim, Nahla Hasabou, Qiaoyang Lu, Ramon V. Tiu, Mark J. Levis

ABSTRACT

7013

Prognostic factors of overall (OS) and relapse-free survival (RFS) for patients with acute myeloid leukemia (AML) in remission after intensive chemotherapy (IC): Multivariate analyses from the QUAZAR AML-001 trial of oral azacitidine (Oral-AZA).

AUTHOR(S)

Gail J. Roboz, Andrew H. Wei, Farhad Ravandi, Christopher Pocock, Pau Montesinos, Hervé Dombret, Kimmo Porkka, Ignazia La Torre, Barry Skikne, Jianhua Zhong, Keshava Kumar, C. L. Beach, Hartmut Dohner

ABSTRACT

7014

A mixed methods study exploring the role of perceived side effects on treatment decision-making in older adults with acute myeloid leukemia (AML).

AUTHOR(S)

Dawn Maze, Roland B. Walter, Diana M. Merino, Timothy J. Bell, Louise O'Hara, Francois Peloquin, Lucy Morgan, Lorian Hernandez, Jasmine Healy, Charlotte Panter, Verna L. Welch, Adam Gater, Karim Amer, Ryan Hohman, Julia Stein, Andrew Brown, Nigel H. Russell, Thomas W. LeBlanc

ABSTRACT

7016

A registry-based, observational safety study of inotuzumab ozogamicin (InO) treatment in patients (pts) with B-cell precursor acute lymphoblastic leukemia (ALL) who proceeded to hematopoietic stem cell transplant (HSCT).

AUTHOR(S)

Marcos J. De Lima, Partow Kebriaei, Francesco Lanza, Christina Cho, Sergio Giral, Gizelle Popradi, Michael T. Hemmer, Xin Zhang, Richa Shah, Verna L. Welch, Erik Vandendries, Matthias Stelljes, David I. Marks, Wael Saber

ABSTRACT

7017

Priorities in Focus: Safety First

DISCUSSANT

Leland L. Metheny, MD | Adult Hematologic Malignancies and Stem Cell Transplant Program, University Hospitals Seidman Cancer Center

Measurable residual disease response in acute myeloid leukemia treated with venetoclax and azacitidine.

AUTHOR(S)

Keith Pratz, Brian A. Jonas, Vinod Pullarkat, Christian Recher, Andre C. Schuh, Michael J. Thirman, Jacqueline S. Garcia, Courtney D. Dinardo, Vladimir Vorobyev, Nicola Fracchiolla, Su-Peng Yeh, Jun Ho Jang, Muhit Ozcan, Kazuhito Yamamoto, Arpad Illes, Ying Zhou, Monique Dail, Brenda Chyla, Jalaja Potluri, Hartmut Dohner

ABSTRACT

7018

Predictive phosphoproteomic signatures for midostaurin plus chemotherapy response in FLT3 mutant positive acute myeloid leukaemia.

AUTHOR(S)

Arran D. Dokal, Andrea Arruda, Ryan Smith, Calum Greenhalgh, Francesca Patella, Pedro M. Casado-Izquierdo, Bela Wrench, Jane Theaker, Andrew Thompson, Mark D. Minden, John G. Gribben, David J. Britton, Pedro R. Cutillas

ABSTRACT

7019

High dimensional mapping of temporal evolution within the marrow microenvironment in response to FLT3 inhibitor therapy.

AUTHOR(S)

Matthew Newman, Sunil K. Joshi, Daniel Bottomly, Shannon McWeeney, Brian J. Druker, Evan Lind, Elie A. Traer

ABSTRACT

7020

Building a Better Map: Advances in Biomarkers for AML

DISCUSSANT

Chris Hourigan | National Heart Lung and Blood Institute at the National Institutes of Health

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

[Back to Program](#)

Showing 16 Presentations

<https://meetinglibrary.asco.org/session/13646>

Acalabrutinib ± obinutuzumab versus obinutuzumab + chlorambucil in treatment-naïve chronic lymphocytic leukemia: Elevate-TN four-year follow up.

AUTHOR(S)

Jeff P. Sharman, Miklos Egyed, Wojciech Jurczak, Alan Skarbnik, John M. Pagel, Manali K. Kamdar, Talha Munir, Gillian Corbett, Laura M. Fogliatto, Yair Herishanu, Versha Banerji, Steve E. Coutre, Patricia Walker, Karin Karlsson, Paolo Ghia, Ann Janssens, William G. Wierda, Priti Patel, Min Hui Wang, John C. Byrd

ABSTRACT

7509

Copanlisib + rituximab versus rituximab + placebo in patients with relapsed follicular (FL) or marginal zone lymphoma (MZL): Subset analysis from the phase III CHRONOS-3 trial.

AUTHOR(S)

Matthew J. Matasar, Marcelo Capra, Muhit Özcan, Fangfang Lv, Wei Li, Eduardo Yanez, Katya Sapunarova, Tongyu Lin, Jie Jin, Wojciech Jurczak, Aryan Hamed, Ming-Chung Wang, Lidia Mongay Soler, Anjun Cao, Charles Phelps, Barrett H. Childs, Yuankai Shi, Pier L. Zinzani

ABSTRACT

7510

Obinutuzumab (G)-atezolizumab (atezo)-lenalidomide (len) for the treatment of relapsed/refractory (R/R) follicular lymphoma (FL): Final analysis of a phase Ib/II trial.

AUTHOR(S)

Nilanjan Ghosh, Gilles A. Salles, Izidore S. Lossos, Maria Lia Palomba, Amitkumar Mehta, Olivier Casasnovas, Don A. Stevens, Sudhakar Katakam, Andrea Knapp, Tina Nielsen, Franck Morschhauser

ABSTRACT

7511

Alternatives to Chemotherapy for Indolent B-Cell Malignancies

DISCUSSANT

Carla Casulo, MD | University of Rochester Medical Center-James P. Wilmot Cancer Center

Polatuzumab vedotin (Pola) + rituximab (R) + lenalidomide (Len) in patients (pts) with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): Primary analysis of a phase 1b/2 trial.

AUTHOR(S)

Catherine S. Magid Diefenbach, Pau Abrisqueta, Eva Gonzalez-Barca, Carlos Panizo, Jose M. Arguinano Perez, Fiona Miall, Mariana Bastos-Oreiro, Armando Lopez-Guillermo, Lalita Banerjee, Andrew McMillan, Jamie Hirata, Lisa Musick, Sourish Saha, Brandon Croft, Erlene K. Seymour

ABSTRACT

7512

Long-term analyses from L-MIND, a phase II study of tafasitamab (MOR208) combined with lenalidomide (LEN) in patients with relapsed or refractory diffuse large B-cell lymphoma (R/R DLBCL).

AUTHOR(S)

Johannes Düll, Kami J. Maddocks, Eva Gonzalez-Barca, Wojciech Jurczak, Anna Marina Liberati, Aleš Obr, Gianluca Gaidano, Pau Abrisqueta, Marc André, Martin H. Dreyling, Tobias Menne, Maren Dirnberger-Hertweck, Johannes Weirather, Sumeet V. Ambarkhane, Gilles A. Salles

ABSTRACT

7513

Multicenter phase II study of romidepsin plus lenalidomide for patients with previously untreated peripheral T-cell lymphoma (PTCL).

AUTHOR(S)

Jia Ruan, Jasmine M. Zain, Brett Palmer, Borko Jovanovic, Xinlei Mi, Alok Swaroop, Jane Winter, Leo I. Gordon, Reem Karmali, Barbara Pro

ABSTRACT

7514

Lenalidomide Combinations for Aggressive Lymphoma

DISCUSSANT

Eliza Anne Hawkes, FRACP, MBBS, MD | Austin Health and Olivia Newton-John Cancer Research Institute

Outcomes in ZUMA-5 with axicabtagene ciloleucel (axi-cel) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) who had the high-risk feature of progression within 24 months from initiation of first anti-CD20-containing chemoimmunotherapy (POD24).

AUTHOR(S)

Caron A. Jacobson, Julio C. Chavez, Alison Sehgal, Basem M. William, Javier Munoz, Gilles A. Salles, Carla Casulo, Pashna N. Munshi, David G. Maloney, Sven De Vos, Ran Reshef, Lori A. Leslie, Ibrahim Yakoub-Agha, Olalekan O. Oluwole, Henry Chi Hang Fung, Vicki Plaks, Yin Yang, Jennifer Lee, Mauro P. Avanzi, Sattva S. Neelapu

ABSTRACT

7515

Preliminary safety and efficacy of PBCAR0191, an allogeneic, off-the-shelf CD19-targeting CAR-T product, in relapsed/refractory (r/r) CD19+ NHL.

AUTHOR(S)

Bijal D. Shah, Caron A. Jacobson, Scott Solomon, Nitin Jain, Monika Vainorius, Christopher R. Heery, Fiona C. He, Ran Reshef, Alex F. Herrera, Luke P. Akard, Craig S. Sauter

ABSTRACT

7516

Engineered immunostimulatory cells can convert PBMCs from chronic lymphocytic leukemia (CLL) patients into potent tumor killing immune cells.

AUTHOR(S)

Joshua W. Keegan, Frank Borriello, Stacey M. Fernandes, Jennifer R. Brown, James A. Lederer

ABSTRACT

7517

Expanding Cellular Solutions for B-Cell Problems

DISCUSSANT

Jeremy S. Abramson, MD | Massachusetts General Hospital Cancer Center, Harvard Medical School

Subcutaneous epcoritamab in patients with relapsed/refractory B-cell non-Hodgkin lymphoma: Safety profile and antitumor activity.

AUTHOR(S)

Michael Roost Clausen, Pieternella Lugtenburg, Martin Hutchings, Peter W. Johnson, Kim M. Linton, David J. Lewis, Martine Chamuleau, Anna Sureda Balari, David Cunningham, Brian Elliott, Dena DeMarco, Kuo-mei Chen, Rogier Mous

ABSTRACT

7518

Glofitamab step-up dosing (SUD): Complete response rates in updated efficacy data in heavily pretreated relapsed/refractory (R/R) non-Hodgkin lymphoma (NHL) patients (pts).

AUTHOR(S)

Carmelo Carlo-Stella, Martin Hutchings, Fritz C. Offner, Franck Morschhauser, Emmanuel Bachy, Michael Crump, Anna Sureda Balari, Gloria Iacoboni, Corinne Haioun, David Perez-Callejo, Linda Lundberg, James Relf, Emma Clark, David Carlile, Emily Piccione, Anton Belousov, Kathryn Humphrey, Michael J. Dickinson

ABSTRACT

7519

Promising tolerability and efficacy results from dose-escalation in an ongoing phase Ib/II study of mosunetuzumab (M) with polatuzumab vedotin (Pola) in patients (pts) with relapsed/refractory (R/R) B-cell non-Hodgkin's lymphoma (B-NHL).

AUTHOR(S)

L E. Budde, Nilanjan Ghosh, Julio C. Chavez, Izidore S. Lossos, Amitkumar Mehta, Kathleen A. Dorritie, Manali K. Kamdar, Raluca Negricea, Song Pham, Maria Hristopoulos, Ling-Yuh Huw, Carol E. O'Hear, Yasuhiro Oki, Iris To, Catherine S. Magid Diefenbach

ABSTRACT

7520

More Specifics About Bispecifics

DISCUSSANT

Mazyar Shadman, MD, MPH | Univ of Washington

Hematologic Malignancies—Plasma Cell Dyscrasia

[Back to Program](#)

Showing 15 Presentations

<https://meetinglibrary.asco.org/session/13650>

MASS-FIX versus standard methods to predict for PFS and OS among multiple myeloma patients participating on the STAMINA trial.

AUTHOR(S)

Angela Dispenzieri, Amrita Y. Krishnan, Bonnie Arendt, Surendra Dasari, Yvonne A. Efebera, Nancy Geller, Sergio Giralt, Theresa Hahn, Mindy C. Kohlhagen, Heather J. Landau, Parameswaran Hari, Marcelo C. Pasquini, Muzaffar H. Qazilbash, Philip L. McCarthy, Nina Shah, David H. Vesole, Dan T. Vogl, Paul K. Wallace, Edward A. Stadtmauer, David L. Murray

ABSTRACT

8009

Analysis of minimal residual disease in bone marrow by NGF and in peripheral blood by mass spectrometry in newly diagnosed multiple myeloma patients enrolled in the GEM2012MENOS65 clinical trial.

AUTHOR(S)

Noemi Puig, Bruno Paiva, Teresa Contreras, M. Teresa Cedena, Laura Rosiñol, Joaquín Martínez, Albert Oriol, Maria Jesus Blanchard, Rafael Rios, María B. Iñigo, Anna Sureda Balari, Hernández-Garcia Miguel Teodoro, Javier de La Rubia, Isabel Krsnik, Moraleda José María, Alberto Orfao, Joan Blade, Jesús F. San-Miguel, Juan José Lahuerta, Maria-Victoria Mateos

ABSTRACT

8010

Interim analysis of a phase 2 minimal residual disease (MRD)-adaptive trial of elotuzumab, carfilzomib, lenalidomide, and dexamethasone (Elo-KRd) for newly diagnosed multiple myeloma (MM).

AUTHOR(S)

Benjamin A. Derman, Jeffrey A. Zonder, Ankit J. Kansagra, David L. Grinblatt, Sunil Narula, Shayan Rayani, Andrew T. Stefka, Ken Jiang, Sarah Major, Brittany Wolfe, Megan Whelan, Bernadette Libao, Amanda McIver, Evangelia Andreatos, Daniel Juergens, Luis Alcantar, Theodore Karrison, Michael R. Bishop, Jagoda Jasielec, Andrzej J. Jakubowiak

ABSTRACT

8011

Prospective comparison of whole body MRI and FDG PET/CT for detection of multiple myeloma and correlation with markers of disease burden: Results of the iTIMM trial.

AUTHOR(S)

Martin F. Kaiser, Nuria Porta, Bhupinder Sharma, Daniel Levine, Dow-Mu Koh, Kevin Boyd, Charlotte Pawlyn, Angela M. Riddell, Kate Downey, Alison Bonner, Veronica A. Morgan, Simon Stern, Lydia Jones, Betty Cheung, Charalampia Kyriakou, Pawel Kaczmarek, Jessica M. Winfield, Matthew D. Blackledge, Wim J. Oyen, Christina Messiou

ABSTRACT

8012

MRD Negativity: Going With the Flow, NGS, Mass-Spec, or PET?

DISCUSSANT

Jens Hillengass, MD, PhD | Roswell Park Cancer Institute

CARTITUDE-2: Efficacy and safety of ciltacabtagene autoleucel (cilta-cel), a BCMA-directed CAR T-cell therapy, in patients with progressive multiple myeloma (MM) after one to three prior lines of therapy.

AUTHOR(S)

Mounzer Agha, Adam D. Cohen, Deepu Madduri, Yael C. Cohen, Michel Delforge, Jens Hillengass, Hartmut Goldschmidt, Katja Weisel, Marc-Steffen Raab, Christof Scheid, Jordan M. Schechter, Kevin C. De Braganca, Helen Varsos, Liwei Wang, Martin Vogel, Marlene Carrasco-Alfonso, Muhammad Akram, Xiaoling Wu, Tonia Nesheiwat, Hermann Einsele

ABSTRACT

8013

Long-term follow-up results of a multicenter first-in-human study of the dual BCMA/CD19 Targeted Fast CAR-T GC012F for patients with relapsed/refractory multiple myeloma.

AUTHOR(S)

Hua Jiang, Baoxia Dong, Li Gao, Li Liu, Jian Ge, Aili He, Lu Li, Jing Lu, Xiequn Chen, Martina A. Serssch, Lianjun Shen, Xun Ye, Hua Zhang, Yi Zhao, Jia Liu, Weijun Fu

ABSTRACT

8014

Phase 1 Study of CART-ddBCMA, a CAR-T therapy utilizing a novel synthetic binding domain, for the treatment of subjects with relapsed and refractory multiple myeloma.

AUTHOR(S)

Matthew J. Frigault, Elizabeth O'Donnell, Noopur S. Raje, Daniella Cook, Andrew Yee, Jacalyn Rosenblatt, Chelsey Gibson, Emma Logan, David Avigan, Michael R. Bishop, Katherine Eckert, Heather Daley, Diego Hernandez Rodriguez, Andrew Mason, Sarah Nikiforow, Carissa Mangus, Aleksandra Gil-Krzewska, Scott Currence, Angela Shen, Marcela V. Maus

ABSTRACT

8015

Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T cell therapy, in relapsed and refractory multiple myeloma: Updated KarMMa results.

AUTHOR(S)

Larry D. Anderson, Jr, Nikhil C. Munshi, Nina Shah, Sundar Jagannath, Jesus G. Berdeja, Sagar Lonial, Noopur S. Raje, David S. Siegel, Yi Lin, Albert Oriol, Philippe Moreau, Ibrahim Yakoub-Agha, Michel Delforge, Fabio Petrocca, Payal Patel, Liping Huang, Timothy B. Campbell, Kristen Hege, Jesús F. San-Miguel

ABSTRACT

8016

CARs in Myeloma: Heading Into a Traffic Jam?

DISCUSSANT

Yi Lin, MD, PhD | Division of Hematology, Mayo Clinic

Updates from ICARIA-MM, a phase 3 study of isatuximab (Isa) plus pomalidomide and low-dose dexamethasone (Pd) versus Pd in relapsed and refractory multiple myeloma (RRMM).

AUTHOR(S)

Paul G. Richardson, Aurore Perrot, Jesús F. San-Miguel, Meral Beksac, Ivan Spicka, Xavier Leleu, Fredrik Schjesvold, Philippe Moreau, Meletios A. Dimopoulos, Jeffrey SY. Huang, Jiri Minarik, Michele Cavo, H. M. Prince, Cheng Zheng, Franck Dubin, Helgi Van De Velde, Kenneth C. Anderson

ABSTRACT

8017

Oral selinexor, pomalidomide, and dexamethasone (XPd) at recommended phase 2 dose in relapsed refractory multiple myeloma (MM).

AUTHOR(S)

Darrell White, Christine Chen, Muhamed Baljevic, Sascha Tuchman, Nizar J. Bahlis, Gary J. Schiller, Brea Lipe, Rami Kotb, Heather J. Sutherland, Sumit Madan, Michael Sebag, Suzanne Lentzsch, Natalie S. Callander, Noa Biran, Christopher P. Venner, Richard LeBlanc, Adriana C. Rossi, Tianjun Zhou, Cristina Gasparetto

ABSTRACT

8018

Survival among older patients with previously treated multiple myeloma treated with selinexor, bortezomib, and dexamethasone (XVd) in the BOSTON study.

AUTHOR(S)

Thierry Facon, Holger W. Auner, Maria Gavriatopoulou, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Luděk Pour, Meletios A. Dimopoulos, Iryna Kriachok, Halyna Pylypenko, Xavier Leleu, Hang Quach, Benjamin Reuben, Tuphan Kanti Dolai, Dinesh Kumar Sinha, Mamta Garg, Don A. Stevens, Jatin J. Shah, Paul G. Richardson, Sebastian Grosicki

ABSTRACT

8019

Oral ixazomib-dexamethasone versus oral pomalidomide-dexamethasone for lenalidomide-refractory, proteasome inhibitor-exposed multiple myeloma (MM) patients: A global, multicenter, randomized, open-label, phase 2 trial.

AUTHOR(S)

Meletios A. Dimopoulos, Fredrik Schjesvold, Vadim Doronin, Olga Vinogradova, Hang Quach, Xavier Leleu, Gonzalez m. Yolanda, Karthik Ramasamy, Alessandra Pompa, Mark-David Levin, Cindy Lee, Ulf-Henrik Mellqvist, Roland Fenk, Hamdi Sati, Alexander Vorog, Richard J. Labotka, Jichang Du, Mohamed Darif, Shaji Kumar

ABSTRACT

8020

Navigating Relapsed Myeloma Therapy: Need a New Map Again

DISCUSSANT

Sandy Wai Kuan Wong, MD | University of California, San Francisco

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

[Back to Program](#)

Showing 16 Presentations

<https://meetinglibrary.asco.org/session/13656>

Real-world multiomic characterization of small cell lung cancer subtypes to reveal differential expression of clinically relevant biomarkers.

AUTHOR(S)

Sonam Puri, Abdul R. Naqash, Andrew Elliott, Kathleen C. Kerrigan, Shiven B. Patel, Andreas Seeber, Florian Kocher, DIPESH UPRETY, Hirva Mamdani, Amit Kulkarni, Gilberto Lopes, Balazs Halmos, Hossein Borghaei, Wallace L. Akerley, Stephen V. Liu, Wolfgang M. Korn, Trudy G. Oliver, Taofeek K. Owonikoko

ABSTRACT

8508

Signatures of plasticity and immunosuppression in a single-cell atlas of human small cell lung cancer.

AUTHOR(S)

Joseph M. Chan, Alvaro Quintanal-Villalonga, Vianne Gao, Viola Allaj, Ignas Masilionis, Ojasvi Chaudhary, Jacklynn V. Egger, Andrew Chow, Thomas Walle, Marissa Mattar, Michael Offin, W. V. Lai, Matthew Bott, Travis Hollman, Tal Nawy, Linas Mazutis, Triparna Sen, Dana Pe'er, Charles M. Rudin

ABSTRACT

8509

Updated results from a phase 1 study of AMG 757, a half-life extended bispecific T-cell engager (BiTE) immuno-oncology therapy against delta-like ligand 3 (DLL3), in small cell lung cancer (SCLC).

AUTHOR(S)

Taofeek K. Owonikoko, Stéphane Champiat, Melissa L. Johnson, Ramaswamy Govindan, Hiroki Izumi, W. V. Lai, Hossein Borghaei, Michael J. Boyer, Rene J. Boosman, Horst-Dieter Hummel, Fiona H. Blackhall, Noemi Reguart, Afshin Dowlati, Yiran Zhang, Sujoy Mukherjee, Mukul Minocha, Yanchen Zhou, Aditya Shetty, Nooshin Hashemi Sadraei, Luis G. Paz-Ares

ABSTRACT

8510

On the Horizon: Personalized Therapy for Small Cell Lung Cancer

DISCUSSANT

Nagla Fawzy Abdel Karim, MD | The University of Cincinnati

Five-year survival outcomes with durvalumab after chemoradiotherapy in unresectable stage III NSCLC: An update from the PACIFIC trial.

AUTHOR(S)

David R. Spigel, Corinne Faivre-Finn, Jhanelle E. Gray, David Vicente, David Planchard, Luis G. Paz-Ares, Johan F. Vansteenkiste, Marina C. Garassino, Rina Hui, Xavier Quantin, Andreas Rimner, Yi-Long Wu, Mustafa Ozguroglu, Ki Hyeong Lee, Terufumi Kato, Maike de Wit, Euan Macpherson, Michael Newton, Piruntha Thiyagarajah, Scott J. Antonia

ABSTRACT

8511

KEYNOTE-799: Phase 2 trial of pembrolizumab plus platinum chemotherapy and radiotherapy for unresectable, locally advanced, stage 3 NSCLC.

AUTHOR(S)

Salma K. Jabbour, Ki Hyeong Lee, Nicolaj Frost, Valeriy V. Breder, Dariusz M. Kowalski, Issam A. Alawin, Evgeny Levchenko, Noemi Reguart, Alex Martinez-Marti, Baerin Houghton, Jean-Baptiste Paoli, Sufia Safina, Keunchil Park, Takefumi Komiya, Amy Sanford, Vishal Boolell, Hong Liu, Ayman Samkari, Steven M. Keller, Martin Reck

ABSTRACT

8512

AFT-16: Phase II trial of neoadjuvant and adjuvant atezolizumab and chemoradiation (CRT) for stage III non-small cell lung cancer (NSCLC).

AUTHOR(S)

Helen J. Ross, David E. Kozono, James J. Urbanic, Terence M. Williams, Carter DuFrane, Ilze Bara, Katja Schulze, Jane M. Brockman, Xiaofei F. Wang, Junheng Gao, Everett E. Vokes, Tom Stinchcombe

ABSTRACT

8513

Sequential or Concurrent Immunoradiotherapy in Locally Advanced Non-Small Cell Lung Cancer

DISCUSSANT

Bradford Perez, MD | Moffitt Cancer Center

Racial differences in incidence, outcomes, and genomic alterations in small cell lung cancer.

AUTHOR(S)

Leyla Bayat, Pingfu Fu, Shufen Cao, Afshin Dowlati

ABSTRACT

8514

Impact of socioeconomic disparities on diagnosis and overall survival in small cell lung cancer: A National Cancer Database analysis.

AUTHOR(S)

Logan Roof, Wei Wei, Katherine Tullio, Nathan A. Pennell, James Stevenson

ABSTRACT

8515

Racial disparities in lung adenocarcinoma: The contribution of African ancestry.

AUTHOR(S)

Michelle J. Lee, Eric Chang, Manan Shah, Sanjay R. Jain

ABSTRACT

8516

Evaluating Health Disparities in Lung Cancer

DISCUSSANT

David Cooke | UC Davis Health System

Residual ctDNA after treatment predicts early relapse in patients with early-stage NSCLC.

AUTHOR(S)

Davina Gale, Katrin Heider, Malcolm Perry, Giovanni Marsico, Andrea Ruiz-Valdepeñas, Viona Rundell, Jerome Wulff, Garima Sharma, Karen Howarth, David Gilligan, Susan Harden, Doris M. Rassl, Robert Rintoul, Nitzan Rosenfeld

ABSTRACT

8517

Leveraging phased variants for personalized minimal residual disease detection in localized non-small cell lung cancer.

AUTHOR(S)

David M. Kurtz, Jacob J. Chabon, Brian Sworder, Lyron Co Ting Keh, Joanne Soo, Stefan Alig, Andre Schultz, Andrea Garofalo, Emily G. Hamilton, Binbin Chen, Mari Olsen, Everett J. Moding, Chih Long Liu, Ash A. Alizadeh, Maximilian Diehn

ABSTRACT

8518

Early detection of lung cancer using cfDNA fragmentation.

AUTHOR(S)

Dimitrios Mathios, Jakob S. Johansen, Stephen Cristiano, Jamie Medina, Jillian Phallen, Klaus Richter Larsen, Daniel Bruhm, Noushin Niknafs, Hans J. Nielsen, Gerrit A. Meijer, Claus L. Andersen, Stig E. Bojesen, Robert Scharpf, Victor E. Velculescu

ABSTRACT

8519

Evolving Applications of Circulating Tumor DNA in Lung Cancer

DISCUSSANT

Vamsidhar Velcheti, MD, FACP, FCCP | Cleveland Clinic Foundation

Lung Cancer—Non-Small Cell Metastatic

[Back to Program](#)

Showing 16 Presentations

<https://meetinglibrary.asco.org/session/13659>

Randomized phase III trial of aumolertinib (HS-10296, Au) versus gefitinib (G) as first-line treatment of patients with locally advanced or metastatic non-small cell lung cancer (NSCLC) and EGFR exon 19 del or L858R mutations (EGFRm).

AUTHOR(S)

Shun Lu, Xiaorong Dong, Hong Jian, Jianhua Chen, Gongyan Chen, Yuping Sun, Yinghua Ji, Ziping Wang, Jianhua Shi, Junguo Lu, Shaoshui Chen, Guojun Zhang, Dongqing Lv, Chunling Liu, Juan Li, Xinmin Yu, Zhong Lin, Zhuang Yu, Zhehai Wang, Jiuwei Cui

ABSTRACT

9013

Mobocertinib (TAK-788) in *EGFR* exon 20 insertion (ex20ins)+ metastatic NSCLC (mNSCLC): Additional results from platinum-pretreated patients (pts) and EXCLAIM cohort of phase 1/2 study.

AUTHOR(S)

Suresh S. Ramalingam, Caicun Zhou, Tae Min Kim, Sang-We Kim, James Chih-Hsin Yang, Gregory J. Riely, Tarek Mekhail, Danny Nguyen, Maria Rosario García Campelo, Enriqueta Felip, Sylvie Vincent, Shu Jin, Veronica Bunn, Jianchang Lin, Huamao M. Lin, Minal Mehta, Pasi A. Janne

ABSTRACT

9014

Combination of trastuzumab, pertuzumab and docetaxel in patients with advanced non-small cell lung cancer (NSCLC) harboring HER2 mutation: Final results from the IFCT-1703 R2D2 trial.

AUTHOR(S)

Julien Mazieres, Claire Lafitte, Charles Ricordel, Laurent Greillier, Jean-Louis Pujol, Gerard Zalcman, Charlotte Domblides, Jeannick Madelaine, Jaafar Bennouna, Celine Mascaux, Denis Moro-Sibilot, François Piquié, Alexis Cortot, Josiane Otto, Jacques Cadranet, Alexandra Langlais, Franck Morin, Virginie Westeel, Benjamin Besse

ABSTRACT

9015

Expanding the Breadth and Scope of ErbB Inhibition in Lung Cancer: New Ways to Target EGFR and HER2 Mutations

DISCUSSANT

Helena Alexandra Yu, MD | Memorial Sloan Kettering Cancer Center

Nivolumab (NIVO) plus ipilimumab (IPI) versus chemotherapy (chemo) as first-line (1L) treatment for advanced non-small cell lung cancer (NSCLC): 4-year update from CheckMate 227.

AUTHOR(S)

Luis G. Paz-Ares, Tudor-Eliade Ciuleanu, Jong-Seok Lee, Laszlo Urban, Reyes Bernabe Caro, Keunchil Park, Hiroshi Sakai, Yuichiro Ohe, Makoto Nishio, Adam Pluzanski, Suresh S. Ramalingam, Julie R. Brahmer, Hossein Borghaei, Kenneth J. O'Byrne, Matthew D. Hellmann, Arteid Memaj, Judith Bushong, Phuong Tran, Martin Reck

ABSTRACT

9016

Effect of antibiotic therapy on immunotherapy outcomes for non-small cell lung cancer: Analysis from the Veterans Health Administration Database.

AUTHOR(S)

William A. Stokes, Madhusmita Behera, Renjian Jiang, David Gutman, Felipe Giuste, Abigail Burns, Nikhil Sebastian, Selvi Ramalingam, Vidula Sukhatme, Michael C. Lowe, Suresh S. Ramalingam, Vikas Sukhatme, Drew Moghanaki

ABSTRACT

9017

Association of a very high tumor mutational load with increased CD8+ and PD-1+ T-cell infiltration and improved clinical outcomes to PD-(L)1 blockade across different PD-L1 expression levels in non-small cell lung cancer.

AUTHOR(S)

Biagio Ricciuti, Kathryn C. Arbour, Joao Victor M. Alessi, Navin Mahadevan, James Lindsay, Rileen Sinha, Natalie I. Vokes, Gonzalo Recondo, Giuseppe Lamberti, Hira Rizvi, Giulia C. Leonardi, Andrew J. Plodkowski, Kristen Felt, Michael Tolstorukov, Pasi A. Janne, Eliezer M. Van Allen, Lynette M. Sholl, Scott J. Rodig, Matthew D. Hellmann, Mark M. Awad

ABSTRACT

9018

Intestinal *Akkermansia muciniphila* predicts overall survival in advanced non-small cell lung cancer patients treated with anti-PD-1 antibodies: Results a phase II study.

AUTHOR(S)

Lisa Derosa, Bertrand Routy, Laurence Zitvogel, Andrew M. Thomas, Gerard Zalcman, Sylvie Friard, Julien Mazieres, Clarisse Audigier-Valette, Denis Moro-Sibilot, Francois Goldwasser, Corentin Richard, François Ghiringhelli, Fabrice Barlesi, Arielle Elkrief, Carolina Alves Costa Silva, David Planchard, Nicola Segata, Stéphanie Martinez, Jean-Charles Soria, Benjamin Besse

ABSTRACT

9019

Bringing More Precision to Immune Checkpoint Inhibitor Therapy in Patients With NSCLC

DISCUSSANT

Anne-Marie C. Dingemans, MD, PhD | Erasmus MC Cancer Institute, University Medical Center Rotterdam, department of Respiratory Medicine

Capmatinib in *MET* exon 14-mutated, advanced NSCLC: Updated results from the GEOMETRY mono-1 study.

AUTHOR(S)

Juergen Wolf, Edward B. Garon, Harry J. Groen, Daniel S. Tan, Anna Robeva, Sylvie Le Mouhaer, Mariana Carбини, Andrea Chassot-Agostinho, Rebecca S. Heist

ABSTRACT

9020

Tepotinib in patients (pts) with advanced non-small cell lung cancer (NSCLC) with *MET* amplification (*METamp*).

AUTHOR(S)

Xiuning Le, Luis G. Paz-Ares, Jan Van Meerbeeck, Santiago Viteri, Carlos Cabrera Galvez, David Vicente Baz, Young-Chul Kim, Jin-Hyoung Kang, Karl-Maria Schumacher, Niki Karachaliou, Svenja Adrian, Rolf Bruns, Paul K. Paik

ABSTRACT

9021

MET in NSCLC: Are We Finally Meeting the Mark?

DISCUSSANT

Giulia Pasello, MD | Istituto Oncologico Veneto IOV IRCCS

Final OS analysis from the phase III j-alex study of alectinib (ALC) versus crizotinib (CRZ) in Japanese ALK-inhibitor naïve *ALK*-positive non-small cell lung cancer (*ALK+* NSCLC).

AUTHOR(S)

Hiroshige Yoshioka, Toyooki Hida, Hiroshi Nokihara, Masahiro Morise, Young Hak Kim, Koichi Azuma, Takashi Seto, Yuichi Takiguchi, Makoto Nishio, Toru Kumagai, Katsuyuki Hotta, Satoshi Watanabe, Koichi Goto, Miyako Satouchi, Toshiyuki Kozuki, Kazuhiko Nakagawa, Tetsuya Mitsudomi, Nobuyuki Yamamoto, Takuya Yoshimoto, Tomohide Tamura

ABSTRACT

9022

Clinicogenomic real-world data analysis of patients (pts) with *KRAS G12C*-mutant advanced non-small cell lung cancer (aNSCLC) from the natural history cohort of the Blood First Assay Screening Trial (BFAST).

AUTHOR(S)

Rafal Dziadziuszko, Xiao Li, Eric C. Anderson, Alona Zer, Luis Corrales-Rodriguez, Parneet Cheema, Aleksandra Szczesna, Manuel Philco, Michael Mathisen, Sarah M. Paul, Vijay Bhagawati-Prasad, Gaurav Pathria, Zhen Shi, Magalie Hilton, qing zhang

ABSTRACT

9023

A phase II study of rucaparib in patients with high genomic LOH and/or BRCA 1/2 mutated stage IV non-small cell lung cancer (Lung-MAP Sub-Study, S1900A).

AUTHOR(S)

Jonathan W. Riess, Mary W. Redman, Paul Wheatley-Price, Bryan A. Faller, Liza C. Villaruz, Larry R. Corum, Aruna C. Gowda, Gordan Srkalovic, Raymond U. Osarogiagbon, Megan A. Baumgart, Lu Qian, Katherine Minichiello, David R. Gandara, Roy S. Herbst, Karen Kelly

ABSTRACT

9024

The ABCs of Lung Cancer Biomarkers in 2021: ALK, BRCA1/2, and KRAS G12C

DISCUSSANT

Mark M. Awad, MD, PhD | Massachusetts General Hospital

Melanoma/Skin Cancers

[Back to Program](#)

Showing 14 Presentations

<https://meetinglibrary.asco.org/session/13662>

Phase II study of ceralasertib (AZD6738), in combination with durvalumab in patients with metastatic melanoma who have failed prior anti-PD-1 therapy.

AUTHOR(S)

Minsuk Kwon, Seung Tae Kim, Simon Smith, Claire Smith, Peter G. Mortimer, Bienvenu LoembE, Iwanka Kozarewa, Emma Dean, Jeeyun Lee

ABSTRACT

9514

Clinical activity of fianlimab (REGN3767), a human anti-LAG-3 monoclonal antibody, combined with cemiplimab (anti-PD-1) in patients (pts) with advanced melanoma.

AUTHOR(S)

Omid Hamid, Ding Wang, Tae Min Kim, Sang-We Kim, Nehal J. Lakhani, Melissa L. Johnson, Roman Groisberg, Kyriakos P. Papadopoulos, John M. Kaczmar, Mark R. Middleton, Alexander I. Spira, Stephen K. Williamson, Guilherme Rabinowits, Rodolfo Gutierrez, Meredith McKean, Shuquan Chen, James Cassidy, Jayakumar Mani, Tasha N. Sims, Glenn Kroog

ABSTRACT

9515

Emerging Therapeutic Approaches for the Management of Metastatic Melanoma

DISCUSSANT

Siwen Hu-Lieskovan, MD, PhD | University of California, Los Angeles

Two dosing regimens of nivolumab (NIVO) plus ipilimumab (IPI) for advanced (adv) melanoma: Three-year results of CheckMate 511.

AUTHOR(S)

Celeste Lebbe, Nicolas Meyer, Laurent Mortier, Ivan Marquez-Rodas, Caroline Robert, Piotr Rutkowski, Marcus O. Butler, Thomas Eigentler, Alexander M. Menzies, Michael Smylie, Ana M. Arance, Paolo A. Ascierto, Inge M. Svane, Mazhar Ajaz, Nikhil I. Khushalani, Maurice Lobo, Jesus Zoco, Jacopo Pigozzo

ABSTRACT

9516

Avelumab in patients with previously treated Merkel cell carcinoma (JAVELIN Merkel 200): Updated overall survival data after more than five years of follow up.

AUTHOR(S)

Paul Nghiem, Shailender Bhatia, Andrew S. Brohl, Omid Hamid, Janice M. Mehnert, Patrick Terheyden, Kent C. Shih, Isaac Brownell, Celeste Lebbe, Karl D. Lewis, Gerald P. Linette, Michele Milella, Huiling Xiong, Guelseren Guezel, Sandra P. D'Angelo

ABSTRACT

9517

Refining Therapies to Maximize Long-Term Benefit in Advanced Skin Cancers

DISCUSSANT

Ragini Reiney Kudchadkar, MD | Winship Cancer Institute

Intrathecal (IT) and intravenous (IV) nivolumab (N) for metastatic melanoma (MM) patients (pts) with leptomeningeal disease (LMD).

AUTHOR(S)

Ida John, Alexandra P. Foster, Cara L. Haymaker, Roland L. Bassett Jr., J. Jack Lee, Michelle L. Rohlfs, Jessie Richard, Masood Iqbal, Ian E. McCutcheon, Sherise D. Ferguson, Amy B. Heimberger, Chantal M. Saberian, Barbara J. O'Brien, Sudhakar Tummala, Nandita Guha- Thakurta, Matthew Debnam, Hussein A. Tawbi, Elizabeth M. Burton, Michael A. Davies, Isabella C. Glitza

ABSTRACT

9519

Phase II Study of TRiplet combination Nivolumab (N) with Dabrafenib (D) and Trametinib (T) (TRIDeNT) in patients (pts) with PD-1 naïve or refractory BRAF-mutated metastatic melanoma (MM) with or without active brain metastases.

AUTHOR(S)

Elizabeth M. Burton, Rodabe N. Amaria, Isabella C. Glitza, Denai R. Milton, Adi Diab, Sapna P. Patel, Jennifer L. McQuade, Virginia Honaker, Michael K. Wong, Patrick Hwu, Jennifer A. Wargo, Michael A. Davies, Hussein A. Tawbi

ABSTRACT

9520

An immunogenomic analysis of melanoma brain metastases (MBM) compared to extracranial metastases (ECM).

AUTHOR(S)

Lucy Kennedy, Amanda E. Van Swearingen, Jeff Sheng, Dadong Zhang, Xiaodi Qin, Eric S. Lipp, Swaminathan Kumar, Gao Zhang, Brent A. Hanks, Michael A. Davies, Kouros Owzar, Carey K. Anders, April K. Salama

ABSTRACT

9521

The Evolving Management of Melanoma CNS Metastases

DISCUSSANT

Priscilla Kaliopi Brastianos, MD | Massachusetts General Hospital and Harvard Medical School

Characterizing the tumor and immune landscape of melanoma patients treated with combined checkpoint blockade and MAPK targeted therapy.

AUTHOR(S)

Liron Zisman, Donald P. Lawrence, David F. McDermott, Mofei Liu, Elizabeth I. Buchbinder, Irena Gushterova, Anna L. Goyne, Justine V. Cohen, David M. Miller, Thomas LaSalle, Emily Blaum, Dennie T. Frederick, Tatyana Sharova, Genevieve M. Boland, Anita Giobbie-Hurder, Moshe Sade-Feldman, Keren Yizhak, Nir Hacohen, Ryan J. Sullivan

ABSTRACT

9522

Effects of baseline lactate dehydrogenase (LDH), interferon gamma (IFN-g) expression, and tumor mutational burden (TMB) on treatment response to first-line atezolizumab (A) + vemurafenib (V) and cobimetinib (C) in *BRAF*^{V600} mutation-positive advanced melanoma.

AUTHOR(S)

Caroline Robert, Karl D. Lewis, Paolo A. Ascierto, Rodrigo R. Munhoz, Gabriella Liskay, Luis de la Cruz-Merino, Judit Olah, Paola Queirolo, Jacek Mackiewicz, Ivor Caro, Kalpit Shah, Harper Forbes, Haocheng Li, Christian Hertig, Yibing Yan, Edward F. Mckenna Jr., Ralf Gutzmer, Grant A. McArthur

ABSTRACT

9523

TMB and *BRAF* mutation status are independent predictive factors in stage IIIC/D/IV melanoma patients receiving adjuvant PD-1 antibodies.

AUTHOR(S)

Andrea Forschner, Julia Eckardt, Peter Martus, Sorin Armeanu-Ebinger, Stephan Ossowski, Irina Bonzheim, Thomas Eigentler, Teresa M. Amaral, Lukas Flatz, Claus Garbe, Christopher Schroeder

ABSTRACT

9524

Integration of Biomarkers Associated With BRAF-Targeted Therapy and Immunotherapy

DISCUSSANT

Dirk Schadendorf, MD | Department of Dermatology, University of Essen; German Cancer Consortium (DKTK), Partner Site Essen

Pediatric Oncology

Back to Program

Showing 16 Presentations

<https://meetinglibrary.asco.org/session/13664>

Feasibility of pevonedistat combined with azacitidine, fludarabine, cytarabine in pediatric relapsed/refractory AML: Results from COG ADVL1712.

AUTHOR(S)

Katherine Tarlock, Xiaowei Liu, Charles G. Minard, Sarah Menig, Joel M. Reid, Emasenyie Isikwei, Sharon Bergeron, Terzah M. Horton, Elizabeth Fox, Brenda Weigel, Todd M. Cooper

ABSTRACT

10018

Phase 1 study of pevonedistat (MLN4924) a NEDD8 activating enzyme inhibitor, in combination with temozolomide (TMZ) and irinotecan (IRN) in pediatric patients with recurrent or refractory solid tumors (ADVL1615).

AUTHOR(S)

Jennifer Foster, Joel M. Reid, Charles G. Minard, Emasenyie Isikwei, Xiaowei Liu, Stacey L. Berg, Sarah G. Injac, Elizabeth Fox, Brenda Weigel

ABSTRACT

10019

Low-dose metronomic topotecan and pazopanib in children with recurrent or refractory solid tumors: A C17 Canadian phase I trial (TOPAZ).

AUTHOR(S)

Arif Manji, Daniel A. Morgenstern, Yvan Samson, Rebecca Deyell, Donna Johnston, Victor A. Lewis, Alexandra P. Zorzi, Jason N. Berman, Kathy Brodeur-Robb, Ellen Morrison, Sylvain Baruchel, James A. Whitlock

ABSTRACT

10020

Leveraging Novel Combinations in Early-Phase Trials

DISCUSSANT

Tanya Maria Trippett, MD | Memorial Sloan Kettering Cancer Center

Naxitamab and GM-CSF for consolidation of high-risk neuroblastoma (HR-NB) patients in complete remission.

AUTHOR(S)

Jaume Mora, Alicia Castañeda, Sara Perez-Jaume, Maite Gorostegui, Vicente Santa-María, Juan Pablo Muñoz, Amalia Varo, Salvador Mañe

ABSTRACT

10021

Efficacy of naxitamab in patients with refractory/relapse (R/R) high-risk neuroblastoma (HR-NB) by bone/bone marrow (BM) evaluation, potential sites of residual disease.

AUTHOR(S)

Brian H. Kushner, Daniel A. Morgenstern, Karsten Nysom, Melissa K. Bear, Karen Tornøe, Nedjad Losic, Jaume Mora

ABSTRACT

10022

Updated outcomes for patients with completely resected pulmonary recurrent osteosarcoma: A report from the Children's Oncology Group.

AUTHOR(S)

Alexander J. Chou, Mark D. Krailo, Ruxu Han, Allen Buxton, Damon R. Reed, Richard G. Gorlick, Steven G. DuBois, Michael Isakoff, Katherine A. Janeway, Pooja Hingorani

ABSTRACT

10023

Inflammatory myofibroblastic tumor: A multi-institutional study from the pediatric surgical oncology research collaborative.

AUTHOR(S)

Barrie S. Rich, Joanna S. Fishbein, Timothy Lautz, Nathan S. Rubalcava, Rodrigo L. Romao, Bindi Naik-Mathuria, Stephanie F. Polites, Eugene Kim, Andreana Butter, Scott S. Short, Marcus M. Malek, Daniel S. Rhee, Alan F. Utria, Sarah J. Commander, Dave Lal, Nelson Piche, Andrew J. Murphy, David H. Rothstein, Roshni Dasgupta, Richard D. Glick

ABSTRACT

10024

Approaches to Achieving and Consolidating Remission in Neuroblastoma and Sarcoma

DISCUSSANT

Ami Vijay Desai, MD, MSCE | University of Chicago Medical Center

Household material hardship and parental distress in a multicenter clinical trial for pediatric acute lymphoblastic leukemia.

AUTHOR(S)

Puja J. Umaretiya, Victoria B. Koch, Kristen E. Stevenson, Peter D. Cole, Lisa M. Gennarini, Justine Kahn, Kara M. Kelly, Thai-Hoa Tran, Bruno Michon, Jennifer J. Welch, Joanne Wolfe, Lewis B. Silverman, Kira O. Bona

ABSTRACT

10025

Financial hardship in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).

AUTHOR(S)

Paul C. Nathan, I-Chan Huang, Yan Chen, Tara O. Henderson, Elyse R. Park, Anne C. Kirchhoff, Leslie L. Robison, Kevin R. Krull, Gregory T. Armstrong, Wendy M. Leisenring, Rena M. Conti, Yutaka Yasui, Robin R. Yabroff

ABSTRACT

10026

Financial Hardship for Patients, Families, and Survivors of Pediatric Cancer

DISCUSSANT

Yousuf Zafar, MD, MHS, FASCO | Duke Cancer Institute

Low-dose radiation to cardiac substructures and late-onset cardiac disease: A report from the Childhood Cancer Survivor Study (CCSS).

AUTHOR(S)

James E. Bates, Suman Shrestha, Qi Liu, Daniel A. Mulrooney, Susan A. Smith, Wendy M. Leisenring, Todd M. Gibson, Eric J. Chow, Kevin C. Oeffinger, Leslie L. Robison, Gregory T. Armstrong, Louis S. Constine, Bradford Hoppe, Choonsik Lee, Yutaka Yasui, Rebecca M. Howell

ABSTRACT

10027

Efficacy of clinical breast examination in chest-irradiated female survivors of childhood Hodgkin lymphoma (HL).

AUTHOR(S)

Florence L. Wong, Janie M. Lee, Wendy M. Leisenring, Joseph P. Neglia, Rebecca M. Howell, Susan A. Smith, Kevin C. Oeffinger, Chaya S. Moskowitz, Tara O. Henderson, Ann Mertens, Paul C. Nathan, Yutaka Yasui, Wendy Landier, Gregory T. Armstrong, Leslie L. Robison, Smita Bhatia

ABSTRACT

10028

Neurocognitive outcomes in survivors of early adolescent and young adult (eAYA) hematologic cancers from the Childhood Cancer Survivor Study (CCSS).

AUTHOR(S)

Amy Y. Wang, Yan Chen, Yutaka Yasui, Wendy Stock, Wendy M. Leisenring, Gregory T. Armstrong, Kevin C. Oeffinger, Eric J. Chow, Kevin R. Krull, Tara O. Henderson

ABSTRACT

10029

Minimizing Late Effects of Radiation in Children

DISCUSSANT

Christine E. Hill-Kayser, MD | Hospital of the University of Pennsylvania

Sarcoma

[Back to Program](#)

Showing 16 Presentations

<https://meetinglibrary.asco.org/session/13680>

A phase II trial of sitravatinib, a multireceptor tyrosine kinase inhibitor, in patients with advanced well-differentiated/dedifferentiated liposarcoma.

AUTHOR(S)

Jay Oza, Sahil Doshi, Shing M. Lee, Brian A. Van Tine, Edwin Choy, Peter J. Oppelt, Shahnaz V. Singh-Kandah, Susana Hernandez, Zoe Singer, Swathi Balaji, Lauren Franks, Matthew Ingham, Gary K. Schwartz

ABSTRACT

11513

Phase 1 trial of seclidemstat (SP-2577) in patients with relapsed/refractory Ewing sarcoma.

AUTHOR(S)

Damon R. Reed, Sant P. Chawla, Bhuvana Setty, Leo Mascarenhas, Paul A. Meyers, Jonathan Metts, Douglas J. Harrison, David Loeb, Brian D. Crompton, David S. Wages, David D. Stenehjem, Daniela Y. Santiesteban, Nadeem Q. Mirza, Steven G. DuBois

ABSTRACT

11514

Outcomes in the dedifferentiated liposarcoma cohort of SAR-096, a phase II trial of ribociclib in combination with everolimus in advanced dedifferentiated liposarcoma (DDL), and leiomyosarcoma (LMS).

AUTHOR(S)

Margaret von Mehren, Sujana Movva, Elizabeth A. Handorf, Priscilla Merriam, Jeffrey A. Morgan, Edwin Choy, Eric D. Tetzlaff, Emma Barker, Allisa C. Harley, April King, Sahar Matloob, Erika Jerome, Lori Rink, Suzanne George

ABSTRACT

11515

Are We Hitting the Target? New Approaches in Sarcoma Care

DISCUSSANT

Benjamin Nacev, MD, PhD | Memorial Sloan Kettering Cancer Center

Eribulin and gemcitabine in previously treated patients with advanced liposarcoma or leiomyosarcoma: A multicenter, single-arm, phase 2-trial.

AUTHOR(S)

Chang Gon Kim, Jin-Hee Ahn, Jeong Eun Kim, Jee Hung Kim, Min Kyung Jeon, Sun Y. Rha, Hyo Song Kim

ABSTRACT

11516

Phase (Ph) 1b/2 evaluation of olaratumab in combination with gemcitabine and docetaxel in advanced soft tissue sarcoma (STS).

AUTHOR(S)

Steven Attia, Victor M. Villalobos, Nadia Hindi, Brian A. Van Tine, Andrew J. Wagner, Bartosz Chmielowski, Donna E. Levy, Matteo Ceccarelli, Robin L. Jones, Mark A. Dickson

ABSTRACT

11517

Updated results of European Organization for Research and Treatment of Cancer (EORTC) phase 2 trial 1202 cabazitaxel in patients with metastatic or inoperable locally advanced dedifferentiated liposarcoma.

AUTHOR(S)

Roberta Sanfilippo, Richard L. Hayward, Jammbe Musoro, Charlotte Benson, Michael G. Leahy, Antonella Brunello, Jean-Yves Blay, Neeltje Steeghs, Ingrid Desar, Nasim Ali, Alice Hervieu, Khin Thway, Sandrine Marreaud, Saskia Litiere, Bernd Kasper

ABSTRACT

11518

Rethinking Cytotoxic Chemotherapy in Soft-Tissue Sarcomas

DISCUSSANT

Vicki Leigh Keedy, MD, MSc | Vanderbilt University Medical Center

Phase II study of atezolizumab in advanced alveolar soft part sarcoma (ASPS).

AUTHOR(S)

Abdul R. Naqash, Geraldine H. O'Sullivan Coyne, Nancy Moore, Elad Sharon, Naoko Takebe, Kristin K. Fino, Katherine V. Ferry-Galow, James S. Hu, Brian A. Van Tine, Melissa A. Burgess, William L. Read, Richard F. Riedel, Suzanne George, John Glod, Anthony P. Conley, Jared C. Foster, Laura K. Fogli, Ralph E. Parchment, James H. Doroshow, Alice P. Chen

ABSTRACT

11519

High clinical activity of pembrolizumab in chordoma, alveolar soft part sarcoma (ASPS) and other rare sarcoma histotypes: The French AcSé pembrolizumab study from Unicancer.

AUTHOR(S)

Jean-Yves Blay, Nicolas Penel, Isabelle L. Ray-Coquard, Sophie Cousin, Francois Bertucci, Emmanuelle Bompas, Jean-Christophe Eymard, Esma Saada-Bouazid, Patrick Soulie, Pascaline Boudou-Rouquette, Armelle Dufresne, Axel Le Cesne, Olivier Mir, Laetitia Gambotti, Frédéric Legrand, Clotilde Simon, Assia Lamrani-Ghaouti, Sylvie Chevret, Christophe Massard

ABSTRACT

11520

Safety and efficacy of letetresgene autoleucel (lete-cel; GSK3377794) in advanced myxoid/round cell liposarcoma (MRCLS) following high lymphodepletion (Cohort 2): Interim analysis.

AUTHOR(S)

Sandra P. D'Angelo, Mihaela Druta, Brian A. Van Tine, David A. Liebner, Scott Schuetze, Aisha N. Hasan, Andrew P. Holmes, Anne Huff, Gurpreet S. Kapoor, Stefan Zajic, Neeta Somaiah

ABSTRACT

11521

Immunotherapy for Rare Sarcomas

DISCUSSANT

Anna Maria Frezza, MD | Adult Mesenchymal and Rare Tumor Unit, Department of Cancer Medicine, Fondazione IRCCS Istituto Nazionale dei Tumori

A phase II, open-label, randomized trial of durvalumab (D) with olaparib (O) or cediranib (C) in patients (pts) with leiomyosarcoma (LMS).

AUTHOR(S)

Olubukola Ayodele, Ben X. Wang, Thomas D. Pfister, Esmail M. Al-Ezzi, Hal Berman, Aaron R. Hansen, Abha A. Gupta, Anna Spreafico, Limore Arones, Philippe L. Bedard, Lindsay Carlsson, Marcus O. Butler, Benjamin Haibe-Kains, Wei Xu, Lillian L. Siu, Albiruni R. Abdul Razak

ABSTRACT

11522

Demographics, outcomes, and risk factors for patients (Pts) with sarcoma and COVID-19: A multi-institutional cohort analysis.

AUTHOR(S)

Michael J. Wagner, Matthew Ingham, Corrie Painter, Rashmi Chugh, Jonathan C. Trent, Vivek Subbiah, Ali R. Khaki, Lisa M. Tachiki, Elizabeth T. Loggers, Chris Labaki, Rana R. McKay, Elizabeth A. Griffiths, Katherine A. Thornton, Anup Kasi, Clara Hwang, James L. Chen, Thorvardur R. Halfdanarson, Daniel Y. Reuben, Cathleen Park, Elizabeth J. Davis

ABSTRACT

11523

Randomized, double-blind, placebo (PL)-controlled, phase III trial of pimitespib (TAS-116), an oral inhibitor of heat shock protein 90 (HSP90), in patients (pts) with advanced gastrointestinal stromal tumor (GIST) refractory to imatinib (IM), sunitinib (SU) and regorafenib (REG).

AUTHOR(S)

Yoshitaka Honma, Yukinori Kurokawa, Akira Sawaki, Yoichi Naito, Shiro Iwagami, Hideo Baba, Yoshito Komatsu, Toshirou Nishida, Toshihiko Doi

ABSTRACT

11524

2020: Immunotherapy, Targeted Therapy, and COVID-19

DISCUSSANT

Suzanne George, MD | Dana-Farber Cancer Institute/Harvard Medical School

Pediatric Oncology II

[Back to Program](#)

Showing 12 Presentations

<https://meetinglibrary.asco.org/session/13667>

Oral selpercatinib in pediatric patients (pts) with advanced *RET*-altered solid or primary CNS tumors: Preliminary results from the phase 1/2 LIBRETTO-121 trial.

AUTHOR(S)

Daniel A. Morgenstern, Leo Mascarenhas, Martin Campbell, David S. Ziegler, Karsten Nysom, Michela Casanova, Alberto S. Pappo, Catherine M. Albert, Meng Xia, Scott S. Barker, Jennifer Wright, Theodore W. Laetsch

ABSTRACT

10009

Phase 2 trial of cabozantinib in children and young adults with refractory sarcomas, Wilms tumor, and rare tumors: Children's Oncology Group Study (ADVL1622).

AUTHOR(S)

Srivandana Akshintala, Brigitte C. Widemann, Donald A. Barkauskas, David Hall, Joel M. Reid, Stephan D. Voss, AeRang Kim, Elizabeth Fox, Brenda Weigel

ABSTRACT

10010

Pilot study of nivolumab in pediatric patients with hypermutant cancers.

AUTHOR(S)

Daniel A. Morgenstern, Natalie B. Collins, Rebecca Deyell, Rina Dvir, Melissa Edwards, Cecile Faure-Conter, Timothy E. Hassall, Lauren Sambira, Emily L. Taylor, Uri Tabori, Eric Bouffet

ABSTRACT

10011

Changes in ctDNA levels after MIBG therapy in patients with relapsed or refractory neuroblastoma.

AUTHOR(S)

Kevin M. Campbell, Kelly S. Klega, David S. Shulman, Denice D. Tsao-Wei, Susan G. Groshen, Fariba Goodarzian, Rachel Berkovich, Hiroyuki Shimada, Araz Marachelian, Judith Villablanca, Julie R. Park, Meaghan Granger, Katherine K. Matthay, Brian D. Crompton, Steven G. DuBois

ABSTRACT

10012

Next-Generation Sequencing for Next-Generation Trials

DISCUSSANT

Neerav Shukla | Memorial Sloan Kettering Cancer Center

Mortality among five-year survivors of childhood cancer: Results over five decades of follow-up in the Childhood Cancer Survivor Study.

AUTHOR(S)

Stephanie B. Dixon, Qi Liu, Matthew J. Ehrhardt, Eric J. Chow, Kevin C. Oeffinger, Ann C. Mertens, Paul C. Nathan, Rebecca M. Howell, Wendy M. Leisenring, Kevin R. Krull, Kirsten K. Ness, Melissa M. Hudson, Leslie L. Robison, Yutaka Yasui, Gregory T. Armstrong

ABSTRACT

10013

Genetic and treatment risks for diabetes mellitus (DM) in survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS) and St. Jude Lifetime (SJLIFE) cohorts.

AUTHOR(S)

Melissa A. Richard, Sogol Mostoufi-Moab, Nisha Rathore, Austin L. Brown, Stephen J. Chanock, Danielle N. Friedman, Maria M. Gramatges, Rebecca M. Howell, Kala Kamdar, Wendy M. Leisenring, Lillian R. Meacham, Lindsay M. Morton, Kevin C. Oeffinger, Leslie L. Robison, Yadav Sapkota, Charles A. Sklar, Yutaka Yasui, Gregory T. Armstrong, Smita Bhatia, Philip Lupo

ABSTRACT

10014

Exercise and QUALity diet After Leukemia (The EQUAL Study): An intervention trial in the Childhood Cancer Survivor Study (CCSS).

AUTHOR(S)

Emily S. Tonorezos, Jeanne M. Clark, Chaya S. Moskowitz, Jennifer S. Ford, Gregory T. Armstrong, Joanne F. Chou, Nidha Z. Mubdi, Aaron McDonald, Charles A. Sklar, Lakshmi Ramanathan, Leslie L. Robison, Kevin C. Oeffinger

ABSTRACT

10015

Risk Factors for Early Mortality in Cancer Survivors: What Is Modifiable?

DISCUSSANT

Karen Elizabeth Effinger, MD, MS | Department of Pediatrics, Emory University and Aflac Cancer and Blood Disorders Center of Children's Healthcare of Atlanta

Racial disparities in pediatric cancer care in the United States: An analysis of the Kids' Inpatient Database.

AUTHOR(S)

Sujith Baliga, Dukagjin Blakaj, Vedat Yildiz, Pranav Puri, Joshua D. Palmer

ABSTRACT

10016

Disparities in cardiovascular risk factors by race/ethnicity among adult survivors of childhood cancer: A report from the Childhood Cancer Survivorship Study (CCSS).

AUTHOR(S)

David H. Noyd, Yutaka Yasui, Nan Li, Eric J. Chow, Smita Bhatia, Andrew Landstrom, Susan Gilchrist, Emily S. Tonorezos, Leah L. Zullig, Jacqueline N. Casillas, Amy M. Berkman, Kirsten K. Ness, Daniel A. Mulrooney, Wendy M. Leisenring, Carrie R. Howell, Jamie M. Shoag, Anne C. Kirchhoff, Rebecca M. Howell, Gregory T. Armstrong, Kevin C. Oeffinger

ABSTRACT

10017

Childhood Cancer Disparities: From Diagnosis to Survivorship

DISCUSSANT

Julie Wolfson, MD, MSHS | University of Alabama at Birmingham

III. POSTER PRESENTATIONS

Breast Cancer—Local/Regional/Adjuvant

[Back to Program](#)

Showing 82 Presentations

<https://meetinglibrary.asco.org/session/13606>

Predict the benefit of metronomic capecitabine maintenance in early-stage triple-negative breast cancer: Results from the SYSUCC-001 study.

AUTHOR(S)

Zhongyu Yuan, Xin Hua, Wang-Zhong Li, Heng Huang, Li Cai, Ying Lin, Lehong Zhang, Qianjun Chen, Jia-Jia Huang, XiWen Bi, Wen Xia, Shu-Sen Wang, Fei Xu, Ruoxi Hong, Kuikui Jiang, Yanxia Shi, Cong Xue, Xin An, Jun Tang, Xi Wang

ABSTRACT

521

Efficacy and safety analysis of Chinese patients in monarchE: Abemaciclib combined with adjuvant endocrine therapy for high risk HR+, HER2- early breast cancer.

AUTHOR(S)

Shao Zhimin, Qingyuan Zhang, Chuan-gui Song, Quchang Ouyang, Zhenzhen Liu, Qiang Liu, Jifeng Feng, Joanne W. Chiu, Ling-Ming Tseng, Chenxi Qian

ABSTRACT

522

Association of statin use with clinical outcomes in patients with triple-negative breast cancer.

AUTHOR(S)

Malgorzata Nowakowska, Xiudong Lei, Mikayla R. Thompson, Simona F. Shaitelman, Mackenzie Wehner, Wendy A. Woodward, Sharon H. Giordano, Kevin T. Nead

ABSTRACT

523

The prognostic performance of PREDICT+ in patients (pts) with HER2-positive (HER2+) early-stage breast cancer (EBC).

AUTHOR(S)

Elisa Agostinetti, Lieveke Ameye, Samuel Martel, Philippe G. Aftimos, Noam Ponde, Christian Maurer, Sarra El-Abed, Yingbo Wang, Maria Lourdes Vicente, Saranya Chumsri, Judith Bliss, Judith R. Kroep, Marco Colleoni, Fausto Petrelli, Lucia Del Mastro, Alvaro Moreno-Aspitia, Martine J. Piccart-Gebhart, Marianne Paesmans, Evandro de Azambuja, Matteo Lambertini

ABSTRACT

524

Retrospective cohort study of estrogen receptor low positive early breast cancer using real world data.

AUTHOR(S)

Shahla Bari, Hung T. Khong, Brian J. Czerniecki, Ricardo L. Costa

ABSTRACT

525

Trastuzumab deruxtecan (T-DXd) in patients with HER2+ metastatic breast cancer with brain metastases: A subgroup analysis of the DESTINY-Breast01 trial.

AUTHOR(S)

Guy H. Jerusalem, Yeon Hee Park, Toshinari Yamashita, Sara A. Hurvitz, Shanu Modi, Fabrice Andre, Ian E. Krop, Xavier Gonzalez, Peter S. Hall, Benoit You, Cristina Saura, Sung-Bae Kim, Cynthia R. Osborne, Yasuaki Sagara, Eriko Tokunaga, Yali Liu, Jillian Cathcart, Caleb C. Lee, Christophe Perrin

ABSTRACT

526

Bone safety profile of steroidal aromatase inhibitor in comparison to non-steroidal aromatase inhibitors in postmenopausal women with breast cancer: A network meta-analysis.

AUTHOR(S)

Shanshan Chen, Bo Lan, Dan Lv, Fei Ma

ABSTRACT

527

The impact of COVID-19 on breast cancer stage at diagnosis.

AUTHOR(S)

Maxwell Lloyd, Sarah Jo Stephens, Julian C. Hong, Ted A. James, Tejas Mehta, Abram Recht, Daphna Spiegel

ABSTRACT

528

Efficacy of epirubicin plus cyclophosphamide followed by taxanes versus carboplatin plus taxanes as adjuvant chemotherapy in triple-negative breast cancer: 8.1 years median follow-up on a randomized clinical trial.

AUTHOR(S)

Fangchao Zheng, Feng Du, Yongsheng Wang, Xue Wang, Jiayu Wang, Jian Yue, Fei Ma, Ying Fan, Binghe Xu, Peng Yuan

ABSTRACT

529

Use of a novel convolutional neural network-based mammographic evaluation to assess response to adjuvant endocrine therapy in women with early-stage breast cancer.

AUTHOR(S)

Julia E. McGuinness, Vicky Ro, Simukayi Mutasa, Richard Ha, Katherine D. Crew

ABSTRACT

530

Breast Cancer Index and prediction of benefit from extended endocrine therapy based on treatment compliance: An IDEAL study.

AUTHOR(S)

Gerrit-Jan Liefers, Iris Noordhoek, Kai Treuner, Hein Putter, Jenna Wong, Yi Zhang, Elma Meershoek – Klein Kranenbarg, Cornelis J. Van De Velde, Catherine A. Schnabel

ABSTRACT

531

A validated model to predict low recurrence risk distinguished by 21-gene recurrence score in hormone receptor-positive invasive breast cancer patients.

AUTHOR(S)

Yasue Tsuchida, Sachiko Ohde, Ryota Nakamura, Yoko Kanada, Sakiko Miura, Masafumi Takimoto, Seigo Nakamura, Naoki Kanomata, Hideko Yamauchi, Naoki Hayashi

ABSTRACT

532

Clinical trial testing superiority of combination plinabulin (Plin) and pegfilgrastim (Peg) versus peg alone in breast cancer treated with high-risk febrile neutropenia

risk chemotherapy (chemo): Final results of the phase 3 protective-2 in chemo-induced neutropenia (CIN) prevention.

AUTHOR(S)

Douglas W. Blayney, Yuankai Shi, Hryhorii Adamchuk, David Feng, Qingyuan Zhang, Lihua Du, Lan Huang, Ramon Mohanlal

ABSTRACT

533

Cost-effectiveness of the Oncotype DX Breast Recurrence Score test in postmenopausal women with node-positive early breast cancer based on the RxPONDER trial.

AUTHOR(S)

Vladislav Berdunov, Steve Millen, Andrew Paramore, Sarah Reynia, Nina Fryer, Jane Griffin, Nadia Georges

ABSTRACT

534

Outcome and immune landscape of HER2-positive invasive lobular carcinoma in the North Central Cancer Treatment Group (NCCTG) N9831 (Alliance) trial.

AUTHOR(S)

Saranya Chumsri, Zhuo Li, Tracy Shachner, Pooja Advani, Kostandinos Sideras, Alvaro Moreno-Aspitia, Gerardo Colon-Otero, Keith L. Knutson, Aziza Nassar, Edith A. Perez

ABSTRACT

535

Dose escalation for mitigating diarrhea: Ranked tolerability assessment of anti-diarrheal regimens in patients receiving neratinib for early-stage breast cancer.

AUTHOR(S)

Gavin M. Marx, Amy J. Chien, José A. García-Sáenz, Arlene Chan, Manuel Ruiz-Borrego, Carlos H. Barcenas, Michael P. Thirlwell, Maureen E. Trudeau, Ron Bose, Daniel Egle, Barbara Pistilli, Johanna Wassermann, Kerry A. Cheong, Dieter Semsek, Christian F. Singer, Daniel Hunt, Utpal Khambholja, Feng Xu, Naisargee Shah, Adam Brufsky

ABSTRACT

536

Clinical validation of EndoPredict in premenopausal women with estrogen receptor-positive (ER+), human epidermal growth factor receptor 2-negative (HER2-) primary breast cancer.

AUTHOR(S)

Anastasia Constantinidou, Yiola Marcou, Timothy Simmons, Ryan Bernhisel, Elisha Hughes, Stephanie Meek, Eleni I. Kakouri, Georgios Georgiou, Ioanna Zouvani, Gabriella Savvidou, Vanessa Kuhl, Jennifer Doedt, Susanne Wagner, Alexander Gutin, Jerry Lanchbury, Ralf Kronenwett, Emad A. Rakha

ABSTRACT

537

De-escalation of five years adjuvant endocrine therapy duration in patients with ER-low positive (immunohistochemical 1% to 10%) early-stage breast cancer: A propensity-matched analysis from the prospectively maintained database.

AUTHOR(S)

Keda Yu, Yuwen Cai, Zhiming Shao

ABSTRACT

538

Comprehensive genomic profiling (CGP) of 275 male breast cancer (BC) tissue (TBx) and liquid (LBx) biopsies: Comparative analysis to a female cohort (FBC) and therapeutic considerations.

AUTHOR(S)

Arun Kadamkulam Syriac, Allison Clark, Mehrad Tavallai, Dexter X. Jin, Ethan Sokol, Kimberly McGregor, Jeffrey S. Ross, Natalie Danziger, Jose P. Leone

ABSTRACT

539

Association between treatment duration and overall survival in early-stage HER2+ breast cancer patients receiving extended adjuvant therapy with neratinib in the ExteNET trial.

AUTHOR(S)

Beverly Moy, Masato Takahashi, Shoichiro Ohtani, Ewa Chmielowska, Naohito Yamamoto, Bruno P. Coudert, Feng Xu, Alvin F. Wong, Arlene Chan

ABSTRACT

540

PD-L1 expression and TOP3A mutation as prognostic factors for adjuvant chemotherapy in triple negative breast cancer.

AUTHOR(S)

Xue Wang, Peng Yuan, Feng Du, Lina Cui, Fangchao Zheng, Jian Yue, Bei Zhang, Jiayu Wang, Ying Fan, Fei Ma, Binghe Xu

ABSTRACT

541

Final five-year median follow-up safety data from a prospective, randomized, placebo-controlled, single-blinded, multicenter, phase IIb study evaluating the use of HER2/neu peptide GP2 + GM-CSF vs. GM-CSF alone after adjuvant trastuzumab in HER2 positive women with operable breast cancer.

AUTHOR(S)

Snehal Patel, David McWilliams, Christine T. Fischette, Jaye Thompson, Mira Patel, F. J. Daugherty

ABSTRACT

542

Survival following locoregional recurrence in breast cancer by clinical subtype.

AUTHOR(S)

Kirsten Allen, Caroline A. Lohrisch, Dan Le, Rekha M. Diocee, Caroline Speers, Alan Nichol, Sara K. Taylor

ABSTRACT

543

Potential non-drug cost differences associated with the use of the fixed-dose combination of pertuzumab and trastuzumab for subcutaneous injection (PH FDC SC) in the treatment of HER2-positive early breast cancer patients in Western Europe and the United States.

AUTHOR(S)

Federico Manevy, Gabriele Filkauskas, Pierre Levy, Judy Fredriksson, Jesse Sussell

ABSTRACT

544

Impact of endocrine therapy on overall survival in ER negative/PR positive locoregional breast cancer: An analysis of the National Cancer Database.

AUTHOR(S)

Vidya Kollu, Kohei Osterloth, Andrew J. Borgert, Susan M. Frankki, Benjamin M. Parsons

ABSTRACT

545

Chemotherapy induced profound neutropenia (PN) in patients (pt) with breast cancer (BC) after chemotherapy and plinabulin (Plin) plus pegfilgrastim (Peg) combination versus (vs) peg alone: Final phase 3 results from protective-2 (BPI-2358-106).

AUTHOR(S)

Yuankai Shi, Douglas W. Blayney, Hryhorii Adamchuk, Qingyuan Zhang, Lihua Du, Lan Huang, Ramon Mohanlal

ABSTRACT

546

Head-to-head comparison of single agent (SA) plinabulin (Plin) versus pegfilgrastim (Peg) for the prevention of chemotherapy-induced neutropenia (CIN) in the phase 3 trial PROTECTIVE-1.

AUTHOR(S)

Douglas W. Blayney, Yuankai Shi, Igor Bondarenko, Stephan Ogenstad, Qingyuan Zhang, Lihua Du, Lan Huang, Ramon Mohanlal

ABSTRACT

547

Long-term outcomes of patients with node-negative (N0), triple-negative breast cancer (TNBC) who did not receive adjuvant chemotherapy according to stromal TILs (sTILs).

AUTHOR(S)

Roberto A. Leon-Ferre, Jodi M. Carter, David W. Hillman, Kathleen S. Tenner, David Zahrieh, Minetta C. Liu, James N. Ingle, Krishna R. Kalari, Daniel W. Visscher, Judy C. Boughey, Fergus Couch, Matthew P. Goetz

ABSTRACT

548

Validation of the RSClin risk calculator using the National Cancer Database (NCDB).

AUTHOR(S)

Frederick Howard, Alexander T. Pearson, Rita Nanda, Olufunmilayo I. Olopade, Dezheng Huo

ABSTRACT

549

Molecular characterization of luminal breast tumors in African American women.

AUTHOR(S)

Yael Simons, Mohamed Hassan, George Chlipala, Oana C. Danciu, Vijayakrishna K. Gadi, Manmeet Singh, Gayatri Mohapatra, Kent Hoskins

ABSTRACT

550

Population-based estimates of the age-specific cumulative risk of breast cancer for pathogenic variants in *CHEK2*: Findings from the Australian Breast Cancer Family Registry.

AUTHOR(S)

Tu Nguyen-Dumont, James Dowty, Jason A. Steen, Anne-Laure Renault, Fleur Hammet, Maryam Mahmoodi, Derrick Theys, Amanda Rewse, Helen Tsimiklis, Ingrid Winship, Graham G. Giles, Roger L. Milne, John L. Hopper, Melissa C. Southey

ABSTRACT

551

Use of a high-sensitivity anti-Mullerian hormone (AMH) assay to determine ovarian function after chemotherapy for early breast cancer.

AUTHOR(S)

Florian Clatot, Kelsey Thomas, Matteo Lambertini, Nathalie Olympios, Orianne Duhamel, Anne Perdrix, Richard Anderson

ABSTRACT

552

A gp78/AMFR protein-driven gene signature that predicts breast cancer outcome.

AUTHOR(S)

Sandeep K. Singhal, Jung Byun, Samson Park, Tingfen Yan, Ryan Yancey, Ambar Caban, Clayton Yates, Paula L. Farré, Adriana D. Siervi, Anna Napoles, Nasreen A. Vohra, Allan M. Weissman, Mei Yang, Yien C. Tsai, Kevin Gardner

ABSTRACT

553

Neoadjuvant talazoparib (TALA) in patients (pts) with germline *BRCA1/2* (g*BRCA1/2*) mutation-positive, early HER2-negative breast cancer (BC): Exploration of tumor *BRCA* mutational status and zygosity and overall mutational landscape in a phase 2 study.

AUTHOR(S)

Melinda L. Telli, Jennifer K. Litton, Joseph T. Beck, Jason M. Jones, Jay Andersen, Lida A. Mina, Raymond Brig, Michael A. Danso, Yuan Yuan, William F. Symmans, Antonello Abbattista, Kay Noonan, Marielena Mata, Douglas Laird, Joanne L. Blum

ABSTRACT

554

ER and immune-related signatures define benefit to palbociclib, trastuzumab, pertuzumab +/- fulvestrant in ER+/HER2+ breast cancer patients in the NA-PHER2 trial.

AUTHOR(S)

Giampaolo Bianchini, Matteo Dugo, Balazs Gyorffy, Giancarlo Bisagni, Marco Colleoni, Mauro Mansutti, Claudio Zamagni, Lucia Del Mastro, Stefania Zambelli, Antonio Frassoldati, Luca Licata, Barbara Galbardi, Maria O. Biasi, Lucia Viganò, Alberta Locatelli, Chanel Smart, Giuseppe Viale, Pinuccia Valagussa, Maurizio Callari, Luca Gianni

ABSTRACT

555

Dysregulation of soluble immune checkpoint proteins in newly-diagnosed early breast cancer patients.

AUTHOR(S)

Bernardo L. Rapoport, Helen C. Steel, Teresa Smit, Liezl Heyman, Annette J. Theron, Luyanda L. Kwofie, Carol Benn, Ronald Anderson

ABSTRACT

556

Genomic characteristics of breast cancer to predict response of neoadjuvant chemotherapy and long-term prognosis.

AUTHOR(S)

Ji-Yeon Kim, Kyunghee Park, Woong-Yang Park, Jeong Eon Lee, Seok Won Kim, Seok Jin Nam, Se-Kyung Lee, Zhengyan Kan, Yeon Hee Park

ABSTRACT

557

MamaPred: A new and innovative approach to determine recurrence risk in HR+/HER2- early-stage breast cancer using HTG EdgeSeq technology.

AUTHOR(S)

Jose Antonio Lopez Guerrero, Carlos Loucera, Marta Ramírez-Calvo, María Peña, Antonio Fernandez-Serra, Angel Guerrero-Zotano, José Palacios, Octavio Burgues, Sonia Servitja, Ignacio Tusquets, Gloria Peiro, Begoña Bermejo, Joan Albanell, Antonio Llombart-Cussac, Joaquin Dopazo

ABSTRACT

558

Gene expression associated with lymphovascular invasion and genomic risk in early-stage breast cancer.

AUTHOR(S)

Nina D'Abreo, Abhinav Rohatgi, Douglas K. Marks, Heather Kling, Josien Haan, William Audeh

ABSTRACT

559

Race, subjective social status and metabolic syndrome in women with breast cancer.

AUTHOR(S)

Giampaolo Greco, Emily J. Gallagher, Derek Leroith, Sylvia Lin, Radhi Yagnik, Sheldon M. Feldman, Brigid K. Killelea, Neil B. Friedman, Melissa L. Pilewskie, Lydia Choi, Nina A. Bickell

ABSTRACT

560

Association of allograft rejection response score with biological cancer aggressiveness and with better survival in triple-negative breast cancer (TNBC).

AUTHOR(S)

Masanori Oshi, Lan Le, Fernando A. Angarita, Yoshihisa Tokumaru, Li Yan, Ryusei Matsuyama, Itaru Endo, Kazuaki Takabe

ABSTRACT

561

Association of changes of pro-inflammatory markers with physical function in women with breast cancer receiving chemotherapy.

AUTHOR(S)

Nikeshia Gilmore, Elizabeth Belcher, Po-Ju Lin, Amber Kleckner, Sindhuja G. Kadambi, Kah Poh Loh, Mostafa R. Mohamed, Karen M. Mustian, Steven W. Corso, Benjamin Esparaz, Jeffrey K. Giguere, Supriya G. Mohile, Michelle C. Janelins

ABSTRACT

562

Molecular profiles of genomically high risk ER+ HER2- breast cancer tumors classified as functionally basal or luminal B by the 80-gene signature.

AUTHOR(S)

Joyce O'Shaughnessy, Virginia G. Kaklamani, Yuan Yuan, Julie Barone, Sami Diab, Jennifer A. Crozier, Pat W. Whitworth, Karen L. Tedesco, Robert Maganini, Rakhshanda Layeequr Rahman, Carlos A. Encarnacion, Josien Haan, Amy M. Truitt, Andrea Menicucci, William Audeh

ABSTRACT

563

Characterization of the tumor immune microenvironment of triple negative breast cancer (TNBC) patients who self-identify as African American (AA) or non-African American (NonAA).

AUTHOR(S)

Kim Blenman, Michal Marczyk, Tao Qing, Tess O'Meara, Vesal Yaghoobi, Vasiliki Pelekanou, Yalai Bai, Emily Reisenbichler, Xiaotong Li, Vignesh Gunasekharan, Eiman Y. Ibrahim, David L. Rimm, Lajos Pusztai, Kimberly Cole

ABSTRACT

564

Whole transcriptome analysis comparing HR+ HER2- breast cancer tumors from patients < 50 years and >50 years.

AUTHOR(S)

Cathy Graham, Douglas K. Marks, Nina D'Abreo, Sami Diab, Vijayakrishna K. Gadi, Midas Kuilman, Andrea Menicucci, Amy M. Truitt, Shiyu Wang, William Audeh

ABSTRACT

565

Long-term results of simplified lymphatic microsurgical preventing healing approach (SLYMPHA) for the prevention of breast cancer-related clinical lymphedema after axillary lymph node dissection.

AUTHOR(S)

Tolga Ozmen, Christina Layton, Orli Friedman-Eldar, Siarhei Melnikau, Susan Kesmodel, Eli Avisar

ABSTRACT

514

Adding carbon nanoparticles to dual-tracers for the sentinel node evaluation after neoadjuvant chemotherapy in patients with pretreatment node-positive breast cancers: The TT-SLNB trial.

AUTHOR(S)

Jie Chen, Jiqiao Yang, Tao He, Yunhao Wu, Xian Jiang, Zhoukai Fu, Qing Lv, Shan Lu, Xiaodong Wang, Hongjiang Li, Jing Wang

ABSTRACT

566

Clinicopathologic features of breast cancers diagnosed in females treated with prior radiation therapy for Hodgkin lymphoma: Results from a population-based cohort.

AUTHOR(S)

Stephanie M. Wong, Lissa Ajjamada, Anna Weiss, Ipshita Prakash, Sonia Skamene, Jean-Francois Boileau, Michael N. Pollak, Mark Basik

ABSTRACT

567

Impact of patient, tumour and treatment factors on psychosocial outcomes in invasive breast cancer.

AUTHOR(S)

David W. Lim, Helene Retrouvey, Isabel Kerrebijn, Kate Butler, Anne C. O'Neill, Tulin D. Cil, Toni Zhong, Stefan O. Hofer, David R. McCready, Kelly A. Metcalfe

ABSTRACT

568

Survival in male breast cancer (MaBC) over the past three decades.

AUTHOR(S)

Jose P. Leone, Rachel A. Freedman, Julieta Leone, Michael J. Hassett, Sara M. Tolaney, Carlos T. Vallejo, Bernardo A. Leone, Eric P. Winer, Nancy U. Lin

ABSTRACT

569

Role of 21- gene recurrence score in patients age ≥ 70 with T1N0 ER/PR+ HER2- breast cancer treated with breast-conserving surgery and endocrine therapy.

AUTHOR(S)

Neil C. Chevli, Waqar Haque, Kevin T. Tran, Andrew M. Farach, Mary R. Schwartz, Charles E. Geyer Jr., Sandra S. Hatch, E. Brian Butler, Bin S. Teh

ABSTRACT

571

Trends in breast cancer mortality according to molecular subtypes: A population-based study.

AUTHOR(S)

Yunan Han, Shuai Xu, Graham A. Colditz, Adetunji T. Toriola

ABSTRACT

572

Pyrotinib as neoadjuvant therapy for HER2+ breast cancer: A multicenter, randomized, controlled, phase II trial.

AUTHOR(S)

Xiaowen Ding, Wenju Mo, Xiaohong Xie, Ouchen Wang, Yuqin Ding, Shuai Zhao, Xiangming He, Weiliang Feng, Dehong Zou, Hongjian Yang

ABSTRACT

574

Racial differences and trends in pathologic complete response following neoadjuvant chemotherapy for breast cancer.

AUTHOR(S)

Sung Jun Ma, Brian Yu, Lucas M. Serra, Austin Bartl, Mark Farrugia, Austin Iovoli, Oluwadamilola T. Oladeru, Joseph Miccio, Saif Aljabab, Simon Fung-Kee-Fung, Daphne A. Haas-Kogan, Anurag K. Singh

ABSTRACT

575

Evaluation of risk-stratification using gene expression assays in patients with breast cancer receiving neoadjuvant chemotherapy.

AUTHOR(S)

Sung Jun Ma, Brian Yu, Lucas M. Serra, Austin Bartl, Mark Farrugia, Austin Iovoli, Oluwadamilola T. Oladeru, Joseph Miccio, Saif Aljabab, Simon Fung-Kee-Fung, Daphne A. Haas-Kogan, Anurag K. Singh

ABSTRACT

576

Evaluation of pharmacodynamic (PD) and biologic activity in a preoperative window-of-opportunity (WOO) study of giredestrant (GDC-9545) in postmenopausal patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) operable breast cancer (BC).

AUTHOR(S)

Heather M. Moore, Valentina Boni, Meritxell Bellet, Begoña Bermejo De Las Heras, Maria Gíon Cortés, Catherine Oakman, Peter Schmid, Xuan Bich Trinh, Duncan Wheatley, Komal L. Jhaveri, Peter Kabos, Elgene Lim, Thierry Velu, Ciara Metcalfe, Mary R. Gates, Ching-Wei Chang, John Bond, Leonard D. Goldstein, Jennifer O. Lauchle, Aditya Bardia

ABSTRACT

577

A phase 2 trial of talimogene laherparepvec (TVEC) in combination with neoadjuvant chemotherapy for the treatment of nonmetastatic triple-negative breast cancer.

AUTHOR(S)

Hatem H. Soliman, Hyo S. Han, Deanna Hogue, Blaise Mooney, Ricardo L. Costa, Marie C. Lee, Bethany Niell, Angela Williams, Alec Chau, Shannon Falcon, Nazanin Khakpour, Aixa Soyano, Avan J. Armaghani, Robert J. Weinfurter, Susan Hoover, John Kiluk, Marilyn Rosa, Brooke Fridley, Hung T. Khong, Brian J. Czerniecki

ABSTRACT

578

Pathological complete response rate and survival in patients with *BRCA*-associated triple-negative breast cancer after 12 weeks of de-escalated neoadjuvant chemotherapy: Translational results of the WSG-ADAPT TN randomized phase II trial (NCT01815242).

AUTHOR(S)

Lisa Katharina K. Richters, Oleg Gluz, Nana Weber-Lassalle, Matthias Christgen, Heinz Haverkamp, Sherko Kuemmel, Mohamad Kayali, Ronald E. Kates, Eva-Maria Grischke, Michael Braun, Mathias Warm, Rachel Wuerstlein, Corinna Ernst, Monika K. Graeser, Jan Hauke, Ulrike Nitz, Hans H. Kreipe, Rita K. Schmutzler, Eric Hahnen, Nadia Harbeck

ABSTRACT

579

Evaluation of sensitivity to endocrine therapy index (SET2,3) for response to neoadjuvant endocrine therapy (NET) and subsequent prognosis.

AUTHOR(S)

William F. Symmans, Lili Du, Tanya L. Hoskin, Meenakshi Anurag, Cynthia X. Ma, Isabelle Bedrosian, Kelly Hunt, Matthew J. Ellis, Vera J. Suman

ABSTRACT

580

Effect of moderate physical exercise on the immune system modulation in patients with breast cancer during preoperative chemotherapy: The NEO-RUNNER study.

AUTHOR(S)

Ornella Garrone, Andrea Abbona, Antonella Falletta, Matteo Paccagnella, Nicoletta Croce, Paola Vanella, Fiorella Ruatta, Daniela Rubini, Anna Maria Vandone, Antonio Votero Prina, Nerina Denaro, Marco C. Merlano

ABSTRACT

581

Independent validation of simbiosys tumorscope to predict response to neoadjuvant chemotherapy (NACT) in early breast cancer (EBC).

AUTHOR(S)

Gong He, Frederick Howard, Tushar Pandey, Hiroyuki Abe, Rita Nanda

ABSTRACT

582

Phase II prospective open label study of neoadjuvant pertuzumab, trastuzumab, and nab-paclitaxel in patients with HER-2 positive advanced breast cancer.

AUTHOR(S)

Sayeh M. Lavasani, Susan E. Yost, Paul H. Frankel, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, Laura Kruper, Lusine Tumyan, Dan Schmolze, Francesca Menghi, Edison T. Liu, Christina H. Yeon, Yuan Yuan, James R. Waisman, George Somlo, Joanne E. Mortimer

ABSTRACT

583

Computational features of tumor-infiltrating lymphocyte architecture of residual disease after chemotherapy on H&E images as prognostic of overall and disease-free survival for triple-negative breast cancer.

AUTHOR(S)

Germán Corredor, Paula Toro, Cheng Lu, Pingfu Fu, Shaveta Vinayak, Miluska Castillo Garcia, Luis A. Bernabe, Carlos A. Castaneda Altamirano, Alberto J. Montero, Aparna Harbhajanka, Hannah L. Gilmore, Anant Madabhushi

ABSTRACT

584

Impact of dendritic cell vaccines added to neoadjuvant CT on pathological complete responses in early breast cancer patients according to PD-L1 expression.

AUTHOR(S)

Ignacio Ortego, Angel M. Vizcay, Susana De La Cruz, Belén Pérez-Solans, Sandra Rubio, Javier Blanco, Miguel A. Idoate, Laura Hato, Susana Inoges Sancho, Ascension Lopez Diaz de Cerio, Salvador Martin-Algarra, Marta Santisteban

ABSTRACT

585

Impact of different sequencing strategies of talazoparib and carboplatin combination upon efficacy and toxicity in BRCA-wild type and BRCA-mutant triple-negative breast cancer models.

AUTHOR(S)

Michele Beniey, Alexia Cotte, Audrey Hubert, Nelly Bechir, Takrima Haque, Danh Tran-Thanh, Saima N. Hassan

ABSTRACT

586

Treatment Efficacy Score (TES), a continuous residual cancer burden-based metric to compare neoadjuvant chemotherapy efficacy between trial arms in the I-SPY 2 trial.

AUTHOR(S)

Michal Marczyk, Anna Mrukwa, Christina Yau, Denise M. Wolf, Laura van 't Veer, Laura Esserman, William F. Symmans, Lajos Pusztai

ABSTRACT

587

Does timing of chemotherapy impact breast satisfaction after breast conservation therapy and mastectomy with immediate reconstruction?

AUTHOR(S)

Kate R. Pawloski, Tracy-Ann Moo, Varadan Sevilimedu, Jonas A. Nelson, Paula Garcia, Laurie J. Kirstein, Monica Morrow, Audree B. Tadros

ABSTRACT

589

The impact of gut microbial composition on response to neoadjuvant chemotherapy (NACT) in early-stage triple negative breast cancer (TNBC).

AUTHOR(S)

Nour Abuhadra, Chia-Chi Chang, Clinton Yam, Jason B. White, Elizabeth Ravenberg, Bora Lim, Naoto T. Ueno, Jennifer K. Litton, Banu Arun, Senthil Damodaran, Rashmi K. Murthy, Nuhad K. Ibrahim, Gabriel N. Hortobagyi, Vicente Valero, Debu Tripathy, Alastair M. Thompson, Elizabeth A. Mittendorf, Lei Huo, Stacy L. Moulder, Robert R. Jenq

ABSTRACT

590

Multi-gene prognostic assays and age-related differences in prediction of pathologic complete response to neoadjuvant chemotherapy and survival in breast cancer.

AUTHOR(S)

Kent Hanson, Kent Hoskins, Naomi Y. Ko, Gregory S. Calip

ABSTRACT

591

Neoadjuvant atezolizumab (atezo) and nab-paclitaxel (nab-p) in patients (pts) with triple-negative breast cancer (TNBC) with suboptimal clinical response to doxorubicin and cyclophosphamide (AC).

AUTHOR(S)

Clinton Yam, Elizabeth A. Mittendorf, Ryan Sun, Lei Huo, Senthil Damodaran, Gaiane M. Rauch, Rosalind P. Candelaria, Beatriz E. Adrada, Sahil Seth, William F. Symmans, Rashmi K. Murthy, Jason B. White, Elizabeth Ravenberg, Alyson Clayborn, Sabitha Prabhakaran, Vicente Valero, Alastair M. Thompson, Debu Tripathy, Stacy L. Moulder, Jennifer K. Litton

ABSTRACT

592

Automated, IHC/FISH-free, H&E histopathology image-based HER2 amplification, tumor infiltrating lymphocyte (TIL) and tumor heterogeneity profiling in breast cancer.

AUTHOR(S)

Satabhisa Mukhopadhyay, Tathagata Dasgupta, Nicolas M. Orsi, Michele Cummings, Angelene Berwick

ABSTRACT

593

Investigating survivin as a novel target in black women with breast cancer.

AUTHOR(S)

Andrea Walens, Linnea T. Olsson, Sarah Van Alsten, Lisa A. Carey, Melissa A. Troester, Yara Abdou

ABSTRACT

594

A011801 (CompassHER2 RD): Postneoadjuvant T-DM1 + tucatinib/placebo in patients with residual HER2-positive invasive breast cancer.

AUTHOR(S)

Ciara C. O'Sullivan, Karla V. Ballman, Linda M. McCall, Tyler J. Zemla, Anna Weiss, Melissa Mitchell, Victoria S. Blinder, Nadine M. Tung, William J. Irvin Jr., Myounghee Lee, Matthew P. Goetz, William F. Symmans, Virginia F. Borges, Ian E. Krop, Ann H. Partridge, Lisa A. Carey

ABSTRACT

TPS595

eMonarchHER: A phase 3 study of abemaciclib plus standard adjuvant endocrine therapy in patients with HR+, HER2+, node-positive, high-risk early breast cancer.

AUTHOR(S)

Sara M. Tolaney, Lesley Fallowfield, Peter A. Kaufman, Eva M. Ciruelos, Mary C. Gainford, Yi Lu, Karla Hurt, Heather A. Wasserstrom, Yanyun Chen, Shom Goel

ABSTRACT

TPS596

ALEXANDRA/IMpassion030: A phase 3 study of standard adjuvant chemotherapy with or without atezolizumab in patients with early-stage triple-negative breast cancer.

AUTHOR(S)

Shigehira Saji, Heather L. McArthur, Michail Ignatiadis, Andrew Bailey, Sarra El-Abed, Mariana Brandao, Otto Metzger, Catherine Lai, Sebastien Guillaume, Debora Fumagalli, Dominique Agbor-tarh, Aicha Seiller, Rosa Altarcheh Xifro, Vanessa Honvault, Giuseppe Viale, Carter DuFrane, Teresa Barata, Eric P. Winer, Richard D. Gelber, Martine J. Piccart-Gebhart

ABSTRACT

TPS597

ADAPTlate: A randomized, controlled, open-label, phase III trial on adjuvant dynamic marker—Adjusted personalized therapy comparing abemaciclib combined with standard adjuvant endocrine therapy versus standard adjuvant

endocrine therapy in (clinical or genomic) high-risk, HR+/HER2- early breast cancer.

AUTHOR(S)

Oleg Gluz, Iris Scheffen, Tom Degenhardt, Norbert W. Marschner, Matthias Christgen, Hans H. Kreipe, Ulrike Nitz, Ronald E. Kates, Timo Schinkoethe, Monika K. Graeser, Rachel Wuerstlein, Sherko Kuemmel, Lelia Bauer, Christian Schem, Tanja N. Fehm, Hans Neubauer, Nadia Harbeck

ABSTRACT

TPS598

Optima: Optimal personalised treatment of early breast cancer using multi-parameter analysis, an international randomized trial of tumor gene expression test-directed chemotherapy treatment in a largely node-positive population.

AUTHOR(S)

Rob C. Stein, Andreas Makris, Iain R. MacPherson, Luke Hughes-Davies, Andrea Marshall, Georgina Dotchin, David A. Cameron, Belinda E. Kiely, Janice Tsang, Bjørn Naume, Daniel W. Rea, Hege O. Ohnstad, Peter S. Hall, Stuart McIntosh, Bethany Shinkins, Chris McCabe, Adrienne Morgan, John Bartlett, Janet Dunn

ABSTRACT

TPS599

Axillary management in T1-3N1M0 breast cancer patients with needle biopsy proven nodal metastases at presentation after neoadjuvant chemotherapy (ATNEC).

AUTHOR(S)

Amit Goyal, Sophie Cramp, Duncan Wheatley, Andrea Marshall, Shama Puri, Natalie Hammonds, Tara Homer, Luke Vale, Romaana Mir, Janice Rose, Helen Teresa Edwards, Samreen Ahmed, Abeer Shaaban, Beatrix Elsberger, Julie Bruce, Sophie Gasson, Valerie Speirs, Jacqui Shaw, Helen Higgins, Janet Dunn

ABSTRACT

TPS600

A single-arm confirmatory study to evaluate the efficacy of nonsurgical therapy for HER2-positive early breast cancer with clinical complete response after primary systemic therapy: (JCOG1806: AMATERAS-BC study).

AUTHOR(S)

Tomomi Fujisawa, Tadahiko Shien, Hiroji Iwata, Hideo Shigematsu, Taro Shibata, Keita Sasaki, Yuko Takahashi

ABSTRACT

TPS601

Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.

AUTHOR(S)

Frederik Marmé, Elmar Stickeler, Jenny Furlanetto, Carsten Denkert, Marcus Schmidt, Mattea Reinisch, Toralf Reimer, Wolfgang Janni, Michael Untch, Bruno V. Sinn, Volker Moebus, Laura Michel, Laura Schoellhorn, Sabine Schmatloch, Julia Rey, Sibylle Loibl

ABSTRACT

TPS602

TRIO-US B-12 TALENT: Phase II neoadjuvant trial evaluating trastuzumab deruxtecan with or without anastrozole for HER2-low, HR+ early stage breast cancer.

AUTHOR(S)

Sara A. Hurvitz, Parvin F. Peddi, Merry L. Tetef, Nicholas P. McAndrew, Aashini K. Master, Maggie L. DiNome, Minna K. Lee, Lisa S. Wang, Laura Spring, Christine Kivork, James Chauv, Aditya Bardia

ABSTRACT

TPS603

A prospective, randomized, multicenter, double-blinded, placebo-controlled phase III trial of the HER2/neu peptide GP2 + GM-CSF versus bacteriostatic saline/WFI placebo as adjuvant therapy after any trastuzumab-based therapy in HER2-positive women with operable breast cancer.

AUTHOR(S)

Snehal Patel, David McWilliams, Christine T. Fischette, Jaye Thompson, F. J. Daugherty, C. K. Osborne, Mothaffar F. Rimawi

ABSTRACT

TPS604

Breast Cancer—Metastatic

[Back to Program](#)

Showing 87 Presentations

<https://meetinglibrary.asco.org/session/13609>

Serial circulating tumor DNA samples from patients with metastatic breast cancer and *BRCA1/2* mutations.

AUTHOR(S)

Katharine Collier, David Tallman, Zachary Weber, Marcy Haynam, Elizabeth J. Adams, Janet Jenison, Sarah Asad, Maryam B. Lustberg, Mathew A. Cherian, Bhuvaneswari Ramaswamy, Sagar D. Sardesai, Nicole O. Williams, Robert Wesolowski, Jeffrey B. VanDeusen, Margaret E. Gatti-Mays, Ashley Pariser, Amir Mortazavi, Daniel G. Stover

ABSTRACT

1025

Favorable prognostic factors of oligometastatic breast cancer: A subset analysis of OLIGO-BC1.

AUTHOR(S)

Kun Wang, XiWen Bi, Guangyu Liu, Takayuki Ueno, Shintaro Takao, Sung Hoon Sim, Young-Hyuck Im, Seock-Ah Im, Sung Gwe Ahn, Jeong Eon Lee, Yeon Hee Park, Manabu Futamura, Masakazu Toi, Yasuhiro Fujiwara, Mari Saito-Oba, Yuko Kitagawa, Masahiko Nishiyama, Shigeru Imoto

ABSTRACT

1026

Refining neutropenia risk assessment in patients treated with first-line endocrine therapy (ET) and cyclin-dependent kinase 4/6 inhibitors (CDK4/6i) for metastatic breast cancer (MBC) through a cell-free DNA workflow (cfDNA).

AUTHOR(S)

lorenza Palmero, Roberta Mazzeo, Silvia Buriolla, Lorenzo Allegri, Lucia Bortot, Alessandra Franzoni, Anna Michelotti, Elisabetta Camilla Stefani, Giulia Turra, Miriam Zilli, Paola Di Nardo, Rossana Roncato, Marta Bonotto, Erika Cecchin, Barbara Belletti, Giuseppe Toffoli, Lorenzo Gerratana, Gustavo Baldassarre, Giuseppe Damante, Fabio Puglisi

ABSTRACT

1027

Identification of pathogenic *CDK12* alterations in cell-free DNA (cfDNA) from patients with breast cancer.

AUTHOR(S)

Mary Love Taylor, Hiba I. Dada, Hannah Florian, Paul K. Marcom, Carey K. Anders, Leylah Drusbosky, Jeremy M. Force

ABSTRACT

1028

Characterization of long-term responders following treatment with talazoparib (TALA) or physician's choice of chemotherapy (PCT) in the phase 3 embraca trial.

AUTHOR(S)

Johannes Ettl, Hope S. Rugo, Sara A. Hurvitz, Miguel Martin, Henri Roche, Kyung-Hun Lee, Annabel Goodwin, Tiziana Usari, Silvana Lanzalone, Carolin Guenzel, Joanne L. Blum, Jennifer K. Litton

ABSTRACT

1029

Deep proteomic analysis of plasma exosomes in patients with advanced, hormone receptor-positive breast cancer treated with palbociclib and tamoxifen.

AUTHOR(S)

Xiuyuan Ma, Yu Gao, Gayatry Mohapatra, Louis Coleman, Yael Simons, Cristina I. Truica, Anne H. Blaes, Jatin Rana, Pavankumar Tandra, Lauren Green, Li C. Liu, Menggang Yu, Deborah Toppmeyer, Ruth O'Regan, Kari B. Wisinski, Oana C. Danciu, Kent Hoskins

ABSTRACT

1030

A retrospective study of characteristics and survival in patients with breast cancer brain metastases classified by subtype using NCI SEER registry.

AUTHOR(S)

Monika Devanaboyina, Morgan M. Bailey, Danae M. Hamouda

ABSTRACT

1031

Overcoming the breast tumor microenvironment by targeting MDSCs through CAR-T cell therapy.

AUTHOR(S)

Saisha A. Nalawade, Paul Shafer, Pradip Bajgain, Katie McKenna, Arushana Ali, Lauren Kelly, Jarrett Joubert, Norihiro Watanabe, Ann Leen, Robin Parihar, Juan Fernando Vera Valdes, Valentina Hoyos Velez

ABSTRACT

1032

Uncovering the differential impact of *ESR1* and *PIK3CA* codon variants on the clinical phenotype of metastatic breast cancer (MBC) through circulating tumor DNA (ctDNA) next-generation sequencing (NGS).

AUTHOR(S)

Lorenzo Gerratana, Andrew A. Davis, Marko Velimirovic, Paolo D'Amico, Ami N. Shah, Katherine Clifton, Qiang Zhang, Charles S. Dai, Carolina Reduzzi, Whitney L. Hensing, Marta Bonotto, Roberta Mazzeo, Firas H. Wehbe, Alessandra Franzoni, Barbara Belletti, Amir Behdad, Cynthia X. Ma, Fabio Puglisi, Aditya Bardia, Massimo Cristofanilli

ABSTRACT

1033

Molecular characterization of the Ras-MAPK pathway in metastatic breast cancer.

AUTHOR(S)

Justin Wayne W. Tiu-lim, Jun Yin, Joanne Xiu, Wolfgang M. Korn, Heinz-Josef Lenz, Gino K. In, Evanthia T. Roussos Torres, Janice M. Lu, Darcy V. Spicer, Bing Xia, Dave S. Hoon, Elisa Krill-Jackson, Arielle L. Heeke, Sarah Sammons, Claudine Isaacs, Foluso O. Ademuyiwa, Cynthia X. Ma, Antoinette R. Tan, Irene Kang

ABSTRACT

1034

Cyclin-dependent kinase 4/6 (CDK4/6) inhibitor SHR6390 combined with pyrotinib and letrozole in patients with human epidermal growth factor receptor 2-positive (HER2+), hormone receptor positive (HR+) metastatic breast cancer (MBC): Phase Ib study results.

AUTHOR(S)

Jian Zhang, Yanchun Meng, Biyun Wang, Leiping Wang, Jun Cao, Zhonghua Tao, Ting Li, Wenqing Yao, Xichun Hu

ABSTRACT

1035

Concordance of HER2+ status by IHC/ISH and *ERBB2* status by NGS in a real-world clinicogenomic database and analysis of outcomes in patients (pts) with metastatic breast cancer (mBC).

AUTHOR(S)

Cheryl D. Cho-Phan, Jeremy Snider, Liangliang Zhang, Kimberly McGregor, Alexa B. Schrock, Emily Castellanos

ABSTRACT

1036

Pyrotinib plus capecitabine for HER2-positive metastatic breast cancer patients with brain metastases (PERMEATE): A multicenter, single-arm phase II study.

AUTHOR(S)

Min Yan, Quchang Ouyang, Tao Sun, Limin Niu, Jin Yang, Li Li, Yuhua Song, Chunfang Hao, Zhanhong Chen

ABSTRACT

1037

Safety and unique pharmacokinetic profile of ARX788, a site-specific ADC, in heavily pretreated patients with HER2-overexpressing solid tumors: Results from two phase 1 clinical trials.

AUTHOR(S)

Sara A. Hurvitz, Haeseong Park, Sophia Frentzas, Catherine M. Shannon, Katharine Cuff, Richard W. Eek, George T. Budd, Amelia McCartney, Joyce O'Shaughnessy, Janice M. Lu, Jian Zhang, Dongmei Ji, Weina Shen, Matt Li, Jinchun Yan, Gang Xia, Yanping Ji, Sulan Yao, Gaozhun Xiong, Xichun Hu

ABSTRACT

1038

Safety of trastuzumab emtansine (T-DM1) in patients (pts) with HER2-positive locally advanced or metastatic breast cancer (mBC): Final results from KAMILLA Cohorts 1 (global) and 2 (Asia).

AUTHOR(S)

Rachel Wuerstlein, Paul Ellis, Filippo Montemurro, Antonio Antón Torres, Suzette Delaloge, Qingyuan Zhang, Xiaojia Wang, Shusen Wang, Shao Zhimin, Huiping Li, Andhika Rachman, Mawin Vongsaisuwon, Haiying Liu, Simon Fear, Claudia Pena-Murillo, Carlos H. Barrios

ABSTRACT

1039

Comparison of therapy benefit from standard anti-HER2 directed approaches in metastatic breast cancer (MBC) between initially HER2-positive patients and patients initially HER2-negative with switch to HER2-positive.

AUTHOR(S)

Hans-Christian Kolberg, Özlem Yüksel, Peter A. Fasching, Sara Brucker, Hans Tesch, Diethelm Wallwiener, Lothar Haeberle, Markus Wallwiener, Peyman Hadji, Tanja N. Fehm, Wolfgang Janni, Diana Lüftner, Michael P. Lux, Johannes Ettl, Andreas D. Hartkopf, Volkmar Müller, Florin-Andrei Taran, Erik Belleville, Alexander Hein, Andreas Schneeweiss

ABSTRACT

1040

Impact of extracranial disease status on survival after initial central nervous system (CNS) involvement and radiation therapy in HER2+ breast cancer brain metastases (BCBM).

AUTHOR(S)

Laura Noteware, Luis Ramirez, Nicole Dalal, James E. Herndon II, Scott R. Floyd, Amanda E. Van Swearingen, Carey K. Anders, Sarah Sammons

ABSTRACT

1041

Phase I study of LZM005, a HER2 antibody, as monotherapy or in combination with trastuzumab and docetaxel in patients with HER2-positive metastatic breast cancer.

AUTHOR(S)

Cong Xue, Herui Yao, Ying Lin, Xin An, Meiting Chen, Yugang Dong, Su Li, Yanxia Shi

ABSTRACT

1042

Updated results of tucatinib versus placebo added to trastuzumab and capecitabine for patients with pretreated HER2+ metastatic breast cancer with and without brain metastases (HER2CLIMB).

AUTHOR(S)

Giuseppe Curigliano, Volkmar Mueller, Virginia F. Borges, Erika P. Hamilton, Sara A. Hurvitz, Sherene Loi, Rashmi K. Murthy, Alicia F. Okines, Elisavet Paplomata, David A. Cameron, Lisa A. Carey, Karen A. Gelmon, Gabriel N. Hortobagyi, Ian E. Krop, Sibylle Loibl, Mark D. Pegram, Dennis J. Slamon, Jorge Ramos, Chiyu Zhang, Eric P. Winer

ABSTRACT

1043

Pharmacokinetic (PK) analyses in CSF and plasma from TBCRC049, an ongoing trial to assess the safety and efficacy of the combination of tucatinib, trastuzumab and capecitabine for the treatment of leptomeningeal metastasis (LM) in HER2 positive breast cancer.

AUTHOR(S)

Erica M. Stringer-Reasor, Barbara J. O'Brien, Ariel Topletz-Erickson, Jason B. White, Mina Lobbous, Kristen Riley, Jennifer Childress, Kim LaMaster, Michelle E. Melisko, Aki Morikawa, John F. De Groot, Ian E. Krop, Vicente Valero, Mothaffar F. Rimawi, Antonio C. Wolff, Debu Tripathy, Nancy U. Lin, Rashmi K. Murthy

ABSTRACT

1044

⁶⁸Ga-HER2 affibody PET/CT imaging as an option in patients whose HER2 status of any tumor in the body needs to be deciphered.

AUTHOR(S)

Haitao Miao, Yuyun Sun, Xichun Hu, Shaoli Song, Jian Zhang

ABSTRACT

1045

Clinicopathological characteristics of exceptional responders who achieve durable remissions beyond five years (DR5) in HER2+(H+) metastatic breast cancer (MBC).

AUTHOR(S)

Darko Skrobo, Naomi Walsh, Jose Berenguer, Janice M. Walshe, Michaela J. Higgins, David W. Fennelly, Jo Ballot, Cecily Quinn, Giuseppe Gullo, John Crown

ABSTRACT

1046

Efficacy of CDK4/6i in the visceral crisis setting: Result from a real-world database.

AUTHOR(S)

Shaheenah S. Dawood, Kaylen Brzozowski

ABSTRACT

1047

Real-world cost-effectiveness of pertuzumab (P) with trastuzumab + chemo (T+Chemo) in patients (pts) with metastatic breast cancer (MBC): A population-based retrospective cohort study by the Canadian Real-world Evidence for Value in Cancer Drugs (CanREValue) collaboration.

AUTHOR(S)

Wei Fang Dai, Jaclyn M. Beca, Chenthila Nagamuthu, Ning Liu, Maureen E. Trudeau, Craig Earle, Claire De Oliveira, Kelvin K. Chan

ABSTRACT

1048

A phase 1b study of chemoimmunotherapy with pegylated liposomal doxorubicin and pembrolizumab in estrogen receptor-positive, endocrine-resistant breast cancer.

AUTHOR(S)

Alberto A. Gabizon, Nathan Cherny, Rut Isacson, Areen Abu Remilah, Alberto Gabizon, Hilary Shmeeda, Ora Rosengarten

ABSTRACT

1049

A first-in-human phase 1a/b trial of LY3484356, an oral selective estrogen receptor (ER) degrader (SERD) in ER+ advanced breast cancer (aBC) and endometrial endometrioid cancer (EEC): Results from the EMBER study.

AUTHOR(S)

Komal L. Jhaveri, Elgene Lim, Erika P. Hamilton, Cristina Saura, Tarek Meniawy, Rinath Jeselsohn, J. T. Beck, Peter A. Kaufman, Sarah Sammons, Kalyan Banda, Meena Okera, Kan Yonemori, Kathleen K. Harnden, Sung-Bae Kim, Joohyuk Sohn, Cynthia X. Ma, Philippe G. Aftimos, Xuejing A. Wang, Suzanne R. Young, Muralidhar Beeram

ABSTRACT

1050

Correlation between work productivity loss (WPL) and European Organization for Research and Treatment of Cancer (EORTC) Quality of Life Questionnaire (QLQ-C30) domains from the MONALEESA-7 (ML-7) trial of premenopausal women with HR+/HER2- advanced breast cancer (ABC).

AUTHOR(S)

Debu Tripathy, Tristan Curteis, Sara A. Hurvitz, Denise A. Yardley, Fabio Franke, Govind Babu Kanakasetty, Paul Wheatley-Price, Young-Hyuck Im, Radost Pencheva, David Chandiwana, Purnima Pathak, Brad Lanoue, Nadia Harbeck

ABSTRACT

1051

The association of HER2 low expression with the efficacy of CDK4/6 inhibitor in hormone receptor positive HER2 negative metastatic breast cancer.

AUTHOR(S)

Kelvin K. Bao, Leone Sutanto, Shirley S. Tse, Ka Man Cheung, Jeffrey C. Chan

ABSTRACT

1052

Resistance to CDK4/6 inhibitors (CDK4/6i): The clinical usefulness of liquid biopsy in metastatic breast cancer (mBC).

AUTHOR(S)

Lucrezia Raimondi, Laura Di Benedetto, Giuseppe Naso, Filippo M. Raimondi, Arianna Di Rocco, Laura Giaconi, Rachele Lazzeroni, Gian Paolo Spinelli

ABSTRACT

1053

Long-term (LT) disease control in patients (pts) with hormone receptor-positive (HR+), *PIK3CA*-altered advanced breast cancer (ABC) treated with alpelisib (ALP) + fulvestrant (FUL).

AUTHOR(S)

Dejan Juric, Fabrice Andre, Udaiveer Panwar, Filip Janku, Yen-Shen Lu, Howard A. Burris III, Josefina Cruz Jurado, Zsuzsanna Papai, Salomon M. Stemmer, Josep Tabernero, Johan Ahlgren, Marianne Leheurteur, Ines Lorenzo, Dragana Jankovic, Cornelia Quadl, Huilin Hu, Xueying Chen, Hope S. Rugo

ABSTRACT

1054

Overall survival in patients with breast cancer treated with a CDK 4/6 inhibitor plus fulvestrant: A U.S. Food and Drug Administration pooled analysis.

AUTHOR(S)

Jennifer J. Gao, Joyce Cheng, Tatiana M. Prowell, Erik Bloomquist, Shenghui Tang, Suparna B. Wedam, Melanie E. Royce, Danielle Krol, Christy Osgood, Gwynn Ison, Rajeshwari Sridhara, Richard Pazdur, Julia A. Beaver, Laleh Amiri-Kordestani

ABSTRACT

1055

A single-arm phase II trial of palbociclib in combination with tamoxifen as first-line therapy for metastatic hormone receptor-positive breast cancer.

AUTHOR(S)

Oana C. Danciu, Kent Hoskins, Cristina I. Truica, Anne H. Blaes, Deimante Tamkus, Jatin Rana, Pavankumar Tandra, Lauren Green, Menggang Yu, Qianqian Zhao, Deborah Toppmeyer, Ruth O'Regan, Kari B. Wisinski

ABSTRACT

1056

A phase Ib study of xentuzumab plus abemaciclib and fulvestrant in patients (pts) with advanced hormone receptor-positive (HR+), HER2-negative breast cancer (BC) with visceral or non-visceral disease.

AUTHOR(S)

Douglas Yee, Patricia LoRusso, Marie Paule Sablin, Aleix Prat, Agostina Stradella, Meri Utriainen, Mafalda Oliveira, Kan Yonemori, Yoichi Naito, Molly C. Hardebeck, Marta Puig, Joy Hu, Tsvetan N. Biyukov, Hiroji Iwata

ABSTRACT

1057

AMEERA-1: Phase 1/2 study of amcenestrant (SAR439859), an oral selective estrogen receptor (ER) degrader (SERD), with palbociclib (palbo) in postmenopausal women with ER+/ human epidermal growth factor receptor 2-negative (HER2-) metastatic breast cancer (mBC).

AUTHOR(S)

Sarat Chandarlapaty, Hannah M. Linden, Patrick Neven, Katarina Petrakova, Aditya Bardia, Peter Kabos, Sofia A. Braga, Valentina Boni, Alice Gosselin, Sylvaine Cartot-Cotton, Séverine Doroumian, Marina Celanovic, Patrick Cohen, Gautier Paux, Mario Campone

ABSTRACT

1058

Systematic review and meta-analysis of post-progression outcomes in ER+/HER2- metastatic breast cancer after treatment with endocrine therapy and CDK 4/6 inhibitors within randomized clinical trials.

AUTHOR(S)

Elisabetta Munzone, Eleonora Pagan, Vincenzo Bagnardi, Emilia Montagna, Giuseppe Cancellato, Silvia Dellapasqua, Monica Iorfida, Manuelita Mazza, Marco Colleoni

ABSTRACT

1059

Impact of duration of prior cyclin-dependent kinase 4/6 inhibitor (CDK4/6i) therapy on alpelisib (ALP) benefit in patients (pts) with hormone receptor-positive (HR+), human epidermal growth factor receptor-2-negative (HER2-), *PIK3CA*-mutated advanced breast cancer (ABC) from BYLieve.

AUTHOR(S)

Stephen K. Chia, Manuel Ruiz-Borrego, Pamela Drullinsky, Dejan Juric, Thomas Bachelot, Hope S. Rugo, Eva M. Ciruelos, Florence Lerebours, Aleix Prat, Murat Akdere, Christina Arce, Ennan Gu, Nicholas C. Turner

ABSTRACT

1060

Results from CONTESSA 2: A multinational, multicenter, phase 2 study of tesetaxel (T) plus a reduced dose of capecitabine (C) in patients (pts) with hormone receptor + (HR+), HER2- metastatic breast cancer (MBC) not previously treated with a taxane.

AUTHOR(S)

Lee S. Schwartzberg, Igor Bondarenko, Sara M. Tolaney, Andrew D. Seidman, Joyce O'Shaughnessy, Yaroslav V. Shparyk, Chi-Feng Chung, Yen-Shen Lu, Nuria Chic, Lawrence C. Panasci, Yee Soo Chae, Sabela Recalde, Yevhen Hotko, Patricia Gomez, Gail L. Wright, Noshir A. Dacosta, Sina Vatandoust, Joseph P. O'Connell, Thomas Wei, Hope S. Rugo

ABSTRACT

1061

Endocrine therapy-based strategies with different endocrine sensitivity statuses for hormone receptor positive/HER2 negative metastatic breast cancer: A network meta-analysis.

AUTHOR(S)

Jiani Wang, Yiqun Han, Jiayu Wang, Binghe Xu

ABSTRACT

1062

Rintodestrant (G1T48), an oral selective estrogen receptor degrader, in combination with palbociclib for ER+/HER2- advanced breast cancer: Phase 1 results.

AUTHOR(S)

Marina Maglakelidze, Iurie Bulat, Dinara Ryspayeva, Boris M. Krastev, Maia Gogiladze, Adrian Crijanovschi, Philippe G. Aftimos, Patrick Neven, Mark D. Pegram, Catharina W. Menke, Elizabeth C. Dees, Carolien P. Schroder, A. Jager, Linnea I. Chap, Erika P. Hamilton, Massimo Cristofanilli, Susanna V. Ulahannan, Jorianne Boers, Ramsha Iqbal, Sarika Jain

ABSTRACT

1063

Alpelisib and fulvestrant efficacy in HR-positive HER2-negative *PIK3CA*-mutant advanced breast cancer: Data from the French early access program.

AUTHOR(S)

Diana Bello, Alexandre Bertucci, Thibault De La Motte Rouge, Cyriac Blonz, Sarra Akla, Julien Grenier, Caroline Bailleux, Marc Antoine Benderra, Helene Simon, Isabelle Desmoulins, Zoé Tharin, Emmanuelle Renaud, Suzette Delaloge, Marion Bertho, Paul H. Cottu, Anthony Goncalves, François-Clément Bidard, Florence Lerebours

ABSTRACT

1064

Landscape of *GATA3* mutations identified from circulating tumor DNA clinical testing and their impact on disease outcomes in estrogen receptor-positive (ER+) metastatic breast cancers treated with endocrine therapies.

AUTHOR(S)

Marko Velimirovic, Lorenzo Gerratana, Andrew A. Davis, Charles S. Dai, Ju Cheng, A. John Iafrate, Bruce A. Chabner, Massimo Cristofanilli, Aditya Bardia

ABSTRACT

1065

On-treatment derived neutrophil-to-lymphocyte ratio and response to palbociclib and letrozole: Analysis of a multicenter retrospective cohort and the PALOMA-2 study.

AUTHOR(S)

Chang Gon Kim, Min Hwan Kim, Jee Hung Kim, Seul-Gi Kim, Gun Min Kim, Tae Yeong Kim, Won-Ji Ryu, Jeeye Kim, Hyung Seok Park, Seho Park, Youngup Cho, Byeong-Woo Park, Seung Il Kim, Joon Jeong, Joohyuk Sohn

ABSTRACT

1066

Phase I safety and efficacy study of autophagy inhibition with hydroxychloroquine to augment the antiproliferative and biological effects of preoperative palbociclib plus letrozole for estrogen receptor-positive, HER2-negative metastatic breast cancer (MBC).

AUTHOR(S)

Akshara Singareeka Raghavendra, Danielle Kwiatkowski, Senthil Damodaran, Nicole M. Kettner, David L. Ramirez, Dan S. Gombos, Kelly Hunt, Yu Shen, Khandan Keyomarsi, Debu Tripathy

ABSTRACT

1067

Real-world (rw) clinical outcomes on alpelisib (ALP) in patients (pts) with breast cancer (BC) and *PIK3CA* mutations (PIK3CAm).

AUTHOR(S)

Hope S. Rugo, Kira Raskina, Alexa B. Schrock, Mason A. Israel, Ethan Sokol, Smruthy Sivakumar, Ashley Ward, James Creeden, Geoffrey R. Oxnard, Kimberly McGregor, Jeffrey M. Venstrom, Hanna Tukachinsky

ABSTRACT

1068

Stereotactic radiosurgery (SRS) for brain metastasis (BM) in hormone receptor positive (HR+) HER2 negative breast cancer (BC).

AUTHOR(S)

Akshara Singareeka Raghavendra, Chao Gao, Fuchenchu Wang, Ran An, Yan Wang, Dima Suki, Amy B. Heimberger, Debu Tripathy, Jing Li, Nuhad K. Ibrahim

ABSTRACT

1069

Efficacy of AI and palbociclib in ER+ HER2- advanced breast cancer patients relapsing during adjuvant tamoxifen: An exploratory analysis of the PADA-1 trial.

AUTHOR(S)

François-Clément Bidard, Florence Dalenc, Thibault De La Motte Rouge, Barbara Pistilli, Caroline Cheneau, Catherine Delbaldo, Olfa Derbel, Claire Garnier Tixidre, Nathalie Marques, Sandrine Marques, Lionel Moreau, Frederique Berger, Anne-Claire Hardy-Bessard, Suzette Delaloge, Thomas Bachelot

ABSTRACT

1070

Real-world quality of life (QoL) in black, indigenous and people of color (BIPOC) treated with palbociclib (PAL) and endocrine therapy for hormone receptor-positive (HR+)/human epidermal growth factor receptor 2-negative (HER2-) advanced breast cancer (ABC): A subgroup analysis from POLARIS.

AUTHOR(S)

Gabrielle B. Rocque, Joanne L. Blum, Aldemar Montero, Meghan S. Karuturi, Kenneth Manning, Lloyd Shabazz, Christopher Gallagher, Lara Zuberi, Joseph C. Cappelleri, Marc Drucker, Yao Wang, Debu Tripathy

ABSTRACT

1071

Relative risk of pneumonitis or interstitial lung disease (ILD) associated with the use of cyclin-dependent kinase inhibitors (CDK4/6i): A systematic review and meta-analysis of phase 3 randomized controlled trials.

AUTHOR(S)

Nusrat Jahan, Sariya Wongsasengsak, Shabnam Rehman, Myrian Vinan-Vega, Lukman A. Tijani, Fred L. Hardwicke

ABSTRACT

1072

Confirmed tumor response by molecular subtype in patients with metastatic breast cancer: Sub-analysis from a phase 3 clinical study comparing oral paclitaxel and encephaloidar to IV paclitaxel.

AUTHOR(S)

Gerardo A. Umanzor Funez, Hope S. Rugo, Jorge Umanzor, Francisco Barrios, Rosa Vasallo, Suyapa A. Bejarano, Julio R. Ramirez, Luis E. Fein, Ruben D. Kowalyszyn, Hui Wang, David Cutler

ABSTRACT

1073

A phase Ib study of TQB2450 plus anlotinib in patients with advanced triple-negative breast cancer.

AUTHOR(S)

Jiayu Wang, Binghe Xu, Tao Sun, Quchang Ouyang, Yiqun Han, Qing Li, Pin Zhang, Fei Ma, Yang Luo, Ying Fan, Ruigang Cai, Qiao Li, Bo Lan, Hongnan Mo, Jian Wang, Yiqun Li

ABSTRACT

1074

Apatinib plus vinorelbine versus vinorelbine for advanced triple-negative breast cancer with failed first or second-line treatment: The NAN trial.

AUTHOR(S)

Doudou Li, Zhonghua Tao, Biyun Wang, Leiping Wang, Jun Cao, Xichun Hu, Jian Zhang

ABSTRACT

1075

Romidepsin (HDACi) plus cisplatin and nivolumab triplet combination in patients with metastatic triple negative breast cancer (mTNBC).

AUTHOR(S)

Priyanka Sharma, Vandana G. Abramson, Anne O'Dea, Lauren E. Nye, Ingrid A. Mayer, Gregory J. Crane, Manana Elia, Rachel Yoder, Joshua M. Staley, Kelsey Schwensen, Karissa Finke, Jaimie Heldstab, Stephanie LaFaver, Micki Prager, Stephen K. Williamson, Milind Phadnis, Gregory A. Reed, Bruce F. Kimler, Qamar J. Khan, Andrew K. Godwin

ABSTRACT

1076

Assessment of sacituzumab govitecan (SG) versus treatment of physician's choice (TPC) cohort by agent in the phase 3 ASCENT study of patients (pts) with metastatic triple-negative breast cancer (mTNBC).

AUTHOR(S)

Joyce O'Shaughnessy, Kevin Punie, Mafalda Oliveira, Filipa Lynce, Sara M. Tolaney, Florence Dalenc, Priyanka Sharma, Michaela L. Tsai, Aditya Bardia, Javier Cortes, Michael A. Danso, Stephanie Henry, Alejandra T. Perez, Sara A. Hurvitz, Kevin Kalinsky, Quan Hong, Martin S. Olivo, Loretta Itri, Hope S. Rugo

ABSTRACT

1077

A phase I/IB study of ipatasertib in combination with carboplatin or carboplatin/paclitaxel or capecitabine and atezolizumab in patients with metastatic triple-negative breast cancer.

AUTHOR(S)

Yuan Yuan, Susan E. Yost, Paul H. Frankel, Christopher Ruel, Mireya Murga, Aileen Tang, Norma Martinez, James R. Waisman, Daphne B. Stewart, Niki H. Patel, Joanne E. Mortimer

ABSTRACT

1078

A phase II trial of stereotactic radiation therapy and *in situ* oncolytic virus therapy in metastatic triple-negative breast cancer (mTNBC) patients followed by pembrolizumab (STOMP).

AUTHOR(S)

Kai Sun, Joe E. Ensor Jr., Yitian Xu, Licheng Zhang, Carlo Guerrero, Polly A. Niravath, Tejal A. Patel, Charles E. Geyer Jr., Dharamvir Jain, Bin S. Teh, Andrew M. Farach, Mark Sultenfuss, Nakul Gupta, Mary R. Schwartz, Susan Haley, Jamie Mejia, E. Brian Butler, Eric Bernicker, Shu-Hsia Chen, Jenny C. Chang

ABSTRACT

1079

Assessment of sacituzumab govitecan (SG) in patients with prior neoadjuvant/adjuvant chemotherapy in the phase 3 ASCENT study in metastatic triple-negative breast cancer (mTNBC).

AUTHOR(S)

Lisa A. Carey, Delphine Loirat, Kevin Punie, Aditya Bardia, Veronique Dieras, Florence Dalenc, Jennifer R. Diamond, Christel Fontaine, Grace Wang, Hope S. Rugo, Sara A. Hurvitz, Kevin Kalinsky, Joyce O'Shaughnessy, Sibylle Loibl, Luca Gianni, Martine J. Piccart-Gebhart, Quan Hong, Martin S. Olivo, Loretta Itri, Javier Cortes

ABSTRACT

1080

Efficacy of DAN-222, a novel investigational polymeric nanoparticle with topoisomerase I inhibitor, as monotherapy in breast cancer models and when combined with PARP inhibitor.

AUTHOR(S)

Ashley P. Wright, Jodi D. Bradley, Timothy Hagerty, Emily A. Wyatt

ABSTRACT

1081

Control arm heterogeneity in trials for unselected advanced triple-negative breast cancer (aTNBC).

AUTHOR(S)

Kinisha Gala, Ankit Kalucha, Samuel Martinet, Anushri Goel, Kalpana D. Narisetty, Bruno Larvol, Kevin Punie

ABSTRACT

1082

miR-503-5p induces doxorubicin resistance in triple-negative breast cancer.

AUTHOR(S)

Iris Garrido-Cano, Anna Adam-Artigues, Ana Lameirinhas, Birlipta Pattanayak, Eduardo Tormo, Vera Mónica Miranda-Gonçalves, Catarina Macedo-Silva, Federico Rojo, Sandra Zazo, Juan Madoz-Gúrpide, Octavio Burgues, Cristina Hernando, Maite Martínez, Santi Moragón, Begoña Bermejo De Las Heras, Ana Lluch, Carmen Jerónimo, Pilar Eroles, Juan Miguel Cejalvo

ABSTRACT

1083

Distant metastases after diagnosis: Racial disparities in breast cancer outcomes.

AUTHOR(S)

Julia Blanter, Ilana Ramer, Justina Ray, Emily J. Gallagher, Nina A. Bickell, Amy Tiersten

ABSTRACT

1084

A randomized phase Ib/IIa study of CApecitabine plus Radium-223 in breast cancer patients with BONE metastases (CARBON): Final efficacy results.

AUTHOR(S)

Matthew Winter, Jessica Kendall, Sarah R. Brown, Emma Rathbone, Caroline Wilson, Sacha J. Howell, Chris Twelves, Carlo Palmieri, Anjana Anand, Iain MacPherson, Robert E. Coleman, Janet Brown

ABSTRACT

1085

The impact of radiological assessment schedules on progression-free survival in metastatic breast cancer: A systemic review and meta-analysis.

AUTHOR(S)

Dor Reuven Dabush, Daniel Shepshelovich, Tzippy Shochat, Eitan Amir, Ariadna Tibau, Hadar Goldvaser

ABSTRACT

1086

A phase 2 study of pamiparib in the treatment of patients with locally advanced or metastatic HER2-negative breast cancer with germline *BRCA* mutation.

AUTHOR(S)

Tao Sun, Yanxia Shi, Jiuwei Cui, Yongmei Yin, Quchang Ouyang, Qiang Liu, Qingyuan Zhang, Yiding Chen, Shao Zhimin, Shouman Wang, Xiaojia Wang, Zhongsheng Tong, Yahua Zhong, Min Yan, Xi Yan, Chuan Wang, Haiyuan Yang, Miao Li, Xiao Xiang, Binghe Xu

ABSTRACT

1087

Survival time in urban center breast cancer patients with CNS metastasis with or without visceral metastasis.

AUTHOR(S)

Miriam P. Klahr, Junwen Deng, Jesus D. Anampa Mesias

ABSTRACT

1088

Clinical and pathological characteristics of breast cancer with resected brain metastasis.

AUTHOR(S)

Shiyuan A. Liu, Jingqin Luo, Yu Tao, Sonika Dahiya, Cynthia X. Ma

ABSTRACT

1089

Clinical outcomes in patients (pts) with a history of central nervous system (CNS) metastases receiving talazoparib (TALA) or physician's choice of chemotherapy (PCT) in the phase 3 EMBRACA trial.

AUTHOR(S)

Jennifer K. Litton, Johannes Ettl, Sara A. Hurvitz, Miguel Martin, Henri Roche, Kyung-Hun Lee, Annabel Goodwin, Tiziana Usari, Silvana Lanzalone, Carolin Guenzel, Joanne L. Blum, Hope S. Rugo

ABSTRACT

1090

Genomic evaluation of tumor mutational burden-high (TMB-H) versus TMB-low (TMB-L) metastatic breast cancer to reveal unique mutational features.

AUTHOR(S)

Sarah Sammons, Andrew Elliott, Jeremy M. Force, Nicholas C. DeVito, Paul K. Marcom, Sandra M. Swain, Antoinette R. Tan, Evanthia T. Roussos Torres, Jia Zeng, Mustafa Khasraw, Justin M. Balko, Wolfgang M. Korn, Carey K. Anders

ABSTRACT

1091

Decreased enrollment of patients with advanced lobular breast cancer compared to ductal breast cancer in interventional clinical trials.

AUTHOR(S)

Mary K. Abel, Michelle E. Melisko, Hope S. Rugo, Amy J. Chien, Italia Diaz, Julia K. Levine, Ann Griffin, Joseph McGuire, Laura Esserman, Hala Borno, Rita A. Mukhtar

ABSTRACT

1092

Systemic chemotherapy in patients with brain only metastatic breast cancer: A retrospective analysis.

AUTHOR(S)

Akshjot Puri, Charisma Mylavarapu, Joe E. Ensor Jr., Parveen Parveen, Ivo Tremont-Lukats, Jenny C. Chang, Polly A. Niravath

ABSTRACT

1093

Metastasectomy versus radiation of secondary sites in stage IV breast cancer.

AUTHOR(S)

Nadeem Bilani, Leah Elson, Elizabeth B. Elimimian, Hong Liang, Diana Saravia, Zeina A. Nahleh

ABSTRACT

1094

Survival among patients with untreated metastatic breast cancer.

AUTHOR(S)

Jennifer K. Plichta, Samantha M. Thomas, Sarah Sammons, Susan G. McDuff, Gayle DiLalla, Gretchen G. Kimmick, Eun-Sil S. Hwang

ABSTRACT

1095

Trastuzumab deruxtecan (T-DXd) combinations in patients with HER2-positive advanced or metastatic breast cancer: A phase 1b/2, open-label, multicenter, dose-finding and dose-expansion study (DESTINY-Breast07).

AUTHOR(S)

Fabrice Andre, Erika P. Hamilton, Sherene Loi, Peter Schmid, Carey K. Anders, Tinghui Yu, Sarice Boston, Celina M. D'Cruz, Pia Herbolzheimer, Komal L. Jhaveri

ABSTRACT

TPS1096

HER2CLIMB-04: Phase 2 open label trial of tucatinib plus trastuzumab deruxtecan in patients with HER2+ unresectable locally advanced or metastatic breast cancer with and without brain metastases (trial in progress).

AUTHOR(S)

Ian E. Krop, Jorge Ramos, Chiyu Zhang, Erika P. Hamilton

ABSTRACT

TPS1097

Trial in progress: A phase 1b/2 study of the PARP inhibitor niraparib in combination with trastuzumab in patients with metastatic HER2+ breast cancer (TBCRC 050).

AUTHOR(S)

Erica M. Stringer-Reasor, Yufeng Li, Felicia Witherspoon, Jennifer M. Specht, Jesus D. Anampa Mesias, Rita Nanda, Elizabeth C. Dees, Antonio C. Wolff, Ian E. Krop, Nancy U. Lin, Mothaffar F. Rimawi, Eddy S. Yang

ABSTRACT

TPS1098

Trial in progress: Phase I/II study of radiation therapy followed by intrathecal trastuzumab/pertuzumab in the management of HER2+ breast leptomeningeal disease.

AUTHOR(S)

Kamran A. Ahmed, Youngchul Kim, Michelle DeJesus, Priya Kumthekar, Nicole O. Williams, Joshua D. Palmer, Pierre Giglio, Adrienne A. Boire, John Arrington, Solmaz Sahebjam, Marilin Rosa, Hatem H. Soliman, Hsiang-Hsuan M. Yu, Hyo S. Han, Peter A. Forsyth

ABSTRACT

TPS1099

acelERA Breast Cancer (BC): Phase II study evaluating efficacy and safety of giredestrant (GDC-9545) versus physician's choice of endocrine monotherapy in patients (pts) with estrogen receptor-positive, HER2-negative (ER+/HER2-) locally advanced or metastatic breast cancer (LA/mBC).

AUTHOR(S)

Miguel Martin, Elgene Lim, Mariana Chavez Mac Gregor, Mahesh Shivhare, Graham Ross, Monika Patre, Laura Roncoroni, Maria Louka, Joohyuk Sohn

ABSTRACT

TPS1100

SERENA-4: A phase 3 comparison of AZD9833 (camizestrant) plus palbociclib, versus anastrozole plus palbociclib, for patients with ER-positive, HER2-negative advanced breast cancer who have not previously received systemic treatment for advanced disease.

AUTHOR(S)

Seock-Ah Im, Erika P. Hamilton, Antonio Llombart Cussac, Richard D. Baird, Johannes Ettl, Matthew P. Goetz, Hiroji Iwata, Anil A. Joy, Patrick Neven, Vincent Haddad, Andrew S. Walding, Manuel Selvi Miralles, Cynthia H. Bartlett, Fabrice Andre

ABSTRACT

TPS1101

Saci-IO HR+: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1+ hormone receptor-positive (HR+) / HER2- metastatic breast cancer (MBC).

AUTHOR(S)

Ana Christina Garrido-Castro, Tanya E. Keenan, Tianyu Li, Paulina Lange, Catherine Callahan, Jennifer Guerriero, Nabihah Tayob, Leilani Anderson, Daniel G. Stover, Keerthi Gogineni, Lisa A. Carey, Rita Nanda, Eric P. Winer, Elizabeth A. Mittendorf, Sara M. Tolaney

ABSTRACT

TPS1102

persevERA Breast Cancer (BC): Phase III study evaluating the efficacy and safety of giredestrant (GDC-9545) + palbociclib versus letrozole + palbociclib in patients (pts) with estrogen-receptor-positive, HER2-negative locally advanced or metastatic BC (ER+/HER2- LA/mBC).

AUTHOR(S)

Nicholas C. Turner, Komal L. Jhaveri, Aditya Bardia, Naoki Niikura, Veronique Dieras, Carlos H. Barrios, Seock-Ah Im, Volkmar Mueller, Meritxell Bellet, Ching-Wei Chang, Graham A. Ross, Monika Patre, Sherene Loi

ABSTRACT

TPS1103

AMEERA-5: A randomized, double-blind phase III study of amcenestrant (SAR439859) + palbociclib versus letrozole + palbociclib for previously untreated ER+/HER2- advanced breast cancer.

AUTHOR(S)

Aditya Bardia, Javier Cortes, Sara A. Hurvitz, Suzette Delaloge, Hiroji Iwata, Shao Zhimin, Dheepak Kanagavel, Patrick Cohen, Qianying Liu, Sylvaine Cartot-Cotton, Vasiliki Pelekanou, Joyce O'Shaughnessy

ABSTRACT

TPS1104

BEGONIA: Phase 1b/2, open-label, platform study of the safety and efficacy of durvalumab (D) ± paclitaxel (P) with novel oncology therapies for first-line metastatic triple-negative breast cancer (mTNBC): Addition of arm 7, D + datopotamab deruxtecan (Dato-DXd; DS-1062).

AUTHOR(S)

Peter Schmid, Ana T. Nunes, Hannah Dry, Rachel Dougherty, Vatsala Karwe, Urban J. Scheuring

ABSTRACT

TPS1105

Saci-IO TNBC: Randomized phase II trial of sacituzumab govitecan (SG) +/- pembrolizumab in PD-L1- metastatic triple-negative breast cancer (mTNBC).

AUTHOR(S)

Ana Christina Garrido-Castro, Tanya E. Keenan, Tianyu Li, Paulina Lange, Catherine Callahan, Jennifer Guerriero, Nabihah Tayob, Leilani Anderson, Clinton Yam, Brooke R. Daniel, Lisa A. Carey, Rita Nanda, Eric P. Winer, Elizabeth A. Mittendorf, Sara M. Tolaney

ABSTRACT

TPS1106

Trial in progress: A phase 3, randomized, double-blind trial of trilaciclib versus placebo in patients receiving first- or second-line gemcitabine and carboplatin for locally advanced unresectable or metastatic triple-negative breast cancer (PRESERVE 2).

AUTHOR(S)

Shom Goel, Joyce O'Shaughnessy, Antoinette R. Tan, Boris M. Krastev, Hope S. Rugo, Philippe G. Aftimos, Denise A. Yardley, Andric Zoran, Curt D. Wolfgang, Jessica Sorrentino, Wenli Tao, Andrew P. Beelen, Rajesh K. Malik, Sarika Jain

ABSTRACT

TPS1107

NBE-002: A novel anthracycline-based antibody-drug conjugate (ADC) targeting ROR1 for the treatment of advanced solid tumors—A phase 1/2 clinical trial.

AUTHOR(S)

Anthony W. Tolcher, Funda Meric-Bernstam, Meredith McKean, Roger R. Beerli, Lorenz Waldmeier, Rémy Gebleux, Ina Hellmann, Pawel Chrom, Ulf Grawunder

ABSTRACT

TPS1108

A phase II clinical trial of talazoparib monotherapy for PALB2 mutation-associated advanced breast cancer.

AUTHOR(S)

Joshua J. Gruber, Wyatt Gross, Alex McMillan, James M. Ford, Melinda L. Telli

ABSTRACT

TPS1109

Phase II multicenter study of talazoparib for somatic *BRCA1/2* mutant metastatic breast cancer.

AUTHOR(S)

Neelima Vidula, Erica Blouch, Nora K. Horick, Erin Basile, Senthil Damodaran, Minetta C. Liu, Ami N. Shah, Alvaro Moreno-Aspitia, Hope S. Rugo, Leif Ellisen, Aditya Bardia

ABSTRACT

TPS1110

Multi-center randomized study of pembrolizumab/carboplatin versus carboplatin alone in patients with chest wall disease from breast cancer: TBCRC 044.

AUTHOR(S)

Neelima Vidula, Rita Nanda, Kathy D. Miller, Leisha A. Emens, Paula R. Pohlmann, Vandana G. Abramson, Ben H. Park, Minetta C. Liu, Andrei Goga, Hope S. Rugo

ABSTRACT

TPS1111

Central Nervous System Tumors

[Back to Program](#)

Showing 48 Presentations

<https://meetinglibrary.asco.org/session/13615>

Radiosurgery dose reduction for brain metastases on immunotherapy (RADREMI): Early results from a multicenter phase I trial.

AUTHOR(S)

Shearwood McClelland, Tim Lautenschlaeger, Kevin Shiue, Amy C. Miller, Yong Zang, Kathryn I. Lauer, Nasser H. Hanna, Ryan Rhome, Namita Agrawal, Paul Anthony, Mu Shan, Jerry J. Jaboin, Gordon A. Watson

ABSTRACT

2025

Changes in the blood-brain barrier properties in vitro after treatment with sera from breast cancer patients with primary cancer and visceral, bone or cerebral metastases.

AUTHOR(S)

Carolyn J. Curtaz, Schmitt Constanze, Patrick Meybohm, Achim Wöckel, Malgorzata Burek

ABSTRACT

2026

Real-world outcomes of breast cancer patients with brain metastases treated with radiotherapy in Ontario: A population-based study.

AUTHOR(S)

Katarzyna J. Jerzak, Michael Rosen, Xin Y. Wang, Rania Chehade, Bo Zhang, Refik Saskin, Sunit Das, Hany Soliman, Arjun Sahgal, Kelvin K. Chan

ABSTRACT

2027

The efficacy and clinical survival outcome of different first-line treatments in EGFR-mutant non-small cell lung cancer with brain metastases.

AUTHOR(S)

Huijuan Wang, Ruyue Xing, Mina Zhang, Xiaojuan Zhang, Jinpo Yang, Mengmeng Li, Zhiyong Ma

ABSTRACT

2028

Heterogeneity of HER2 expression in circulating tumor cells of patients with breast cancer brain metastases and impact on brain disease control.

AUTHOR(S)

Douglas G. Castro, Antonio C. Pellizzon, Alexcia C. Braun, Michael J. Chen, Maria Leticia G. Silva, Ricardo Fogaroli, Guilherme R. Gondim, Henderson Ramos, Elson S. Neto, Carolina H. Abrahao, Liao S. Yu, Emne A. Abdallah, Vinicius F. Calsavara, Ludmilla T. Chinen

ABSTRACT

2029

Outcomes of immunotherapy (ICI) alone vs tyrosine kinase inhibitors (TKI) alone versus ICI and TKI combined in renal cell carcinoma brain metastasis.

AUTHOR(S)

Patrick J. O'Shea, Vineeth Tatineni, Yasmeen Rauf, Xuefei Jia, Erin S. Murphy, Samuel T. Chao, John H. Suh, David M. Peereboom, Manmeet S. Ahluwalia

ABSTRACT

2030

Outcomes of first-generation versus third-generation epidermal growth factor receptor (EGFR) inhibitors in non-small cell lung cancer with brain metastases (NSCLCBM).

AUTHOR(S)

Vineeth Tatineni, Patrick J. O'Shea, Yasmeen Rauf, Xuefei Jia, Erin S. Murphy, Samuel T. Chao, John H. Suh, David M. Peereboom, Manmeet S. Ahluwalia

ABSTRACT

2031

Clinical and genomic predictors of brain metastases (BM) in non-small cell lung cancer (NSCLC): An AACR Project GENIE analysis.

AUTHOR(S)

Protiva Rahman, Michele LeNoue-Newton, Sandip Chaugai, Marilyn Holt, Neha M. Jain, Christina Maxwell, Christine Micheel, Yuanchu J. Yang, Cheng Ye, Nikolaus Schultz, Gregory J. Riely, Caroline G. McCarthy, Hira Rizvi, Deborah Schrag, Kenneth L. Kehl, Eva M. Lepisto, Celeste Yu, Philippe L. Bedard, Daniel Fabbri, Jeremy L. Warner

ABSTRACT

2032

Presentation and management of patients with brain metastases of primary melanoma, non-small cell lung cancer, and breast cancer origin.

AUTHOR(S)

Yuki Kawahara, Matthew Mills, Thrisha Potluri, Matthew Fahey, Nicholas B. Figura, Aixa Soyano, Iman Washington, Roberto Diaz, Daniel E. Oliver, Hsiang-Hsuan M. Yu, Arnold B. Etame, Michael A. Vogelbaum, Brian J. Czerniecki, John Arrington, Solmaz Sahebjam, Hatem H. Soliman, Peter A. Forsyth, Hyo S. Han, Kamran A. Ahmed

ABSTRACT

2033

Outcomes of first, second, and third-generation anaplastic lymphoma kinase (ALK) inhibitors in non-small cell lung cancer brain metastases (NSCLCBM).

AUTHOR(S)

Vineeth Tatineni, Patrick J. O'Shea, Yasmeen Rauf, Xuefei Jia, Erin S. Murphy, Samuel T. Chao, John H. Suh, David M. Peereboom, Manmeet S. Ahluwalia

ABSTRACT

2034

An investigation into the impact of next generation sequencing on the use of targeted treatments in glioblastoma.

AUTHOR(S)

Jordan John, Rimas V. Lukas, Priya Kumthekar

ABSTRACT

2035

Palliative care service utilization and advance care planning issues for adult glioblastoma patients: A systematic review.

AUTHOR(S)

Adela Wu, Gabriela R. Colon, Rebecca Aslakson, Erqi L. Pollom, Chirag B. Patel

ABSTRACT

2036

Phase 1 dose-escalation study of ACT001 in patients with recurrent glioblastoma and other advanced solid tumors.

AUTHOR(S)

Jason D. Lickliter, Ross Jennens, Charlotte R. Lemech, Ganessan Kichenadasse, Dongpo Cai, Steven Y. Su

ABSTRACT

2037

Efficacy finding cohort of a cancer peptide vaccine, TAS0313, in treating recurrent glioblastoma.

AUTHOR(S)

Yoshiki Arakawa, Yoshiko Okita, Yoshitaka Narita

ABSTRACT

2038

A phase II study of anlotinib combined with STUPP regimen in the treatment of patients with newly diagnosed glioblastoma (GBM).

AUTHOR(S)

Peijing Li, Yuan yuan Y. Chen, Shuzhen Lai, Fagui Jiang, Xiaohui Liu, Changjuan Tao, Lei Wang, Guihong Liu, Jing Huang, Yiqiang Tang, Zhigang Liu, Guoping Shen, Chaoming Li, Tieming Xie, Fangxiao Lu

ABSTRACT

2039

A phase I/II study to evaluate the safety and efficacy of a novel long-acting interleukin-7, NT-I7, for patients with newly diagnosed high-grade gliomas after chemoradiotherapy: The interim result of the phase I data.

AUTHOR(S)

Jian L. Campian, Jingqin Luo, Chai Avvaru, Ruth Katumba, Albert H. Kim, Gavin P. Dunn, Christopher Abraham, Puspanjali Bhatta, Se Hwan Yang, Jean Fan, Byung Ha Lee, Sunita Ranjitka, Ngocdiep T. Le, George Ansstas, Tanner M. Johanns, Milan G. Chheda, Jiayi Huang

ABSTRACT

2040

PD-L1-R: A MR based surrogate for PD-L1 expression in Glioblastoma multiforme.

AUTHOR(S)

Francesco Sforazzini, Patrick Salome, Andreas Kudak, Matthias Ulrich, Laila König, Rolf Warta, Nina Bougatf, Juergen Debus, Christel Herold-Mende, Maximilian Knoll, Amir Abdollahi

ABSTRACT

2041

Gene fusions in glioblastoma: Results of Gliocat project.

AUTHOR(S)

Ainhoa Hernandez Gonzalez, Anna Esteve-Codina, Cristina Carrato, Ana Munoz, Estela Pineda, Oscar Gallego Rubio, Oriol Arpi, Marta Gut, Maria Martinez Garcia, Raquel Lopez, Carlos Mesia, Sonia D. Barco Berron, Carolina Sanz, Sun Chen, Marta Domenech, Francesc Alameda, Carmen Balana

ABSTRACT

2042

Improved risk stratification via integration of radiomics and dosiomics features in patients with recurrent high-grade glioma undergoing carbon ion radiotherapy (CIRT).

AUTHOR(S)

Patrick Salome, Francesco Sforazzini, Andreas Kudak, Laila König, Philipp Kickingereeder, Nina Bougatf, Wolfgang Wick, Oliver Jäkel, Juergen Debus, Maximilian Knoll, Amir Abdollahi

ABSTRACT

2043

A phase I dose-escalation study to evaluate pharmacokinetics, safety and tolerability of ACT001 in patients with advanced glioma.

AUTHOR(S)

Yehui Shi, Guiying Bai, Peng Wang, Dongpo Cai, Yue Chen, Ping Wang

ABSTRACT

2044

Pilot trial treating recurrent GBM patients with precision medicine regimens.

AUTHOR(S)

Jennifer L. Clarke, David Solomon, Nancy Ann Oberheim Bush, Jennifer A. Grabowsky, Cassie Kline, Deanna L. Kroetz, Jennie W. Taylor, Javier Villanueva-Meyer, Annette Molinaro, David Gibson, Meghan Tedesco, Jane E. Rabbitt, Eduardo Rodriguez Almaraz, Jessica Schulte, Robin A. Buerki, Shawn L. Hervey-Jumper, Manish K. Aghi, Mitchel S. Berger, Edward Chang, Susan M. Chang

ABSTRACT

2045

ATRX^{Loss} to impair glioma stem cell viability and self-renewal via proton radiotherapy induced necrosis.

AUTHOR(S)

Angel Garces, Lawrence Bronk, Krishna Bhat, David R. Grosshans

ABSTRACT

2046

Evaluation of GM-CSF and AS01_B adjuvants in a phase I/IIa trial of a therapeutic CMV vaccine (VBI-1901) against recurrent glioblastoma (GBM).

AUTHOR(S)

Patrick Y. Wen, David A. Reardon, Deborah A. Forst, Eudocia Q. Lee, Fabio M. Iwamoto, Francisco Diaz-Mitoma, David E. Anderson, Andrew B. Lassman

ABSTRACT

2047

Targeted agents recommended by the CNS TAP tool compared to those selected by a tumor board in a molecularly-driven clinical trial in children and young adults with DIPG.

AUTHOR(S)

Holly Roberts, Karthik Ravi, Cassie Kline, Sabine Mueller, Carl J. Koschmann, Bernard Marini, Andrea Franson

ABSTRACT

2048

A phase I/IIa study to evaluate the safety and efficacy of blood-brain barrier (BBB) opening with the SonoCloud-9 implantable ultrasound device in recurrent glioblastoma patients receiving IV carboplatin.

AUTHOR(S)

Ahmed Idbaih, Francois Ducray, Roger Stupp, Nathalie Baize, Olivier L. Chinot, John F. De Groot, Jacques Guyotat, Adam M. Sonabend, Philippe Menei, Henry Dufour, Jeffrey S. Weinberg, Carole Desseaux, Michael Canney, Charlotte Schmitt, Alexandre Carpentier

ABSTRACT

2049

Malignant glioma subset from Actuate 1801: A phase 1/2 study of 9-ING-41, a glycogen synthase kinase 3 beta (GSK-3 β) inhibitor, as a single agent and combined with chemotherapy, in patients with refractory hematologic malignancies or solid tumors.

AUTHOR(S)

Yazmin Odia, Ludimila Cavalcante, Howard Safran, Steven F. Powell, Pamela N. Munster, Wen Wee Ma, Benedito A. Carneiro, Bruno R. Bastos, Francis J. Giles, Solmaz Sahebjam

ABSTRACT

2051

The clinical significance of telomerase reverse transcriptase (*TERT*) promoter mutations, telomere length and O6-methylguanine DNA methyltransferase (*MGMT*) promoter methylation status in newly diagnosed and recurrent *IDH*-wildtype glioblastoma (GBM) patients (PTS): A large mono-institutional study.

AUTHOR(S)

Giuseppe Lombardi, Silvia Giunco, Francesco Cavallin, Chiara Angelini, Mario Caccese, Giulia Cerretti, Pasquale De Bonis, Anita De Rossi, Vittorina Zagone

ABSTRACT

2053

Resection and surgically targeted radiation therapy for locally recurrent GBM.

AUTHOR(S)

David Brachman, Peter Nakaji, Kris Smith, Theresa Thomas, Christopher Dardis, Dilini Pinnaduwaage, Garrick Wallstrom, Leland Rogers, Mehee Choi, Emad Youssef

ABSTRACT

2054

Health-related quality of life for glioblastoma short and long-term survivors receiving treatment with TTfields.

AUTHOR(S)

Joshua D. Palmer, Po-Ya Chuang, Gordon Chavez, Bruce C. Wang, Christina Proescholdt

ABSTRACT

2055

Scalp-sparing radiation with concurrent temozolomide and tumor treating fields (SPARE) for patients with newly diagnosed glioblastoma.

AUTHOR(S)

Ryan C. Miller, Andrew J. Song, Ayesha Ali, Voichita C. Bar-Ad, Nina L. Martinez, Jon Glass, Iyad Alnahhas, David W. Andrews, Kevin Judy, James J. Evans, Christopher Farrell, Maria Werner-Wasik, Inna Chervoneva, Michele Ly, Joshua D. Palmer, Haisong Liu, Wenyin Shi

ABSTRACT

2056

Phase 1 trial of drug resistant immunotherapy: A first-in-class combination of MGMT-modified $\gamma\delta$ t cells and temozolomide chemotherapy in newly diagnosed glioblastoma.

AUTHOR(S)

Louis B. Nabors, Lawrence S. Lamb Jr., Melissa J. Beelen, Thriumaine Pillay, Mariska ter Haak, Samantha Youngblood, Louis Vaickus, Mina Lobbous

ABSTRACT

2057

Cost-effectiveness of concomitant and adjuvant temozolomide for glioblastoma patients with unmethylated O⁶-methylguanine-DNA methyltransferase promoter regions in the United States.

AUTHOR(S)

Manav D. Midha, Mark E. Votruba

ABSTRACT

2058

Comprehensive molecular pharmacodynamic assessment identifies response markers of intermediary metabolism associated with BPM 31510-IV treatment in advanced glioblastoma multiforme patients.

AUTHOR(S)

Seema Nagpal, Rangaprasad Sarangarajan, Can Bruce, Greg M. Miller, Leonardo O. Rodrigues, Punit Shah, Richard Searfoss, Kennedy Ofori-Mensa, Vladimir Tolstikov, Bennett Greenwood, Valerie Bussberg, Michael A. Kiebish, Elder Granger, Niven R. Narain, Lawrence D. Recht

ABSTRACT

2059

Phase I study of ruxolitinib with radiation and temozolomide in patients with newly diagnosed grade III gliomas and glioblastoma.

AUTHOR(S)

Yasmeen Rauf, Rachel Hufsey, Kathy Robinson, John H. Suh, Samuel T. Chao, Erin S. Murphy, Jennifer S. Yu, David M. Peereboom, Manmeet S. Ahluwalia, Wei Wei

ABSTRACT

2060

Safety and feasibility of rhenium-186 nanoliposome (¹⁸⁶RNL) in recurrent glioma: The ReSPECT phase 1 trial.

AUTHOR(S)

Andrew J. Brenner, Ande Bao, William Phillips, Gregory Stein, Vibhudutta Awasthi, Toral R. Patel, Jeffrey S. Weinberg, John Floyd

ABSTRACT

2061

Autologous stem cell transplantation (ASCT) versus whole brain radiation (WBRT) as a consolidation therapy in primary CNS lymphoma (PCNSL): A nationwide analysis.

AUTHOR(S)

Yazan Samhoury, Moaath M. Ali, Thejus T. Jayakrishnan, Veli Bakalov, Salman Fazal, Cyrus Khan, Rodney E. Wegner, Seung Tae Lee, John Lister

ABSTRACT

2062

Predictive value of lymphocyte immunophenotyping (LIP) in primary central nervous system lymphoma (PCNSL).

AUTHOR(S)

Axel Berthelot, Celine Boucard, Gregorio Petrirena, Chantal Campello, Olivier L. Chinot, Emeline Tabouret

ABSTRACT

2063

A phase II, open-label, single-arm trial of pembrolizumab for refractory atypical and anaplastic meningioma and hemangiopericytoma.

AUTHOR(S)

Shlomit Yust-Katz, Alexandera Amiel, Tali Siegal, Dror Limon

ABSTRACT

2064

LUMINOS-101: Phase 2 study of PVSRIPO with pembrolizumab in recurrent glioblastoma.

AUTHOR(S)

Andrew E. Sloan, Robin A. Buerki, Christopher Murphy, Andrea T. Kelly, Prakash Ambady, Michael Brown, Nicholas A. Butowski, Robert Cavaliere, William T. Curry, Annick Desjardins, Lisa Franklin, Henry S. Friedman, Matthias Gromeier, LeAnn Jackson, Lori Mixson, Shirley S. Ong, Dina Randazzo, Patrick Y. Wen, Garrett Nichols

ABSTRACT

TPS2065

BrainStorm: A brain metastases research platform to tackle the challenge of central nervous system (CNS) metastases in solid tumors (Oncodistinct 006).

AUTHOR(S)

Nuria Kotecki, Maria Alice B. Franzoi, Marianne Paesmans, Florian Clatot, Edith Borcoman, Anthony Goncalves, Philippe Barthelemy, Claire Cheymol, Jean-Pierre Delord, Andrea Gombos, Vincent Vanhaudenarde, Stephane Holbrechts, Francois P. Duhoux, Jean-Luc R. Canon, Lore Decoster, Hannelore denys, Caroline Duhem, Nadège Kindt, Ahmad Awada

ABSTRACT

TPS2066

A phase III multicenter randomized controlled trial of postsurgical stereotactic radiotherapy versus surgically targeted radiation therapy (STaRT) for the treatment of large (>2.5cm) newly diagnosed brain metastases: Trial in progress.

AUTHOR(S)

Jeffrey S. Weinberg, Mary Frances McAleer, Jason M. Johnson, Rajat Kudchadker, Jeffrey S. Wefel, Ying Yuan, Heather Y. Lin

ABSTRACT

TPS2067

The potential utility of end-binding protein 1 (EB1) as response-predictive biomarker for lisavanbulin: A phase 2 study of lisavanbulin (BAL101553) in adult patients with recurrent glioblastoma.

AUTHOR(S)

Crescens D. Tiu, Sarah Derby, Noor M. Haris, Liam Welsh, Anna Stansfeld, Thomas Hundsberger, Patrick Roth, Fatima König, Joel R. Eisner, Malte Kleinschmidt, Stephanie Anderson, Felix Bachmann, Heidi A. Lane, Marc Engelhardt, Thomas Kaindl, Karine Litherland, Alexandru C. Stan, T.R. Jeffry Evans, Elizabeth R. Plummer, Juanita S. Lopez

ABSTRACT

TPS2068

Phase 2 trial of newly diagnosed high-grade glioma treated with concurrent radiation therapy, temozolomide, and BMX-001.

AUTHOR(S)

Katherine B. Peters, John L. Villano, Nicholas A. Butowski, Adam L. Cohen, Joe S. Mendez, Pierre Giglio, Chi Zhang, Shahzad Raza, Tresa McGranahan, Mina Lobbous, David MacLeod, Shayne Gad, Sara Penchev, David Silberstein, James Crapo

ABSTRACT

TPS2069

Safety and efficacy study of retifanlimab and epacadostat in combination with radiation and bevacizumab in patients with recurrent glioblastoma.

AUTHOR(S)

Jian L. Campian, Christopher Abraham, Jingqin Luo, Grayson Talcott, Ruth Katumba, Albert H. Kim, Gavin P. Dunn, George Ansstas, Tanner M. Johanns, Matthew A. Ciorba, Milan G. Chheda, Jiayi Huang

ABSTRACT

TPS2070

A phase 1/2 study of selinexor in combination with standard of care therapy for newly diagnosed or recurrent glioblastoma.

AUTHOR(S)

Yazmin Odia, Samuel A. Goldlust, Minesh P. Mehta, Andrew B. Lassman, Howard Colman, Priya Kumthekar, Warren P. Mason, Rebecca A. Harrison, Nicholas A. Butowski, Vyshak Venur, Scott R. Plotkin, Michael Schulder, John A. Boockvar, J Paul Duic, Kai Li, Yang Liu, Sharon Tamir, Gregory Mundy, Sharon Shacham, Patrick Y. Wen

ABSTRACT

TPS2071

First-in-human dose escalation and food effect study of oral ONC206 in adults with recurrent primary CNS neoplasms.

AUTHOR(S)

Brett J. Theeler, Jinkyu Jung, Eric Burton, Heather Leeper, Jing Wu, Kareem Zaghloul, Abhik Ray-Chaudhury, Martha Quezado, Mark Raffeld, Ying Yuan, Kenneth D. Aldape, Marta Penas-Prado, Varun Vijay Prabhu, Martin Stogniew, Joshua E. Allen, Terri S. Armstrong, Mark R. Gilbert

ABSTRACT

TPS2072

A multicenter observational study of cs-131 seeds embedded in a collagen carrier tile in intracranial brain neoplasms: Trial in progress.

AUTHOR(S)

K. Stuart Lee, Matthew Peach, Clark C. Chen, Kathryn Dusenbery, Clara Ferreira, Colette Shen, Sivakumar Jaikumar, Michael W. McDermott, Rupesh Kotecha, David J. McCracken, Adam W. Nowlan, Erin M. Dunbar, John E. Trusheim, David J. Monyak, John Wanebo, Mehee Choi, David Brachman, Lisa Misell

ABSTRACT

TPS2073

GBM AGILE: A global, phase 2/3 adaptive platform trial to evaluate multiple regimens in newly diagnosed and recurrent glioblastoma.

AUTHOR(S)

Patrick Y. Wen, Ingo K. Mellinghoff, Meredith B. Buxton, Webster K. Cavenee, Howard Colman, John F. De Groot, Benjamin M. Ellingson, Gary B. Gordon, Mustafa Khasraw, Andrew B. Lassman, Michael Lim, James R. Perry, Kirk Tanner, Michael Weller, W. K. Alfred A. Yung, Timothy F. Cloughesy

ABSTRACT

TPS2074

Developmental Therapeutics—Immunotherapy

[Back to Program](#)

Showing 160 Presentations

<https://meetinglibrary.asco.org/session/13618>

Early safety and efficacy from a phase I open-label clinical trial of CD137(4-1BB) agonistic antibody LVGN6051 as monotherapy and in combination with pembrolizumab.

AUTHOR(S)

Siqing Fu, Wael A. Harb, Sapna P. Patel, Charles Lu, Daniel M. Halperin, Yi Hsin Hsu, Naiyi Shi, Yuko Yamamura, Tony Tang, Lynn Jiang, Fusheng Su, Julia W. Cohen, Emmett V. Schmidt, Jieyi Wang

ABSTRACT

2521

Activity results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab or panitumumab in patients with refractory solid tumors.

AUTHOR(S)

Elena Garralda, Gianluca Del Conte, Marina Macchini, Ignacio Matos, Konrad F. Klinghammer, Omar Saavedra Santa Gadea, Walter M. Fiedler, Christina C. Rolling, Maxim Kebenko, Francesco Raspagliesi, Domenica Larusso, Isabelle ahrens-Fath, Beate Habel, Hans Baumeister, Alfredo Zurlo, Sebastian Ochsenreither

ABSTRACT

2522

Phase I study of LBL-007, a novel anti-human lymphocyte activation gene 3 (LAG-3) antibody in patients with advanced solid tumors.

AUTHOR(S)

Yuankai Shi, Suxia Luo, Huan Zhou, Shengyu Zhou, Shan An, Zishu Wang, Sheng Yang, Ning Li, Xiaoli Li, Xinyi Yang

ABSTRACT

2523

Safety and tolerability results of the GATTO study, a phase Ib study combining the anti-TA-MUC1 antibody gatipotuzumab with the anti-EGFR tomuzotuximab or panitumumab in patients with refractory solid tumors.

AUTHOR(S)

Sebastian Ochsenreither, Alfredo Zurlo, Elena Garralda, Ignacio Matos, Konrad F. Klinghammer, Gianluca Del Conte, Marina Macchini, Christina C. Rolling, Maxim Kebenko, Omar Saavedra Santa Gadea, Francesco Raspagliesi, Domenica Larusso, Isabelle ahrens-Fath, Beate Habel, Hans Baumeister, Walter M. Fiedler

ABSTRACT

2524

Changes in T lymphocyte subsets in different tumors before and after radiotherapy: A meta-analysis.

AUTHOR(S)

Xiaoxia Zhu, Qin Wang, Shangbiao Li, Simiao Qiao, Zhihao Zheng, Xiaotong Duan

ABSTRACT

2525

A phase 1, open-label, dose escalation study of the safety and tolerability of T3011 in advanced cutaneous or subcutaneous malignancies.

AUTHOR(S)

Andrew M. Haydon, Ganessan Kichenadasse, John M. Kirkwood, Howard E. Kaufman, Elizabeth I. Buchbinder, Vinod Ganju, Minal A. Barve, Haifang Jiang, Huinan Xu, Xusha Zhou, Huan J. Zhu, Dongyao Ni, Jiaxin Niu

ABSTRACT

2526

Safety and PK/PD of ALLO-647, an anti-CD52 antibody, with fludarabine (Flu)/cyclophosphamide (Cy) for lymphodepletion in the setting of allogeneic CAR-T cell therapy.

AUTHOR(S)

Michael T. Tees, Sattva S. Neelapu, Parameswaran Hari, Sham Mailankody, David B. Miklos, Frederick L. Locke, Rajneesh Nath, Sacha L. Prasad, Xiangdong Zhou, Eren Demirhan, Srinand Ponnathapura Nandakumar, Dennis Fisher, Gregory Opiteck, Ena Wang

ABSTRACT

2527

Novel CoupledCAR technology for treating colorectal cancer.

AUTHOR(S)

Lei Xiao, Song Li, Chengfei Pu, Zhiyuan Cao, Xinyi Yang, Ning Li, Youli Luo, Haiyan Zhao, Hang Yang, Xi Huang, Xiaogang Shen, Xiuwen Wang, Yongping Song, Junjie Mao, Pengfei Pang, Qun Hu, Zhao Wu, Victor Lu

ABSTRACT

2528

First-in-human data of ALLO-501A, an allogeneic chimeric antigen receptor (CAR) T-cell therapy and ALLO-647 in relapsed/refractory large B-cell lymphoma (R/R LBCL): ALPHA2 study.

AUTHOR(S)

Frederick L. Locke, Shahbaz Malik, Michael T. Tees, Sattva S. Neelapu, Leslie Popplewell, Jeremy S. Abramson, Jennifer T. McDavitt, Chu R. Shin, Eren Demirhan, Cyril Konto, Lazaros J. Lekakis

ABSTRACT

2529

CAR-T cells to deliver engineered peptide antigens and reprogram antigen specific T cell responses against solid tumors.

AUTHOR(S)

Daniel Y. Lee, Andy J. Minn, Lexus R. Johnson

ABSTRACT

2530

A single-arm phase Ib study of autologous cytokine-induced killer (CIK) cell immunotherapy in combination with sintilimab plus chemotherapy in patients with advanced non-small cell lung cancer (NSCLC)-CCICC-002.

AUTHOR(S)

Xiubao Ren, Li Zhou

ABSTRACT

2531

A phase I-IIa study of genetically modified Tie-2 expressing monocytes in patients with glioblastoma multiforme (TEM-GBM Study).

AUTHOR(S)

Gaetano Finocchiaro, Bernhard Gentner, Francesca Farina, Alessia Capotondo, Marica Eoli, Elena Anghileri, Matteo G. Carabba, Valeria Cuccarini, Francesco DI Meco, Federico Legnani, Bianca Pollo, Maria Grazia Bruzzone, Marco Saini, Paolo Ferroli, Roberto Pallini, Alessandro Olivi, Stefania Mazzoleni, Carlo Russo, Luigi Naldini, Fabio Ciceri

ABSTRACT

2532

In-depth immune and molecular profiling of melanoma patients receiving adoptive T-cell therapy reveals biomarkers of efficacy in ATATIL study.

AUTHOR(S)

Angela Orcurto, Johanna Chiffelle, Eleonora Ghisoni, David Barras, Isaac Crespo, Blanca Navarro Rodrigo, María Ochoa de Olza, Martina Imbimbo, Sylvie Rusakiewicz, Stephanie Tissot, Philippe O. Gannon, Urania Dafni, Stefan Zimmermann, Lana E. Kandalaf, Olivier Michielin, Michal Bassani-Sternberg, Denarda Dangaj, Lionel Trueb, Alexander Harari, George Coukos

ABSTRACT

2533

PSMA targeted armored chimeric antigen receptor (CAR) T-cells in patients with advanced mCRPC: A phase I experience.

AUTHOR(S)

Matthew H. Carabasi, Meredith McKean, Mark N. Stein, Michael T. Schweizer, Jason J. Luke, Vivek Narayan, Russell K. Pachynski, Rahul A. Parikh, Jingsong Zhang, Thomas J. Fountaine, Jamie Rosen, Pam Hufner, Whitney Gladney, Karen Chagin

ABSTRACT

2534

A single-arm phase Ib study of multiple target cytotoxic T-lymphocyte (MCTL) in combination with toripalimab as second-line therapy in advanced non-small cell lung cancer (NSCLC).

AUTHOR(S)

Xiubao Ren, Weihong Zhang

ABSTRACT

2535

Initial results of a first-in-human, dose escalation study of a cell-based vaccine in HLA A*02+ patients (pts) with recurrent, locally advanced or metastatic HPV16+ solid tumors: SQZ-PBMC-HPV-101.

AUTHOR(S)

Antonio Jimeno, Joaquina C. Baranda, Monica M. Mita, Michael S. Gordon, Matthew H. Taylor, Wade T. Iams, Filip Janku, Ursula A. Matulonis, Howard Bernstein, Scott Loughhead, Martin Kornacker, Ricardo F. Zwartes, Oliver Rosen, Cathy Eng

ABSTRACT

2536

Anakinra (AKR) prophylaxis (ppx) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) receiving orvacabtagene autoleucel (orva-cel).

AUTHOR(S)

Luciano J. Costa, Sham Mailankody, Paul Shaughnessy, Parameswaran Hari, Jonathan L. Kaufman, Sarah M. Larson, David Dingli, Kelvin Lee, Kristin Conte, Todd DeVries, Julia Piasecki, Meng Li, Ronald L. Dubowy, Myo Htut

ABSTRACT

2537

Preliminary analysis of a phase 1/2 study of NEXI-001 donor-derived multi-antigen-specific CD8⁺ T-cells for the treatment of relapsed acute myeloid leukemia (AML) after allogeneic hematopoietic cell transplantation (HCT).

AUTHOR(S)

Monzr Al Malki, Sumithira Vasu, Dipenkumar Modi, Miguel-Angel Perales, Donna Bui, Vineetha Edavana, Sojung Kim, Lauren Suarez, Mathias Oelke, Dan Bednarski, Robert D. Knight, Juan C. Varela

ABSTRACT

2538

Progression prediction model for solid tumors with clinical and immunological parameters.

AUTHOR(S)

Aleksei V. Novik, Dmitrii V. Girdyuk, Tatyana L. Nekhaeva, Natalia V. Emelyanova, Anna Semenova, Gulfiya M. Teletaeva, Dilorom K. Latipova, Svetlana Protsenko, Irina A. Baldueva

ABSTRACT

2539

Concordance of blood and tissue TMB from NGS testing in real-world settings and their ability to predict response to immunotherapy.

AUTHOR(S)

Emma Sturgill, Amanda Misch, Carissa Jones, Daniel Lockett, Xiaotong Fu, Suzanne F. Jones, Howard A. Burris III, David R. Spigel, Andrew J. McKenzie

ABSTRACT

2540

Genomic immunotherapy (IO) biomarkers detected on comprehensive genomic profiling (CGP) of tissue and circulating tumor DNA (ctDNA).

AUTHOR(S)

Takayuki Yoshino, Hanna Tukachinsky, Jessica K. Lee, Ethan Sokol, Dean C. Pavlick, Aparna Aiyer, David Fabrizio, Jeffrey M. Venstrom, Saori Mishima, Yoshiaki Nakamura, Geoffrey R. Oxnard

ABSTRACT

2541

Impact of circulating tumor DNA (ctDNA) detection on survival outcomes of patients (pts) treated with immune-checkpoint inhibitors (ICIs) in early clinical trials.

AUTHOR(S)

Vladimir Galvao, Ignacio Matos, Ana Moreno, Guzman Alonso, Irene Brana, Maria Villar, Omar Saavedra Santa Gadea, Honey K. Oberoi, Javier Ros, Roger Berche, Natassia Ann Wornham, Carlota Arenillas, Cristina Saura, Ana Oaknin, Enriqueta Felip, Eva Muñoz-Couselo, Elena Elez, Josep Tabernero, Rodrigo Toledo, Elena Garraalda

ABSTRACT

2542

Analysis of immune checkpoint blockade biomarkers in elderly patients using large-scale cancer genomics data.

AUTHOR(S)

Rossin Erbe, Zheyu Wang, Sharon Wu, Joanne Xiu, Neeha Zaidi, Marc E. Lippman, Claudine Isaacs, Reva K. Basho, Heinz-Josef Lenz, Igor A. Astsaturov, John Marshall, Stephen Baylin, Elizabeth M. Jaffee, Evanthia T. Roussos Torres, Ashani Weeraratna, Hariharan Easwaran, Elana J. Fertig

ABSTRACT

2543

SER-ONCOVID: Seroconversion in solid-tumor cancer patients after COVID-19 diagnosis.

AUTHOR(S)

Anna Pous, Eudald Felip, Olatz Etzaniz, Ainhoa Hernandez Gonzalez, Sofia España, Margarita Romeo, David J. Pinato, Anna Esteve, Ricard Mesia

ABSTRACT

2544

Using the tumor microenvironment to identify predictors of immunotoxicity to checkpoint inhibitors.

AUTHOR(S)

William Alexander, Kristopher Attwood, Kayla Catalfamo, Grace K. Dy, Saby George, Marc S. Ernstoff, Yara Abdou

ABSTRACT

2545

A 4-chemokine signature to predict intermediate immunogenicity in homologous recombination repair deficient tumors.

AUTHOR(S)

Joan Miguel Romero, Yifan Wang, Alain Pacis, Robert E. Denroche, Gun Ho Jang, Barbara Grunwald, Steven Gallinger, George Zogopoulos

ABSTRACT

2546

First-in-human dose escalation of ALPN-202, a conditional CD28 costimulator and dual checkpoint inhibitor, in advanced malignancies.

AUTHOR(S)

Justin C. Moser, Mark Voskoboynik, Nehal J. Lakhani, Michael Millward, Diwakar Davar, Wael A. Harb, Jing Yang, Gary Means, Kristi Manjarrez, Almudena Tercero, Hany Zayed, Jan Hillson, Christine Dela Cruz, Graciela N. Perez, Stanford L. Peng

ABSTRACT

2547

Phase 1A clinical trial of the first-in-class fascin inhibitor NP-G2-044 evaluating safety and anti-tumor activity in patients with advanced and metastatic solid tumors.

AUTHOR(S)

Vincent Chung, Komal L. Jhaveri, Daniel D. Von Hoff, Xin-Yun Huang, Edward G. Garmey, Jillian Zhang, Frank Y. Tsai

ABSTRACT

2548

Preliminary results from a phase 1/2 study of BDC-1001, a novel HER2 targeting TLR7/8 immune-stimulating antibody conjugate (ISAC), in patients (pts) with advanced HER2-expressing solid tumors.

AUTHOR(S)

Manish Sharma, Richard D. Carvajal, Glenn J. Hanna, Bob T. Li, Kathleen N. Moore, Mark D. Pegram, Drew W. Rasco, Alexander I. Spira, Michael Alonso, Liang Fang, Amreen Husain, Edith A. Perez, Ecaterina E. Dumbrava

ABSTRACT

2549

Preliminary results of a first-in-human phase I study of IMM01, SIRP α Fc protein in patients with relapsed or refractory lymphoma.

AUTHOR(S)

Mingyuan Sun, Junyuan Qi, Weiwei Zheng, Lin Song, Bo Jiang, Zhenzhen Wang, Cheng Huang, Wenzhi Tian, Lugui Qiu

ABSTRACT

2550

Results of a phase 1 study of SRF388, a first-in-human, first-in-class, high-affinity anti-IL-27 antibody in advanced solid tumors.

AUTHOR(S)

Amita Patnaik, Daniel Morgensztern, Charlene Mantia, Nizar M. Tannir, Lauren C. Harshman, Jonathan Hill, Kerry White, Jou-Ku Chung, Beth Bowers, Gaia Sciaranghella, Benjamin Lee, Toni K. Choueiri, Lon S. Smith, Aung Naing

ABSTRACT

2551

Selection of the recommended phase 2 dose (RP2D) for subcutaneous nemvaleukin alfa: ARTISTRY-2.

AUTHOR(S)

Omid Hamid, Stephen V. Liu, Ralph V. Boccia, Justin A. Call, Trisha M. Wise-Draper, Angela T. Alistar, John D. Powderly II, Bradley C. Carthon, Ulka N. Vaishampayan, Anthony J. Olszanski, John M. Wrangle, Anthony F. Shields, Sarina Anne A. Piha-Paul, Monali Desai, MD, Yangchun Du, Lei Sun, PhD, Yan Wang, Heather Losey, Craig Hopkinson, Marc S. Ernstoff

ABSTRACT

2552

Initial results from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with advanced solid tumors.

AUTHOR(S)

Raghad M. Abdul-Karim, Anthony W. Tolcher, Shivaani Kummar, Manish R. Patel, Alexander I. Spira, Shekeab Jauhari, Maureen Duff, Rongda Xu, Ann Johnson, Anneleen Daemen, Pratik S. Multani, Edna Chow Maneval, Pamela N. Munster

ABSTRACT

2553

Results of a phase 1 dose-escalation study of AMV564, a novel T-cell engager, alone and in combination with pembrolizumab in patients with relapsed/refractory solid tumors.

AUTHOR(S)

Niharika B. Mettu, Alexander Starodub, Sarina Anne A. Piha-Paul, Raghad M. Abdul-Karim, Gabriel Tinoco, Michael R. Shafique, Victoria Smith, Christina Baccei, Patrick Y. Chun

ABSTRACT

2555

A phase 1b, open-label, dose-escalation study to evaluate camidanlumab tesirine (Cami) as monotherapy in patients (pts) with advanced solid tumors.

AUTHOR(S)

Igor Puzanov, Patricia LoRusso, Kyriakos P. Papadopoulos, Christopher T. Chen, Yvan LeBruchec, Xiaomin He, Thierry Cousin, Karin Havenith, Joseph Boni, Johanna C. Bendell

ABSTRACT

2556

ItRECIST adapted efficacy assessment in solid tumors treated with intratumoral immunotherapy.

AUTHOR(S)

Honey Kumar Oberoi, Xavier Serres-Créixams, Guzman Alonso, Ignacio Matos, Alberto Hernando-Calvo, Eva Muñoz-Couselo, Marc Diez, Iosune Baraibar, Maria Vieito, Omar Saavedra Santa Gadea, Vladimir Galvao, Gemma Mur-Bonet, Guillem Cunill-Macià, Mafalda Oliveira, Enriqueta Felip, Teresa Macarulla, Elena Elez, Josep Tabernero, Irene Brana, Elena Garraalda

ABSTRACT

2557

Targeting innate immunity with BXCL701 in combination with pembrolizumab in patients with advanced solid cancers: Phase 2 basket study.

AUTHOR(S)

Ozgur Karakuzu, Apostolia M. Tsimberidou, Veronica R. Holley, Abha Adat, Sapna P. Patel, Anil K. Sood, Anthony P. Conley, Gabriele E. Urschel, Diane I. Healey, Vincent O'Neill, Filip Janku

ABSTRACT

2558

GS-3583, a novel FLT3 agonist Fc fusion protein, to expand conventional dendritic cells in healthy volunteers.

AUTHOR(S)

Nishanthan Rajakumaraswamy, Anees Dauki, Michelle R. Kuhne, Torsten Trowe, Jing He, Christopher Clarke, Brian Carr, Angela Worth, Anshu Vashishtha, Christian Schwabe, Ahmed A. Othman

ABSTRACT

2559

Safety and efficacy of murine PVSRIPO plus anti-PD-1 immune checkpoint inhibitor (ICI) in a melanoma tumor model.

AUTHOR(S)

Lauren Neighbours, Zachary P. McKay, Matthias Gromeier, Garrett Nichols, Andrea T. Kelly, Daniel Corum, Michael Brown

ABSTRACT

2560

Resetting the tumor microenvironment to favor anti-tumor immunity after local ablation.

AUTHOR(S)

Corrine A. Nief, Júlia Sroda Agudogo, Alana Gonzales, Rebecca A. Previs, Smita K. Nair, Nimmi Ramanujam

ABSTRACT

2561

Phase 1 trial of the adenosine A_{2A} receptor antagonist inupadenant (EOS-850): Update on tolerability, and antitumor activity potentially associated with the expression of the A_{2A} receptor within the tumor.

AUTHOR(S)

Laurence Buisseret, Sylvie Rottey, Johann S. De Bono, Ariane Migeotte, Brant Delafontaine, Thubeena Manickavasagar, Chiara Martinoli, Noémie Wald, Maura Rossetti, Esha A. Gangolli, Erol Wiegert, Nicola McIntyre, Joanne J. Lager, Jean-Pascal H. Machiels

ABSTRACT

2562

Tumor-selective activity of XTX202, a protein-engineered IL-2, in mice without peripheral toxicities in nonhuman primates.

AUTHOR(S)

Jennifer O'Neil, Wilson Guzman, Oleg Yerov, Parker Johnson, Manoussa Fanny, Justin Greene, Megan McLaughlin, Kurt Jenkins, Rebekah O'Donnell, Huawei Qiu, Benjamin Nicholson, William Avery, Ronan C. O'Hagan

ABSTRACT

2563

Antitumor activity of dostarlimab in patients with mismatch repair-deficient/microsatellite instability-high tumors: A combined analysis of two cohorts in the GARNET study.

AUTHOR(S)

Dominique Berton, Susana N. Banerjee, Giuseppe Curigliano, Sara Cresta, Hendrik-Tobias Arkenau, Cyril Abdeddaim, Rebecca S. Kristeleit, Andrés Redondo, Charles A. Leath III, Antonio Antón Torres, Wei Guo, Ellie Im, Thierry Andre

ABSTRACT

2564

Pembrolizumab in microsatellite instability high (MSI-H)/mismatch repair deficient (dMMR) cancers: Updated analysis from phase 2 KEYNOTE-158 study.

AUTHOR(S)

Michele Maio, Paolo A. Ascierto, Ludmila Manzyuk, Daniel Motola-Kuba, Nicolas Penel, Philippe A. Cassier, Giovanni Bariani, Ana De Jesus-Acosta, Toshihiko Doi, Federico Longo, Wilson H. Miller Jr., Do-Youn Oh, Maya Gottfried, Ruixue Wang, Fan Jin, Kevin G. Norwood, Aurelien Marabelle

ABSTRACT

2565

Efficacy and safety of HLX10, a novel anti-PD-1 antibody, in patients with previously treated unresectable or metastatic microsatellite instability-high or mismatch repair-deficient solid tumors: A single-arm, multicenter, phase 2 study.

AUTHOR(S)

Shukui Qin, Jin Li, Haijun Zhong, Chuan Jin, Lili Chen, Xianglin Yuan, Qingxia Fan, Kehe Chen, Peiguo Cao, Jianjun Xiao, Da Jiang, Tao Zhang, Hongyu Zhang, Xicheng Wang, Wei Wang, Qingyu Wang

ABSTRACT

2566

Multi-center phase 1 safety and efficacy study of nivolumab in renal transplant patients with metastatic malignancy.

AUTHOR(S)

John R. Zalcberg, Michael J. Boyer, Anne E. Taylor, Thean H. Tan, Bronwyn Hockley, Rob Carroll

ABSTRACT

2567

Phase I dose escalation of KD033, a PDL1-IL15 bispecific molecule, in advanced solid tumors.

AUTHOR(S)

Jason J. Luke, Anthony J. Olszanski, Igor Puzanov, Dan Lu, Adrian Hackett, Stella Martomo, Jeegar Patel, Olivier Schueller, Alessandro Mora, Miranda Schlitt, Linghui Li

ABSTRACT

2568

A phase 2 study of tislelizumab monotherapy in patients with previously treated, locally advanced unresectable ormetastatic microsatellite instability-high/mismatch repair deficient solid tumors.

AUTHOR(S)

Jian Li, Ye Xu, Aimin Zang, Yunong Gao, Quanli Gao, Yanqiao Zhang, Dong Wang, Jianming Xu, Ying Yuan, Haiping Jiang, Jieer Ying, Chunmei Shi, Yanhong Deng, Jing Wang, Tianshu Liu, Yi Huang, Zhezhen Li, Huanli Wang, Shou Liu, Lin Shen

ABSTRACT

2569

Mega- and meta-analyses of fecal metagenomic studies in predicting response to immune checkpoint inhibitors.

AUTHOR(S)

Alya Heirali, Bo Chen, Matthew Wong, Pierre H. Schneeberger, Victor Rey, Anna Spreafico, Wei Xu, Bryan Coburn

ABSTRACT

2570

Phase 2 study of retifanlimab (INCMGA00012) in patients (pts) with selected solid tumors (POD1UM-203).

AUTHOR(S)

Michele Maio, Michael Schenker, Jacques Medioni, Slawomir Mandziuk, Margarita Majem, Gwenaëlle Gravis, Mark J. Cornfeld, Sulabha Ranganathan, Yubing Yao, Howard S. Yeh, Tibor Csősz

ABSTRACT

2571

Efficacy of HX008 in high microsatellite instability/mismatch repair-deficient (MSI-H/dMMR) solid tumors: Results from a multicenter phase II open-label study.

AUTHOR(S)

Jing Huang, Yan Song, Suxia Luo, Xianli Yin, Enxiao Li, Hui Wang, Yifu He, Zhihui Liu, Qingxia Fan, Xinjun Liang Sr., Yongqian Shu, Yunpeng Liu, Nong Xu, Shu Zhang, Zhixiang Zhuang, Jingdong Zhang, Xiaoge Kou, Fen Wang, Xiaodong Zhu, Shengmian Li

ABSTRACT

2572

An exploratory study of nivolumab (nivo) with or without ipilimumab (ipi) according to the percentage of tumoral CD8 cells in advanced metastatic cancer.

AUTHOR(S)

Apostolia M. Tsimberidou, Alexandra Drakaki, Danny Khalil, Shivaani Kummar, F. S. Hodi, David Y. Oh, Christopher R. Cabanski, Michael Tezlaff, Theresa LaVallee, Marko Spasic, Leo Nissola, Lacey J. Kitch, Nicholas L. Bayless, Cheryl Selinsky, Jennifer C. Ayran, Jill O'Donnell-Tormey, Vanessa M. Hubbard-Lucey, Ute Dugan, James P. Allison, Padmanee Sharma

ABSTRACT

2573

Assessment of cancer-specific microbiome signature of response to immune checkpoint inhibitors.

AUTHOR(S)

Michal Sarfaty, Christopher A. Desjardins, Paul Giardina, Kankana Bardhan, Swarna Pandian, Keith Halley, Elizabeth M. Halvorsen, Margaret K. Callahan, Michael A. Postow, Chung-Han Lee, Ritesh Kotecha, Daniel Kashani, Neha Ratna, Ashley M. Regazzi, Matthew R. Henn, Matthew D. Hellmann, Gopa Iyer, Christopher B. Ford, Jonathan U. Peled

ABSTRACT

2574

CheckMate 8KX: Phase 1/2 multitumor preliminary analyses of a subcutaneous formulation of nivolumab ($\pm$ rHuPH20).

AUTHOR(S)

Sara Lonardi, Iwona Lugowska, Christopher G. Jackson, Anne O'Donnell, Rastilav Bahleda, Marcelo Garrido, Loes Latten-Jansen, Matias Chacon, Habte A. Yimer, Trixia Camacho, Srivani Konduri, Urvi Aras, Kinjal Sanghavi, Heather Vezina, Sonia Dolfi, Federica Alessi, José Trigo, Aitana Calvo

ABSTRACT

2575

Final results of a phase I “RadVax” trial of hypofractionated radiation combined with pembrolizumab in patients with metastatic solid tumors.

AUTHOR(S)

John N. Lukens, Rosemarie Mick, Alexander C. Huang, Nicholas Han, Michael Farwell, Tara C. Mitchell, Ravi K. Amaravadi, Lynn M. Schuchter, Abigail T. Berman, Mark H. O'Hara, Alisha Maity, David Miller, Andy Minn, Robert H. Vonderheide, E. John Wherry, Amit Maity

ABSTRACT

2576

A first-in-human phase I dose escalation of YH001, an anti-CTLA-4 monoclonal antibody (mAb) in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.

AUTHOR(S)

Vinod Ganju, Adam Cooper, Bo Gao, Kate Wilkinson

ABSTRACT

2577

Phase I/II study of nivolumab plus vorolanib in patients with thoracic malignancies: Interim efficacy of the SCLC and primary refractory NSCLC cohorts, and safety data across all cohorts.

AUTHOR(S)

Selina K. Wong, Jennifer G. Whisenant, Christine M. Bestvina, Lynne D. Berry, Taofeek K. Owonikoko, Rachel E. Sanborn, Philip E. Lammers, Badi E. El Osta, Suresh S. Ramalingam, Jennifer W. Carlisle, Conor E. Steuer, Hossein Borghaei, Giovanni Selvaggi, Yu Shyr, Heather A. Wakelee, Leora Horn, Katy Beckermann

ABSTRACT

2578

Phase Ib study of BI 836880 (VEGF/Ang2 nanobody) plus ezabenlimab (BI 754091; anti-PD-1 antibody) in patients (pts) with solid tumors.

AUTHOR(S)

Nicolas Girard, Martin Wermke, Fabrice Barlesi, Dong-Wan Kim, Francois Ghiringhelli, Jaafar Bennouna, Thierry Lesimple, Enriqueta Felip, David Berz, Jong-Seok Lee, Arnaud Jeanson, Celine Mascaux, Mark Voskoboynik, Piotr Serwatowski, Michael C. Burger, Harald T. Landsteiner, Victoria Chen, Girish Jayadeva, Juergen Alt, Bjoern Hackanson

ABSTRACT

2579

Phase I open-label, dose escalation of YH003, an anti-CD40 monoclonal antibody in combination with toripalimab (anti-PD-1 mAb) in patients with advanced solid tumors.

AUTHOR(S)

Jermaine Coward, Afaf Abed, Adnan Nagrial, Ben Markman

ABSTRACT

2580

Anlotinib enhanced penpulimab efficacy through remodeling of tumor vascular architecture and immune microenvironment in hPD-L1/hPD-1 humanized mouse model.

AUTHOR(S)

Yunlong Shan, Chongjin Zhong, Qi Ni, Mengying Zhang, Guangji Wang, Fang Zhou

ABSTRACT

2581

Platform trial of ezabenlimab (BI 754091), an anti-PD-1 antibody, in patients (pts) with previously treated advanced solid tumors: Combination with BI 836880, a VEGF/Ang2-blocking nanobody.

AUTHOR(S)

Maen A. Hussein, Ivor J. Percent, Johanna C. Bendell, Edward Arrowsmith, Hendrik-Tobias Arkenau, Quincy S. Chu, Aaron R. Hansen, Damijan Erzen, Sheng Qiu, Anthony Lucarelli, Susanna V. Ulahannan

ABSTRACT

2582

AdvanTIG-105: Phase 1 dose-escalation study of anti-TIGIT monoclonal antibody ociperlimab (BGB-A1217) in combination with tislelizumab in patients with advanced solid tumors.

AUTHOR(S)

Sophia Frentzas, Tarek Meniawy, Steven C. Kao, Ruihua Wang, Yunxia Zuo, Hao Zheng, Wei Tan

ABSTRACT

2583

IFN- α , IFN- γ , IL-2 combined with TNF- α for predicting efficacy of PD-1 inhibitors combination therapy in patients with solid cancers.

AUTHOR(S)

Penghui Xing, Jinyan Zhang, Rongfeng Liu, Junyan Wang, Ming Ma, Lixing Wang, Wenjing Jiao, Junguo Shao, Yuxiang Wang, Hongtao He, Baoen Shan, Jian Shi

ABSTRACT

2584

A phase 1 dose-escalation study of a PD-L1xCD27 bispecific antibody CDX-527 in patients with advanced malignancies.

AUTHOR(S)

Rachel E. Sanborn, Rodolfo E. Bordoni, Gini F. Fleming, Mustafa Khasraw, Thomas Hawthorne, Lawrence J. Thomas, Tracey Rawls, Diane C. Young, Philip Golden, Tibor Keler, Michael J. Yellin

ABSTRACT

2585

The predictive values of loss-of-function variants in histone methyltransferases for response to immune checkpoint inhibitors in solid tumors.

AUTHOR(S)

Naixin Liang, Yanling Niu, Xin Zhang, Tonghui Ma

ABSTRACT

2586

Association of *KMT2C/D* loss-of-function mutations with tumor infiltrating lymphocytes and response to immune checkpoint inhibitors in solid tumors.

AUTHOR(S)

Ruiqi Liu, Yanling Niu, Xin Zhang, Tonghui Ma

ABSTRACT

2587

Risk of immunosuppression and hospitalization after checkpoint inhibitor therapy in patients with cancer and radiation therapy.

AUTHOR(S)

Kate E. Lee, David A. Bender, Catherine S. Spina, Brigham Hyde, Adam S. Faye, Simon Cheng

ABSTRACT

2588

Phase Ia/Ib dose-escalation study of IBI110 (anti-LAG-3 mAb) as a single agent and in combination with sintilimab (anti-PD-1 mAb) in patients (pts) with advanced solid tumors.

AUTHOR(S)

Cai Zhou, Yayi He, Shengxiang Ren, Wei Li, Jun Zhu, Jia Yu, Lei Wang, Anwen Xiong, Nong Xu, Chenyu Mao, Beiqing Pan, Ying Liu, Hui Zhou

ABSTRACT

2589

A phase I trial evaluating NBTXR3 activated by radiotherapy in combination with nivolumab or pembrolizumab in patients with advanced cancers.

AUTHOR(S)

Colette Shen, Jessica M. Frakes, Jiaxin Niu, Ari Rosenberg, Jared Weiss, Jimmy J. Caudell, Katherine L. Jameson, Patricia Said, Tanguy Y. Seiwert

ABSTRACT

2590

Overcoming resistance to anti-PD-1 with tumor agnostic NBTXR3: From bench to bed side.

AUTHOR(S)

Tanguy Y. Seiwert, Colette Shen, Jessica M. Frakes, Jiaxin Niu, Jared Weiss, Jimmy J. Caudell, Yun Hu, Hampartsoum B. Barsoumian, Juliette Thariat, Sylvie Bonvalot, Zsuzsanna Papai, Maria A. Cortez, Ping Zhang, Katherine L. Jameson, Patricia Said, Sébastien Paris, James W. Welsh

ABSTRACT

2591

A phase 1/2 study of intratumoral INT230-6 alone (IT-01) or in combination with pembrolizumab [KEYNOTE-A10] in adult subjects with locally advanced, unresectable and metastatic solid tumors refractory to therapy.

AUTHOR(S)

Anthony B. El-Khoueiry, Jacob S. Thomas, Anthony J. Olszanski, Nilofer S. Azad, Giles F. Whalen, Diana L. Hanna, Matthew Ingham, Syed Mahmood, Lewis H. Bender, Ian B. Walters, Lillian L. Siu

ABSTRACT

2592

Nivolumab/ipilimumab primed immunotransplant in post-CAR-T and post-ASCT DLBCL.

AUTHOR(S)

Bailey G. Fitzgerald, Thomas U. Marron, Dana Ostrowski, Jonah Shulman, Matko Kalac, Netonia Marshall, Joshua Brody

ABSTRACT

2593

Safety, pharmacokinetics, pharmacodynamics profiles and preliminary antitumor activity of phase 1b/2a study of NT-17, a long-acting interleukin-7, plus pembrolizumab in patients with advanced solid tumors: The phase 1b data report.

AUTHOR(S)

Aung Naing, Jean Fan, Byung Ha Lee, Debashree Basudhar, Shubham Pant, Marya F. Chaney, Cristina Laviada, Cynthia Rajan, Ngocdiep T. Le, Minal A. Barve

ABSTRACT

2594

Phase II trial of MEDI0457 and durvalumab for patients with recurrent/metastatic HPV-associated cancers.

AUTHOR(S)

Van K. Morris, Amir A. Jazaeri, Shannon N. Westin, Curtis A. Pettaway, Solly George, Ryan Huey, Michaela Onstad, Shi-Ming Tu, Jennifer Wang, Aaron Shafer, Benny Johnson, Lianchun Xiao, David J. Vining, Ming Guo, Ying Yuan, Michael M. Frumovitz

ABSTRACT

2595

Preliminary data from QUILT 3.055: A phase 2 multi-cohort study of N803 (IL-15 superagonist) in combination with checkpoint inhibitors (CPI).

AUTHOR(S)

John M. Wrangle, Mark M. Awad, Firas B. Badin, Mark P. Rubinstein, Paul Bhar, Chad Garner, Sandeep K. Reddy, Patrick Soon-Shiong

ABSTRACT

2596

Evaluating the role of immune-checkpoint inhibitor (ICI) combinations in patients (pts) with unselected “cold” tumors enrolled in early clinical trials (CT).

AUTHOR(S)

Omar Saavedra Santa Gadea, Alberto Hernando-Calvo, Roger Berche, Maria Vieito, Irene Brana, Ignacio Matos, Guzman Alonso, Vladimir Galvao, Analia Azaro, Honey Kumar Oberoi, Natassia Ann Wornham, Javier Ros, Juan Francisco Grau Béjar, Carmen García, Teresa Macarulla, Jaume Capdevila, Elena Elez, Josep Tabernero, Rodrigo Dienstmann, Elena Garraida

ABSTRACT

2597

A pan-cancer analysis of MUC family genes as potential biomarkers for immune checkpoint therapy.

AUTHOR(S)

Yang Li, Qianqian Duan, Yuan Tan

ABSTRACT

2598

Real-world pan-cancer landscape of frameshift mutations (FSM) and their role in predicting responses to immune checkpoint inhibitors (ICI) in patients (pts) with tumors with low tumor mutational burden (TMB).

AUTHOR(S)

Vaia Florou, Charalampos S. Floudas, Asaf Maoz, Abdul R. Naqash, Gregory Hildebrand, Ethan Sokol, Garrett M. Frampton, Sonam Puri, Umang Swami, Breelyn A. Wilky, Peter J. Hosein, Jonathan C. Trent, Gilberto Lopes, Wungki Park, Ignacio Garrido-Laguna

ABSTRACT

2599

Association of KMT2C mutations with favorable outcomes with immune checkpoint inhibitors across multiple tumor types.

AUTHOR(S)

Chunling Liu, Qianqian Duan, Qin Zhang

ABSTRACT

2600

MSIFinder: A python package for detecting MSI status using random forest classifier.

AUTHOR(S)

Tao Zhou, Libin Chen, Jing Guo, Mengmeng Zhang, Huanhuan Liu, Yanrui Zhang, Huina Wang, Shanbo Cao, Haijun Wang, Feng Lou

ABSTRACT

2601

A cancer organogram test as a guide for oncology treatments in SOLID tumors: An analysis of 628 tests in 419 patients.

AUTHOR(S)

Astrid Margossian, Madison Pollastro, Annie Richardson, Payel Chatterjee, Mia Lints, Danielle Peretti, Rachele Rosati, Lauren Appleyard, Grace Durenberger, G. A. Whitney, Hallie Swan, Shalini Pereira, Adam Diehl, Christopher J. Kemp, Barbara A. Goff, Kalyan Banda, William P. Harris, Elizabeth M. Swisher, Vijayakrishna K. Gadi, Carla Grandori

ABSTRACT

2602

Relationship between DICER1 mutations and immunotherapy biomarkers in solid tumors.

AUTHOR(S)

Jie Gao, Xia You, Taiyan Guo, Qin Zhang, Qianqian Duan, Chuang Qi

ABSTRACT

2603

YAP1 mutation as a novel predictor of response to anti-PD-1/PD-L1 treatment in pan-cancers.

AUTHOR(S)

Wei-guo Xu, Jing Zhu, Lin Li, Dongsheng Chen, Qin Zhang, Qianqian Duan, Si Li, Mingzhe Xiao

ABSTRACT

2604

Pan-cancer analysis of *CD274* (PD-L1) mutations in 314,631 patient samples and subset correlation with PD-L1 protein expression.

AUTHOR(S)

Richard S. Huang, Brennan Decker, Karthikeyan Murugesan, Matthew Hiemenz, Douglas A. Mata, Gerald Li, James Creeden, Shakti H. Ramkissoon, Jeffrey S. Ross

ABSTRACT

2605

Investigating the various predictive values of *POLE/POLD1* mutations for response to immune checkpoint inhibitors (ICIs) in different solid tumors.

AUTHOR(S)

Yanling Niu, Tonghui Ma, Tao Li

ABSTRACT

2606

Artificial intelligence-powered spatial analysis of tumor-infiltrating lymphocytes predicts survival after immune checkpoint inhibitor therapy across multiple cancer types.

AUTHOR(S)

Jeanne Shen, Taebum Lee, Jun-Eul Hwang, Yoon-La Choi, Se-Hoon Lee, Hyojin Kim, Jin-haeng Chung, Stephanie Bogdan, Maggie Huang, Tyler Raclin, George A. Fisher Jr., Sergio Pereira, Seonwook Park, Minuk Ma, Donggeun Yoo, Seunghwan Shin, Kyunghyun Paeng, Chan-Young Ock, Tony S. Mok, Yung-Jue Bang

ABSTRACT

2607

Awareness and utilization of tumor mutation burden (TMB) as a biomarker for administration of immuno-oncology (I-O) therapeutics by practicing community oncologists in the United States (U.S.).

AUTHOR(S)

Kristin M. Savill, Marjorie E. Zettler, Bruce A. Feinberg, Yolaine Jeune-Smith, Ajeet Gajra

ABSTRACT

2608

Comprehensive genomic and transcriptomic profiling (CGTP) to predict pembrolizumab (P) benefit in patients (pts) with advanced solid tumors (STs).

AUTHOR(S)

Dan Rhodes, Daniel H. Hovelson, Malek M. Safa, Mark E. Burkard, Eddy S. Yang, William J. Edenfield, Travis Reeder, Hana Vakil, Kat Kwiatkowski, Khalis Mitchell, Bryan Johnson, Scott A. Tomlins

ABSTRACT

2609

YAP1 transcription factor expression to define subsets of cancers with T-cell inflamed phenotype in a pan-tumor analysis across 33 tumor types.

AUTHOR(S)

Bhakti Dwivedi, Andrey Ivanov, Guojing Zhang, Fadlo R. Khuri, Suresh S. Ramalingam, Haian Fu, Gabriel Sica, Taofeek K. Owonikoko

ABSTRACT

2610

Therapeutic effect of DDR pathway with different functional annotations for immune checkpoint inhibitor.

AUTHOR(S)

Wei Nie, Hua Zhong, Fengcai Wen, Ding Zhang, Shiqing Chen, Baohui Han

ABSTRACT

2611

First-in-human, phase I study of PF-06753512, a vaccine-based immunotherapy regimen (PrCa VBIR), in biochemical relapse (BCR) and metastatic castration-resistant prostate cancer (mCRPC).

AUTHOR(S)

Karen A. Autio, Celestia S. Higano, Luke T. Nordquist, Leonard J. Appleman, Tian Zhang, Xinhua Zhu, Hani M. Babiker, Nicholas J. Vogelzang, Sandip Prasad, Michael T. Schweizer, Stephane Billotte, Joseph Binder, Nora Cavazos, Ruifeng Li, Kam Chan, Helen Cho, Michael Dermeyer, Robert Hollingsworth, Kenneth A. Kern, Daniel P. Petrylak

ABSTRACT

2612

Long term results from a phase 1 trial of GEN-009, a personalized neoantigen vaccine, combined with PD-1 inhibition in advanced solid tumors.

AUTHOR(S)

Maura L. Gillison, Mark M. Awad, Przemyslaw Twardowski, Ammar Sukari, Melissa L. Johnson, Mark N. Stein, Richard Hernandez, Jessica Price, Kevin J. Mancini, Mara Shainheit, Vijetha Vemulapalli, Jessica Flechtner, Thomas A. Davis, Roger B. Cohen

ABSTRACT

2613

Phase I trial to determine safety and immunogenicity of amplivant, a synthetic toll-like receptor 2 ligand, conjugated to two HPV16 E6 synthetic long peptides.

AUTHOR(S)

Frank M. Speetjens, Marij J. Welters, Marije Slingerland, Peggy de Vos van Steenwijk, Inge C. Roozen, Sanne Boekestijn, Nikki Loof, Gijs G. Zom, Rob Valentijn, Willem-Jan Krebber, Cornelis J. Melief, Dmitri V. Filippov, Hans Gelderblom, Sjoerd H. van der Burg, Ferry Ossendorp

ABSTRACT

2614

A phase 1b study of personalized neoantigen vaccine plus pembrolizumab in adults with advanced cancer.

AUTHOR(S)

Aaron Miller, Zeynep Kosaloglu-Yalcin, Luise Westernberg, Leslie Montero, Milad Bahmanof, Angela Frentzen, Ashmitaa Logandha Ramamoorthy Premal, Jason Greenbaum, Gregory Seumois, Roxanne Habbaba, Amanda Natsuhara, Kim McConnell, Elaine Eng, Alessandro Sette, Bjoern Peters, Stephen P. Schoenberger, Ezra E. Cohen

ABSTRACT

2615

A phase 1 study of an off-the shelf, multi-neoantigen vector (ADXS-503) in subjects with metastatic non-small cell lung cancer (NSCLC) progressing on pembrolizumab as last therapy.

AUTHOR(S)

Missak Haigentz, Suresh S. Ramalingam, Gregory J. Gerstner, Balazs Halmos, Neil Morganstein, Surya Vangala, Megan Parsi, Victor Kabala, Dinesh Simkhada, Cristiane Metran, ANDRES A. GUTIERREZ, Jonathan W. Goldman

ABSTRACT

2616

A phase 1 open label trial of intravenous administration of MVA-BN-Brachyury vaccine in patients with advanced cancer.

AUTHOR(S)

Peter J. DeMaria, Katherine Lee-Wisdom, Ravi A. Madan, Fatima Karzai, Renee N. Donahue, Claudia Palena, Caroline Jochems, Charalampos S. Floudas, Julius Strauss, Jennifer L. Marte, Jason Redman, Houssein Abdul Sater, Borys Korchin, Tatiana Adams, Guenter Silbernagl, Cesar Pico-Navarro, Jeffrey Schlom, James L. Gulley, Marijo Bilusic

ABSTRACT

2617

Long-term follow up of patients with mesothelioma treated with dendritic cell therapy in three phase I trials.

AUTHOR(S)

Daphne W. Dumoulin, Robin Cornelissen, Koen Bezemer, Sara Baart, Joachim Aerts

ABSTRACT

2618

Final report and long-term outcomes: Phase I trial of a HER2 intracellular plasmid-based vaccine in HER2+ advanced stage breast cancer.

AUTHOR(S)

Mary L. Disis, Yushe Dang, Andrew L. Coveler, Doreen Higgins, Jennifer Childs, Lupe G. Salazar

ABSTRACT

2619

A phase I clinical trial investigating the telomerase vaccine UV1 in combination with pembrolizumab in patients with advanced melanoma.

AUTHOR(S)

Yousef Zakharia, Steven O'Day, Wenche Rasch, Mohammed M. Milhem

ABSTRACT

2620

Adverse effects of COVID-19 vaccination among cancer patients: Results from an Internet-based survey.

AUTHOR(S)

Brian Loew, Richard Tsai, John Hervey, Kathleen D. Hoffman, John Novack, Jennifer Johnson, Don S. Dizon, Stuart L. Goldberg

ABSTRACT

2621

Risk factors for immune mediated adverse events with immune checkpoint inhibitors.

AUTHOR(S)

Ari Pelcovits, Hetal Mistry, Rani Chudasama, Sarah Andrea, Humera Khurshid

ABSTRACT

2622

Safety, pharmacokinetics, efficacy, and preliminary biomarker data of first-in-class BI 765063, a selective SIRP α inhibitor: Results of monotherapy dose escalation in phase 1 study in patients with advanced solid tumors.

AUTHOR(S)

Stéphane Champiat, Philippe A. Cassier, Nuria Kotecki, Iphigenie Korakis, Armelle Vinceneux, Christiane Jungels, Jon Blatchford, Mabrouk M. Elgadi, Nicole Clarke, Claudia Fromond, Nicolas Poirier, Berangere Vasseur, Aurelien Marabelle, Jean-Pierre Delord

ABSTRACT

2623

A phase 1/2 open-label study of KY1044, an anti-ICOS antibody with dual mechanism of action, as single agent and in combination with atezolizumab, in adult patients with advanced malignancies.

AUTHOR(S)

Manish R. Patel, Aung Naing, Howard A. Burris III, Chia-Chi Lin, Giuseppe Curigliano, Fiona Thistlethwaite, Anna R. Minchom, Paolo A. Ascierto, Filippo G. De Braud, Michael Cecchini, Wouter Hanekom, Richard C. Sainson, Rosamund J. Wilson, Sonia Quarantino

ABSTRACT

2624

Real world experience with standalone immunotherapy regimens: Immune-related adverse events, healthcare utilization and cost among patients with commercial or Medicare Advantage insurance.

AUTHOR(S)

Krishna S. Gunturu, Timothy Pham, Sonali Shambhu, Michael J. Fisch, John Barron, David J. Debono

ABSTRACT

2625

KY1044 to target the ICOS pathways inducing intratumoral Treg depletion and agonism of effector T cells: Preliminary pharmacodynamic markers from a phase 1/2 multicenter trial.

AUTHOR(S)

Chia-Chi Lin, Aung Naing, Manish R. Patel, Howard A. Burris III, Giuseppe Curigliano, Fiona Thistlethwaite, Anna R. Minchom, Paolo A. Ascierto, Filippo G. De Braud, Joseph P. Eder, Matthew Wake, Cintia C. Palu, Anthea L. Newton, Cecilia Deantonio, Wouter Hanekom, Richard C. Sainson, Sonia Quarantino

ABSTRACT

2626

Association and prevalence of venous thromboembolism in cancer patients with COVID-19: A single healthcare system experience.

AUTHOR(S)

Aneesha Ananthula, Dat Tran, Katharine Thomas, Katie L. McQueen Amaker, Anh Nguyen, Soham Mahato, Brandon T. Thrash, Andrew G. Chapple, Suki Subbiah

ABSTRACT

2627

Priming immunotherapy with radiotherapy (RT) in advanced non-small cell lung cancer (NSCLC) and head and neck squamous cell cancer (HNSCC): Interim analysis of phase II clinical trial.

AUTHOR(S)

Aasems Jacob, Alexander Kreimer, Jing Wei, Jianrong Wu, Lauren Corum, Ellen Reusch, Jerold Woodward, Donald Cohen, Subbarao Bondada, Val R. Adams, Rachael Morgan, Ronald C. McGarry, William H. St Clair, Mahesh R. Kudrimoti, Zin Myint, Susanne M. Arnold, John L. Villano

ABSTRACT

2628

The Tim3-galectin-9 interactions in the tumor microenvironment of nasopharyngeal cancer.

AUTHOR(S)

Dora L. Kwong, Ngar-Woon Kam, Wai Chun Tse, Sing Hei Lok, George Tsao, Victor H. Lee

ABSTRACT

2629

Safety of AK117, an anti-CD47 monoclonal antibody, in patients with advanced or metastatic solid tumors in a phase I study.

AUTHOR(S)

Hui K. Gan, Jermaine Coward, Anna R. Mislang, Rasha Cosman, Adnan Nagrial, Xiaoping Jin, Baiyong Li, Zhongmin M. Wang, Kon Yew Kwek, Dennis Xia, Yu Xia

ABSTRACT

2630

Phase 1 dose escalation study of MGC018, an anti-B7-H3 antibody-drug conjugate (ADC), in patients with advanced solid tumors.

AUTHOR(S)

Sekwon Jang, John D. Powderly II, Alexander I. Spira, Ouïam Bakkacha, Deryk Loo, Gerry C. Bohac, Manish Sharma

ABSTRACT

2631

Comparison of checkpoint inhibitor treatment-related cutaneous adverse events in racial and ethnic minority and Caucasian cohorts at Memorial Sloan Kettering Cancer Center.

AUTHOR(S)

Amaris Geisler, Dulce M. Barrios, Gregory Phillips, Rosa Nouvini, Mario E. Lacouture, Sarah J. Noor

ABSTRACT

2632

Proton pump inhibitor use (PPI) in patients treated with immune checkpoint inhibitors (ICI) for advanced cancer: Survival and prior therapy.

AUTHOR(S)

Marium Husain, Menglin Xu, Sandipkumar Patel, Andrew Johns, Madison Grogan, Mingjia Li, Gabrielle Lopez, Abdul Miah, Rebecca Hoyd, YunZhou Liu, Mitchell Muniak, Tyler Haddad, Gabriel Tinoco, Kari L. Kendra, Gregory A. Otterson, Carolyn J. Presley, Daniel Spakowicz, Dwight H. Owen

ABSTRACT

2633

Initial findings of the first-in-human phase I study of AGEN2373, a conditionally active CD137 agonist antibody, in patients (pts) with advanced solid tumors.

AUTHOR(S)

Anthony W. Tolcher, Richard D. Carvajal, Anthony B. El-Khoueiry, Waldo Ortuzar Feliu, Hong Zang, Marek Ancukiewicz, Irina Shapiro, James F. Strauss

ABSTRACT

2634

Late immune-related adverse events with immune checkpoint inhibitors.

AUTHOR(S)

Andrew Ip, Shuo Wang, Divya Cheruku, Kanchi Krishnamurthy, Melinda Weber, Brittany Sinclair, Elli Gournas Paleoudis, Adil Alaoui, Shaked Lev-Ari, Michael T. Serzan, Shari Adams, Jordan Kaufman, Sahil B. Parikh, Emily Tonti, Eric Muller, Aquino Williams, Jaeil Ahn, Andrew Pecora, Michael B. Atkins, Neil J. Shah

ABSTRACT

2635

Cardiovascular toxicity incidence following immune checkpoint inhibitors in randomized clinical trials: A systematic review and meta-analysis.

AUTHOR(S)

Camila B. Xavier, Carlos Diego H. Lopes, Guilherme Harada, Artur Katz, Denis L. Fontes Jardim

ABSTRACT

2636

Infections in cancer patients treated with immune checkpoint inhibitors: Data from randomized trials.

AUTHOR(S)

Cinzia Solinas, Anna Maria Morelli, Andrea Luciani, Antonio Ghidini, Fausto Petrelli

ABSTRACT

2637

Age affects the efficacy of immune checkpoint inhibitors in patients with advanced cancer.

AUTHOR(S)

Yongjie Wang, Ronghua Yang, Dong Wang, Donghua Zhao, Peng Li, Mengjun Li, Yingxue Qi, Ningning Luo, Yaqing Wu, Qin Zhang

ABSTRACT

2638

Improving tolerability of pembrolizumab with weight based dosing: A meta-analysis.

AUTHOR(S)

Nabeela K. Patail, Amna F. Sher, Shenhong Wu

ABSTRACT

2639

Pan-Canadian cohort of immune checkpoint inhibitor-induced insulin-dependent diabetes mellitus (CANDIED).

AUTHOR(S)

Thiago Pimentel Muniz, Daniel V. Araujo, Kerry J. Savage, Tina Cheng, Moumita Saha, Xinni Song, Sabrina Gill, Jose G. Monzon, Debjani Grenier, Sofia Genta, Anna Spreafico, David Hogg

ABSTRACT

2640

Real-world outcomes of treatment with immune checkpoint inhibitors in unique patient cohorts: Elderly, non-caucasian race, poor performance status, obese, chronic viral infections, and autoimmune diseases.

AUTHOR(S)

Neil J. Shah, Shuo Wang, Aquino Williams, Melinda Weber, Brittany Sinclair, Elli Gournas Paleoudis, Adil Alaoui, Shaked lev-Ari, Shari Adams, Jordan Kaufman, Sahil B. Parikh, Emily Tonti, Eric Muller, Michael T. Serzan, Divya Cheruku, Jaeil Ahn, Andrew Pecora, Andrew Ip, Michael B. Atkins

ABSTRACT

2641

Maintenance immunosuppressive therapy with resumption of immune checkpoint inhibitor treatment to reduce recurrence of immune-mediated colitis.

AUTHOR(S)

Hamzah Abu-Sbeih, Fangwen Zou, Barbara Dutra, Mehmet Altan, Jennifer L. McQuade, John A. Thompson, Anusha Thomas, Yinghong Wang

ABSTRACT

2642

Outcomes of immune checkpoint inhibitor-mediated colitis: Multicenter cohort study.

AUTHOR(S)

Hamzah Abu-Sbeih, Tenglong Tang, David M. Faleck, Michael L. Dougan, Anna Olsson-Brown, Douglas B. Johnson, Dwight H. Owen, David E. Warner, Alexander B. Philipp, Nick Powell, Ella Daniels, Jessica Philpott, Alison M. Weppler, David J. Pinato, Yinghong Wang

ABSTRACT

2643

Pancreatic volumes in immune checkpoint inhibitor-induced diabetes.

AUTHOR(S)

Rebecca Jeun, Sireesha Yedururi, Victor Lavis, Conor Best, Jeena Varghese, Ramona Dadu, Isabella C. Glitza, Sonali Thosani

ABSTRACT

2644

Incidence of hepatitis associated with addition of immune checkpoint blockade to conventional solid tumor therapy: A meta-analysis of phase 3 randomized clinical trials.

AUTHOR(S)

Yu Fujiwara, Nobuyuki Horita, Ho Namkoong, Hirotaka Miyashita, Matthew Harrington, Matt D. Galsky

ABSTRACT

2645

A first-in-human, multicenter, open-label, phase 1 study of ATOR-1017, a 4-1BB antibody, in patients with advanced solid malignancies.

AUTHOR(S)

Gustav J. Ullenhag, Jeffrey Yachnin, Ana Carneiro, Emma Elison, Malin Carlsson, Charlotte A. Russell, Karin Enell Smith

ABSTRACT

2646

Consensus disease definitions for the spectrum of neurologic immune related adverse events.

AUTHOR(S)

Amanda C. Guidon, Leeann B. Burton, Bart K. Chwalisz, James M. Hillis, Teilo Schaller, Kerry L. Reynolds

ABSTRACT

2647

A risk stratification model for toxicities in phase 1 immuno-oncology (P1-IO) trials.

AUTHOR(S)

Alberto Hernando-Calvo, Abdulazeez Salawu, Marc Oliva Bernal, Daniel V. Araujo, Zhihui (Amy) Liu, Rachel Chen, Lillian L. Siu

ABSTRACT

2648

Prevalence of hyperprogressive disease (HPD) mutations and correlations to immune-related biomarkers in a large pan-cancer Chinese cohort.

AUTHOR(S)

Shengli Yang, Xinyi Liu, Ting Bei, Mengli Huang

ABSTRACT

2649

Pembrolizumab patient reported benefits: A perspective based on multiple tumors.

AUTHOR(S)

Elise Wu, Paivi H. Miskala, Mohd Kashif Siddiqui, Pankaj Rai, Eva Hajdukova, Nathalie Erpelding, Jacqueline Vanderpuye-Orgle

ABSTRACT

2650

Pseudoprogression and cancer immunotherapy: A seven year retrospective study of rate, temporal course, and predictive markers in an Irish tertiary referral center.

AUTHOR(S)

Kate McKendry, Fiona Desmond, Cian Ward, Austin G. Duffy

ABSTRACT

2651

Proton pump inhibitors and antibiotics impact on toxicities and clinical outcomes in cancer patients treated with immunotherapy.

AUTHOR(S)

Haniel a. Araujo, Camila M. Moniz, Oddone F. Braghiroli, Milena P. Mak, Lucas F. Uratani, Ricardo Dahmer Tiecher, Priscila M. Moraes, Ingrid Barbosa, Veridiana P. Camargo, Maria Ignez F. Braghiroli, Gilberto Castro Jr., Paulo M. Hoff, Maria Del Pilar Diz

ABSTRACT

2652

Impact of pharmacodynamic biomarkers in immuno-oncology (IO) phase 1 clinical trials.

AUTHOR(S)

Abdulazeez Salawu, Rachel Chen, Alberto Hernando-Calvo, Daniel V. Araujo, Marc Oliva Bernal, Zhihui (Amy) Liu, Lillian L. Siu

ABSTRACT

2653

Impact of multidisciplinary severe immunotherapy complication service on outcomes for cancer patients receiving immune checkpoint inhibition.

AUTHOR(S)

Leyre Zubiri, Gabriel E. Molina, Meghan Mooradian, Sienna Durbin, Michael Dougan, Molly Thomas, Alexander Faje, Michelle Rengarajan, Amanda C. Guidon, Steven T. Chen, Mazen Nasrallah, Minna Kohler, Meghan Sise, Tomas G. Neilan, Daniel A. Zlotoff, Aditya Bardia, Ryan J. Sullivan, Yevgeniy R. Semenov, Alexandra C. Villani, Kerry L. Reynolds

ABSTRACT

2654

Patients with steroid-refractory toxicity following immune checkpoint inhibitors: Frequent hospitalizations and long duration of illness.

AUTHOR(S)

Mia Bothwell, Aaron Cheng, Leyre Zubiri, Meghan Mooradian, Yevgeniy R. Semenov, Gayle C. Blouin, Erica Tavares, Jennifer Hutchinson, Leila Rostamjad, Monica Jackson, Kerry L. Reynolds

ABSTRACT

2655

Zanidatamab, an anti-HER2 bispecific antibody, plus chemotherapy with/without tislelizumab as first-line treatment for patients with advanced HER2-positive breast cancer or gastric/gastroesophageal junction adenocarcinoma: A phase 1B/2 trial-in-progress.

AUTHOR(S)

Keun Wook Lee, Young-Hyuck Im, Keun Seok Lee, Jae Y. Cho, Do-Youn Oh, Hyun Cheol C. Chung, Yee Chao, Li-Yuan Bai, Chia Jui Yen, In-Ho Kim, Sang Cheul Oh, Chia-Chi Lin, Jin Wang, Xin Wang, Huiyan Li, Yen-Yang Chen, Yoon-Koo Kang

ABSTRACT

TPS2656

SGNTGT-001: A phase 1 study of SEA-TGT, an effector-function enhanced monoclonal antibody (mAb), in advanced malignancies (trial in progress).

AUTHOR(S)

Elena Garralda, Rachel E. Sanborn, Anna R. Minchom, Diwakar Davar, Giuseppe Curigliano, Vincent Ribrag, Amitkumar Mehta, Francine M. Foss, Jasmine M. Zain, Andres Forero-Torres, Stephen M. Ansell

ABSTRACT

TPS2657

A phase I, first-in-human clinical trial of the GDF-15 neutralizing antibody CTL-002 in subjects with advanced-stage solid tumors (ACRONYM: GDFATHER).

AUTHOR(S)

Ignacio Melero, Emiliano Calvo, Reinhard Dummer, Elena Garralda, Martin H. Schuler, Maria-Elisabeth Goebeler, Ralf C. Bargou, Tanja Gromke, Josep Tabernero, Egle Ramelyte, Maria De Miguel, Miguel F. Sanmamed, Maria E. Rodriguez-Ruiz, Petra Fettes, Kathrin Klar, Manfred Ruediger, Christine Schuberth-Wagner, Markus Haake, Joerg Wischhusen, Eugen Leo

ABSTRACT

TPS2658

A phase 1/2, open-label, dose-escalation, safety and tolerability study of NC410 in subjects with advanced or metastatic solid tumors.

AUTHOR(S)

Martin Gutierrez, Filip Janku, Linjie Tian, Jason J. Luke, Elaine Shum, John Shin, Ido Weiss, Linda N. Liu, Dallas Files, Solomon Langermann, Han Myint, Marijo Bilusic

ABSTRACT

TPS2659

A phase 1, first in human study of adenovirally transduced autologous macrophages engineered to contain an anti-HER2 chimeric antigen receptor (CAR) in subjects with HER2 overexpressing solid tumors.

AUTHOR(S)

Joshua Bauml, Natalie S. Grover, Amy Ronczka, Daniel Cushing, Michael Klichinsky, Debora Barton, Elizabeth C. Dees

ABSTRACT

TPS2660

Master protocol to assess safety and recommended phase 2 dose of next generation NY-ESO-1-specific TCR T-cells in HLA-A*02 patients with synovial sarcoma or non-small cell lung cancer (Substudies 1 and 2).

AUTHOR(S)

Adam J. Schoenfeld, Mehmet Altan, Taofeek K. Owonikoko, Sandra P. D'Angelo, Brian H. Ladle, Jonathan C. Noujaim, Kai He, David A. Liebner, Adrian G. Sacher, John B. Haanen, Jeffrey Yachnin, Chao H. Huang, Brian A. Van Tine, Aisha N. Hasan, Thomas H. Faitg, Emily Butler, Aiman Shalabi, Steven Attia, Dejka M. Araujo

ABSTRACT

TPS2661

A phase 1 study to evaluate chimeric antigen receptor (CAR) T cells incorporating a chlorotoxin tumor-targeting domain for patients with MMP2+ Recurrent or progressive glioblastoma (NCT04214392).

AUTHOR(S)

Behnam Badie, Michael E. Barish, Ammar Chaudhry, Massimo D'Apuzzo, Stephen J. Forman, Jana Portnow, Shirong (Sean) Wang, Julie A. Ressler, Jennifer Simpson, Julie Kilpatrick, Paige McNamara, Jamie Wagner, Suzette Blanchard, Dongrui Wang, Christine Brown

ABSTRACT

TPS2662

Phase I study of adoptive immunotherapy for advanced MUC1* positive breast cancer with autologous T cells engineered to express a chimeric antigen receptor, huMNC2-CAR44 specific for a cleaved form of MUC1 (MUC1*).

AUTHOR(S)

Jennifer M. Specht, David G. Maloney, Cecilia Yeung, Vicky Wu, Cynthia Bamdad

ABSTRACT

TPS2663

A phase 1 study of RTX-321, an engineered red blood cell as an artificial antigen-presenting cell expressing HLA-A*02 with the HPV-16 E7 peptide and 4-1BB ligand with membrane-bound IL-12 for the treatment of HPV 16-positive cancers.

AUTHOR(S)

Johanna C. Bendell, Alexander I. Spira, Ramez N. Eskander, Ezra E. Cohen, Geoffrey Kuesters, Christopher Plescia, Karen Campbell, Tiffany Chen, Omid Hamid

ABSTRACT

TPS2664

Identification of a microbiome signature predicting immune checkpoint inhibitor outcomes across multiple cancer types in the MITRE study.

AUTHOR(S)

Philippa G. Corrie, Sarah J. Welsh, Grant D. Stewart, Gary Doherty, Kevin Vervier, Anne Neville, Christine Parkinson, Kate Fife, Guy Faust, Kamalram T. Jayaprakash, Thomas R. Geldart, Ewan Brown, Matthew Wheeler, Jenny P. Nobes, David Bruce, Nikos Demiris, Katy M. Dalchau, David Adams, Mat Robinson, Trevor Lawley

ABSTRACT

TPS2665

Phase I/Ib study with INT-1B3, a novel LNP-formulated micro-RNA (miR-193a-3p mimic) therapeutic for patients with advanced solid cancer.

AUTHOR(S)

Nuria Kotecki, Frans Opdam, Debbie Robbrecht, Michiel Strijbos, Karlijn Kroon, Michel Janicot, Sanaz Yahyanejad, Bryony Telford, Marion van den Bosch, Farshid Alemdehy, Thijs de Gunst, Harm den Boer, Rogier M. Vos, Laurens van Pinxteren, Roel Schaapveld

ABSTRACT

TPS2666

Phase 1/2 study of the novel SUMOylation inhibitor TAK-981 in adult patients (pts) with advanced or metastatic solid tumors or relapsed/refractory (RR) hematologic malignancies.

AUTHOR(S)

Arkadiusz Z. Dudek, Dejan Juric, Afshin Dowlati, Erlene K. Seymour, Jordi Rodon Ahnert, Bingxia Wang, Dennis Huszar, Allison J. Berger, Sharon Friedlander, Alejandro Gomez-Pinillos, Igor Proscurshim, Anthony J. Olszanski

ABSTRACT

TPS2667

Association of combined phase I/II study of a novel bicyclic peptide and MMAE conjugate BT8009 in patients with advanced malignancies with Nectin-4 expression.

AUTHOR(S)

Meredith McKean, Gerald S. Falchook, Johanna C. Bendell, Babar Bashir, Neil Palmisiano, Roshawn Watson, Mary-Anne McKenna, Carly Campbell, Dominic P. Smethurst, Phil Jeffrey, Julius Kirui, Hendrik-Tobias Arkenau, Elisa Fontana

ABSTRACT

TPS2668

Trial in progress: A phase 1b study of sotorasib, a specific and irreversible KRAS^{G12C} inhibitor, as monotherapy in non-small cell lung cancer (NSCLC) with brain metastasis and in combination with other anticancer therapies in advanced solid tumors (CodeBreakK 101).

AUTHOR(S)

David S. Hong, John H. Strickler, Marwan Fakih, Gerald S. Falchook, Bob T. Li, Greg A. Durm, Timothy F. Burns, Suresh S. Ramalingam, Sarah B. Goldberg, Tammy Lo, Kristen Marrone, Catherine A. Shu, David R. Gandara, Neelesh Soman, Haby A. Henary, Ramaswamy Govindan

ABSTRACT

TPS2669

A phase 1 dose-escalation study of intravenously (IV) administered TAK-676, a novel STING agonist, alone and in combination with pembrolizumab in patients (pts) with advanced or metastatic solid tumors.

AUTHOR(S)

Gerald S. Falchook, Jason J. Luke, James F. Strauss, Xin Gao, Patricia LoRusso, PEI Jye Voon, Cong Li, Michael Shaw, Richard C. Gregory, Kristin Horn, John Gibbs, Neil Lineberry, Kate Stumpo, Karim Malek, Anthony J. Olszanski

ABSTRACT

TPS2670

Trials in progress: A phase 1, open-label, dose-escalation, pharmacokinetic, safety and tolerability study of the selective TAM kinase inhibitor PF-07265807 in patients with advanced or metastatic solid tumors.

AUTHOR(S)

Vivek Subbiah, Mark M. Awad, Adil Daud, Martin Gutierrez, Jessica D. McDermott, Sai-Hong Ignatius Ou, Tomoko Hirohashi, Kim Ingram, Colleen Oliver, Derek Smith, Lance Wollenberg, James L. Abbruzzese

ABSTRACT

TPS2671

Phase 1, first-in-human trial of JTX-8064, an anti-LILRB2/ILT4 monoclonal antibody, as monotherapy and in combination with anti-PD-1 in adult patients with advanced solid tumors (INNATE).

AUTHOR(S)

Kyriakos P. Papadopoulos, Nehal J. Lakhani, Timothy A. Yap, Allison L. Naumovski, Karen S. Brown, Ben Umiker, Lara McGrath, Weidong Zhang, Edward Stack, Gosia Riley, Nancy Mota, Christina Tasillo, Haley Laken, Elizabeth G. Trehu, Johan Baeck

ABSTRACT

TPS2672

A phase 1, multicenter, open-label, dose-escalation, safety, pharmacodynamic, pharmacokinetic study of Q702 with a cohort expansion at the RP2D in patients with advanced solid tumors.

AUTHOR(S)

Angela T. Alistar, Anthony B. El-Khoueiry, Devalingam Mahalingam, Monica M. Mita, Hwankyu Kang, Yeong-In Yang, Jiye Ahn, Jeongjun Kim, Baejung Choi, Yeejin Jeon, Chunwon Jung, Borami Jeon, Jaeseung Kim, Kiyeon Nam

ABSTRACT

TPS2673

Phase 1 first-in-human study of ABBV-184 monotherapy in adult patients with previously treated acute myeloid leukemia or non-small cell lung cancer.

AUTHOR(S)

Abraham Avigdor, Pierre Peterlin, Junichiro Yuda, Mor T. Moskovitz, Nashat Y. Gabrail, Yakir Moshe, Bruno Quesnel, William R. Henner, Edward B. Reilly, Donghui Huang, Maria Kovalenko, Apurvasena Parikh, Stacy Jaryno, Rachel S. Leibman, Kevin J. Freise, Esma Saada-Bouazid, Toshio Shimizu

ABSTRACT

TPS2674

A phase I study of AK119, an anti-CD73 monoclonal antibody, in combination with AK104, an anti-PD-1/CTLA-4 bispecific antibody, in patients with advanced or metastatic solid tumors.

AUTHOR(S)

Ben Markman, Amy H. Hsieh, Jermaine Coward, Matteo S. Carlino, Sophia Frentzas, Xiaoping Jin, Baiyong Li, Zhongmin M. Wang, Kon Yew Kwek, Yu Xia

ABSTRACT

TPS2675

A phase 1b study of nivolumab in patients with autoimmune disorders and advanced malignancies (AIM-NIVO).

AUTHOR(S)

Ecaterina E. Dumbrava, Michael L. Dougan, Sarthak Gupta, Laura Cappelli, Tamiko R. Katsumoto, Osama E. Rahma, Jeane Painter, Yinghong Wang, Maria E. Suarez-Almazor, Pankti Reid, Sarah F. Wesley, David A. Hafler, Clifton O. Bingham, Blake M. Warner, Lorinda Chung, Patrick A. Ott, Harriet M. Kluger, Arezou Khosroshahi, Hussein A. Tawbi, Elad Sharon

ABSTRACT

TPS2676

An open-label phase 1b/2 study of surufatinib in combination with tislelizumab in subjects with advanced solid tumors.

AUTHOR(S)

Arvind Dasari, John S. Kauh, Christopher Tucci, Shivani Nanda, Marek K. Kania, Jennifer W. Carlisle, Andrew S. Paulson

ABSTRACT

TPS2677

Combination of atezolizumab and pirfenidone in second-line and beyond NSCLC: A phase I/II study.

AUTHOR(S)

Takefumi Komiya, Jun Zhang, Prakash C. Neupane, Kathan Mehta, Chao H. Huang

ABSTRACT

TPS2678

Immune Resistance Interrogation Study (IRIS): A prospective comprehensive multi-omic analysis in patients with intrinsic and acquired resistance to immunotherapy.

AUTHOR(S)

Sofia Genta, Ming S. Tsao, Ben X. Wang, Aaron R. Hansen, Trevor J. Pugh, Mathieu Lupien, Bryan Coburn, Javier Diaz-Mejia, Marcus O. Butler, Philippe L. Bedard, Albiruni R. Abdul Razak, Sevan Hakgor, Vanessa Speers, Heidi Wagner, Laura Tamblyn, Troy Ketela, Dax Torti, Nikolina Radulovich, Lillian L. Siu, Anna Spreafico

ABSTRACT

TPS2679

Personalized DNA neoantigen vaccine in combination with plasmid IL-12 and pembrolizumab for the treatment of patients with advanced hepatocellular carcinoma.

AUTHOR(S)

Mark Yarchoan, Edward Gane, Thomas U. Marron, Sarah Rochestie, Neil Cooch, Joann Peters, Ildiko Csiki, Alfredo Perales-Puchalt, Niranjana Sardesai

ABSTRACT

TPS2680

Phase I study investigating the safety of stereotactic body radiotherapy (SBRT) with anti-PD-1 and anti-IL-8 for the treatment of multiple metastases in advanced solid tumors.

AUTHOR(S)

Lilit Karapetyan, Adam C. Olson, William E. Gooding, Riyue Bao, Steven J. Chmura, Jason J. Luke

ABSTRACT

TPS2681

Developmental Therapeutics—Molecularly Targeted Agents and Tumor Biology

[Back to Program](#)

Showing 138 Presentations

<https://meetinglibrary.asco.org/session/13621>

A phase 1 trial of FID-007, a novel nanoparticle paclitaxel formulation, in patients with solid tumors.

AUTHOR(S)

Jacob S. Thomas, Diane Habib, Diana L. Hanna, Irene Kang, Syma Iqbal, Jorge J. Nieva, Denice Tsao-Wei, Francisco Acosta, Ming Hsieh, Yilong Zhang, Anthony B. El-Khoueiry

ABSTRACT

3021

Bosutinib in combination with pemetrexed in patients with selected metastatic solid tumors: A phase I study (NCT03023319).

AUTHOR(S)

Nagla F. Abdel Karim, Mahran Shoukier, Ihab Eldessouki, Ahmed Khaled, John Morris

ABSTRACT

3022

Profiling 523 cancer associated genes in circulating tumor DNA of children with CNS tumors.

AUTHOR(S)

Erin R. Bonner, Robin Harrington, Biswajit Das, Paul M. Williams, Chris A. Karlovich, Amanda Peach, D'Andra Howell, Maria Saeed, Javad Nazarian

ABSTRACT

3023

Interleukin-1-beta concentration and neutrophil-lymphocyte ratio as possible predicting biomarkers of response to therapy with checkpoint inhibitors.

AUTHOR(S)

Rashida Orlova, Natalia V. Zhukova, Anna Malkova, Ekaterina Kaledina, Anna Gubal, Vladimir Sharoyko

ABSTRACT

3024

Genes copy number as a marker of low-invasive assessment of rectal tumors radiotherapy effectiveness.

AUTHOR(S)

Marina A. Gusareva, Natalia G. Kosheleva, Natalya B. Fatkina, Anna A. Solntseva, Lyudmila Y. Rozenko, Aliya K. Donskaya, Ekaterina O. Vasilieva, Elena A. Karnauhova, Julia N. Krokhmal, Peter N. Gabrichidze, Vladimir A. Dontsov, Umar M. Gaziev, Vladislav M. Legostaev, Olga V. Shlyakhova, Natalia A. Lyman, Gennady V. Balitsky, V. A. Nosov, A. B. Kravchenko, Denis S. Kutilin

ABSTRACT

3025

Liquid biopsy testing: Impact on treatment assignment and survival in a community-based oncology practice—A real-world experience.

AUTHOR(S)

Khalil Choucair, Bassam I. Mattar, Quoc V. Truong, Travis L. Koeneke, Phu V. Truong, Christopher Dakhil, Michael W. Cannon, Seth J. Page, Jeremy M. Deutsch, Eric A. Carlson, Dennis F. Moore Jr., Nassim H. Nabbout, K. James Kallail, Shaker R. Dakhil, Pavan S. Reddy

ABSTRACT

3027

Circulating tumor DNA as markers of dynamic recurrence risk and adjuvant chemotherapy benefit in resected non-small cell lung cancer.

AUTHOR(S)

Wei Guo, Fan Zhang, Fang Lv, Ying Ji, Yue Peng, Xiaoxi Chen, Hua Bao, Yang Xu, Yang Shao, Fengwei Tan, Qi Xue, Bin Qiu, Shugeng Gao

ABSTRACT

3028

Plasma hPG₈₀ circulating progestin levels in cancer patients in Nigeria: Prolevcan study.

AUTHOR(S)

Omolara A. Fatiregun, Dominique Joubert, Berengere Vire, Abigail A. Simon-Hart, Olaniyi A. Adekeye, Younes Mahi, Alexandre Prieur

ABSTRACT

3029

Genetic predictor of severe sorafenib-induced diarrhea and hand-foot syndrome (HFS).

AUTHOR(S)

Julia C. Quintanilha, Susan M. Geyer, Jin Wang, Amy Etheridge, Stefanie Denning, Alessandro Racioppi, Kelli Hammond, Daniel Crona, Carol E. Pena, Sawyer B. Jacobson, Ghassan K. Abou-Alfa, Federico Innocenti

ABSTRACT

3030

Tumor-educated platelets for breast cancer detection: Biological and technical insights.

AUTHOR(S)

Marte C. Liefwaard, Kat Moore, Myron Best, Nik Sol, Sjors G. In 't Veld, Gabe S. Sonke, Bakhos A. Tannous, Thomas Wurdinger, Matti A. Rookus, Lodewyk F. Wessels, Esther H. Lips

ABSTRACT

3031

Detection of prognostic cancer-specific circular RNA in plasma.

AUTHOR(S)

Jason Brown, Palak Shah, Josh Vo, Alex Tsodikov, Lena Kleiman, Xuhong Cao, Arul Chinnaiyan

ABSTRACT

3032

Prognostic value of plasma hPG₈₀ (circulating progastrin), alone or in combination with Alpha-fetoprotein (AFP) in patients with hepatocellular carcinoma.

AUTHOR(S)

Alexandre Prieur, Eric Assenat, Marie Dupuy, Sarah Iltache, Berengere Vire, Julien Soulé, Pierre Liaud, Thierry Cousin, Younes Mahi, Dominique Joubert

ABSTRACT

3033

Detection of any-stage cancer using plasma and urine glycosaminoglycans.

AUTHOR(S)

Francesco Gatto, Sinisa Bratulic, Ilaria Teresa Rita Cavarretta, Massimo Alfano, Francesca Maccari, Fabio Galeotti, Nicola Volpi, Per-Henrik Edqvist, Max Levin, Jan Nyman, Bengt Bergman, Andrea Salonia, Sven Lundstam, Ulrika Stierner, Henrik Kjölhede, Jens Nielsen

ABSTRACT

3034

Dynamics of circulating tumor DNA in patients with advanced solid tumors treated with cediranib and olaparib.

AUTHOR(S)

Yiduo Hu, Azeet Narayan, Julia Wolfe, Dennis Vu, Trinh Thi, Chaitanya Kantak, S. P. Ivy, Joseph P. Eder, Patricia LoRusso, Joseph W. Kim, Abhijit Patel

ABSTRACT

3035

Correlation between different levels of HER2 expression in Circulating Tumor Cells (cHER2 ratio) and metastatic behavior in stageIV_{aggressive} breast cancer.

AUTHOR(S)

Paolo D'Amico, Carolina Reduzzi, Sara Gandini, Lorenzo Gerratana, Wenan Qiang, Qiang Zhang, Frederique St-Pierre, Youbin Zhang, Ami N. Shah, Andrew A. Davis, Saya Jacob, Elena Vagia, Firas H. Wehbe, Amir Behdad, Giuseppe Curigliano, Massimo Cristofanilli

ABSTRACT

3036

Machine learning-based multiple cancer detections with circulating miRNA profiles in the blood.

AUTHOR(S)

Juntaro Matsuzaki, Yusuke Yamamoto, Ouyang Yi, Sandeep Ayyar, Ryo Miyajima, Yutaka Takeda, Timothy Nolan, Nobuhiro Kawai, Ken Kato, Nobuyuki Ota, Takahiro Ochiya

ABSTRACT

3037

A single institution experience with droplet digital polymerase chain reaction (dd-PCR) liquid biopsy (LB) for therapeutic decision in advanced solid tumors.

AUTHOR(S)

Andre M. Murad, Juliana G. Carneiro, José C. Casali-da-Rocha

ABSTRACT

3038

Hyper engorged cancer associated macrophage-like cells in circulation predict for multi-organ metastatic disease in solid tumors.

AUTHOR(S)

Daniel J. Gironda, Raymond C. Bergan, Steven H. Lin, R. K. Alpaugh, Massimo Cristofanilli, Saranya Chumsri, Rena G. Lapidus, William Williams, Markus Lacher, Daniel C. Danila, Tuan L. Chuang, Thai H. Ho, Martin Edelman, Cha-Mei Tang, Daniel L. Adams

ABSTRACT

3039

Blood-based tumor mutational burden from circulating tumor DNA (ctDNA) across advanced solid malignancies using a commercially available liquid biopsy assay.

AUTHOR(S)

Leylah Drusbosky, Mehmet A. Bilen, Georges Azzi, Pedro C. Barata, Patrick M. Boland, Alan H. Bryce, Young Kwang Chae, Jeremy M. Force, Martin Gutierrez, Pashtoon M. Kasi, Hiba I. Dada, Caroline Weipert, Chuck Hensel, Lesli A. Kiedrowski, Che-Yu Lee, Martina Lefterova, David R. Gandara

ABSTRACT

3040

Single cell RNA-sequence analysis to identify transcriptomic differences associated with treatment outcome and ethnicity in circulating tumor cells (CTCs) from patients (pts) with metastatic colorectal cancer (mCRC).

AUTHOR(S)

Francesca Battaglin, Yonatan Amzaleg, Masahiro Kozuka, Priya Jayachandran, Satoshi Matsusaka, Mitsuharu Hirai, Jingyuan Wang, Hiroyuki Arai, Natsuko Kawanishi, Shivani Soni, Wu Zhang, Min Yu, Heinz-Josef Lenz

ABSTRACT

3041

Targeted ctDNA sequencing analysis reveals concurrent genomic alterations and its impact on TKI and immune checkpoint inhibitor therapy in advanced NSCLC from Asian population.

AUTHOR(S)

Wei Wu, Jing Shan Lim, Jonathan Poh, Trever G. Bivona

ABSTRACT

3042

A dual target sequencing solution to assess genomic and epigenomic alterations in cell-free DNA with no sample splitting.

AUTHOR(S)

Grace Q. Zhao, Yun Bao, Heng Wang, Wanping Hu, John Collier, Shengrong Lin

ABSTRACT

3043

Genome-wide 5hmC profiles to enable cancer detection and tissue of origin classification in breast, colorectal, lung, ovarian, and pancreatic cancers.

AUTHOR(S)

David Haan, Anna Bergamaschi, Yuhong Ning, William Gibb, Michael Kesling, Adriana Pitea, Maryam Nabiyouni, Chris Ellison, Roger Malta, Albert Nguyen, Gulfem Guler, Erin McCarthy, Tierney Phillips, Aaron Scott, Kyle Hazen, Judy Sheard, Melissa Peters, Kelly Bethel, Wayne Volkmuth, Samuel Levy

ABSTRACT

3044

Multimic, plasma-only ctDNA NGS assay for minimal residual disease (MRD) detection in solid tumors.

AUTHOR(S)

Jessica Kurata, Kristin S. Price, Kimberly Banks, Elena Zotenko, Dustin Hite, Donovan Cheng, Princy Parsana, Jin H. Ju, Tara Dinman, Zong Miao, AmirAli Talasaz

ABSTRACT

3045

Addition of selpercatinib to overcome osimertinib resistance in non-small cell lung cancer (NSCLC) with acquired RET fusion detected in ctDNA at very low allele frequency.

AUTHOR(S)

Leeseul Kim, Young Kwang Chae, Chan Mi Jung, Alice D. Lee, Emma Yu

ABSTRACT

3046

Concordancy of immunocytochemistry profiling of circulating tumor cells with immunohistochemistry for analysis of therapeutically relevant biomarkers.

AUTHOR(S)

Dadasaheb B. Akolkar, Darshana Patil, Sudha S. Murthy, Kiran Bendale, Revati Patil, Vineet Datta, Pradip Fulmali, Pooja Fulmali, Archana Adhav, Shoeb Patel, Rohit Chougule, Vishal Ranjan, Shabista Khan, Raja Dhasarathan, Sachin Apurwa, Stefan Schuster, Ajay Srinivasan, Rajan Datar

ABSTRACT

3047

Development of extracellular vesicles-based classifier for detection of early-stage bladder, ovarian, and pancreatic cancer.

AUTHOR(S)

Juan Pablo Hinestrosa, Razelle Kurzrock, Jean Lewis, Nick Schork, Ashish M. Kamat, Andrew M. Lowy, Ramez N. Eskander, Orlando Perrera, David Searson, Iryna Clark, Heath Balcer, Mark J. Adler, Scott M. Lippman, Rajaram Krishnan

ABSTRACT

3048

Dermatologic adverse events of brentuximab vedotin: Characteristics, management, and their relationship with dose regimen.

AUTHOR(S)

Yuna Oh, Alexander Bang, Nicholas Kurtansky, Niloufer Khan, Melissa Pulitzer, Sarah J. Noor

ABSTRACT

3049

A phase 1 study of TAK-164, an anti-guanylyl cyclase C (GCC) antibody-drug conjugate (ADC), in patients (pts) with advanced gastrointestinal (GI) cancers expressing GCC.

AUTHOR(S)

Richard D. Kim, James M. Cleary, Alexis D. Leal, Aparna R. Parikh, David P. Ryan, Shining Wang, Brittany Bahamon, Neeraj Gupta, Aaron Moss, Joanna Pye, Harry H. Miao, Johanna C. Bendell

ABSTRACT

3050

Phase I study of mesothelin-targeted immunotoxin LMB-100 in combination with tofacitinib in patients with advanced pancreaticobiliary cancer.

AUTHOR(S)

Nebojsa Skorupan, Mehwish I. Ahmad, Guillaume J. Pegna, Cody J. Peer, Jane B. Trepel, Min-Jung Lee, Sunmin Lee, Shraddha Rastogi, Nahoko Sato, William D. Figg, Raffit Hassan, David J. FitzGerald, Ira Pastan, Christine Alewine

ABSTRACT

3051

RNA sequencing effectively identifies gene fusions undetected by DNA sequencing in lung adenocarcinomas.

AUTHOR(S)

Ruiying Zhao, Yuchen Han, Chan Xiang, Shengnan Chen, Jikai Zhao, Lianying Guo, Anbo Yu, Jinchen Shao, Lei Zhu, Yue Tian, Fan Yang, Lin Shao, Xuejing Li, Lu Zhang

ABSTRACT

3052

Sputum supernatant as a viable alternative for liquid biopsy in advanced non-small cell lung cancer.

AUTHOR(S)

Chengzhi Zhou, Xiaohong Xie, Jianhui Wu, Bingpeng Guo, Yinyin Qin, Xinqing Lin, Ming Liu, Luting Qiu, Xiao Zou, Zhange Chen

ABSTRACT

3053

Novel imaging biomarkers predict progression-free survival in stage 3 NSCLC treated with chemoradiation and durvalumab.

AUTHOR(S)

Khalid Jazieh, Mohammadhadi Khorrami, Anas M. Saad, Mohamed M. Gad, Vidya S. Viswanathan, Pingfu Fu, Prabhakar Rajiah, Anant Madabhushi, Nathan A. Pennell

ABSTRACT

3054

Differences of US-FNA BSRTC class, postoperative pathology, and mutation landscape of thyroid nodules between China and other countries.

AUTHOR(S)

Yuntao Song, Jie Liu, Weiran Wang, Tonghui Ma

ABSTRACT

3055

Circulating genetically abnormal cells combined with artificial intelligence for accurate and non-invasive early detection on NSCLC.

AUTHOR(S)

Han Yang, Hongjie Chen, Ran Ni, Guorui Zhang, Yongjie Huang, Xin Ye, Xianjun Fan, Yinglan Kuang, Juncheng Zhang, Chuoji Huang, Hong Liu

ABSTRACT

3056

Prediction of adenocarcinoma among other subtypes of lung cancer from CT using deep learning.

AUTHOR(S)

Noah Waterfield Price, Sam Janes, Fergus Gleeson, Pierre P. Massion, Jonathan Lehman

ABSTRACT

3057

Modeling cell-free DNA fragment size densities for non-invasive detection of cancer.

AUTHOR(S)

Jacob Carey, Bryan Chesnick, Denise Butler, Michael Rongione, Giovanni Parmigiani, Victor E. Velculescu, Nicholas C. Dracopoli, Robert B. Scharpf

ABSTRACT

3058

Advanced imaging to assess longitudinal vascular changes in brain metastases treated with checkpoint inhibition.

AUTHOR(S)

Albert E. Kim, Ken Chang, Kyrre E. Emblem, Jayashree Kalpathy-Cramer, Eudocia Q. Lee, Nancy U. Lin, Sara M. Tolaney, Lakshmi Nayak, Ugonma N. Chukwueke, Kevin S. Oh, Helen A. Shih, Michael White, Don P. Lawrence, Beverly Moy, Justine V. Cohen, Anita Giobbie-Hurder, Daniel P. Cahill, Ryan J. Sullivan, Priscilla K. Brastianos, Elizabeth R. Gerstner

ABSTRACT

3059

Genetic profiling across multiple cancer types using molecular prescreening comprehensive gene panels offered by clinical trials (CT).

AUTHOR(S)

Iván Victoria, Debora Moreno Fernandez, Laura Angelats, Alberto Indacochea, Francisco Pelegrín, Pol Sole i Bentz, Lydia Gaba, Begona Mellado, Estela Pineda, Tamara Sauri, Francis Esposito, Laura Ferrer-Mileo, Helena Oliveres, Montserrat Muñoz, Maria Vidal, Olga Martinez Saez, Neus Basté Rotllán, Nuria Vinolas, Miquel Nogue, Javier Garcia-Corbacho

ABSTRACT

3060

Machine learning models to quantify HER2 for real-time tissue image analysis in prospective clinical trials.

AUTHOR(S)

Benjamin Glass, Michel E. Vandenberghe, Surya T. Chavali, Syed A. Javed, Marlon Rebelatto, Shamira Sridharan, Hunter Elliott, Sudha Rao, Michael Montalto, Murray Resnick, Ilan Wapinski, Andrew Beck, Craig Barker

ABSTRACT

3061

Comprehensive molecular profiling of advanced cancers in a real-world setting using an ultrasensitive amplicon-based next-generation sequencing (NGS) liquid biopsy assay.

AUTHOR(S)

Jonathan Poh, Kao Chin Ngeow, Michelle Pek, Daniel Tan, Jing Shan Lim, Yukti Choudhury

ABSTRACT

3062

Feasibility and clinical utility of cancer whole genome and transcriptome sequencing for pediatric and young adult solid tumors.

AUTHOR(S)

Neerav Shukla, Max Levine, Gunes Gundem, Barbara Spitzer, Jesus Gutierrez-Abril, Nancy Bouvier, Juan E. Arango Ossa, Juan Medina-Martinez, Emily Stockfisch, Tara O'Donohue, Ahmet Zehir, Agnes Viale, Shakeel Modak, Filemon S. Dela Cruz, Emily K. Slotkin, Matthias A. Karajannis, Julia L. Glade Bender, Michael F. Walsh, Andrew Kung, Elli Papaemmanuil

ABSTRACT

3063

Improving differential diagnosis of pulmonary large cell neuroendocrine carcinoma (LCNEC) and small cell lung cancer via a transcriptomic, biological pathway-based ridge regression model.

AUTHOR(S)

Jun Hong, Likun Hou, Wei Zhang, Zhengwei Dong, Zhan Huang, Wuzhou Yuan, Lei Zhang, Chunyan Wu

ABSTRACT

3065

Validation of FAPi PET biodistribution by immunohistochemistry in patients with solid cancers: A prospective exploratory study.

AUTHOR(S)

Christine Mona, Matthias R. Benz, Firas Hikmat, Tristan Grogan, Katharina Lueckerath, Ali A. Razmaria, Rana Riahi, Roger Slavik, Mark D. Grigis, Giuseppe Carlucci, Kimberly A. Kelly, Johannes Czernin, David D. Dawson, Jeremie Calais

ABSTRACT

3066

Safety profile and disease stabilization in late stage, heavily pretreated, solid tumor patients in a first-in-human (FIH) study of ATX-101, a drug targeting proliferating cell nuclear antigen (PCNA).

AUTHOR(S)

Charlotte R. Lemeche, Ganessan Kichenadasse, Jens-Peter Marschner, Kostas Alevizopoulos, Marit Otterlei, Michael Millward

ABSTRACT

3067

Association of low RKIP expression with poor prognosis in non-small cell lung cancer.

AUTHOR(S)

Lingbin Meng, Rui Ji, Damian A. Laber, Xuebo Yan, Xiaochun Xu

ABSTRACT

3068

Mutational analysis of rare insertions and deletions in exon 18 and 19 of HER2 in Chinese patients with different cancer types.

AUTHOR(S)

Jianwen Qin, Dongsheng Shi, Lijie Song, Yan Yin, Bin Liu, Xiangke Li, Minjie Yang, Ting Hou, Yuxi Zhou, Jianxing Xiang, Yan Zheng, Bihao Liu, Dejuan Wang

ABSTRACT

3069

A prespecified interim analysis of the PATHFINDER study: Performance of a multicancer early detection test in support of clinical implementation.

AUTHOR(S)

Tomasz M. Beer, Charles H. McDonnell III, Lincoln Nadauld, Minetta C. Liu, Eric A. Klein, Robert L. Reid, Karen Chung, Margarita Lopatin, Eric T. Fung, Deborah Schrag

ABSTRACT

3070

Performance of a targeted methylation-based multi-cancer early detection test by race/ethnicity.

AUTHOR(S)

Wai Hong Wilson Tang, Habte A. Yimer, Mohan K. Tummala, Spencer Shao, Gina G. Chung, Jessica M. Clement, Jingjing Gao, Earl Hubbell, Kathryn Kurtzman, Charles Swanton, Lewis R. Roberts

ABSTRACT

3071

Detection of cancer signal for over 50 AJCC cancer types with a multi-cancer early-detection test.

AUTHOR(S)

Habte A. Yimer, Wai Hong Wilson Tang, Mohan K. Tummala, Spencer Shao, Gina G. Chung, Fergus Couch, Jingjing Gao, Oliver Venn, Kathryn Kurtzman, Charles Swanton, Jessica M. Clement

ABSTRACT

3072

Preliminary efficacy from an ongoing phase 1 dose escalation study of seclidemstat (SP-2577) in patients (pts) with advanced solid tumors (AST).

AUTHOR(S)

Sant P. Chawla, Victoria S. Chua-Alcala, Jasgit C. Sachdev, David S. Wages, David D. Stenehjem, Daniela Y. Santiesteban, Nadeem Q. Mirza, Michael S. Gordon

ABSTRACT

3073

First-in-human phase I study of the bifunctional EGFR/TGF β fusion protein BCA101 in patients with EGFR-driven advanced solid cancers.

AUTHOR(S)

Filip Janku, Glenn J. Hanna, Richard D. Carvajal, Paul K. Paik, Alberto Hernando-Calvo, Maura L. Gillison, Siqing Fu, Jennifer J. Wheler, David Bohr, Ralf Reiners, Seng-Lai Tan, Sanela Bilic, Philippe L. Bedard

ABSTRACT

3074

Phase 1 study of OKI-179, an oral class 1-selective depsipeptide HDAC inhibitor, in patients with advanced solid tumors: Final results.

AUTHOR(S)

Jodi A. Kagihara, Bradley Corr, Jose M. Pacheco, S. Lindsey Davis, Christopher H. Lieu, Sunnie S. Kim, Antonio Jimeno, Amy M. Heim, John A. DeMattei, Gilad Gordon, Todd A. Triplett, S. G. Eckhardt, James D. Winkler, Anthony D. Piscopio, Jennifer R. Diamond

ABSTRACT

3075

Patient-derived micro-organospheres recapitulate tumor microenvironment and heterogeneity for precision oncology.

AUTHOR(S)

Shengli Ding, Zhaohui Wang, Marcos N. Obando, Grecia r. Palomino, Tomer Rotstein, Ian Williamson, Shiao wen D. Hsu, Xiling Shen

ABSTRACT

3076

Phase Ia study of CBP-1008, a bi-specific ligand drug conjugate targeting FR α and TRPV6, in patients with advanced solid tumors.

AUTHOR(S)

Jifang Gong, Xichun Hu, Jian Zhang, Yiqun Du, Robert Huang, Yan Teng, Wei Tan, Lin Shen

ABSTRACT

3077

First-in-human study of PM14 in patients with advanced solid tumors.

AUTHOR(S)

Maria Vieito, Santiago Ponce Aix, Luis G. Paz-Ares, Rastilav Bahleda, Christophe Massard, Leyre Agreda, Eva Banus, Cristian M. Fernandez, Elena Y. Cristoveanu, Gema Corral, Lourdes Llanero, Rubin Lubomirov, Carmen M. Kahatt, Salvador Fudio, Antonio Nieto, Martin Cullell-Young, Ali H. Zeaiter, Honey Kumar Oberoi, Elena Garralda

ABSTRACT

3078

Clinical activity and safety of the RET inhibitor pralsetinib in patients with *RET* fusion-positive solid tumors: Update from the ARROW trial.

AUTHOR(S)

Vivek Subbiah, Philippe A. Cassier, Salvatore Siena, Guzman Alonso, Luis G. Paz-Ares, Pilar Garrido, Ernest Nadal, Giuseppe Curigliano, Jacqueline Vuky, Gilberto Lopes, Gregory P. Kalemkerian, Daniel W. Bowles, Mahesh Seetharam, Jianhua Chang, Hui Zhang, Chaoyang Ye, Jennifer Green, Alena Zalutskaya, Martin H. Schuler, Yun Fan

ABSTRACT

3079

A phase 1/2 trial of ORIN1001, a first-in-class IRE1 inhibitor, in patients with advanced solid tumors.

AUTHOR(S)

Nashat Y. Gabrail, Erika P. Hamilton, Anthony D. Elias, Mothaffar F. Rimawi, Chao Li, Maria M. Corvez, Wei Li, Ying Feng, Jiao Wei, Stephanie Greene, John Patterson, Qingping Zeng, Ai-Min Hui

ABSTRACT

3080

First-time in-human study of VMD-928, an oral allosteric TrkA selective inhibitor targeting TrkA protein overexpression, in patients with solid tumors or lymphoma.

AUTHOR(S)

Vincent Chung, Ling Wang, Margaret S. Fletcher, Erminia Massarelli, Mihaela C. Cristea, Sailaja Kamaraju, Angela T. Alistar, Chao Feng, You Li, Roger L. Whiting, Giuseppe Giaccone, David S. Hong, Jay Wu

ABSTRACT

3081

High-intensity focused ultrasound ablation for treatment of chemotherapy-induced thrombocytopenia and hypersplenism.

AUTHOR(S)

Min Yuan, Qing Xu, Zhongzheng Zhu, Wei Mao, Xianling Guo, Hui Wang, Hong Qian, Jianguo Wu

ABSTRACT

3082

Phase 1 trial of a novel, first-in-class G protein-coupled estrogen receptor (GPER) agonist, LNS8801, in patients with advanced or recurrent treatment-refractory solid malignancies.

AUTHOR(S)

Carolyn Muller, Ursa A. Brown-Glaberman, Marya F. Chaney, Tina Garyantes, Patricia LoRusso, Jennifer L. McQuade, Alain C. Mita, Monica M. Mita, Christopher Natale, Marlana Orloff, Kyriakos P. Papadopoulos, Takami Sato, Emrullah Yilmaz, Jordi Rodon

ABSTRACT

3084

A phase II study investigating biological effects of maintenance usage of hydroxychloroquine on Par-4 levels in patients with resected tumors.

AUTHOR(S)

Peng Wang, Ravshan Burikhanov, Heidi Weiss, Rani Jayswal, Susanne M. Arnold, John L. Villano, Vivek Rangnekar

ABSTRACT

3085

Safety and preliminary efficacy from the phase 1 portion of MasterKey-01: A First-in-human dose-escalation study to determine the recommended phase 2 dose (RP2D), pharmacokinetics (PK) and preliminary antitumor activity of BDTX-189, an

inhibitor of allosteric *ErbB* mutations, in patients (pts) with advanced solid malignancies.

AUTHOR(S)

Alison M. Schram, Jordi Rodon Ahnert, Manish R. Patel, Shekeab Jauhari, Jasgit C. Sachdev, Viola W. Zhu, Patricia LoRusso, Danny Nguyen, Xiuning Le, Matthew O'Connor, Nigel Waters, Carl Cook, Karsten Witt, Rachel W. Humphrey, Pasi A. Janne, Erika P. Hamilton

ABSTRACT

3086

A phase 2 study of defactinib (VS-6063) in patients with NF2 altered tumors: Results from NCI-match (EAY131) subprotocol U.

AUTHOR(S)

David M. Jackman, Opeyemi Jegede, Marjorie G. Zauderer, Edith P. Mitchell, James Zwiebel, Robert J. Gray, Shuli Li, Lisa McShane, Lawrence Rubinstein, David R. Patton, Paul M. Williams, Stanley R. Hamilton, Barbara A. Conley, Carlos L. Arteaga, Lyndsay Harris, Peter J. O'Dwyer, Alice P. Chen, Keith Flaherty

ABSTRACT

3087

Phase I trial of 5-aza-4'-thio-2'-deoxycytidine (Aza-TdC) in patients with advanced solid tumors.

AUTHOR(S)

James Nguyen, Geraldine H. O'Sullivan Coyne, Naoko Takebe, Abdul R. Naqash, Jessica Mukherjee, Ashley Bruns, Richard Piekarz, Jerry M. Collins, Larry Anderson, Brandon Miller, Ralph E. Parchment, Larry V. Rubinstein, Shivaani Kummar, Elad Sharon, Howard Streicher, Alice P. Chen, James H. Doroshow

ABSTRACT

3088

Evaluating clinical activity of MAPK targeted therapies (TT) in cancer patients (pts) with non-V600 BRAF mutations: A systematic scoping review and meta-analysis.

AUTHOR(S)

Matthew Dankner, Yifan Wang, Rouhi Fazelzad, Anna Spreafico, David W. Cescon, George Zogopoulos, April A. Rose

ABSTRACT

3089

Phase I study of TT-00420, a multiple kinase inhibitor, as a single agent in advanced solid tumors.

AUTHOR(S)

Sarina Anne A. Piha-Paul, Binghe Xu, Filip Janku, Ecaterina E. Dumbrava, Siqing Fu, Daniel D. Karp, Funda Meric-Bernstam, David S. Hong, Jordi Rodon Ahnert, Apostolia M. Tsimberidou, Milind M. Javle, Ying Fan, Peng Peng, Wendy J. Levin, Brenda Ngo, Hui Wang, Caixia Sun, Qinhua C. Ru, Frank Wu

ABSTRACT

3090

Incidence of *ERBB* gene fusions (*EGFR*, *ERBB2*, *ERBB4*) across tumor types.

AUTHOR(S)

Laura Schubert, Andrew Elliott, Robert C. Doebele, Emil Lou, Hossein Borghaei, Michael J. Demeure, Razelle Kurzrock, Anh T. Le, Joshua E. Reuss, Sai-Hong I. Ou, David R. Braxton, Christian A. Thomas, Sourat Darabi, Wolfgang M. Korn, Wafik S. El-Deiry, Stephen V. Liu

ABSTRACT

3091

Association of high gene expression levels of *ARF6* with the immune microenvironment and prediction of poor outcomes.

AUTHOR(S)

Natsuko Kawanishi, Yasmine Baca, Joanne Xiu, Hiroyuki Arai, Francesca Battaglin, Priya Jayachandran, Shivani Soni, Wu Zhang, Philip A. Philip, Davendra Sohal, Mohd Khushman, Benjamin A. Weinberg, Michael J. Hall, David J. Park, Anthony F. Shields, A. C. Lockhart, Wolfgang M. Korn, Heinz-Josef Lenz, Emil Lou

ABSTRACT

3092

Optimal dose selection in oncology biologics development: Need for a paradigm shift.

AUTHOR(S)

Rajendar K. Mittapalli, Kai H. Liao, Jason Williams, Ramesh Raja Palaparthi, Donghua Yin

ABSTRACT

3093

Anticancer drugs associated with venous thromboembolic event: Analysis of the WHO pharmacovigilance database.

AUTHOR(S)

Angélique DA Silva, Joachim Alexandre, Damien Laneelle, Marion Sassier, Basile Chrétien, Sophie Fedrizzi, Florence Joly, George Emile, Laurent Bertoletti, Benoîte Mery, Anne Flore Plane, Damien Legallois, Charles Dolladille

ABSTRACT

3094

Does oxaliplatin pharmacokinetics (PKs) explain associations between body composition and chemotherapy toxicity risk in older adults with gastrointestinal (GI) cancers?

AUTHOR(S)

Grant R. Williams, Mustafa Al-Obaidi, Joseph Rower, Christian Harmon, Chen Dai, Edward Acosta, Smith Giri, William Zamboni, Andrew T. Lucas, Shlomit S. Shachar, Olumide B. Gbolahan, Jeffrey A. Meyerhardt, Bette J. Caan, Smita Bhatia

ABSTRACT

3095

Pre-therapeutic dihydropyridimidine dehydrogenase (DPD) deficiency screening: Impact on fluoropyrimidine dose reduction at the second chemotherapy cycle and on early severe toxicity.

AUTHOR(S)

Côme De Metz, Benjamin Hennart, Marie-Cecile Le Deley, Pierre-Yves Cren, Christophe Desauw, Vincent Bourgeois, Fredrik Laestadius, Emilia Rad, Loic Lebellec, Nicolas Penel, Aurelien Carnot

ABSTRACT

3096

Clinical pharmacokinetics of bdtx-189, an inhibitor of allosteric ErbB mutations, in patients with advanced solid malignancies in MasterKey-01 study.

AUTHOR(S)

Nigel Waters, Manish R. Patel, Alison M. Schram, Jordi Rodon Ahnert, Shekeab Jauhari, Jasgit C. Sachdev, Viola W. Zhu, Patricia LoRusso, Danny Nguyen, David S. Hong, Leticia Tarilonte, Rachel W. Humphrey, Pasi A. Janne, Erika P. Hamilton, Karsten Witt

ABSTRACT

3097

A phase I study of a TGF- β receptor I kinase inhibitor YL-13027 in patients with advanced solid tumors.

AUTHOR(S)

Jin Li, Tianshu Liu, Hanying Bao, Zusheng Xu, Yang Shu, Binghua Zheng

ABSTRACT

3098

A phase Ib study of the PI3K δ inhibitor liperlisib in patients with advanced solid tumors.

AUTHOR(S)

Jin Li, Nong Xu, Tianshu Liu, Jianjin Huang, Yongmei Yin, Haibo Mou, Jun Zhang, Lihua Wu, Zong I. Liu, Hanying Bao, Zusheng Xu

ABSTRACT

3099

Antibiotic use reduces efficacy of tyrosine kinase inhibitors in patients with advanced melanoma and non-small cell lung cancer.

AUTHOR(S)

Nadina Tinsley, Natalie Cook, Cong Zhou, Sharon H. Nahm, Samuel Rack, Grace C. Tan, Paul Lorigan, Fiona H. Blackhall

ABSTRACT

3100

A phase I study of an IDO inhibitor (SHR9146) plus camrelizumab and in combination with/without apatinib in patients with advanced solid tumors: Safety and efficacy analysis.

AUTHOR(S)

Ying Cheng, Ying Liu, Jinhua Xu, Jing Zhu, Ying Wang, Ying Xin, Yanping Wang, Chunjiao Wu, Hongxia Cui, Xianhong Liu, Jixin Dai, Zili Li, XiangHua Zhang, Jing Zhang, Ben Zhang

ABSTRACT

3101

Phase 1b/2 SEASTAR trial: Safety, pharmacokinetics, and preliminary efficacy of the poly(ADP)-ribose polymerase (PARP) inhibitor rucaparib and angiogenesis inhibitor lucitanib in patients with advanced solid tumors.

AUTHOR(S)

Ecaterina E. Dumbrava, Geoffrey Shapiro, Johanna C. Bendell, Timothy A. Yap, Rinath Jeselsohn, Denise M. Lepley, Sabrina Hurley, Kevin K. Lin, Michelle Liao, Jenn Habeck, Aaron Enke, Erika P. Hamilton

ABSTRACT

3102

A phase Ib trial of ERK inhibition with ulixertinib combined with palbociclib in patients (Pts) with advanced solid tumors.

AUTHOR(S)

Alison L. Raybould, Brian Burgess, Clarissa Urban, Rashid Naim, Michael S. Lee, Autumn J. McRee

ABSTRACT

3103

Phase 1/2 first-in-human (FIH) study of CPI-0209, a novel small molecule inhibitor of enhancer of zeste homolog 2 (EZH2) in patients with advanced tumors.

AUTHOR(S)

Nehal J. Lakhani, Martin Gutierrez, Linda R. Duska, Khanh T. Do, Manish Sharma, Leena Gandhi, Kyriakos P. Papadopoulos, Jennifer Truong, Xiaolin Fan, Ji Hyun Lee, Suresh Bobba, Ronda Rippley, Rentian Wu, Jike Cui, Kaiming Sun, Jing Y. Wang, Patrick Trojer, Drew W. Rasco

ABSTRACT

3104

Inhibition of histone lysine demethylases with TACH101, a first-in-class pan-inhibitor of KDM4.

AUTHOR(S)

Chandtip Chandhasin, Sanghee Yoo, Joselyn Del Rosario, Young K. Chen, Jeffrey Stafford, Frank Perabo, Michael F. Clarke

ABSTRACT

3105

WX390, a high-potent PI3K-mTOR dual inhibitor, first-in-human (FIH) phase I study in advanced relapsed or refractory solid tumor, and lymphoma.

AUTHOR(S)

Wenbo Tang, Ye Guo, Liqiong Xue, Wei Peng, Xiaoxiao Ge, Junli Xue, Wei Wei, Juncai Xu, Yongguo Li, Jin Li

ABSTRACT

3106

First-in-human dose-finding study of venadaparib (IDX-1197), a potent and selective PARP inhibitor, in patients with advanced solid tumors.

AUTHOR(S)

Yong Man Kim, Kyun-Seop Bae, Nam Seok Baek, Kyungun Kim, Won Sik Lee, Eun-Jihn Roh, Chan-Young Ock, Sung-Bae Kim

ABSTRACT

3107

Long-term efficacy and safety of larotrectinib in an integrated dataset of patients with TRK fusion cancer.

AUTHOR(S)

David S. Hong, Lin Shen, Cornelis M. van Tilburg, Daniel S. Tan, Shivaani Kummar, Jessica J. Lin, Francois P. Doz, Raymond S. McDermott, Catherine M. Albert, Jordan Berlin, Stefan S. Bielack, Ulrik N. Lassen, Makoto Tahara, Ricarda Norenberg, Anna Shurshalina, Marc M. Fellous, Hendrik Nogai, Rui-hua Xu, Theodore W. Laetsch, Alexander E. Drilon

ABSTRACT

3108

PARALLEL 303: Phase 2 randomized study of pamiparib vs placebo as maintenance therapy in patients (pts) with inoperable locally advanced or

metastatic gastric cancer that responded to platinum-based first-line (1L) chemotherapy.

AUTHOR(S)

Fortunato Ciardiello, Yung-Jue Bang, Johanna C. Bendell, Andres Cervantes, Mikhail Dvorkin, Charles D. Lopez, Jean-Philippe Metges, Antonio Sanchez, Mariona Calvo, Andrew Strickland, George Kannourakis, Kei Muro, Hisato Kawakami, Jia Wei, Christophe Borg, Song Mu, Kathy Zhang, Maggie Zhang, Lin Shen

ABSTRACT

3109

Biomarker results supporting selection of RP2D from a phase 1b study of ORIC-101, a glucocorticoid receptor antagonist, in combination with nab-paclitaxel in patients with advanced solid tumors.

AUTHOR(S)

Anneleen Daemen, Aleksandr Pankov, Shravani Barkund, Haiying Zhou, Maureen Duff, Ann Johnson, Rongda Xu, Pratik S. Multani, Edna Chow Maneval, Lori Friedman

ABSTRACT

3110

Institutional experience with *nab*-sirolimus in patients with malignancies harboring *TSC1* or *TSC2* mutations.

AUTHOR(S)

Mark A. Dickson, Vinod Ravi, Kristen N. Ganjoo, Gopa Iyer

ABSTRACT

3111

Dosing, drug reduction, drug interruption, and drug discontinuation rates among U.S. FDA approved tyrosine kinase inhibitors.

AUTHOR(S)

Neha K. Reddy, Jason Roszik, David C. Norris, Roman Groisberg, Niamh Coleman, Omar Alhalabi, Ethan B. Ludmir, Cullen M. Taniguchi, Ishwaria M. Subbiah, Vivek Subbiah

ABSTRACT

3112

A phase I dose-escalation and expansion study of JPI-547, a dual inhibitor of PARP/tankyrase in patients with advanced solid tumors.

AUTHOR(S)

Seock-Ah Im, SeungHwan Lee, Keun Wook Lee, Youngjoo Lee, Joohyuk Sohn, Jee Hyun Kim, Young-Hyuck Im, Kyong Hwa Park, Do-Youn Oh, Min Hwan Kim, Yeon Hee Park, Tae Min Kim, Yoon Ji Choi, Chang-Seok Lee, Jiseon Park, Nam Seok Baek, MiKyung CHOI, John Kim, Eunyoung Yu, Yung-Jue Bang

ABSTRACT

3113

Intra-patient comparison from larotrectinib clinical trials in TRK fusion cancer: An expanded dataset.

AUTHOR(S)

David S. Hong, Antoine Italiano, Andrew Briggs, Jesus Garcia-Foncillas, Ulrik N. Lassen, Gilles Vassal, Shivaani Kummar, Cornelis M. van Tilburg, Karen N. Keating, John A. Reeves, Marc M. Fellous, Hendrik Nogai, Theodore W. Laetsch, Alexander E. Drilon

ABSTRACT

3114

Phase I expansion study of the first-in-class monocarboxylate transporter 1 (MCT1) inhibitor AZD3965 in patients with diffuse large B-cell lymphoma (DLBCL) and Burkitt lymphoma (BL).

AUTHOR(S)

Sarah E. Halford, Harriet Walter, Pamela McKay, William Townsend, Kim Linton, Kathrin Heinzmann, Ilaria Dragoni, Laura Brotherton, Gareth Veal, Alexandros Siskos, Hector C. Keun, Chris Bacon, Steve Wedge, George Petrides, Martin J. Dyer, Elizabeth R. Plummer

ABSTRACT

3115

The next-generation pan-RAF inhibitor, KIN-2787, is active in class II and class III BRAF mutant models.

AUTHOR(S)

Aleksandra Franovic, Nichol Miller, Paul Severson, Toufike Kanouni, Noelito Timple, Ping Jiang, Eric Murphy, Eric Martin

ABSTRACT

3116

Prognostic factors in RET dependent cancers treated with RET inhibitors in early phase clinical trials.

AUTHOR(S)

Max Gordon, Jason Roszik, Maria E. Cabanillas, Mimi I. Hu, Naifa L. Busaidy, Steven I. Sherman, Ramona Dadu, Elizabeth G. Grubbs, Yasir Y. Elamin, Tina Cascone, Lauren A. Byers, George R. Blumenschein, Frank V. Fossella, Aung Naing, David S. Hong, John Heymach, Funda Meric-Bernstam, Vivek Subbiah

ABSTRACT

3117

Expression of end-binding protein 1 (EB1), a potential response-predictive biomarker for lisavanbulin, in glioblastoma and various other solid tumor types.

AUTHOR(S)

Magdalena Skowronska, Crescens D. Tiu, Alexandar Tzankov, Fatima König, Joanne Lewis, Igor Vivanco, Malte Kleinschmidt, Kirk Beebe, Stephanie Anderson, Felix Bachmann, Marc Engelhardt, Heidi A. Lane, Thomas Kaindl, Alexandru C. Stan, Elizabeth R. Plummer, T.R. Jeffry Evans, Inti Zlobec, Juanita S. Lopez

ABSTRACT

3118

***TP53* and *CHEK2* germline mutations in malignant solid tumors.**

AUTHOR(S)

Zhiye Zhang, Yaqing Wu, Ningning Luo, Qin Zhang, Tiantian Han, Xuesong Bu, Qin Shuai, Yingxue Qi

ABSTRACT

3119

A comprehensive landscape of BRCA1 versus BRCA2 associated molecular alterations and survival outcome across 35 cancer types.

AUTHOR(S)

Alberto Puccini, Joanne Xiu, Arielle L. Heeke, Andreas Seeber, Richard M. Goldberg, Wafik S. El-Deiry, Stephen V. Liu, Sarah Sammons, Emil Lou, Philip A. Philip, John Marshall, Anthony F. Shields, Heinz-Josef Lenz, Thomas J. Herzog, W. M. Korn, Mohamed E. Salem

ABSTRACT

3120

Analysis of the MOSAIC correlative cancer database integrating molecular cancer classification and tumor profiling to identify targeted treatment options for metastatic cancer.

AUTHOR(S)

Li Ma, Kai Treuner, Jenna Wong, David R. Spigel, Catherine A. Schnabel

ABSTRACT

3121

Temporal and spatial topography of cell proliferation in cancer.

AUTHOR(S)

Sheheryar K. Kabraji, Giorgio Gaglia, Danae Argyropoulou, Yang Dai, Shu Wang, Johann Bergholz, Shannon Coy, Jia-Ren Lin, Rinath Jeselsohn, Otto Metzger, Eric P. Winer, Deborah Dillon, Jean Zhao, Peter Sorger, Sandro Santagata

ABSTRACT

3122

Multi-cancer detection and tissue of origin determination based on 5-hydroxymethylcytosine biomarkers in circulating cell-free DNA.

AUTHOR(S)

Zhou Zhang, Wenju Chang, Jiabin Cai, Yijiu Ren, Qiancheng You, Chang Zeng, Xiao-Long Cui, Zeliang Deng, Zeqiang Yu, Liang Zhang, Xiao Wang, Sen Sun, Brian C. Chiu, Chuan He, Dongdong Li, Chang Chen, Jianmin Xu, Jia Fan, Wei Zhang

ABSTRACT

3123

Frequency of longitudinal changes in *TP53* mutation status from gene sequencing of serial tumor biopsies from a large cohort of cancer patients.

AUTHOR(S)

D. Allen A. Annis, Dean C. Pavlick, Garrett M. Frampton, Lee A. Albacker, Vojislav M. Vukovic, Manuel Aivado

ABSTRACT

3124

A comprehensive literature review and meta-analysis on prognostic value of BRCAm, HRRm and HRD+ across tumor types.

AUTHOR(S)

Changxia Shao, Andrew Marley, Huilin Tang, Jun Wan, Chelsey Miller, Madeline Brown, Yiqing Song, Jiali Han, Gboyega Adeboyeje

ABSTRACT

3125

The value of defining molecular resistance in patients with progressive *EGFR* and *ALK*-driven lung cancer in a public system.

AUTHOR(S)

Carly C. Barron, Tracy Stockley, Jennifer H. Law, Muqdas Shabir, Roxanne Fernandes, Tong Zhang, Lisa W. Le, Ming S. Tsao, Suzanne Kamel-Reid, Prodipto Pal, Michael Cabanero, Joerg Schwock, Hyangmi Ko, Geoffrey Liu, Penelope A. Bradbury, Adrian G. Sacher, Frances A. Shepherd, Natasha B. Leighl, Kirstin Perdrizet

ABSTRACT

3126

Landscape of *KRAS*^{G12C}, associated genomic alterations, and interrelation with immuno-oncology (IO) biomarkers.

AUTHOR(S)

Mohamed E. Salem, Sherif El-Refai, Wei Sha, Axel Grothey, Alberto Puccini, Thomas J. George, Jimmy J. Hwang, Laura W. Musselwhite, David King, Kunal C. Kadakia, Derek Raghavan, Eric Van Cutsem, Josep Tabernero, Jeanne Tie

ABSTRACT

3127

The impact of clinical decision making in a molecular tumor board at a tertiary care center.

AUTHOR(S)

Meena Sadaps, Kathryn Demski, Ying Ni, Vicky Konig, Brandie Leach, Emily Mazzei, Pauline Funchain

ABSTRACT

3128

The mutational landscape of the sensitivity of cancer to ionizing radiation.

AUTHOR(S)

Priyanka Gopal, Brian Yard, Aaron Petty, Jessica Castrillon, Jyoti D. Patel, Mohamed E. Abazeed

ABSTRACT

3129

Clinically advanced pelvic squamous cell carcinomas (pSCC) in men and women: A comprehensive genomic profiling (CGP) study.

AUTHOR(S)

Philippe E. Spiess, Petros Grivas, Douglas A. Mata, Gennady Bratslavsky, Joseph M. Jacob, Andrea Necchi, Natalie Danziger, Douglas I. Lin, Brennan Decker, Ethan Sokol, Richard S. Huang, Jeffrey S. Ross

ABSTRACT

3130

Partitioning of cancer therapeutics in nuclear condensates.

AUTHOR(S)

Isaac Klein, Ann Boija, Lena Afeyan, Susana Hawken, Mengyang Fan, Dylan Taatjes, Arup Chakraborty, Phillip Sharp, Young Tae Chang, Anthony Hyman, Nathanael Gray, Richard Young

ABSTRACT

3131

The genomic landscape of gene fusions across solid tumors and clinical outcome of targeted therapies: A real-world retrospective analysis.

AUTHOR(S)

Yumeng Zhang, Bindiya G. Patel, Todd C. Knepper, Dung-Tsa Chen, Jhanelle E. Gray, James K. Hicks

ABSTRACT

3132

Differential response rates in early-phase cancer clinical trials (EPCCT).

AUTHOR(S)

Rozana Abdul Rahman, Neethu Billy Graham Mariam, Hitesh Mistry, Sreeja Aruketty, Matt Church, Aidi Adamson-Raieste, Julie-Anne Scott, Fiona Thistlethwaite, Matthew Krebs, Louise Carter, Donna M. Graham, Natalie Cook

ABSTRACT

3133

A phase Ib trial of alpelisib and weekly cisplatin in patients with solid tumor malignancies.

AUTHOR(S)

Erica S. Tsang, Rahul R. Aggarwal, Mallika S. Dhawan, Romain Pacaud, Delaire Fattah, Scott Thomas, Jennifer A. Grabowsky, Pamela N. Munster

ABSTRACT

3134

Cancer and COVID-19: A proposed mechanism with therapeutic interventions.

AUTHOR(S)

Yan Leyfman, Nancy Emmanuel, Aleksey Tentler, Jared Cappelli, Timothy K. Erick, Pushpa Sharma, Chandler H. Park

ABSTRACT

3135

Genome-wide cfDNA fragmentation in patients with cancer and other diseases.

AUTHOR(S)

Jacob Carey, Sian Jones, Alessandro Leal, Bryan Chesnick, Denise Butler, Michael Rongione, Robert B. Scharpf, Julia S. Johansen, Victor E. Velculescu, Nicholas C. Dracopoli

ABSTRACT

3136

Outcomes of active cancer patients with COVID-19 infection treated with COVID-19 neutralizing monoclonal antibodies.

AUTHOR(S)

Justin Shaya, Aaron Lee, Angelo Cabal, Rana R. McKay

ABSTRACT

3137

Patients with advanced solid cancers treated with ERK inhibitors exhibit pseudo-progression in lymphatic nodes.

AUTHOR(S)

Reem Abo-Zahrah, Daniel D. Karp, Abha Adat, Timothy A. Yap, Siqing Fu, Jordi Rodon Ahnert, Sarina Anne A. Piha-Paul, Apostolia M. Tsimberidou, Aung Naing, Vivek Subbiah, Ecaterina E. Dumbrava, Michael J. Overman, Sapna P. Patel, Rodabe N. Amaria, Shannon N. Westin, Funda Meric-Bernstam, Filip Janku

ABSTRACT

3138

Germline polymorphisms in genes maintaining replication fork to predict the efficacy of oxaliplatin and irinotecan in metastatic colorectal cancer (mCRC) patients enrolled in MAVERICC trial.

AUTHOR(S)

Hiroyuki Arai, Yi Xiao, Jingyuan Wang, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Zhang Wu, Christoph Mancao, Bodour Salhia, Shannon M. Mumenthaler, Joshua Millstein, Heinz-Josef Lenz

ABSTRACT

3139

Initiative for Molecular Profiling and Advanced Cancer Therapy (IMPACT2): Challenges and Opportunities in Conducting an MD Anderson Randomized Study in Precision Oncology.

AUTHOR(S)

Henry H. Vo, Siqing Fu, David S. Hong, Daniel D. Karp, Sarina Anne A. Piha-Paul, Vivek Subbiah, Filip Janku, Aung Naing, Timothy A. Yap, Jordi Rodon Ahnert, Jaffer A. Ajani, Carrie Cartwright, Mohammad F. Naqvi, Graciela M. Nogueras-Gonzalez, Vincent A. Miller, Gary A. Palmer, David J. Vining, Donald A. Berry, Funda Meric-Bernstam, Apostolia M. Tsimberidou

ABSTRACT

3140

A phase 2 basket trial of combination therapy with trastuzumab and pertuzumab in patients with solid cancers harboring HER2 amplification (JUPITER trial).

AUTHOR(S)

Ryo Kudo, Toshio Kubo, Yukiko Mori, Yohei Harada, Hidekazu Shiota, Hideyuki Hayashi, Masayuki Kano, Yasushi Shimizu, Eri Ishibashi, Hirotohi Akita, Hisahiro Matsubara, Hiroshi Nishihara, Chikashi Ishioka, Naoko Sueoka-Aragane, Manabu Muto, Shinichi Toyooka, Ukihide Tateishi, Akihiro Hirakawa, Satoshi Miyake, Sadakatsu Ikeda

ABSTRACT

TPS3141

A phase 1b, open-label, single-arm study of cofetuzumab pelidotin (a PTK7-targeting antibody-drug conjugate) in patients with PTK7-expressing, recurrent non-small cell lung cancer (NSCLC).

AUTHOR(S)

Eric S. Schaefer, D. R. Camidge, Kiyotaka Yoh, Alona Zer, Tatiana Hernandez Guerrero, Jair Bar, Yusuke Okuma, Julio A. Peguero, Maria De Miguel, Mor T. Moskovitz, Daniel Morgensztern, Shawn Jeffries, Lan Wang, Satwant Lally, Christopher Conn, Xiaohua Xin, Edwin E. Jeng, Melissa L. Johnson

ABSTRACT

TPS3142

TCF-001 TRACK (Target Rare Cancer Knowledge): A national patient-centric precision oncology trial for rare cancers.

AUTHOR(S)

Vivek Subbiah, Roman Groisberg, Catherine Skefos, James M. Cleary, Ishwaria M. Subbiah, Jim Palma, Mary Oster, Steven W. Young, Julia A. Elvin, Jason K. Sicklick, Sarah Gaffey, Ashley Ward, Brian M. Alexander, J. Jack Lee, Pradip De, Shumei Kato, Razelle Kurzrock

ABSTRACT

TPS3143

A phase 1 study of SGN-B6A, an antibody-drug conjugate targeting integrin beta-6, in patients with advanced solid tumors (SGNB6A-001, Trial in Progress).

AUTHOR(S)

Amita Patnaik, Emiliano Calvo, Sarina Anne A. Piha-Paul, Antoine Hollebecque, Vladimir Galvao, Juanita S. Lopez, Fadi S. Braiteh, Rachel E. Sanborn, Peigen Zhou, Natalya N. Nazarenko, Afshin Dowlati

ABSTRACT

TPS3144

Phase I trial of acoustic cluster therapy (ACT) with chemotherapy in patients with liver metastases of gastrointestinal origin (ACTIVATE study).

AUTHOR(S)

Udai Banerji, Crescens D. Tiu, Andra Curcean, Sumita Gurung, Mark O'Leary, Nigel Bush, Spiros Kotopoulos, Andrew Healey, Svein Kvåle, Hilary Hilary McElwaine-Johnn, Jeff Bamber, Robert Miller, Per Sontum, Sarah Arbe-Barnes, Nina Tunariu

ABSTRACT

TPS3145

First-in-human phase 1 trial (DRAGON) of SRK-181, a potential first-in-class selective latent TGFβ1 inhibitor, alone or in combination with anti-PD-(L)1 treatment in patients with advanced solid tumors.

AUTHOR(S)

Timothy A. Yap, Minal A. Barve, Justin F. Gainor, Colin D. Weekes, Bruno Bockorny, Yawen Ju, Ryan Faucette, Sanela Bilic, Si Tuen Lee-Hoeflich, Guochen Song, Yung Chyung, Michelle Legler, Lu Gan, Johanna C. Bendell

ABSTRACT

TPS3146

Phase 1b dose escalation study to evaluate the safety, tolerability, pharmacokinetics, and preliminary efficacy of GS-3583, a FLT3 agonist Fc fusion protein, in patients with advanced solid tumors.

AUTHOR(S)

Joshua Brody, John A. Thompson, Anthony W. Tolcher, Michelle R. Kuhne, Xi (Rochelle) Huang, Ellen Kwan, Michael Petrarca, Anees Dauki, Indrajeet Singh, Nishanthan Rajakumaraswamy, Shivaani Kummar

ABSTRACT

TPS3147

Phase 1 and phase 2a, first-in-human (FIH) study, of DRP-104, a broad glutamine antagonist, in adult patients with advanced solid tumors.

AUTHOR(S)

Melissa L. Johnson, Deborah B. Doroshow, Tanguy Y. Seiwert, Michael K. Gibson, Vamsidhar Velcheti, Aaron E. Lisberg, Shetal A. Patel, Matthias Scheffler, Francois Lafleur, Margaret H. Dugan, Sunil Sharma

ABSTRACT

TPS3149

Subcutaneous delivery of amivantamab in patients with advanced solid malignancies: PALOMA, an open-label, multicenter, dose escalation phase 1b study.

AUTHOR(S)

Matthew Krebs, Melissa L. Johnson, Byoung Chul Cho, Keunchil Park, Nahor Haddish-Berhane, Donna Zemlickis, Anna Mitselos, Francis Meacle, Roland E. Knoblauch, Peter Helleman, Anna R. Minchom

ABSTRACT

TPS3150

SGNTUC-019: Phase 2 basket study of tucatinib and trastuzumab in previously treated solid tumors with HER2 alterations (trial in progress).

AUTHOR(S)

Tom Stinchcombe, Bradley J. Monk, Alicia F. Okines, Paula R. Pohlmann, Evan Y. Yu, Tanios S. Bekaii-Saab, Yoshiaki Nakamura, David M. O'Malley, Vicky Kang, Luke N. Walker, Martin Reck

ABSTRACT

TPS3151

Trial in progress: Phase 1a/b study of PF-07284890 (brain-penetrant BRAF inhibitor) with/without binimetinib in patients with BRAF V600-mutant solid tumors.

AUTHOR(S)

Vivek Subbiah, Martin Gutierrez, Carey K. Anders, George Ansstas, Taofeek K. Owonikoko, Varun Monga, Peter A. Forsyth, Ibiayi Dagogo-Jack, Sunandana Chandra, Katy K. Tsai, Eli L. Diamond, Meredith McKean, Elizabeth I. Buchbinder, Dale Nepert, Kim Ingram, Colleen Oliver, Micaela Reddy, Kati Maharry, Yan Xing

ABSTRACT

TPS3152

A first-in-human phase I study of ATR inhibitor M1774 in patients with solid tumors.

AUTHOR(S)

Timothy A. Yap, Anthony W. Tolcher, Elizabeth R. Plummer, Andreas Becker, Patricia Fleuranceau-Morel, Thomas Goddemeier, Giuseppe Locatelli, Ioannis Gounaris, Johann S. De Bono

ABSTRACT

TPS3153

Tumor-agnostic precision immuno-oncology and somatic targeting rationale for you (TAPISTRY): A novel platform umbrella trial.

AUTHOR(S)

Alexander E. Drilon, Haiying Liu, Felice Wu, David Chen, Timothy R. Wilson, Brian P. Simmons, Fabrice Barlesi

ABSTRACT

TPS3154

Alpha-T: An innovative decentralized (home-based) phase 2 trial of alectinib in *ALK*-positive (*ALK*+) solid tumors in a histology-agnostic setting.

AUTHOR(S)

Razelle Kurzrock, Amy R. MacKenzie, Adham A. Jurdi, Basem Goueli, Walter Bordogna, Magalie Hilton, Erika Ferreira, Venice R. Archer, Bettyna Brivet-Jones, Johannes Noe, Abba Elizabeth Theogaraj, Lincoln Pasquina, Christine M. Lovly

ABSTRACT

TPS3155

A phase 1/2 study with open-label, dose escalation phase followed by single-arm expansion at the maximum tolerated dose to assess the safety, tolerability, pharmacokinetics, pharmacodynamics, and efficacy of NT219 injection alone and in combination with cetuximab in adults with advanced solid tumors and head and neck cancer.

AUTHOR(S)

Alberto Bessudo, Ezra E. Cohen, Rodolfo Gutierrez, Daniel H. Johnson, Ari Rosenberg, Ammar Sukari, Salomon M. Stemmer, Benjamin A. Weinberg, Hadas Reuveni, Michael Schickler, Bertrand C. Liang

ABSTRACT

TPS3156

Trial in progress: A phase 1-2 multicenter, open-label, dose-escalation and dose-expansion study to evaluate the safety, pharmacokinetics, pharmacodynamics, and antitumor activity of ABN401 in patients with advanced solid tumors.

AUTHOR(S)

Dae Ho Lee, Aflah Roohullah, Byoung Chul Cho, Charlotte R. Lemech, Paul L. de Souza, Michael Millward, Jun Young Choi, Kyung Eui Park, Minseon Lee, YeongMun Kim, YOUNGKEE Shin, Ji-Youn Han

ABSTRACT

TPS3157

First-in-man phase I clinical trial evaluating TTI-101, an orally bioavailable, small molecule inhibitor of STAT3, in patients with advanced solid tumors.

AUTHOR(S)

Apostolia M. Tsimberidou, Sofia de Achaval, Imran Alibhai, Ahmed O. Kaseb

ABSTRACT

TPS3158

A multicenter open-label phase 1 study evaluating the safety and tolerability of HMPL-306 in patients with locally advanced or metastatic solid tumors with IDH mutations.

AUTHOR(S)

Filip Janku, John S. Kauh, Christopher Tucci, Zhao Yang, Marek K. Kania, Olatunji B. Alese

ABSTRACT

TPS3159

EPIK-P2: A prospective phase 2, double-blind, randomized, placebo-controlled study of alpelisib in pediatric and adult patients (Pts) with *PIK3CA*-related overgrowth spectrum (PROS).

AUTHOR(S)

Guillaume Canaud, Juan Carlos López Gutiérrez, Adrienne M. Hammill, Lisa Weibel, Ghislaine Vincent, Séverine Niglis, Michaela Paul, Denise M. Adams

ABSTRACT

TPS3160

Phase 1/2 study of eprenetapopt (APR-246) in combination with pembrolizumab in patients with solid tumor malignancies.

AUTHOR(S)

Ecaterina E. Dumbrava, Amit Mahipal, Xin Gao, Geoffrey Shapiro, Jason S. Starr, Parminder Singh, Muhammad Furqan, Afzal Ahrorov, Denice Hickman, Amy Gubits, Eyal C. Attar, Mark M. Awad, Satya Das, Haeseong Park

ABSTRACT

TPS3161

A phase 2, multicenter, open-label study evaluating trastuzumab deruxtecan (T-DXd) for the treatment of solid tumors harboring specific HER2-activating mutations (DESTINY-PanTumor01).

AUTHOR(S)

Bob T. Li, Funda Meric-Bernstam, Soham D. Puvvada, Jacqui Rowbottom, Darren Jolliffe, Mark Gustavson, Ariadna Mendoza-Naranjo

ABSTRACT

TPS3162

Gastrointestinal Cancer—Colorectal and Anal

[Back to Program](#)

Showing 100 Presentations

<https://meetinglibrary.asco.org/session/13624>

HPV-mediated anal squamous cell carcinoma and precancerous lesions in HIV positive patients.

AUTHOR(S)

Omar Bushara, Brian Finkelman, Sam Weinberg, Katrina Krogh, Aparna Kalyan, Guang-Yu Yang

ABSTRACT

3520

Final analysis of dose-finding and single-arm confirmatory study (phase I/II study) of definitive chemoradiotherapy (dCRT) with S-1/mitomycin-C (MMC) in patients (pts) with clinical (c) Stage II/III squamous cell carcinoma of the anal canal (SCCA): JCOG0903.

AUTHOR(S)

Yoshinori Ito, Tetsuya Hamaguchi, Atsuo Takashima, Junki Mizusawa, Yasuhiro Shimada, Manabu Shiozawa, Takeshi Kodaira, Masayuki Ohue, Makoto Kinouchi, Kohei Murata, Gen Iinuma, Fumihiko Fujita, Hirohisa Miura, Fumio Ishida, Yoshihisa Saida, Takahisa Matsuda, Hiroshi Katayama, Haruhiko Fukuda, Yukihide Kanemitsu

ABSTRACT

3521

Association between cancer stem cell marker ALDH1 and clinical and morphological factors of colorectal cancer prognosis.

AUTHOR(S)

Elena A. Dzhenkova, Inna A. Novikova, Oleg I. Kit, Elena Y. Zlatnik, Elena P. Ulianova, Anastasia O. Sitkovskaya, Oksana G. Shulgina, Yuriy A. Gevorkyan, Natalya V. Soldatkina, Vladimir E. Kolesnikov, Maksim K. Aleksandrovich, Andrey V. Dashkov, Sergey I. Poluektov, Dmitry O. Kaymakchi, Ellada A. Mirzoyan, Vladislav K. Pavlov, Maksim A. Vereshchak, Oksana V. Katelnitskaya, Dmitriy A. Savchenko, Roman E. Tolmakh

ABSTRACT

3522

Circulating tumor DNA-based genomic profiling of small bowel adenocarcinoma.

AUTHOR(S)

Pat Gulhati, Karan Pandya, Hiba I. Dada, Christopher R. Cogle, Jason S. Starr, Sujith R. Kalmadi, Fadi S. Braiteh, Leylah Drusbosky

ABSTRACT

3523

Association of HER2 expression with pathologic features and prognosis in stage II and III colon cancer.

AUTHOR(S)

Zehua Wu, Huabin Hu, Yanhong Deng

ABSTRACT

3524

Clinical utility of stool-based *SDC2* methylation test for the detection and screening of colorectal cancer in a Chinese population.

AUTHOR(S)

Yanmei Liu, Weiguo Yin, Lei Peng, Xianshu Wang, Hongzhi Zou, Haibo Zhou

ABSTRACT

3525

Patient-reported quality of life data from patients with pre-treated metastatic colorectal cancer receiving trifluridine/tipiracil: Interim results of the TALLISUR study.

AUTHOR(S)

Meinolf Karthaus, Albrecht Kretschmar, Stefan Fuxius, Jorge Riera Knorrenschild, Florian Kaiser, Rolf Mahlberg, Manfred Welslau, Henning Pelz, Volker Heinemann

ABSTRACT

3526

Globo H expression in metastatic colorectal cancer (CRC).

AUTHOR(S)

Priya Jayachandran, Yasmine Baca, Joanne Xiu, Jian Zhang, Francesca Battaglin, Hiroyuki Arai, Richard M. Goldberg, Benjamin A. Weinberg, Emil Lou, Michael J. Hall, Moh'd M. Khushman, Davendra Sohal, Shivani Soni, Jingyuan Wang, Wu Zhang, Joshua Millstein, Wolfgang M. Korn, Heinz-Josef Lenz

ABSTRACT

3527

Use of circulating tumor DNA in colorectal cancer patients to assess tumor burden and response to therapy: An observational study.

AUTHOR(S)

Erin L. Symonds, Susanne K. Pedersen, Bernita H. Yeo, Hiba Al Naji, Susan E. Byrne, Amitesh C. Roy, Graeme P. Young

ABSTRACT

3528

Profiling plasma angiogenesis factors after use of biologics in metastatic colorectal cancer (mCRC): Update results from GI-SCREEN CRC Ukit study.

AUTHOR(S)

Yu Sunakawa, Satoshi Yuki, Manabu Shiozawa, Toshiki Masuishi, Tomohiro Nishina, Hisateru Yasui, Takashi Ohta, Naoki Takahashi, Hironaga Satake, Akiyoshi Kanazawa, Masahiro Goto, Hideaki Bando, Hiroya Taniguchi, Yoshinaga Okugawa, Kentaro Yamazaki, Hiromichi Ebi, Yukiko Abe, Shogo Nomura, Chiharu Asano, Takayuki Yoshino

ABSTRACT

3529

The role of *HPSE* in *BRAF* V600E-mutant colorectal cancer.

AUTHOR(S)

Mengling Liu, Xiaojing Xu, Ke Peng, Pengcong Hou, Qing Liu, Yiyi Yu, Tianshu Liu

ABSTRACT

3530

The impact of colorectal cancer screening on incidence and stage IV disease in the Netherlands.

AUTHOR(S)

Myrtle F. Krul, Marloes A. Elferink, Niels F. Kok, Evelien Dekker, Iris Lansdorp-Vogelaar, Gerrit A. Meijer, Iris D. Nagtegaal, Theo J. Ruers, Monique E. van Leerdam, Koert F. Kuhlmann

ABSTRACT

3531

Resectability, conversion and resections rates, and outcomes in *RAS*&*BRAF* wildtype (wt), *RAS* mutant (mt) and *BRAF*mt metastatic colorectal cancer (mCRC) subgroups in the prospective Finnish RAXO-study.

AUTHOR(S)

Pia J. Osterlund, Emerik Osterlund, Aki Uutela, Päivi Halonen, Raija S. Kallio, Annika Ålgars, Tapio Salminen, Annamarja Lamminmäki, Leena-Maija Soveri, Raija Ristimäki, Kaisa I. Lehtomäki, Hanna Stedt, Eetu Heervä, Arno Nordin, Ali Ovissi, Jari Sundström, Lasse Nieminen, Markus J. Mäkinen, Ari Ristimäki, Helena Isoniemi

ABSTRACT

3532

A model combining an immune-related genes signature and an extracellular matrix-related genes signature in predicting prognosis of left- and right-sided colon cancer.

AUTHOR(S)

Min-Er Zhong, Du Cai, Dejun Fan, Wei Wang, Cheng-Hang Li, Ze-Ping Huang, Qiqi Zhu, Min-Yi Lv, Chuling Hu, Xiaojian Wu, Feng Gao

ABSTRACT

3533

Automated computed tomography (CT)-derived skeletal muscle mass determination as a significant prognostic factor in colorectal cancer patients using deep neural network model.

AUTHOR(S)

Dongjin Seo, Han Sang Kim, Yu Rang Park

ABSTRACT

3534

Genetic variants involved in the cGAS-STING pathway to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials.

AUTHOR(S)

Jingyuan Wang, Yi Xiao, Fotios Loupakis, Sebastian Stintzing, Hiroyuki Arai, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Wu Zhang, Christoph Mancao, Chiara Cremolini, Volker Heinemann, Alfredo Falcone, Joshua Millstein, Heinz-Josef Lenz

ABSTRACT

3535

Multimodal circulating tumor DNA (ctDNA) colorectal neoplasia detection assay for asymptomatic and early-stage colorectal cancer (CRC).

AUTHOR(S)

Jeeyun Lee, Hee C. Kim, Seung Tae Kim, Yupeng He, Paul Sample, Yoshiaki Nakamura, Victoria M. Raymond, Ariel Jaimovich, AmirAli Talasaz

ABSTRACT

3536

Comprehensive characterization of neurotransmitters and neuronal signaling (NT) pathway alterations in colorectal cancer (CRC).

AUTHOR(S)

Francesca Battaglin, Joanne Xiu, Jia Zeng, Yasmine Baca, Priya Jayachandran, Natsuko Kawanishi, Hiroyuki Arai, Krutika Deshpande, Richard M. Goldberg, A. C. Lockhart, Jimmy J. Hwang, Andreas Seeber, Wu Zhang, Shannon M. Mumenthaler, Anthony F. Shields, John Marshall, Wolfgang M. Korn, Josh Neman, Heinz-Josef Lenz

ABSTRACT

3537

KMT2C as a positive predictor for treatment of immune checkpoint inhibitor and correlation with immune infiltrates in colorectal cancer (CRC).

AUTHOR(S)

Ling Zhang, Jianping Song, Yiting Wang, Yaouxu Chen

ABSTRACT

3538

Multi-omics analysis to reveal the role of gut microbiome-associated serum metabolites in the detection of colorectal cancer and adenoma.

AUTHOR(S)

Feng Chen, Xudong Dai, Wei Cui

ABSTRACT

3539

Serial circulating tumor DNA analysis to assess recurrence risk, benefit of adjuvant therapy, growth rate and early relapse detection in stage III colorectal cancer patients.

AUTHOR(S)

Tenna V V. Henriksen, Noelia Tarazona, Amanda Frydendahl, Thomas Reinert, Juan Antonio Carbonell-Asins, Shruti Sharma, Derrick Renner, Desamparados Roda, Marisol Huerta, Susana Roselló, Kåre A. Gotschalck, Lene H. Iversen, Uffe S. Løve, Ole Thorlacius-Ussing, Himanshu Sethi, Alexey Aleshin, Andres Cervantes, Claus L. Andersen

ABSTRACT

3540

The effect of primary tumor location on second- or later-line treatment with anti-EGFR antibodies in patients with metastatic colorectal cancer: A single-center cohort study.

AUTHOR(S)

Anita Archwamety, Naravat Pongvarin, Charuwan Akewanlop, Krittiya Korphaisarn

ABSTRACT

3541

Multi-omics characterization of left-right colorectal cancer.

AUTHOR(S)

John Marshall, Takayuki Yoshino, Sun Y. Rha, David N. Church, Anelisa K. Coutinho, Carlos A. Sampaio-Filho, David J. Gallagher, Jesús García-Foncillas, Silvia von der Heyde, Hartmut Juhl, Jonathan Woodsmith, David J. Kerr

ABSTRACT

3542

Genome-wide analysis indicating cancer associated fibroblast (CAF) impacts on colorectal cancer (CRC) prognosis via immunosuppression.

AUTHOR(S)

Yu-feng Chen, Xiaojian Wu, Feng Gao

ABSTRACT

3543

***NTRK* fusion positive colorectal cancer as a unique subset of CRC with high tumor mutation burden and microsatellite instability.**

AUTHOR(S)

Hui WANG, Qiuxiang Ou, Xue Wu, Misako Nagasaka, Sai-Hong I. Ou, Yang Shao

ABSTRACT

3544

A panel of DNA methylation markers for the classification of consensus molecular subtypes 2 and 3 in patients with colorectal cancer.

AUTHOR(S)

Inge van Den Berg, Marcel Smid, Robert R. Coebergh van den Braak, Mark A. van de Wiel, Carolien H. Van Deurzen, Vanja de Weerd, John W. Martens, Jan N. IJzermans, Saskia M. Wilting

ABSTRACT

3545

Clinical performance of methylation-based liquid biopsy test COLVERA after optimization of test interpretation rules.

AUTHOR(S)

Zivjena Vucetic, Naima Loayza, Susanne K. Pedersen, Missy Tuck, Lawrence C. LaPointe

ABSTRACT

3546

Effect of Medicaid expansion on incidence of early-onset colorectal cancer incidence among Hispanics.

AUTHOR(S)

Shafia Rahman, Riya J. Patel, Jianyou Liu, Ana Acuna-Villaorduna, Mimi Kim, Sanjay Goel

ABSTRACT

3547

PMC: A more precise classifier of POLE mutations to identify candidates for immune therapy.

AUTHOR(S)

Fadi Zeineddine, Benjamin Garmez, Timothy A. Yap, John Paul Y. Shen

ABSTRACT

3548

Are current family-history based colorectal cancer screening guidelines adequate for early detection and potential prevention of young-onset cases?

AUTHOR(S)

Y. Nancy You, Miguel A. Rodriguez-Bigas, George J. Chang, Brian K. Bednarski, John M. Skibber, Maureen E. Mork, Julie B. Moskowitz, Sa T. Nguyen, Selvi Thirumurthi, Patrick M. Lynch, Scott Kopetz, Eduardo Vilar Sanchez

ABSTRACT

3549

A nationwide analysis of outcomes and healthcare utilization in HIV versus non-HIV patients with colon cancer.

AUTHOR(S)

Syed Ali A. Sherazi, Ikechukwu Achebe, Yaseen Alkaddoumi, Jennifer C. Asotibe, Bashar Attar, Shweta Gupta, Michael R. Mullane

ABSTRACT

3550

Investigating intra-tumor microbes, blood microbes, and CEA for development of non-invasive biomarkers in colorectal cancer.

AUTHOR(S)

Pannaga G. Malalur, Xiaokui Mo, Rebecca Hoyd, John L. Hays, David P. Carbone, Daniel Spakowicz

ABSTRACT

3551

Consensus molecular subtypes and RAS status as biomarker of treatment intensity with fluoropyrimidine, bevacizumab, and irinotecan in metastatic colorectal cancer (XELAVIRI, AIO KRK 0110).

AUTHOR(S)

Arndt Stahler, Volker Heinemann, Veronika Schuster, Annabel H. Alig, Laura E. Fischer, Lena Weiss, Kathrin Heinrich, Annika Kurreck, Ivan Jelas, Jobst C. von Einem, Clemens Giessen-Jung, Ludwig Fischer von Weikersthal, Ursula Vehling-Kaiser, Thomas Decker, Jens Neumann, Thomas Kirchner, Andreas Jung, Joerg Kumbrink, Sebastian Stintzing, Dominik P. Modest

ABSTRACT

3552

FOLFOX plus panitumumab or FOLFOX alone as additive therapy following R0/1 resection of RAS wild-type colorectal cancer liver metastases: The PARLIM trial (AIO KRK 0314).

AUTHOR(S)

Dominik P. Modest, Meinolf Karthaus, Stefan Kasper, Nicolas Moosmann, Verena Keitel, Alexander Kiani, Ludwig Fischer von Weikersthal, Jens Uhlig, Lutz Jacobasch, Martin Fuchs, Florian Kaiser, Christian A. Lerchenmuller, Christian Junghanss, Swantje Held, Kathrin Heinrich, Andreas Jung, Arndt Stahler, Sebastian Stintzing, Volker Heinemann

ABSTRACT

3553

Impact of a metastatic site on circulating tumor DNA (ctDNA) analysis in patients (pts) with metastatic colorectal cancer (mCRC).

AUTHOR(S)

Hideaki Bando, Yoshiaki Nakamura, Hiroya Taniguchi, Manabu Shiozawa, Hisateru Yasui, Taito Esaki, Takashi Ohta, Tadamichi Denda, Taroh Satoh, Kentaro Yamazaki, Yu Sunakawa, Takeshi Kato, Masahiro Goto, Satoshi Yuki, Tomohiro Nishina, Eiji Oki, Eiji Shinozaki, Nobuhisa Matsuhashi, Masayuki Hata, Takayuki Yoshino

ABSTRACT

3554

Pertuzumab plus trastuzumab and real-world standard of care (SOC) for patients (pts) with treatment refractory metastatic colorectal cancer (mCRC) with *HER2* (*ERBB2*) amplification (amp) confirmed by tumor tissue or ctDNA analysis (TRIUMPH, EPOC1602).

AUTHOR(S)

Wataru Okamoto, Yoshiaki Nakamura, Takeshi Kato, Taito Esaki, Masato Komoda, Ken Kato, Yoshito Komatsu, Toshiki Masuishi, Tomohiro Nishina, Kentaro Sawada, Hiroya Taniguchi, Nozomu Fuse, Shogo Nomura, Makoto Fukui, Steven R. Olsen, Justin I. Odegaard, Akihiro Sato, Satoshi Fujii, Atsushi Ohtsu, Takayuki Yoshino

ABSTRACT

3555

Repeat sequential oxaliplatin-based chemotherapy (FLOX) and nivolumab versus FLOX alone as first-line treatment of microsatellite-stable (MSS) metastatic colorectal cancer (mCRC): Initial results from the randomized METIMMOX study.

AUTHOR(S)

Anne H. Ree, Hanne Hamre, Christian Kersten, Eva Hofslø, Marianne G. Guren, Halfdan Sorbye, Christin Johansen, Anne Negård, Kjersti Flatmark, Sebastian Meltzer

ABSTRACT

3556

Impact of BRAF mutations on prognosis and immunotherapy response in microsatellite instability/mismatch repair deficient metastatic colorectal cancer: A systematic review and meta-analysis.

AUTHOR(S)

Robin Park, Laércio Lopes da Silva, Sunggon Lee, Anwaar Saeed

ABSTRACT

3557

Phase II study of panitumumab monotherapy in chemotherapy-naïve frail or elderly patients with unresectable, *RAS* wild type colorectal cancer: OGSF 1602, survival update data.

AUTHOR(S)

Shingo Noura, Takeshi Kato, Tetsuji Terazawa, Masahiro Goto, Katsuya Ohta, Hironaga Satake, Yoshinori Kagawa, Hisato Kawakami, Hiroko Hasegawa, Kazuhiro Yanagihara, Tatsushi Shingai, Ken Nakata, Masahito Kotaka, Masayuki Hiraki, Ken Konishi, Shiro Nakae, Daisuke Sakai, Yukinori Kurokawa, Toshio Shimokawa, Taroh Satoh

ABSTRACT

3558

Phase Ib/II open-label, randomized evaluation of atezolizumab (atezo) + Imprime PGG (Imprime) + bevacizumab (bev) vs regorafenib (rego) in MORPHEUS: Microsatellite-stable (MSS) metastatic colorectal cancer (mCRC).

AUTHOR(S)

Marwan Fakih, James M. Cleary, Yong Sang Hong, Tae-You Kim, Rachael A. Safyan, Simon Allen, Lorna Bailey, Edward Cha, Christelle Lenain, Danny Lu, Jochen Schulze, Colby S. Shemesh, Stefan Zimmermann

ABSTRACT

3559

Single-arm, phase 2 study of regorafenib plus nivolumab in patients with mismatch repair-proficient (pMMR)/microsatellite stable (MSS) colorectal cancer (CRC).

AUTHOR(S)

Marwan Fakih, Kanwal P. Raghav, David Z. Chang, Johanna C. Bendell, Timothy Larson, Allen L. Cohn, Timothy K. Huyck, David Cosgrove, Joseph A. Fiorillo, Lawrence E. Garbo, Shruthi Ravimohan, Von Potter, David D'Adamo, Neelesh Sharma, Ying A. Wang, Sabine Coppieters, Matthias Herpers, Carolina Soares Viana de Oliveira, Andrew S. Paulson

ABSTRACT

3560

Concurrent BRAFV600E and BRCA mutations in microsatellite stable (MSS) metastatic colorectal cancer (mCRC): Prevalence and case series of mCRC (pts) with prolonged overall survival (OS).

AUTHOR(S)

Timothy L. Cannon, Jamie Randall, Ethan Sokol, Sonja Alexander, Raymond C. Wadlow, Daniel Barnett, Danny Rayes, John F. Deeken, Halla Nimeiri, Kimberly McGregor

ABSTRACT

3561

Increased neutrophil infiltration and lower prevalence of tumor mutation burden and microsatellite instability are hallmarks of RAS mutant colorectal cancers.

AUTHOR(S)

Emil Lou, Yasmine Baca, Joanne Xiu, Andrew Nelson, Subbaya Subramanian, Mohamed E. Salem, Muhammad S. Beg, Elisa Fontana, Maria Diab, Philip A. Philip, Richard M. Goldberg, Ritu Pandey, Tobias Arkenau, Weijing Sun, Heinz-Josef Lenz, Anthony F. Shields, Wafik S. El-Deiry, Wolfgang M. Korn

ABSTRACT

3563

LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the colorectal cancer cohort.

AUTHOR(S)

Carlos A. Gomez-Roca, Eduardo Yanez, Seock-Ah Im, Eduardo Castanon Alvarez, Hélène Senellart, Mark Doherty, Javier Garcia-Corbacho, Juanita S. Lopez, Bristi Basu, Corinne Maurice-Dror, Sanjeev S. Gill, Razi Ghori, Peter Kubiak, Fan Jin, Kevin G. Norwood, Hyun Cheol C. Chung

ABSTRACT

3564

Circulating tumor derived cell-free DNA (ctDNA) to predict recurrence of metastatic colorectal cancer (mCRC) following curative intent surgery or radiation.

AUTHOR(S)

Bryant Chee, Faaiz Ibrahim, Mikaela Esquivel, Emily E. Van Seventer, Joy X. Jarnagin, Li Zhang, Jin H. Ju, Kristin S. Price, Victoria M. Raymond, Carlos U. Corvera, Kenzo Hirose, Eric K. Nakakura, Katherine Van Loon, Ryan B. Corcoran, Aparna R. Parikh, Chloe E. Atreya

ABSTRACT

3565

RAMucirumab in combination with TAS102 versus TAS102 monotherapy in metastatic colorectal cancer: Safety results from the phase IIb part of the RAMTAS phase II/III trial of the German AIO (AIO-KRK-0316).

AUTHOR(S)

Stefan Kasper, Thorsten O. Goetze, Sebastian Stintzing, Ralf D. Hofheinz, Marianne Sinn, Tobias N. Dechow, Thomas J. Ettrich, Verena Keitel, Ullrich Graeven, Ludwig Fischer von Weikersthal, Alexander Kolov, Thomas Edelmann, Alexander Stein, Tanja Trarbach, Sabine Junge, Claudia Pauligk, Isabel Virchow, Jens T. Siveke, Salah-Eddin Al-Batran, Martin H. Schuler

ABSTRACT

3566

Neoadjuvant chemotherapy improves colon cancer survival in resectable metastatic colon cancer: A real world NCDB data analysis.

AUTHOR(S)

Saurabh Parasramka, Aasems Jacob, Quan Chen, Bin Huang, Zhonglin Hao

ABSTRACT

3567

Influence of dietary insulin scores on survival in patients with metastatic colorectal cancer (mCRC): Findings from CALGB (Alliance) 80405.

AUTHOR(S)

Katherine DiNardo, Chao Ma, Fang-Shu Ou, Chen Yuan, Brendan J. Guercio, Vicente Morales-Oyarvide, Erin Van Blarigan, Donna Niedzwiecki, I-Wen Chang, Heinz-Josef Lenz, Charles D. Blanke, Alan P. Venook, Robert J. Mayer, Charles S. Fuchs, Federico Innocenti, Andrew B. Nixon, Richard M. Goldberg, Eileen M. O'Reilly, Jeffrey A. Meyerhardt, Kimmie Ng

ABSTRACT

3568

Exploratory biomarker findings from cohort 2 of MODUL: An adaptable, phase 2, signal-seeking trial of fluoropyrimidine + bevacizumab ± atezolizumab maintenance therapy for BRAF^{wt} metastatic colorectal cancer.

AUTHOR(S)

Josep Tabernero, Axel Grothey, Dirk Arnold, Michel Ducreux, Peter J. O'Dwyer, Maurizio Perdicchio, Alexander Abbas, Meghna Das Thakur, Natsumi Irahara, Anila Tahiri, Hans-Joachim Schmoll, Eric Van Cutsem

ABSTRACT

3570

Treatment responses and disease dynamics in patients with untreated metastatic colorectal cancer receiving bevacizumab-based sequential versus combination chemotherapy: Analysis of a phase 3 trial (AIO KRK0110, XELAVIRI study).

AUTHOR(S)

Annika Kurreck, Volker Heinemann, Ludwig Fischer von Weikersthal, Thomas Decker, Florian Kaiser, Jens Uhlig, Michael Schenk, Jens Freiberg-Richter, Bettina Peuser, Claudio Denzlinger, Ullrich Graeven, Kathrin Heinrich, Swantje Held, Arndt Stahler, Annabel H. Alig, Ivan Jelas, Jobst C. von Einem, Sebastian Stintzing, Clemens Giessen-Jung, Dominik P. Modest

ABSTRACT

3571

Serial circulating tumor DNA (ctDNA) monitoring in metastatic colorectal cancer (mCRC) reveals dynamic profile of actionable alterations.

AUTHOR(S)

Jonathan M. Loree, Jason Henry, Kanwal P. Raghav, Christine M. Parseghian, Kimberly Banks, Victoria M. Raymond, Rebecca Nagy, Chuck Hensel, John H. Strickler, Ryan B. Corcoran, Michael J. Overman, AmirAli Talasaz, Scott Kopetz

ABSTRACT

3572

Efficacy and safety of vactosertib and pembrolizumab combination in patients with previously treated microsatellite stable metastatic colorectal cancer.

AUTHOR(S)

Tae Won Kim, Keun Wook Lee, Joong Bae Ahn, Jin Lee, Jiyeon Ryu, Bitna Oh, Chan-Young Ock, Sunjin Hwang, Ki Baik Hahm, Seong-Jin Kim, Young Suk Park

ABSTRACT

3573

Safety and pharmacokinetic analysis of *UGT1A1* genotype-guided dosing of irinotecan.

AUTHOR(S)

Emma C. Hulshof, Mirjam de With, Femke M. de Man, Geert-Jan Creemers, Birgit A. Deiman, Jesse J. Swen, Saskia Houterman, Stijn L. Koolen, Marjan Laven, Saskia Luelfmo, Ron H. van Schaik, Henk-jan Guchelaar, Ron H. Mathijssen, Hans Gelderblom, Maarten J. Deenen

ABSTRACT

3574

Characteristics of patients (pts) and prognostic factors across treatment lines (TL) in metastatic colorectal cancer (mCRC): An analysis from the Analysis and Research in Cancers of the Digestive System (ARCAD) database.

AUTHOR(S)

Jean-Baptiste Bachet, Benoist Chibaudel, Manel Rakez, Richard M. Goldberg, Niall C. Tebbutt, Eric Van Cutsem, Daniel G. Haller, J. Randolph R. Hecht, Robert J. Mayer, Stuart M. Lichtman, Al Benson, Alberto F. Sobrero, Josep Tabernero, Richard Adams, John R. Zalberg, Axel Grothey, Takayuki Yoshino, Qian Shi, Aimery De Gramont

ABSTRACT

3575

Liquid biopsy-driven anti-EGFR rechallenge in patients with metastatic colorectal cancer.

AUTHOR(S)

Stefano Mariani, Marco Puzzoni, Nicole Liscia, Valentino Impera, Andrea Pretta, Simona Tolu, Anna Grazia Pireddu, Mara Persano, Francesca Musio, Clelia Donisi, Giovanna Pinna, Eleonora Lai, Laura Demurtas, Pina Ziranu, Valeria Pusceddu, Marina Pisano, Grazia Palomba, Milena Casula, Giuseppe Palmieri, Mario Scartozzi

ABSTRACT

3577

Final results from the CAVE (cetuximab rechallenge plus avelumab) mCRC phase II trial: Skin toxicity as a predictor of clinical activity.

AUTHOR(S)

Giulia Martini, Stefania Napolitano, Vincenzo Famiglietti, Filippo G. De Braud, Marinella Terminiello, Carola Borrelli, Pietro Paolo Vitiello, Antonio Avallone, Nicola Normanno, Evaristo Maiello, Alfredo Falcone, Giuseppe Santabarbara, Carmine Pinto, Daniele Santini, Alessandra Di Liello, Daniela Renato, Lucia Esposito, Francesca Marrone, Teresa Troiani, Davide Ciardiello

ABSTRACT

3578

Circulating tumor DNA and circumferential resection margin as key prognostic indicators for survival in rectal cancer.

AUTHOR(S)

Mia Shepherdson, Erin L. Symonds, Susan Byrne, Kirsten Gormly, Christos S. Karapetis, Sina Vatandoust, Graeme P. Young, Amitesh C. Roy

ABSTRACT

3579

Parameters associated with outcomes in pretreated MSI/dMMR metastatic colorectal cancer (mCRC) treated with immune checkpoint inhibitors (ICI): Subgroup analysis of a prospective cohort.

AUTHOR(S)

Raphael Colle, Marine Cachanado, Alexandra Rousseau, Magali Svrcek, Yves Menu, Romain Cohen, Thierry Andre

ABSTRACT

3580

The role of PP2A variants to predict outcome in patients (pts) with metastatic colorectal cancer (mCRC): Data from FIRE-3 and TRIBE trials.

AUTHOR(S)

Jingyuan Wang, Joshua Millstein, Fotios Loupakis, Sebastian Stintzing, Hiroyuki Arai, Francesca Battaglin, Natsuko Kawanishi, Priya Jayachandran, Shivani Soni, Wu Zhang, Christoph Mancao, Chiara Cremolini, Volker Heinemann, Alfredo Falcone, Heinz-Josef Lenz

ABSTRACT

3581

The prognostic impact of *RAS* and *TP53* mutation according to primary tumor location in colorectal liver metastases.

AUTHOR(S)

Yongjun Cha, Bun Kim, Seung Jae Roh, Moon Ki Choi, Dong Woon Lee, Sung-Sik Han, Seong Hoon Kim, Sang-Jae Park, Ji Yeon Baek, Sung Chan Park, Hee Jin Chang, Jae Hwan Oh

ABSTRACT

3582

Overall survival (OS) with encorafenib (enco) + cetuximab (cetux) in BEACON CRC: Effect of prior therapy for *BRAF* V600E-mutant metastatic colorectal cancer (mCRC).

AUTHOR(S)

Scott Kopetz, Dan Aderka, Axel Grothey, Eric Van Cutsem, Rona Yaeger, Harpreet S. Wasan, Takayuki Yoshino, Jayesh Desai, Fortunato Ciardiello, Ashwin Gollerkeri, Adele Golden, Michelle L. Edwards, Josep Tabernero

ABSTRACT

3583

A phase 1 first-in-human study of the anti-LAG-3 antibody MK4280 (favezelimab) plus pembrolizumab in previously treated, advanced microsatellite stable colorectal cancer.

AUTHOR(S)

Elena Garraalda, Ammar Sukari, Nehal J. Lakhani, Amita Patnaik, Yanyan Lou, Seock-Ah Im, Talia Golan, Ravit Geva, Martin Wermke, Maria De Miguel, John Palcza, Sujata Jha, Marya F. Chaney, Jane A. Healy, Gerald S. Falchook

ABSTRACT

3584

Differential impact of different TP53 gain-of-function mutations on overall survival of patients with metastatic colorectal cancer: Results from a large integrated healthcare system.

AUTHOR(S)

Minggui Pan, Chen Jiang, Pamela Tse, Elaine Chung, Aleyda Solorzano, Wenwei Hu, Thach-Giao Truong, Amit Arora, Tilak K. Sundaresan, Jennifer Marie M. Suga, Laurel A. Habel, Sachdev P. Thomas

ABSTRACT

3585

Mucinous colorectal cancer: Disease characteristics, treatment outcomes and the impact of metastasectomy.

AUTHOR(S)

Darren Cowzer, Emily Harrold, Jane S. Sui, Mairi Lucas, Helen M. Fenlon, Karen C. Redmond, Donna Eaton, John B. Conneely, Gerry P. McEntee, Ann E. Brannigan, Conor J. Shields, Jurgen Mulsow, Catherine M. Kelly, Megan Greally, John McCaffrey

ABSTRACT

3586

Young-onset colorectal cancer treatment side effects: Infertility, sexual dysfunction, and quality-of-life outcomes.

AUTHOR(S)

Laura D. Porter, Ronit Yarden, Kim L. Newcomer, Negeen Fathi

ABSTRACT

3587

Dietary fat in relation to overall and progression-free survival among patients (pts) with advanced or metastatic colorectal cancer (CRC): Data from CALGB 80405 (Alliance).

AUTHOR(S)

Erin Van Blarigan, Chao Ma, Fang-Shu Ou, Alan P. Venook, Kimmie Ng, Donna Niedzwiecki, Edward L. Giovannucci, Heinz-Josef Lenz, Federico Innocenti, James E. Shaw, Blase N. Polite, Howard S. Hochster, Richard M. Goldberg, Robert J. Mayer, Eileen M. O'Reilly, Charles S. Fuchs, Jeffrey A. Meyerhardt

ABSTRACT

3588

Assessment of HER2 (*ERBB2*) amplification (HER2amp) using blood-based circulating tumor DNA (ctDNA) next generation sequencing (NGS) and correlation with tissue-based testing in metastatic colorectal cancer (mCRC).

AUTHOR(S)

Kanwal P. Raghav, Yoshiaki Nakamura, Silvia Marsoni, John H. Strickler, Rona Yaeger, Aakash T. Shah, Wataru Okamoto, Giovanni Crisafulli, Rebecca Nagy, Victoria M. Raymond, Mark Routbort, Salvatore Siena, Ryan B. Corcoran, Alberto Bardelli, Scott Kopetz, Takayuki Yoshino

ABSTRACT

3589

XELOX or mFOLFOX6 chemotherapy combined with resection of primary lesion versus chemotherapy alone for colon cancer with unresectable metastases: A randomized clinical trial.

AUTHOR(S)

Weijian Guo, Xinxiang Li, Mingzhu Huang, Ya'nan Yang, Qingguo Li, Chenchen Wang, Lei Liang, Xiaodong Zhu, Wen Zhang, Zhiyu Chen, Wenhua Li, Xiaowei Zhang, Xiaoying Zhao, Lixin Qiu, Qirong Geng, Xuedan Sheng

ABSTRACT

3590

Association of plasma adiponectin with tumor infiltrating lymphocytes and survival in patients with stage III colon cancer (NCCTG N0147; Alliance).

AUTHOR(S)

Frank A. Sinicrope, Qian Shi, Thomas C. Smyrk, Richard M. Goldberg, Steven J. Cohen, Sharlene Gill, Morton S. Kahlenberg, Suresh Nair, Anthony F. Shields, Balkrishna N. Jahagirdar, Sawyer B. Jacobson, Nathan R. Foster, Michael N. Pollak, Steven R. Alberts

ABSTRACT

3591

Young-onset colorectal: Emotional and psychosocial effects on patients, survivors, and caregivers.

AUTHOR(S)

Laura D. Porter, Ronit Yarden, Kim L. Newcomer

ABSTRACT

3592

Doublet (FOLFOX or FOLFIRI) versus triplet (FOLFOXIRI) backbone chemotherapy regimen as first-line treatment of metastatic colorectal cancer: A meta-analysis and systematic review.

AUTHOR(S)

Vishal Jindal, Ruby Gupta, Kamal K. Sahu, Mandeep Singh Rahi, Michael J. Stender, Ishmael A. Jaiyesimi

ABSTRACT

3593

A novel clinical tool to estimate risk of false negative KRAS mutation in circulating tumor DNA testing.

AUTHOR(S)

Stefania Napolitano, Ryan Sun, Aparna R. Parikh, Jason Henry, Christine M. Parseghian, Jason Willis, Kanwal P. Raghav, Van K. Morris II, Arvind Dasari, Michael J. Overman, Rajyalakshmi Luthra, Ryan B. Corcoran, Scott Kopetz

ABSTRACT

3594

Impact of time to treatment initiation on real-world (RW) outcomes in metastatic colorectal cancer (mCRC) in the United States.

AUTHOR(S)

Olumide B. Gbolahan, Darryl A. Outlaw, Neda Hashemi, Ravi K. Paluri, Grant R. Williams

ABSTRACT

3595

Real-world survival outcomes associated with completion of adjuvant chemotherapy for stage III colon cancer.

AUTHOR(S)

Jemma M. Boyle, Angela Kuryba, Thomas E. Cowling, Jan van der Meulen, Nicola S. Fearnhead, Kate Walker, Michael Braun, Ajay Aggarwal

ABSTRACT

3596

Clinicopathological and molecular characteristics of early-onset stage III colon adenocarcinoma: An analysis of 25 studies with 35,713 patients in the Adjuvant Colon Cancer End Points (ACCENT) database.

AUTHOR(S)

Zhaohui Jin, Jesse G. Dixon, Hiral Parekh, Frank A. Sinicrope, Greg Yothers, Daniel G. Haller, Hans Schmoll, Aimery De Gramont, Rachel Kerr, Julien Taieb, Eric Van Cutsem, Chris Twelves, Leonard B. Saltz, Naohiro Tomita, Takayuki Yoshino, Thierry Andre, Amit Mahipal, Richard M. Goldberg, Thomas J. George, Qian Shi

ABSTRACT

3597

Clinical efficacy and safety of early adjuvant chemotherapy for stage III colon cancer: Short-term outcomes of a multicenter, randomized, open-label, phase 3 trial.

AUTHOR(S)

Jun Seok Park, Soo Yeun Park, Gyu-Seog Choi, Hye Jin Kim, Jong Gwang Kim, Byung Woog Kang, In Kyu Lee, Yoon Suk Lee, Sohyun Kim, Seong Kyu Baek, Gyung Mo Son, Ki Beom Bae, Ji Yeon Kim, Kyung-ha Lee

ABSTRACT

3598

Patient-specific meta-analysis of 3 validation studies of the 12-gene colon cancer recurrence score assay for recurrence risk assessment after surgery with or without 5FU and oxaliplatin.

AUTHOR(S)

Greg Yothers, Alan P. Venook, Takeharu Yamanaka, Yan Lin, Michael Crager, Calvin Y. Chao, Frederick L. Baehner, Takayuki Yoshino

ABSTRACT

3599

Prognostic value of baseline and early changes of circulating-free (cf) and circulating tumor (ct) DNA in the neoadjuvant (NA) setting of early stage colon cancer (CC).

AUTHOR(S)

Giacomo Bregni, Chiara Senti, Caroline Vandeputte, Elena Acedo Reina, Paraskevas Gkolfakis, Jean-Luc Van Laethem, Philippe Vergauwe, Marc Van Den Eynde, Jos Janssens, Gauthier Demolin, Stephane Holbrechts, Marylene Clausse, Thierry De Grez, Lionel A. D'Hondt, Karen P. Geboes, Tatiana Besse-Hammer, Francoise Rothe, Patrick Flamen, Alain Hendlitz, Francesco Sclafani

ABSTRACT

3600

Association of suboptimal lymph node yield with inferior survival in resected stage 1 colon cancer patients.

AUTHOR(S)

Alexander C. Chacon, Alexa D. Melucci, Nicholas A. Ullman, Paul Burchard, Anthony S. Casabianca, Alexandra Reitz, David A. Swift, Vasileios Tsagkalidis, Jeffrey M. Switchenko, Subir Goyal, Darren R. Carpizo, Mihir M. Shah

ABSTRACT

3601

Phase I study of transarterial chemoembolization of lung metastases.

AUTHOR(S)

Franz E. Boas, Nancy E. Kemeny, Constantinos T. Sofocleous, Randy Yeh, Vanessa R. Thompson, Meier Hsu, Chaya S. Moskowitz, Etay Ziv, Hooman Yarmohammadi, Achiude Bendet, Stephen B. Solomon

ABSTRACT

3602

Long-term outcome of a phase III trial on neoadjuvant chemoradiation with capecitabine and irinotecan in patients with locally advanced rectal cancer: Updated results of the CinClare trial.

AUTHOR(S)

Ji Zhu, Xinchun Sun, Anwen Liu, Yaqun Zhu, Tao Zhang, Luying Liu, Jianhui Jia, Shisheng Tan, Junxin Wu, Xin Wang, Juying Zhou, Jialin Yang, Chen Zhang, Hongyan Zhang, Xinjia He, Gang Cai, Wei Zhang, Sanjun Cai, Zhen Zhang

ABSTRACT

3603

Impact of radiotherapy for local control in T3 N0 rectal cancer managed with total mesorectal excision: A systematic review and meta-analysis.

AUTHOR(S)

Jesus C. Fabregas, Andrew Bang, Michael Tjong, Michael Kucharczyk

ABSTRACT

3604

H101 treatment of hepatic metastasis of colorectal cancer with recombinant human adenovirus 5 injection: A phase I clinical trial-TROJAN 021.

AUTHOR(S)

Yang He, Jianhua Chen, Zhongzheng Zhu, Song Gao, Hui Wang, Wei Mao, Hong Qian, Weixing Liu, Xianling Guo, Huanlong Qing, Qing Xu

ABSTRACT

3605

Accurate early-stage colorectal cancer detection through analysis of cell-free circulating tumor DNA (ctDNA) methylation patterns.

AUTHOR(S)

James M. Kinross, Pol Canal-Noguer, Marko Chersicola, Primož Knap, Marko Bitenc, Alexandre Perera-Lluna, Michael H. Roehrl, Kristi Kruusmaa

ABSTRACT

3606

A phase II study of capecitabine plus concomitant radiation therapy followed by durvalumab (MEDI4736) as preoperative treatment in rectal cancer: PANDORA study first-stage.

AUTHOR(S)

Stefano Tamberi, Elisa Grassi, Jody Corbelli, Giorgio Papiani, Maria a. Barbera, Chiara Zingaretti, Chiara Carli Moretti, Isacco Montroni, Elisabetta Petracci, Dora Caruso, Sofia Nosseir, Oriana Nanni, Giovanni Luca Frassinetti, Maria Di Bartolomeo, Marina Marzola, Andrea Bonetti, Fabio Gelsomino, Carmine Pinto, Davide Tassinari, Giampaolo Ugolini

ABSTRACT

3607

Minimal residual disease by circulating tumor DNA analysis for colorectal cancer patients receiving radical surgery: An initial report from CIRCULATE-Japan.

AUTHOR(S)

Hiroki Yukami, Yoshiaki Nakamura, Jun Watanabe, Masahito Kotaka, Kentaro Yamazaki, Keiji Hirata, Yasunori Emi, Mitsuru Yokota, Kentaro Kato, Tatsuro Yamaguchi, Masataka Ikeda, Alexey Aleshin, Daisuke Kotani, Saori Mishima, Hiromichi Shirasu, Eiji Oki, Ichiro Takemasa, Takeshi Kato, Hiroya Taniguchi, Takayuki Yoshino

ABSTRACT

3608

Pharmacologic ascorbate enhances the therapeutic index of ATM-inhibitor based chemoradiation for colorectal cancer.

AUTHOR(S)

Cameron Callaghan, Ibrahim Abukhiran, Richard VanRheeden, Michael Petronek, Kranti Mapuskar, Md Yousuf Ali, Amanda Kalen, Samuel Rodman, Steven N. Seyedin, Joseph J. Cullen, Mitchell Coleman, John M. Buatti, Prabhat Goswami, Bryan G. Allen, Douglas Spitz, Joseph M. Caster

ABSTRACT

3609

Evaluating longitudinal toxicity of cetuximab in patients with metastatic colorectal cancer (mCRC): A pooled analysis from 1,302 patients in the ARCAD database.

AUTHOR(S)

Guilherme Lopes, Jane Y. So, Katrin M. Sjoquist, Curtis L. Olswold, Eric Van Cutsem, Carsten Bokemeyer, Richard Adams, Benoist Chibaudel, Axel Grothey, Takayuki Yoshino, Aimery De Gramont, Qian Shi, Christophe Tournigand, John R. Zalberg

ABSTRACT

3610

Influence of preoperative chemoradiation on tumor-infiltrating lymphocytes in locally advanced rectal cancer: The STAR-01 cohort.

AUTHOR(S)

Francesca Negri, Letizia Gnetti, Lorena Bottarelli, Nicoletta Campanini, Maria Emanuela Negru, Francesca Bergamo, Salvatore Siena, Michela Frisinghelli, Marija Petric, Germana Chiaulon, Valeria Smiroldo, Domenico C. Corsi, Giulia A. Vita, Enrico M. Silini, Cinzia Azzoni, Federica Gaiani, Luigi Laghi, Gian Luigi de'Angelis, Luca Boni, Carlo Aschele

ABSTRACT

3611

Impact of the COVID-19 pandemic in treating gastrointestinal (GI) cancer patients receiving systemic anticancer treatment (SACT): The Guy's Cancer Centre experience.

AUTHOR(S)

Jose Roca, Ailsa Sita-Lumsden, Eirini Tsotra, Charalampos Gousis, Beth Russell, Charlotte Moss, Victoria Harris, Kasia Owczarczyk, Julien De Naurois, Nicholas R. Maisey, Sarah Ngan, Debashis Sarker, Kiruthikah Thillai, Vasiliki Michalarea, Asad Qureshi, Imran Petkar, Anne S. Rigg, Mieke Van Hemelrijck, Paul J. Ross, Saoirse Dolly

ABSTRACT

3612

Multi-omics longitudinal analyses in stages I to III CRC patients: Surveillance liquid biopsy test to predict early recurrence and enable risk-stratified postoperative CRC management.

AUTHOR(S)

Xuanhui Liu, Yani Zhang, Xiurui Zhu, Sheeno P. Thyparambil, Wei-Li Liao, Xiao-bin Zheng, Jin You, Ashiq Masood, Zhen Li, Gabriel Yang, Xiaoming Yao, Shiyong Hao, Robert Heaton, James Schilling, Karl G. Sylvester, Jiayu Liao, Feng Gao, Ping Lan, Xuefeng Ling, Xiaojian Wu

ABSTRACT

3613

A randomized phase III study of immune checkpoint inhibition with chemotherapy in treatment-naïve metastatic anal cancer patients: A trial of the ECOG-ACRIN cancer research group (EA2176).

AUTHOR(S)

Marc T. Roth, Paul J. Catalano, Kristen K. Ciombor, Al B. Benson III, Xin Yao, Rona Yaeger, Mohamed E. Salem, Van K. Morris II, David H. Henry, Jennifer G. Whisenant, Peter J. O'Dwyer, Cathy Eng

ABSTRACT

TPS3614

Total neoadjuvant treatment versus standard chemoradiation to increase the sphincter preservation rate for distal locally advanced rectal cancer (TESS).

AUTHOR(S)

Weiwei Xiao, Xiaojun Wu, Peiqiang Cai, YeZhong Zhuang, Xiaozhong Wang, Shoumin Bai, Qiaoxuan Wang, Yijing Ye, Qing Liu, Min Liu, Shuang Liu, ZhiFan Zeng, Zhi-Zhong Pan, Yuanhong Gao, Gong Chen

ABSTRACT

TPS3615

PERSPECTIVE: Tepotinib + cetuximab in patients (pts) with *RAS/BRAF* wild-type left-sided metastatic colorectal cancer (mCRC) and acquired resistance to anti-EGFR antibody therapy due to *MET* amplification (*METamp*).

AUTHOR(S)

Tanios S. Bekaii-Saab, Eric Van Cutsem, Antonio Cubillo, Caroline Petorin-Lesens, Nuria Rodriguez-Salas, Kanwal P. Raghav, Olivier Dupuis, Carlos López-López, Christophe Tournigand, Nicolas Isambert, Khalid Abubaker, Karl-Maria Schumacher, Karin Berghoff, Soetkin Vlassak, Gordon Otto, Josep Tabernero

ABSTRACT

TPS3616

Colorectal Cancer Metastatic dMMR Immuno-Therapy (COMMIT) Study: A randomized phase III study of atezolizumab (atezo) monotherapy versus mFOLFOX6/bevacizumab/atezo in the first-line treatment of patients (pts) with deficient DNA mismatch repair (dMMR) or microsatellite instability high (MSI-H) metastatic colorectal cancer (mCRC)—NRG-GI004/SWOG-S1610.

AUTHOR(S)

Michael J. Overman, Greg Yothers, Samuel A. Jacobs, Hanna K. Sanoff, Deirdre J. Cohen, Katherine A. Guthrie, Norah L. Henry, Patricia A. Ganz, Scott Kopetz, Peter C. Lucas, Charles D. Blanke, Norman Wolmark, Howard S. Hochster, Thomas J. George, Caio Max S. Rocha Lima

ABSTRACT

TPS3618

BREAKWATER: Randomized phase 3 study of encorafenib (enco) + cetuximab (cetux) ± chemotherapy for first-line (1L) treatment (tx) of *BRAF* V600E-mutant (*BRAF*^{V600E}) metastatic colorectal cancer (mCRC).

AUTHOR(S)

Scott Kopetz, Axel Grothey, Rona Yaeger, Fortunato Ciardiello, Jayesh Desai, Tae Won Kim, Tim Maughan, Eric Van Cutsem, Harpreet S. Wasan, Takayuki Yoshino, Michelle L. Edwards, Adele Golden, Ashwin Gollerkeri, Josep Tabernero

ABSTRACT

TPS3619

Trastuzumab deruxtecan in patients with HER2-overexpressing locally advanced, unresectable, or metastatic colorectal cancer (mCRC): A randomized, multicenter, phase 2 study (DESTINY-CRC02).

AUTHOR(S)

Kanwal P. Raghav, Takayuki Yoshino, Rosine Guimbaud, Ian Chau, Marc Van Den Eynde, Joan Maurel, Jeanne Tie, Tae Won Kim, Kun-Huei Yeh, Daniel Barrios, Kojiro Kobayashi, Emarjola Bako, Mehreteab Aregay, Gerold Meinhardt, Salvatore Siena

ABSTRACT

TPS3620

JCOG1805 (PanDRa-BD study): A randomized controlled study of adjuvant chemotherapy for stage II colorectal cancer patients at high-risk of developing recurrence according to T-stage and three selected pathological factors (Pn, DR, and BD).

AUTHOR(S)

Megumi Ishiguro, Hideki Ueno, Atsuo Takashima, Junki Mizusawa, Keita Sasaki, Hiroshi Katayama, Tetsuya Hamaguchi, Shunsuke Tsukamoto, Yukihide Kanemitsu

ABSTRACT

TPS3621

Phase II/III study of Circulating tumOr DNA as a predictive BiomaRker in Adjuvant chemotherapy in patients with stage II colon cancer: NRG-GI005 (COBRA).

AUTHOR(S)

Van K. Morris, Greg Yothers, Scott Kopetz, Samuel A. Jacobs, Peter C. Lucas, Atif Iqbal, Patrick M. Boland, Dustin A. Deming, Aaron J. Scott, Howard J. Lim, Norman Wolmark, Thomas J. George

ABSTRACT

TPS3622

Neoadjuvant chemoradiotherapy with sequential ipilimumab and nivolumab in rectal cancer (CHINOREC): A prospective randomized, open-label, multicenter, phase II clinical trial.

AUTHOR(S)

Johannes Laengle, Irene Kuehrer, Dietmar Pils, Julijan Kabiljo, Judith Stift, Friedrich Herbst, Bernhard Dauser, Matthias Monschein, Peter Razek, Stefanie Haegele, Wolfgang Huller, Reinhold Fuegger, Hans Geinitz, Andreas L. Petzer, Clemens Bitterman, Friedrich Laengle, Dietmar Tamandl, Joachim Widder, Rainer Schmid, Michael Bergmann

ABSTRACT

TPS3623

Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary

[Back to Program](#)

Showing 151 Presentations

<https://meetinglibrary.asco.org/session/13627>

The prognostic value of tumor markers in patients (pts) with resectable gastric cancer (GC) receiving perioperative therapy in the CRITICS trial.

AUTHOR(S)

Astrid E. Slagter, Marieke A. Vollebergh, Irene A. Caspers, Johanna W. van Sandick, Karolina Sikorska, Pehr A. Lind, Marianne Nordsmark, Hein Putter, Jeffrey P. Braak, Elma Meershoek – Klein Kranenburg, Cornelis J. Van De Velde, Edwin P. Jansen, Annemieke Cats, Hanneke W. Van Laarhoven, Nicole C. van Grieken, Marcel Verheij

ABSTRACT

4024

Phase 1 study of the liposomal formulation of eribulin (E7389-LF): Results from the advanced gastric cancer expansion cohort.

AUTHOR(S)

Kensei Yamaguchi, Satoru Iwasa, Motohiro Hirao, Takashi Oshima, Kazuaki Harada, Yasuyoshi Sato, Akihito Kawazoe, Kan Yonemori, Kazuhiro Nishikawa, Nozomu Machida, Yoshito Komatsu, Takuya Suzuki, Shiori Okumura, Reiko Nagai, Takao Takase, Kohei Shitara

ABSTRACT

4025

Neoadjuvant nivolumab monotherapy in patients with resectable gastric cancer: Preliminary results from a multicenter study.

AUTHOR(S)

Shuji Takiguchi, Kohei Shitara, Noriaki Takiguchi, Seiji Ito, Mitsugu Kochi, Hidehito Horinouchi, Takahiro Kinoshita, Kei Muro, Takaki Yoshikawa, Hirotaka Hasegawa, Hiroyoshi Nishikawa, Yasuhiro Kodaera

ABSTRACT

4026

A phase II study of chemoselection with docetaxel, cisplatin, and 5-fluorouracil as a strategy for organ preservation in patients with resectable esophageal cancer (CROC trial).

AUTHOR(S)

Chikatoshi Katada, Hiroki Hara, Hirofumi Fujii, Takako E. Nakajima, Takayuki Ando, Motoo Nomura, Takashi Kojima, Keishi Yamashita, Tetsuji Yokoyama, Yasutoshi Sakamoto, Hiroki Sasaki, Yusuke Inoue, Shogo Kawakami, Hideki Ishikawa, Ayumu Hosokawa, Yasuo Hamamoto, Manabu Muto, Makoto Tahara, Wasaburo Koizumi

ABSTRACT

4027

Camrelizumab plus chemotherapy as neoadjuvant therapy for resectable, locally advanced esophageal squamous cell carcinoma (NIC-ESCC2019): A multicenter, open-label, single-arm, phase 2 study.

AUTHOR(S)

Jingpei Li, Jun Liu, Zhuoyi Li, Fei Cui, Yuan Zeng, Wenhua Liang, Hengrui Liang, Wei Wang, Ke Xu, Weipeng Cai, JunHui Fu, Jianxing He

ABSTRACT

4028

Nivolumab and ipilimumab for second-line therapy in elderly patients with advanced esophageal squamous cell cancer: Safety interim analysis of the RAMONA trial.

AUTHOR(S)

Nicolai Hartel, Nadja M. Meindl-Beinker, Martin Maenz, Wolfgang Hiegl, Johannes Betge, Ralf D. Hofheinz, Arndt Vogel, Stefan Angermeier, Claus Bolling, Maïke de Wit, Ralf Jakobs, Meinolf Karthaus, Gertraud Stocker, Peter C. Thuss-Patience, Matthias P. Ebert

ABSTRACT

4029

LEAP-005: A phase 2 multicohort study of lenvatinib plus pembrolizumab in patients with previously treated selected solid tumors—Results from the gastric cancer cohort.

AUTHOR(S)

Hyun Cheol C. Chung, Zarnie Lwin, Carlos A. Gomez-Roca, Federico Longo, Eduardo Yanez, Eduardo Castanon Alvarez, Donna M. Graham, Mark Doherty, Philippe Cassier, Juanita S. Lopez, Bristi Basu, Andrew E. Hendifar, Corinne Maurice-Dror, Sanjeev S. Gill, Razi Ghori, Peter Kubiak, Fan Jin, Kevin G. Norwood, Esma Saada-Bouzid

ABSTRACT

4030

Frequency of homologous recombination-related (HRR) genes mutations in gastric cancer.

AUTHOR(S)

Wei Wang, Wang Huaiming, Yuhong Chen, Huanhuan Liu, Yanrui Zhang, Xiayuan Liang, Yun Zhang, Feng Lou, Shanbo Cao, Huina Wang

ABSTRACT

4031

ENSURE: An international multicenter study exploring whether surveillance after esophageal cancer surgery impacts oncological and quality-of-life outcomes.

AUTHOR(S)

Jessie A. Elliott, Sheraz Markar, Fredrik Klevebro, Asif Johar, Lucas Goense, Maeve A. Lowery, Pernilla Lagergren, Giovanni Zaninotto, Richard van Hillegersberg, Magnus Nilsson, George Hanna, John V. Reynolds

ABSTRACT

4032

Circulating tumor DNA (ctDNA) analysis by low-coverage whole genome sequencing (lcWGS) of resectable esophageal adenocarcinoma (rEAC) patients.

AUTHOR(S)

Tom van den Ende, Aafke Creemers, Ymke van der Pol, Dries Boers, Mark I. Van Berge Henegouwen, Suzanne S. Gisbertz, E. Debby Geijsen, Maarten C. Hulshof, Frederike Dijk, Nicole C. van Grieken, D. Michiel Pegtel, Sarah Derks, Maarten F. Bijlsma, Florent Moulière, Hanneke W. Van Laarhoven

ABSTRACT

4033

DNA and RNA sequencing analysis revealed alterations of *ANK3*, *PKHD1* and olfactory transduction as potential biomarker of three-year survival in gastric cancer.

AUTHOR(S)

Jian Wang, Si Li, Wenjing Xi, Dongsheng Chen, Mingzhe Xiao

ABSTRACT

4034

The prognosis of gastric adenocarcinoma depends on the crosstalk between immune profiles and tumor genomic alterations.

AUTHOR(S)

Deqiang Wang, Xiaofeng Chen, Yaping Xu, Yuange He, Lifeng Li, Yongqian Shu

ABSTRACT

4035

Camrelizumab combined with FLOFOX as neoadjuvant therapy for resectable locally advanced gastric and gastroesophageal junction adenocarcinoma: Updated results of efficacy and safety.

AUTHOR(S)

Ying Liu, Guangsen Han, Hongle Li, Yuzhou Zhao, Zhi Li, Jing Zhuang, Gangcheng Wang, Baodong Li, Jinbang Wang, Zhimeng Li, Qingxin Xia, Chengjuan Zhang, Juan Yu, Ke Li, Shuning Xu, Lei Qiao, Gaizhen Kuang, Danyang Li

ABSTRACT

4036

Randomized phase II study comparing docetaxel versus paclitaxel in patients with esophageal squamous cell carcinoma who are refractory to fluoropyrimidine and platinum-based chemotherapy: OGS1201.

AUTHOR(S)

Takayuki Kii, Sachiko Yamamoto, Hiroki Hara, Ryohei Kawabata, Junji Kawada, Atsushi Takeno, Jin Matsuyama, Shugo Ueda, Hisato Kawakami, Yoshihiro Okita, Shunji Endo, Yutaka Kimura, Kazuhiro Yanagihara, Tatsuya Okuno, Toshio Shimokawa, Taroh Satoh

ABSTRACT

4037

Real-world data (RWD) reveals benefit for adjuvant chemotherapy with docetaxel, oxaliplatin and fluorouracil/leucovorin (FLOT) is limited to those with tumour regression grade (TRG) ≥ 3 in oesophago-gastric cancer (OGC).

AUTHOR(S)

Brindley S. Hapuarachi, Rebecca Lee, Adeel Khan, Laura Woodhouse, Valentinos Kounnis, Fiona Britton, Jessica Coyle, Kathleen Connors, Neethu Billy Graham Mariam, Jamie Weaver, Tom Waddell, Richard Hubner, Konstantinos Kamposioras, Wasat Mansoor

ABSTRACT

4039

SHARED: Efficacy and safety of sintilimab in combination with concurrent chemoradiotherapy (cCRT) in patients with locally advanced gastric (G) or gastroesophageal junction (GEJ) adenocarcinoma.

AUTHOR(S)

Jia Wei, Xiaofeng Lu, Qin Liu, Yao Fu, Song Liu, Ju Yang, Meng Wang, Liming Zheng, Yang Yang, Xiangshan Fan, Yang Zhao, Wenxian Guan, Baorui Liu

ABSTRACT

4040

Final survival results from a multicenter, randomized phase II trial of intravenous paclitaxel plus FOLFOX (ivPOF) and/or intraperitoneal paclitaxel plus FOLFOX (ipPOF) versus mFOLFOX6 as first-line treatment of advanced gastric cancer (AGC): SYLT/FNF 004.

AUTHOR(S)

Shen Zhao, Rongbo Lin, Nan-Feng Fan, Yigui Chen, Xiaofeng Li, Peicheng Lin, Wujin Chen, Wenzheng Fang, Jinfeng Zhu, Hui Li, Jie Liu

ABSTRACT

4041

Immunogenomic features of pathologic response to neoadjuvant immune checkpoint blockade in esophageal cancer.

AUTHOR(S)

Zineb Belcaid, Archana Balan, Christopher Cherry, Mara Lanis, Kristen Marrone, Benjamin P. Levy, Heather Schneider, Hanika Rodavia, Blair A. Jobe, Elizabeth Thompson, Victor E. Velculescu, Richard J. Battaifarano, Stephen Yang, Stephen Broderick, Jinny S. Ha, Ali H. Zaidi, Ronan J. Kelly, Josephine L. Feliciano, Valsamo Anagnostou, Vincent K. Lam

ABSTRACT

4042

A multicenter phase II study of S-1 plus ramucirumab as first-line treatment in elderly patients with advanced/recurrent gastric cancer (KSCC1701).

AUTHOR(S)

Hiroo Katsuya, Koichi Suyama, Kazuma Kobayashi, Naoki Izawa, Yoshikazu Uenosono, Qingjiang Hu, Tetsuya Kusumoto, Hajime Otsu, Hiroyuki Orita, Hirofumi Kawanaka, Kazunori Shibao, Satoshi Koga, Mototsugu Shimokawa, Akitaka Makiyama, Hiroshi Saeki, Eiji Oki, Hideo Baba, Masaki Mori

ABSTRACT

4043

Survival analysis by tumor response from real-world data in advanced gastric cancer treated with nivolumab: The DELIVER trial (JACCRO GC-08).

AUTHOR(S)

Yosuke Kito, Eisuke Inoue, Yusuke Akamaru, Masazumi Takahashi, Jin Matsuyama, Hiroshi Yabusaki, Akitaka Makiyama, Takahisa Suzuki, Masahiro Tsuda, Hisateru Yasui, Naoki Hirabayashi, Atsushi Takeno, Hisato Kawakami, Hiroyuki Okuda, Takashi Yoshioka, Junji Kawada, Yasuhiro Koderu, Wataru Ichikawa, Masashi Fujii, Yu Sunakawa

ABSTRACT

4044

ERBB2 copy number (CN) as a quantitative biomarker for real-world (RW) outcomes to anti-HER2 therapy in advanced gastroesophageal adenocarcinoma (adv GEA).

AUTHOR(S)

Samuel J. Klempner, Liangliang Zhang, Ryon Graf, Russell Madison, Jeremy Snider, Cheryl D. Cho-Phan, Emily Castellanos, Gerald Li, Halla Nimeiri, Garrett M. Frampton, Geoffrey R. Oxnard, Jeffrey M. Venstrom, Kimberly McGregor, Alexa B. Schrock

ABSTRACT

4045

Phase II trial of perioperative chemotherapy + avelumab in locally advanced gastroesophageal adenocarcinoma: Preliminary results.

AUTHOR(S)

Thierry Alcindor, Touhid Opu, Arielle Elkrief, Farzin Khosrow-Khavar, Carmen L. Mueller, Jonathan Cools-Lartigue, Marc Hickeson, Giovanni Artho, Gertruda Evaristo, Victoria Marcus, Sophie Camilleri-Broët, Pierre-Olivier Fiset, Alan Spatz, Zoe Koulouris, Lorenzo Ferri

ABSTRACT

4046

Neoadjuvant camrelizumab combined with chemotherapy and apatinib for locally advanced thoracic esophageal squamous cell carcinoma (ESCC): A single-arm, open-label, phase Ib study.

AUTHOR(S)

Zhen Wang

ABSTRACT

4047

Trastuzumab deruxtecan (T-DXd; DS-8201) in patients with HER2-positive advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma: Final overall survival (OS) results from a randomized, multicenter, open-label, phase 2 study (DESTINY-Gastric01).

AUTHOR(S)

Kensei Yamaguchi, Yung-Jue Bang, Satoru Iwasa, Naotoshi Sugimoto, Min-Hee Ryu, Daisuke Sakai, Hyun Cheol C. Chung, Hisato Kawakami, Hiroshi Yabusaki, Jeeyun Lee, Kaku Saito, Yoshinori Kawaguchi, Takahiro Kamio, Akihito Kojima, Masahiro Sugihara, Kohei Shitara

ABSTRACT

4048

First-line pembrolizumab plus chemotherapy versus chemotherapy in patients with advanced esophageal cancer: Chinese subgroup analysis of KEYNOTE-590.

AUTHOR(S)

Zhigang Li, Yubei Sun, Feng Ye, Dong Ma, Xianli Yin, Wu Zhuang, Xianglin Yuan, Shukui Qin, Yiping Zhang, Kangsheng Gu, Kuailie Zhao, Juxiang Xiao, Ying Cheng, Yuxian Bai, Suxia Luo, Liwei Wang, Cailian Wang, Yi Cui, Lingling Mei, Lin Shen

ABSTRACT

4049

Phase II study of perioperative toripalimab in combination with FLOT in patients with locally advanced resectable gastric/gastroesophageal junction (GEJ) adenocarcinoma.

AUTHOR(S)

Hongli Li, Jingyu Deng, Shaohua Ge, Fenglin Zang, Le Zhang, Peng Ren, Baogui Wang, Fuliang Cao, Ting Deng, Rui Liu, Tao Ning, Yuchong Yang, Ming Bai, Xia Wang, Zhi Ji, Jingjing Duan, Yong Liu, Dejun Zhou, Han Liang, Yi Ba

ABSTRACT

4050

The sequence of chemotherapy and anti-PD-1 antibody influence the efficacy of neoadjuvant immunochemotherapy in locally advanced esophageal squamous cell cancer: A phase II study.

AUTHOR(S)

Lingdi Zhao, Wenqun Xing, Yonghao Yang, Yong Zhang, Baozhen Ma, Xiaomin Fu, Guanghui Liang, Yiman Shang, Zibing WANG, Hongwei Lin, Quanli Gao

ABSTRACT

4051

Risk factors for recurrence in each pattern after curative gastrectomy for pStage II/III gastric cancer: An exploratory analysis of a randomized controlled trial (JCOG1001).

AUTHOR(S)

Tetsuro Toriumi, Masanori Terashima, Junki Mizusawa, Yuya Sato, Yukinori Kurokawa, Shuji Takiguchi, Yuichiro Doki, Yasuyuki Kawachi, Hisashi Shinohara, Yasuhiro Choda, Seiji Ito, Takaki Yoshikawa, Takeshi Sano, Mitsuru Sasako

ABSTRACT

4052

Risk factors of metachronous peritoneal carcinomatosis after potentially curative gastric cancer resection in the CRITICS trial.

AUTHOR(S)

Irene A. Caspers, Karolina Sikorska, Astrid E. Slagter, Elma Meershoek – Klein Kranenbarg, Cornelis J. Van De Velde, Pehr A. Lind, Marianne Nordmark, Edwin P. Jansen, Marcel Verheij, Johanna W. van Sandick, Annemieke Cats, Nicole C. van Grieken

ABSTRACT

4053

Long-term quality of life and nutritional results after laparoscopic sentinel node navigation surgery versus laparoscopic standard gastrectomy for early gastric cancer: Secondary outcomes of a multicenter, randomized phase 3 trial (SENORITA).

AUTHOR(S)

Bang Wool Eom, Hong Man Yoon, Young-Woo Kim, Jae Seok Min, Ji Yeong An, Hoon Hur, Young-Joon Lee, Gyu Seok Cho, Young-Kyu Park, Mi Ran Jung, Ji-Ho Park, Woo Jin Hyung, Sang-Ho Jeong, Myeong-Cherl Kook, Mira Han, Byung-Ho Nam, Keun Won Ryu

ABSTRACT

4054

Apatinib in combination with docetaxel and S1 chemotherapy in the first-line treatment of metastatic gastric cancer.

AUTHOR(S)

Ling Xia, Yu Gao, Jun Gong, Jing Dai, Jin Peng, Lilin He, Weidong Chen, Wei Gong, Lei Yang, Wang Wen-bo, Huangang Jiang, Hui Xu, Qing-Yun Wang, Han Wu, You Wang, Lu Wu, Fuxiang Zhou

ABSTRACT

4055

Real-world outcomes of second-line ramucirumab plus paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma: A nationwide retrospective study in Korea (KCSG-ST19-16).

AUTHOR(S)

Dae Young Zang, Hye Sook Han, Bum Jun Kim, Hee-Jung Jee, Young Ju Suh, Hyonggin An, Ji-Hye Byun, Dong Sook Kim, Se Hoon Park, Sun Y. Rha, Do-Youn Oh, Jong Gwang Kim, Woo Kyun Bae, In-Ho Kim, Sun Jin Sym, So Yeon Oh, Hyeong Su Kim, Keun Wook Lee, Min-Hee Ryu

ABSTRACT

4056

Quality-adjusted time without symptoms or toxicity (Q-TWiST) of trastuzumab deruxtecan (T-DXd) versus chemotherapy in patients with advanced gastric cancer from the DESTINY-Gastric01 trial.

AUTHOR(S)

David Cella, Michelle D. Hackshaw, Gerard T. Vondeling, Lee Bennett, Diana Garbinsky, Kaku Saito, Masahiro Sugihara, Yung-Jue Bang, Kensei Yamaguchi, Kohei Shitara

ABSTRACT

4057

Early predictors of benefit to dual anti-PD1/HER2 inhibition: Biomarker analysis from phase 2 trial of pembrolizumab/trastuzumab in HER2-positive metastatic esophagogastric (mEG) cancer.

AUTHOR(S)

Steven B. Maron, Walid K. Chatila, Henry S. Walch, Ryan Ptashkin, Shalom Sabwa, Lilan Ling, Rebecca Nagy, Marc Simmons, Richard K. Do, Viktoriya Paroder, Neeta Pandit-Taskar, Geoffrey Y. Ku, David H. Ilson, Jaclyn F. Hechtman, Taha Merghoub, David B. Solit, Nikolaus Schultz, Yelena Y. Janjigian

ABSTRACT

4058

A phase II study of neoadjuvant immunotherapy combined with chemotherapy (camrelizumab plus albumin paclitaxel and carboplatin) in resectable thoracic esophageal squamous cell cancer (NICE study): Interim results.

AUTHOR(S)

Zhigang Li, Jun Liu, Ming Zhang, Jinchen Shao, Yang Yang, Hongxuan Li, Zhichao Liu, Renquan Zhang, Bentong Yu, Hezhong Chen

ABSTRACT

4060

A prospective, phase II, single-arm study of neoadjuvant/conversion therapy with camrelizumab, apatinib, S-1 ± oxaliplatin for locally advanced cT4a/bN+ gastric cancer.

AUTHOR(S)

Song Li, Wenbin Yu, Fei Xie, Zhimin Liu, Weiwei Lv, Duanbo Shi, Dexin Yu, Meng Wei, Jiaqian Wang, Yongtian Zhao, Cheng Chen, Zhikun Zhao, Jing Gao, Lei Sheng, Lian Liu

ABSTRACT

4061

Efficacy and safety of KN046 plus paclitaxel/cisplatin as first-line treatment for unresectable locally advanced, recurrent or metastatic esophageal squamous cell carcinoma (ESCC).

AUTHOR(S)

Jianming Xu, Rongrui Liu, Yanqiao Zhang, Nong Xu, Qingxia Fan, Shengan Gao, Hongming Pan, Mingquan Cai, Dong Yan, Qianqian Liang, Qiong Wu, Baohong Guo, Yakun Qi, Ting Xu

ABSTRACT

4062

Multicenter phase Ib/II study of second-line trastuzumab, ramucirumab, and paclitaxel in patients with HER2-positive advanced gastric or gastroesophageal junction cancer (HER-RAM study).

AUTHOR(S)

Sun Y. Rha, Chang Gon Kim, Minkyu Jung, Hyo Song Kim, Choong-kun Lee, Hei-Cheul Jeung, Dong-Hoe Koo, Woo Kyun Bae, Dae Young Zang, Hyunki Kim, Hyun Cheol C. Chung

ABSTRACT

4063

A phase II/III study of perioperative nivolumab and ipilimumab in patients (pts) with locoregional esophageal (E) and gastroesophageal junction (GEJ) adenocarcinoma: Results of a safety run-in—A trial of the ECOG-ACRIN Cancer Research Group (EA2174).

AUTHOR(S)

Jennifer R. Eads, Michelle Weitz, Paul J. Catalano, Michael K. Gibson, Lakshmi Rajdev, Onkar Khullar, Steven H. Lin, Constantine Gatsonis, Ignacio I. Wistuba, Aravind Sanjeevaiah, Al B. Benson III, Nathan Bahary, Kristen R. Spencer, Nabil F. Saba, Stanley R. Hamilton, Charles A. Staley, Bapsi Chakravarthy, George A. Fisher Jr., Terence Z. Wong, Peter J. O'Dwyer

ABSTRACT

4064

Intraperitoneal aerosolized nanoparticle albumin based paclitaxel (NAB-PTX) for irresectable peritoneal metastases: A first in human phase I study.

AUTHOR(S)

Wim Ceelen, Louis Sandra, Leen Van de Sande, Martin Graversen, An Vermeulen, Dries Reynders, Sarah Cosyns, Anne Hoorens, Wouter Willaert

ABSTRACT

4065

Health-related quality of life (HRQOL) in patients (pts) with advanced gastric cancer/gastroesophageal junction cancer (GC/GEJC) or esophageal adenocarcinoma (EAC): Interim results of nivolumab plus chemotherapy (N+C) versus (C) from CheckMate 649.

AUTHOR(S)

Lucjan Wyrwicz, Elena Elimova, Steven I. Blum, Hong Xiao, Eric Davenport, Jinyi Wang, Shannon Hunter, Mingshun Li, Kaoru Kondo, Markus H. Moehler

ABSTRACT

4066

Individual patient data meta-analysis of neoadjuvant chemotherapy followed by surgery versus upfront surgery in esophageal or gastro-esophageal carcinoma.

AUTHOR(S)

Matthieu Faron, Armel Maurice Cheugoua-Zanetsie, Matthew G. Nankivell, Kathryn A. Winter, Simon Law, Ate V. van der Gaast, Marc Ychou, Murielle Mauer, Michele Valmasoni, Jack A. Roth, Pierre Blanchard, Pierre G. Thirion, Jayne F. Tierney, Val GebSKI, Bryan H. Burmeister, Xavier Paoletti, Hong Yang, Johanna W. van Sandick, Michel Ducreux, Stefan Michiels

ABSTRACT

4067

Imaging HER2-positive metastatic esophagogastric cancer with ⁸⁹Zr-trastuzumab PET and ¹⁸F-FDG PET.

AUTHOR(S)

Melissa A. Lumish, Steven B. Maron, Viktoriya Paroder, Steven Philemond, Joseph A. O' Donoghue, Heiko Schöder, Jason S. Lewis, Yelena Y. Janjigian, Neeta Pandit-Taskar

ABSTRACT

4068

Final results from ClarIDHy, a global, phase 3, randomized, double-blind study of ivosidenib (IVO) versus placebo (PBO) in patients (pts) with previously treated cholangiocarcinoma (CCA) and an isocitrate dehydrogenase 1 (IDH1) mutation.

AUTHOR(S)

Ghassan K. Abou-Alfa, Teresa Macarulla, Milind M. Javle, Robin Kate Kelley, Sam J. Lubner, Jorge Adeva, James M. Cleary, Daniel V. Catenacci, Mitesh J. Borad, John A. Bridgewater, William P. Harris, Adrian G. Murphy, Do-Youn Oh, Jonathan R. Whisenant, Christina X. Chamberlain, Liewen Jiang, Camelia Gliser, Shuchi S. Pandya, Juan W. Valle, Andrew X. Zhu

ABSTRACT

4069

Adjuvant nivolumab for hepatocellular carcinoma (HCC) after surgical resection (SR) or radiofrequency ablation (RFA) (NIVOLVE): A phase 2 prospective multicenter single-arm trial and exploratory biomarker analysis.

AUTHOR(S)

Masatoshi Kudo, Kazuomi Ueshima, Shin Nakahira, Naoshi Nishida, Hiroshi Ida, Yasunori Minami, Takuya Nakai, Hiroshi Wada, Shoji Kubo, Kazuyoshi Ohkawa, Asahiro Morishita, Takeo Nomi, Koji Ishida, Shogo Kobayashi, Makoto Umeda, Masakatsu Tsurusaki, Yasutaka Chiba, Kenichi Yoshimura, Kazuko Sakai, Kazuto Nishio

ABSTRACT

4070

IMbrave150: Exploratory analysis to examine the association between treatment response and overall survival (OS) in patients (pts) with unresectable hepatocellular carcinoma (HCC) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor).

AUTHOR(S)

Michel Ducreux, Andrew X. Zhu, Ann-Lii Cheng, Peter R. Galle, Masafumi Ikeda, Alan Nicholas, Wendy Verret, Lindong Li, Vincent E. Gaillard, Riccardo Lencioni, Richard S. Finn

ABSTRACT

4071

Pembrolizumab (pembro) versus placebo (pbo) in patients (pts) with advanced hepatocellular carcinoma (aHCC) previously treated with sorafenib: Updated data from the randomized, phase 3 KEYNOTE-240 study.

AUTHOR(S)

Richard S. Finn, Julien Edeline, Mohamed Bouattour, Ann-Lii Cheng, Stephen L. Chan, Thomas Yau, Marcelo Garrido, Jennifer J. Knox, Bruno Daniele, Andrew X. Zhu, Valeriy V. Breder, Ho Yeong Lim, Sadahisa Ogasawara, Abby B. Siegel, Ahmadur Rahman, Ziwen Wei, Philippe Merle

ABSTRACT

4072

IMbrave150: Exploratory efficacy and safety results of hepatocellular carcinoma (HCC) patients (pts) with main trunk and/or contralateral portal vein invasion (Vp4) treated with atezolizumab (atezo) + bevacizumab (bev) versus sorafenib (sor) in a global Ph III study.

AUTHOR(S)

Valeriy V. Breder, Arndt Vogel, Philippe Merle, Richard S. Finn, Peter R. Galle, Andrew X. Zhu, Ann-Lii Cheng, Yin-Hsun Feng, Daneng Li, Vincent E. Gaillard, Lindong Li, Alan Nicholas, Riccardo Lencioni

ABSTRACT

4073

Pembrolizumab (pembro) monotherapy for previously untreated advanced hepatocellular carcinoma (HCC): Phase 2 KEYNOTE-224 study.

AUTHOR(S)

Jean-Luc Van Laethem, Ivan Borbath, Mark Karwal, Chris Verslype, Hans Van Vlierberghe, Adel Kardosh, Vittorina Zagonel, Per Stal, Debashis Sarker, Daniel H. Palmer, Arndt Vogel, Julien Edeline, Stéphane Cattan, Masatoshi Kudo, Ann-Lii Cheng, Sadahisa Ogasawara, Abby B. Siegel, Michael J. Chisamore, Anran Wang, Andrew X. Zhu

ABSTRACT

4074

A phase Ib study of anlotinib plus TQB2450 as second-line therapy for advanced biliary tract adenocarcinoma.

AUTHOR(S)

Yongkun Sun, Aiping Zhou, Wen Zhang, Zhichao Jiang, Wang Qu

ABSTRACT

4075

Update on overall survival (OS) of RESCUE: An open-label, phase 2 trial of camrelizumab (C) in combination with apatinib (A) in patients with advanced hepatocellular carcinoma (HCC).

AUTHOR(S)

Yun Zhang, Jianming Xu, Jie Shen, Shanzhi Gu, Lihua Wu, Jian Wu, Guoliang Shao, Yanqiao Zhang, Li Xu, Tao Yin, Jingfeng Liu, Zhenggang Ren, Jianping Xiong, Xianhai Mao, Ling Zhang, Jiayin Yang, Lequn Li, Xiaoming Chen, Zhiming Wang, Quanren Wang

ABSTRACT

4076

A randomized, double-blinded, phase III study of icaritin versus huachashu as the first-line therapy in biomarker-enriched HBV-related advanced hepatocellular carcinoma with poor conditions: Interim analysis result.

AUTHOR(S)

Yan Sun, Shukui Qin, Wei Li, Yabing Guo, Ying Zhang, Lingzhan Meng, Yuping Sun, Hongbo Ji, Yueyin Pan, Xiufeng Liu, Bin Hu, Yongqian Shu, Yi Li, Zhiqiang Meng, Kangsheng Gu, Hong Guo, Gang Chen, Bin Ye, Kun Meng

ABSTRACT

4077

Updated results of a phase 1b study of regorafenib (REG) 80 mg/day or 120 mg/day plus pembrolizumab (PEMBRO) for first-line treatment of advanced hepatocellular carcinoma (HCC).

AUTHOR(S)

Anthony B. El-Khoueiry, Richard D. Kim, William P. Harris, Max W. Sung, Dirk Waldschmidt, Roniel Cabrera, Vittorio Luigi Garosi, Hong Zebger-Gong, Barbara J. Brennan, Ying A. Wang, Udo Mueller, Tatiane C. Ishida, Peter R. Galle

ABSTRACT

4078

Association of cell-free DNA dominant clone allele frequency with poor outcomes in advanced biliary cancers treated with platinum-based chemotherapy.

AUTHOR(S)

Umair Majeed, Pedro L. Uson Junior, Jun Yin, Mohamad B. Sonbol, Daniel H. Ahn, Tanios S. Bekaii-Saab, Jason S. Starr, Jeremy C. Jones, Samantha R. Inabinett, Natasha Wylie, Ashton W. Boyle, Mitesh J. Borad, Kabir Mody

ABSTRACT

4079

Lenvatinib plus pembrolizumab for patients with previously treated biliary tract cancers in the multicohort phase 2 LEAP-005 study.

AUTHOR(S)

Luis Villanueva, Zarnie Lwin, Hyun Cheol C. Chung, Carlos A. Gomez-Roca, Federico Longo, Eduardo Yanez, Hélène Senellart, Mark Doherty, Javier Garcia-Corbacho, Andrew E. Hendifar, Corinne Maurice-Dror, Sanjeev S. Gill, Tae Won Kim, Daniel Heudobler, Nicolas Penel, Razi Ghori, Peter Kubiak, Fan Jin, Kevin G. Norwood, Donna M. Graham

ABSTRACT

4080

Preliminary results of molecular screening for *FGFR* alterations (alts) in the RAGNAR histology-agnostic study with the *FGFR*-inhibitor (FGFRi) erdafitinib.

AUTHOR(S)

Christophe Massard, Shubham Pant, Gopa Iyer, Martin H. Schuler, Olaf Witt, Shukui Qin, Josep Tabernero, Toshihiko Doi, Darren R. Hargrave, Constance Hammond, Shonda M. Little, Qi Xia, Jing Cao, Ademi E. Santiago-Walker, Hussein Sweiti

ABSTRACT

4081

Preliminary efficacy and safety of perioperative treatment of camrelizumab combined with apatinib in resectable hepatocellular carcinoma (HCC): A prospective phase II study.

AUTHOR(S)

Yongxiang Xia, Ping Wang, Liyong Pu, Xiaofeng Qian, Feng Cheng, Ke Wang, Chuanyong Zhang, Donghua Li, Xiangcheng Li, Feng Zhang, Jie Zhao, Si Li, Wenjing Xi, Xuehao Wang

ABSTRACT

4082

A phase II trial of lenvatinib plus toripalimab and hepatic arterial infusion chemotherapy as a first-line treatment for advanced hepatocellular carcinoma (LTHAIC study).

AUTHOR(S)

MinKe He, Shi Ming, Zhicheng Lai, Qijiong Li

ABSTRACT

4083

Exploratory circulating biomarker analyses: lenvatinib + pembrolizumab (L + P) in a phase 1b trial in unresectable hepatocellular carcinoma (uHCC).

AUTHOR(S)

Andrew X. Zhu, Josep M Llovet, Masahiro Kobayashi, Masafumi Ikeda, Marc Pracht, Max W. Sung, Ari D. Baron, Masatoshi Kudo, Tim Meyer, Takuji Okusaka, Hiromitsu Kumada, Shuichi Kaneko, Taisuke Hoshi, Kenichi Saito, Shuyu D. Li, Yasuhiro Funahashi, Yukinori Minoshima, Leonid Dubrovsky, Richard S. Finn

ABSTRACT

4084

Treatment-related toxicity and improved outcomes with immune checkpoint inhibitors in patients with hepatocellular carcinoma.

AUTHOR(S)

Alessio Cortellini, Thomas U. Marron, Pallavi S. Mishra-Kalyani, Yutao Gong, Anwaar Saeed, Tomi Jun, Sirish Dharmapuri, Abdul R. Naqash, Uqba Khan, Ahmed O. Kaseb, Yi-Hsiang Huang, Celina Ang, Julie A. Schneider, Anjana Pillai, Lorenza Rimassa, Richard Pazdur, Marc R. Theoret, Steven Lemery, Lorraine C. Pelosof, David J. Pinato

ABSTRACT

4085

Pemigatinib for previously treated locally advanced/metastatic cholangiocarcinoma (CCA): Update of FIGHT-202.

AUTHOR(S)

Ghassan K. Abou-Alfa, Vaibhav Sahai, Antoine Hollebecque, Gina M. Vaccaro, Davide Melisi, Raed M. Al-Rajabi, Andrew S. Paulson, Mitesh J. Borad, David H. Gallinson, Adrian G. Murphy, Do-Youn Oh, Efrat Dotan, Daniel Catenacci, Eric Van Cutsem, Christine F. Lihou, Huiling Zhen, Luis Féliz, Arndt Vogel

ABSTRACT

4086

T-cell receptor pharmacodynamics associated with survival and response to tremelimumab (T) in combination with durvalumab (D) in patients (pts) with unresectable hepatocellular carcinoma (uHCC).

AUTHOR(S)

Patricia McCoon, Young S. Lee, Robin Kate Kelley, Violeta B. Guthrie, Song Wu, Stephanie A. Bien, Alejandra Negro, Philip He, John Kurland, Fernanda Pilataxi, Steven Ching, Ghassan K. Abou-Alfa

ABSTRACT

4087

Phase I trial of fourth-generation chimeric antigen receptor T-cells targeting glypican-3 for advanced hepatocellular carcinoma.

AUTHOR(S)

Weijia Fang, Qihan Fu, Qingwei Zhao, Yi Zheng, Lulu Liu, Zonghai Li, Xiaomeng Dai, Huamao Wang, Xudong Zhu, Peng Zhao, Meihua Lin, Hangyu Zhang, Jun Xiao, Jian Liu, Zhou Tong, Zhen Wang, Tingbo Liang

ABSTRACT

4088

Natural history of patients (pts) with advanced cholangiocarcinoma (CCA) with *FGFR2* gene fusion/rearrangement or wild-type (WT) *FGFR2*.

AUTHOR(S)

Rachna T. Shroff, Jessica Rearden, Ai Li, Susan Moran, Stacie P. Shepherd, Angela Lamarca

ABSTRACT

4089

Phase I study of H3B-6527 in hepatocellular carcinoma (HCC) or intrahepatic cholangiocarcinoma (ICC).

AUTHOR(S)

Teresa Macarulla, Victor Moreno, Li-Tzong Chen, Michael B. Sawyer, Lipika Goyal, Andres J. Muñoz Martín, Yang Sheng-Shun, Samuel Le Sourd, John Morris, Michael Fuchs, Thomas B. Karasic, Yoon-Koo Kang, Wei-Peng Yong, Anand Selvaraj, Benoit Destenaves, Jianjun A. Xiao, Ronald Gomez Jr., Antonio Gualberto, J. Marc M. Pipas, Richard S. Finn

ABSTRACT

4090

Relationship between *Helicobacter pylori* and development of hepatocellular carcinoma: A systematic review and meta-analysis.

AUTHOR(S)

Samragnyi Madala, Kira MacDougall, Balarama K. Surapaneni, Robin Park, Anup Kasi, Mohit Girotra

ABSTRACT

4091

Phase I result of ICP-192 (gunagratinib), a highly selective irreversible FGFR inhibitor, in patients with advanced solid tumors harboring FGFR pathway alterations.

AUTHOR(S)

Ye Guo, Chunwang Yuan, Jieer Ying, Xu Zhu, Guodong Luan, Bin Zhang, Renbin Zhao, Jin Li

ABSTRACT

4092

A multicenter randomized controlled trial to evaluate the efficacy of surgery versus radiofrequency ablation for small hepatocellular carcinoma (SURF trial): Analysis of overall survival.

AUTHOR(S)

Masatoshi Kudo, Kiyoshi Hasegawa, Yoshikuni Kawaguchi, Tadatashi Takayama, Namiki Izumi, Naoki Yamanaka, Mitsuo Shimada, Masahumi Inomata, Shuichi Kaneko, Hideo Baba, Kazuhiko Koike, Masao Omata, Masatoshi Makuuchi, Yutaka Matsuyama, Norihiro Kokudo

ABSTRACT

4093

Gemox chemotherapy in combination with anti-PD1 antibody toripalimab and lenvatinib as first-line treatment for advanced intrahepatic cholangiocarcinoma: A phase 2 clinical trial.

AUTHOR(S)

Zhou Jian, Jia Fan, Guo-Ming Shi, Xiao-Yong Huang, Dong Wu, Guo-Huan Yang, Yuan Ji, Yi Chen, Fei Liang, Jia-Cheng Lu, Ning-Ling Ge, Hui-Chuan Sun, Xiao-Wu Huang, Shuang-Jian Qiu, Yi-Feng He, Xin-Rong Yang, Yang Xu, Qiang Gao, Jian Sun

ABSTRACT

4094

An armored GPC3-directed CAR-T for refractory or relapsed hepatocellular carcinoma in China: A phase I trial.

AUTHOR(S)

Zhongwei Zhao, Wenyuan Guo, Shiji Fang, Shaohua Song, Jingjing Song, Fei Teng, Liyun Zheng, Jianting Mao, Hao Guo, Wang Huajing, Xiaofeng Feng, Xiaowen He, Guoshan Ding, Jiansong Ji

ABSTRACT

4095

Regomune: A phase II study of regorafenib + avelumab in solid tumors—Results of the biliary tract cancer (BTC) cohort.

AUTHOR(S)

Sophie Cousin, Carine A. Bellera, Jean Philippe Guégan, Thibault Mazard, Carlos A. Gomez-Roca, Jean Philippe Metges, Coralie Cantarel, Antoine Adenis, Iphigenie Korakis, Pierre-guillaume Poureau, Mariella spalato-Ceruso, Kevin Bourcier, Michèle Kind, Isabelle Soubeyran, Alban Bessede, Antoine Italiano

ABSTRACT

4096

FOENIX-CCA2 quality of life data for futibatinib-treated intrahepatic cholangiocarcinoma (iCCA) patients with *FGFR2* fusions/rearrangements.

AUTHOR(S)

Juan W. Valle, Antoine Hollebecque, Junji Furuse, Lipika Goyal, Funda Meric-Bernstam, Robert S. Epstein, Tehseen Salimi, Volker Wacheck, Mei Liu, Karim A. Benhadji, John A. Bridgewater

ABSTRACT

4097

The cost effectiveness of lenvatinib versus atezolizumab and bevacizumab or sorafenib in patients with unresectable hepatocellular carcinoma (uHCC) in Canada.

AUTHOR(S)

David Trueman, Yifeng Liu, Marc Geadah, Nicholas Hon, Suthakar Sabapathy, Laveena Kamboj, Huimin Li, Melanie Lucero, Genevieve Meier

ABSTRACT

4098

Lenvatinib plus toripalimab as first-line treatment for advanced intrahepatic cholangiocarcinoma: A single-arm, phase 2 trial.

AUTHOR(S)

Zhou Jian, Jia Fan, Guo-Ming Shi, Xiao-Yong Huang, Dong Wu, Fei Liang, Guo-Huan Yang, Jia-Cheng Lu, Yi Chen, Ning-Ling Ge, Yuan Ji, YY Hou, Hui-Chuan Sun, Shuang-Jian Qiu, Qing-Hai Ye, Xiao-Wu Huang, Ying-Hong Shi, Qiang Gao, Xin-Rong Yang, Xiao-Ying Wang

ABSTRACT

4099

Molecular markers of response to anti-PD1 therapy in advanced hepatocellular carcinoma.

AUTHOR(S)

Philipp K. Haber, Miguel Torres-Martin, Jean-Francois Dufour, Chris Verslype, Jens Marquardt, Peter R. Galle, Arndt Vogel, Tim Meyer, Ismail Labgaa, Lewis R. Roberts, Beatriz Minguez, Vincenzo Mazzaferro, Fabian Finkelmeier, Tobias Müller, Moritz Schmelzle, Richard S. Finn, Swan Thung, Augusto Villanueva, Daniela Sia, Josep M Llovet

ABSTRACT

4100

Phase 2 study of AK104 (PD-1/CTLA-4 bispecific antibody) plus lenvatinib as first-line treatment of unresectable hepatocellular carcinoma.

AUTHOR(S)

Li Bai, Meili Sun, Aibing Xu, Yuxian Bai, Jian Wu, Guoliang Shao, Lijie Song, Xiaoping Jin, Weifeng Song, Baiyong Li, Yu Xia, Shunchang Jiao

ABSTRACT

4101

Comparative effectiveness of sorafenib, lenvatinib, and nivolumab as first-line systemic therapy for patients with advanced hepatocellular carcinoma and Child-Pugh class B cirrhosis treated at VA Medical Centers.

AUTHOR(S)

William J. Chapin, Wei-Ting Hwang, Thomas B. Karasic, Anne Marie McCarthy, David E. Kaplan

ABSTRACT

4102

Tumor-informed assessment of circulating tumor DNA and its incorporation into practice for patients with hepatobiliary cancers.

AUTHOR(S)

Pashtoon M. Kasi, Griffin Budde, Farshid Dayyani, Gregory P. Botta, Adam Diehl, Gentry T. King, Midhun Malla, Maen Abdelrahim, Diana L. Hanna, Liudmila N. Schafer, Mohamedtaki A. Tejani, Michael Krainock, Paul R. Billings, Perry Olshan, Vasily N. Aushev, Alexey Aleshin

ABSTRACT

4103

Does adjuvant chemoradiation benefit patients with lymph node-positive biliary tract cancer? A secondary analysis of SWOG S0809.

AUTHOR(S)

Sepideh Gholami, Mai T. Duong, David P. Horowitz, Katherine A. Guthrie, Edgar Ben-Josef, Anthony B. El-Khoueiry, Charles D. Blanke, Philip A. Philip, Syed A. Ahmad, Flavio G. Rocha

ABSTRACT

4104

ARID1A mutation to predict disease progression during first-line chemotherapy in biliary tract cancer patients.

AUTHOR(S)

Sung Hwan Lee, Jaekyung Cheon, Seoyoung Lee, Hye Jin Choi, Beodeul Kang, Hyeon-Su Im, Chan Kim, Sung Hoon Choi, Choong-kun Lee, Hongjae Chon

ABSTRACT

4105

Clinical outcomes analysis of TP53-mutated advanced and metastatic biliary tract cancers.

AUTHOR(S)

Sunyoung S. Lee, Hop S. Tran Cao, Ching-Wei D. Tzeng, Zeyad Metwalli, Eugene J. Koay, Ethan B. Ludmir, Yun Shin Chun, Stephen G. Chun, Milind M. Javle

ABSTRACT

4106

Impact of cell density in lymphocyte-rich areas in the tumor microenvironment on prognosis and gene expression landscape in hepatocellular carcinoma.

AUTHOR(S)

Jeonghyuk Park, Kyungdoc Kim, Hong-Seok Lee, Guhyun Kang, Kyu-Hwan Jung, Ahmed O. Kaseb, Sunyoung S. Lee

ABSTRACT

4107

Should all pancreatic neuroendocrine tumors (PNET) over 1 cm be resected?

AUTHOR(S)

Diana Hsu, Sidney Le, Alex Chang, Austin Spitzer, George Kazantsev, Peter D. Peng, CK Chang, Thach-Giao Truong

ABSTRACT

4108

Validation of a clinical score (CS) for patients (pts) with well-differentiated neuroendocrine tumors (WD NETs) under consideration for peptide receptor radionuclide therapy (PRRT) with Lu 177 dotatate.

AUTHOR(S)

Satya Das, Aman Chauhan, Liping Du, Katharine Thomas, Aasems Jacob, Aimee Schad, Shikha Jain, Aaron Jessop, Chirayu Shah, David Eisner, Dana B. Cardin, Kristen K. Ciombor, Laura W. Goff, Marques Bradshaw, Dominique Delbeke, Martin P. Sandler, Jordan Berlin, Robert A. Ramirez

ABSTRACT

4109

The safety and efficacy of PEN-221 somatostatin analog (SSA)-DM1 conjugate in patients (PTS) with advanced GI mid-gut neuroendocrine tumor (NET): Phase 2 results.

AUTHOR(S)

Daniel M. Halperin, Melissa L. Johnson, Jennifer A. Chan, Lowell L. Hart, Natalie Cook, Vipul M. Patel, Benjamin L. Schlechter, Judith Cave, Afshin Dowlati, Lawrence S. Blaszkowsky, Tim Meyer, Jennifer R. Eads, Daniel Culp, Kristina Kriksciukaite, Laura Mei, Mark Bilodeau, Jeffrey Bloss, Matthew H. Kulke

ABSTRACT

4110

Subgroup analysis by Ki-67 and baseline CgA of the randomized, placebo-controlled phase 3 study of surufatinib in advanced well-differentiated pancreatic neuroendocrine tumors (SANET-p).

AUTHOR(S)

Xianjun Yu, Jianming Xu, Lin Shen, Chunmei Bai, Jie Li, Zhiwei Zhou, Zhiping Li, Enxiao LI, Xianglin Yuan, Yihebal Chi, Yongmei Yin, Wenhui Lou, Nong Xu, Yuxian Bai, Tao Zhang, Dianrong Xiu, Xiuwen Wang, Sha Guan, Qian Xu, Weiguo Su

ABSTRACT

4111

Final overall survival in the phase 3 NETTER-1 study of lutetium-177-DOTATATE in patients with midgut neuroendocrine tumors.

AUTHOR(S)

Jonathan R. Strosberg, Martyn E. Caplin, Pamela L. Kunz, Philippe B. Ruszniewski, Lisa Bodei, Andrew E. Hendifar, Erik Mittra, Edward M. Wolin, James C. Yao, Marianne E. Pavel, Enrique Grande, Eric Van Cutsem, Ettore Seregni, Hugo Duarte, Gerardo Gericke, Amy Bartalotta, Arnaud Demange, Sakir Mutevelic, Eric Krenning

ABSTRACT

4112

Plasma biomarker study of lenvatinib in gastroenteropancreatic neuroendocrine tumors reveals Ang2 and FGF2 as predictors of treatment response: Results from the international phase II TALENT trial (GETNE 1509).

AUTHOR(S)

Jaume Capdevila, Gabriela Jimenez-Valerio, Alba Martinez, Jorge Hernando, Toni Ibrahim, Nicola Fazio, Carlos Lopez, Alex Teule, Juan W. Valle, Salvatore Tafuto, Ana B. Custodio, Nicholas S. Reed, Markus Raderer, Enrique Grande, Rocio Garcia-Carbonero, Paula Jiménez-Fonseca, Vicente Alonso, Oriol Casanovas

ABSTRACT

4113

Interim analysis results of surufatinib in U.S. patients with neuroendocrine tumors (NETs).

AUTHOR(S)

Andrew S. Paulson, Daneng Li, Max W. Sung, Christopher Tucci, John S. Kauh, Shivani Nanda, Marek K. Kania, Arvind Dasari

ABSTRACT

4114

Phase I study of autolytic immunotherapy of metastatic neuroendocrine tumors using intralesional rose bengal disodium.

AUTHOR(S)

Timothy J. Price, Gabby Cehic, Eric A. Wachter, Ian D. Kirkwood, Jessica Reid, Ruben Sebbon, Anas Alawawdeh, Mark McGregor, Dominic Rodrigues, Susan Neuhaus, Guy Maddern

ABSTRACT

4115

Efficacy and safety of ¹⁷⁷Lu-DOTATATE in patients (pts) with advanced pancreatic neuroendocrine tumors (pNETs): Data from the NETTER-R international, retrospective registry.

AUTHOR(S)

Dominique Clement, Shaunak Navalkisoor, Rajaventhana Srirajaskanthan, Frédéric Courbon, Lawrence Dierickx, Amy Eccles, Valerie Lewington, Mercedes Mitjavila, Juan Carlos Percovich, Benoît Lequoy, Beilei He, Ilya Folitar, John Ramage

ABSTRACT

4116

Phase I dose-escalation study of AlphaMedix for targeted-alpha-emitter therapy of PRRT-naive neuroendocrine patients.

AUTHOR(S)

Ebrahim Delpassand, Izabela Tworowska, Rouzbeh Esfandiari, Julien Torgue, Jason D. Hurt, Rodolfo Nunez

ABSTRACT

4117

Clinical impact of pathogenic germline variants in pancreatic cancer: Results from a multicenter prospective universal genetic testing study.

AUTHOR(S)

Pedro L. Uson Junior, Douglas Riegert-Johnson, Lisa A. Boardman, Mitesh J. Borad, Daniel H. Ahn, Mohamad B. Sonbol, Douglas O. Faigel, Norio Fukami, Rahul Pannala, Katie Kunze, Michael A. Golafshar, Edward D. Esplin, Robert L. Nussbaum, Tanios S. Bekaii-Saab, Jewel Samadder

ABSTRACT

4118

Modified FOLFIRINOX versus S-1 as second-line chemotherapy in patients with gemcitabine-failed metastatic pancreatic cancer: A randomized phase III trial (MPACA-3).

AUTHOR(S)

Se-Il Go, Sang-Cheol Lee, Woo Kyun Bae, Dae Young Zang, Hyun Woo Lee, Joung Soon Jang, Jun Ho Ji, Jung Hoon Kim, Sanggon Park, Sun Jin Sym, Yaewon Yang, So Yeon Jeon, Sung Yong Oh, Jung Hun Kang

ABSTRACT

4119

A phase I/IIa trial of the RNA oligonucleotide STNM01 by EUS-FNI to investigate the safety and efficacy in patients with first-line refractory, unresectable pancreatic cancer.

AUTHOR(S)

Takayoshi Tsuchiya, Toshio Fujisawa, Motohiko Kato, Masafumi Mizuide, Yuichi Torisu, Makoto Nishimura, Takashi Kurosawa, Ko Tomishima, Kazuki Takakura, Hiromu Kutsumi, Yoko Matsuda, Tomio Arai, Hideyuki Saya, Shomei Ryozaawa, Hiroyuki Isayama, Takao Itoi, Naohisa Yahagi

ABSTRACT

4120

Genomic profiling of *KRAS* wide-type pancreatic ductal adenocarcinomas identifies targetable genetic alterations.

AUTHOR(S)

Deng Wei, Xiaomo Li, Xinsheng Zhang, Tonghui Ma, Rong Liu

ABSTRACT

4121

Baseline level and early on-treatment clearance of circulating mutant *KRAS* in metastatic pancreatic ductal adenocarcinoma treated with chemotherapy with or without immunotherapy.

AUTHOR(S)

Jacob E. Till, Aseel Abdalla, Neha Bhagwat, Taylor A. Black, Zhuoyang Wang, Stephanie S. Yee, Pier F. Gherardini, Lacey J. Kitch, Cheryl Selinsky, Jaclyn P. Lyman, Theresa LaVallee, George A. Fisher Jr., Osama E. Rahma, Andrew H. Ko, Zev A. Wainberg, Robert A. Wolff, Eileen M. O'Reilly, Robert H. Vonderheide, Mark H. O'Hara, Erica L. Carpenter

ABSTRACT

4122

Gemcitabine plus nab-paclitaxel versus gemcitabine alone in elderly patients aged 76 years or older with unresectable pancreatic cancer: A propensity score-matched multicenter prospective observational study.

AUTHOR(S)

Satoshi Kobayashi, Motoko Suzuki, Makoto Ueno, Yuta Maruki, Junji Furuse, Akiko Todaka, Masato Ozaka, Kunihiro Tsuji, Kazuhiko Shioji, Keitaro Doi, Yasushi Kojima, Hidetaka Tsumura, Kazunari Tanaka, Hajime Higuchi, Ken Kawabe, Takeharu Yamanaka, Hiroshi Ishii

ABSTRACT

4123

Genomic alterations for novel targeted therapies in pancreatobiliary cancers from real-world data.

AUTHOR(S)

Kumiko Umemoto, Hiroyuki Yamamoto, Ritsuko Oikawa, Hiroyuki Takeda, Ayako Doi, Yoshiki Horie, Takashi Ogura, Takuro Mizukami, Naoki Izawa, Jay A. Moore, Ethan Sokol, Yu Sunakawa

ABSTRACT

4124

Alternating gemcitabine/nab-paclitaxel (GA) and 5-FU/leucovorin/irinotecan (FOLFIRI) as first-line treatment for *de novo* metastatic pancreatic cancer (MPC): Safety and effect.

AUTHOR(S)

Brett A. Schroeder, Margaret T. Mandelson, Vincent J. Picozzi

ABSTRACT

4125

Impact of G-CSF during neoadjuvant therapy on outcomes of operable pancreatic cancer.

AUTHOR(S)

Pranav Murthy, Mazen S. Zenati, Samer S. AlMasri, Aatur D. Singhi, Annissa DeSilva, Alessandro Paniccia, Kenneth K. Lee, Richard L. Simmons, Nathan Bahary, Michael T. Lotze, Amer H. Zureikat

ABSTRACT

4126

SBP-101, a polyamine metabolic inhibitor, administered in combination with gemcitabine and nab-paclitaxel, shows signals of efficacy as first-line treatment for subjects with metastatic pancreatic ductal adenocarcinoma.

AUTHOR(S)

Nimit Singhal, Darren Sigal, Niall C. Tebbutt, Aram F. Hezel, Adnan Nagrial, Sumit Lumba, Thomas J. George, Sheri L. Smith, Suzanne Gagnon, Michael Walker, Michael T. Cullen

ABSTRACT

4127

Randomized multicenter phase Ib/II study of neoadjuvant chemoradiation therapy (CRT) alone or in combination with pembrolizumab in patients with resectable or borderline resectable pancreatic cancer.

AUTHOR(S)

Osama E. Rahma, Matthew H. Katz, Brian M. Wolpin, Andressa Dias-Costa, Jonathan Nowak, Scott J. Rodig, Stephanie Dougan, Tanios S. Bekaii-Saab, Chee-Chee H. Stucky, Rawad Elias, Gina R. Petroni, Todd W. Bauer, Craig L. Slingluff Jr.

ABSTRACT

4128

Fecal microbiome composition in pancreatic cancer cachexia and response to nutrition support.

AUTHOR(S)

Natalie Moshayedi, Julianne Yang, Venu Lagishetty, Jonathan Jacobs, Veronica Placencio-Hickok, Arsen Osipov, Andrew E. Hendifar, Jun Gong

ABSTRACT

4129

Circulating cell free tumor DNA detection as a prognostic tool in advanced pancreatic cancer.

AUTHOR(S)

Gehan Botrus, Pedro L. Uson Junior, Puneet Raman, Adrienne Kaufman, Heidi E. Kosiorek, Mohamad B. Sonbol, Mitesh J. Borad, Daniel H. Ahn, Isabela Chang, Leylah Drusbosky, Jason S. Starr, Kabir Mody, Tanios S. Bekaii-Saab

ABSTRACT

4130

Body composition measurements and overall survival in patients with resectable pancreatic adenocarcinoma receiving neoadjuvant chemotherapy: Analysis from SWOG S1505.

AUTHOR(S)

Davendra Sohal, Mai T. Duong, Robert Boutin, Leon Lenchik, Jiyoung Kim, Namita Gandhi, Muhammad S. Beg, Andrea Wang-Gillam, James L. Wade III, Katherine A. Guthrie, Elena G. Chiorean, Syed A. Ahmad, Andrew M. Lowy, Howard S. Hochster, Philip A. Philip, Victor T. Chang

ABSTRACT

4131

The fear of cancer progression and recurrence in patients with pancreatic cancer.

AUTHOR(S)

Esther N. Pijnappel, Willemieke P. Dijksterhuis, Mirjam A. Sprangers, Simone Augustinus, Lonneke V. van de Poll-Franse, Judith de Vos-Geelen, Hjalmar van Santvoort, Ignace H. de Hingh, I. Q. Molenaar, Olivier R. Busch, Marc G. Besselink, Johanna Wilmink, Hanneke W. Van Laarhoven

ABSTRACT

4132

Local and systemic recurrence following total neoadjuvant therapy (TNT) and resection for borderline resectable and locally advanced pancreatic adenocarcinoma: Long-term follow up from two phase II studies.

AUTHOR(S)

Grace E. Ryan, Janet E. Murphy, Christine A. Ulysse, Beow Y. Yeap, Jennifer Y. Wo, Colin D. Weekes, Jeffrey W. Clark, Jill N. Allen, Lawrence S. Blaszkowsky, Ryan D. Nipp, Lorraine C. Drapek, Aparna R. Parikh, Christine Bolton, Jacob Maruna, Cristina R. Ferrone, Motaz Qadan, Keith D. Lillemoe, David P. Ryan, Carlos Fernandez Del-Castillo, Theodore S. Hong

ABSTRACT

4133

A phase 2 study of cyclophosphamide (CY), GVAX, pembrolizumab (Pembro), and stereotactic body radiation (SBRT) in patients (pts) with locally advanced pancreas cancer (LAPC).

AUTHOR(S)

Valerie Lee, Ding Ding, Christina Rodriguez, Beth Onners, Amol Narang, Jeffrey Meyer, Joseph M. Herman, Amy Hacker-Prietz, Richard A. Burkhart, William Burns, Jin He, Ana De Jesus-Acosta, Rachel B. Klein, Dan Laheru, Dung T. Le, Amy Ryan, Elizabeth Sugar, Lei Zheng

ABSTRACT

4134

Predictive value of germline *ATM* mutations in the CCTG PA.7 trial: Gemcitabine (GEM) and nab-paclitaxel (Nab-P) versus GEM, nab-P, durvalumab (D) and tremelimumab (T) as first-line therapy in metastatic pancreatic ductal adenocarcinoma (mPDAC).

AUTHOR(S)

Daniel J. Renouf, Jonathan M. Loree, Jennifer J. Knox, Petr Kavan, Derek J. Jonker, Stephen Welch, Felix Couture, Frederic Lemay, Mustapha Tehfe, Mohammed Harb, Nathalie Aucoin, Yoo-Joung Ko, Patricia A. Tang, James T. Topham, Shidong Jia, Pan Du, David F. Schaeffer, Sharlene Gill, Dongsheng Tu, Christopher J. O'Callaghan

ABSTRACT

4135

Impact of KRAS alterations in pancreatic ductal adenocarcinoma (PDAC).

AUTHOR(S)

Maahum Mehdi, Mandana Kamgar, Ben George, Aniko Szabo, Kaitlin Annunzio, Bradley W. Taylor, Aditya V. Shreenivas, Sakti Chakrabarti, James P. Thomas, Susan Tsai, Kathleen K. Christians, Douglas B. Evans, Callisia Clarke, William A. Hall, Beth Erickson, Gulrayz Ahmed, Bicky Thapa

ABSTRACT

4136

Impact of the COVID-19 pandemic on care delivery and outcomes for patients with metastatic pancreatic ductal adenocarcinoma (mPDAC).

AUTHOR(S)

Ravi K. Paluri, Paul Cockrum, Ashley A. Laursen, Joseph L. Gaeta, Shu Wang, Andy Surinach

ABSTRACT

4137

Efficacy and safety of KN046 plus nab-paclitaxel/gemcitabine as first-line treatment for unresectable locally advanced or metastatic pancreatic ductal adenocarcinoma (PDAC).

AUTHOR(S)

Gang Jin, Shiwei Guo, Yanqiao Zhang, Yue Ma, Xiaodong Guo, Xiaocui Zhou, Qin Yu

ABSTRACT

4138

A phase II trial combining tumor-targeting *TP53* gene therapy with gemcitabine/nab-paclitaxel as a second-line treatment for metastatic pancreatic cancer.

AUTHOR(S)

Chris P. Leung, Minal A. Barve, Ming-Shiang Wu, Kathleen F. Pirollo, James F. Strauss, Wei-Chih Liao, Shih-Hung Yang, Robert A. Nunan, Jana Adams, Joe B. Harford, Esther H. Chang

ABSTRACT

4139

Genetic and immune divergence in pancreatic cancer lesions at the time of metastatic relapse compared to primary tumor.

AUTHOR(S)

Bereket Gebregziabher, Derek A. Oldridge, Emma E. Furth, Michael D. Feldman, Andrew J. Rech, Robert H. Vonderheide

ABSTRACT

4140

Identification of pancreatic adenocarcinoma molecular subtypes on histology slides using deep learning models.

AUTHOR(S)

Charlie Saillard, Flore Delecourt, Benoit Schmauch, Olivier Moindrot, Magali Svrcek, Armelle Bardier-Dupas, Jean Francois Emile, Mira Ayadi, Louis De Mestier, Pascal Hammel, Cindy Neuzillet, Jean-Baptiste Bachet, Juan Iovanna, Dusetti J. Nelson, Valerie Paradis, Mikhail Zaslavskiy, Aurelie Kamoun, Pierre Courtiol, Remy Nicolle, Jerome Cros

ABSTRACT

4141

Impact of KRAS mutational status on outcomes in patients with pancreatic cancer (PDAC).

AUTHOR(S)

Lucy X. Ma, Gun Ho Jang, Amy Zhang, Robert E. Denroche, Anna Dodd, Stephanie Ramotar, Shawn Hutchinson, Yifan Wang, Mustapha Tehfe, Ravi Ramjeesingh, James J. Biagi, Bernard Lam, Julie Wilson, Faiyaz Notta, Sandra Fischer, Robert C. Grant, George Zogopoulos, Steven Gallinger, Jennifer J. Knox, Grainne M. O'Kane

ABSTRACT

4142

TCOG T5217 trial: A phase II randomized study of SLOG versus modified FOLFIRINOX as the first-line treatment in locally advanced or metastatic pancreatic ductal adenocarcinoma.

AUTHOR(S)

Nai-Jung Chiang, Yan-Shen Shan, Li-Yuan Bai, Chung-Pin Li, Jen-Shi Chen, Shih-Hung Yang, Yung-Chia Kuo, Yee Chao, Yao-yu Hsieh, Hsiang-fong Kao, Chin-Fu Hsiao, Li-Tzong Chen

ABSTRACT

4143

Treatment with pembrolizumab in combination with the oncolytic virus pelareorep promotes anti-tumor immunity in patients with advanced pancreatic adenocarcinoma.

AUTHOR(S)

Devalingam Mahalingam, Siqi Chen, Ping Xie, Aparna Kalyan, Sheetal M. Kircher, Masha Kocherginsky, Jiahui Xu, Victoria Maurer, Pedro A. Viveiros, Elena Vagia, Grey A. Wilkinson, Matthew C. Coffey, Mary F. Mulcahy, Al B. Benson III, Bin Zhang

ABSTRACT

4144

Association of total neoadjuvant therapy with major pathologic response and survival in localized pancreatic cancer: A multi-institutional analysis of 504 patients.

AUTHOR(S)

Jashodeep Datta, Amber Collier, Joshua Kronenfeld, Gregory Wilson, Ugwuji Maduekwe, Rebecca A. Snyder, Sharon M. Weber, William G. Hawkins, Hong Jin J. Kim, Alexander A. Parikh, Chet Hammill, David A. Kooby, Daniel Abbott, Shishir K. Maithel, Peter J. Hosein, Syed A. Ahmad, Nipun B. Merchant

ABSTRACT

4145

Prognostic and predictive factors in patients treated with ramucirumab (RAM) with advanced hepatocellular carcinoma (aHCC) and elevated alpha-fetoprotein (AFP): Results from two phase III trials.

AUTHOR(S)

Josep M. Llovet, Amit G. Singal, Augusto Villanueva, Richard S. Finn, Masatoshi Kudo, Peter R. Galle, Chunxiao Wang, Ryan C. Widau, Elena Gonzalez Gugel, Andrew X. Zhu

ABSTRACT

4146

Prognostic impact of pSTAT3 on overall survival (OS) in gastrointestinal (GI) cancers: Data from 3 phase 3, randomized controlled trials (RCTs).

AUTHOR(S)

Emily Brooks, Claudia Lebedinsky, Tanios S. Bekaii-Saab, Manish A. Shah, Derek J. Jonker, Kamesh Kuchimanchi, Ewa Wybieralska, Marilyn Fontaine, Cindy Oh, Suha Sari, Emma Foos, Bo Xu, Matthew Hitron

ABSTRACT

4147

Phase II study of pembrolizumab-based therapy in previously treated extrapulmonary poorly differentiated neuroendocrine carcinomas: Results of Part B (pembrolizumab + chemotherapy).

AUTHOR(S)

Jennifer A. Chan, Nitya P. Raj, Rahul R. Aggarwal, Susan Calabrese, April DeMore, Mallika S. Dhawan, Delaire Fattah, Lawrence Fong, Jennifer Grabowsky, Thomas A. Hope, Kanti P. Kolli, Pamela N. Munster, Kimberly Perez, Diane L. Reidy, Sofia Von Fedak, Li Zhang, Emily K. Bergsland

ABSTRACT

4148

Preventive HIPEC in combination with perioperative FLOT versus FLOT alone for resectable diffuse type gastric and gastroesophageal junction type II/III adenocarcinoma: The phase III “PREVENT” trial of the AIO /CAOGI /ACO.

AUTHOR(S)

Thorsten O. Goetze, Pompiliu Piso, Sylvie Lorenzen, Ulli S. Bankstahl, Marcin Ostrzyzek, Claudia Pauligk, Timursah Habibzade, Daniel Reim, Wolf O. Bechstein, Alfred Königsrainer, Stefan P. Mönig, Beate Rau, Matthias Schwarzbach, Salah-Eddin Al-Batran

ABSTRACT

TPS4149

AdvanTIG-203: A randomized phase 2 study comparing anti-TIGIT ociperlimab plus tislelizumab versus tislelizumab plus placebo as second-line treatment in patients with advanced or recurrent esophageal squamous cell carcinoma (ESCC) expressing programmed death-ligand 1 (PD-L1).

AUTHOR(S)

Rui-hua Xu, Sung-Bae Kim, David Tougeron, Yunxia Zuo, Haiyuan Yang, Juan Zhang, Jingwen Shi, Eric Van Cutsem

ABSTRACT

TPS4150

MATTERHORN: Efficacy and safety of neoadjuvant-adjuvant durvalumab and FLOT chemotherapy in resectable gastric and gastroesophageal junction cancer—A randomized, double-blind, placebo-controlled, phase 3 study.

AUTHOR(S)

Yelena Y. Janjigian, Eric Van Cutsem, Kei Muro, Zev A. Wainberg, Salah-Eddin Al-Batran, Woo Jin Hyung, Daniela Molena, Brent Evans, Dario Ruscica, Scott H. Robbins, Alejandra Negro, Josep Tabernero

ABSTRACT

TPS4151

Phase II trial of docetaxel and ramucirumab combination therapy as second-line treatment in patients with metastatic or advanced gastric cancer (HGCSG1903).

AUTHOR(S)

Rika Saito, Yasuyuki Kawamoto, Satoshi Yuki, Susumu Sogabe, Masayoshi Dazai, Ayumu Hosokawa, Kentaro Sawada, Atsushi Sato, Michio Nakamura, Kazuteru Hatanaka, Atsushi Ishiguro, Osamu Muto, Yoshiaki Shindo, Yasushi Tsuji, Miki Tateyama, Akira Ueda, Takahide Sasaki, Masaki Katagiri, Naoya Sakamoto, Yoshito Komatsu

ABSTRACT

TPS4152

Biomarker-oriented study of durvalumab in combination with olaparib and paclitaxel in gastric cancer: A phase 2 trial-in-progress.

AUTHOR(S)

Tae Yong Kim, Jee Sun Yoon, Ah-Rong Nam, Ju-Hee Bang, Kyoung Seok Oh, Hye-Rim Seo, Jae-Min Kim, Do-Youn Oh

ABSTRACT

TPS4153

TGF- β and PD-L1 inhibition combined with definitive chemoradiotherapy in esophageal squamous cell carcinoma: A phase II clinical trial (NCT04595149).

AUTHOR(S)

Linde M. Veen, Maarten C. Hulshof, Connie R. Jimenez, Edwin P. Cuppen, Laurens V. Beerepoot, Geert-Jan Creemers, W. Edward Fiets, Paul M. Jeene, Djoeri Lipman, Nadia Haj Mohammad, Vera Oppedijk, Marije Slingerland, Walter L. Vervenne, Maarten F. Bijlsma, Hanneke W. Van Laarhoven

ABSTRACT

TPS4154

MONEO: A phase II study of avelumab (Av) plus FLOT in the peri-operative treatment for patients (pts) with resectable gastric or gastroesophageal junction cancer (GC).

AUTHOR(S)

Maria Alsina, Mariano Ponz-Sarvise, Dario Lopez Garcia, Marta Gonzalez, Carlos E De Andrea, Alena Gros, Ana Vivancos, Paula Jiménez-Fonseca, Marc Diez Garcia, Virginia Arrazubi, Enrique Sanz-Garcia, Eva Martínez de Castro, Raquel Guardeno, Mariona Calvo, Cristina Buges, Federico Longo, Josep Tabernero, Guillermo Villacampa, Susana Muñoz, Ignacio Melero

ABSTRACT

TPS4155

EORTC 1707 VESTIGE: Adjuvant immunotherapy in patients with resected gastric cancer following preoperative chemotherapy with high risk for recurrence (ypN+ and/or R1)—An open-label randomized controlled phase II study.

AUTHOR(S)

Elizabeth C. Smyth, Ellen Peeters, Maren Kristina Knoedler, Anne Giraut, Anna D. Wagner, Markus H. Moehler, Nicole C. van Grieken, Magnus Nilsson, Murielle E. Mauer, Florian Lordick

ABSTRACT

TPS4156

A phase II study of short course FOLFOX chemotherapy with either nivolumab (Nivo) or Nivo plus radiation in the first line treatment of metastatic or unresectable gastroesophageal (GEA) cancers.

AUTHOR(S)

Rutika Mehta, Sarbajit Mukherjee, Kelsey Klute, Haeseong Park, Uqba Khan, Sahrish Khan, Carina Puella, Sabrina Machado, Paul J. Christos, Nicholas J. Sanfilippo, Manish A. Shah

ABSTRACT

TPS4157

A multicenter, randomized phase 1b/2 study of gemcitabine and cisplatin with or without CPI-613 as first-line therapy for patients with advanced unresectable biliary tract cancer (BiT-04).

AUTHOR(S)

Vaibhav Sahai, Amy E. Chang, Oxana V. Crysler, David B. Zhen, Muhammad S. Beg, Timothy S. Pardee, Sanjeev Luther, Kent A. Griffith, Mark Zalupski

ABSTRACT

TPS4158

The IMMULAB trial: A phase II trial of immunotherapy with pembrolizumab in combination with local ablation for patients with early stage hepatocellular carcinoma (HCC).

AUTHOR(S)

Arndt Vogel, Thorsten O. Goetze, Guido Hausner, Michael Geißler, Gabriele M. Siegler, Ludwig Fischer von Weikersthal, Angelika M. Kestler, Matthias Kleiß, Tobias Müller, Andreas Teufel, Jens Marquardt, Maria A. Gonzalez-Carmona, Daniel W. Mueller, Regina Eickhoff, Enrico N. de Toni, Oliver Waidmann, Salah-Eddin Al-Batran

ABSTRACT

TPS4159

Camrelizumab plus apatinib combined with TACE and cryoablation in the first-line treatment of advanced hepatocellular carcinoma.

AUTHOR(S)

Wenge Xing, Zhi Guo

ABSTRACT

TPS4160

A phase II trial of trastuzumab plus modified-FOLFOX for gemcitabine/cisplatin refractory HER2-positive biliary tract cancer (BTC): Multi-institutional study of the Korean Cancer Study Group (KCSG-HB19-14).

AUTHOR(S)

Choong-kun Lee, Jaekyung Cheon, Hong Jae Chon, Min Hwan Kim, Jin Won Kim, Myung Ah Lee, Hyung Soon Park, Myoung Joo Kang, Joung-Soon Jang, Hye Jin Choi

ABSTRACT

TPS4161

REPLACEMENT trial in progress: Combination therapy with atezolizumab plus bevacizumab for TACE unsuitable patients with beyond up-to-seven criteria in intermediate stage hepatocellular carcinoma: A phase II study.

AUTHOR(S)

Kazuomi Ueshima, Masatoshi Kudo, Takeharu Yamanaka, Hiroshi Aikata, Tatsuya Yamashita, Masafumi Ikeda, Ryosuke Tateishi, Michihisa Moriguchi, Atsushi Hiraoka, Kaoru Tsuchiya, Sadahisa Ogasawara, Satoshi Mochida, Shiro Miyayama, Kiyoshi Hasegawa, Kenichi Yoshimura, Tetsuo Takehara

ABSTRACT

TPS4162

CaboRISE: A phase II study evaluating reduced starting dose and dose escalation of cabozantinib as second-line therapy for advanced HCC in patients with compensated liver cirrhosis.

AUTHOR(S)

Jorg Trojan, Stefan Pluntke, Florian van Boemmel, Ursula Ehmer, Thorsten O. Goetze, Lutz Jacobasch, Daniel Pink, Christina Kopp, Sarah Lehnerts, Johanna Riedel, Oliver Waidmann, Fabian Finkelmeier, Michael Geißler

ABSTRACT

TPS4163

Phase III study of NUC-1031 + cisplatin versus gemcitabine + cisplatin for first-line treatment of patients with advanced biliary tract cancer (NuTide:121).

AUTHOR(S)

Jennifer J. Knox, Mairead G. McNamara, Lipika Goyal, David Cosgrove, Christoph Springfeld, Katrin M. Sjoquist, Joon Oh Park, Helena Verdager, Chiara Braconi, Paul J. Ross, Do-Youn Oh, Aimery De Gramont, John R. Zalberg, Daniel H. Palmer, Juan W. Valle

ABSTRACT

TPS4164

First-in-human study of highly selective FGFR2 inhibitor, RLY-4008, in patients with intrahepatic cholangiocarcinoma and other advanced solid tumors.

AUTHOR(S)

Alison M. Schram, Suneel D. Kamath, Anthony B. El-Khoueiry, Mitesh J. Borad, Kabir Mody, Amit Mahipal, Lipika Goyal, Vaibhav Sahai, Oleg Schmidt-Kittler, Jinshan Shen, Kai Yu Jen, Alicia Deary, Cori Ann Sherwin, Mahesh Padval, Beni B. Wolf, Vivek Subbiah

ABSTRACT

TPS4165

DNA-damage response-umbrella study of the combination of ceralasertib and olaparib, or ceralasertib and durvalumab in advanced biliary tract cancer: A phase 2 trial-in-progress.

AUTHOR(S)

Jee Sun Yoon, Jin Won Kim, Ji-Won Kim, Tae-Yong Kim, Ah-Rong Nam, Ju-Hee Bang, Hye-Rim Seo, Jae-Min Kim, Kyoung Seok Oh, Peter G. Mortimer, Simon Smith, Do-Youn Oh

ABSTRACT

TPS4166

Assessing safety and activity of cabozantinib combined with lanreotide in gastroenteropancreatic (GEP) and thoracic neuroendocrine tumors (NETs): The phase II LOLA trial.

AUTHOR(S)

Francesca Corti, Vito Amoroso, Davide Campana, Maria Pia Brizzi, Francesco Panzuto, Ivana Puliafito, Natalie Prinzi, Massimo Milione, Monica Niger, Maria Antista, Alessandra Raimondi, Federica Morano, Michele Prisciandaro, Teresa Beninato, Filippo Pagani, Giovanni Randon, Iolanda Pulice, Maria Di Bartolomeo, Filippo G. De Braud, Sara Pusceddu

ABSTRACT

TPS4167

Biologically optimized schedule of gemcitabine and nab-paclitaxel regimen in metastatic pancreatic adenocarcinoma.

AUTHOR(S)

Laith I. Abushahin, Anne M. Noonan, John L. Hays, Pannaga G. Malalur, Ashish Manne, Ning Jin, Arjun Mittra, Rifat T. Elkhatib, Sameek Roychowdhury, Terence M. Williams

ABSTRACT

TPS4168

Camrelizumab combined with ablation and chemotherapy for pancreatic cancer with liver metastases: A single-arm, phase II, prospective clinical study.

AUTHOR(S)

Zhiwei Li, Qingwei Li, Zhigang Ma, Yue Ma, Dan Su, Changjie Lou, Guangyu Wang, Chao Liu, Yanqiao Zhang

ABSTRACT

TPS4169

A phase II, open-label pilot study evaluating the safety and activity of liposomal irinotecan (Nal-IRI) in combination with 5-FU and oxaliplatin (NALIRIFOX) in preoperative treatment of pancreatic adenocarcinoma (NEO-Nal-IRI study) (NCT03483038).

AUTHOR(S)

Sherise C. Rogers, Brian H. Ramnarain, Kathryn Hitchcock, Steven J. Hughes, Ji-Hyun Lee, Z. H. Fan, Carmen J. Allegra, Jose Trevino, Ahmad El-Far, Anita A. Turk, Karen B. Russell, David L. DeRemer, Thomas J. George

ABSTRACT

TPS4170

Total neoadjuvant FOLFIRINOX or gemcitabine-based chemoradiotherapy and adjuvant gemcitabine for resectable and borderline resectable pancreatic cancer (PREOPANC-2): A nationwide multicenter randomized controlled trial.

AUTHOR(S)

Quisette Janssen, Jacob L. van Dam, Marc G. Besselink, Marjolein Y. Homs, Geertjan van Tienhoven, Johanna W. Wilmink, Bas Groot Koerkamp

ABSTRACT

TPS4171

Australasian Gastro-Intestinal Trials Group (AGITG) MASTERPLAN: Randomized phase II study of modified neoadjuvant FOLFIRINOX alone or in combination with stereotactic radiotherapy (SBRT) for patients with high-risk and locally advanced pancreatic cancer.

AUTHOR(S)

Andrew Oar, Andrew Kneebone, Mark Lee, David Goldstein, Katrin M. Sjoquist, Hien Le, Julie Chu, Andrew Barbour, Leily Gholamrezaei, James F. Lynam, Andrej Bece, Sandra Bahamad, Sonia Yip, David Espinoza, Lorraine A. Chantrell, Alisha Moore, Dominique Lee, Quoc Nam Nguyen, Jaswinder Samra, No Firstname Jan.Mumford@Tics.Com.Au

ABSTRACT

TPS4172

Phase II study of the anti-TGF- β monoclonal antibody (mAb) NIS793 with and without the PD-1 inhibitor spartalizumab in combination with nab-

paclitaxel/gemcitabine (NG) versus NG alone in patients (pts) with first-line metastatic pancreatic ductal adenocarcinoma (mPDAC).

AUTHOR(S)

Peter Grell, Chia-Chi Lin, Michele Milella, Cheng E. Chee, Shivan Sivakumar, Katriina J. Peltola, Geraldine Bostel, Dragana Jankovic, Maria-Athina Altzerinakou, Claire Fabre, Armando Santoro

ABSTRACT

TPS4173

Trial in progress: Open-label, randomized, comparative phase 2/3 study of combination immunotherapy plus standard-of-care chemotherapy and SBRT versus standard-of-care chemotherapy for the treatment of locally advanced or metastatic pancreatic cancer.

AUTHOR(S)

Tara E. Seery, Chaitali S. Nangia, Leonard S. Sender, Sandeep K. Reddy, Patrick Soon-Shiong

ABSTRACT

TPS4174

GRECO-2: A randomized, phase 2 study of stereotactic body radiation therapy (SBRT) in combination with GC4711 in the treatment of unresectable or borderline resectable nonmetastatic pancreatic cancer (PC).

AUTHOR(S)

Sarah E. Hoffe, Dae W. Kim, James Costello, Mokenge P. Malafa, Todd A. Aguilera, Muhammad S. Beg, Parag Parikh, Joseph M. Herman, Jon Holmlund, Kara Terry, Elizabeth C. Moser

ABSTRACT

TPS4175

A phase II open-label study of cpi-613 in combination with modified (m)FOLFIRINOX in patients with locally advanced pancreatic cancer.

AUTHOR(S)

David L. Bajor, AMR MOHAMED, J. Eva Selfridge, Erin E. Anderson, Jeffrey Hardacre, John B. Ammori, Richard T. Lee, Joel N. Saltzman, Jordan M. Winter

ABSTRACT

TPS4176

Genitourinary Cancer—Kidney and Bladder

[Back to Program](#)

Showing 79 Presentations

<https://meetinglibrary.asco.org/session/13630>

Safety and efficacy of rogaratinib in combination with atezolizumab in cisplatin-ineligible patients (pts) with locally advanced or metastatic urothelial cancer (UC) and *FGFR* mRNA overexpression in the phase Ib/II FORT-2 study.

AUTHOR(S)

Jonathan E. Rosenberg, Pablo Gajate, Rafael Morales-Barrera, Jae-Lyun Lee, Andrea Necchi, Nicolas Penel, Vittorina Zagonel, Mitchell R. Sierecki, Weichao Bao, Yinghui Zhou, Peter Ellinghaus, Randy F. Sweis

ABSTRACT

4521

Phase I/II study to evaluate the efficacy of TAS0313, a cancer peptide vaccine, combined with pembrolizumab for locally advanced or metastatic urothelial carcinoma.

AUTHOR(S)

Ryuji Matsumoto, Junji Yonese, Takashi Kawahara, Hideaki Miyake, Nobuaki Matsubara, Hiroji Uemura, Masatoshi Eto, Haruhito Azuma, Wataru Obara, Akito Terai, Satoshi Fukasawa, Shigetaka Suekane, Hiroyuki Nishiyama

ABSTRACT

4522

Circulating tumor cell-driven use of neoadjuvant chemotherapy in patients with muscle-invasive bladder cancer.

AUTHOR(S)

Nick Beije, Ingeborg E. de Kruijff, Joep de Jong, Sjoerd O. Klaver, Peter de Vries, Rens Jacobs, Diederik M. Somford, Ed te Slaa, Toine van der Heijden, Johannes A. Witjes, Laurent Fossion, Egbert Boeve, John van der Hoeven, Harm H. van Melick, Carl J. Wijburg, John W. Martens, Ronald De Wit, Jaco Kraan, Stefan Sleijfer, Joost L. Boormans

ABSTRACT

4523

Enfortumab vedotin in cisplatin-ineligible patients with locally advanced or metastatic urothelial cancer who received prior PD-1/PD-L1 inhibitors: An updated analysis of EV-201 Cohort 2.

AUTHOR(S)

Bradley A. McGregor, Arjun V. Balar, Jonathan E. Rosenberg, Michiel S. Van Der Heijden, Se Hoon Park, Jae-Lyun Lee, Takahiro Kojima, Michael R. Harrison, Elisabeth I. Heath, Mark N. Stein, Yohann Loriot, Andrea Necchi, Joyce L. Steinberg, Shang-Ying Liang, Janet Trowbridge, Daniel P. Petrylak, Evan Y. Yu

ABSTRACT

4524

Avelumab first-line (1L) maintenance plus best supportive care (BSC) versus BSC alone for advanced urothelial carcinoma (UC): Analysis of time to end of next-line therapy in JAVELIN Bladder 100.

AUTHOR(S)

Petros Grivas, Se Hoon Park, Eric Voog, Evgeny Kopyltsov, Howard Gurney, David Q. Muniz, Frederic Rolland, Anne B. Als, Begoña P. Valderrama, Jing Wang, Nuno M. Costa, Robert J. Laliberte, Alessandra Di Pietro, Thomas Powles, Joaquim Bellmunt

ABSTRACT

4525

Large cell neuroendocrine carcinoma of the urothelial tract (LNEC): The MSKCC experience.

AUTHOR(S)

Brendan J. Guercio, Jatin Gandhi, Min Yuen Teo, Michael Lattanzi, Samuel A. Funt, David H. Aggen, Ying-Bei Chen, Samson Fine, Eugene J. Pietzak, Bernard H. Bochner, Guido Dalbagni, Michael F. Berger, David B. Solit, Satish Tickoo, Victor E. Reuter, Dean F. Bajorin, Jonathan E. Rosenberg, Hikmat A. Al-Ahmadie, Gopa Iyer

ABSTRACT

4526

Avelumab first-line (1L) maintenance for advanced urothelial carcinoma (UC) in the JAVELIN Bladder 100 trial: Subgroup analysis by duration of treatment-free interval (TFI) from end of chemotherapy to start of maintenance.

AUTHOR(S)

Srikala S. Sridhar, Thomas Powles, Yohann Loriot, Miguel A. Climent Durán, Shilpa Gupta, Norihiko Tsuchiya, Aristotelis Bamias, Andrea Ardizzoni, Anders Ullén, Bo Huang, Nuno M. Costa, Robert J. Laliberte, Alessandra Di Pietro, Cora N. Sternberg, Petros Grivas

ABSTRACT

4527

Study EV-103: Update on durability results and long term outcome of enfortumab vedotin + pembrolizumab in first line locally advanced or metastatic urothelial carcinoma (la/mUC).

AUTHOR(S)

Terence W. Friedlander, Matthew I. Milowsky, Mehmet A. Bilen, Sandy Srinivas, Rana R. McKay, Thomas W. Flaig, Christopher J. Hoimes, Arjun V. Balar, Elizabeth Henry, Daniel P. Petrylak, Carolyn Sasse, Ritesh S. Kataria, Yao Yu, Anne-Sophie Carret, Jonathan E. Rosenberg

ABSTRACT

4528

Effect of Bacillus Calmette-Guerin (BCG) exposure on severity of COVID-19 infection: A COVID-19 and Cancer Consortium (CCC19) study.

AUTHOR(S)

Andrew L. Schmidt, Ziad Bakouny, Chris Labaki, Babar Bashir, Jessica M. Clement, Natasha C. Edwin, Daniel B. Flora, Jennifer Girard, Shuchi Gulati, Clara Hwang, Chinmay Jani, Gilberto Lopes, Ruben A. Mesa, Gil Redelman-Sidi, Sanjay Mishra, Jeremy L. Warner, Toni K. Choueiri

ABSTRACT

4529

Fibroblast growth factor receptor alteration (*FGFRα*) status and progression outcomes of patients with advanced or metastatic urothelial cancer (mUC).

AUTHOR(S)

Sarah Fleming, Dina Gifkins, Waleed Shalaby, Jianjun Gao, Philip Rosenberg, Christopher Gaj, Albert Crawford, Grace L. Lu-Yao, Vittorio Maio, Arlene O. Siefker-Radtke

ABSTRACT

4530

Safety evaluation of combined PD-1+CTLA4 inhibition concurrently to chemoradiotherapy (CRT) in localized muscle invasive bladder carcinoma (MIBC).

AUTHOR(S)

Ben-Max de Ruiter, Jons W. van Hattum, Theo M. De Reijke, Jorg R. Oddens, Maarten C. Hulshof, Adriaan D. Bins

ABSTRACT

4531

Pembrolizumab (pembro) versus investigator's choice of paclitaxel, docetaxel, or vinflunine in recurrent, advanced urothelial cancer (UC): 5-year follow-up from the phase 3 KEYNOTE-045 trial.

AUTHOR(S)

Joaquim Bellmunt, Andrea Necchi, Ronald De Wit, Jae-Lyun Lee, Lawrence Fong, Nicholas J. Vogelzang, Miguel A. Climent Durán, Daniel P. Petrylak, Toni K. Choueiri, Winald R. Gerritsen, Howard Gurney, David I. Quinn, Stephane Culine, Cora N. Sternberg, Jin Zhi Xu, Blanca Homet Moreno, James L. Godwin, Dean F. Bajorin, David J. Vaughn, Yves Fradet

ABSTRACT

4532

Stool microbiota profiling of patients with muscle invasive bladder cancer receiving neoadjuvant pembrolizumab.

AUTHOR(S)

Filippo Pederzoli, Irene Locatelli, Michela Riba, Marco Bandini, Daniele Raggi, Laura Marandino, Elisa Alchera, Patrizia Giannatempo, Paolo Provero, Dejan Lazarevic, Roberta Lucianò, Andrea Gallina, Alberto Briganti, Francesco Montorsi, Andrea Salonia, Andrea Necchi, Massimo Alfano

ABSTRACT

4533

RC48-ADC combined with toripalimab, an anti-PD-1 monoclonal antibody (Ab), in patients with locally advanced or metastatic urothelial carcinoma (UC): Preliminary results of a phase Ib/II study.

AUTHOR(S)

Li Zhou, Huayan Xu, Xieqiao Yan, Zhihong Chi, Chuanliang Cui, Lu Si, Bixia Tang, Lili Mao, Bin Lian, Xuan Wang, Siming Li, Xue Bai, Jun Guo, Xinan Sheng

ABSTRACT

4534

Influence of first-line chemotherapy regimen on survival outcomes of patients with advanced urothelial carcinoma who receive second-line immunotherapy.

AUTHOR(S)

Benjamin Miron, Elizabeth A. Handorf, Kevin Zarrabi, Matthew R. Zibelman, Pooja Ghatalia, Fern Anari, Elizabeth R. Plimack, Daniel M. Geynisman

ABSTRACT

4535

Use of neoadjuvant chemotherapy in elderly patients with muscle invasive bladder cancer: A population-based study, 2006 to 2017.

AUTHOR(S)

Natasza Posielski, Nathan Jung, Hannah Koenig, On Ho, John P. Flores, Christopher Porter

ABSTRACT

4536

Response and outcomes to immune checkpoint inhibitors (ICI) in advanced urothelial cancer (aUC) based on prior intravesical BCG.

AUTHOR(S)

Rafee Talukder, Dimitrios Makrakis, Daniel Castellano, Vadim S. Koshkin, Ajjai S. Alva, Tyler F. Stewart, Victor S. Santos, Jayanshu Jain, Rafael Morales-Barrera, Michael Grant, Ariel A. Nelson, Evan Shreck, Alexander Sankin, Roubini Zakopoulou, Alejo Rodriguez-Vida, Sandy Liu, Ana Fröbe, Giuseppe Di Lorenzo, Petros Grivas, Ali R. Khaki

ABSTRACT

4537

Real-world treatment patterns and clinical outcomes among patients with metastatic urothelial carcinoma.

AUTHOR(S)

Daniel M. Geynisman, Edward Broughton, Hasan Alhasani, Yi Hao, Ying Zhang, Brian Stwalley, Trong K. Le, Stephen Huo

ABSTRACT

4538

Quality of life, functioning, and symptoms in patients with previously treated locally advanced or metastatic urothelial carcinoma from EV-301: A randomized phase 3 trial of enfortumab vedotin versus chemotherapy.

AUTHOR(S)

Ronac Mamtani, Jonathan E. Rosenberg, Thomas Powles, Guru P. Sonpavde, Yohann Loriot, Ignacio Duran, Jae-Lyun Lee, Nobuaki Matsubara, Christof Vulsteke, Daniel Castellano, Srikala S. Sridhar, Helle Pappot, Begoña P. Valderrama, Howard Gurney, Jens Bedke, Michiel S. Van Der Heijden, Chunzhang Wu, Zsolt Hepp, Caroline McKay, Daniel P. Petrylak

ABSTRACT

4539

Impact of recurrence on health-related quality of life in patients at high risk of recurrence after radical surgery for muscle-invasive urothelial carcinoma (MIUC): Results from the phase 3 CheckMate 274 trial.

AUTHOR(S)

Matt D. Galsky, Johannes A. Witjes, Jürgen Gschwend, Julia Braverman, Edward Broughton, Federico Nasroulah, Hasan Alhasani, Mario Maira-Arce, Xiaomei Ye, Ling Shi, Melissa Hamilton, Dean F. Bajorin

ABSTRACT

4540

Phase II trial of atezolizumab in BCG-unresponsive non-muscle invasive bladder cancer: SWOG S1605 (NCT #02844816).

AUTHOR(S)

Peter C. Black, Catherine Tangen, Parminder Singh, David J. McConkey, Scott Lucia, William T. Lowrance, Vadim S. Koshkin, Kelly L. Stratton, Trinity Bivalacqua, Wassim Kassouf, Sima P. Porten, Rick Bangs, Melissa Plets, Seth P. Lerner, Ian M. Thompson Jr.

ABSTRACT

4541

Genomic predictors of response to PD-1 axis inhibitors in metastatic urothelial cancer (mUC) patients using machine learning analysis of tissue comprehensive genomic profiling (CGP).

AUTHOR(S)

Raquel Reisinger, Victor Sacristan Santos, Roberto Nussenzeig, Sergiusz Wesolowski, Edgar J. Hernandez, Alexander R. Henrie, Benjamin L. Maughan, Umang Swami, Mark Yandell, Petros Grivas, Neeraj Agarwal

ABSTRACT

4542

Survival outcomes in patients receiving immune checkpoint inhibitor (ICI) for metastatic small cell urothelial cancer (SCUC).

AUTHOR(S)

Omar Alhalabi, Nathaniel Wilson, Neema Navai, Matthew T. Campbell, Amishi Y. Shah, Jianjun Gao, Paul G. Corn, Ana Aparicio, Bogdan Czerniak, Charles Guo, Christopher Logothetis, Nizar M. Tannir, Seungtaek Choi, Arlene O. Siefker-Radtke

ABSTRACT

4543

Phase I/II trial of pembrolizumab and cabozantinib in the treatment of metastatic renal cell carcinoma (mRCC).

AUTHOR(S)

Elizabeth R. Kessler, Junxiao Hu, Geetika Srivastava, Douglas J. Kemme, Praveena Iruku, Vishal Rana, Steven R. Schuster, Mali Amirault, Eryn Callihan, Thomas W. Flaig, Elaine T. Lam

ABSTRACT

4544

Health care disparities and barriers to palliative care among metastatic renal cell carcinoma patients: An NCDB analysis.

AUTHOR(S)

Janvi Wadiwala, Mausam Patel, Chenghui Li, Sanjay Maraboyina, Ahmed Safar, Thomas Kim

ABSTRACT

4545

TIVO-3: Durability of response and updated overall survival of tivozanib versus sorafenib in metastatic renal cell carcinoma (mRCC).

AUTHOR(S)

Elena Verzoni, Bernard Escudier, Thomas E. Hutson, David F. McDermott, Sumanta K. Pal, Camillo Porta, Brian I. Rini, Michael N. Needle, Michael B. Atkins

ABSTRACT

4546

Integrating peripheral biomarker analyses from JAVELIN Renal 101: Avelumab + axitinib (A + Ax) versus sunitinib (S) in advanced renal cell carcinoma (aRCC).

AUTHOR(S)

Toni K. Choueiri, Amber C. Donahue, Brian I. Rini, Thomas Powles, John B. Haanen, James Larkin, Xinmeng J. Mu, Jie Pu, Despina Thomaïdou, Alessandra Di Pietro, Paul B. Robbins, Robert J. Motzer

ABSTRACT

4547

Association of C-reactive protein (CRP) with efficacy of avelumab + axitinib (A + Ax) in advanced renal cell carcinoma (aRCC): Long-term follow-up results from JAVELIN Renal 101.

AUTHOR(S)

Yoshihiko Tomita, James Larkin, Balaji Venugopal, John B. Haanen, Hiro-Omi Kanayama, Masatoshi Eto, Marc-Oliver Grimm, Yosuke Fujii, Yoshiko Umeyama, Mariangela Mariani, Alessandra Di Pietro, Toni K. Choueiri

ABSTRACT

4548

Association between neutrophil-to-eosinophil ratio (NER) and efficacy outcomes in the JAVELIN Renal 101 study.

AUTHOR(S)

Matthew D. Tucker, Martin H. Voss, Toni K. Choueiri, Mehmet A. Bilen, Marc-Oliver Grimm, Paul D. Nathan, Christian K. Kollmannsberger, Yoshihiko Tomita, Bo Huang, Despina Thomaïdou, Mariangela Mariani, Alessandra Di Pietro, Brian I. Rini

ABSTRACT

4549

Camrelizumab plus famitinib for advanced renal cell carcinoma or unresectable urothelial carcinoma: Updated results from a phase II trial.

AUTHOR(S)

Yuan-Yuan Qu, Qing Zou, Hongqian Guo, Nianzeng Xing, Zhongquan Sun, Weiqing Han, Hong Luo, Shujie Xia, Xuepei Zhang, Chaohong He, Hailiang Zhang, Jinling Cai, Xiao Zhang, Quanren Wang, Dingwei Ye

ABSTRACT

4550

Real-world outcomes in patients with metastatic clear cell renal cell carcinoma receiving front-line axitinib plus pembrolizumab versus ipilimumab plus nivolumab.

AUTHOR(S)

Kevin Zarrabi, Elizabeth A. Handorf, Benjamin Miron, Matthew R. Zibelman, Fern Anari, Pooja Ghatalia, Elizabeth R. Plimack, Daniel M. Geynisman

ABSTRACT

4551

The impact of antibiotic (Ab) exposure on clinical outcomes in patients with metastatic renal cell carcinoma (mRCC) treated with immune checkpoint inhibitors (ICI) or VEGF targeted therapy (VEGF-TT).

AUTHOR(S)

Matthew S. Ernst, Sarah Abou Alaiwi, Nazli Dizman, Chris Labaki, Pier Vitale Nuzzo, Elio Adib, Andrew L. Schmidt, Luis A. Meza, Chun Loo Gan, Ziad Bakouny, Sumanta K. Pal, Toni K. Choueiri, Daniel Y. Heng, Shaan Dudani

ABSTRACT

4552

Nivolumab plus cabozantinib (N+C) versus sunitinib (S) for advanced renal cell carcinoma (aRCC): Outcomes by baseline disease characteristics in the phase 3 CheckMate 9ER trial.

AUTHOR(S)

Andrea B. Apolo, Thomas Powles, Mauricio Burotto, Maria T. Bourlon, James J. Hsieh, Umberto Basso, Amishi Y. Shah, Cristina Suarez, Camillo Porta, Carlos H. Barrios, Howard Gurney, Elizabeth R. Kessler, Margitta Retz, Saby George, Bernard Escudier, Joshua Zhang, Burcin Simsek, Christian Scheffold, Robert J. Motzer, Toni K. Choueiri

ABSTRACT

4553

Outcomes of first-line (1L) ipilimumab and nivolumab (IPI-NIVO) and subsequent therapy in metastatic renal cell carcinoma (mRCC): Results from the International mRCC Database Consortium (IMDC).

AUTHOR(S)

Chun Loo Gan, Andrew L. Schmidt, Thomas Powles, Ben Tran, Luis A. Meza, Chris Labaki, Jae-Lyun Lee, Lori Wood, Julia Shapiro, D. S. Ernst, Anil Kapoor, Christina M. Canil, Takeshi Yuasa, Rana R. McKay, Benoit Beuselinck, Frede Donskov, Shaan Dudani, Toni K. Choueiri, Daniel Y. Heng

ABSTRACT

4554

Phase 2 study of belzutifan (MK-6482), an oral hypoxia-inducible factor 2 α (HIF-2 α) inhibitor, for Von Hippel-Lindau (VHL) disease-associated clear cell renal cell carcinoma (ccRCC).

AUTHOR(S)

Ramaprasad Srinivasan, Frede Donskov, Othon Iliopoulos, Wendy Kimryn Rathmell, Vivek Narayan, Benjamin L. Maughan, Stephane Oudard, Tobias Else, Jodi K. Maranchie, Sarah J. Welsh, Ananya Roy, Yanfang Liu, Rodolfo F. Perini, W. M. Linehan, Eric Jonasch

ABSTRACT

4555

Randomized phase Ib study to evaluate safety, pharmacokinetics and therapeutic activity of simlukafusp α in combination with atezolizumab $\pm$ bevacizumab in patients with unresectable advanced/ metastatic renal cell carcinoma (RCC) (NCT03063762).

AUTHOR(S)

Jose L. Perez-Gracia, Aaron R. Hansen, Rikke Helene Loevendahl Eefsen, Carlos A. Gomez-Roca, Sylvie Negrier, Paolo Pedrazzoli, Jae-Lyun Lee, Teresa Alonso Gordo, Cristina Suarez Rodriguez, Begona Mellado, Victor Moreno, Alejo Rodriguez-Vida, Arif Hussain, Nicole Getzmann, David Dejardin, Christophe Boetsch, Anton Kraxner, Taner Vardar, Volker Teichgräber, Thomas Powles

ABSTRACT

4556

Treatment outcomes in renal cell carcinoma patients with metastases to the pancreas and other sites.

AUTHOR(S)

Cassandra Duarte, Benoit Beuselinck, Nicole Weise, Nazli Dizman, Katharine Collier, Haoran Li, Nieves Martinez Chanza, Roy Elias, Tracy L. Rose, James Brugarolas, Neeraj Agarwal, Amir Mortazavi, Sumanta K. Pal, Rana R. McKay, Junxiao Hu, Elaine T. Lam

ABSTRACT

4557

Programmed death ligand-1 (PD-L1) expression in patients (pts) with metastatic renal cell carcinoma (mRCC) treated with nivolumab (NIVO) in combination with stereotactic body radiotherapy (SBRT) in NIVES study.

AUTHOR(S)

Cristina Masini, Gabriele Carlinfante, Cinzia Iotti, Ugo De Giorgi, Roberto S. Bellia, Sebastiano Buti, Francesco Salaroli, Ilaria Zampiva, Renzo Mazzarotto, Claudia Mucciarini, Maria Giuseppa Vitale, Alessio Bruni, Giuseppe Procopio, Stefania Kinspergher, Valentina Vanoni, Franco Nole, Franco Morelli, Susanne Baier, Consuelo Buttigliero, Carmine Pinto

ABSTRACT

4558

An FDA-pooled analysis of frontline combination treatment benefits by risk groups in metastatic renal cell carcinoma (mRCC).

AUTHOR(S)

Daniel Lee, Haley Gittleman, Chana Weinstock, Daniel L. Suzman, Erik Bloomquist, Sundeep Agrawal, Michael H. Brave, Jamie R. Brewer, Harpreet Singh, Shenghui Tang, Richard Pazdur, Julia A. Beaver, Amna Ibrahim, Laleh Amiri-Kordestani

ABSTRACT

4559

Analysis of the CLEAR study in patients (pts) with advanced renal cell carcinoma (RCC): Depth of response and efficacy for selected subgroups in the lenvatinib (LEN) + pembrolizumab (PEMBRO) and sunitinib (SUN) treatment arms.

AUTHOR(S)

Viktor Grünwald, Thomas Powles, Evgeny Kopyltsov, Vadim Kozlov, Teresa Alonso Gordo, Masatoshi Eto, Thomas E. Hutson, Robert J. Motzer, Eric Winquist, Pablo Maroto-Rey, Bhumsuk Keam, Giuseppe Procopio, Shirley Wong, Bohuslav Melichar, Frederic Rolland, Mototsugu Oya, Karla Rodriguez-Lopez, Kenichi Saito, Alan D. Smith, Camillo Porta

ABSTRACT

4560

Cabozantinib (C) exposure-response (ER) analysis for the phase 3 CheckMate 9ER (CM 9ER) trial of nivolumab plus cabozantinib (N+C) versus sunitinib (S) in first-line advanced renal cell carcinoma (1L aRCC).

AUTHOR(S)

Amishi Y. Shah, Robert J. Motzer, Andrea B. Apolo, Thomas Powles, Bernard Escudier, Joshua Zhang, Christian Scheffold, Sravan Karumanchi, Linh T. Nguyen, Toni K. Choueiri

ABSTRACT

4561

Post hoc analysis of the CLEAR study in advanced renal cell carcinoma (RCC): Effect of subsequent therapy on survival outcomes in the lenvatinib (LEN) + everolimus (EVE) versus sunitinib (SUN) treatment arms.

AUTHOR(S)

Thomas E. Hutson, Toni K. Choueiri, Robert J. Motzer, Sun Y. Rha, Anna Alyasova, Jaime R. Merchan, Howard Gurney, Avivit Peer, Toshio Takagi, Camillo Porta, Thomas Powles, Viktor Grünwald, Ugo De Giorgi, Ulka N. Vaishampayan, Manuela Schmidinger, Hilary Glen, Karla Rodriguez-Lopez, Dongyuan Xing, Lea Dutta, Masatoshi Eto

ABSTRACT

4562

Association of baseline neutrophil-to-eosinophil ratio (NER) and neutrophil-to-lymphocyte ratio (NLR) with response to combination immunotherapy (IO) with ipilimumab plus nivolumab (ipi/nivo) in patients with metastatic renal cell carcinoma (mRCC).

AUTHOR(S)

Matthew D. Tucker, Landon C. Brown, Chester Kao, Nathan Hirshman, Emily N. Kinsey, Yu-Wei Chen, Kristin K. Ancell, Katy Beckermann, Nancy B. Davis, Renee McAlister, Kerry Schaffer, Andrew J. Armstrong, Michael R. Harrison, Daniel J. George, Wendy Kimryn Rathmell, Brian I. Rini, Tian Zhang

ABSTRACT

4563

Phase II trial of stereotactic ablative radiation (SAbR) for oligoprogressive kidney cancer.

AUTHOR(S)

Raquibul Hannan, Michael Christensen, Aurelie Garant, Hans J. Hammers, Waddah Arafat, Kevin D. Courtney, Isaac A. Bowman, Suzanne Cole, David Sher, Chul Ahn, Robert D. Timmerman, James Brugarolas

ABSTRACT

4564

Ipilimumab + nivolumab in people with rare variant renal cell carcinoma refractory to nivolumab alone: Part 2 of UNISON (ANZUP 1602) nivolumab then ipilimumab + nivolumab in advanced non-clear cell renal cell carcinoma.

AUTHOR(S)

Craig Gedye, David W. Pook, Laurence E. Krieger, Carole A. Harris, Jeffrey C. Goh, Ganessan Kichenadasse, Howard Gurney, Craig Underhill, Francis Parnis, Anthony M. Joshua, Tom Ferguson, Felicia Roncolato, Michelle L. Harrison, Stephen Begbie, Michelle F. Morris, Elizabeth J. Hovey, Mathew George, Prashanth Prithviraj, Emma Link, Ian D. Davis

ABSTRACT

4565

Survival trends of men and women with metastatic clear cell renal cell carcinoma.

AUTHOR(S)

Claud Grigg, Sally Trufan, Peter E. Clark, Stephen B. Riggs, Jason Zhu, Justin T. Matulay, Derek Raghavan, Earle F. Burgess

ABSTRACT

4566

Temporal characteristics of treatment-emergent adverse events and dose modifications with tivozanib and sorafenib in the phase 3 TIVO-3 study of relapsed or refractory mRCC.

AUTHOR(S)

Sumanta K. Pal, David F. McDermott, Bernard Escudier, Thomas E. Hutson, Camillo Porta, Elena Verzoni, Michael B. Atkins, Michael N. Needle, Brian I. Rini

ABSTRACT

4567

Immune checkpoint inhibitors (ICI) in advanced sarcomatoid renal cell carcinoma (sRCC): A multicenter study.

AUTHOR(S)

Dharmesh Gopalakrishnan, Katharine Collier, Joseph J. Park, Jacob P. Zaemes, Elaine T. Lam, Sabah Alaklabi, Ellen Jaeger, Rahul A. Parikh, Pedro C. Barata, Eric Kauffman, Michael B. Atkins, Ajai S. Alva, Yuanquan Yang, Saby George

ABSTRACT

4568

A phase 2 single-arm study of cabozantinib in patients with advanced or unresectable renal cell carcinoma pretreated with one immune checkpoint inhibitor: The BREAKPOINT trial (MeetUro trial 03-NCT03463681).

AUTHOR(S)

Giuseppe Procopio, Melanie Claps, Chiara Pircher, Luca Porcu, Pierangela Sepe, Valentina Guadalupi, Ugo De Giorgi, Cristian Lolli, Marco Maruzzo, Franco Nole, Roberto Iacovelli, Cristina Masini, Cinzia Baldessari, Laura Doni, Antonio Cusmai, Angela Gernone, Sarah Scagliarini, Sandro Pignata, Filippo G. De Braud, Elena Verzoni

ABSTRACT

4569

Plasma exosome microRNA-155 expression in patients with metastatic renal cell carcinoma treated with immune checkpoint inhibitors: A potential biomarker of response to systemic therapy.

AUTHOR(S)

Maryam Soleimani, Marisa Thi, Neetu Saxena, Bernhard J. Eigel, Daniel J. Khalaf, Kim N. Chi, Christian K. Kollmannsberger, Lucia Nappi

ABSTRACT

4570

A phase 2 prospective trial of cabozantinib as first-line treatment for metastatic collecting ducts renal cell carcinoma: The BONSAI trial (Meeturo 2) clinical trial information—NCT03354884.

AUTHOR(S)

Giuseppe Procopio, Pierangela Sepe, Sebastiano Buti, Melanie Claps, Maurizio Colecchia, Loris De Cecco, Devecchi Andrea, Matteo Dugo, Chiara Gargiuli, Patrizia Giannatempo, Valentina Guadalupi, Luigi Mariani, Arianna Ottini, Marialuisa Sensi, Filippo G. De Braud, Elena Verzoni

ABSTRACT

4571

Characterization of the tumor immune microenvironment in clear cell renal cell carcinoma (ccRCC): Prognostic value and therapeutic implications of an M0-macrophage enriched subtype.

AUTHOR(S)

Mark Farha, Randy Vince, Srinivas Nallandhighal, Judith Stangl-Kremser, Steven Goldenthal, Daniel Triner, Todd M. Morgan, Ganesh S. Palapattu, Aaron M. Udager, Simpa S. Salami

ABSTRACT

4572

Dynamic changes of the immune infiltrate after neoadjuvant avelumab/axitinib in patients (pts) with localized renal cell carcinoma (RCC) who are at high risk of relapse after nephrectomy (NeoAvAx).

AUTHOR(S)

Axel Bex, Yasmin Abu-Ghanem, Johannes V. Van Thienen, Niels Graafland, Brunolf Lagerveld, Patricia Zondervan, Harrie Beerlage, Jeroen van Moorselaar, Mark Kockx, Pieter-Jan Van Dam, Bernadett Szabados, Christian U. Blank, Thomas Powles, John B. Haanen

ABSTRACT

4573

Efficacy of avelumab + axitinib (A + Ax) versus sunitinib (S) by IMDC risk group in advanced renal cell carcinoma (aRCC): Extended follow-up results from JAVELIN Renal 101.

AUTHOR(S)

John B. Haanen, James Larkin, Toni K. Choueiri, Laurence Albiges, Brian I. Rini, Michael B. Atkins, Manuela Schmidinger, Konstantin Penkov, Despina Thomaïdou, Jing Wang, Mariangela Mariani, Alessandra Di Pietro, Robert J. Motzer

ABSTRACT

4574

Association with immune checkpoint inhibitor efficacy of a 27-gene classifier in renal cell cancer.

AUTHOR(S)

Robert Seitz, Tyler J. Nielsen, Brock L. Schweitzer, David R. Gandara, Mamta Parikh, Douglas T. Ross

ABSTRACT

4575

Efficacy of nivolumab/ipilimumab in patients with initial or late progression with nivolumab: Updated analysis of a tailored approach in advanced renal cell carcinoma (TITAN-RCC).

AUTHOR(S)

Marc-Oliver Grimm, Emilio Esteban, Philippe Barthélémy, Manuela Schmidinger, Jonas Busch, Begoña P. Valderrama, Marc Schmitz, Ulrike Schumacher, Gustavo B. Baretton, Ignacio Duran, Guillermo de Velasco, Frank Priou, Pablo Maroto-Rey, Giovanni Schinzari, Laurence Albiges

ABSTRACT

4576

Retrospective study for the characterization of COVID-19 in renal cancer (COVID-REN) patients treated with antiangiogenics or immunotherapy and outcome comparison with non-infected cases.

AUTHOR(S)

Jesus G. Donas, Guillermo de Velasco, Teresa Alonso Gordo, Jesús Chamorro, Diana Rosero, Olatz Etxaniz, Jose L. Perez-Gracia, Alvaro Pinto, Ignacio Duran, Diego Cacho, María Barba, Monica Yagüe, Pablo Borrega, Martín Lázaro, Laura Rodriguez, Maria Laura L. Villalobos Leon, Lourdes Garcia Sanchez, Xavier Garcia del Muro, M. Andres Cuellar, Juan Francisco Rodriguez-Moreno

ABSTRACT

4577

Efficacy outcomes of nivolumab + cabozantinib versus pembrolizumab + axitinib in patients with advanced renal cell carcinoma (aRCC): Matching-adjusted indirect comparison (MAIC).

AUTHOR(S)

Bradley A. McGregor, Daniel M. Geynisman, Mauricio Burotto, Camillo Porta, Cristina Suarez Rodriguez, Maria T. Bournalon, Pedro C. Barata, Shuchi Gulati, Brian Stwalley, Viviana Del Tejo, Ella X. Du, Aozhou Wu, Andi Chin, Keith A. Betts, Stephen Huo, Toni K. Choueiri

ABSTRACT

4578

Patient-reported experience of diagnosis, management, and burden of renal cell carcinomas: Results from the 2020 Global Patient Survey from 41 countries.

AUTHOR(S)

Rachel H. Giles, Deb Maskens, Robin Martinez, Karin Kastrati, Carlos Castro, Juan Carlo Julian Mauro, Robert Bick, Malcolm Packer, Daniel Y. Heng, James Larkin, Axel Bex, Eric Jonasch, Sara J. MacLennan, Michael A. Jewett

ABSTRACT

4579

Outcomes with novel combinations in non-clear cell renal cell carcinoma(nccRCC): ORACLE study.

AUTHOR(S)

Deepak Kilari, Aniko Szabo, Pooja Ghatalia, Tracy L. Rose, Nicole Weise, Matthew D. Tucker, Ariel A. Nelson, Huaying Dong, Danubia Hester, Luna Acharya, Rohit K. Jain, Benjamin L. Maughan, Ajjai S. Alva, Abhishek Tripathi, Arnab Basu, Vadim S. Koshkin, Hamid Emamekhoo, Nancy B. Davis, Arpita Desai, Rana R. McKay

ABSTRACT

4580

Disease-free survival as a predictor of overall survival in localized renal cell carcinoma (RCC) following first nephrectomy.

AUTHOR(S)

Naomi B. Haas, Yan Song, Jaqueline Willemann Rogerio, Su Zhang, Oluwakayode Adejoro, Christopher Carley, Jingjing Zhu, Rituparna Bhattacharya, James Signorovitch, Murali Sundaram

ABSTRACT

4581

Role of cytoreductive nephrectomy (CN) in metastatic renal cell carcinoma (mRCC).

AUTHOR(S)

Pooja Ghatalia, Elizabeth A. Handorf, Mengying Deng, Matthew R. Zibelman, Philip Abbosh, Fern Anari, Richard E. Greenberg, Rosalia Viterbo, David Chen, Marc C. Smaldone, Alexander Kutikov, Daniel M. Geynisman, Robert G. Uzzo

ABSTRACT

4582

Effect of high-dose corticosteroid use on efficacy of immune checkpoint inhibitors in patients with renal cell carcinoma (RCC).

AUTHOR(S)

Chris Labaki, Sarah A. Alaiwi, Andrew L. Schmidt, Talal El Zarif, Ziad Bakouny, Pier Vitale Nuzzo, Wenxin Xu, David A. Braun, Bradley A. McGregor, Toni K. Choueiri

ABSTRACT

4583

An open-label, single-arm, multicenter, phase II study of RC48-ADC to evaluate the efficacy and safety of subjects with HER2 overexpressing locally advanced or metastatic urothelial cancer (RC48-C009).

AUTHOR(S)

Xinan Sheng, Zhisong He, Weiqing Han, Ai-Ping Zhou, Hong Luo, Yanxia Shi, Changlu Hu, Ziling Liu, Hongqian Guo, Xin Yao, Benkang Shi, Jiyuan Liu, Zhigang Ji, Jianming Guo, Yi Hu, Shi Ying Yu, Guohua Yu, Jianming Ying, Jianmin Fang, Jun Guo

ABSTRACT

4584

Circulating tumor DNA (ctDNA) in patients with advanced adrenocortical carcinoma.

AUTHOR(S)

Bassel Nazha, Hiba I. Dada, Leylah Drusbosky, Jacqueline T. Brown, Deepak Ravindranathan, Bradley C. Carthon, Omer Kucuk, Viraj A. Master, Mehmet A. Bilen

ABSTRACT

4585

A phase 3, multicenter, randomized study evaluating the efficacy of TAR-200 in combination with cetrelimab versus concurrent chemoradiotherapy in participants with muscle-invasive urothelial carcinoma of the bladder.

AUTHOR(S)

Stephen B. Williams, Christopher Cutie, Kirk A. Keegan, Bradley Raybold, Milin Acharya, Wei Zhu, Xiang Li, Lang A. O'Dondi, Neil Beeharry, Daniel E. Spratt

ABSTRACT

TPS4586

KEYNOTE-B15/EV-304: Randomized phase 3 study of perioperative enfortumab vedotin plus pembrolizumab versus chemotherapy in cisplatin-eligible patients with muscle-invasive bladder cancer (MIBC).

AUTHOR(S)

Christopher J. Hoimes, Jens Bedke, Yohann Loriot, Hiroyuki Nishiyama, Xiao Fang, Ritesh S. Kataria, Blanca Homet Moreno, Matt D. Galsky

ABSTRACT

TPS4587

Consolidative radiotherapy for metastatic urothelial bladder cancer patients without progression and with no more than three residual metastatic lesions following first line systemic therapy: A prospective randomized comparative phase II trial (BLAD RAD01/GETUG-AFU V07).

AUTHOR(S)

Jonathan Khalifa, Damien Pouessel, Mathieu Roumiguie, Paul Sargos, Genevieve Loos, Ulrike Schick, Naji Salem, Nathalie Mesgouez-Nebout, Yohann Lorient, Christophe Hennequin, Emmanuel Meyer, Pierre Blanchard, Valentine Guimas, Laurent Votron, Pierre Graff-Cailleaud, Gilles Crehange, Muriel Mounier, Angélique Massoubre, Leonor Chaltiel, Thomas Filleron

ABSTRACT

TPS4588

AUREA study: Atezolizumab (Atezo) combined with split-dose gemcitabine plus cisplatin (s-GC) in locally advanced or metastatic urothelial cancer (LA/mUC): A SOGUG study.

AUTHOR(S)

Alfonso Gomez De Liano Lista, Georgia Anguera, Emilio Esteban, Ovidio Fernandez Calvo, Iciar García-Carbonero, Xavier Garcia del Muro, Iria González Maeso, David Lorente-Estelles, Esther Martínez Ortega, Alvaro Pinto, Javier Puente, Guillermo de Velasco

ABSTRACT

TPS4589

EA8185: Phase 2 study of bladder-sparing chemoradiation (chemoRT) with durvalumab in clinical stage III, node positive urothelial carcinoma (INSPIRE)—An ECOG-ACRIN and NRG Collaboration.

AUTHOR(S)

Monika Joshi, Se E. Kim, Abhishek A. Solanki, David T. Miyamoto, David Degraff, Jennifer W. Zou, Joshua J. Meeks, Timur Mitin, Sean P. Collins, Edouard J. Trabulsi, Noah M. Hahn, Jason A. Efstathiou, Michael A. Carducci

ABSTRACT

TPS4590

A phase 2 study of cabozantinib in combination with atezolizumab as neoadjuvant treatment for muscle-invasive bladder cancer (HCRN GU18-343) ABATE study.

AUTHOR(S)

Deepak Kilari, Aniko Szabo, Kathryn A. Bylow, Robert S. Alter, Ariel A. Nelson, Emily Lemke, William A. Hall, Scott Johnson, Peter Langenstroer, Kenneth Jacobsohn, Nancy B. Davis, Chunkit Fung, Matthew I. Milowsky

ABSTRACT

TPS4591

Cabozantinib (C) in combination with nivolumab (N) and ipilimumab (I) (CaNI) for advanced renal cell carcinoma with variant histology (aRCCVH).

AUTHOR(S)

Bradley A. McGregor, Wanling Xie, Mehmet A. Bilen, David A. Braun, Wenxin Xu, Praful Ravi, Elisabeth I. Heath, David F. McDermott, Rana R. McKay, Hans J. Hammers, Toni K. Choueiri

ABSTRACT

TPS4592

A randomized trial of radium-223 (Ra-223) dichloride and cabozantinib in patients (pts) with advanced renal cell carcinoma (RCC) with bone metastases (RADICAL/Alliance A031801).

AUTHOR(S)

Rana R. McKay, Heather Jacene, Pamela J. Atherton, Gabriela Perez Burbano, Archana Ajmera, Shiva Baghaie, Janet Koball, Tyler J. Zemla, Ronald C. Chen, Atish D. Choudhury, Joshua M. Lang, Suzanne Cole, Tareq Al Baghdadi, Young Kwok, Himisha Beltran, Daniel J. George, Michael J. Morris, Toni K. Choueiri

ABSTRACT

TPS4593

A phase 1b/2 umbrella study of investigational immune and targeted combination therapies as first-line therapy for patients with advanced renal cell carcinoma (RCC).

AUTHOR(S)

Elizabeth R. Plimack, Hans J. Hammers, Toni K. Choueiri, Brian I. Rini, Robert J. Motzer, Leah Suttner, Rodolfo F. Perini, Jaqueline Willemann Rogerio, Laurence Albiges

ABSTRACT

TPS4594

KEYNOTE-B61: Open-label phase 2 study of pembrolizumab in combination with lenvatinib as first-line treatment for non-clear cell renal cell carcinoma (nccRCC).

AUTHOR(S)

Chung-Han Lee, Chenxiang Li, Rodolfo F. Perini, Daniela Hoehn, Laurence Albiges

ABSTRACT

TPS4595

PROSPER: Phase III RandOmized Study Comparing PERioperative nivolumab versus observation in patients with renal cell carcinoma (RCC) undergoing nephrectomy (ECOG-ACRIN EA8143).

AUTHOR(S)

Mohamad E. Allaf, Se E. Kim, Viraj A. Master, David F. McDermott, Sabina Signoretti, David Cella, Rajan T. Gupta, Suzanne Cole, Brian M. Shuch, Primo "Lucky" N. Lara Jr., Anil Kapoor, Daniel Y. Heng, Bradley C. Leibovich, M. Dror Michaelson, Toni K. Choueiri, Michael A. Jewett, Deb Maskens, Lauren C. Harshman, Michael A. Carducci, Naomi B. Haas

ABSTRACT

TPS4596

A randomized phase II study of nivolumab plus ipilimumab versus standard of care in previously untreated and advanced non-clear cell renal cell carcinoma (SUNIFORECAST).

AUTHOR(S)

Marit Ahrens, Bernard Escudier, John B. Haanen, Ekaterini Boleti, Marine Gross Goupil, Marc-Oliver Grimm, Sylvie Negrier, Philippe Barthelemy, Gwenaëlle Gravis, Philipp Ivanyi, Jens Bedke, Daniel Castellano, Andrej Panic, Begona Mellado, Pablo Maroto-Rey, Sylvie Rottey, Stefanie Zschaebitz, Dorothee Deckbar, Arndt Hartmann, Lothar Bergmann

ABSTRACT

TPS4597

Cyto-KIK: A phase II trial of cytoreductive surgery in kidney cancer plus immunotherapy (nivolumab) and targeted kinase inhibition (cabozantinib).

AUTHOR(S)

Karie Runcie, Eric A. Singer, Moshe C. Ornstein, Christopher B. Anderson, Matthew Dallos, Jessica Hawley, Emerson A. Lim, Charles G. Drake, Benjamin Izar, Hiram A. Shaish, Mark N. Stein

ABSTRACT

TPS4598

A phase I study of bintrafusp alfa (M7824) and NHS-IL12 (M9241) alone and in combination with stereotactic body radiation therapy (SBRT) in adults with metastatic non-prostate genitourinary malignancies.

AUTHOR(S)

Scot A. Niglio, Daniel d. Girardi, Lisa M. Cordes, Lisa Ley, Marissa Mallek, Olena Sierra Ortiz, Jacqueline Cadena, Carlos Diaz, Heather Chalfin, Andre Kydd, Rene Costello, Ariel E. Marciscano, Jennifer C. Jones, Kilian E. Salerno, Vladimir Valera, William D. Figg, William L. Dahut, James L. Gulley, Jeffrey Schlom, Andrea B. Apolo

ABSTRACT

TPS4599

Genitourinary Cancer—Prostate, Testicular, and Penile

[Back to Program](#)

Showing 78 Presentations

<https://meetinglibrary.asco.org/session/13633>

Concordance of DNA damage repair (DDR) gene mutations in paired primary and metastatic prostate cancer (PC) samples.

AUTHOR(S)

Michael T. Schweizer, Smruthy Sivakumar, Hanna Tukachinsky, Ilsa Coleman, Navonil De Sarkar, Evan Y. Yu, Eric Q. Konnick, Peter Nelson, Colin C. Pritchard, Robert B. Montgomery

ABSTRACT

5020

Copy number profiles of primary tumors for risk stratification of advanced prostate cancer: A biomarker study embedded in the multicenter STAMPEDE trial.

AUTHOR(S)

Emily Grist, Marina Parry, Stefanie Friedrich, Christopher D. Brawley, Larissa Mendes, Sharanpreet Lall, Leila Zakka, Sara Santos Vidal, Nafisah B. Atako, Malissa Richmond, Sofeya Ishaq, Alex Hoyle, Adnan Ali, Noel W. Clarke, Nicholas D. James, Mahesh K. Parmar, Daniel Berney, Paolo Cremaschi, Louise C. Brown, Gerhardt Attard

ABSTRACT

5021

Characterization of findings on prostate cancer tumor sequencing that should prompt consideration for germline testing.

AUTHOR(S)

Hong Truong, Kelsey Breen, Yelena Kemel, Andrew T. Lenis, Peter Reisz, Nicole Benfante, Behfar Ehdaie, Karim A. Touijer, Vincent P. Laudone, Peter T. Scardino, James A. Eastham, Vijai Joseph, Ozge Birsoy, Diana Mandelker, Zsofia K. Stadler, Kenneth Offit, Michael J. Morris, Wassim Abida, Mark E. Robson, Maria I. Carlo

ABSTRACT

5022

PSMA-targeted imaging with ¹⁸F-DCFPyL-PET/CT in patients (pts) with biochemically recurrent prostate cancer (PCa): A phase 3 study (CONDOR)—A subanalysis of correct localization rate (CLR) and positive predictive value (PPV) by standard of truth.

AUTHOR(S)

Frederic Pouliot, Michael A. Gorin, Steven P. Rowe, Lawrence Saperstein, David Josephson, Peter R. Carroll, Jeffrey Y. Wong, Austin R. Pantel, Steve Y. Cho, Kenneth L. Gage, Morand Piert, Andrei Iagaru, Janet H. Pollard, Vivien Wong, Jessica Jensen, Nancy Stambler, Michael J. Morris, Barry A. Siegel

ABSTRACT

5023

Evaluation of PSA progression after initiation of enzalutamide or abiraterone: Real-world data on metastatic castration-resistant prostate cancer (mCRPC).

AUTHOR(S)

Fernando López-Campos, David Lorente, Casilda Llacer Perez, Miguel Ramirez-Backhaus, Paula Peleteiro, Alfonso Gomez-Iturriaga, Ivan Henriquez-López, Rebeca Lozano, Nuria Romero, Teresa Alonso-Gordoa, Javier Molina-Cerrillo, Joaquin Navarro-Castellón, Ana Castaño, Lira Pelari, Antonio Hernández-Corrales, Virginia Morillo, Raquel García, Carlos Ferrer Albiach, Elena Castro, David Olmos

ABSTRACT

5024

Factors associated with use of medications for anxiety and depression in testicular cancer survivors after cisplatin-based chemotherapy.

AUTHOR(S)

Shirin Ardeshirrouhanifard, Paul C. Dinh Jr., Patrick O. Monahan, Sophie Fosså, Robert A. Huddart, Chunkit Fung, Yiqing Song, Darren R. Feldman, Robert J. Hamilton, David J. Vaughn, Neil E. Martin, Christian K. Kollmannsberger, Lifang Hou, Lawrence Einhorn, Kurt Kroenke, Lois B. Travis

ABSTRACT

5025

Adjuvant chemotherapy with CAV/IE for malignant transformation of teratoma to primitive neuroectodermal tumor (PNET): An institutional analysis from Indiana University.

AUTHOR(S)

Cynthia Wei, Clint Cary, Timothy A. Masterson, Richard Foster, Ryan Ashkar, Nabil Adra, Nasser H. Hanna, Lawrence H. Einhorn

ABSTRACT

5026

Clinical utility of FDG PET-CT in stage 1 and advanced testicular seminoma.

AUTHOR(S)

Ciara Conduit, Michael S. Hofman, Jeremy H. Lewin, Guy C. Toner, Ben Tran

ABSTRACT

5027

Efficacy of TIP (paclitaxel, ifosfamide and cisplatin) as salvage chemotherapy for relapsed germ cell cancer patients stratified by the modified International Prognostic Factors Study Group (IPFSG) score: The Northern Ireland (NI) Experience.

AUTHOR(S)

Adam Uprichard, Julie-Anne Scott, James Mcaleer, Judith Carser, Olabode Oladipo

ABSTRACT

5028

Outcomes of patients with germ cell tumors diagnosed with stage I disease who subsequently received high dose chemotherapy (HDCT) with peripheral stem cell transplant (PBSCT) following failure of initial therapy for metastatic disease: The Indiana University experience.

AUTHOR(S)

Stephen B. Benzinger, Ryan Ashkar, Rafat Abonour, Mohammad I. Abu Zaid, Nabil Adra, Lawrence H. Einhorn, Nasser H. Hanna

ABSTRACT

5029

Very late recurrence in germ cell tumor of the testis: Lessons and implications.

AUTHOR(S)

Joseph A. Moore, Rebecca Tidwell, Matthew T. Campbell, Amishi Y. Shah, Miao Zhang, Charles Guo, John F. Ward, Jose A. Karam, Christopher G. Wood, Christopher Logothetis, Louis L. Pisters, Shi-Ming Tu

ABSTRACT

5030

First-in-human study of TAS3681, an oral androgen receptor (AR) antagonist with AR and AR splice variant (AR-SV) downregulation activity, in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC) refractory to abiraterone (ABI) and/or enzalutamide (ENZ) and chemotherapy (CT).

AUTHOR(S)

Johann S. De Bono, Natalie Cook, Evan Y. Yu, Primo "Lucky" N. Lara Jr., Judy S. Wang, Yoshihiko Yamasaki, Ikuo Yamamiya, Ping Gao, Elizabeth M. Calleja, Dana E. Rathkopf

ABSTRACT

5031

Survival of veterans treated with enzalutamide and abiraterone in advanced prostate cancer.

AUTHOR(S)

Martin W. Schoen, Kenneth R. Carson, Suhong Luo, Seth Eisen, Melissa A. Reimers, Bettina F. Drake, Charles L. Bennett, Eric M. Knoche, Yan Yan, Kristen M. Sanfilippo

ABSTRACT

5032

A methodology for the extraction and analysis of real-world radiographic and electronic medical record data to reconstruct treatment arms of historical prostate cancer clinical trials.

AUTHOR(S)

William D. Lindsay, Christopher A. Ahern, Aaron Kamaau, Robert Wilder, Karen Chagin, Timmothy Taps

ABSTRACT

5033

A phase 2 study of berzosertib (M6620) in combination with carboplatin compared with docetaxel in combination with carboplatin in metastatic castration-resistant prostate cancer.

AUTHOR(S)

Atish D. Choudhury, Wanling Xie, Edmund Folefac, Daniel Lee, Mamta Parikh, David J. Einstein, Elizabeth R. Kessler, Tina M. Mayer, Rana R. McKay, Amanda F. Pace, Bose Kochupurakkal, Kent W. Mouw, Eliezer M. Van Allen, Charles Kunos, Alan D. D'Andrea, Mary-Ellen Taplin, Geoffrey Shapiro

ABSTRACT

5034

Cortisol as biomarker for CYP17 inhibition in mCRPC patients treated with abiraterone acetate.

AUTHOR(S)

Maaïke Bruin, Merel van Nuland, Bart Jacobs, Andre M. Bergman, Hilde Rosing, Jos H. Beijnen, Alwin Huitema

ABSTRACT

5035

Biomarker analysis of phase (Ph) IB trial of radium-223 (Rad) and niraparib (Nira) in patients (Pts) with metastatic castrate-resistant prostate cancer (mCRPC) (NiraRad).

AUTHOR(S)

Eddy S. Yang, Benjamin Leiby, Guru P. Sonpavde, David J. Einstein, Zachary L. Quinn, Russell Z. Szmulewitz, A. O. Sartor, William K. Kelly

ABSTRACT

5036

Analysis of two poor prognosis subgroups in ACIS evaluating apalutamide + abiraterone acetate plus prednisone (APA + AAP) versus placebo (PBO) + AAP in metastatic castration-resistant prostate cancer (mCRPC).

AUTHOR(S)

Fred Saad, Eleni Efstathiou, Gerhardt Attard, Thomas W. Flaig, Fabio Franke, Oscar Goodman Jr., Stephane Oudard, Thomas Steuber, Hiroyoshi Suzuki, Christopher M. Pieczonka, Francis Parnis, Daphne Wu, Kesav Yeruva, Peter De Porre, Sabine Brookman-May, Susan Li, Jinhui Li, Suneel Mundle, Sharon A. McCarthy, Dana E. Rathkopf

ABSTRACT

5037

Complementary detection of genomic alterations in metastatic castration-resistant prostate cancer (mCRPC) from CheckMate 9KD through analyses of tumor tissue and plasma DNA.

AUTHOR(S)

Mark Sausen, Jonathan F. Baden, Natallia Kalinava, Xuya Wang, Jun Li, Esperanza Anguiano, Keziban Unsal-Kacmaz, Megan Wind-Rotolo, Katie Quinn, George Green

ABSTRACT

5038

ARC-6: A phase 1b/2, open-label, randomized platform study to evaluate efficacy and safety of etrumadenant (AB928)-based treatment combinations in patients with metastatic castrate-resistant prostate cancer (mCRPC).

AUTHOR(S)

Sumit K. Subudhi, Johanna C. Bendell, Michael A. Carducci, Lisa M. Kopp, Jennifer Scott, Michele M. Grady, Olivia Gardner, David R. Wise

ABSTRACT

5039

Differential responses to taxanes and PARP inhibitors (PARPi) in *ATM*- versus *BRCA2*-mutated metastatic castrate-resistant prostate cancer (mCRPC) patients (pts).

AUTHOR(S)

Christopher T. Su, Emily Nizialek, Jacob E. Berchuck, Panagiotis J. Vlachostergios, Ryan Ashkar, Alexandra Sokolova, Pedro C. Barata, Rahul R. Aggarwal, Heather McClure, Nellie Nafissi, Alan H. Bryce, A. O. Sartor, Heather H. Cheng, Nabil Adra, Cora N. Sternberg, Mary-Ellen Taplin, Marcin Cieslik, Emmanuel S. Antonarakis, Ajjai S. Alva

ABSTRACT

5040

Molecular, immunologic, and clinicodemographic landscape of MYC-amplified (MYCamp) advanced prostate cancer (PCa).

AUTHOR(S)

Brandon A. Mahal, Liangliang Zhang, Mohamed Alshalalfa, Ryon Graf, Hanna Tukachinsky, Richard S. Huang, Kimberly McGregor, Alexa B. Schrock, Jeffrey M. Venstrom

ABSTRACT

5041

Pembrolizumab plus enzalutamide for enzalutamide-resistant metastatic castration-resistant prostate cancer (mCRPC): Updated analyses after one additional year of follow-up from cohorts 4 and 5 of the KEYNOTE-199 study.

AUTHOR(S)

Julie N. Graff, Scott T. Tagawa, Christopher J. Hoimes, Winald R. Gerritsen, Ulka N. Vaishampayan, Tony Elliott, Clara Hwang, A. J. Ten Tije, Aurelius Omlin, Raymond S. McDermott, Yves Fradet, Deepak Kilari, Cristiano Ferrario, Hiroji Uemura, Cuizhen Niu, Christian H. Poehlein, Ronald De Wit, Charles Schloss, Johann S. De Bono, Emmanuel S. Antonarakis

ABSTRACT

5042

A phase (Ph) 1b/2 study of ribociclib (R) in combination with docetaxel (D) plus prednisone (P) in metastatic castration-resistant prostate cancer (mCRPC).

AUTHOR(S)

Ivan de Kouchkovsky, Arpit Rao, Benedito A. Carneiro, Li Zhang, Catriona Lewis, Audrey Phone, Eric J. Small, Terence W. Friedlander, Lawrence Fong, Pamela Paris, Charles J. Ryan, Russell Z. Szmulewitz, Rahul R. Aggarwal

ABSTRACT

5043

CheckMate 9KD cohort A1 final analysis: Nivolumab (NIVO) + rucaparib for post-chemotherapy (CT) metastatic castration-resistant prostate cancer (mCRPC).

AUTHOR(S)

Russell K. Pachynski, Margitta Retz, Jeffrey C. Goh, Mauricio Burotto, Gwenaëlle Gravis, Daniel Castellano, Aude Flechon, Stefanie Zschaebitz, David R. Shaffer, Juan Carlos Vazquez Limon, Marc-Oliver Grimm, Steven L. McCune, Neha P. Amin, Jia Li, Xuya Wang, Keziban Unsal-Kacmaz, Fred Saad, Daniel P. Petrylak, Karim Fizazi

ABSTRACT

5044

The impact of prior radiation therapy on outcome in a phase 2 trial combining sipuleucel-T (SipT) and ipilimumab (Ipi) in patients (pts) with metastatic castration resistant prostate cancer (mCRPC).

AUTHOR(S)

Li Zhang, Meenal Sinha, Sumit K. Subudhi, Brandon Chen, Jaqueline Marquez, Eric Liu, Kathryn Allaire, Alexander Cheung, Sharon Ng, Christopher Nguyen, Terence W. Friedlander, Rahul R. Aggarwal, Matthew Spitzer, James P. Allison, Eric J. Small, Padmanee Sharma, Lawrence Fong

ABSTRACT

5045

ODENZA: A French prospective, randomized, open-label, multicenter, cross-over phase II trial of preference between darolutamide and enzalutamide in men with asymptomatic or mildly symptomatic metastatic castrate-resistant prostate cancer (CRPC).

AUTHOR(S)

Emeline Colomba, Sarah F. Jonas, Jean-Christophe Eymard, Remy Delva, Pierre-Emmanuel Brachet, Yann Neuzillet, Nicolas Penel, Guilhem Roubaud, Emmanuelle Bompas, Hakim Mahammedi, Raffaele Longo, Carole Helissey, Philippe Barthelemy, Delphine Borchiellini, Ali Hasbini, Franck Priou, Carolina Saldana, Eric Voog, Stéphanie Foulon, Karim Fizazi

ABSTRACT

5046

Talazoparib (TALA), an oral poly (ADP-ribose) polymerase (PARP) inhibitor for men with metastatic castration-resistant prostate cancer (mCRPC) and DNA damage response (DDR) alterations: Detailed safety analyses from TALAPRO-1 trial.

AUTHOR(S)

Niven Mehra, Karim Fizazi, Johann S. De Bono, Philippe Barthélémy, Tanya B. Dorff, Adam P. Stirling, Jean-Pascal H. Machiels, Davide Bimbatti, Deepak Kilari, Herlinde Dumez, Consuelo Buttigliero, Inge M. van Oort, Elena Castro, Hsiang-Chun Chen, Nicola Di Santo, Liza L. DeAnnuntis, Cynthia G. Healy, Giorgio V. Scagliotti

ABSTRACT

5047

Association of plasma tumor DNA (ptDNA) with increased risk of venous thromboembolism (VTE) in metastatic castration resistant prostate cancer patients (mCRPC).

AUTHOR(S)

Vincenza Conteduca, Emanuela Scarpi, Daniel Wetterskog, Fabio Ferroni, Alice Rossi, Alessandro Romanel, Giorgia Gurioli, Sara Bleve, Caterina Gianni, Nicole Brighi, Giuseppe Schepisi, Cristian Lolli, Pietro Cortesi, Domenico Barone, Francesca Demichelis, Giovanni Paganelli, Himisha Beltran, Gerhard Attard, Ugo De Giorgi

ABSTRACT

5048

Circulating tumor DNA fraction (ctDNA%) to independently predict for clinical outcomes in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC).

AUTHOR(S)

Corinne Maurice-Dror, Nicolette Fonseca, Cameron Herberts, William Fan, Alexander W. Wyatt, Kim N. Chi

ABSTRACT

5049

Title: An open-label, pharmacokinetic study to determine the bioavailability, safety and tolerability of single dose oral docetaxel (Oradoxel) in metastatic prostate cancer (mPC) patients treated with IV docetaxel.

AUTHOR(S)

Christopher G. Jackson, Yen-chuan Ou, Meng En, Tsu-Yi Chao, Noelyn A. Hung, David Wang, David Cutler, Douglas Kramer, Jay Zhi, Wing Kai Chan, Min-Fun R. Kwan, Tak Hung

ABSTRACT

5050

Indirect treatment comparison of the efficacy of olaparib 300 mg tablets BID and cabazitaxel 25 mg/m² every 3 weeks plus daily prednisolone and granulocyte colony-stimulating factor in the treatment of patients with metastatic castration-resistant prostate cancer (mCRPC).

AUTHOR(S)

Tim Reason, Charles McCrea, Robert Hettle, Sameer Ghatge, Christian H. Poehlein, David Olmos

ABSTRACT

5051

A phase II study evaluating the efficacy of enzalutamide and the role of ARv7 in metastatic castration-resistant prostate cancer (mCRPC) patients (pts) with visceral disease.

AUTHOR(S)

Pierangela Sepe, Giuseppe Procopio, Umberto Basso, Orazio Caffo, Vera Cappelletti, Melanie Claps, Ugo De Giorgi, Lucia Fratino, Valentina Guadalupi, Patrizia Miodini, Bruno Perrucci, Alessia Mennitto, Daniele Santini, Francesco Spina, Arianna Ottini, Filippo G. De Braud, Elena Verzoni

ABSTRACT

5052

Immunogenic priming with ¹⁷⁷Lu-PSMA-617 plus pembrolizumab in metastatic castration resistant prostate cancer (mCRPC): A phase 1b study.

AUTHOR(S)

Rahul R. Aggarwal, Srey Luch Sam, Vadim S. Koshkin, Eric J. Small, Felix Y. Feng, Ivan de Kouchkovsky, Daniel H. Kwon, Terence W. Friedlander, Hala Borno, Rohit Bose, Jonathan Chou, Arpita Desai, Tammy J. Rodvelt, Maya Aslam, Medini Rastogi, Lawrence Fong, Thomas A. Hope

ABSTRACT

5053

Using real-world outcomes to evaluate the predictive power of tissue-assessed genomic biomarkers for taxane versus novel hormonal therapy (NHT) outcomes in metastatic castration-resistant prostate cancer (mCRPC).

AUTHOR(S)

Ryon Graf, Virginia Fisher, Ole Gjoerup, Alexa B. Schrock, Russell Madison, Samantha Morley, Lei Zhong, Geoffrey R. Oxnard, Jeffrey M. Venstrom, Amado J. Zurita

ABSTRACT

5054

Long-term adverse events (AE) in patients with metastatic castration-resistant prostate cancer (mCRPC) receiving prostate-specific membrane antigen (PSMA)-based targeted radionuclide therapy (TRT).

AUTHOR(S)

Michael Sun, Charlene Thomas, Benedict Ho, Muhammad Junaid Niaz, Ana M. Molina, Cora N. Sternberg, David M. Nanus, Neil H. Bander, Scott T. Tagawa

ABSTRACT

5055

VERU-111, an oral cytoskeleton disruptor, to treat men with metastatic castration-resistant prostate cancer (mCRPC) who failed an androgen receptor targeting agent.

AUTHOR(S)

Mark C. Markowski, Ronald F. Tutrone, Mario A. Eisenberger, Christopher M. Pieczonka, Robert H. Getzenberg, Domingo Rodriguez, K. G. Barnette, Mitchell S. Steiner, Daniel Saltzstein, Emmanuel S. Antonarakis

ABSTRACT

5056

Radiographic progression-free survival as a surrogate endpoint of overall survival in men with metastatic castrate-resistant prostate cancer.

AUTHOR(S)

Susan Halabi, Akash Roy, Qian Yang, Wanling Xie, William K. Kelly, Christopher Sweeney

ABSTRACT

5057

Differences in the tumor genomic landscape between African Americans (AA) and Caucasians (CA) advanced prostate cancer (aPC) patients (pts) by comprehensive genomic profiling (CGP) of cell-free DNA (cfDNA).

AUTHOR(S)

Pedro C. Barata, Raquel Reisinger, Mehmet A. Bilen, Elisabeth I. Heath, Lakshminarayanan Nandagopal, Umang Swami, Adam Kessel, Ellen Jaeger, Sergiusz Wesolowski, Jonathan Chipman, Alleda Mack, Deepak Ravindranathan, Benjamin L. Maughan, Roberto Nussenzeig, Mark Yandell, Manish Kohli, Michael B. Lilly, A. O. Sartor, Neeraj Agarwal

ABSTRACT

5058

First results from a randomized phase II study of cabazitaxel (CBZ) versus an androgen receptor targeted agent (ARTA) in patients with poor-prognosis castration-resistant prostate cancer (mCRPC).

AUTHOR(S)

Kim van der Zande, Vincent van der Noort, Milou Busard, Paul Hamberg, Suzan Ras - van Spijk, Jeantine De Feijter, Vincent O. Dezentjé, Metin Tascilar, Danny Houtsma, Aart Beeker, Diederik ten Oever, Irma M. Oving, Wilbert Zwart, Andre M. Bergman

ABSTRACT

5059

TROP-2 co-expression with androgen receptor splice variants as a new therapeutic target in prostate cancer.

AUTHOR(S)

Charlotte Stahlfeld, Jamie Sperger, Susan F. Slovin, Scott T. Tagawa, Christos Kyriakopoulos, Manish Kohli, Ligu Wang, Liewei Wang, Scott Dehm, Joshua M. Lang

ABSTRACT

5060

The national impact of the COVID-19 pandemic on U.S. prostate cancer community care.

AUTHOR(S)

Matthew R. Cooperberg, Paul Brendel, Daniel J. Lee, Rahul Doraiswami, Hariesh Rajasekar, Danil V. Makarov, William Meeks, Raymond Fang, Matthew T. Roe, Jeremy B. Shelton

ABSTRACT

5061

Genomic landscape of *MSH6*-mutated clinically advanced castrate-resistant prostate cancer (mCRPC).

AUTHOR(S)

Gennady Bratslavsky, Brennan Decker, Joseph M. Jacob, Andrea Necchi, Philippe E. Spiess, Petros Grivas, Douglas I. Lin, Shakti H. Ramkissoon, Eric A. Severson, Richard S. Huang, Douglas A. Mata, Russell Madison, Meagan Montesion, Ole Gjoerup, Ethan Sokol, Dean C. Pavlick, Natalie Danziger, Jeffrey S. Ross

ABSTRACT

5062

Association of ATM mutations in metastatic prostate cancer with differential genomic alteration profiles from homologous recombination deficient and proficient tumors.

AUTHOR(S)

Charles J. Ryan, Julie E. McGrath, Joanne Xiu, Justin Hwang, Chadi Nabhan, Andre L. De Souza, Pedro C. Barata, Shuchi Gulati, Shuanzeng Wei, Jaime R. Merchan, Arpit Rao, Daniel M. Geynisman, Inas Abuali, Wolfgang M. Korn, Elisabeth I. Heath

ABSTRACT

5063

PSMA-PET/CT Registry for Recurrent Prostate Cancer (PREP): Initial findings from a single center.

AUTHOR(S)

Anil Kapoor, Katherine Zukotynski, Camilla Tajzler, Jen Hoogenes, Edward Matsumoto, Michael Uy, Glenn Bauman, Ur Metser, Antonio Finelli, Maylynn Ding, Bobby Shayegan

ABSTRACT

5064

Single-lesion PSMA protein expression and response to Lu-177 PSMA therapy in patients with castration-resistant prostate cancer.

AUTHOR(S)

Judith Stangl-Kremser, Sazan Rasul, Jeffrey J. Tosoian, Simpa Salami, Alexander Zaslavsky, Aaron M. Udager, Peter Mazal, Renate Kain, Eva Comperat, Carmen Pozo Salido, Christina Steinbach, Melanie Hassler-Di Fratta, Gero Kramer, Shahrokh Shariat, Ganesh S. Palapattu

ABSTRACT

5065

Interim PSMA PET/CT for response evaluation during LuPSMA treatment in mCRPC (INTERIM PET): An explorative, multicenter study.

AUTHOR(S)

Andrei Gafita, Isabel Rauscher, Manuel Weber, Boris A. Hadaschik, Hui Wang, Wesley R. Armstrong, Robert Tauber, Johannes Czernin, Matthew Rettig, Ken Herrmann, Jeremie Calais, Wolfgang A. Weber, Matthias R. Benz, Wolfgang P. Fendler, Matthias Eiber

ABSTRACT

5066

Impact of androgen deprivation therapy on mortality of prostate cancer patients with COVID-19: A propensity score-based analysis.

AUTHOR(S)

Mateus B. Duarte, Frederico Leal, Juliana L. Argenton, Jose B. Carvalheira

ABSTRACT

5067

Health-related quality of life (HRQoL) and patient-reported outcomes at final analysis of the TITAN study of apalutamide (APA) versus placebo (PBO) in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) receiving androgen deprivation therapy (ADT).

AUTHOR(S)

Neeraj Agarwal, Simon Chowdhury, Anders Bjartell, Byung Ha Chung, Andrea J. Pereira de Santana Gomes, Robert Given, Álvaro Juárez, Axel S. Merseburger, Mustafa Ozguroglu, Hirotugu Uemura, Dingwei Ye, Sabine Brookman-May, Suneel Mundle, Sharon A. McCarthy, Florence Lefresne, Shiva Dibaj, Katherine B. Bevans, Kim N. Chi

ABSTRACT

5068

Association of androgen receptor signature and *RB1*, *PTEN*, *TP53* gene expression with clinical outcome in metastatic hormone-sensitive prostate cancer treated with docetaxel and androgen deprivation therapy.

AUTHOR(S)

Laura Ferrer-Mileo, Natalia Jiménez, Oscar Reig, Miguel Ángel Climent, Sara Cros, Mariona Figols, Albert Font, Isabel Chirivella, Alejo Rodriguez-Vida, Montserrat Domenech, Enrique Gonzalez-Billalabeitia, Mayra Orrillo, Giancarlo Castellano, Leonardo Rodriguez-Carunchio, Sherley Diaz, Aleix Prat, Mercedes Marín-Aguilera, Begona Mellado

ABSTRACT

5069

The efficacy of enzalutamide (ENZA) plus androgen deprivation therapy (ADT) on bone oligometastatic hormone-sensitive prostate cancer: A post hoc analysis of ARCHES.

AUTHOR(S)

Andrew J. Armstrong, Taro Iguchi, Arun Azad, Arnauld Villers, Boris Alekseev, Daniel P. Petrylak, Russell Z. Szmulewitz, Antonio Alcaraz, Neal D. Shore, Jeffrey Holzbeierlein, Francisco Gomez-Veiga, Brad Rosbrook, Fabian Zohren, Gabriel P. Haas, Georgia Gourgioti, Nader N. El-Chaar, Arnulf Stenzl

ABSTRACT

5071

Real-world first-line (1L) treatment patterns in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a U.S. health insurance database.

AUTHOR(S)

Umang Swami, Agnes Hong, Nader N. El-Chaar, David Nimke, Krishnan Ramaswamy, Elizabeth J. Bell, Rickard Sandin, Neeraj Agarwal

ABSTRACT

5072

Real-world utilization of advanced therapies and racial disparity among patients with metastatic castration-sensitive prostate cancer (mCSPC): A Medicare database analysis.

AUTHOR(S)

Stephen J. Freedland, Neeraj Agarwal, Krishnan Ramaswamy, Rickard Sandin, Dave Russell, Agnes Hong, Hongbo Yang, Wei Gao, Kaitlin Hagan, Daniel J. George

ABSTRACT

5073

Real-world treatment patterns among patients diagnosed with metastatic castration-sensitive prostate cancer (mCSPC) in community oncology settings.

AUTHOR(S)

Daniel J. George, Neeraj Agarwal, Jennifer R. Rider, Benjamin Li, Rohan Shirali, Rickard Sandin, Agnes Hong, Dave Russell, Krishnan Ramaswamy, Stephen J. Freedland

ABSTRACT

5074

Impact of age on efficacy and safety of relugolix: A subgroup analysis from the randomized, phase 3 hero study versus leuprolide in men with advanced prostate cancer.

AUTHOR(S)

Michael Cookson, Neal D. Shore, Daniel J. George, Hideyuki Akaza, Daniel Saltzstein, Ronald F. Tutrone, Alberto Bossi, Bruce Brown, Bryan Selby, Sophia Lu, Jacqueline M. Walling, Bertrand F. TOMBAL, Fred Saad

ABSTRACT

5075

Proliferation index and survival in men with prostate cancer starting long-term androgen deprivation therapy in the STAMPEDE clinical trial.

AUTHOR(S)

Larissa Mendes, Christopher D. Brawley, Emily Grist, Adnan Ali, Sara Santos Vidal, Marina Parry, Sharanpreet Lall, Nafisah B. Atako, Sofeya Ishaq, Malissa Richmond, Aine Haran, Alex Hoyle, Leila Zakka, Christopher Sweeney, Noel W. Clarke, Mahesh K. Parmar, Nicholas D. James, Louise C. Brown, Daniel Berney, Gerhardt Attard

ABSTRACT

5076

Correlation of baseline circulating tumor cells (CTC) and associated genomic profile with survival outcomes in patients (pts) with metastatic castration-sensitive prostate cancer (mCSPC) in a real-world cohort.

AUTHOR(S)

Umang Swami, Taylor R. McFarland, Benjamin Haaland, Adam Kessel, Roberto Nussenzeig, Nicolas Sayegh, Andrew W. Hahn, Nityam Rathi, Deepika Sirohi, John Esther, Haoran Li, Manish Kohli, Benjamin L. Maughan, Amir Goldkorn, Neeraj Agarwal

ABSTRACT

5077

Diagnostic performance of Gallium-68 prostate-specific membrane antigen (PSMA) PET/CT imaging in early-relapsed prostate cancer: Phase 3, prospective, multicenter study (IAEA-PSMA study).

AUTHOR(S)

Juliano J. Cerci, Stefano Fanti

ABSTRACT

5078

Darolutamide (DARO) tolerability from extended follow up and treatment response in the phase 3 ARAMIS trial.

AUTHOR(S)

Karim Fizazi, Neal D. Shore, Matthew R. Smith, Teuvo Tammela, Christopher M. Pieczonka, Jeanny B. Aragon-Ching, David Morris, Marie-Aude Le Berre, Shankar Srinivasan, Oana Petrenciuc, Christian Zurth, Iris Kuss

ABSTRACT

5079

A phase II randomized controlled trial of exercise on biochemical progression in men with prostate cancer on active surveillance.

AUTHOR(S)

Dong-Woo Kang, Adrian S. Fairey, Normand G. Boulé, Catherine J. Field, Stephanie A. Wharton, Kerry S. Courneya

ABSTRACT

5080

Active surveillance of postradical prostatectomy biochemical recurrence: Long-term assessment of outcomes.

AUTHOR(S)

Tom E. Ahlering, Erica Huang, Linda M. Huynh, Huang Wei Su

ABSTRACT

5081

The somatic mutation landscape of germline *CHEK2*-altered prostate cancer.

AUTHOR(S)

Emily Nizialek, Tamara L. Lotan, William B. Isaacs, Srinivasan Yegnasubramanian, Channing J. Paller, Emmanuel S. Antonarakis

ABSTRACT

5084

The Courage study: A first-in-human phase 1 study of the CBP/p300 inhibitor FT-7051 in men with metastatic castration-resistant prostate cancer.

AUTHOR(S)

Andrew J. Armstrong, Michael S. Gordon, Melissa A. Reimers, Alex Sedkov, Kate Lipford, Juliana Snaveley-Merhaut, Sonia Kumar, Sylvie M. Guichard, Neal Shore

ABSTRACT

TPS5085

CYCLONE 1: A phase 2 study of abemaciclib in patients with metastatic castration-resistant prostate cancer (mCRPC) previously treated with a novel hormonal agent and taxane-based chemotherapy.

AUTHOR(S)

Neeraj Agarwal, Stephane Oudard, Josep M. Piulats, Michael T. Schweizer, Aude Flechon, Teresa Alonso Gordo, Karim Nacerddine, Andrew Lithio, Erica L. Johnston, Matthew R. Smith

ABSTRACT

TPS5086

Study evaluating metastatic castrate resistant prostate cancer (mCRPC) treatment using ¹⁷⁷Lu-PNT2002 PSMA therapy after second-line hormonal treatment (SPLASH).

AUTHOR(S)

Kim N. Chi, Ur Metser, Johannes Czernin, Jeremie Calais, Vikas Prasad, Matthias Eiber, Neal D. Shore, Jessica Jensen, Neil E. Fleshner, Scott T. Tagawa, A. O. Sartor

ABSTRACT

TPS5087

Safety and efficacy of AMG 160, a half-life extended BiTE immune therapy targeting prostate-specific membrane antigen (PSMA), and other therapies for metastatic castration-resistant prostate cancer (mCRPC).

AUTHOR(S)

Sumit K. Subudhi, Bilal A. Siddiqui, Joseph J. Maly, Lakshminarayanan Nandagopal, Elaine T. Lam, Young E. Whang, Mukul Minocha, Vinita Gupta, Xianne Penny, Freda Cooner, Camila Jhones, Andrew Paluch, Mark Salvati, Margit Janat-Amsbury, Tobias Eggert, Hosein Kouros-Mehr, Anthony M. Joshua, Rahul R. Aggarwal, Johann S. De Bono

ABSTRACT

TPS5088

TALAPRO-2: A phase 3 randomized study of enzalutamide (ENZA) plus talazoparib (TALA) versus placebo in patients with new metastatic castration-resistant prostate cancer (mCRPC).

AUTHOR(S)

Neeraj Agarwal, Arun Azad, Neal D. Shore, Joan Carles, Andre P. Fay, Curtis Dunshee, Lawrence I. Karsh, Maria L. Paccagnella, Nicola Di Santo, Mohamed Elmeliegy, Xun Lin, Alexander Niyazov, Akos Czibere, Karim Fizazi

ABSTRACT

TPS5089

A phase 1/2a, open-label, multicenter study of intramuscular (IM) abiraterone decanoate (PRL-02) depot in patients with advanced prostate cancer (NCT04729114).

AUTHOR(S)

Tim Warneke, Michael R. Kurman, Robert Dreicer, Daniel J. George, Neal Shore, William D. Figg, Robert Schotzinger, William R. Moore

ABSTRACT

TPS5090

A phase III trial of docetaxel versus docetaxel and radium-223 (Ra-223) in patients with metastatic castration-resistant prostate cancer (mCRPC): DORA.

AUTHOR(S)

Michael J. Morris, Ronald De Wit, Nicholas J. Vogelzang, Scott T. Tagawa, Celestia S. Higano, Paul Hamberg

ABSTRACT

TPS5091

TNB585.001: A multicenter, phase 1, open-label, dose-escalation and expansion study of tnb-585, a bispecific T-cell engager targeting PSMA in subjects with metastatic castrate resistant prostate cancer.

AUTHOR(S)

Ben Buelow, Pranjali Dalvi, Kevin Dang, Ashwin Patel, Kiran Johal, Duy Pham, Shailee Panchal, Yvonne Liu, Lawrence Fong, A. O. Sartor, Meredith McKean, Ute Schellenberger, Suhasini Iyer

ABSTRACT

TPS5092

Radium-223 (Ra-223) versus novel antihormone therapy (NAH) for progressive metastatic castration-resistant prostate cancer (mCRPC) after 1 line of NAH: RADIANT, an international phase 4, randomized, open-label study.

AUTHOR(S)

Karim Fizazi, Aránzazu González del Alba, Özgüroğlu Mustafa, Iwona A. Skoneczna, Heiko Krissel, Deise Uema, Huanyu Chen, Volker J. Wagner, Martin Boegemann

ABSTRACT

TPS5093

Phase I study of CCW702, a bispecific small molecule-antibody conjugate targeting PSMA and CD3 in patients with metastatic castration-resistant prostate cancer (mCRPC).

AUTHOR(S)

Mark C. Markowski, Deepak Kilari, Mario A. Eisenberger, Rana R. McKay, Robert Dreicer, Mohit Trikha, Elisabeth I. Heath, Jing Li, Pamela D. Garzone, Travis S. Young

ABSTRACT

TPS5094

Open label phase II trial of cabozantinib (cabo) in patients with metastatic castrate resistant prostate cancer (mCRPC) and known amplifications or

activating mutations in gene targets who have received prior anti-androgen therapy.

AUTHOR(S)

Jones T. Nauseef, Sharon Singh, Angela Tan, Amie Patel, Brian D. Robinson, Francesca Khani, Charles G. Drake, Emerson A. Lim, Mark N. Stein, Elisabeth I. Heath, Himisha Beltran, Ana M. Molina, Bishoy M. Faltas, Karla V. Ballman, Cora N. Sternberg, Scott T. Tagawa, David M. Nanus

ABSTRACT

TPS5095

A phase I/II study of bintrafusp alfa and NHS-IL12 in combination with docetaxel in adults with metastatic castration sensitive (mCSPC) and castration-resistant prostate cancer (mCRPC).

AUTHOR(S)

Mohammad O. Atiq, Marijo Bilusic, Fatima Karzai, Lisa M. Cordes, Julius Strauss, Houssein Abdul Sater, Jason Redman, Charalampos S. Floudas, James W. Hodge, Sofia Gameiro, William D. Figg, Jeffrey Schlom, William L. Dahut, James L. Gulley, Ravi A. Madan

ABSTRACT

TPS5096

Identifying androgen receptor (AR) and genomic characteristics that define populations of patients with mHSPC who benefit from early PARP inhibition therapy with talazoparib.

AUTHOR(S)

Saro Kasparian, Leanne Burnham, Rick Kittles, Zj Sun, Fornati Bedell, Justin Tran, Min Li, Tanya B. Dorff

ABSTRACT

TPS5097

Phase III study of local or systemic therapy INTensification Directed by PET in prostate CAncer patients with post-prostaTEctomy biochemical recurrence (INDICATE): ECOG-ACRIN EA8191.

AUTHOR(S)

Neha Vapiwala, Yu-Hui Chen, Steve Y. Cho, Fenghai Duan, Christos Kyriakopoulos, Daniel H. Shevrin, Rana R. McKay, Bridget F. Koontz, Evan Y. Yu, Volkan Beylertgil, David A. Mankoff, Jonathan McConathy, Glenn Liu, Terence Z. Wong, Michael A. Carducci

ABSTRACT

TPS5098

The fluciclovine (FACBC) PET/CT site-directed therapy of oligometastatic prostate cancer (Flu-BLAST-PC) trial.

AUTHOR(S)

Risa L. Wong, Sarah K. Holt, Jing Zeng, Laura Graham, Rachel Kang, Nathan Conrad, Andrea Toulouse, Zoya Bauer, Michael Lai, Todd Yezefski, Jonathan L. Wright, Emily S. Weg, Andrew C. Hsieh, Heather H. Cheng, Jean H. Lee, Delphine L. Chen, Daniel W. Lin, Evan Y. Yu

ABSTRACT

TPS5099

Phase 1b study of AMG 757, a half-life extended bispecific T-cell engager (HLE BiTE immune-oncology therapy) targeting DLL3, in de novo or treatment emergent neuroendocrine prostate cancer (NEPC).

AUTHOR(S)

Rahul R. Aggarwal, Ana Aparicio, Axel Heidenreich, Shahneen K. Sandhu, Yiran Zhang, Mark Salvati, Aditya Shetty, Nooshin Hashemi Sadraei

ABSTRACT

TPS5100

Gynecologic Cancer

[Back to Program](#)

Showing 84 Presentations

<https://meetinglibrary.asco.org/session/13636>

Parametrial evaluation in cervical cancer by magnetic resonance imaging and clinical examination: Analysis of data from the prospective Leipzig School MMR study.

AUTHOR(S)

Benjamin Wolf, Paulina Sodeikat, Massimiliano Lia, Mireille Martin, Lars-Christian Horn, Michael Höckel, Bahriye Aktas

ABSTRACT

5525

Discovery and validation of novel methylated DNA markers of cervical cancer.

AUTHOR(S)

Jamie N. Bakkum-Gamez, Rondell P. Graham, Brendan T. Broderick, Seth Slettedahl, Douglas W. Mahoney, Maureen Lemens, Xiaoming Cao, Patrick H. Foote, Kelli Burger, Calise K. Berger, Maria O'Connell, Karen A. Doering, J. Kenneth Schoolmeester, Sarah Kerr, William R. Taylor, Mark E. Sherman, John B. Kiesel

ABSTRACT

5526

A phase II trial of bevacizumab and rucaparib in recurrent carcinoma of the cervix or endometrium.

AUTHOR(S)

Camille C. Jackson, Leigh Cantrell, Britt K. Erickson, Kathleen N. Moore, Linda R. Duska, Debra L. Richardson, Lisa M. Landrum, Laura L. Holman, Joan L. Walker, Robert S. Mannel, Katherine M. Moxley, Lurdes Queimado, Kai Ding, Andrew Cohoon, Sara Vesely, Lauren E. Dockery

ABSTRACT

5527

Defective mismatch repair associated mutational signatures, a prognostic and predictive biomarker in endometrial cancer.

AUTHOR(S)

Yifan E. Chang, Naomi N. Adjei, Wafa Khadraoui, Gary Altwerger

ABSTRACT

5528

Differentiated activity profile for the PD-1 inhibitor balstilimab.

AUTHOR(S)

Cailin Joyce, Dhan Chand, Benjamin Duckless, Manuel Hidalgo, Joseph E. Grossman, Remigiusz Kaleta, David M. O'Malley

ABSTRACT

5529

Differential benefit from fractionated dose-dense first-line chemotherapy for epithelial ovarian cancer (EOC) according to KELIM-evaluated tumor primary chemosensitivity: Exploratory analyses of ICON-8 trial.

AUTHOR(S)

Benoit You, Andrew Clamp, Adrian D. Cook, Iain A. McNeish, Olivier Colombari

ABSTRACT

5530

An international, multicenter, real-world analysis of epithelial ovarian cancer treatment and outcomes.

AUTHOR(S)

Geoff Hall, Sue Cheeseman, Bethany Levick, Eun Ji Nam, Subin Lim, Jean-Marc Classe, Elodie Martin, Paul Kubelac, Patriciu Achimaş-Cadariu, Joana Savva-Bordalo, Marina Borges, Sven Becker, Shabnam Shaid, Nicolas Niklas, Mariana Guergova-Kuras

ABSTRACT

5531

Metronomic cyclophosphamide and bevacizumab for the treatment of recurrent gynecologic carcinosarcoma: A multi-institution, retrospective study.

AUTHOR(S)

Sara Bouberhan, Jill S. Hyde, McKenzie Foxall, Richard T. Penson, Rebecca C. Arend

ABSTRACT

5532

Anlotinib plus pemetrexed as a further treatment for patients with platinum-resistant ovarian cancer: A single-arm, open-label, phase II study.

AUTHOR(S)

Jueming Chen, Wei Wei, Lie Zheng, Han Li, Yanling Feng, Ting Wan, Jiaqi Qiu, Xingyu Jiang, Ying Xiong, Min Zheng, Jundong Li, He Huang, Libing Song, Jihong Liu, Yanna Zhang

ABSTRACT

5533

Efficacy of niraparib maintenance therapy in Chinese women with platinum-sensitive recurrent ovarian cancer with and without secondary cytoreductive surgery: Results from the NORA trial.

AUTHOR(S)

Lingying Wu, Xiaohua Wu, Jianqing Zhu, Rutie Yin, Jiaxin Yang, Jihong Liu, Jing Wang, Ziling Liu, Yunong Gao, Danbo Wang, Ge Lou, Hongying Yang, Qi Zhou, Beihua Kong, Yi Huang, Lipai Chen, Guiling Li, Ruifang An, Tao Tan, Juan Dong

ABSTRACT

5534

Safety assessment of niraparib individualized starting dose in patients with platinum-sensitive recurrent ovarian cancer: A randomized, double-blind, placebo-controlled, phase III NORA trial.

AUTHOR(S)

Jing Wang, Xiaohua Wu, Jianqing Zhu, Rutie Yin, Jiaxin Yang, Qidan Huang, Lingying Wu, Ziling Liu, Yunong Gao, Danbo Wang, Ge Lou, Hongying Yang, Qi Zhou, Beihua Kong, Yi Huang, Lipai Chen, Guiling Li, Ruifang An, Tao Tan, Juan Dong

ABSTRACT

5535

Association of homologous recombination deficiency in ovarian cancer with neoantigen load and expression of immune checkpoints.

AUTHOR(S)

Kathleen Fenerty, Charlene M. Fares, Gottfried E. Konecny

ABSTRACT

5536

Clinical and molecular characteristics of ARIEL3 patients who derived exceptional benefit from rucaparib maintenance treatment for high-grade ovarian cancer (HGOC).

AUTHOR(S)

Tanya Kwan, Amit M. Oza, Domenica Lorusso, Carol Aghajanian, Ana Oaknin, Andrew P. Dean, Nicoletta Colombo, Johanne I. Weberpals, Andrew R. Clamp, Giovanni Scambia, Alexandra Leary, Robert W. Holloway, Margarita Amenedo, Peter C. Fong, Jeffrey C. Goh, David M. O'Malley, Lara Maloney, Sandra Goble, Jonathan A. Ledermann, Robert L. Coleman

ABSTRACT

5537

LIO-1: Lucitanib + nivolumab in patients with advanced solid tumors—Updated phase 1b results and initial experience in phase 2 ovarian cancer cohort.

AUTHOR(S)

Erika P. Hamilton, Camille C. Jackson, Ramez N. Eskander, Floor J. Backes, Vicky Makker, Fernanda Musa, Alexander Olawaiye, Jill Alldredge, Bhavana Pothuri, Angeles A. Secord, Nicole Concin, Antonio Gonzalez Martin, Jowell Go, Kenton Wride, Denise M. Lepley, Teresa Cameron, Manish R. Patel

ABSTRACT

5538

Underutilization of germline BRCA testing in commercially-insured women diagnosed with ovarian cancer.

AUTHOR(S)

Stephanie Cham, Alexi A. Wright

ABSTRACT

5539

Postoperative adjuvant dose-dense chemotherapy with bevacizumab and maintenance bevacizumab after neoadjuvant chemotherapy for advanced ovarian cancer: A phase II AGOG/TGOG trial.

AUTHOR(S)

Wei-Chun Chen, Hung-Hseuh Chou, Lan-Yan Yang, Huei-Jean Huang, Wei-Yang Chang, Hao Lin, Ren-Chin Wu, Min-Yu Chen, J. Timothy Qiu, Kuan-Gen Huang, Angel Chao, Ting-Chang Chang, Chyong-Huey Lai

ABSTRACT

5540

Patient self-reporting of tolerability using PRO-CTCAE: A randomized double-blind placebo controlled phase II trial comparing gemcitabine in combination with adavosertib or placebo in women with platinum resistant epithelial ovarian cancer.

AUTHOR(S)

Ainhoa Madariaga, Sandra A. Mitchell, Tyler Pittman, Lisa Wang, Valerie Bowering, Nisan Kavak, Judy Quintos, Karen Chang, Janelle Ramsahai, Katherine Karakasis, Stephen Welch, Neesha C. Dhani, Stephanie Lheureux, Amit M. Oza

ABSTRACT

5541

A phase I study of mirvetuximab soravtansine (MIRV) and gemcitabine (G) in patients (Pts) with selected fr α -positive solid tumors: Results in the ovarian cancer (EC) cohort.

AUTHOR(S)

Mihaela C. Cristea, Nora H. Ruel, Paul H. Frankel, Timothy W. Synold, Daphne B. Stewart, Edward W. Wang, Alex Jung, Sharon Wilczynski, Michael Tran, Gottfried E. Konecny, Melissa Eng, Lindsay Kilpatrick, Yi-Jen Chen, Scott Glaser, Thanh H. Dellinger, Amy Hakim, Stephen Lee, Robert Morgan, Ernest S. Han

ABSTRACT

5542

The correlation between BRCA status and surgical cytoreduction in high-grade serous ovarian carcinoma.

AUTHOR(S)

Rachel Soyoun Kim, Janet Malcolmson, Xuan Li, Marcus Bernardini, Liat F. Hogen, Taymaa May

ABSTRACT

5543

Nanoanalysis of plasma volatile organic compounds using novel DNA-decorated carbon nanotube vapor sensors to noninvasively distinguish ovarian and pancreatic cancer from benign and control samples.

AUTHOR(S)

A. T. Charlie Johnson, Christopher Kehayias, Erica L. Carpenter, Jody Piltz-Seymour, Janos L. Tanyi, Cindy Otto, Young E. Lee, Taylor A. Black, Stephanie S. Yee, George Preti

ABSTRACT

5544

Olaparib maintenance monotherapy for non-germline BRCA1/2-mutated (non-gBRCAm) platinum-sensitive relapsed ovarian cancer (PSR OC) patients (pts): Phase IIb OPINION primary analysis.

AUTHOR(S)

Andres Poveda, Stephanie Lheureux, Nicoletta Colombo, David Cibula, Kristina Lindemann, Johanne I. Weberpals, Maria Bjurberg, Ana Oaknin, Magdalena Sikorska, Antonio Gonzalez Martin, Radoslaw Madry, María J. Rubio, Jonathan A. Ledermann, Richard Davidson, Christopher Blakeley, James Bennett, Jessica Brown, Alan Barnicle, Erik Skof

ABSTRACT

5545

Feasibility of an adapted schedule of carboplatin plus paclitaxel in elderly women with advanced ovarian cancer: A retrospective cohort.

AUTHOR(S)

Benjamin Nicaise, Soraya Mebarki, Mathilde Gisselbrecht, Elisabeth Ashton, Henri Azais Sr., Meriem Koual, Anne-Sophie Bats, Laure Fournier, Marie-Aude Le Frère - Belda, Jacques Medioni, Elena Paillaud, Stephane Oudard, Nicolas Delanoy

ABSTRACT

5546

Stage I Sertoli-Leydig cell tumors: An interim report from the International PPB/DICER1 & OTST Registry.

AUTHOR(S)

Alexander Nelson, Anne Harris, Dave Watson, Sean R. Pyper, Nathan Hall, Junne Kamihara, Douglas R. Stewart, Louis P. Dehner, D. Ashley Hill, Yoav H. Messinger, Lindsay L. Frazier, Deborah F. Billmire, Dominik T. Schneider, Kris Ann P. Schultz

ABSTRACT

5547

Circulating tumor DNA as a noninvasive marker of resectability in ovarian carcinomas.

AUTHOR(S)

Roxane Mari, Christophe Pomel, Pierre-Emmanuel Colombo, Fabrice Narducci, Séverine Garnier, Nadine Carbuccia, Arnaud Guille, Magali Provansal, Maria-Antonietta Cappiello, Frédérique Rousseau, Guillaume Blache, Eric Lambaudie, Daniel Birnbaum, Francois Bertucci, Renaud Sabatier

ABSTRACT

5548

Health-related quality of life (QoL) in platinum-resistant ovarian cancer patients treated with olaparib and pegylated liposomal doxorubicin (PLD), a multicenter single-arm phase II clinical trial (ROLANDO, GEICO-1601).

AUTHOR(S)

José Alejandro Perez-Fidalgo, Alfonso Cortés Salgado, Yolanda García, María Iglesias, Uriel Bohn Sarmiento, Elisa Calvo García, Luis Manso Sánchez, Ana Santaballa, Ana Oaknin, Andrés Redondo, María J. Rubio, Antonio González-Martín

ABSTRACT

5549

Phase 1 dose-escalation study of STRO-002, an antifolate receptor alpha (FR α) antibody drug conjugate (ADC), in patients with advanced, progressive platinum-resistant/refractory epithelial ovarian cancer (EOC).

AUTHOR(S)

R. W. Naumann, Fadi S. Braiteh, Lainie P. Martin, Erika P. Hamilton, John P. Diaz, Sami Diab, Russell J. Schilder, John W. Moroney, Denise Uyar, David M. O'Malley, Richard T. Penson, Clifford DiLea, Michael Palumbo, Venita I. De Almeida, Shannon L. Matheny, Lin Lu, Craig J. Berman, Arturo Molina

ABSTRACT

5550

Serum-based assay for adnexal mass risk of ovarian malignancy.

AUTHOR(S)

Daniel Ure, Rowan Bullock, Gary Altwerger, Elena Ratner, Lesley Northrop

ABSTRACT

5551

Disparities in ovarian cancer treatment and overall survival according to race: An update.

AUTHOR(S)

Deanna Huffman, Thejus T. Jayakrishnan, Karthik Shankar, Chelsea Peterson, Rodney E. Wegner

ABSTRACT

5552

Next generation sequencing in ovarian cancer patients: Does personalized medicine improve oncological outcomes?

AUTHOR(S)

Tamar Safra, Dov Hershkovich, Eliya Shachar, Lyri Adar, Miriam R. Brezis, Yuval Raviv, Lee Galmor, Shira Peleg Hasson

ABSTRACT

5553

Symptom identification and management in epithelial ovarian cancer.

AUTHOR(S)

Ashley D. Hickman, Kathryn J. Ruddy, Deirdre R. Pachman, Kristin Fischer, Parvez Rahman, Krista M. Goergen, Minji Lee, Andrea L. Cheville, Andrea E. Wahner Hendrickson

ABSTRACT

5554

Association of the Khorana Score with development of venous thromboembolism in ovarian cancer.

AUTHOR(S)

Ellen Marcus, Dennis Y. Kuo, Nicole S. Nevadunsky, Gregory M. Gressel

ABSTRACT

5555

Does aggressive surgery only benefit patients with less advanced ovarian cancer?

AUTHOR(S)

Shinichi Tate, Kyoko Nishikimi, Ayumu Matsuoka, Satoyo Otsuka, Makio Shozu

ABSTRACT

5556

Anlotinib in combination with TQB2450 in patients with recurrent ovarian cancer (ACTION): A multicenter, single-arm, open-label, phase Ib trial.

AUTHOR(S)

Chunyan Lan, Jing Zhao, Fan Yang, Rong Li, Yu Huang, Jing Wang, Weihong Zhao, Li Zhang, Chang Liu, Xuehan Bi, Haihong Jin, Jin Meng, Xin Huang

ABSTRACT

5557

Improving the prediction of surgical outcome at secondary cytoreduction in patients with ovarian cancer: Results from retrospective part of HELP-ER study NOGGO TR2/ENGOT OV47-TR.

AUTHOR(S)

Ioana Braicu, Wanja Nikolai Kassuhn, Hagen Kulbe, Pauline Wimberger, Cagatay Taskiran, Klaus Pietzner, Alexander Mustea, Robert Armbrust, J.P. P. Grabowski, Felix Schmidt, Ali Ayhan, Carmen R. Beteta, Christina Fotopoulou, Jalid Sehouli

ABSTRACT

5558

Real-life data of niraparib maintenance treatment in patients with recurrent platinum-sensitive ovarian cancer.

AUTHOR(S)

Bente Vilming, Jørgen Fallås-Dahl, Anne-Gry Bentzen, Vibeke Anett Ingebrigtsen, Elisabeth Berge Nilsen, Ingvild Vistad, Anne Dørum, Olesya Solheim, Line Bjørge, Guro Aune, Kristina Lindemann

ABSTRACT

5560

Role of CD10 expression in endometriosis-associated mesenchymal stem cells on the progression of endometriosis-associated carcinoma.

AUTHOR(S)

Huda Atiya, Taylor Orellana, Lan G. Coffman

ABSTRACT

5561

Outcomes of ovarian cancer patients treated with platinum or non-platinum based chemotherapy after PARP inhibitor maintenance.

AUTHOR(S)

Ralynn Brann, Kevin M. Kremer, Matthew Carlson, Salvatore LoCoco, Jayanthi S. Lea, David S. Miller, Jessica Lee

ABSTRACT

5563

Patient care and clinical trials in gynecological oncology: Implications of the COVID-19 pandemic.

AUTHOR(S)

Sara Nasser, Christina Fotopoulou, Murat Guktekin, Desislava Dimitrova, Philippe Morice, Jalid Sehouli

ABSTRACT

5564

Selinexor in combination with weekly paclitaxel in patients with advanced or metastatic solid tumors: Results of an open label, single-center, multiarm phase 1b study.

AUTHOR(S)

Shannon N. Westin, Siqing Fu, Apostolia M. Tsimberidou, Sarina Anne A. Piha-Paul, Fechukwu Akhmedzhanov, Bulent Yilmaz, Lacey McQuinn, Amanda L. Brink, Jing Gong, Cheuk Hong Leung, Heather Y. Lin, David S. Hong, Shubham Pant, Amir A. Jazaeri, David M. Gershenson, Anil K. Sood, Robert L. Coleman, Jatin J. Shah, Funda Meric-Bernstam, Aung Naing

ABSTRACT

5565

Phase 1b study of GAS6/AXL inhibitor (AVB-500) in recurrent, platinum-resistant ovarian carcinoma.

AUTHOR(S)

Katherine C. Fuh, Michael A. Bookman, Robert L. Coleman, Thomas J. Herzog, Premal H. Thaker, Joyce F. Liu, Michelle W. Lane, Reshma A. Rangwala, Gail McIntyre, Bradley J. Monk, Kathleen N. Moore

ABSTRACT

5566

Assessment of predictive biomarker prevalence in molecularly defined adult-type ovarian granulosa cell tumors.

AUTHOR(S)

Robert T. Hillman, Douglas I. Lin, David M. Gershenson

ABSTRACT

5567

Correlation of HRD status with clinical and survival outcomes in patients with advanced-stage ovarian cancer.

AUTHOR(S)

Travis T. Sims, Anil K. Sood, Shannon N. Westin, Bryan M. Fellman, Jenna Unke, Kelly M. Rangel, Tyler Hilton, Nicole D. Fleming

ABSTRACT

5568

Final results of phase 1 evaluation of the safety and clinical activity of sapanisertib in combination with serabelisib and paclitaxel in patients with advanced ovarian, endometrial, or breast cancer.

AUTHOR(S)

David Starks, Luis A. Rojas-Espaillet, Nandini Dey, Pradip De, Brian Leyland-Jones, Casey B. Williams

ABSTRACT

5569

Health-related quality of life (HRQoL) in advanced endometrial cancer (aEC) patients (pts) treated with lenvatinib plus pembrolizumab or treatment of physician's choice (TPC).

AUTHOR(S)

Domenica Lorusso, Nicoletta Colombo, Antonio Casado Herraes, Alessandro Santin, Emeline Colomba, David S. Miller, Keiichi Fujiwara, Sandro Pignata, Sally E. Baron-Hay, Isabelle L. Ray-Coquard, Ronnie Shapira-Frommer, Yong Man Kim, Mary McCormack, Steven Bird, Vimalanand S. Prabhu, Allison Martin Nguyen, Qi Zhao, Lea Dutta, Vicky Makker

ABSTRACT

5570

Race-related disparities in patterns of uterine cancer recurrence.

AUTHOR(S)

Camilla Dagum, Nicole Vilardo, Gregory M. Gressel

ABSTRACT

5571

Phase II trial assessing niraparib with or without dostarlimab (anti-PD-1) in recurrent endometrial carcinoma.

AUTHOR(S)

Ainhoa Madariaga, Swati Garg, Nairi Tchakian, Neesha C. Dhani, Waldo Jimenez, Stephen Welch, Helen Mackay, Josee-Lyne Ethier, Lucy Gilbert, Angela Rodriguez, Lucy Chan, Valerie Bowering, Blaise Clarke, Tracy Stockley, Xuan Li, Lisa Wang, Smitha Udagani, Amit M. Oza, Stephanie Lheureux

ABSTRACT

5574

Evaluating the role of aromatase inhibitors (AIs) in the treatment of endometrial stromal sarcomas (ESS).

AUTHOR(S)

Fionnuala Crowley, Karen A. Cadoo, Sarah Chiang, Jennifer J. Mueller, Martee L. Hensley, Roisin E. O'Cearbhaill

ABSTRACT

5575

Open-label, multicenter, phase 1b/2 study of rebastinib in combination with paclitaxel to assess safety and efficacy in patients with advanced or metastatic endometrial cancer.

AUTHOR(S)

Filip Janku, Erika P. Hamilton, Cara A. Mathews, Christina Chu, Jennifer R. Diamond, John L. Hays, Rebecca C. Arend, Massimo Cristofanilli, Andrea Jewell, William Reichmann, Keisuke Kuida, Haroun Achour, Rodrigo Ruiz-Soto, Debra L. Richardson

ABSTRACT

5576

High prevalence of actionable germline variants in unselected endometrial cancer (EC) patients.

AUTHOR(S)

Monica Levine, Rachel Pearlman, Heather Hampel, Casey Cosgrove, David E. Cohn, Alexis Chassen, Adrian Suarez, Steven E. Waggoner, Caroline Billingsley, Kimberly E. Resnick, Steve Andrews, Sareena Singh, Eric Jenison, Aine E. Clements, Robert Neff, Paul J. Goodfellow

ABSTRACT

5577

Trends in the incidence of endometrial cancer among young women in the United States, 2001 to 2017.

AUTHOR(S)

Fangjian Guo, Lyuba Levine, Abbey Berenson

ABSTRACT

5578

Exploring molecular profiles and survival in hormone receptor-positive uterine serous carcinoma.

AUTHOR(S)

Amaranta Craig, Annelise M. Wilhite, Sharon Wu, Joanne Xiu, Gina Mantia-Smaldone, Enrique Hernandez, Jubilee Brown, Nathaniel L. Jones

ABSTRACT

5579

HER2 in uterine serous carcinoma: Testing platforms and implications for targeted therapy.

AUTHOR(S)

Tenley Klc, Sharon Wu, Annelise M. Wilhite, Nathaniel L. Jones, Matthew A. Powell, Alexander Olawaiye, Fiona Simpkins, Eugenia Girda, Jubilee Brown, Allison Puechl, Rouba Ali-Fehmi, Ira S. Winer, Thomas J. Herzog, Wolfgang M. Korn, Britt K. Erickson

ABSTRACT

5580

Treatment patterns and outcomes among patients with microsatellite stable (MSS) advanced endometrial cancer in the United States: Endometrial Cancer Health Outcomes (ECHO) retrospective chart review Study.

AUTHOR(S)

Shelby Corman, Sneha Kelkar, Shardul Odak, Jingchuan Zhang, Vimalanand S. Prabhu, Nifasha Rusibamayila, Cynthia Macahilig, Linda R. Duska

ABSTRACT

5581

Molecular determinants of response to immune-oncology therapy in uterine carcinosarcoma.

AUTHOR(S)

Annelise M. Wilhite, Sharon Wu, Joanne Xiu, Britt K. Erickson, Rodney P. Rocconi, Jubilee Brown, Thomas J. Herzog, Robert W. Holloway, John Wallbillich, Ira S. Winer, Matthew A. Powell, Wolfgang M. Korn, Nathaniel L. Jones

ABSTRACT

5582

Anlotinib plus sintilimab in patients with recurrent advanced endometrial cancer: A prospective open-label, single-arm, phase II clinical trial.

AUTHOR(S)

Wei Wei, Xiaohua Ban, Fan Yang, Yongwen Huang, Jibin Li, Ya Qiu, Xiaqin Cheng, Jundong Li, Min Zheng

ABSTRACT

5583

Tumor-associated immune cells and progression-free survival in advanced endometrial cancer (EC), results from the PHAEDRA trial (ANZGOG 1601).

AUTHOR(S)

Deborah Smith, Kristy Robledo, Sonia Yip, Michelle Cummins, Peey-Sei Kok, Yeh Chen Lee, Michael Friedlander, Sally E. Baron-Hay, Catherine M. Shannon, Jermaine Coward, Philip J. Beale, Geraldine Goss, Tarek Meniawy, Janine M. Lombard, Amanda B. Spurdle, John Andrews, Martin R. Stockler, Linda R. Mileshekin, Yoland C. Antill

ABSTRACT

5584

Computational features of TIL architecture are differentially prognostic of uterine cancer between African and Caucasian American women.

AUTHOR(S)

Sepideh Azarianpour Esfahani, Pingfu Fu, Haider Mahdi, Anant Madabhushi

ABSTRACT

5585

Lurbinectedin (LUR) in combination with Irinotecan (IRI) in patients (pts) with advanced endometrial carcinoma.

AUTHOR(S)

Alejandro Falcon Gonzalez, Luis G. Paz-Ares, Gregory M. Cote, Santiago Ponce Aix, Julia Martinez, Elizabeth Jimenez Aguilar, Elena Brehcist, Rafael Nuñez, Jesus R. Fernandez, Sonia Extremera, Carmen M. Kahatt, Ali H. Zeaiter, Inmaculada Sanchez-Simon

ABSTRACT

5586

Exploring molecular profiles of uterine carcinosarcoma with alterations in the chromatin remodeling pathway.

AUTHOR(S)

Annelise M. Wilhite, Sharon Wu, Joanne Xiu, Rodney P. Rocconi, Britt K. Erickson, Tenley Klc, Jamie L. Lesnock, Jubilee Brown, Thomas J. Herzog, Robert W. Holloway, Wolfgang M. Korn, Matthew A. Powell, Nathaniel L. Jones

ABSTRACT

5587

Association of the presence of estrogen and progesterone receptors in uterine carcinosarcoma with improved survival and increased immunogenicity.

AUTHOR(S)

Nathaniel L. Jones, Sharon Wu, Joanne Xiu, Rodney P. Rocconi, Britt K. Erickson, Premal H. Thaker, Jubilee Brown, Thomas J. Herzog, Robert W. Holloway, Wolfgang M. Korn, Matthew A. Powell, Annelise M. Wilhite

ABSTRACT

5588

Use of Khorana score to predict VTE in patients undergoing chemotherapy for uterine cancer.

AUTHOR(S)

Vincent Wagner, Monica Levine, Rachael Piver, Floor J. Backes, David E. Cohn, Larry J. Copeland, Casey Cosgrove, Jeffery Fowler, David M. O'Malley, Kristin L. Bixel

ABSTRACT

5589

Immune-response markers and actual response to immune-oncology therapy in uterine serous carcinoma.

AUTHOR(S)

Nathaniel L. Jones, Sharon Wu, Joanne Xiu, Amaranta Craig, Gina Mantia-Smaldone, Enrique Hernandez, Rodney P. Rocconi, Jubilee Brown, Thomas J. Herzog, Robert W. Holloway, Wolfgang M. Korn, Matthew A. Powell, Annelise M. Wilhite

ABSTRACT

5590

Metabolic and bariatric surgery among endometrial cancer survivors: Are we missing an opportunity to help?

AUTHOR(S)

Justin Gray, Ajay A. Myneni, Lorin M. Towle-Miller, Iman Simmonds, Matthew Burnstein, Steven Schwaitzberg, Aaron B. Hoffman, Emese Zsiros, Katia Noyes

ABSTRACT

5591

Photodynamic therapy for preinvasive vaginal cancer.

AUTHOR(S)

Viktoria A. Ivanova, Ekaterina V. Verenikina, Vera P. Nikitina, Oksana E. Zhenilo, Anna Y. Ardzha

ABSTRACT

5592

Does time to completion of radiation treatment in locally advanced vulvar cancer impact survival?

AUTHOR(S)

Nancy T. Nguyen, Xiao Zhao, Matthew Ponzini, Machel Wilson, Gary S. Leiserowitz, Rebecca A. Brooks

ABSTRACT

5593

Potential impact of HPV vaccine on incidence of high-grade vulvar, vaginal, and anal precancers among females and males aged 15 to 39 years, United States 2000 to 2017.

AUTHOR(S)

Mona Saraiya, Virginia Senkomago

ABSTRACT

5594

AdvanTIG-202: A phase 2 study investigating anti-TIGIT monoclonal antibody ociperlimab plus anti-PD-1 monoclonal antibody tislelizumab in patients with previously treated recurrent or metastatic cervical cancer.

AUTHOR(S)

Lingying Wu, Peng-Hui Wang, Sheng-Yen Hsiao, Chih-Long Chang, Hee Seung Kim, Jung-Yun Lee, Sang-Young Ryu, Yunxia Zuo, Xiyan Mu, Yajuan Gao, Silu Yang, Jae-Kwan Lee

ABSTRACT

TPS5595

Tisotumab vedotin versus investigator's choice chemotherapy in second- or third-line recurrent or metastatic cervical cancer (innovaTV 301/ENGOT-cx12/GOG 3057, trial in progress).

AUTHOR(S)

Ignace Vergote, Bradley J. Monk, Robert L. Coleman, Leslie M. Randall, Keiichi Fujiwara, Christian Marth, Linn L. Woelber, Els Van Nieuwenhuysen, David Cibula, Paula Calvert, Ingrid Boere, Antonio González-Martín, Elsa Kalbacher, Nicoletta Colombo, Domenica Lorusso, Susana N. Banerjee, Fernando C. Maluf, Ibrahima Soumaoro, Brian M. Slomovitz

ABSTRACT

TPS5596

Immunotherapy in combination with PARP inhibition in advanced cervical cancer patients functionally competent or deficient for the Fanconi anemia repair pathway.

AUTHOR(S)

John P. Diaz, Wenrui Duan, Eric Schroeder, Zuanel Diaz, Nicholas Lambrou, Troy A. Gatliffe, Thomas Morrissey, Miguel A. Villalona-Calero

ABSTRACT

TPS5597

ENGOT-ov54/Swiss-GO-2/MATAO including LOGOS (Low-Grade Ovarian cancer Sub-study): MAintenance Therapy with Aromatase inhibitor in epithelial Ovarian cancer—A randomized, double-blinded, placebo-controlled, multicenter phase III Trial.

AUTHOR(S)

Viola A. Heinzelmann-Schwarz, Christian Kurzeder, Seraina Schmid, Natalie Gabriel, Andreas Mueller, Mathias K. Fehr, Christian Marth, Andreas Du Bois, Maximilian Klar

ABSTRACT

TPS5598

Clinical trial in progress: Pivotal study of VB-111 combined with paclitaxel versus paclitaxel for treatment of platinum-resistant ovarian cancer (OVAL, VB-111-701/GOG-3018).

AUTHOR(S)

Rebecca C. Arend, Bradley J. Monk, Thomas J. Herzog, Jonathan A. Ledermann, Kathleen N. Moore, Angeles A. Secord, Ronnie Shapira-Frommer, Krishnansu S. Tewari, Tamar Rachmilewitz Minei, Dror Harats, Richard T. Penson

ABSTRACT

TPS5599

Trial in progress: A phase 1, multicenter, open-label, dose-exploration and dose-expansion study evaluating the safety, tolerability, pharmacokinetics, and efficacy of AMG650 in subjects with advanced solid tumors.

AUTHOR(S)

Ramaswamy Govindan, Amanda R. Townsend, Kathy D. Miller, Inderjit Mehmi, Yasutoshi Kuboki, Ecaterina E. Dumbrava, Erika P. Hamilton, Irene Vuu, Erik Rasmussen, Linda R. Mileshekin, Sofia Genta, Hiroji Iwata, Sylvia Adams, Hisaki Fujii, Sant P. Chawla

ABSTRACT

TPS5600

A randomized phase III, two-arm trial of paclitaxel, carboplatin, and maintenance letrozole versus letrozole monotherapy in patients with stage II-IV, primary low-grade serous carcinoma of the ovary or peritoneum.

AUTHOR(S)

Amanda Nickles Fader, Lilian T. Gien, Austin Miller, Al Covens, David M. Gershenson

ABSTRACT

TPS5601

A phase I/II, multicenter, open-label study of REGN5668 (mucin [MUC]16 x CD28 bispecific antibody [bsAb]) with cemiplimab (programmed death [PD]-1 Ab) or REGN4018 (MUC16 x CD3 bsAb) in recurrent ovarian cancer (rOVCA).

AUTHOR(S)

Ira S. Winer, Anthony F. Shields, Oladapo O. Yeku, Joyce F. Liu, Mary J. Peterman, Suk-Young Yoo, Israel Lowy, N. Alice Yama-Dang, Priscila H. Goncalves, Glenn Kroog

ABSTRACT

TPS5602

ENGOT-ov60/GOG3052/RAMP 201: A phase 2 study of VS-6766 (dual RAF/MEK inhibitor) alone and in combination with defactinib (FAK inhibitor) in recurrent low-grade serous ovarian cancer (LGSOC).

AUTHOR(S)

Susana N. Banerjee, Bradley J. Monk, Els Van Nieuwenhuysen, Kathleen N. Moore, Ana Oaknin, Michel Fabbro, Nicoletta Colombo, David M. O'Malley, Robert L. Coleman, Jonathan A. Pachter, Andrew G. Koustenis, Gloria Patrick, Lorna Leonard, Rachel N. Grisham

ABSTRACT

TPS5603

ROCSAN trial (GINECO-EN203b/ENGOT-EN8): A multicentric randomized phase II/III evaluating dostarlimab in combination with niraparib versus niraparib alone compared to chemotherapy in the treatment of endometrial/ovarian carcinosarcoma after at least one line of platinum based chemotherapy.

AUTHOR(S)

Isabelle L. Ray-Coquard, Alexandra Leary, Frédéric Bigot, Laure Montane, Michel Fabbro, Anne-Claire Hardy-Bessard, Frederic Selle, Camille Chakiba, Alain Lortholary, Dominique Berton, Valérie Chevalier-Evain, Magali Provansal, Laurence Gladieff, Marie-Christine Kaminsky, Sandro Pignata, Elena I. Braicu, Christophe Caux, Marc-Henri Stern, Audrey Bellesoeur, Elsa Kalbacher

ABSTRACT

TPS5604

A phase 3, randomized, double-blind, adaptive, placebo/paclitaxel-controlled study of AVB-S6-500 in combination with paclitaxel in patients with platinum-resistant recurrent ovarian cancer (GOG-3059/ENGOT OV-66/AVB500-OC-004).

AUTHOR(S)

Katherine C. Fuh, Thomas J. Herzog, Kathleen N. Moore, Tashanna K. Myers, BJ Rimel, Joyce F. Liu, Angeles A. Secord, Erika P. Hamilton, Thomas J. Reid, Sharyn N. Lewin, Mary M. Mullen, Kathryn A. Mills, Randy Anderson, Reshma A. Rangwala

ABSTRACT

TPS5605

FLORA-5: Front-line chemoimmunotherapy (Paclitaxel-Carboplatin-Oregovomab [PCO] versus chemotherapy (Paclitaxel-Carboplatin-Placebo [PCP]) in patients with advanced epithelial ovarian cancer (EOC)—Phase III double-blind placebo controlled multinational study.

AUTHOR(S)

Angeles A. Secord, Sunil Gupta, Cathy Reddick, Jyoti Chauhan, Sarah Gill, John O. Schorge, Michael Gold, Devansu Tewari, Christopher A. Breed, Patricia S. Braly, Dennis Y. Kuo, Susan C. Modesitt, Robert W. Holloway

ABSTRACT

TPS5606

Uplift (ENGOT-ov67): A pivotal cohort to evaluate XMT-1536 (upifitamab rilsodotin), a NaPi2b-directed antibody drug conjugate for platinum-resistant ovarian cancer.

AUTHOR(S)

Debra L. Richardson, Erika P. Hamilton, Ana Oaknin, Leslie M. Randall, Susana N. Banerjee, Sara K. Taylor, Linda R. Mileskin, Robert L. Coleman, Bradley J. Monk, Mansoor R. Mirza, Patricia Bernardo, Rebecca Mosher, Valerie M. Jansen, Antonella Savarese, Toon Van Gorp, Radoslaw Madry, Isabelle L. Ray-Coquard, Nicole Concin

ABSTRACT

TPS5607

ENGOT-en11/GOG-3053/KEYNOTE-B21: Phase 3 study of pembrolizumab or placebo in combination with adjuvant chemotherapy with/without radiotherapy in patients with newly diagnosed high-risk endometrial cancer.

AUTHOR(S)

Toon Van Gorp, Mansoor Raza Mirza, Alain Lortholary, David Cibula, Axel Walther, Antonella Savarese, Maria P. Barretina-Ginesta, Firat Ortaç, Christos Papadimitriou, Lubomir Bodnar, Chyong-Huey Lai, Jacob Korach, Christian Marth, Kosei Hasegawa, Xing Xie, Emma L. Barber, Robert L. Coleman, Stephen M. Keefe, Robert Orlowski, Brian Slomovitz

ABSTRACT

TPS5608

A phase 2, two-stage study of avelumab and axitinib in patients with mismatch repair proficient (MMR-P) recurrent or persistent endometrial cancer (EC).

AUTHOR(S)

Elizabeth K. Lee, Niya Xiong, Nabihah Tayob, Carolyn N. Krasner, Mary K. Buss, Susana M. Campos, Alexi A. Wright, Joyce F. Liu, Meghan Shea, Oladapo O. Yeku, Cesar M. Castro, Rebecca Porter, Elizabeth Stover, Sara Boubberhan, John W. Moroney, Stephen A. Cannistra, Richard T. Penson, Gini F. Fleming, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos

ABSTRACT

TPS5609

SIENDO/ENGOT-EN5/GOG-3055: A randomized phase 3 trial of maintenance selinexor versus placebo after combination platinum-based chemotherapy in advanced or recurrent endometrial cancer.

AUTHOR(S)

Ignace Vergote, Jose A. Perez-Fidalgo, Erika P. Hamilton, Toon Van Gorp, Giorgio Valabrega, Annouschka Laenen, Amit M. Oza, Tally Levy, David Cibula, Jalid Sehouli, Eva Guerra, Hye Sook Chon, Alice Bergamini, Ignacio Romero, Dayana Michel, Jatin J. Shah, Bradley J. Monk, Brian M. Slomovitz, Mansoor R. Mirza, Vicky Makker

ABSTRACT

TPS5610

A phase 2, two-stage study of mirvetuximab soravtansine (IMGN853) in combination with pembrolizumab in patients with microsatellite stable (MSS) endometrial cancer (EC).

AUTHOR(S)

Rebecca L. Porter, Jennifer T. Veneris, Nabihah Tayob, Gabriela West, Madeline Polak, Jeanette Gardner, Susana M. Campos, Carolyn N. Krasner, Elizabeth K. Lee, Joyce F. Liu, Elizabeth Stover, Alexi A. Wright, Ursula A. Matulonis, Panagiotis A. Konstantinopoulos

ABSTRACT

TPS5611

ADAGIO: A phase IIb, open-label, single-arm, multicenter study assessing the efficacy and safety of adavosertib (AZD1775) as treatment for recurrent or persistent uterine serous carcinoma.

AUTHOR(S)

Joyce F. Liu, Nicoletta Colombo, Amit M. Oza, Ana Oaknin, Lydia Gaba, Jean-Sebastien Frenel, Nicole Nevadunsky, Victoria de Giorgio-Miller, Pingping Ni, Dana C. Ghiorghiu

ABSTRACT

TPS5612

Head and Neck Cancer

[Back to Program](#)

Showing 74 Presentations

<https://meetinglibrary.asco.org/session/13639>

Long-term follow-up of bintrafusp alfa, a bifunctional fusion protein targeting TGF- β and PD-L1, in advanced squamous cell carcinoma of the head and neck (SCCHN).

AUTHOR(S)

Byoung Chul Cho, Amaury Daste, Alain Ravaud, Sébastien Salas, Nicolas Isambert, Edward F. McClay, Ahmad Awada, Christian Borel, Christoph Helwig, P. A. Rolfe, Laureen S. Ojalvo, James L. Gulley, Nicolas Penel

ABSTRACT

6020

The association of skeletal muscle mass and cisplatin pharmacokinetics in head and neck cancer patients: The prospective PLATISMA study.

AUTHOR(S)

Laura Molenaar-Kuijsten, Najiba Chargi, Lot Devriese, Remco de Bree, Alwin Huitema

ABSTRACT

6021

Anlotinib in radioiodine-refractory differentiated thyroid carcinoma: A subanalysis based on ALTER01032 study for patients with poor baseline characteristics.

AUTHOR(S)

Yihebal Chi, Ming Gao, Yuan Zhang, Feng Shi, Ying Cheng, Zhuming Guo, Minghua Ge, Jianwu Qin, Jiewu Zhang, Zhendong Li, Xiaohong Zhou, Rui Huang, Xiaohong Chen, Hui Liu, Ruochuan Cheng, Zhengang Xu, Xiangqian Zheng, Dapeng Li, Pingzhang Tang

ABSTRACT

6022

Toripalimab plus intensity-modulated radiotherapy for recurrent nasopharyngeal carcinoma: An open-label single-arm, phase II trial.

AUTHOR(S)

Mingyuan Chen, Yijun Hua, Rui You, Zhi-Qiang Wang, Peiyu Huang, Mei Lin, Yan-Feng Ouyang

ABSTRACT

6023

Afatinib and pembrolizumab for recurrent or metastatic head and neck squamous cell carcinoma (ALPHA Study): A phase II study with biomarker analysis.

AUTHOR(S)

Hsiang-fong Kao, Bin-Chi Liao, Yen-Lin Huang, Huai-Cheng Huang, Chun-Nan Chen, Tseng-Cheng Chen, Yuan-Jing Hong, Ching-Yi Chan, Ruey-Long Hong

ABSTRACT

6024

A phase 2 study of liposomal irinotecan with 5-fluorouracil and leucovorin in squamous cell carcinoma of head and neck or esophagus after prior platinum-based chemotherapy or chemoradiotherapy.

AUTHOR(S)

Li-Yuan Bai, Muh-Hwa Yang, Nai-Jung Chiang, Shang-Yin Wu, Chen-Yuan Lin, Ming-Yu Lien, Jia-Hong Chen, Mu-Hsin Chang, Ching-Yun Hsieh, Ruey-Long Hong, Hsiang-fong Kao, Ren-Hua Ye, Shang-Hung Chen, Chin-Fu Hsiao, Li-Tzong Chen, Tsang-Wu Liu

ABSTRACT

6025

Preliminary results of the efficacy and safety of all-trans retinoic acid combined with low-dose apatinib in the treatment of patients with recurrent/metastatic adenoid cystic carcinoma of the head and neck.

AUTHOR(S)

Lulu Ye, Lin Zhang, Rongrong Li, Guopei Zhu

ABSTRACT

6026

Mathematical predication models to optimize post-treatment surveillance in HPV-associated oropharyngeal cancer.

AUTHOR(S)

Vivek Nair, Samuel Auger, Sara Kochanny, Frederick Howard, Daniel Ginat, Olga Pasternak-Wise, Aditya Juloori, Evgeny Izumchenko, Nishant Agrawal, Ari Rosenberg, Everett E. Vokes, Reza Skandari, Alexander T. Pearson

ABSTRACT

6027

Results from a phase II study of eftilagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic second-line squamous head and neck carcinoma.

AUTHOR(S)

Irene Brana, Martin Forster, Antonio Lopez-Pousa, Bernard Doger, Patricia Roxburgh, Pawan Bajaj, Daniela Urueta Portillo, Vanesa Quiroga, Matthew Krebs, Christian Mueller, Frederic Triebel

ABSTRACT

6028

Update on safety and efficacy of a phase 1/2 of SNS-301 added to pembrolizumab in patients with advanced squamous cell carcinoma of the head and neck (SCCHN).

AUTHOR(S)

Alain P. Algazi, Dhaval Shah, William Smith, Timothy J. Panella, Dong M. Shin, Justine Y. Bruce, Ramzi Melhem, Jean S. Campbell, Lauren Abell, Marie-Louise Fjaellskog, John K. Celebi, Robert H. Pierce, Ann W. Gramza

ABSTRACT

6029

Expansion cohort validation of a clinical predictive model for head and neck cancer survival in patients treated with immune checkpoint inhibitors.

AUTHOR(S)

Georgios Laliotis, Majd Issa, Brett Klamer, Vidhya Karivedu, Priyanka Bhateja, Khaled Dibs, Nikol Mladkova, Xueliang J. Pan, Matthew O. Old, Mauricio Gamez, John C. Grecula, Sachin R. Jhawar, Darrion L. Mitchell, Sujith Baliga, Ricardo Carrau, James W. Rocco, Dukagjin Blakaj, Marcelo R. Bonomi

ABSTRACT

6030

Adjuvant nivolumab following salvage resection in head and neck squamous cell carcinoma patients previously treated with definitive therapy: A single-arm phase II multi-institutional study.

AUTHOR(S)

Jennifer Leddon, Sulsal Haque, Shuchi Gulati, Casey Allen, Sarah Palackdharry, Aubrey Hamilton, Sarah Wilson, Sheena M. Lanverman, Muhammad Kashif K. Riaz, Vinita Takiar, Misako Nagasaka, Yash Patil, Chad Zender, Roman Jandarov, Alice L. Tang, Brian Cervenka, Li Zhang, Ammar Sukari, Trisha M. Wise-Draper

ABSTRACT

6031

A phase III multicenter randomized clinical trial to compare cisplatin plus fluorouracil with or without docetaxel as the first-line induction chemotherapy for locoregionally advanced nasopharyngeal carcinoma: Long-term outcomes update.

AUTHOR(S)

Wang F. FangZheng

ABSTRACT

6032

Effect of neoadjuvant systemic therapy given during window trials on quality metrics in resectable head and neck squamous cell carcinoma.

AUTHOR(S)

Marco A. Mascarella, Varun Vendra, Mark Kubik, Shaum Sridharan, Seungwon Kim, Robert L. Ferris, Moon J. Fenton, James Ohr, Dan P. Zandberg, Umamaheswar Duvvuri

ABSTRACT

6033

Phase II trial of combined durvalumab plus tremelimumab with proton therapy to boost the abscopal effect for recurrent or metastatic head and neck squamous cell carcinoma.

AUTHOR(S)

Hana Kim, Myung-Ju Ahn, Dongryul Oh, Sehhoon Park, Hyun Ae Jung, Se-Hoon Lee, Keunchil Park, Yong Chan Ahn

ABSTRACT

6034

Maintenance intervention to improve survival in patients with metastatic nasopharyngeal carcinoma who benefit from first-line treatment: A prospective multicenter randomized controlled clinical study.

AUTHOR(S)

Ying Lu, Haixin Huang, Hui Yang, Xiaohua Hu, Xianbing Feng, Changjie Huang

ABSTRACT

6035

Final analysis of a phase 1b, randomized, multicenter study of talimogene laherparepvec (T-VEC) plus pembrolizumab (pembro) combination for the treatment (Tx) of recurrent/metastatic squamous cell carcinoma of the head and neck (R/M HNSCC): MASTERKEY-232.

AUTHOR(S)

Kevin J. Harrington, Anthony Kong, Nicolas Mach, Jason A. Chesney, Beatriz Castelo, Danny Rischin, Ezra E. Cohen, Hoi-Shen Radcliffe, Burak Gumuscu, Wendy Snyder, Lillian L. Siu

ABSTRACT

6036

Interim analysis of IMMUNEBOOST-HPV: A multicenter, randomized, open label, phase II study evaluating the feasibility, and tolerance of neoadjuvant nivolumab in high-risk HPV driven oropharynx cancer.

AUTHOR(S)

Haitham Mirghani, Caroline Even, Alicia Larive, Jerome Fayette, Karen Benezery, Florian Clatot, Lionnel Geoffrois, Yungan Tao, France Nguyen, Emmanuelle Fabiano, Sarah Kreps, Eve Marie Neidhardt, Florence Garic, Anne Auperin, Pierre Blanchard

ABSTRACT

6037

Use of cetuximab added to weekly chemotherapy to improve progression-free survival in patients with recurrent metastatic head and neck squamous cell carcinoma after progression on immune checkpoint inhibitors.

AUTHOR(S)

Majd Issa, Brett Klamer, Vidhya Karivedu, Priyanka Bhateja, Georgios Laliotis, Khaled Dibs, Nikol Mladkova, Xueliang J. Pan, Matthew O. Old, Mauricio Gamez, John C. Grecula, Sachin R. Jhavar, Darrion L. Mitchell, Sujith Baliga, Ricardo Carrau, James W. Rocco, Dukagjin Blakaj, Marcelo R. Bonomi

ABSTRACT

6038

Adjuvant toripalimab or combined with S-1 in recurrent, previously irradiated head and neck squamous cell carcinoma treated with salvage surgery: A phase II clinical trial (The RePASS study).

AUTHOR(S)

Shengjin Dou, Rongrong Li, Lin Zhang, Wen Jiang, Lulu Ye, Guopei Zhu

ABSTRACT

6039

Update and external validation of a multivariable prediction model for tube feeding dependency for at least four weeks during chemoradiotherapy for head and neck cancer.

AUTHOR(S)

Anna C. Willemsen, Annemieke Kok, Laura W. Baijens, J. P. De Boer, Remco de Bree, Lot Devriese, Chantal M. Driessen, Carla M. Van Herpen, F. J. Hoebers, Johannes H. Kaanders, Rebecca T. Karsten, Sander Van Kuijk, Roy I. Lalisang, Arash Navran, Susanne R. Pereboom, Annemie M. Schols, Chris H. Terhaard, Ann Hoeben

ABSTRACT

6040

Racial and regional differences in incidence of oropharyngeal cancer in the United States during 2001 to 2017.

AUTHOR(S)

Fangjian Guo, Mihyun Chang, Abbey Berenson

ABSTRACT

6041

Efficacy and toxicity of weekly paclitaxel, carboplatin, and cetuximab as induction chemotherapy or in cases of metastases or relapse for head and neck cancer in elderly or frail patients.

AUTHOR(S)

Rebecca Forman, Aarti K. Bhatia, Barbara Burtness

ABSTRACT

6042

Palbociclib (P) in patients (pts) with head and neck cancer (HNC) with *CDKN2A* loss or mutation: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

AUTHOR(S)

Evan P. Pisick, Michael Roth, Pam K. Mangat, Liz Garrett-Mayer, Francis P. Worden, Jessica R. Bauman, Siqing Fu, Rom S. Leidner, Ani S. Balmanoukian, Carmen Calfa, Daniel R. Carrizosa, Stacy D. D'Andre, Lisle Nabell, Min S. Park, Steven F. Powell, Ramya Thota, Richard L. Schilsky

ABSTRACT

6043

Capecitabine maintenance therapy after induction chemotherapy in newly diagnosed metastatic nasopharyngeal carcinoma: An open-label, randomized, controlled, phase III trial.

AUTHOR(S)

Guo-Ying Liu, Wang-Zhong Li, De-Shen Wang, Hu Liang, Xing Lv, Yan-Fang Ye, Chong Zhao, Liang-Ru Ke, Mengyun Qiang, Xun Cao, Shu-Hui Lv, Nian Lu, Wei-Xin Bei, Zhuocheng Cai, Xi Chen, Jun-Zhi Xie, Chixiong Liang, Xiang Guo, Weixiong Xia, Xiang Yanqun

ABSTRACT

6044

Evaluation of radiomics as a predictor of tumor hypoxia and response to anti-PD-1 mab treatment (IO) in recurrent/metastatic HNSCC patients (R/M).

AUTHOR(S)

Dan P. Zandberg, Serafettin Zenkin, Murat AK, Priyadarshini Mamindla, Vishal Peddagangireddy, Ashley V. Menk, Greg Delgoffe, Maria A. Velez, Angen Liu, Heath D. Skinner, Robert L. Ferris, Rivka R. Colen

ABSTRACT

6045

Refining TNM-8 M1 categories with anatomic subgroups for previously untreated de novo metastatic nasopharyngeal carcinoma.

AUTHOR(S)

Sik-Kwan Chan, Cheng Lin, Shao Hui Huang, Tin Ching Chau, Qiaojuan Guo, Brian O'Sullivan, Ka-On Lam, Sze Chun Chau, Ann S. Chan, Chi-Chung Tong, Varut Vardhanabhuti, Dora L. Kwong, Tsz Him So, Sherry C. Ng, To Wai Leung, Mai-Yee Luk, Anne W. Lee, Cheuk-Wai Choi, Jianji Pan, Victor H. Lee

ABSTRACT

6046

Outcomes and prediction of lethal recurrence after transoral robotic surgery for HPV+ head and neck cancer.

AUTHOR(S)

Devraj Basu, David Shimunov, Roger B. Cohen, Alexander Lin, Samuel Swisher-McClure, John N. Lukens, Joshua Bauml, Lee P. Hartner, Charu Aggarwal, Umamaheswar Duvvuri, Karthik Rajasekaran, Ara Chalian, Christopher Rassekh, Steven Cannady, Jason Newman, Bert W. O'Malley, Gregory S. Weinstein, Phyllis A. Gimotty, Robert Brody

ABSTRACT

6047

Ultra-sensitive detection and quantification of HPV DNA in the plasma of patients with oropharyngeal squamous cell carcinoma (OPSCC) enrolled in the OPTIMA 2 treatment de-escalation trial.

AUTHOR(S)

Hillary Sloane, Evgeny Izumchenko, Austin Mattox, Rifat Hasina, Aashay Patel, Frederick Jones, Hannah Quinn, Kirsten Keyser, Johannes Fredebohm, Frank Holtrup, Alexander T. Pearson, Everett E. Vokes, Tanguy Y. Seiwert, Daniel L. Edelstein, Ari Rosenberg, Nishant Agrawal

ABSTRACT

6048

The impact of tumor infiltrating lymphocytes (TILs) on disease progression in human papillomavirus (HPV)-related oropharyngeal squamous cell carcinoma.

AUTHOR(S)

Linda X. Yin, Michael Rivera, Joaquin J. Garcia, Kathleen Bartemes, Derrick B. Lewis, Christine M. Lohse, David Routman, Daniel J. Ma, Eric J. Moore, Kathryn M. Van Abel

ABSTRACT

6049

Endostar combined with intensity-modulated radiotherapy in low-risk local advanced nasopharyngeal carcinoma: A phase II, randomized, multicentric clinical trial.

AUTHOR(S)

Min Kang, Shaomin Lin, Haisheng Zhu, Sihui Liao, Haixin Huang, Bin Yu, Hongqian Wang, Meilian Liu, Jinxian Zhu, Guang Huang, Tingting Zhang, Zhendong Yang, Pingting Zhou, Ziyang Zhou, Yutao Qin, Zhuxin Wei, Qinghua Du, Changhong Zhao, Mingjun Shen, Rensheng Wang

ABSTRACT

6050

Phase I study of functionalized hafnium oxide nanoparticles (NBTXR3) activated by radiotherapy in cisplatin-ineligible locally advanced HNSCC patients.

AUTHOR(S)

Christophe Le Tourneau, Valentin Calugaru, Zoltan Takacs-Nagy, Xavier Liem, Zsuzsanna Papai, Jacek Fijuth, Victor Moreno, Jordi Giralt, Sébastien Salas, Gilles Poissonnet, Emiliano Calvo, Bernard Doger, Olivier Choussy, Xavier Mirabel, Samar Krhili, Katell Bernois, Nicolas Fakhry, Stéphanie Wong-Hee-Kam, Edith Borcoman, Caroline Hoffmann

ABSTRACT

6051

Inductive camrelizumab and apatinib for patients with locally advanced and resectable oral squamous cell carcinoma: A single-arm trial (Icemelting trial).

AUTHOR(S)

Lai-Ping Zhong, Wu-tong Ju, Rong-hui Xia, Qi Zhu, Guopei Zhu, Shengjin Dou, Jiang Li, Min-jun Dong

ABSTRACT

6052

Neoadjuvant and adjuvant nivolumab and lirilumab in patients with recurrent, resectable squamous cell carcinoma of the head and neck.

AUTHOR(S)

Glenn J. Hanna, Anne M. O'Neill, Vickie Y. Jo, Kristine Wong, Patrick H. Lizotte, Donald J. Annino Jr., Laura A. Goguen, Jason I. Kass, Eleni M. Rettig, Rosh K. Sethi, Jochen H. Lorch, Jonathan D. Schoenfeld, Danielle N. Margalit, Roy B. Tishler, Peter C. Everett, Anupam M. Desai, Cloud P. Paweletz, Ann Marie Egloff, Ravindra Uppaluri, Robert I. Haddad

ABSTRACT

6053

Transoral robotic surgery for human papillomavirus-associated oropharynx squamous cell carcinoma: Recurrence and survival in the Veterans Affairs health system.

AUTHOR(S)

Abhishek Kumar, Daniel R. Cherry, Rohith S. Voora, Farhoud Faraji, Patrick T. Courtney, Andrey Finegersh, Theresa Guo, Ezra E. Cohen, Joseph A. Califano III, Loren K. Mell, Brent S. Rose, Ryan K. Orosco

ABSTRACT

6054

Survival outcomes in primary head and neck adult sarcoma: A systematic review and meta-analysis.

AUTHOR(S)

Sondos Zayed, Cindy Lin, Gabriel Boldt, Pencilla Lang, Nancy Read, Varagur Venkatesan, Jinka Sathya, Fung Kevin, Danielle MacNeil, Adrian Mendez, John Yoo, Andrew Warner, Anthony C. Nichols, David A. Palma

ABSTRACT

6055

A phase II study of PRV111 nanoengineered cisplatin patch as a neoadjuvant therapy for early-stage oral squamous cell carcinoma (OSCC).

AUTHOR(S)

Nishant Agrawal, Evgeny Izumchenko, Kenneth Hodge, Simon Young, James C. Melville, Jonathan Shum, Dhafer Alsuwied, Vlad Sandulache, Michael Harris, Aaron Manzi, Manijeh Goldberg

ABSTRACT

6056

Impact of comprehensive geriatric assesment (CGA) in the treatment decision and outcome of older patients with locally advanced head and neck squamous cell carcinoma (LA-HNSCC).

AUTHOR(S)

Sandra Llop Serna, Clara Ejarque Martinez, Jesús Brenes Castro, Macarena Honorato, M. Esther Vilajosana Altamis, Mireia Melero, Oriol Bermejo, Victoria Gomez Garcia, Marta Fulla, Montse Goma, Isabel Linares, Alicia Lozano, Miren Taberna, Ricard Mesia, Maria Plana, Maite Antonio Rebollo, Marc Oliva Bernal

ABSTRACT

6057

Survival (OS) and progression-free survival (PFS) results after induction chemotherapy (IC) followed by de-escalated chemoradiotherapy (RDCRT) for locally advanced (LA) HPV positive oropharynx cancer (HPVOPC).

AUTHOR(S)

Marshall R. Posner, Krzysztof Misiukiewicz, Brett A. Miles, Sonam Sharma, Vishal Gupta, Eric M. Genden, John Botzler, Isaiah Selkridge, Erin Moshier, Vruti Virani, Richard L. Bakst

ABSTRACT

6058

Prospective manipulation of the gut microbiome with Microbial Ecosystem Therapeutic 4 (MET4) in locoregionally advanced oropharyngeal squamous cell carcinoma (LA-OPSCC) undergoing primary chemoradiation (ROMA2).

AUTHOR(S)

Geoffrey A. Watson, Alya Heirali, Marc Oliva Bernal, Kyla Cochrane, Emma Allen-Vercoe, Anneli Eliason, Sarah Jennings, Rachel Taylor, Ali Hosni, Andrew Hope, Scott V. Bratman, Douglas B. Chepeha, Ilan Weinreb, Bayardo Perez-Ordóñez, John Waldron, Wei Xu, Aaron R. Hansen, Lillian L. Siu, Bryan Coburn, Anna Spreafico

ABSTRACT

6059

Postoperative PET/CT for detection of early recurrence (ER) after surgery for squamous cell carcinomas (SCC) of the oral cavity (OC).

AUTHOR(S)

Yao Yu, Heiko Schöder, Jung Kang, Sean M. McBride, C. Jillian Tsai, Linda Chen, Kaveh Zakeri, Daphna Y. Gelblum, Jay Boyle, Jennifer R. Cracchiolo, Marc Cohen, Bhuvanesh Singh, Ian Ganly, Snehal G. Patel, Loren S. Michel, Lara Dunn, David G. Pfister, Richard J. Wong, Nadeem Riaz, Nancy Y. Lee

ABSTRACT

6060

Impact of COVID19 pandemic on treatment outcome of locally-advanced head and neck squamous cell carcinoma (LA-HNSCC): IMPACCT study.

AUTHOR(S)

Pau Guillen Sentis, Carmen Castillo Manzano, Beatriz Quirós, Francisca Morey Cortes, Sara Tous, Maria Plana, Jesús Brenes Castro, Alicia Lozano, Isabel Linares, M. Esther Vilajosana Altamis, Victoria Gomez Garcia, Maria Labori Trias, Montse Goma, Antonio Mari Roig, Oriol Bermejo, Jordi Tornero Salto, Miren Taberna, Laia Alemany, Ricard Mesia, Marc Oliva Bernal

ABSTRACT

6061

Quality of life analysis of HPV-positive oropharyngeal cancer patients in a randomized trial of reduced-dose (rdCRT) versus standard (sdCRT) chemoradiotherapy: Five-year follow-up.

AUTHOR(S)

Mai Takahashi, Michael Hwang, Krzysztof Misiukiewicz, Richard L. Bakst, Brett A. Miles, Vishal Gupta, Marcelo R. Bonomi, Sonam Sharma, John Botzler, Eric M. Genden, Erin Moshier, Isaiah Selkridge, Marshall R. Posner

ABSTRACT

6062

Evaluating a clinically validated circulating tumor HPV DNA assay in saliva as a proximal biomarker in HPV+ oropharyngeal squamous cell carcinoma.

AUTHOR(S)

Sophie P. Gerndt, Ricardo J. Ramirez, Benjamin M. Wahle, Charlotte Kuperwasser, Alicia Gunning, Aadel A. Chaudhuri, Jose P. Zevallos

ABSTRACT

6063

Quantitative immunofluorescence and mRNA analysis of immune-related biomarker groups in matched paired tumor samples from OPHELIA window study in head and neck squamous cell carcinoma (HNSCC).

AUTHOR(S)

Amanda Psyrris, Myrto Moutafi, Georgia-Angeliki Koliou, George Papaxoinis, Niki Gavrielatou, Panagiot Economopoulou, Ioannis Kotsantis, Maria Gkotsamanidou, Maria Anastasiou, Dimitrios G. Pectasides, Aileen Fernandez, Vesal Yaghoobi, Saba Shafi, Ioannis Vathiotis, Thazin Nwe Aung, Stavros Gkolfinopoulos, Periklis Foukas, George Fountzilas, David L. Rimm

ABSTRACT

6064

Cisplatin and capecitabine induction chemotherapy in nasopharyngeal carcinoma.

AUTHOR(S)

Zhiyuan Xu, Li Yang, Victor H. Lee, Anne W. Lee

ABSTRACT

6065

The SINTART 1 study: A phase II trial of induction chemotherapy (IC), surgery, photon-, proton-and carbon ion-based radiotherapy (RT) integration in locally advanced operable sinonasal epithelial tumors patients (pts).

AUTHOR(S)

Carlo Resteghini, Paolo Castelnuovo, Piero Nicolai, Ester Orlandi, Paolo Bossi, Barbara Vischioni, Alberto Schreiber, Nicola Alessandro Iacovelli, Paolo Battaglia, Davide Mattavelli, Nadia Facchinetti, Simone Gambazza, Giuseppina Calareso, Marco Ravanelli, Carla Facco, Tiziana Tartaro, Andrea Pietro Sponghini, Fabio Pagella, Luigi Mariani, Lisa F. Licitra

ABSTRACT

6066

Comparative assessment of the eighth and seventh AJCC staging edition prognostic performance of patients with p16 positive oropharynx cancer.

AUTHOR(S)

Felippe Lazar Neto, Luana G. Sousa, Faye M. Johnson, J. Jack Lee, Steven J. Frank, Amy C. Moreno, Kristina Dahlstrom, Renata Ferrarotto

ABSTRACT

6067

Pathologic and radiographic responses in a window of opportunity for durvalumab plus metformin trial for squamous cell carcinoma of the head and neck (HNSCC).

AUTHOR(S)

Joseph M. Curry, Angela Alnemri, Brian Swendseid, Uche Nwagu, David M. Cignetti, Voichita C. Bar-Ad, Adam Luginbuhl, Rita S. Axelrod, Diana Whitaker-Menezes, Larry Harshyne, Andrew South, My G. Mahoney, Alban Linnenbach, Athanassios Argiris, Ulrich Rodek, Ubaldo Martinez-Outschoorn, Jennifer M. Johnson

ABSTRACT

6068

The efficacy and safety of anlotinib in neoadjuvant treatment in locally advanced thyroid cancer: A single-arm phase II clinical trial.

AUTHOR(S)

Naisi Huang, Guohua Sun, Yulong Wang, Jiaying Chen, Qing Guan, Zhongwu Lu, Jun Xiang, Wenjun Wei, Ben Ma, Qinghai Ji, Yu Wang

ABSTRACT

6069

Planned drug holiday in a cohort study exploring the effect of lenvatinib on differentiated thyroid cancer.

AUTHOR(S)

Makoto Tahara, Hiroshi Takami, Yasuhiro Ito, Takahiro Okamoto, Iwao Sugitani, Kiminori Sugino, Shunji Takahashi, Hiroshi Takeyama, Hidemitsu Tsutsui, Hisato Hara, Ayako Mitsuma, Hiroyuki Yamashita, Yasuo Ohashi, Tsuneo Imai

ABSTRACT

6070

Predictive and prognostic biomarker identification in a large cohort of androgen receptor-positive salivary duct carcinoma patients scheduled for combined androgen blockade.

AUTHOR(S)

Gerben Lassche, Yuichiro Tada, Carla M. Van Herpen, Marianne A. Jonker, Diederick Keizer, Wim Verhaegh, Toshitaka Nagao, Takashi Saotome, Hideaki Hirai, Natsuki Saigusa, Adriana C. van Engen - van Grunsven, Jack A. Schalken, Chihiro Fushimi, Gerald W. Verhaegh

ABSTRACT

6071

Clinical disease course and survival outcomes following disease recurrence in adenoid cystic carcinoma (ACC) with NOTCH signaling pathway activation.

AUTHOR(S)

Brindley S. Hapuarachi, Laura Feeney, Sam Rack, Helen Adderley, David Morgan, Guy Betts, Russell Walker, Rami Rauch, Elad Herz, Kevin J. Harrington, Robert Metcalf

ABSTRACT

6072

Selpercatinib efficacy and safety in patients with *RET*-altered thyroid cancer: A clinical trial update.

AUTHOR(S)

Eric J. Sherman, Lori J. Wirth, Manisha H. Shah, Maria E. Cabanillas, Bruce Robinson, Janessa J. Laskin, Matthias Kroiss, Vivek Subbiah, Alexander E. Drilon, Jennifer Wright, Victoria Soldatenkova, Pearl P. French, Antoine Italiano, Daniela Weiler

ABSTRACT

6073

Efficacy of selpercatinib after prior systemic therapy in patients with *RET* mutant medullary thyroid cancer.

AUTHOR(S)

Lori J. Wirth, Eric J. Sherman, Daniela Weiler, Maria E. Cabanillas, Bruce Robinson, Antoine Italiano, Janessa J. Laskin, Vivek Subbiah, Alexander E. Drilon, Victoria Soldatenkova, Pearl P. French, Jennifer Wright, Matthias Kroiss, Manisha H. Shah

ABSTRACT

6074

Phase Ib, international, dose-escalation study to evaluate the safety, pharmacokinetics (PK) and efficacy of ST-617 for the attenuation of oral mucositis (OM) in patients receiving chemoradiation (CRT) for head and neck (H&N) cancer.

AUTHOR(S)

Daniel Osei-Fofie, Julie Wetter, Greg A. Landers, Peter A. Kraus, Shawgi Sukumaran, Hui Mun, Brian N. Stein, Victoria J. Bray, Bomi Framroze, Jeffrey Gelfand, Paul Y. Song, Andries Lategan, Mikaela Dimitriu, Stephen T. Sonis

ABSTRACT

6075

Randomized phase II study of sorafenib with or without everolimus in patients with radioactive iodine refractory Hürthle cell thyroid cancer (HCC) (Alliance A091302/ ITOG 1706).

AUTHOR(S)

Eric J. Sherman, Nathan R. Foster, Yungpo B. Su, Ardaman Shergill, Alan L. Ho, Bhavana Konda, Ronald A. Ghossein, Ian Ganly, Gary K. Schwartz

ABSTRACT

6076

Radiomics-based prediction of response to multikinase inhibitors in radioiodine-refractory differentiated thyroid cancer patients.

AUTHOR(S)

Valentina Corino, Elena Colombo, Marco Bologna, Giuseppina Calareso, Luca Mainardi, Stefano Cavalieri, Daria Maria Filippini, Carlo Resteghini, Cristiana Bergamini, Lisa F. Licitra, Laura D. Locati

ABSTRACT

6077

A pooled analysis of response to selective RET inhibitors among patients with medullary thyroid cancer with M918T versus non-M918T RET mutations.

AUTHOR(S)

Janice Kim, Diana Bradford, Somak Chatterjee, Pallavi S. Mishra-Kalyani, Yuan-Li Shen, Julia A. Beaver, Harpreet Singh

ABSTRACT

6078

Trastuzumab deruxtecan (T-DXd) in patients with human epidermal growth factor receptor 2 (HER2)-expressing salivary duct carcinoma: Subgroup analysis of two phase 1 studies.

AUTHOR(S)

Hideaki Bando, Ichiro Kinoshita, Shanu Modi, Junji Tsurutani, Yung-Jue Bang, Hiroji Iwata, Yuta Sato, Shunsuke Nakatani, Caleb C. Lee, Masahiro Sugihara, Yasuyuki Okuda, Shunji Takahashi

ABSTRACT

6079

Patient-reported outcomes (PROs) from a phase II trial of pembrolizumab for HPV-associated papilloma patients with laryngeal, tracheal and/or pulmonary involvement.

AUTHOR(S)

Sara I. Pai, Ramon Franco, Ashok Muniappan, Aaron D. Friedman, Jong C. Park, Nicholas P. Campbell, Seth B. Krantz, Phillip C. Song, Cheryl Nocon, Thomas L. Carroll, William C. Faquin, Kee-Young Shin, Anne M. O'Neill, Lori J. Wirth

ABSTRACT

6080

Molecular profiling and targeted agents in recurrent, metastatic salivary gland tumor (R/M SGT) patients (pts) treated at two academic centers.

AUTHOR(S)

Alberto Hernando-Calvo, Alejandra Rezaqallah, Eoghan R. Malone, Omar Saavedra Santa Gadea, Anna Spreafico, Maria Vieito, Ilan Weinreb, Susana Aguilar, Anneli Eliason, Juan D. Assaf, Angela Rodriguez, Coro Bescos, Katherine Lajkosz, Juan Lorente, Sarah Jennings, Enriqueta Felip, Elena Garraalda, Lillian L. Siu, Aaron R. Hansen, Irene Brana

ABSTRACT

6081

Benefits of pembrolizumab in progressive radioactive iodine refractory thyroid cancer: Results of the AcSé Pembrolizumab Study from Unicancer.

AUTHOR(S)

Sophie Leboulleux, Yann Godbert, Nicolas Penel, Segolene Hescot, Christelle De La Fouchardiere, Marie Blonski, Livia Lamartina, Sophie Cousin, Christine Do Cao, Julien Hadoux, Clotilde Simon, Natalie Hoog Labouret, Sylvie Chevret, Christophe Massard

ABSTRACT

6082

***NTRK, RET, BRAF, and ALK* fusions in thyroid fine-needle aspirates (FNAs).**

AUTHOR(S)

Lori J. Wirth, Mimi I. Hu, Steven G. Waguespack, Chrysoula Dosiou, Paul Ladenson, Masha J. Livhits, Peter M. Sadow, Jeffrey Krane, Brendan C. Stack, Mark Zafereo, Syed Z. Ali, Steven P. Weitzman, Yangyang Hao, Joshua Babiarz, Giulia Kennedy, Richard Kloos

ABSTRACT

6083

Treatment patterns and systemic therapy outcomes for patients with salivary duct carcinoma and adenocarcinoma NOS.

AUTHOR(S)

Luana G. Sousa, Kaiwen Wang, Danice Torman, Bailee Binks, Clark Andersen, Whitney E. Lewis, Melvin Rivera, Diana Kaya, Adel K. El-Naggar, Ehab Y. Hanna, Bitá Esmali, Steven J. Frank, Diana Bell, Bonnie S. Glisson, Jordi Rodon Ahnert, Funda Meric-Bernstam, J. Jack Lee, Renata Ferrarotto

ABSTRACT

6084

Encorafenib and binimetinib with or without nivolumab in treating patients with metastatic radioiodine refractory BRAF V600 mutant thyroid cancer.

AUTHOR(S)

Matthew H. Taylor, Rom S. Leidner, Richard B. Bell, Bernard Fox, Hong Xiao, Marcus Couey, Andrew Baker, George Morris, Lessli Rushforth

ABSTRACT

TPS6085

Phase II multicenter randomized trial to assess the efficacy and safety of first line nivolumab in combination with paclitaxel in subjects with R/M HNSCC unable for cisplatin-based chemotherapy (NIVOTAX): A TTCC study.

AUTHOR(S)

Lara Iglesias, Alberto Carral, Marc Oliva Bernal, Javier Martinez-Trufero, Almudena García Castaño, Vanesa Gutierrez Calderon, Beatriz Cirauqui, Ana Medina, Virginia Arrazubi, Gema Bruixola, Pedro Perez, Neus Basté Rotllán, Ruth Alvarez, Laura Basterretxea, Jordi Rubió-Casadevall, Javier Caballero Daroqui, Joaquina Martínez-Galán, Julio J. Lambea- Sorrosal, Edel del Barco, Ricard Mesia

ABSTRACT

TPS6086

The AIM-HN Study: A pivotal study evaluating the efficacy of tipifarnib in patients with recurrent or metastatic head and neck squamous cell carcinoma with *HRAS* mutations.

AUTHOR(S)

Robert I. Haddad, Douglas Adkins, Lisa F. Licitra, Justine Y. Bruce, Maura L. Gillison, Myung-Ju Ahn, Ching-Yun Hsieh, Hung-Ming Wang, Amanda Psyrrri, Jean-Pascal H. Machiels, Binaifer Balsara, Mollie Leoni, Kevin J. Harrington, Nabil F. Saba, Alan L. Ho

ABSTRACT

TPS6087

CMP-001-007: Open-label, phase 2 study of intratumoral CMP-001 + pembrolizumab in patients with recurrent or metastatic head and neck squamous cell carcinoma.

AUTHOR(S)

Deborah J. Wong, Aru Panwar, Ari Rosenberg, Vidhya Karivedu, Douglas E. Laux, Dan P. Zandberg, Dmitri Bobilev, Luping Zhao, James Wooldridge, Art M. Krieg, Ezra E. Cohen

ABSTRACT

TPS6089

The BURAN study of buparlisib (AN2025) in combination with paclitaxel compared to paclitaxel alone, in patients with recurrent or metastatic head and neck squamous cell carcinoma.

AUTHOR(S)

Denis Soulieres, Sandrine J. Faivre, Kevin Dreyer, Lisa F. Licitra

ABSTRACT

TPS6090

TrilynX: A phase 3 trial of xevinapant and concurrent chemoradiation for locally advanced head and neck cancer.

AUTHOR(S)

Jean Bourhis, Barbara Burtneess, Lisa F. Licitra, Christopher Nutting, Jonathan D. Schoenfeld, Rafik Ait Sarkouh, Florilene Bouisset, Heidi Nauwelaerts, Yulia Urfer, Claudio Zanna, Ezra E. Cohen

ABSTRACT

TPS6091

First-in-human phase I/II trial of PRGN-2009 vaccine as monotherapy or with bintrafusp alfa in patients with recurrent/metastatic (R/M) human papillomavirus (HPV)-associated cancers (HPVC) and as neoadjuvant/induction therapy in locoregionally advanced (LA) HPV oropharyngeal (OP) and sinonasal (SN) squamous cell cancer (SCC).

AUTHOR(S)

Charalampos S. Floudas, Julius Strauss, Clint Allen, Nyal R. London Jr., Renee N. Donahue, Caroline Jochems, Seth M. Steinberg, Lisa M. Cordes, Sheri McMahon, Jenn Marte, Houssein Abdul Sater, Jason Redman, Fatima Karzai, Marijo Bilusic, Ravi A. Madan, Douglas E. Brough, Amy Lankford, Jeffrey Schlom, James L. Gulley

ABSTRACT

TPS6092

NRG Oncology HN006: Randomized phase II/III trial of sentinel lymph node biopsy versus elective neck dissection for early-stage oral cavity cancer.

AUTHOR(S)

Stephen Y. Lai, Pedro A. Torres-Saavedra, Neal E. Dunlap, Beth M. Beadle, Steven S. Chang, Rathan M. Subramaniam, Jian Q. Yu, Val J. Lowe, Saad A. Khan, Minh T. Truong, Diana Bell, Cheng Z. Liu, Nataliya Kovalchuk, Yi Rong, Mohamed E. Abazeed, S. C. Kappadath, Jonathan Harris, Quynh-Thu Le

ABSTRACT

TPS6093

Trial in progress: A phase I/II trial of novel MDM2 inhibitor alrizomadlin (APG-115), with or without platinum chemotherapy, in patients with p53 wild-type salivary gland carcinoma.

AUTHOR(S)

Paul Swiecicki, Yuefen Tang, Alexander T. Pearson, Jameel Muzaffar, Mary J. Fidler, Robert Winkler, Tommy Fu, Mingyu Li, Mohammad Ahmad, Dajun Yang, Yifan Zhai

ABSTRACT

TPS6094

Hematologic Malignancies—Leukemia, Myelodysplastic Syndromes, and Allograft

[Back to Program](#)

Showing 37 Presentations

<https://meetinglibrary.asco.org/session/13645>

Effect of geriatric assessment (GA) and genetic profiling on overall survival (OS) of older adults with acute myeloid leukemia (AML).

AUTHOR(S)

Vijaya R. Bhatt, Christopher S. Wichman, Zaid Al-Kadhimi, Thuy T. Koll, Alfred Fisher, Ram I. Mahato, R. K. Hyde, Ann M. Berger, James O. Armitage, Sarah A. Holstein, Lori J. Maness, Krishna Gundabolu

ABSTRACT

7021

Adult Philadelphia-like B-cell acute lymphoblastic leukemia: Characteristics, outcomes, and role of allogeneic hematopoietic cell transplantation in comparison to Philadelphia-positive and Philadelphia-negative acute lymphoblastic leukemia.

AUTHOR(S)

Zaid Abdel Rahman, Michael Heckman, Theodora Anagnostou, Launia White, Sara M. Kloft-Nelson, Ryan A. Knudson, Hassan Alkhateeb, Lisa O. Sproat, Nandita Khera, Hemant S. Murthy, Ernesto Ayala, William J. Hogan, Vivek Roy, Jess Peterson, Mohamed Kharfan-Dabaja, Rhett P. Ketterling, Mark R. Litow, Mrinal Patnaik, James M. Foran, Patricia T. Greipp

ABSTRACT

7022

Updated results from DIAMOND-01 (CL124-001) trial: A phase I/II study of SEL24/MEN1703, a first-in-class dual PIM/FLT3 kinase inhibitor, in acute myeloid leukemia.

AUTHOR(S)

Scott R. Solomon, Pau Montesinos, Aziz Nazha, Stephen A. Strickland, Giovanni Martinelli, Armando Santoro, Roland B. Walter, Rachel J. Cook, Maria Calbacho, Susana Vives, Salman Fazal, Krzysztof Brzózka, Setareh Shamsili, Simone Baldini, Dirk Laurent, Andrea U. Pellacani, Farhad Ravandi

ABSTRACT

7023

Molecular annotation of extramedullary acute myeloid leukemia to identify prevalence of targetable mutations.

AUTHOR(S)

Somedeb Ball, Todd C. Knepper, Yehuda E. Deutsch, Chirag K. Bhagat, Justin M. Watts, Terrence J. Bradley, Wassim Samra, Onyee Chan, Mohammad O. Hussaini, Kendra L. Sweet, Chetasi Talati, Eric Padron, Rami S. Komrokji, Jeffrey E. Lancet, David A. Sallman

ABSTRACT

7024

Contemporary outcomes for adults with AML requiring ICU admission.

AUTHOR(S)

Danielle Hammond, Koji Sasaki, Alexis Geppner, Fadi Haddad, Shehab Mohamed, Daniel Rivera, Maria Siddiqui, Yasmin Alwash, Jorge Ramos Perez, Kiyomi Morita, Kunhwa Kim, Sherry Pierce, Cristina Gutierrez, Naveen Pemmaraju, Gautam Borthakur, Courtney D. Dinardo, Farhad Ravandi, Guillermo Garcia-Manero, Hagop M. Kantarjian, Tapan M. Kadia

ABSTRACT

7025

Preliminary results of V-FAST, a phase 1b master trial to investigate CPX-351 combined with targeted agents in newly diagnosed AML.

AUTHOR(S)

Vinod Pullarkat, Mark J. Levis, Gabriel N. Mannis, Stephen A. Strickland, Tara L. Lin, Stefan Faderl, Divya Chakravarthy, Vijayalakshmi Chandrasekaran, Ronald Cheung, Harry P. Erba

ABSTRACT

7026

Cellworks Omics Biology Model (CBM) to predict therapy response and identify biomarkers for all-*trans* retinoic acid (ATRA) benefit as addition to induction chemotherapy in adults with acute myeloid leukemia (AML).

AUTHOR(S)

Scott C. Howard, Ansu Kumar, Himanshu Grover, Vivek Patil, Ashish Agrawal, Anuj Tyagi, Subrat Mohapatra, Humera Azam, Karthik S. Raju, Mohammed Sauban, Rahul K. Raman, Neelesh Lunkad, Upasana Mitra, Poornachandra G, Nirjhar Mundkur, Neha Gupta, Jyoti Chauhan, Swati Khandelwal, Shweta Kapoor, Michael Castro

ABSTRACT

7027

Clinical utility of whole genome sequencing in hematological neoplasms.

AUTHOR(S)

Jesus Gutierrez-Abril, Daniel Leongamornlert, Yangyu Zhou, SooWah Lee, Max Levine, Juan E. Arango Ossa, Gunes Gundem, Juan Medina-Martinez, Rachel Mitchell, Amy A. Kirkwood, Laura Clifton-Hadley, Pip Patrick, Bela Wrench, Andrew Kung, Maria L. Sulis, Neerav Shukla, Anthony Moorman, Adele K. Fielding, Elli Papaemmanuil

ABSTRACT

7028

Retrospective analysis of a novel molecular genetic risk score, “MRplus”, in BCR-ABL1 negative pediatric B-ALL: A single-center experience.

AUTHOR(S)

Sanjeev K. Gupta, Sameer Bakhshi, Ritu Gupta, Preity Sharma, Deepam Pushpam, Ranjit K. Sahoo, Atul Sharma

ABSTRACT

7029

TP53/NPM1-mutated acute myeloid leukemia as a molecularly distinct disease entity.

AUTHOR(S)

Frank J. Scarpa, Madhuri Paul, Rachel Daringer, Wendy A. Wolfson, Fernando Lopez Diaz, Sally Agersborg, Vincent A. Funari, Lawrence M. Weiss, Forrest Blocker

ABSTRACT

7030

Predictors of clinical trial enrollment and impact on outcome in children and adolescents with acute lymphoblastic leukemia: A population based study.

AUTHOR(S)

Paul J. Gibson, Uma H. Athale, Vicky R. Breakey, Nicole Mittmann, Mylene Bassal, Mariana Silva, Serina Patel, Veda Zabih, Petros Pechlivanoglou, Jason D. Pole, Sumit Gupta

ABSTRACT

7031

Distress in a pandemic: The association of the coronavirus disease-2019 (COVID-19) pandemic with distress and quality of life in hematopoietic stem cell transplantation (HSCT).

AUTHOR(S)

Hermioni L. Amonoo, Carlisle E. Topping, Madison A. Clay, Thomas W. LeBlanc, Joseph A. Greer, Stephanie Lee, Jennifer Temel, Areej El-Jawahri

ABSTRACT

7032

Outcomes with COVID-19 in hematopoietic stem cell transplant and cellular therapy patients.

AUTHOR(S)

Muhammad Umair Mushtaq, Mary Luder, Moazzam Shahzad, Nausheen Ahmed, Haitham Abdelhakim, Rajat Bansal, Ramesh Balusu, Sibgha Gull Chaudhary, Shaun DeJarnette, Clint Divine, Robert Kribs, Leyla Shune, Anurag K. Singh, Sunil H. Abhyankar, Siddhartha Ganguly, Joseph McGuirk

ABSTRACT

7033

Characterizing advance care planning, palliative care utilization, and location of end-of-life for adult allogeneic hematopoietic stem cell transplant recipients.

AUTHOR(S)

Stephanie Hoffman, Pavan Reddy, John M. Magenau, Attaphol Pawarode, Brian Parkin, Sarah M. Anand, Monalisa Ghosh, John J. Maciejewski, Darren P. King, Mary Riwes

ABSTRACT

7034

Early results of phase 1 study of JSP191, an anti-CD117 monoclonal antibody, with non-myeloablative conditioning in older adults with MRD-positive MDS/AML undergoing allogeneic hematopoietic cell transplantation.

AUTHOR(S)

Lori S. Muffy, Michelle Chin, Hye-Sook Kwon, Cara Lieber, Steven Smith, Robert Sikorski, Judith Shizuru, Wendy Pang, Andrew S. Artz

ABSTRACT

7035

Phase 1 trial of anti-CD22 recombinant immunotoxin moxetumomab pasudotox combined with rituximab for relapsed/refractory hairy cell leukemia.

AUTHOR(S)

Robert J. Kreitman, Maryalice Stetler-Stevenson, Constance Yuan, Hao-Wei Wang, Hong Zhou, Mark Raffeld, Liqiang Xi, Evgeny Arons, Julie Feurtado, Lacey James-Echenique, Raul Braylan, Katherine R. Calvo, Irina Maric, Alina Dulau, Ira Pastan

ABSTRACT

7036

The effect of body mass index on efficacy and safety of bosutinib or imatinib in patients with newly diagnosed chronic myeloid leukemia.

AUTHOR(S)

Tim H. Brümmendorf, Jorge E. Cortes, Lambert Busque, Carlo Gambacorti-Passerini, Leif Stenke, Andrea Viqueira, Eric Leip, Simon Purcell, Michael W. Deininger

ABSTRACT

7037

Novel application of Kaplan-Meier methods to model tolerance for nonadherence to imatinib in patients with chronic myeloid leukemia (CML) in the ADAGIO study.

AUTHOR(S)

Mavis Obeng-Kusi, Karen MacDonald, Marie-Anne van Lierde, Ivo Abraham

ABSTRACT

7038

Outcomes before and after dose reduction in patients with newly diagnosed chronic myeloid leukemia receiving bosutinib or imatinib.

AUTHOR(S)

Michael W. Deininger, Tim H. Brümmendorf, Dragana Milojkovic, Francisco Cervantes, Françoise Huguet, Andrea Viqueira, Eric Leip, Simon Purcell, Jorge E. Cortes

ABSTRACT

7039

Health-related quality of life (HRQoL) in patients (pts) with myelodysplastic syndromes (MDS) in the Connect Myeloid Disease Registry.

AUTHOR(S)

Dennis A. Revicki, David L. Grinblatt, Rami S. Komrokji, Guillermo Garcia-Manero, Michael R. Savona, Bart L. Scott, Mikkael A. Sekeres, E. Dawn Flick, Adeola Y. Makinde, Pavel Kiselev, Chrystal U. Louis, Melissa Nifenecker, Irene S. DeGutis, Christopher R. Cogle

ABSTRACT

7040

Comparison of dose modification strategies to address expected hematologic toxicities in treatment-naïve higher-risk (HR) MDS patients treated with venetoclax + azacitidine.

AUTHOR(S)

Jacqueline S. Garcia, Andrew Wei, Uma Borate, Chun Y. Fong, Maria R. Baer, Daniel Nowak, Pierre Peterlin, Joseph G. Jurcic, Meagan Jacoby, Uwe Platzbecker, Olatoyosi Odenike, Ilona Cunningham, Ying Zhou, David Hoffman, Kiran Naqvi, Steve Kye, Guillermo Garcia-Manero

ABSTRACT

7041

Model-based analysis to support dose selection of pevonedistat (PEV) combined with azacitidine (AZA) in patients (pts) with higher-risk myelodysplastic syndromes (MDS)/chronic myelomonocytic leukemia (CMML) and acute myeloid leukemia (AML).

AUTHOR(S)

Xiaofei Zhou, Diane R. Mould, Dan Zhao, Mikkael A. Sekeres, Lionel Adès, Ronan T. Swords, Hiroshi Handa, Robert J. Fram, Douglas V. Faller, Olga Tsukurov, Neeraj Gupta

ABSTRACT

7042

Predictors of hypomethylating agent discontinuation among patients with higher-risk myelodysplastic syndromes.

AUTHOR(S)

Amer M. Zeidan, Namita Joshi, Hrishikesh Kale, Wei-Jhih Wang, Shelby Corman, Kala Hill, Tehseen Salimi, Robert S. Epstein

ABSTRACT

7043

Using tissue microarray to detect inflammasome signaling components that contribute to the pathogenesis of myelodysplastic syndrome.

AUTHOR(S)

Tony Kurian, Kathy L. McGraw, Sanjay Bridgelall, Rohit Sharma, Jeffrey E. Lancet, Rami S. Komrokji, Seongseok Yun, Ling Zhang

ABSTRACT

7044

Outcomes of allogeneic hematopoietic cell transplantation in patients with myelofibrosis: A systematic review and meta-analysis.

AUTHOR(S)

Jan Philipp Bewersdorf, Amar Sheth, Shaurey Vetsa, Alyssa Grimshaw, Smith Giri, Nikolai A. Podoltsev, Lohith Gowda, Roni Tamari, Martin S. Tallman, Raajit Rampal, Amer M. Zeidan, Maximilian Stahl

ABSTRACT

7045

Association of transfusion independence with improved overall survival in myelofibrosis patients receiving momelotinib.

AUTHOR(S)

Ruben A. Mesa, Stephen T. Oh, Aaron T. Gerds, Vikas Gupta, John V. Catalano, Francisco Cervantes, Timothy Devos, Marek Hus, Jean-Jacques Kiladjian, Ewa Lech-Maranda, Donal P. McIornan, Jeanne Palmer, Uwe Platzbecker, Jacek Trelinski, Kazuya Shimoda, Rafe Donahue, Bryan Strouse, Mark M. Kowalski, Srdan Verstovsek

ABSTRACT

7046

Clinical characteristics, treatment patterns, and overall survival of real-world patients with idiopathic multicentric Castleman disease.

AUTHOR(S)

Aaron B. Cohen, Akshay Swaminathan, Xiaoliang Wang, Stephen Zamora, Michael A. Repucci, Jonathan Kelly, Mark D. Hannan, Daniel Sepler, Suganya Sridharma, Abigail Orlando, Barry Leybovich, David Fajgenbaum

ABSTRACT

7048

Phenotypes and prognostic factors in adults with Langerhans cell histiocytosis.

AUTHOR(S)

Gaurav Goyal, Aldo A. Acosta-Medina, Marie Hu, Jithma P. Abeykoon, Aishwarya Ravindran, N. Nora Bennani, Caroline Davidge-Pitts, Mithun V. Shah, W. O. Tobin, Jason R. Young, Jay H. Ryu, Robert Vassallo, Karen Rech, Ronald S. Go

ABSTRACT

7049

***BRAF*^{V600E} frequency and impact on outcomes in adults with langerhans cell histiocytosis.**

AUTHOR(S)

Aldo A. Acosta-Medina, Jithma P. Abeykoon, N. Nora Bennani, Caroline Davidge-Pitts, Matthew J. Koster, Aishwarya Ravindran, Karen Rech, Jay H. Ryu, Susan M. Schram, Mithun V. Shah, W. O. Tobin, Robert Vassallo, Jason R. Young, Ronald S. Go, Gaurav Goyal

ABSTRACT

7050

A phase 4 study to evaluate outpatient blinatumomab in patients with minimal/measurable residual disease (MRD) positivity (+) of B-cell precursor acute lymphoblastic leukemia (BCP-ALL).

AUTHOR(S)

Sharif S. Khan, Shahram Mori, Deepa Jeyakumar, Michael K. Keng, Hemant S. Murthy, Michal Bar-Natan, Krishna Gundabolu, Kristen M. O'Dwyer, Tulio Rodriguez, Anthony S. Stein, Wendy Stock, Caspian Oliai, Christopher McCann, Faraz Zaman, Gerhard Zugmaier, Paul Gordon, Timothy S. Pardee

ABSTRACT

TPS7051

V2 Trial: A phase I study of venetoclax and CPX-351 for young patients with relapsed/refractory acute leukemia.

AUTHOR(S)

Laura Agresta, Maureen M. O'Brien, Eric J. O'Brien, Robin E. Norris, Erin H. Breese, Karen C. Burns, Benjamin Mizukawa, Thomas D. Ryan, Pankaj B. Desai, A.a. Vinks, H. Leighton Grimes, Michael Absalon, John P. Perentesis

ABSTRACT

TPS7052

A prospective phase I/IIa trial to evaluate the safety and efficacy of GTA002, an off-the-shelf, *ex vivo*-cultured allogeneic NK cell preparation in patients with acute myeloid leukemia in complete morphological remission who have measurable residual disease.

AUTHOR(S)

Michael Heuser, Walter M. Fiedler, Tessa Kerre, Johan Maertens, Jakob Passweg, Arjan Van De Loosdrecht, Antonia M. Mueller, Jean-Henri Bourhis, Katarzyna Nowek, Jan Spanholtz, Virginie Bonnamain, Stephan Winckels, Arnold Ganser

ABSTRACT

TPS7053

Phase 3 VERONA study of venetoclax with azacitidine to assess change in complete remission and overall survival in treatment-naïve higher-risk myelodysplastic syndromes.

AUTHOR(S)

Amer M. Zeidan, Jacqueline S. Garcia, Pierre Fenaux, Uwe Platzbecker, Yasushi Miyazaki, Zhi-Jian Xiao, Ying Zhou, Kiran Naqvi, Steve Kye, Guillermo Garcia-Manero

ABSTRACT

TPS7054

Magrolimab + azacitidine versus azacitidine + placebo in untreated higher risk (HR) myelodysplastic syndrome (MDS): The phase 3, randomized, ENHANCE study.

AUTHOR(S)

Guillermo Garcia-Manero, Naval G. Daver, Jin Xu, Mark Chao, Trisha Chung, Anderson Tan, Vivian Wang, Andrew Wei, Paresh Vyas, David A. Sallman

ABSTRACT

TPS7055

IMerge: A phase 3 study to evaluate imetelstat in transfusion-dependent subjects with IPSS low or intermediate-1 risk myelodysplastic syndromes that are relapsed/refractory to erythropoiesis-stimulating agent treatment.

AUTHOR(S)

Uwe Platzbecker, Rami S. Komrokji, Pierre Fenaux, Amer M. Zeidan, Mikkael A. Sekeres, Michael R. Savona, Yazan Madanat, Laurie J. Sherman, Souria Dougherty, Libo Sun, Fei Huang, Ying Wan, Aleksandra Rizo, Tymara Berry, Faye Feller, Valeria Santi ni

ABSTRACT

TPS7056

BOREAS: A global phase 3 study of KRT-232, a first-in-class murine double minute 2 (MDM2) inhibitor in *TP53*^{WT} relapsed/refractory (R/R) myelofibrosis (MF).

AUTHOR(S)

Srdan Verstovsek, Haifa K. Al-Ali, John Mascarenhas, Adam J. Mead, Andrew Perkins, Alessandro M. Vannucchi, Anne Uyei, Wayne P. Rothbaum, Jesse McGreivy, Jean-Jacques Kiladjian

ABSTRACT

TPS7057

A phase 3, randomized, double-blind, placebo-controlled study of ruxolitinib plus pascalisib in patients with JAK- and PI3K-inhibitor treatment-naïve myelofibrosis.

AUTHOR(S)

Abdulraheem Yacoub, Susan Erickson-Viitanen, Feng Zhou, Albert Assad

ABSTRACT

TPS7058

Hematologic Malignancies—Lymphoma and Chronic Lymphocytic Leukemia

[Back to Program](#)

Showing 55 Presentations

<https://meetinglibrary.asco.org/session/13647>

Effect of time to relapse on overall survival (OS) in Mantle cell lymphoma (MCL) patients (pts) following frontline high-dose therapy and autologous hematopoietic cell transplantation (autoHCT).

AUTHOR(S)

Peter A. Riedell, Mehdi Hamadani, Kwang W. Ahn, Carlos Litovich, Mohamed Kharfan-Dabaja, Alex F. Herrera, Craig S. Sauter, Sonali M. Smith

ABSTRACT

7521

Progression-free survival at 24 months as a landmark after autologous stem cell transplant in relapsed or refractory diffuse large B-cell lymphoma.

AUTHOR(S)

Aung M. Tun, Seth Maliske, Yucai Wang, Matthew J. Maurer, Ivana N. Micallef, David J. Inwards, Luis F. Porrata, Allison C. Rosenthal, Mohamed Kharfan-Dabaja, Jacob Orme, Brian K. Link, James R. Cerhan, Carrie A. Thompson, Thomas M. Habermann, Thomas E. Witzig, Stephen M. Ansell, Grzegorz S. Nowakowski, Umar Farooq, Patrick B. Johnston

ABSTRACT

7522

Up to seven years of follow-up in the RESONATE-2 study of first-line ibrutinib treatment for patients with chronic lymphocytic leukemia.

AUTHOR(S)

Paul M. Barr, Carolyn Owen, Tadeusz Robak, Alessandra Tedeschi, Osnat Bairey, Jan A. Burger, Peter Hillmen, Steve E. Coutre, Stephen Devereux, Sebastian Grosicki, Helen McCarthy, Jianyong Li, David Simpson, Fritz C. Offner, Carol Moreno, Sandra Dai, Anita Szoke, James P. Dean, Thomas J. Kipps, Paolo Ghia

ABSTRACT

7523

Survival trends in chronic lymphocytic leukemia in the era of oral targeted therapies in the United States: SEER database analyses (1985 to 2017).

AUTHOR(S)

Neda AlRawashdh, Ali McBride, Daniel O. Persky, Joann Sweasy, Brian Erstad, Ivo Abraham

ABSTRACT

7524

Updated results of the selective Bruton tyrosine kinase (BTK) inhibitor TG-1701, as monotherapy and in combination with ublituximab and umbralisib (U2) in patients (pts) with B-cell malignancies.

AUTHOR(S)

Chan Cheah, Wojciech Jurczak, Masa Lasica, Nicholas W. Wickham, Tomasz Wrobel, Jan A. Walewski, Costas K. Yannakou, Stanley Cheung, Katharine L. Lewis, Monika Długosz-Danecka, Krzysztof Giannopoulos, Hari P. Miskin, Jian-Ping Tang, Emmanuel Normant, Owen A. O'Connor, Alejandro D. Ricart, Constantine S. Tam

ABSTRACT

7525

Identification of genetic markers associated with ibrutinib-related cardiovascular toxicity.

AUTHOR(S)

Issam Hamadeh, Ryan Jacobs, Bei Hu, Tamara K. Moyo, Amy Soni, Steven I. Park, Jai N. Patel, Nury Steuerwald, Nilanjan Ghosh

ABSTRACT

7526

Herpes zoster in chronic lymphocytic leukemia: Effect of vaccination and treatment.

AUTHOR(S)

Nirav Antao, Abhishek R. Chilkulwar, Suhong Luo, Kenneth R. Carson, Kristen M. Sanfilippo, Martin W. Schoen

ABSTRACT

7527

Brentuximab vedotin with chemotherapy in adolescents and young adults (AYAs) with stage III or IV Hodgkin lymphoma: A subgroup analysis from the phase 3 Echelon-1 study.

AUTHOR(S)

Howland E. Crosswell, Ann S. LaCasce, Nancy L. Bartlett, David J. Straus, Kerry J. Savage, Pier L. Zinzani, Graham P. Collins, Michelle A. Fanale, Keenan Fenton, Cassie Dong, Harry H. Miao, Andrew Grigg

ABSTRACT

7528

A phase II study of penpulimab, an anti-PD-1 antibody, in patients with relapsed or refractory classic Hodgkin lymphoma (cHL).

AUTHOR(S)

Yueqin Song, Keshu Zhou, Chuan Jin, Zhengzi Qian, Ming Hou, Lei Fan, Fei Li, Kaiyang Ding, Hui Zhou, Xiaoling Li, Bing Chen, Xiuhua Sun, Xianmin Song, Ming Jiang, Qingyuan Zhang, Xiaoping Jin, Zhongmin M. Wang, Baiyong Li, Yu Xia, Jun Zhu

ABSTRACT

7529

Salvage therapies in transplant-eligible relapsed classic Hodgkin lymphoma, are novel regimens better?

AUTHOR(S)

Sanjal Desai, Yucai Wang, Allison C. Rosenthal, Craig B. Reeder, David J. Inwards, Ernesto Ayala, Grzegorz S. Nowakowski, Han W. Tun, Jonas Paludo, Jose C. Villasboas, Luis F. Porrata, Muhamad Alhaj Moustafa, Mohamed Kharfan-Dabaja, Patrick B. Johnston, Stephen M. Ansell, Thomas M. Habermann, Ivana N. Micallef

ABSTRACT

7530

A phase Ib study of a PI3K δ inhibitor Linperlisib in patients with relapsed or refractory peripheral T-cell lymphoma.

AUTHOR(S)

Jie Jin, Hong Cen, Keshu Zhou, Xiaohong Xu, Fei Li, Tao Wu, Haiyan Yang, Zheng Wang, Zhiming Li, Lugui Qiu, Hanying Bao, Zusheng Xu, Yang Shu

ABSTRACT

7531

CD19 CAR T-cell product type independently impacts CRS and ICANS severity in patients with aggressive NHL.

AUTHOR(S)

Jordan Gauthier, Aisling Cearley, Paula Perkins, Angela Kirk, Mazyar Shadman, Staci Williamson, Jessie Myers, Andy I. Chen, Sarah Nagle, Brandon M. Hayes-Lattin, Levanto G. Schachter, David G. Maloney, Cameron J. Turtle, Mohamed L. Sorrow, Richard T. Maziarz

ABSTRACT

7532

Update of a phase II, multicenter study of high-dose chemotherapy with autologous stem cell transplant followed by maintenance romidepsin for T-cell lymphoma.

AUTHOR(S)

Niloufer Khan, Farhad Khimani, Andrei R. Shustov, Mazyar Shadman, Jia Ruan, Alison J. Moskowitz, David J. Straus, Anita Kumar, Craig S. Sauter, Andrew D. Zelenetz, Ariela Noy, Gunjan L. Shah, Matthew J. Matasar, Pamela Drullinsky, Audrey M. Hamilton, Esther N. Drill, Koen Van Besien, Sergio Giralt, Steven M. Horwitz, Parastoo Dahi

ABSTRACT

7533

Polatuzumab vedotin + obinutuzumab + venetoclax in patients with relapsed/refractory (R/R) follicular lymphoma (FL): Primary analysis of a phase 1b/2 trial.

AUTHOR(S)

Rajat Bannerji, Sam Yuen, Tycel Phillips, Christopher Arthur, Iris Isufi, Paula Marlton, John F. Seymour, Paolo Corradini, Annalia Molinari, Giuseppe Gritti, Robert Emmons, Jamie Hirata, Lisa Musick, Sourish Saha, Brandon Croft, Christopher Flowers

ABSTRACT

7534

Comparative efficacy of tisagenlecleucel (tisa-cel) and lisocabtagene maraleucel (liso-cel) in patients with relapsed/refractory diffuse large B-cell lymphoma (r/r DLBCL).

AUTHOR(S)

Stephen J. Schuster, Jie Zhang, Hongbo Yang, Abhijit Agarwal, Wenxi Tang, Marcela Martinez-Prieto, Vamsi Bollu, Qiufei Ma, David Kuzan, Richard T. Maziarz, Marie J. Kersten

ABSTRACT

7535

Favorable tumor immune microenvironment (TME) and robust chimeric antigen receptor (CAR) T-cell expansion may overcome tumor burden (TB) and promote durable efficacy with axicabtagene ciloleucel (axi-cel) in large B-cell lymphoma (LBCL).

AUTHOR(S)

Justin Chou, Vicki Plaks, Soumya Poddar, Zixing Wang, Frederick L. Locke, Sattva S. Neelapu, David B. Miklos, Caron A. Jacobson, Philippe Armand, Zahid Bashir, Jérôme Galon, John M. Rossi, Adrian Bot

ABSTRACT

7536

Combination of sintilimab, anlotinib and pegaspargase "sandwich" with radiotherapy in localized natural killer/T cell lymphoma: A multicenter, phase 2 study.

AUTHOR(S)

Zhiming Li, Peng Sun, Yu Wang, Hang Yang, Yajun Li, Hui Zhou, Haiyan Yang, Liqun Zou

ABSTRACT

7537

Safety and efficacy of VIP152, a CDK9 inhibitor, in patients with double-hit lymphoma (DHL).

AUTHOR(S)

Victor Moreno, Raul Cordoba, Daniel Morillo, Jennifer R. Diamond, Ahmed M. Hamdy, Raquel Izumi, Claudia Merz, Oliver Boix, Isabelle Genvresse, Grzegorz S. Nowakowski

ABSTRACT

7538

Lenalidomide plus rituximab in patients with rituximab-resistant indolent B-cell and mantle cell lymphomas: 10-year follow-up.

AUTHOR(S)

Aditi Gupta, Stephen J. Schuster, Jakub Svoboda, Sunita Nasta, Ellen Napier, Kristy Walsh, Elise A. Chong

ABSTRACT

7539

First-MIND: A phase Ib, open-label, randomized study to assess safety of tafasitamab (tafa) or tafa + lenalidomide (LEN) in addition to R-CHOP in patients with newly diagnosed DLBCL.

AUTHOR(S)

David Belada, Katerina Kopeckova, Juan M. Bergua, Marc André, Ernesto Perez Persona, Petra Pichler, Pia Klöpfer, Bettina Brackertz, Emanuel Lohrmann, Anirban Lahiry, Neha Shah, Wolfram Brugger, John M. Burke, Grzegorz S. Nowakowski

ABSTRACT

7540

Preliminary results of a phase I trial of FT516, an off-the-shelf natural killer (NK) cell therapy derived from a clonal master induced pluripotent stem cell (iPSC) line expressing high-affinity, non-cleavable CD16 (hnCD16), in patients (pts) with relapsed/refractory (R/R) B-cell lymphoma (BCL).

AUTHOR(S)

Paolo Strati, Veronika Bachanova, Aaron Goodman, John M. Pagel, Januario E. Castro, Kelly Griffis, Marlisa Anderson, Siminder K. Atwal, Cara Bickers, Daniel Fremgen, Christina Ly, Sarah A. Cooley, Rebecca L. Elstrom, Krish Patel

ABSTRACT

7541

Survival trends of older adult patients with diffuse large B-cell lymphoma: A National Cancer Database analysis.

AUTHOR(S)

Xavier Andrade-Gonzalez, Antoine N. Saliba, Harry E. Fuentes, Zhuoer Xie, Thomas M. Habermann, Jose C. Villasboas, Jonas Paludo, Gita Thanarajasingam, Carrie A. Thompson, Yi Lin, N. Nora Bennani, Patrick B. Johnston, Ivana N. Micallef, Luis F. Porrata, David J. Inwards, Thomas E. Witzig, Stephen M. Ansell, Grzegorz S. Nowakowski, Yucai Wang

ABSTRACT

7542

CNS relapse in DLBCL patients below 60 years treated with R-ACVBP, R-CHOEP, or R-CHOP: A joint analysis of LYSA and GLA/DSHNHL.

AUTHOR(S)

Catherine Thieblemont, Bettina Altmann, Olivier Casasnovas, Fabian Frontzek, Franck Morschhauser, Lucie Oberic, Viola Poeschel, Olivier Fitoussi, Loïc Renaud, Georg Lenz, Nicolas Mounier, Andreas Rosenwald, German Ott, Thierry Molina, Marie Parrens, Loic Chartier, Marita Ziepert, Herve Tilly, Norbert Schmitz

ABSTRACT

7543

Atezolizumab + obinutuzumab + venetoclax in patients with relapsed or refractory indolent non-Hodgkin's lymphoma (R/R iNHL): Primary analysis of a phase 2 trial from LYSA.

AUTHOR(S)

Charles Herbaux, Herve Ghesquieres, Reda Bouabdallah, Stephanie Guidez, Emmanuel Gyan, Remi Gressin, Nadine Morineau, Loic Ysebaert, Steven Le Gouill, Camille Laurent, Herve Tilly, Roch Houot, Gandhi Damaj, David Sibon, Pierre Feugier, Catherine Thieblemont, Corinne Haïoun, Karine Tarte, Franck Morschhauser, Guillaume Cartron

ABSTRACT

7544

Obinutuzumab short-duration infusion (SDI) in previously untreated advanced follicular lymphoma: Results from the end of induction analysis of the phase IV GAZELLE study.

AUTHOR(S)

Miguel Angel A. Canales Albendea, Thomas A. Buchholz, Koji Izutsu, Takayuki Ishikawa, Laura M. Fogliatto, Ekaterina Vorozheikina, Dirk Klingbiel, Sunny Pokala, Monique Tomiczek, Joana Parreira, Kai Hübel

ABSTRACT

7545

Duration of response to loncastuximab tesirine in relapsed/refractory diffuse large B-cell lymphoma by demographic and clinical characteristics: Subgroup analyses from LOTIS 2.

AUTHOR(S)

Paolo Caimi, Weiyun Z. Ai, Juan P. Alderuccio, Kirit Ardeshta, Mehdi Hamadani, Brian T. Hess, Brad S. Kahl, John A. Radford, Melhem M. Solh, Anastasios Stathis, Pier L. Zinzani, Jay M. Feingold, David Ungar, Yajuan Qin, Shui He, Carmelo Carlo-Stella

ABSTRACT

7546

Outcomes with KTE-X19 in patients (pts) with relapsed/refractory (R/R) mantle cell lymphoma (MCL) in ZUMA-2 who had progression of disease within 24 months of diagnosis (POD24).

AUTHOR(S)

Michael Wang, Javier Munoz, Andre Goy, Frederick L. Locke, Caron A. Jacobson, Brian T. Hill, John Timmerman, Houston Holmes, Samantha Jaglowski, Ian Flinn, Peter A. McSweeney, David B. Miklos, Marie J. Kersten, Krime Bouabdallah, Max S. Topp, Rhine Shen, Ioana Kloos, Weimin Peng, Xiang Fang, Patrick M. Reagan

ABSTRACT

7547

Updated outcomes with axicabtagene ciloleucel (axi-cel) retreatment (reTx) in patients (pts) with relapsed/refractory (R/R) indolent non-Hodgkin lymphoma (iNHL) in ZUMA-5.

AUTHOR(S)

Julio C. Chavez, Caron A. Jacobson, Alison Sehgal, Sattva S. Neelapu, David G. Maloney, Gilles A. Salles, Basem M. William, Yin Yang, Lovely Goyal, Justin Chou, Vicki Plaks, Mauro P. Avanzi

ABSTRACT

7548

NVG-111, a novel ROR1xCD3 bispecific antibody for non-Hodgkin lymphoma.

AUTHOR(S)

David Granger, Satyen Gohil, Alessandro Barbarulo, Annalisa Baccaro, Vincent Muczynski, Kerry Chester, Fiona Germaschewski, Toby Batten, Kathryn Brown, Sarah Cook, Kieran O'Donovan, Parag Jasani, Amit C. Nathwani, Peter Phillips

ABSTRACT

7549

Efficacy and safety of the PI3K δ inhibitor zandelisib (ME-401) on an intermittent schedule (IS) in patients with relapsed/refractory follicular lymphoma (FL) with progression of disease within 24 months of first-line chemoimmunotherapy (POD24).

AUTHOR(S)

John M. Pagel, Nishitha Reddy, Deepa Jagadeesh, Anastasios Stathis, Adam S. Asch, Huda S. Salman, Vaishalee P. Kenkre, Jacob D. Soumerai, Judith Llorin-Sangalang, Igor Gorbachevsky, Joanne Li, Andrew D. Zelenetz

ABSTRACT

7550

Long-term follow-up results of a phase II study of dose-adjusted (DA)-EPOCH-R with high-dose methotrexate (HD-MTX) for newly diagnosed stage II-IV CD5-positive diffuse large B-cell lymphoma (CD5+ DLBCL).

AUTHOR(S)

Kana Miyazaki, Rika Sakai, Noriko Iwaki, Go Yamamoto, Tomomi Yamada, Yuki Nishimura, Satoshi Tamaru, Naoko Asano, Kohta Miyawaki, Koji Izutsu, Tomohiro Kinoshita, Ritsuro Suzuki, Koichi Ohshima, Koji Kato, Naoyuki Katayama, Motoko Yamaguchi

ABSTRACT

7551

Real-world evidence of axicabtagene ciloleucel (Axi-cel) for the treatment of large B-cell lymphoma (LBCL) in the United States (US).

AUTHOR(S)

Caron A. Jacobson, Frederick L. Locke, Zhen-Huan Hu, Tanya Siddiqi, Sairah Ahmed, Armin Ghobadi, David B. Miklos, Yi Lin, Miguel-Angel Perales, Matthew A. Lunning, Megan Herr, Brian T. Hill, Siddhartha Ganguly, Hua Dong, Sarah Nikiforow, Jing Xie, Hairong Xu, Michele Hooper, Jun Kawashima, Marcelo C. Pasquini

ABSTRACT

7552

Initial results of the combination of PI3K δ inhibitor zandelisib (ME-401) and the BTK inhibitor zanubrutinib in patients (pts) with relapsed or refractory (R/R) B-cell malignancies.

AUTHOR(S)

Jacob D. Soumerai, Deepa Jagadeesh, Huda S. Salman, Izidore S. Lossos, Adam S. Asch, Nishitha Reddy, Vaishalee P. Kenkre, John M. Pagel, Daniel O. Persky, Farrukh T. Awan, Catherine S. Magid Diefenbach, Wenying Huang, Judith Llorin-Sangalang, Igor Gorbachevsky, Andrew D. Zelenetz

ABSTRACT

7553

Outpatient practice pattern and remote patient monitoring for axicabtagene ciloleucel CAR-T therapy in patients with aggressive lymphoma.

AUTHOR(S)

Radhika Bansal, Jonas Paludo, Adam Holland, Spsychalla Megan, McClanahan Alli, Matthew Hathcock, Hassan Alkhateeb, David Dingli, Yucai Wang, Saad Kenderian, Shaji Kumar, Mithun V. Shah, Siddiqui Mustaqeem, Rahma M. Warsame, Jose C. Villasboas, Nabila N. Bennani, Patrick B. Johnston, Stephen M. Ansell, Tufia C. Haddad, Yi Lin

ABSTRACT

7554

Vaccine titers in lymphoma patients receiving chimeric antigen receptor T-cell therapy.

AUTHOR(S)

Radhika Bansal, Paschalis Vergidis, Pritish Tosh, John W. Wilson, Matthew Hathcock, N. Nora Bennani, Jonas Paludo, Jose C. Villasboas, Yucai Wang, Stephen M. Ansell, Patrick B. Johnston, Catherine M. Freeman, Yi Lin

ABSTRACT

7555

Phase 1/2 study of cirmtuzumab and ibrutinib in mantle cell lymphoma (MCL) or chronic lymphocytic leukemia (CLL).

AUTHOR(S)

Hun J. Lee, Michael Y. Choi, Tanya Siddiqi, Jacqueline C. Barrientos, William G. Wierda, Iris Isufi, Joseph M. Tuscano, Nicole Lamanna, Suki Subbiah, Jean L. Koff, Lori A. Leslie, Alec Goldenberg, Gina G. Chung, James B. Breitmeyer, Frank J. Hsu, Michael Wang, Catriona Jamieson, Thomas J. Kipps

ABSTRACT

7556

Survival outcomes, treatment toxicity, and healthcare utilization in older adults with aggressive non-Hodgkin lymphoma (NHL).

AUTHOR(S)

Mitchell W. Lavoie, Alisha Yi, Ryan D. Nipp, Nora K. Horick, Hermioni L. Amonoo, Richard Newcomb, Julia Rice, Matthew J. Reynolds, Areej El-Jawahri, Patrick C. Johnson

ABSTRACT

7557

Prognostic role of lymphocyte to monocyte ratio in patients treated with CAR-T for aggressive lymphoma.

AUTHOR(S)

Henan Zhang, Radhika Bansal, Kodi Peterson Martinez, Matthew Hathcock, Zuoyi Shao, Gabriele McCoy, Antilde Gonzalez-Guerrico, N. Nora Bennani, Jonas Paludo, Yucai Wang, Patrick Johnston, Stephen M. Ansell, Saad Kenderian, Luis F. Porrata, Jose C. Villasboas, Yi Lin

ABSTRACT

7558

Efficacy and safety of zanubrutinib versus rituximab-based chemoimmunotherapy in Waldenström macroglobulinemia (WM): Matching-adjusted indirect comparisons.

AUTHOR(S)

Jorge J. Castillo, Keri Yang, Rongzhe Liu, Yu Wang, Aileen Cohen, Todd M. Zimmerman, Qian Zhao, Xin Gao, Boxiong Tang

ABSTRACT

7559

Immune priming with nivolumab followed by nivolumab and rituximab in first-line treatment of follicular lymphoma: The phase 2 1st FLOR study.

AUTHOR(S)

Eliza A. Hawkes, Sze Ting Lee, Geoff Chong, Michael Gilbertson, Andrew Grigg, Leonid Churilov, Tineke Fancourt, Colm Keane, David Ritchie, Rachel Koldej, Rishu Agarwal, Kate Manos, Charmaine Smith, Kristen Houdyk, Joanne Hawking, Allison Barraclough

ABSTRACT

7560

Treatment free remission (TFR) and overall response rate (ORR) results in patients with relapsed/refractory Waldenstrom's macroglobulinemia (WM) treated with CLR 131.

AUTHOR(S)

Sikander Ailawadhi, Asher Alban A. Chanan-Khan, Jennifer L. Peterson, Jarrod Longcor, Katherine Oliver, Matthew F. Brown, John Friend, Damian J. Green

ABSTRACT

7561

A novel index using inflammatory markers improves the diagnosis of hemophagocytic lymphohistiocytosis in patients with hematologic malignancies.

AUTHOR(S)

Adi Zoref Lorenz, Jun Murakami, Liron Hofstetter, Swaminathan P. Iyer, Ahmed Alotaibi, Shehab Mohamed, Peter G. Miller, Elad Guber, Shiri Weinstein, Joanne Jacobovich, Sarah Nikiforow, Benjamin L. Ebert, Oren Pasvolsky, Pia Raanani, Arnon Nagler, Nancy Berliner, Naval G. Daver, Martin Ellis, Michael Jordan

ABSTRACT

7563

Post-transplant lymphoproliferative disorder in kidney transplant patients: A multicenter report.

AUTHOR(S)

Elise A. Chong, Daniel E. Tsai, Mitchell E. Hughes, Mary Ann C. Lim, Behdad D. Besharatian, Yvonne El Kassiss, Roy Bloom, Deepa Jagadeesh

ABSTRACT

7564

Phased variants improve DLBCL minimal residual disease detection at the end of therapy.

AUTHOR(S)

David M. Kurtz, Jacob J. Chabon, Joanne Soo, Lyron Co Ting Keh, Stefan Alig, Andre Schultz, Michael C. Jin, Florian Scherer, Alexander F. Craig, Chih Long Liu, Ulrich Duehrsen, Andreas Huettmann, René-Olivier Casasnovas, Jason Westin, Mark J. Roschewski, Wyndham H. Wilson, Gianluca Gaidano, Davide Rossi, Maximilian Diehn, Ash A. Alizadeh

ABSTRACT

7565

IL-1 receptor antagonist for prevention of severe immune effector cell-associated neurotoxicity syndrome.

AUTHOR(S)

Caspian Oliai, Anna Crosetti, Sven De Vos, Herbert Eradat, Monica D. Mead, Sarah M. Larson, Steven Tsai, Annabel Liu, Gina Khachatryan, Christopher Hannigan, Reiko E. Yamada, Neiki Rokni, John Timmerman

ABSTRACT

7566

Randomized, phase III study of early intervention with venetoclax and obinutuzumab versus delayed therapy with venetoclax and obinutuzumab in newly diagnosed asymptomatic high-risk patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL): EVOLVE CLL/SLL study (SWOG S1925, NCT#04269902).

AUTHOR(S)

Deborah M. Stephens, Anna Moseley, Brian T. Hill, John M. Pagel, Mazyar Shadman, Michael J. Fisch, Alexey V. Danilov, David Ng, Anthony R. Mato, Danielle M. Brander, Megan Othus, Steve E. Coutre, Susan M. O'Brien, Harry P. Erba

ABSTRACT

TPS7567

A phase 3 study to evaluate the efficacy and safety of tafasitamab plus lenalidomide and rituximab versus placebo plus lenalidomide and rituximab in patients with relapsed/refractory (R/R) follicular lymphoma (FL) or marginal zone lymphoma (MZL).

AUTHOR(S)

Laurie H. Sehn, Christian W. Scholz, Stefano Luminari, Antonio Salar, Bjorn E. Wahlin, Ajay K. Gopal, Christophe M. Bonnet, Shankara Paneesha, Oliver Manzke, Francis Seguy, Di Li, Kai Hübel

ABSTRACT

TPS7568

Phase 3 trial (GCT3013-05) of epcoritamab versus standard of care in patients with relapsed or refractory diffuse large B-cell lymphoma (DLBCL).

AUTHOR(S)

Catherine Thieblemont, Michael Roost Clausen, Anna Sureda Balari, Pier L. Zinzani, Christopher Fox, Su Young Kim, Signe Diness Vindeloev, Pieterella Lugtenburg

ABSTRACT

TPS7569

A phase 1 dose escalation and cohort expansion study of the safety and efficacy of allogeneic CRISPR-Cas9-engineered T cells (CTX110) in patients (Pts) with relapsed or refractory (R/R) B-cell malignancies (CARBON).

AUTHOR(S)

Joseph McGuirk, Carlos R. Bachier, Michael R. Bishop, P. Joy Ho, Hemant S. Murthy, Michael J. Dickinson, Joseph E. Maakaron, Charalambos Andreadis, Armin Ghobadi, Edmund K. Waller, Mark D. Benton, Susanna Suh, Huansheng Xu, Ewelina Morawa, Farrukh T. Awan, Paul Shaughnessy, Constantine S. Tam, Nicolaus Kroeger, Richard T. Maziarz

ABSTRACT

TPS7570

Brentuximab vedotin in combination with lenalidomide and rituximab in subjects with relapsed or refractory diffuse large B-cell lymphoma (DLBCL) (Trials in Progress).

AUTHOR(S)

Nancy L. Bartlett, Christopher A. Yasenchak, Khaleel K. Ashraf, William N. Harwin, Robert B. Sims, Grzegorz S. Nowakowski

ABSTRACT

TPS7571

ESCALADE: A phase 3 study of acalabrutinib in combination with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) for patients ≤65y with untreated non-germinal center B-cell-like (non-GCB) diffuse large B-cell lymphoma (DLBCL).

AUTHOR(S)

Laurie H. Sehn, Brad S. Kahl, Matthew J. Matasar, Georg Lenz, Koji Izutsu, Weili Zhao, Lin Tao, Roser Calvo, Pier L. Zinzani

ABSTRACT

TPS7572

Coastal: A phase 3 study of the PI3Kδ inhibitor zandelisib with rituximab (R) versus immunochemotherapy in patients with relapsed indolent non-Hodgkin's lymphoma (iNHL).

AUTHOR(S)

Wojciech Jurczak, Pier L. Zinzani, David Cunningham, Sharon Yavrom, Wenying Huang, Igor Gorbachevsky, Vincent Ribrag

ABSTRACT

TPS7573

Phase 3 randomized study of loncastuximab tesirine plus rituximab versus immunochemotherapy in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL): LOTIS-5.

AUTHOR(S)

Mehdi Hamadani, Yuliya Linhares, Mitul Gandhi, Michael Chung, Helena Adamis, David Ungar, Carmelo Carlo-Stella

ABSTRACT

TPS7574

A phase III trial evaluating glofitamab in combination with gemcitabine plus oxaliplatin versus rituximab in combination with gemcitabine and oxaliplatin in patients with relapsed/refractory (R/R) diffuse large B-cell lymphoma (DLBCL).

AUTHOR(S)

Mark Hertzberg, Matthew Ku, Olivier Catalani, Betsy Althaus, Stephen Simko, Gareth P. Gregory

ABSTRACT

TPS7575

Randomized, double-blind, placebo-controlled phase 3 study of ibrutinib plus rituximab in patients with previously untreated marginal zone lymphoma (MZL).

AUTHOR(S)

Ariela Noy, Stephanie Hughes, Erin Biggar, Matthew Bogdan

ABSTRACT

TPS7576

Hematologic Malignancies—Plasma Cell Dyscrasia

[Back to Program](#)

Showing 35 Presentations

<https://meetinglibrary.asco.org/session/13651>

High-dose lenalidomide and melphalan as conditioning for autologous stem cell transplantation in relapsed or refractory multiple myeloma.

AUTHOR(S)

Adriana C. Rossi, Jorge Monge, Ruben Niesvizky, Jing Mei Hsu, Tsiporah Shore, Koen Van Besien, Roger Pearce, Tomer Mark, David Jayabalan, Sebastian A. Mayer

ABSTRACT

8021

Improved outcomes with maintenance therapy after salvage autologous hematopoietic cell transplantation (AHCT) in multiple myeloma: A CIBMTR study.

AUTHOR(S)

Oren Pasvolsky, Raphael Fraser, Noel Estrada-Merly, Moshe Yeshurun, Uri Rozovski, Liat Shargian-Alon, Shaji Kumar, Nina Shah, Muzaffar H. Qazilbash, Anita D'Souza

ABSTRACT

8022

Phase 2 study of MGTA-145 + plerixafor for rapid and reliable hematopoietic stem cell (HSC) mobilization for autologous transplant in multiple myeloma.

AUTHOR(S)

Surbhi Sidana, Andriyana Bankova, Hitomi Hosoya, Lori S. Muffly, Shaji Kumar, Laura J. Johnston, Robert Lowsky, Everett Meyer, Andrew Rezvani, Wen-Kai Weng, Sally Arai, Matthew J. Frank, Parveen Shiraz, Haley Howell, Kevin A. Goncalves, Veit Schmelmer, John Davis, Judith Shizuru, David B. Miklos

ABSTRACT

8023

Effects of refractory status to lenalidomide on safety and efficacy of selinexor, bortezomib, and dexamethasone (XVd) versus bortezomib and dexamethasone (Vd) in patients with previously treated multiple myeloma.

AUTHOR(S)

Xavier Leleu, Maria-Victoria Mateos, Sundar Jagannath, Sosana Delimpasi, Maryana Simonova, Ivan Spicka, Luděk Pour, Iryna Kriachok, Maria Gavriatopoulou, Meletios A. Dimopoulos, Halyna Pylypenko, Holger W. Auner, Benjamin Reuben, Vadim Doronin, Christopher P. Venner, Mamta Garg, Andrew DeCastro, Jatin J. Shah, Sebastian Grosicki, Paul G. Richardson

ABSTRACT

8024

The clinical study of anti-BCMA CAR-T with single-domain antibody as antigen binding domain.

AUTHOR(S)

Lu Han, Quanli Gao, Keshu Zhou, Jian Zhou, Qing-Song Yin, Baijun Fang, Xing-Hu Zhu, Jishuai Zhang, Chaolemeng Bao, Yongping Song

ABSTRACT

8025

Isatuximab plus carfilzomib and dexamethasone versus carfilzomib and dexamethasone in elderly patients with relapsed multiple myeloma: IKEMA subgroup analysis.

AUTHOR(S)

Thierry Facon, Philippe Moreau, Thomas G. Martin, Ivan Spicka, Albert Oriol, Youngil Koh, Andrew Lim, Gabor Mikala, Laura Rosiñol, Münci Yağci, Michele Cavo, Kwee Yong, Marie-Laure Risse, Gaëlle Asset, Sandrine Schwab, Gracia Martinez

ABSTRACT

8026

Effects of weekly selinexor, bortezomib, dexamethasone (XVd) versus standard twice weekly bortezomib and dexamethasone (Vd) on *RAS*-mutated previously treated multiple myeloma (MM).

AUTHOR(S)

Christopher J. Walker, Shirong Li, Yi Chai, Jatin J. Shah, Sharon Shacham, Suzanne Lentzsch, Yosef Landesman

ABSTRACT

8027

Incidence, mitigation, and management of neurologic adverse events in patients with multiple myeloma (MM) treated with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-2.

AUTHOR(S)

Hermann Einsele, Samir S. Parekh, Deepu Madduri, Bianca Santomaso, Jaime Gállego Pérez De Larraya, Niels W. van de Donk, Bertrand Arnulf, Maria-Victoria Mateos, Kevin C. De Braganca, Helen Varsos, Marlene Carrasco-Alfonso, Muhammad Akram, Nikoletta Lendvai, Carolyn C. Jackson, Yunsu Olyslager, Enrique Zudaire, Claire Li, Dong Geng, Andrzej J. Jakubowiak, Adam D. Cohen

ABSTRACT

8028

Personalized, ctDNA analysis to detect minimal residual disease and identify patients at high risk of relapse with multiple myeloma.

AUTHOR(S)

Binod Dhakal, Shruti Sharma, Svetlana Shchegrova, Minu Maninder, Meenakshi Malhotra, Himanshu Sethi, Bernhard Zimmermann, Paul R. Billings, Alexey Aleshin, Parameswaran Hari

ABSTRACT

8029

Cilta-cel versus conventional treatment in patients with relapse/refractory multiple myeloma.

AUTHOR(S)

Luciano J. Costa, Yi Lin, Thomas G. Martin, Saurabh Chhabra, Saad Z. Usmani, Sundar Jagannath, Natalie S. Callander, Jesus G. Berdeja, Yubin Kang, Ravi Vij, Hong Tian, Satish Valluri, Jennifer Marino, Carolyn C. Jackson, Arnob Banerjee, Ankit Kansagra, Jordan M. Schecter, Shaji Kumar, Parameswaran Hari

ABSTRACT

8030

Assessing financial difficulty in patients with multiple myeloma: Preliminary results of ALLIANCE A231602CD.

AUTHOR(S)

Rena M. Conti, Shaylene McCue, Travis Dockter, Bruce D. Rapkin, Stacie Dusetzina, Antonia V. Bennett, Gabriela Gracia, Michelle E. Johnson, Sarah A. Martin, George J. Chang, Paul G. Richardson, Robert J. Behrens, Elisa S. Weiss

ABSTRACT

8031

5-Hydroxymethylcytosines in circulating cell-free DNA and overall survival in patients with multiple myeloma.

AUTHOR(S)

Brian C. Chiu, Zhou Zhang, Benjamin A. Derman, Jason Karpus, Spencer Langerman, Chang Zeng, Parveen Bhatti, Andrzej J. Jakubowiak, Chuan He, Wei Zhang

ABSTRACT

8032

Relationship between corneal exam findings, best-corrected visual acuity (BCVA), and ocular symptoms in patients with relapsed or refractory multiple myeloma (RRMM) receiving belantamab mafodotin (belamaf).

AUTHOR(S)

Evangelos Terpos, Ashraf Badros, Rakesh Popat, Paula Rodríguez-Otero, Asim Farooq, Bennie Jeng, Simona Degli Esposti, Eric Lewis, Ira Gupta, Joanna Opalinska, Antonio Palumbo, Suzanne Trudel

ABSTRACT

8033

Isatuximab plus carfilzomib and dexamethasone in patients with relapsed multiple myeloma according to prior lines of treatment and refractory status: IKEMA subgroup analysis.

AUTHOR(S)

Roman Hajek, Philippe Moreau, Bradley Augustson, Nelson Castro, Tomas Pika, Sosana Delimpasi, Javier de La Rubia, Angelo Maiolino, Tony J. Reiman, Irina Kryuchkova, Joaquin Martinez-Lopez, Thomas G. Martin, Joseph Mikhael, Kwee Yong, Marie-Laure Risse, Gaëlle Asset, Sylvia Marion, Meletios A. Dimopoulos

ABSTRACT

8034

Daratumumab (DARA) maintenance therapy following DARA + cyclophosphamide, bortezomib, and dexamethasone (CyBorD) induction therapy in multiple myeloma (MM): End-of-study analysis of LYRA.

AUTHOR(S)

Robert M. Rifkin, Jason M. Melear, Edward Faber, William I. Bensinger, John M. Burke, Mohit Narang, Don A. Stevens, Kathleen Gray, Yana Lutska, Padma Bobba, Keqin Qi, Ming Qi, Thomas S. Lin, Habte A. Yimer

ABSTRACT

8035

Characteristics of neurotoxicity associated with idecabtagene vicleucel (ide-cel, bb2121) in patients with relapsed and refractory multiple myeloma (RRMM) in the pivotal phase II KarMMa study.

AUTHOR(S)

Salomon Manier, Ankit J. Kansagra, Larry D. Anderson, Jr, Jesus G. Berdeja, Sundar Jagannath, Yi Lin, Sagar Lonial, Nina Shah, Noopur S. Raje, David S. Siegel, Albert Oriol, Anna Truppel-Hartmann, Everton Rowe, Payal Patel, Amit Agarwal, Timothy B. Campbell, Paula Rodríguez-Otero, Nikhil C. Munshi

ABSTRACT

8036

ANCHOR (OP-104): Melflufen plus dexamethasone (dex) and bortezomib (BTZ) in relapsed/refractory multiple myeloma (RRMM)—Optimal dose, updated efficacy and safety results.

AUTHOR(S)

Roman Hajek, Luděk Pour, Miquel Granell, Vladimir Maisnar, Paul G. Richardson, Stefan Norin, Malin Sydvander, Jakob Obermüller, Enrique M. Ocio

ABSTRACT

8037

Once weekly selinexor, carfilzomib, and dexamethasone (XKd) in carfilzomib nonrefractory multiple myeloma (MM) patients.

AUTHOR(S)

Cristina Gasparetto, Gary J. Schiller, Sascha Tuchman, Natalie S. Callander, Muhamed Baljevic, Suzanne Lentzsch, Adriana C. Rossi, Rami Kotb, Darrell White, Nizar J. Bahlis, Christine Chen, Heather J. Sutherland, Sumit Madan, Richard LeBlanc, Michael Sebag, Christopher P. Venner, Noa Biran, Dane Van Domelen, Brea Lipe

ABSTRACT

8038

Phase Ib trial of vactosertib in combination with pomalidomide in relapsed multiple myeloma: A corticosteroid-free approach by targeting TGF- β signaling pathway.

AUTHOR(S)

Ehsan Malek, Sunjin Hwang, Paolo F. Caimi, Leland L. Metheny, Benjamin K. Tomlinson, Brenda W. Cooper, Kirsten M. Boughan, Folashade Otegbeye, Molly Gallogly, James J. Driscoll, Marcos J. De Lima

ABSTRACT

8039

Using mobile wearables to establish sleep bioprofiles in newly diagnosed multiple myeloma (MM) patients.

AUTHOR(S)

Gil Hevroni, Donna Mastey, Elizabet Tavitian, Andriy Derkach, Meghan Salcedo, Sham Mailankody, Hani Hassoun, Alexander M. Lesokhin, Eric L. Smith, Malin Hultcrantz, Urvi A. Shah, Carlyn Rose C. Tan, Sydney X. Lu, Gunjan L. Shah, Sergio Giralt, Sean M. Devlin, Thomas M. Atkinson, Joseph M. Lengfellner, Carl O. Landgren, Neha Korde

ABSTRACT

8040

LocoMMotion: A prospective, non-interventional, multinational study of real-life current standards of care in patients with relapsed/refractory multiple myeloma (RRMM) receiving ≥ 3 prior lines of therapy.

AUTHOR(S)

Maria-Victoria Mateos, Katja Weisel, Valerio De Stefano, Aurore Perrot, Niels W. van de Donk, Hartmut Goldschmidt, Martin F. Kaiser, Ravi Vij, Francesca Gay, Annemiek Broijl, Anna Potamianou, Caline Sakabedoyan, Vadim Strulev, Jordan M. Schechter, Martin Vogel, Tonia Nesheiwat, Robert Wapenaar, Michel Delforge, Hermann Einsele, Philippe Moreau

ABSTRACT

8041

Isatuximab plus carfilzomib and dexamethasone in relapsed multiple myeloma patients with high-risk cytogenetics: IKEMA subgroup analysis.

AUTHOR(S)

Ivan Spicka, Philippe Moreau, Thomas G. Martin, Thierry Facon, Gracia Martinez, Albert Oriol, Youngil Koh, Andrew Lim, Gabor Mikala, Laura Rosiñol, Münci Yağci, Michele Cavo, Marie-Laure Risse, Gaëlle Asset, Sandrine Macé, Helgi Van De Velde, Kwee Yong

ABSTRACT

8042

Ixazomib (IXA), carfilzomib (CAR), elotuzumab (ELO) or daratumumab (DAR) with lenalidomide and dexamethasone (LEN+DEX) versus LEN+DEX only in relapsed/refractory multiple myeloma (R/R MM): A comparative cost-effectiveness analysis.

AUTHOR(S)

Mavis Obeng-Kusi, Daniel Arku, Neda AlRawashdh, Briana Choi, Nimer S. Alkhatib, Ali McBride, Ivo Abraham

ABSTRACT

8043

ISB 1342: A first-in-class CD38 T cell engager for the treatment of relapsed refractory multiple myeloma.

AUTHOR(S)

Marie-Agnès Doucey, Blandine Pouleau, Carole Estoppey, Cian Stutz, Amelie Croset, Amélie Laurendon, Thierry Monney, Mégane Pluess, Christelle Ries-Fecourt, Julie Macoin, Riccardo Turrini, Perrine Suere, M.Lamine Mbow, Emilie Nallet, Adam Drake, Mario Perro, Stanislas Blein

ABSTRACT

8044

Comparison of outcomes with ciltacabtagene autoleucel (cilta-cel) in CARTITUDE-1 versus real-world standard of care (RW SOC) for patients (pts) with triple-class exposed relapsed/refractory multiple myeloma (RRMM).

AUTHOR(S)

Thomas G. Martin, Amrita Y. Krishnan, Kwee Yong, Katja Weisel, Maneesha Mehra, Sandhya Nair, Keqin Qi, Anil Londhe, Joris Diels, Concetta Crivera, Carolyn C. Jackson, Yunsu Olyslager, Martin Vogel, Jordan M. Schecter, Arnob Banerjee, Satish Valluri, Saad Z. Usmani, Jesus G. Berdeja, Sundar Jagannath

ABSTRACT

8045

Health-related quality of life (HRQoL) in patients with relapsed/refractory multiple myeloma (RRMM) treated with pomalidamide and dexamethasone ± subcutaneous daratumumab: Patient-reported outcomes (PROs) in APOLLO.

AUTHOR(S)

Evangelos Terpos, Meletios A. Dimopoulos, Mario Boccadoro, Sosana Delimpasi, Meral Beksac, Eirini Katodritou, Philippe Moreau, Luca Baldini, Argiris Symeonidis, Jelena Bila, Albert Oriol, Maria-Victoria Mateos, Hermann Einsele, Ioannis Orfanidis, Katharine S. Gries, John Fastenau, Tobias Kampfenkel, Yanping Qiu, Himal Amin, Pieter Sonneveld

ABSTRACT

8046

Teclistamab and talquetamab modulate levels of soluble B-cell maturation antigen in patients with relapsed and/or refractory multiple myeloma.

AUTHOR(S)

Suzette Girgis, Shun Xin Wang Lin, Kodandaram Pillarisetti, Raluca Verona, Diego Vieyra, Tineke Casneuf, Damien Fink, Xin Miao, Yang Chen, Tara Stephenson, Arnob Banerjee, Brandi W. Hilder, Jeffery S. Russell, Jennifer Smit, Jenna D. Goldberg

ABSTRACT

8047

Melflufen plus dexamethasone (dex) in patients (pts) with relapsed/refractory multiple myeloma (RRMM) exposed/refractory to prior alkylators: A pooled analysis of the O-12-M1 and HORIZON studies.

AUTHOR(S)

Paula Rodríguez-Otero, Maria-Victoria Mateos, Albert Oriol, Alessandra Larocca, Joan Blade, Michele Cavo, Xavier Leleu, Omar Nadeem, John W. Hiemenz, Hani Hassoun, Cyrille Touzeau, Adrian Alegre, Agne Paner, Christopher Maisel, Amitabha Mazumder, Anastasios Raptis, Marcus Thuresson, Johan Harmenberg, Olof Harlin, Paul G. Richardson

ABSTRACT

8048

Prognostic impact of depth of response in Waldenström macroglobulinemia patients treated with fixed duration chemoimmunotherapy.

AUTHOR(S)

Nirosha D. Perera, Jithma P. Abeykoon, Jorge J. Castillo, Joshua Gustine, Marzia Varettoni, Alessandra Tedeschi, Chiara Cavalloni, Anna Maria Frustaci, Matthew J. Maurer, Prashant Kapoor, Thomas M. Habermann, Thomas E. Witzig, Robert A. Kyle, Morie A. Gertz, Steven P. Treon, Stephen M. Ansell, Jonas Paludo

ABSTRACT

8049

An animal model of MGUS/SMM to investigate the role of cellular senescence in progression to MM.

AUTHOR(S)

Hengwei Zhang, Omar S. Aljitawi, Lianping X. Zhang, Thomas Conley, Frank C. Passero, Brea Lipe

ABSTRACT

8050

LIGHTHOUSE (OP-108): A phase 3 study of melflufen in combination with dexamethasone (dex) and daratumumab (dara) versus dara in relapsed/refractory multiple myeloma (RRMM) patients (pts).

AUTHOR(S)

Maria-Victoria Mateos, Luděk Pour, Enrique M. Ocio, Pieter Sonneveld, Catarina Jansson Blixt, Kajsa Larsson, Linda Palmér, Paul G. Richardson

ABSTRACT

TPS8051

ECOG-ACRIN EAA181: Effective quadruplet utilization after treatment evaluation (EQUATE)—a randomized phase 3 trial for newly diagnosed multiple myeloma (NDMM) not intended for early autologous transplantation.

AUTHOR(S)

Shaji Kumar, Zihan Wei, Michael A. Thompson, Bradley Snyder, Matthias Weiss, Lynne I. Wagner, Lale Kostakoglu, S. V. Rajkumar

ABSTRACT

TPS8052

KarMMa-4: Idecabtagene vicleucel (ide-cel, bb2121), a BCMA-directed CAR T-cell therapy in high-risk newly diagnosed multiple myeloma.

AUTHOR(S)

Saad Z. Usmani, Jesus G. Berdeja, Anna Truppel-Hartmann, Yizhou Fei, Honeylet Wortman-Vayn, Suresh Shelat, Steven Novick, Nina Shah

ABSTRACT

TPS8053

Subcutaneous daratumumab (DARA SC) plus lenalidomide versus lenalidomide alone as maintenance therapy in patients (pts) with newly diagnosed multiple myeloma (NDMM) who are minimal residual disease (MRD) positive after frontline autologous stem cell transplant (ASCT): The phase 3 AURIGA study.

AUTHOR(S)

Nina Shah, Sharmila Patel, Huiling Pei, Ming Qi, Maria Krevvata, Thomas S. Lin, Vipin Khare

ABSTRACT

TPS8054

A randomized, open-label, phase 3 study of low-dose selinexor and lenalidomide (Len) versus len maintenance post autologous stem cell transplant (ASCT) for newly diagnosed multiple myeloma (NDMM): ALLG MM23, Sealand.

AUTHOR(S)

Hang Quach, Masa Lasica, David Routledge, Anna Kalff, Andrew Lim, Michael Low, Jane A. Estell, M Hasib Siddiqi, Philip Campbell, Richard W. Eek, Hock C. Lai, Georgia J. McCaughan, James D'Rozario, Peter Browlett, Rajeev Rajagopal, Jessica Heenan, Nicholas E. Murphy, William Renwick, Georgina Huan, Peter Mollee

ABSTRACT

TPS8055

Lung Cancer—Non-Small Cell Local-Regional/Small Cell/Other Thoracic Cancers

[Back to Program](#)

Showing 69 Presentations

<https://meetinglibrary.asco.org/session/13657>

Updated overall survival (OS) and exploratory analysis from the randomized, phase II EVAN study of erlotinib (E) versus vinorelbine plus cisplatin (NP) as adjuvant therapy in Chinese patients with stage IIIA EGFR+ NSCLC.

AUTHOR(S)

Dongsheng Yue, Shi-Dong Xu, Qun Wang, Xiaofei Li, Yi Shen, Heng Zhao, Chun Chen, Weimin Mao, Wei Liu, Junfeng Liu, Lan-Jun Zhang, Haitao Ma, Qiang Li, Yue Yang, Yongyu Liu, Haiquan Chen, Zhenfa Zhang, Bin Zhang, Fuyu Gong, Changli Wang

ABSTRACT

8520

Different exposure duration of adjuvant icotinib in stage II-IIIa non-small cell lung cancer patients with positive EGFR mutation (ICOMPARE study): A randomized, open-label phase 2 study.

AUTHOR(S)

Chao Lyu, Rui Wang, Shaolei Li, Shi Yan, Yuzhao Wang, Jinfeng Chen, Liang Wang, Yinan Liu, Zhanlin Guo, Jia Wang, Yuquan Pei, Lei Yu, Nan Wu, Jun Chen, Yanheng Liu, Shanqing Li, Bing Han, Lieming Ding, Li Mao, Yue Yang

ABSTRACT

8521

Two-year follow-up of single PD-1 blockade in neoadjuvant resectable NSCLC.

AUTHOR(S)

Shugeng Gao, Ning Li, Shunyu Gao, Qi Xue, Shuhang Wang, Fang Lv, Liang Zhao, Fan Zhang, Ziran Zhao, Kai Su, Fengwei Tan, Yun Ling, Zhijie Wang, Wei Tang, Jianming Ying, Ning Wu, Jie Wang, Jie He

ABSTRACT

8522

Statewide rates of adjuvant checkpoint inhibitor use after definitive chemoradiation for stage III non-small cell lung cancer.

AUTHOR(S)

Alex K. Bryant, Huiying Yin, Matthew J. Schipper, Peter A. Paximadis, Thomas P. Boike, Derek P. Bergsma, Benjamin Movsas, Munther I. Ajlouni, Robert T. Dess, Melissa A. Mietzel, Randi Kendrick, Merita Seferi, Michael M. Dominello, Martha Matuszak, Reshma Jagsi, James Hayman, Lori J. Pierce, Shruti Jolly

ABSTRACT

8523

Osimertinib as neoadjuvant treatment for resectable stage II-IIIB EGFR mutant lung adenocarcinoma (NEOS).

AUTHOR(S)

Chao Lyu, Wentao Fang, Haitao Ma, Jia Wang, Wenjie Jiao, Rui Wang, Nan Wu, Shi-Dong Xu, Yue Yang

ABSTRACT

8524

Cost evaluation of adjunctive osimertinib use in resected epidermal growth factor receptor-positive non-small cell lung cancer.

AUTHOR(S)

Briana Choi, Neda AlRawashdh, Ali McBride, Ivo Abraham

ABSTRACT

8525

Minimal residual disease (MRD) in patients with resected stage I NSCLC: Results of the prospective adjuvant IFCT-0703 trial.

AUTHOR(S)

Damien Vasseur, Cécile Jovelet, Nathalie Cozic, Julien Mazieres, Fabrice Barlesi, Jaafar Bennouna, Radj Gervais, Lionel Moreau, Henri Berard, Olivier Molinier, Denis Moro-Sibilot, Pierre J. Souquet, Elodie Amour, Franck Morin, Gerard Zalcman, Jean-Charles Soria, Virginie Westeel, Ludovic Lacroix, Benjamin Besse

ABSTRACT

8526

Modeling the cost-effectiveness of adjuvant osimertinib in resected EGFR-mutant non-small cell lung cancer patients.

AUTHOR(S)

Christopher Lemmon, Emily C. Zabor, Nathan A. Pennell

ABSTRACT

8527

Driver mutations to predict for poorer outcomes in non-small cell lung cancer patients treated with concurrent chemoradiation and consolidation durvalumab.

AUTHOR(S)

Yufei Liu, Zhe Zhang, Waree Rinsurongkawong, Xiuning Le, Carl M. Gay, Matthew S. Ning, John Heymach, Jianjun Zhang, Steven H. Lin

ABSTRACT

8528

Natural history of curatively resected stage IB-IIIA EGFR mutation (+) NSCLC: Clinicopathologic and molecular prognostic factors (ROOT-EGFR-ADJ).

AUTHOR(S)

Hyun Ae Jung, Yeong Jeong Jeon, Jhingook Kim, Sehhoon Park, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Myung-Ju Ahn, Keunchil Park

ABSTRACT

8529

Molecular characteristics of EGFR exon 19 deletion subtypes in NSCLC patients.

AUTHOR(S)

Weiquan Gu, Zhongyu Lu, Shulin Shi, Juan Ma, Guanghua Lu, Wanglong Deng, Ran Ding, Fanfeng Bu

ABSTRACT

8530

Seroprevalence and immunological memory against SARS-CoV-2 in lung cancer patients (p): SOLID study.

AUTHOR(S)

Mariano Provencio, Delvys Rodriguez-Abreu, Ana C. Lorduy, Gloria M^a Serrano, Ana Laura Ortega Granados, Carlos Aguado, Guillermo Lopez Vivanco, Maria Guirado, Anna Estival, Beatriz Jimenez Munarriz, Hugo Arasanz, Juan Coves, Margarita Majem, Bartomeu Massuti, Sergio Vazquez-Estevez, Oscar Juan-Vidal, Clara Lucia, Edel del Barco, Manuel Cobo

ABSTRACT

8531

Association of high level of plasma tissue factor activity with venous thromboembolism and early death in lung cancers.

AUTHOR(S)

Helene Doubre, Isabelle Monnet, Reza Azarian, Philippe Girard, Guy Meyer, Julie Trichereau, Philippe Devillier, Patrick Van Dreden, Louis-Jean Couderc, Christos Chouaid, Marc Vasse

ABSTRACT

8532

Noninvasive identification of emergent mutations following cytotoxic therapy for lung cancer.

AUTHOR(S)

Everett J. Moding, Angela B. Hui, Yonina R. Murciano-Goroff, Barzin Nabat, Andre Schultz, Yawei Qiao, Bob T. Li, Steven H. Lin, Ash A. Alizadeh, Maximilian Diehn

ABSTRACT

8533

Sequential monitoring of PD-L1 on circulating stromal cells in blood predicts PFS in NSCLC patients undergoing immunotherapy after definitive chemoradiation.

AUTHOR(S)

Daniel L. Adams, Alexander Augustyn, Jianzhong He, Yawei Qiao, Ting Xu, Zhongxing X. Liao, Kirby J. Gardner, Jillian Moran, Cha-Mei Tang, Steven H. Lin

ABSTRACT

8534

Genomic and immunologic characterization of large-cell neuroendocrine carcinoma of the lung.

AUTHOR(S)

Chul Kim, Julie E. McGrath, Joanne Xiu, Misako Nagasaka, Patrick C. Ma, Jorge J. Nieva, Gilberto Lopes, Hossein Borghaei, Chukwuemeka Ikpeazu Sr., Taofeek K. Owonikoko, Michael J. Demeure, Antoinette J. Wozniak, Chadi Nabhan, Wolfgang M. Korn, Stephen V. Liu

ABSTRACT

8535

Deep learning to predict subtypes of poorly differentiated lung cancer from biopsy whole slide images.

AUTHOR(S)

Gouji Toyokawa, Fahdi Kanavati, Seiya Momosaki, Kengo Tateishi, Hiroaki Takeoka, Masaki Okamoto, Koji Yamazaki, Sadanori Takeo, Osamu Iizuka, Masayuki Tsuneki

ABSTRACT

8536

A new model using artificial intelligence to predict recurrence after surgical resection of stage I-II non-small cell lung cancer.

AUTHOR(S)

Natalie Lui, Nien Wei, Winston Trope, Shannon Nesbit, Prasha Bhandari, Chin-Hui Lee, Hu Hu, H. H. Guo, Douglas Z. Liou, Joseph B. Shrager, Leah M. Backhus, Mark F. Berry, Eric Yang

ABSTRACT

8537

Surgical outcomes for early-stage non-small cell lung cancer at facilities with stereotactic body radiation therapy programs.

AUTHOR(S)

Yusef Syed, William A. Stokes, Onkar Khullar, Nikhil Sebastian, Manali Rupji, Liu Yuan, Jeffrey D. Bradley, Kristin A. Higgins, Walter J. Curran, Suresh S. Ramalingam, Manu Sancheti, Felix Fernandez, Drew Moghanaki

ABSTRACT

8538

Prognostic value of SUVmax on FDG-PET/CT before and after stereotactic body radiotherapy (SBRT) on recurrence and survival in early-stage non-small cell lung cancer (NSCLC).

AUTHOR(S)

Saarang Deshpande, Tarun K. Podder, Yuxia Zhang, Yiran Zheng, William Grubb, Michael Kharouta, Philip A. Linden, Tithi Biswas

ABSTRACT

8539

Multomics analysis reveals high-immune infiltration in tumor-adjacent lung tissues affects the prognosis of stage I NSCLC.

AUTHOR(S)

Lisa Ying, Dan Su, Zhang Chunliu, Yiping Tian, Jing Bai, Canming Wang, Jianfei Fang, Andrew Futreal, Jianjun Zhang

ABSTRACT

8540

Phase II trial of toripalimab plus chemotherapy as neoadjuvant treatment in resectable stage III non-small cell lung cancer (NeoTPD01 Study).

AUTHOR(S)

Zerui Zhao, Si Chen, Han Qi, Chao-Pin Yang, Yao-Bin Lin, Jie-Tian Jin, Shan-Shan Lian, Yi-Zhi Wang, Hui Yu, Long Hao

ABSTRACT

8541

Impact of genomic aberrations and additional therapies on survival outcomes of patients with operable non-small cell lung cancer (NSCLC) from the NEOSTAR study.

AUTHOR(S)

Nicolas Zhou, Boris Sepesi, Cheuk Hong Leung, Heather Y. Lin, William N. William Jr., Annikka Weissferdt, Apar Pataer, Myrna Godoy, Frank V. Fossella, George Blumenschein Jr., Xiuning Le, Anne S. Tsao, Jianjun Zhang, Wayne L. Hofstetter, Stephen Swisher, Ara A. Vaporciyan, J. Jack Lee, Don L. Gibbons, John Heymach, Tina Cascone

ABSTRACT

8542

PIT-2: A multicenter phase II trail of S-1 plus cisplatin with concurrent radiotherapy followed by surgery in stage IIIA (N2) lung squamous cell carcinoma.

AUTHOR(S)

Kazuya Takamochi, Masahiro Tsuboi, Morihito Okada, Seiji Niho, Satoshi Ishikura, Shunsuke Oyamada, Takuhiro Yamaguchi, Fumihiro Tanaka, Ichiro Yoshino, Masanori Tsuchida, Satoshi Shiono, Hiroyuki Oizumi, Norihito Okumura, Tomohiro Haruki, Kenji Suzuki

ABSTRACT

8543

Impact of society and national guidelines on patient selection for lung cancer surgery in the United Kingdom.

AUTHOR(S)

Aina Pons, Paulo De Sousa, Chiara Proli, Sarah Ann Booth, Abigail Palmares, Maria Leung, Abdullah Alshammari, Dimitrios Vlastos, Hilgardt Raubenheimer, Anant Patel, Mohan Devbhandari, Eric K. Lim

ABSTRACT

8544

The efficacy of PD-1 antibody sintilimab on ground glass opacity lesions in patients with early-stage multiple primary lung cancer (CCTC-1901, NCT04026841).

AUTHOR(S)

Bo Cheng, Caichen Li, Yi Zhao, Jianxing He

ABSTRACT

8545

Doubling of median overall survival in a nationwide cohort of Veterans with stage III non-small cell lung cancer in the durvalumab era.

AUTHOR(S)

Kamya Sankar, Alex K. Bryant, Michael Green, Nithya Ramnath

ABSTRACT

8546

Elderly patients with unresectable stage 3 NSCLC treated with definitive chemoradiation with or without durvalumab: Safety and outcomes.

AUTHOR(S)

Malcolm I. Ryan, Jessica Weiss, Aline F. Fares, Ming S. Tsao, Geoffrey Liu, Penelope A. Bradbury, Natasha B. Leighl, Frances A. Shepherd, Adrian G. Sacher, Sally C. Lau

ABSTRACT

8547

NRG-RTOG 1106/ACRIN 6697: A phase IIR trial of standard versus adaptive (mid-treatment PET-based) chemoradiotherapy for stage III NSCLC—Results and comparison to NRG-RTOG 0617 (non-personalized RT dose escalation).

AUTHOR(S)

Feng-Ming S. Kong, Chen Hu, Randall Ten Haken, Ying Xiao, Martha Matuszak, Vera Hirsh, Daniel A. Pryma, Barry A. Siegel, Daphna Y. Gelblum, James Hayman, Clifford G. Robinson, Billy W. Loo, Gregory M. Videtic, Sergio Faria, Catherine Ferguson, Neal E. Dunlap, Vijayananda Kundapur, Rebecca Paulus, Jeffrey D. Bradley, Mitchell Machtay

ABSTRACT

8548

The impact of Percepta Genomic Sequencing Classifier (GSC) on clinical decision making in patients with a high-risk lung nodule.

AUTHOR(S)

Sonali Sethi, Scott Oh, Alexander Chen, Christina Bellinger, Lori Lofaro, Jennifer Tom, Marla Johnson, Jing Huang, Sangeeta M. Bhorade, Giulia Kennedy

ABSTRACT

8549

Patients with early-stage (T1-2N0) adenosquamous lung cancer have worse long-term survival compared to patients with early-stage lung adenocarcinoma or squamous cell histology.

AUTHOR(S)

Larisa Shagabayeva, Patel B. Heer, Chi-Fu J. Yang, Michael Lanuti

ABSTRACT

8550

Early candidate nasal swab classifiers developed using machine learning and whole transcriptome sequencing may improve early lung cancer detection.

AUTHOR(S)

Peter J. Mazzone, Carla Lamb, Kimberly M. Rieger-Christ, Chakravarthy B. Reddy, Jianghan Qu, Shuyang Wu, Jie Ding, Duncan Whitney, Daniel G. Pankratz, Joshua Babiarz, Lori Lofaro, P. S. Walsh, Jonathon Wilde, Sangeeta M. Bhorade, Jing Huang, Giulia Kennedy, Avrum Spira

ABSTRACT

8551

A comparative analysis of mortality between black and white stage III non-small cell lung cancer patients in the United States.

AUTHOR(S)

Elizabeth B. Elimimian, Rafael Arteta-Bulos, Hong Liang, Nadeem Bilani, Leah Elson, Diana Saravia, Evan W. Alley

ABSTRACT

8552

Early detection of lung cancer with an incidental lung nodule program (ILNP).

AUTHOR(S)

Matthew Smeltzer, Wei Liao, Meghan Meadows-Taylor, Nicholas Faris, Carrie Fehnel, Jordan Goss, Sara C. Williams, Olawale Akinbobola, Alicia Pacheco, Amanda Epperson, Joy Luttrell, Denise McCoy, Keith Tokin, Rob Optican, Jeffrey Wright, Edward T. Robbins, Shailesh Satpute, Parker Harris, Meredith Ray, Raymond U. Osarogiagbon

ABSTRACT

8553

Radical surgery in malignant pleural mesothelioma (MPM): An analysis of SEER database.

AUTHOR(S)

Qian Wang, Yaning Zhang, Meng Ru, Changchuan Jiang, Jessica Tran, Juan P. Wisnivesky, Rajwanth Veluswamy

ABSTRACT

8554

Comprehensive molecular profiling of pleural mesothelioma according to histologic subtype.

AUTHOR(S)

Ibiayi Dagogo-Jack, Russell Madison, Douglas A. Mata, Alexa B. Schrock, Tyler Janovitz, Brennan Decker, Richard S. Huang, Douglas I. Lin, Jonathan K. Killian, Shakti H. Ramkissoon, Ole Gjoerup, Natalie Danziger, Jeffrey M. Venstrom, Brian M. Alexander, Jeffrey S. Ross

ABSTRACT

8555

Improved survival among patients with malignant pleural mesotheliomas who develop immune-related adverse events on immunotherapy.

AUTHOR(S)

Michael Offin, Jacklynn V. Egger, Caroline G. McCarthy, Vasilisa Rudneva, Jason Beattie, Michelle S. Ginsberg, Jennifer L. Sauter, Andreas Rimner, Valerie W. Rusch, Prasad S. Adusumilli, Marjorie G. Zauderer

ABSTRACT

8556

Comprehensive genomic profiling of malignant peritoneal mesothelioma (MPeM) reveals key genomic alterations (GAs) distinct from malignant pleural mesothelioma (MPM).

AUTHOR(S)

Lynne O. Chapman, Michael J. Overman, Anneleis Willett, Mark Knafl, Szu-Chin Fu, Anais Malpica, Christopher Scally, Paul F. Mansfield, Aurelio A. Matamoros Jr., Ajaykumar Morani, Scott E. Woodman, Boris Sepesi, Reza J. Mehran, Cara L. Haymaker, Gauri R. Varadhachary, Anne S. Tsao, Keith Fournier, Kanwal P. Raghav

ABSTRACT

8557

A phase II trial of abemaciclib in patients with p16ink4a negative, relapsed mesothelioma.

AUTHOR(S)

Dean A. Fennell, Amy King, Seid Mohammed, Amy Branson, Alastair Greystoke, Sam Moody, Margaret Hutka, Alan G. Dawson, Liz Darlison, Molly Scotland, Vina Bhundia, Amrita Bajaj, Bruno Morgan, Adrian Nicholson, Cassandra Brookes, Aarti Gaba, Peter Wells-Jordan, Catherine J. Richards, Anne Thomas

ABSTRACT

8558

Genomic landscape of malignant mesothelioma by site and histology.

AUTHOR(S)

Elio Adib, Elie Akl, Amin Nassar, Talal El Zarif, Sarah Abou Alaiwi, David J. Kwiatkowski

ABSTRACT

8559

Efficacy and safety analysis of anlotinib combined with etoposide plus cisplatin/carboplatin as first-line therapy for extensive-stage small cell lung cancer (SCLC): The final results from a phase II single-arm trial.

AUTHOR(S)

Tiandong Kong, Lu Chen, Fangfang Duan, Xiaoxia Hou, Liuyan Wang, Hanli Zhou, Lanrong Wang, Shanshan Hu, Danna Liu

ABSTRACT

8560

Real-world evidence of cancer immunotherapy (CIT) combination treatment in first-line (1L) extensive-stage small cell lung cancer (ES-SCLC).

AUTHOR(S)

Eric S. Nadler, Anupama Vasudevan, Kalatu Davies, Yunfei Wang, Ann Johnson, Sarika Ogale

ABSTRACT

8561

The clinical efficacy of olaparib monotherapy or combination with ceralasertib (AZD6738) in relapsed small cell lung cancer.

AUTHOR(S)

Sehhoon Park, Peter G. Mortimer, Simon Smith, Heejung (Rosa) Kim, Hyun Ae Jung, Jong-Mu Sun, Jin Seok Ahn, Myung-Ju Ahn, Woong-Yang Park, Se-Hoon Lee, Keunchil Park

ABSTRACT

8562

Analysis of homologous recombination DNA repair gene mutation status in patients with metastatic small cell lung cancer treated with cediranib and olaparib on NCI 9881 study.

AUTHOR(S)

Joseph W. Kim, Marc R. Radke, Navid Hafez, Hatem H. Soliman, Siqing Fu, Shumei Kato, Primo "Lucky" N. Lara Jr., Ulka N. Vaishampayan, Albiruni R. Abdul Razak, Dana B. Cardin, Pamela N. Munster, Joseph P. Eder, Yu Shyr, S. P. Ivy, Patricia LoRusso, Elizabeth M. Swisher

ABSTRACT

8563

Circulating tumor DNA (ctDNA) mutations may predict treatment response in extensive-stage small cell lung cancer (ES-SCLC) treated with talazoparib and temozolomide (TMZ).

AUTHOR(S)

Matthew Mulroy, Amy L. Cummings, Melody A. Mendenhall, David E. Kanamori, Andrew V. Nguyen, David D. Kim, William E. Lawler, Tirrell T. Johnson, Jennifer Tseng, Sunil Babu, Andrew B. Brown, Shaker R. Dakhil, Sidharth Anand, Zev A. Wainberg, Dennis J. Slamon, Edward B. Garon, Jonathan W. Goldman

ABSTRACT

8564

Cisplatin versus carboplatin for the treatment of limited-stage small cell lung cancer (LS-SCLC).

AUTHOR(S)

Ibrahim Azar, Adam Austin, Seongho Kim, Hyejeong Jang, Malini Surapaneni, Daniel Kurtz, Omid Yazdanpanah, Amit Chopra, Syed Mehdi, Hirva Mamdani

ABSTRACT

8565

Application value of plasma exosomal long RNA in SCLC diagnosis and prognosis.

AUTHOR(S)

Chang Liu, Jialei Wang, Shenglin Huang, Hui Yu, Zhengfei Zhu, Min Fan

ABSTRACT

8566

Imfirst: A phase IIIb, safety, single arm study of carboplatin (CB) or cisplatin (CP) plus etoposide (ET) with atezolizumab (ATZ) in patients with untreated extensive-stage small cell lung cancer (ES-SCLC) in Spain—Primary safety results of the induction phase.

AUTHOR(S)

Maria Rosario García Campelo, Manuel Domine, Javier De Castro, Alberto Moreno, Santiago Ponce Aix, Edurne Arriola, Enric Carcereny, Margarita Majem, Gerardo Huidobro Vence, Emilio Esteban, Jose Fuentes Pradera, Bartomeu Massuti, Ana Laura Ortega, Guillot Mónica, Juan F. Cordoba, Natalia Fernandez, Ruben Alonso, Leonardo Crama, Natalia Leronés, Manuel Cobo

ABSTRACT

8567

Penpulimab plus anlotinib as second-line treatment for the small cell lung cancer after failure of platinum-based systemic chemotherapy.

AUTHOR(S)

Changgong Zhang, Sheng Yang, Jianhua Chen, Huijuan Wu, Jun Wang, Yingping Li, Liying Gao, Zhongyao Jia, Yan Sun, Jun Zhao, Xin L. Mu, Chunmei Bai, Rui Wang, Kailiang Wu, Qiang Liu, Xiaoping Jin, Xiaowen Tan, Yuankai Shi

ABSTRACT

8568

Chemoimmunotherapy for the treatment of extensive-stage small cell lung cancer (ES-SCLC) in patients with an Eastern Cooperative Group (ECOG) performance status (PS) of two or greater.

AUTHOR(S)

Daniel Almquist, Blake Langlais, Nathan Y. Yu, Terence T. Sio, Panos Savvides, Ping Yang, Steven E. Schild, Aaron S. Mansfield, Vinicius Ernani

ABSTRACT

8569

A phase I trial of plinabulin in combination with nivolumab and ipilimumab in patients with relapsed small cell lung cancer (SCLC): Big Ten Cancer Research Consortium (BTCRC-LUN17-127) study.

AUTHOR(S)

Jyoti Malhotra, Nasser H. Hanna, Alberto Chiappori, Lawrence E. Feldman, Naomi Fujioka, Igor I. Rybkin, Shadia I. Jalal, Malini Patel, Dirk Moore, Chunxia Chen, Salma K. Jabbour

ABSTRACT

8570

A randomized phase II/III study comparing carboplatin and irinotecan with carboplatin and etoposide for the treatment of elderly patients with extensive-disease small cell lung cancer (JCOG1201/TORG1528).

AUTHOR(S)

Tsuneo Shimokawa, Yuki Misumi, Hiroaki Okamoto, Yukio Hosomi, Isamu Okamoto, Hiroshi Tanaka, Shinji Atagi, Toyoaki Hida, Koichi Goto, Hiroaki Akamatsu, Kaoru Kubota, Kazuhiko Nakagawa, Hidehito Horinouchi, Masahiko Ando, Ryunosuke Machida, Junko Eba, Tomoko Kataoka, Yuichiro Ohe

ABSTRACT

8571

Combination of quantitative features from H&E biopsies and CT scans predicts response to chemotherapy and overall survival in small cell lung cancer (SCLC).

AUTHOR(S)

Cristian Barrera, Mohammadhadi Khorrami, Prantesh Jain, Pingfu Fu, Kate Butler, Abdullah Osme, Paula Toro, Vidya S. Viswanathan, Satyapal Chahar, Afshin Dowlati, Anant Madabhushi

ABSTRACT

8572

Myasthenia gravis-associated thymoma and myasthenia gravis-free thymoma have distinct somatic mutation and gene expression profiles.

AUTHOR(S)

Yi Zhang, Xiaomo Li, Gaojun Lu, Tonghui Ma, Kejian Shi

ABSTRACT

8573

First long-term results on efficacy and safety of long-acting pasireotide in combination with everolimus in patients with advanced carcinoids (NET) of the lung/thymus: Phase II LUNA trial.

AUTHOR(S)

Eric Baudin, Alfredo Berruti, Mario Giuliano, Wasat Mansoor, Catalin Bobirca, Erik Houtsma, Niamh Fagan, Kjell E. Oberg, Piero Ferolla

ABSTRACT

8574

Cancer activation pathways of thymic epithelial tumors (TETs) by targeted gene expression analysis.

AUTHOR(S)

Jose Carlos Benitez, Bastien Job, Vincent Thomas de Montpreville, Ludovic Lacroix, Patrick Saulnier, Riad Arana, Olivier Lambotte, Foundation Cancer and Autoimmune/inflammatory diseases Relationships, Sacha Mussot, Olaf Mercier, Elie Fadel, Jean-Yves Scoazec, Benjamin Besse

ABSTRACT

8575

A phase II study of palbociclib for recurrent or refractory advanced thymic epithelial tumor (KCSG LU17-21).

AUTHOR(S)

Myung-Ju Ahn, Hyun Ae Jung, Miso Kim, Joo-Hang Kim, Yoon Hee Choi, Jinhyun Cho, Ji Hyun Park, Keon Uk Park, Sehhoon Park, Jong-Mu Sun, Se-Hoon Lee, Jin Seok Ahn, Keunchil Park

ABSTRACT

8576

Cell-free circulating tumor DNA (cfDNA) analysis of advanced thymic epithelial tumors (TETs).

AUTHOR(S)

Hiba I. Dada, Leylah Drusbosky, Giuseppe Giaccone

ABSTRACT

8577

Outcomes of thymic epithelial tumors (TETs) with pleural metastases: Real-world insight from RYTHMIC.

AUTHOR(S)

Jean-Michel Maury, Jose Carlos Benitez, Marie Eve Boucher, Eric Dansin, Mallorie Kerjouan, Laurence Bigay-Game, Eric Pichon, Francois Thillays, Pierre-Emmanuel Falcoz, Lyubimova Svetlana, Youssef Oulkhoudir, Calcagno Fabien, Luc Thiberville, Christelle Clément Duchene, Virginie Westeel, Pascale Missy, Pascal Alexandre Thomas, Thierry Molina, Nicolas Girard, Benjamin Besse

ABSTRACT

8578

Clinicogenomic characterization of metastatic thymic epithelial tumors.

AUTHOR(S)

Fatemeh Ardeshtir-Larijani, Milan Radovich, Bryan P. Schneider, Patrick J. Loehrer Sr.

ABSTRACT

8579

Phase 3 study of pembrolizumab with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy followed by durvalumab in unresectable, locally advanced, stage III non-small cell lung cancer: KEYLYNK-012.

AUTHOR(S)

Salma K. Jabbour, Byoung Chul Cho, Emilio Bria, Terufumi Kato, Jaishree Bhosle, Justin F. Gainor, Noemi Reguart, Luhua Wang, Daniel Morgensztern, Ellen Gurary, Tanya B. Ashraf, Humberto Lara-Guerra, Martin Reck

ABSTRACT

TPS8580

A phase III clinical trial of adjuvant chemotherapy versus chemoimmunotherapy for stage IB-IIIA completely resected non-small cell lung cancer (NSCLC) patients nadim-adjuvant: New adjuvant trial of chemotherapy versus chemoimmunotherapy.

AUTHOR(S)

Virginia Calvo, Manuel Domine, Ivana Sullivan, Jose-Luis Gonzalez-Larriba, Ana Laura Ortega, Reyes Bernabé, Maria A. Sala, Begona Campos, Javier De Castro, Paloma Martín-Martorell, Joaquim Bosch-Barrera, Xabier Mielgo, Laia Vilà, Joaquin Casal, Silver Ros, Maite Martinez Aguillo, Airam Padilla, Sergio Sandiego, Jonathan Aires Machado, Mariano Provencio-Pulla

ABSTRACT

TPS8581

A randomized phase II trial of adjuvant pembrolizumab versus observation following curative resection for stage I non-small cell lung cancer (NSCLC) with primary tumors between 1-4 cm: Big Ten Cancer Research Consortium BTCRC-LUN18-153.

AUTHOR(S)

Greg A. Durm, Muhammad Furqan, Lawrence E. Feldman, Malini Patel, Richard D. Hall, Shadia I. Jalal, Thomas J. Birdas, Kenneth Kesler, Karen M. Rieger, DuyKhanh Ceppa, Nasser H. Hanna

ABSTRACT

TPS8583

Randomized phase III Trial of MEDI4736 (durvalumab) as concurrent and consolidative therapy or consolidative therapy alone for unresectable stage 3 NSCLC: A trial of the ECOG-ACRIN Cancer Research Group (EA5181).

AUTHOR(S)

John M. Varlotto, Zhuoxin Sun, Suresh S. Ramalingam, Heather A. Wakelee, Christine M. Lovly, Kurt R. Oettel, Gregory A. Masters, Nate Pennell

ABSTRACT

TPS8584

Thoracic radiotherapy PLUS durvalumab in elderly and/or frail NSCLC stage III patients unfit for chemotherapy: Employing optimized (hypofractionated) radiotherapy to foster durvalumab efficacy—The TRADE-hypo trial.

AUTHOR(S)

Farastuk Bozorgmehr, Jessica Juergens, Michaela Hammer-Hellmig, Christian Meyer Zum Bueschenfelde, Johannes Classen, Juergen Alt, Marcus Stockinger, Matthias Ulmer, Arndt-Christian Müller, Philipp Schütt, Michael J. Eble, Juergen R. Fischer, Christian A. Lerchenmuller, Tobias R. Overbeck, Henning Pelz, Bernd Schmidt, Thomas Wehler, Johannes Krisam, Michael Thomas, Stefan Rieken

ABSTRACT

TPS8585

DREAM3R: DuRvalumab with chEmotherapy as first-line treAtment in advanced pleural Mesothelioma—A phase 3 Randomized trial.

AUTHOR(S)

Patrick M. Forde, Anna K. Nowak, Peey-Sei Kok, Chris Brown, Zhuoxin Sun, Valsamo Anagnostou, Kenneth J. O'Byrne, Sonia Yip, Alistair Cook, Willem J. Lesterhuis, Brett G. Hughes, Nick Pavlakakis, Julie R. Brahmer, Hedy L. Kindler, Anne S. Tsao, Marjorie G. Zauderer, Suresh S. Ramalingam, Martin R. Stockler

ABSTRACT

TPS8586

KEYLYNK-013: A phase 3 study of pembrolizumab in combination with concurrent chemoradiation therapy followed by pembrolizumab with or without olaparib versus concurrent chemoradiation therapy in patients with newly diagnosed limited-stage SCLC.

AUTHOR(S)

Andreas Rimner, W. V. Lai, Raffaele Califano, Salma K. Jabbour, Corinne Faivre-Finn, Byoung Chul Cho, Terufumi Kato, Jinming Yu, Li Yu, Bin Zhao, Maria Catherine Pietanza, Lauren A. Byers

ABSTRACT

TPS8587

A phase I, open-label, dose-escalation trial of BI 764532, a DLL3/CD3 bispecific antibody, in patients (pts) with small cell lung carcinoma (SCLC) or other neuroendocrine neoplasms expressing DLL3.

AUTHOR(S)

Martin Wermke, Enriqueta Felip, Valentina Gambardella, Yasutoshi Kuboki, Daniel Morgensztern, Zohra Oum'Hamed, Junxian Geng, Matus Studeny, Taofeek K. Owonikoko

ABSTRACT

TPS8588

Trial in progress: A multicenter phase Ib/II study of pelcitoclax (APG-1252) in combination with paclitaxel in patients with relapsed/refractory small-cell lung cancer (R/R SCLC).

AUTHOR(S)

Angel Qin, Gregory P. Kalemkerian, Jyoti D. Patel, Nisha A. Mohindra, Jennifer W. Carlisle, Jacob Sands, Zhicong He, Robert Winkler, Zhiyan Liang, Vakessa Hammock, Riccardo Bombelli, Ming Lu, Yang Xu, Tommy Fu, Cunlin Wang, Dajun Yang, Yifan Zhai

ABSTRACT

TPS8589

Lung Cancer—Non-Small Cell Metastatic

[Back to Program](#)

Showing 111 Presentations

<https://meetinglibrary.asco.org/session/13660>

Anti PD-(L)1 in KRAS mutant advanced nsclds: A meta-analysis of randomized controlled trials.

AUTHOR(S)

Thierry Landre, Gregoire Justeau, Jean-baptiste Assié, Kader Chouahnia, Chérifa Taleb, Christos Chouaid, Boris Duchemann

ABSTRACT

9025

Clinical performance of artificial intelligence-powered annotation of tumor cell PD-L1 expression for treatment of immune-checkpoint inhibitor (ICI) in advanced non-small cell lung cancer (NSCLC).

AUTHOR(S)

Hyojin Kim, Sangjoon Choi, Seokhwi Kim, Jaehong Aum, Sergio Pereira, Seonwook Park, Minuk Ma, Seunghwan Shin, Kyunghyun Paeng, Donggeun Yoo, Wonkyung Jung, Chan-Young Ock, Se-Hoon Lee, Jin-haeng Chung, Yoon-La Choi, Tony S. Mok

ABSTRACT

9026

Clinical outcomes for plasma-based comprehensive genomic profiling versus tissue testing in advanced lung adenocarcinoma.

AUTHOR(S)

Ray D. Page, Leylah Drusbosky, Hiba I. Dada, Victoria M. Raymond, Davey B. Daniel, Stephen G. Divers, Karen L. Reckamp, Miguel A. Villalona-Calero, Justin I. Odegaard, Richard B. Lanman, Vassiliki Papadimitrakopoulou, Natasha B. Leighl

ABSTRACT

9027

Changes in PD-L1 tumor proportion score are associated with *CD274* gene (encoding PD-L1) copy number variation in non-small cell lung cancer.

AUTHOR(S)

Stephanie L. Alden, Biagio Ricciuti, Giuseppe Lamberti, Liam F. Spurr, Lynette M. Sholl, Andrew D. Cherniack, Mark M. Awad, Yvonne Y. Li

ABSTRACT

9029

Concordance of tissue- and plasma-derived genomic profiling in CheckMate 9LA, using the FoundationOne CDx and GuardantOMNI assays.

AUTHOR(S)

Jonathan F. Baden, Mark Sausen, Natallia Kalinava, William J. Geese, David Balli, Jaclyn Neely, George Green

ABSTRACT

9010

The combination of EGFR-TKIs and anlotinib as a first-line therapy for *EGFR*-mutant advanced non-small cell lung cancer: A multicenter, single-arm, phase II clinical trial.

AUTHOR(S)

Zhiyong He, Jinghui Lin, Yueming He, Jing Zhang, Dongyong Yang, Wenbin Qiu, Jinhua Lai, Xi Chen, Wenzheng Fang, Feng Ye, Tianwen Xu, Huita Wu, Dongfa Qiu, Wujin Chen, Lifang Cai, Shengchi Chen, Qunying Lin, Li Lin

ABSTRACT

9030

A randomized phase III study comparing carboplatin with nab-paclitaxel versus docetaxel for elderly patients with squamous-cell lung cancer: Capital study.

AUTHOR(S)

Yoichiro Hamamoto, Yoshihito Kogure, Akiko Kada, Hiroya Hashimoto, Shinji Atagi, Yuichi Takiguchi, Hideo Saka, Noriyuki Ebi, Akira Inoue, Takayasu Kurata, Takeharu Yamanaka, Masahiko Ando, Shunichiro Iwasawa, Kaoru Kubota, Mitsuhiro Takenoyama, Takashi Seto, Nobuyuki Yamamoto, Akihiko Gemma

ABSTRACT

9031

Response to selpercatinib versus prior systemic therapy in patients (pts) with *RET* fusion+ non-small-cell lung cancer (NSCLC).

AUTHOR(S)

Alexander E. Drilon, Oliver Gautschi, Benjamin Besse, Vivek Subbiah, Daniel S. Tan, Keunchil Park, Filippo G. De Braud, Guzman Alonso, Juergen Wolf, Victoria Soldatenkova, Pearl P. French, Aimee K. Lin, Koichi Goto, Benjamin J. Solomon

ABSTRACT

9032

Second-line nintedanib plus docetaxel for patients with lung adenocarcinoma after failure on first-line immune checkpoint inhibitor combination therapy: Initial efficacy and safety results from VARGADO Cohort C.

AUTHOR(S)

Christian Grohé, Thomas Wehler, Tobias Dechow, Sven Henschke, Wolfgang Schuette, Ina Dittrich, Stefan Hammerschmidt, Harald Müller-Huesmann, Christian Schumann, Stefan Krüger, Judith Atz, Rolf Kaiser

ABSTRACT

9033

Phase II trial of atezolizumab (A) + carboplatin (C) + pemetrexed (P) + bevacizumab (B) in pts with stage IV non-squamous non-small cell lung cancer (NSq-NSCLC): Big Ten Cancer Research Consortium Study LUN 17-139.

AUTHOR(S)

Fatemeh Ardeshtir-Larijani, Sandra K. Althouse, Ticiana Leal, Lawrence E. Feldman, Taher Abu Hejleh, Malini Patel, Ryan D. Gentzler, Adam R. Miller, Nasser H. Hanna

ABSTRACT

9034

Efficacy and safety of pan-ErbB inhibitor pyrotinib combined with antiangiogenic agent apatinib for HER2-mutant or amplified metastatic NSCLC: A phase II clinical study.

AUTHOR(S)

Guangjian Yang, Haiyan Xu, Lu Yang, Shuyang Zhang, Fei Xu, Hongshuai Li, Yaning Yang, Xin Ai, Yan Wang

ABSTRACT

9035

Treatment outcome and functional characterization of uncommon EGFR mutations in the German National Network Genomic Medicine Lung Cancer (nNGM).

AUTHOR(S)

Melanie Janning, Juliane Sueptitz, Anika Forstreuter, Corinna Albers-Leischner, Amanda Tufman, Janna-Lisa Velthaus-Rusik, Martin Reck, Andreas Jung, Irina Bonzheim, Stephanie Brändlein, Marcel Wiesweg, Jan Stratmann, Juergen Alt, Juliane Limberg, Felix Carl Saalfeld, Johannes Berger, Lars Tögel, Reinhard Buettner, Juergen Wolf, Sonja Loges

ABSTRACT

9036

A randomized phase II study comparing nivolumab (NIVO) with carboplatin-pemetrexed (CbPEM) for patients (pts) with EGFR mutation-positive non-small cell lung cancer (NSCLC) who acquire resistance to tyrosine kinase inhibitors (TKIs) not due to a secondary T790M mutation (WJOG8515L).

AUTHOR(S)

Hidetoshi Hayashi, Shunichi Sugawara, Yasushi Fukuda, Yuki Sato, Satoru Miura, Keiichi Ota, Yuichi Ozawa, Satoshi Hara, Junko Tanizaki, Koichi Azuma, Shota Omori, Motoko Tachihara, Kazumi Nishino, Shinobu Hosokawa, Yasutaka Chiba, Koji Haratani, Kazuko Sakai, Kazuto Nishio, Nobuyuki Yamamoto, Kazuhiko Nakagawa

ABSTRACT

9037

Health-related quality of life for pembrolizumab (pembro) plus ipilimumab (ipi) versus pembro plus placebo in patients with metastatic NSCLC with PD-L1 tumor proportion score $\geq$ 50%: KEYNOTE-598.

AUTHOR(S)

Mehmet N. Sendur, Martin Reck, Delvys Rodriguez-Abreu, Keunchil Park, Dae Ho Lee, Irfan Cicin, Perran F. Yumuk, Francisco J. Orlandi, Ticiana A. Leal, Olivier Molinier, Nopadol Soparattanapaisarn, Adrian Langleben, Raffaele Califano, Balazs Medgyasszay, Te-Chun Hsia, Gregory A. Otterson, Lu Xu, Thomas A. Burke, Ayman Samkari, Michael J. Boyer

ABSTRACT

9038

Whole-exome sequencing in advanced-stage sensitizing *EGFR* mutation non-small cell lung cancer: Explore resistance biomarkers to EGFR TKI treatment.

AUTHOR(S)

Chanida Vinayanuwattikun, Piyada Sitthideatphaiboon, Chinachote Teerapakpinyo, Krittiya Korphaisarn, Naravat Pongvarin, Poonchavist Chantranuwatana, Shanop Shuangshoti, Chatchawit Aporn Dewan, Virote Sriuranpong

ABSTRACT

9039

Phase II study of brigatinib in ROS1 positive non-small cell lung cancer (NSCLC) patients previously treated with crizotinib: Barossa cohort 2.

AUTHOR(S)

Haruko Daga, Seiji Niho, Jun Sakakibara-Konishi, Hiroshi Tanaka, Yasushi Goto, Kadoaki Ohashi, Ryo Toyozawa, Masahiro Kodani, Toshiaki Takahashi, Yoshihiro Hattori, Masahiro Morise, Takaya Ikeda, Shingo Matsumoto, Kiyotaka Yoh, Shogo Nomura, Koichi Goto

ABSTRACT

9040

Determination of clinical benefit among patients with radiological stable disease to immune checkpoint inhibitors.

AUTHOR(S)

Jia Luo, Song Wu, Hira Rizvi, Qu Zhang, Jacklynn V. Egger, Juan C. Osorio, Adam J. Schoenfeld, Andrew J. Plodkowski, Michelle S. Ginsberg, Ashok K. Gupta, Rajiv Raja, Mark G. Kris, Matthew D. Hellmann

ABSTRACT

9041

Brigatinib in Japanese patients with anaplastic lymphoma kinase (ALK)-positive non-small cell lung cancer (NSCLC): First results from the J-ALTA tyrosine kinase inhibitor (TKI)-naïve expansion cohort.

AUTHOR(S)

Masashi Kondo, Shunichi Sugawara, Toshihide Yokoyama, Toru Kumagai, Makoto Nishio, Koichi Goto, Yuichiro Ohe, Takashi Seto, Nobuyuki Yamamoto, Kentarou Kudou, Takayuki Asato, Pingkuan Zhang, Kazuhiko Nakagawa

ABSTRACT

9042

A large real-world study on the effectiveness of the combined inhibition of *EGFR* and *MET* in *EGFR*-mutant advanced non-small cell lung cancer (NSCLC).

AUTHOR(S)

Liu Li, Jingjing Qu, Jianfu Heng, Chunhua Zhou, Yi Xiong, Haiyan Yang, Wenjuan Jiang, Liang Zeng, Songlin Zhu, Yongchang Zhang, Jiarong Tan, Ting Hou, Analyn Lizaso, Zhiqiu Chen, Chengping Hu, Pengbo Deng, Nong Yang

ABSTRACT

9043

Differential immune-related microenvironment determines PD-1/PD-L1 blockade efficacy in advanced non-small cell lung cancer patients.

AUTHOR(S)

Masayuki Shirasawa, Tatsuya Yoshida, Yukiko Shimoda, Daisuke Takayanagi, Kouya Shiraishi, Takashi Kubo, Sachiyo Mitani, Yuji Matsumoto, Ken Masuda, Yuki Shinno, Yusuke Okuma, Yasushi Goto, Hidehito Horinouchi, Hitoshi Ichikawa, Takashi Kohno, Noboru Yamamoto, Shun-ichi Watanabe, Noriko Motoi, Yuichiro Ohe

ABSTRACT

9044

Predicting response to pembrolizumab in non-small cell lung cancer, by analyzing the spatial arrangement of tumor infiltrating lymphocytes using deep learning.

AUTHOR(S)

Efrat Ofek, Jair Bar, Alona Zer, Damien Urban, Chen Mayer, Chen Sade, Ori Zelichov, Alon Groisman, Avi Laniado, Yuval Gabay, Willy Polychenko, Roman Gluskin, Albert Achtenberg, Meora Feinmesser, Iris Barshack

ABSTRACT

9045

Results from a phase II study of efitlagimod alpha (soluble LAG-3 protein) and pembrolizumab in patients with PD-L1 unselected metastatic non-small cell lung carcinoma.

AUTHOR(S)

Timothy D. Clay, Margarita Majem, Enriqueta Felip, Bernard Doger, Enric Carcereny Costa, Martin Forster, Matthew Krebs, Julio A. Peguero, Christian Mueller, Frederic Triebel

ABSTRACT

9046

Safety and efficacy of the anti-CD73 monoclonal antibody (mAb) oleclumab ± durvalumab in patients (pts) with advanced colorectal cancer (CRC), pancreatic ductal adenocarcinoma (PDAC), or EGFR-mutant non-small cell lung cancer (EGFRm NSCLC).

AUTHOR(S)

Johanna C. Bendell, Patricia LoRusso, Michael J. Overman, Anne M. Noonan, Dong-Wan Kim, John Strickler, Sang-We Kim, Stephen J. Clarke, Thomas J. George, Peter S. Grimison, Minal A. Barve, Manik A. Amin, Jayesh Desai, Trisha Wise-Draper, Zachary Cooper, Nairouz Elgeioushi, Nancy K. Mueller, Rakesh Kumar, Kevin Y. Wu, Sandip P. Patel

ABSTRACT

9047

Phase 1b/2 study of capmatinib plus gefitinib in patients with EGFR-mutated, MET-dysregulated non-small cell lung cancer who received prior therapy: Final overall survival and safety.

AUTHOR(S)

Yi-Long Wu, Li Zhang, Dong-Wan Kim, Xiaoqing Liu, Dae Ho Lee, James Chih-Hsin Yang, Myung-Ju Ahn, Johan F. Vansteenkiste, Wu-Chou Su, Enriqueta Felip, Mariana Carhini, Sabine Glaser, Oezlem Tanriverdi, Andrea Chassot-Agostinho, Daniel S. Tan

ABSTRACT

9048

Response to immune checkpoint inhibition as monotherapy or in combination with chemotherapy in metastatic *ROS1*-rearranged lung cancers.

AUTHOR(S)

Noura J. Choudhury, Jaime L. Schneider, Tejas Patil, Viola W. Zhu, Debra A. Goldman, Soo-Ryum Yang, Christina Falcon, Andrew Do, Yunan Nie, Andrew J. Plodkowski, Jamie E. Chaft, Subba Digumarthy, Natasha Rekhtman, Maria E. Arcila, Alexia Iasonos, Sai-Hong I. Ou, Jessica J. Lin, Alexander E. Drilon

ABSTRACT

9049

Complete metabolic response in advanced non-small cell lung cancer patients with prolonged response to immune checkpoint inhibitor therapy.

AUTHOR(S)

Daniel C. Christoph, Justin Ferdinandus, Martin Metzenmacher, Peter Kessler, Lale Umutlu, Clemens Aigner, Karl-Otto Kambartel, Viktor Grünwald, Wilfried E. Eberhardt, Wolfgang P. Fendler, Ken Herrmann, Martin Faehling

ABSTRACT

9050

Comprehensive investigation of mutational features of adenocarcinoma in situ and invasive adenocarcinoma among Chinese lung cancer patients.

AUTHOR(S)

Chan Xiang, Yuchen Han, Wentao Fang, Haohua Teng, Shengnan Chen, Lianying Guo, Zhanxian Shang, Jikai Zhao, Jinzhi Wei, Jiaxin Liu, Lei Zhu, Analyn Lizaso, Yiran Cai, Jing Lin, Li Yan

ABSTRACT

9051

Amivantamab compared with real-world therapies in patients with NSCLC with EGFR Exon 20 insertion mutations who have progressed after platinum doublet chemotherapy.

AUTHOR(S)

Anna R. Minchom, Nicolas Girard, Lyudmila Bazhenova, Sai-Hong I. Ou, Shirish M. Gadgeel, José Trigo, Santiago Viteri, Daniel Backenroth, Archan Bhattacharya, Tracy Li, Parthiv Mahadevia, Joshua Bauml

ABSTRACT

9052

Totality outcome of afatinib sequential treatment in patients with EGFR mutation-positive NSCLC in Korea: KCSG LU-19-22.

AUTHOR(S)

Hyun Ae Jung, Min Hee Hong, Hyun Woo Lee, Kyung Hee Lee, Ilhwan Kim, Young Joo Min, Hee Kyung Ahn, Byoung Yong Shim, Yoon Hee Choi, Yun-Gyoo Lee, Jeong A. Kim, Joung Soon Jang, Seong-Hoon Shin, Keon Uk Park, Keunchil Park, Jin Hyoung Kang

ABSTRACT

9053

Clinico-pathological and genomic features of *NRAS*- or *HRAS*-mutated non-small cell lung cancer (NSCLC) identified in large-scale genomic screening project (LC-SCRUM-Asia).

AUTHOR(S)

Yutaro Tamiya, Shingo Matsumoto, Takaya Ikeda, Kiyotaka Yoh, Terufumi Kato, Kazumi Nishino, Masahiro Kodani, Atsushi Nakamura, Naoki Furuya, Shoichi Kuyama, Shingo Miyamoto, Ryo Toyozawa, Masato Shingyoji, Tomoyuki Naito, Satoshi Oizumi, Hiroshi Tanaka, Hibiki Udagawa, Kaname Nosaki, Yoshitaka Zenke, Koichi Goto

ABSTRACT

9054

SHR-1701, a bifunctional fusion protein targeting PD-L1 and TGF- β , for advanced NSCLC with *EGFR* mutations: Data from a multicenter phase 1 study.

AUTHOR(S)

Meiqi Shi, Jianhua Chen, KunYan Li, Yong Fang, Guilan Wen, Xingya Li, Yunpeng Liu, Yuping Sun, Bo Zhu, Lizhu Lin, Yuankai Shi, Linna Wang, Junqin Yang, Pan Liu, Jifeng Feng

ABSTRACT

9055

Patient-reported outcomes in capmatinib-treated patients with *MET*ex14-mutated advanced NSCLC: Results from the phase II GEOMETRY mono-1 study.

AUTHOR(S)

Juergen Wolf, Edward B. Garon, Harry J. Groen, Daniel S. Tan, Isabelle Gilloteau, Sylvie Le Mouhaer, Can Cai, Andrea Chassot-Agostinho, Maria Reynolds, Dawn Odom, Rebecca S. Heist

ABSTRACT

9056

Patient-reported outcomes (PRO) from the phase 2 CodeBreaK 100 trial evaluating sotorasib in *KRAS* p.G12C mutated non-small cell lung cancer (NSCLC).

AUTHOR(S)

Alexander I. Spira, Frederick H. Wilson, Geoffrey Shapiro, Christophe Doms, Alessandra Curioni-Fontecedro, Taito Esaki, Fabrice Barlesi, Kim Cocks, Andrew Trigg, Kendall Stevinson, Tara Matsuda, Qui Tran, Jhanelle E. Gray

ABSTRACT

9057

TROPION-PanTumor01: Dose analysis of the TROP2-directed antibody-drug conjugate (ADC) datopotamab deruxtecan (Dato-DXd, DS-1062) for the treatment (Tx) of advanced or metastatic non-small cell lung cancer (NSCLC).

AUTHOR(S)

Funda Meric-Bernstam, Alexander I. Spira, Aaron E. Lisberg, Jacob Sands, Noboru Yamamoto, Melissa L. Johnson, Kiyotaka Yoh, Edward B. Garon, Rebecca S. Heist, Adam Petrich, Jonathan Greenberg, Naoyuki Tajima, Yui Kawasaki, Wen Gu, Fumiaki Kobayashi, Yasong Lu, Ferdinand M. Guevara, Toshio Shimizu

ABSTRACT

9058

The role of chemotherapy plus immune checkpoint inhibitors in oncogenic driven non-small cell lung cancer: A University of California Lung Cancer Consortium retrospective study.

AUTHOR(S)

Karen Kelly, Shuai Chen, Joanna B. Eldredge, David J. Benjamin, Matthew Mulroy, Nadeem Tabbara, John Sharp, Jonathan W. Goldman, Matthew A. Gubens, Jeremy P. Harris, Megan E. Daly, Sandip P. Patel, Jason Chan, Amy L. Cummings, Viola W. Zhu

ABSTRACT

9059

A phase 2, open-label, multicenter study to evaluate the efficacy, safety, and tolerability of KN046 in combination with chemotherapy in subjects with advanced non-small cell lung cancer.

AUTHOR(S)

Yunpeng Yang, Wenfeng Fang, Yan Huang, Xingya Li, Siyuan Huang, Jingxun Wu, Yibin Li, Baoping Chang, Sheng Hu, Shujun Yang, June Xu, Hardy Van, Lihua Zhi, Yue Xia, Fei Yang, Yi Xia, Paul Kong, Wei Dong, Ting Xu, Li Zhang

ABSTRACT

9060

Comparison of time to failure of pembrolizumab plus chemotherapy versus pembrolizumab monotherapy: A consecutive analysis of NSCLC patients with high PD-L1 expression.

AUTHOR(S)

Hiroshi Takumida, Hidehito Horinouchi, Ken Masuda, Yuki Shinno, Yusuke Okuma, Tatsuya Yoshida, Yasushi Goto, Noboru Yamamoto, Yuichiro Ohe

ABSTRACT

9061

EGFR Exon 20 insertion: Prognostic and predictive values in advanced non-small cell lung cancer, a real-world study.

AUTHOR(S)

Christos Chouaid, Thomas Filleron, Didier Debievre, Maurice Perol, Nicolas Girard, Eric Dansin, Radj Gervais, Sophie Cousin, Josiane Otto, Roland Schott, David Planchard, Anne Madroszyk, Coureche Kaderbhai, Pascale Dubray-Longeras, Sandrine Huret, Eric Pichon, Christelle A. Clement-Duchene, Anne-Laure Martin, Gaetane Simon, Xavier Quantin

ABSTRACT

9062

Features in genomics and tumor immune microenvironment in NSCLC treated with neoadjuvant PD-1 blockade.

AUTHOR(S)

Shuhang Wang, Ning Li, Beibei Mao, Jianming Ying, Xiuli Tao, Wei Tang, Lei Zhang, Xiao Geng, Fan Zhang, Qi Xue, Lijia Wu, Henghui Zhang, Shugeng Gao, Jie He

ABSTRACT

9063

Subgroup-level network meta-analysis for efficacy of first-line immunotherapy-based treatments in advanced non-small cell lung cancer.

AUTHOR(S)

Fang Wu, Wentao Tian, Chenghui Cao, Jiawen Ke, Nuopei Tan, Yuwen Cai, Yue Zeng, Yue Pan, Xiaohan Liu, Lishu Zhao, Long Shu, Junqi Liu

ABSTRACT

9064

Updated overall efficacy and safety of selpercatinib in patients (pts) with *RET* fusion+ non-small cell lung cancer (NSCLC).

AUTHOR(S)

Benjamin Besse, Alexander E. Drilon, Benjamin J. Solomon, Vivek Subbiah, Daniel S. Tan, Keunchil Park, Filippo G. De Braud, Guzman Alonso, Juergen Wolf, Victoria Soldatenkova, Aimee K. Lin, Pearl P. French, Koichi Goto, Oliver Gautschi

ABSTRACT

9065

Taletrectinib (AB-106; DS-6051b) in metastatic non-small cell lung cancer (NSCLC) patients with *ROS1* fusion: Preliminary results of TRUST.

AUTHOR(S)

Caicun Zhou, Huijie Fan, Yongsheng Wang, Huijuan Wu, Nong Yang, KunYan Li, Xicheng Wang, Xintian Qin, Qitao Yu, Yong Fang, Min Tao, Xue Meng, Baohui Han, Xiaorong Dong, Bing Yan

ABSTRACT

9066

Physician concern about delaying lung cancer treatment while awaiting biomarker testing: Results of a survey of U.S. oncologists.

AUTHOR(S)

Kathryn F. Mileham, Upal K. Basu Roy, Suanna S. Bruinooge, Janet Freeman-Daily, Edward B. Garon, Liz Garrett-Mayer, Shadia I. Jalal, Bruce E. Johnson, Amy Moore, Raymond U. Osarogiagbon, Lauren Rosenthal, Caroline Schenkel, Robert A. Smith, Shamsuddin Virani, Mary W. Redman, Gerard A. Silvestri

ABSTRACT

9067

Neratinib efficacy in a subgroup of patients with *EGFR* exon 18-mutant non-small cell lung cancer (NSCLC) and central nervous system (CNS) involvement: Findings from the SUMMIT basket trial.

AUTHOR(S)

Jonathan W. Goldman, Santiago Viteri Ramirez, Amit Mahipal, Jennifer Marie M. Suga, Lisa D. Eli, Alshad S. Lalani, Richard Bryce, Feng Xu, Naisargee Shah, Fairouz Kabbinar, Valentina Boni, Barbara B. Haley

ABSTRACT

9068

The effects of tislelizumab treatment on the health-related quality of life of non-small cell lung cancer patients who progressed on a prior platinum-containing regimen.

AUTHOR(S)

Cai Zhou, Dingzhi Huang, Yiyuan Ma, Zhenyu Pan, Gisoo Barnes, Boxiong Tang

ABSTRACT

9069

Brigatinib (BRG) in ALK+ crizotinib (CRZ)-refractory non-small cell lung cancer (NSCLC): Final results of the phase 1/2 and phase 2 (ALTA) trials.

AUTHOR(S)

Scott N. Gettinger, Rudolf M. Huber, Dong-Wan Kim, Lyudmila Bazhenova, Karin Holmskov Hansen, Marcello Tiseo, Corey J. Langer, Luis G. Paz-Ares, Howard West, Karen L. Reckamp, Glen J. Weiss, Egbert F. Smit, Maximilian Hochmair, Sang-We Kim, Myung-Ju Ahn, Edward S. Kim, Harry J. Groen, Joanna Pye, Florin Vranceanu, D. R. Camidge

ABSTRACT

9071

Activity of epidermal growth factor receptor tyrosine kinase inhibitors (EGFR TKIs) in patients (pts) with NSCLC with uncommon *EGFR* mutations: A real-world cohort study (UpSwinG).

AUTHOR(S)

Satoru Miura, Te-Chun Hsia, Jen-Yu Hung, Hyun Ae Jung, Jin-Yuan Shih, Cheol-Kyu Park, Seung Hyeun Lee, Tatsuro Okamoto, Hee Kyung Ahn, Yong Chul Lee, Yuki Sato, Sung Sook Lee, Celine Mascaux, Hasan Daoud, Angela Maerten, Sanjay Popat

ABSTRACT

9072

A phase II trial of chemotherapy plus pembrolizumab in patients with advanced NSCLC previously treated with a PD-1 or PD-L1 inhibitor: Big Ten Cancer Research Consortium BTCRC-LUN15-029.

AUTHOR(S)

Nikhil Shukla, Sandra K. Althouse, Susan Perkins, Muhammad Furqan, Ticiana Leal, Nasser H. Hanna, Greg A. Durm

ABSTRACT

9073

Phase I study of the aurora kinase A inhibitor alisertib in combination with osimertinib in EGFR-mutant lung cancer.

AUTHOR(S)

Collin M. Blakely, Matthew A. Gubens, Gregory M. Allen, Shruti Shah, Matthew Jereza, Bianca Bacaltos, Sourav Bandyopadhyay

ABSTRACT

9074

Phase II randomized study of ramucirumab plus pembrolizumab versus standard of care for advanced non-small cell lung cancer previously treated with a checkpoint inhibitor: Toxicity update (Lung-MAP non-matched sub-study S1800A).

AUTHOR(S)

Karen L. Reckamp, Mary W. Redman, Konstantin H. Dragnev, Liza C. Villaruz, Bryan A. Faller, Tareq Al Baghdadi, Susan Hines, Lu Qian, Katherine Minichiello, David R. Gandara, Roy S. Herbst, Karen Kelly

ABSTRACT

9075

PD-(L)1 inhibitors as monotherapy for the first-line treatment of non-small cell lung cancer patients with high PD-L1 expression: A network meta-analysis.

AUTHOR(S)

Margarita Majem, Manuel Cobo, Dolores Isla, Diego Marquez-Medina Jr., Delvys Rodriguez-Abreu, Joaquín Casal Rubio, Teresa Moran Bueno, Reyes Bernabe Caro, Diego Perez Parente, Pedro Ruiz Gracia, Marta Marina Arroyo, Luis G. Paz-Ares

ABSTRACT

9076

Safety and activity of CLN-081 (TAS6417) in NSCLC with EGFR Exon 20 insertion mutations (Ins20).

AUTHOR(S)

Zofia Piotrowska, Helena A. Yu, James Chih-Hsin Yang, Marianna Koczywas, Egbert F. Smit, Daniel S. Tan, Victor H. Lee, Ross A. Soo, John M. Wrangle, Alexander I. Spira, Vamsidhar Velcheti, Mark A. Socinski, Asher Page, David Witter, Leigh Zawel, Jon M. Wigginton, Myles S. Clancy, Danny Nguyen

ABSTRACT

9077

Patient-reported symptoms, functioning, and quality of life (QoL) in patients treated with cemiplimab monotherapy for first-line treatment of advanced NSCLC with PD-L1 $\geq$ 50%: Results from EMPOWER-Lung 1 study.

AUTHOR(S)

Mahmut Gumus, Chieh-I Chen, Cristina Ivanescu, Saadettin Kilickap, Igor Bondarenko, Mustafa Ozguroglu, Miranda Gogishvili, Haci M. Turk, Irfan Cicin, James Harnett, Vera Mastey, Ulrike Naumann, Matthew Reaney, Gerasimos Konidakis, Medha Sasane, Keri Brady, Siyu Li, Giuseppe Gullo, Petra Rietschel, Ahmet Sezer

ABSTRACT

9078

Real-world patterns of biomarker testing and targeted therapy in metastatic non-small cell lung cancer (mNSCLC) in the community oncology setting.

AUTHOR(S)

Eric S. Nadler, Anupama Vasudevan, Kalatu Davies, Yunfei Wang, Ravindra Gupta, Sarika Ogale

ABSTRACT

9079

Identification of recurrence-associated gene signature and tumor immune microenvironment features in resected stage I NSCLC.

AUTHOR(S)

Fang Wu, Chunhong Hu, Long Shu, Chen Chen, Songqing Fan, Qingchun Liang, Hongmei Zheng, Yue Pan, Lishu Zhao, Fangwen Zou, Chaoyuan Liu, Wenliang Liu, Fenglei Yu, Xianling Liu, Lijuan Liu, Lingling Yang, Yang Shao

ABSTRACT

9080

Update analysis of NEJ009: Gefitinib alone (G) versus gefitinib plus chemotherapy (GCP) for non-small cell lung cancer with mutated EGFR.

AUTHOR(S)

Eisaku Miyauchi, Satoshi Morita, Atsushi Nakamura, Yukio Hosomi, Kana Watanabe, Satoshi Ikeda, Masahiro Seike, Yuka Fujita, Koichi Minato, Ryo Ko, Toshiyuki Harada, Koichi Hagiwara, Kunihiro Kobayashi, Toshihiro Nukiwa, Akira Inoue

ABSTRACT

9081

Discontinuation of immune checkpoint inhibitor (ICI) above 18 months of treatment in real-life patients with non-small cell lung cancer (NSCLC): INTEPI, a multicentric retrospective study.

AUTHOR(S)

Geoffroy Bilger, Nicolas Girard, Helene Doubre, Matteo Giaj Levra, Etienne Giroux Leprieur, Frédérique Giraud, Chantal Decroisette, Alain Livartowski, Marie Ange Massiani

ABSTRACT

9082

Intracranial activity of tepotinib in patients (pts) with *MET* exon 14 (*MET*ex14) skipping NSCLC enrolled in VISION.

AUTHOR(S)

Jyoti D. Patel, Xiuning Le, Remi Veillon, Ian C. Anderson, Christine M. Bestvina, Ingel Demedts, Marina C. Garassino, Julien Mazieres, Masahiro Morise, Egbert F. Smit, S. Peter Eggleton, Aurora OBrate, Gordon Otto, Rolf Bruns, Karl-Maria Schumacher, Paul K. Paik

ABSTRACT

9084

Cemiplimab monotherapy as first-line (1L) treatment of patients with brain metastases from advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) $\geq$ 50%: EMPOWER-Lung 1 subgroup analysis.

AUTHOR(S)

Mustafa Ozguroglu, Ahmet Sezer, Saadettin Kilickap, Mahmut Gumus, Igor Bondarenko, Miranda Gogishvili, Haci M. Turk, Irfan Cicin, Dmitry Bentsion, Oleg Gladkov, Philip R. Clingan, Virote Sriuranpong, Naiyer A. Rizvi, Jennifer McGinniss, Jean-Francois Pouliot, Sue Lee, Frank A. Seebach, Israel Lowy, Giuseppe Gullo, Petra Rietschel

ABSTRACT

9085

Real-world outcomes and clinical characteristics of patients with brain metastases from EGFR mutated non-small cell lung cancer: Data from a large retrospective study (REFLECT).

AUTHOR(S)

Urska Janzic, Alfredo Addeo, Elizabeth Dudnik, Andriani Charpidou, Adam Pluzanski, Tudor-Eliade Ciuleanu, Ivan Donev, Una Rigney, Judith Elbaz, Jorgen Aaroe, Nir Peled, Maximilian Hochmair

ABSTRACT

9086

***STK11/TP53* co-mutated non-small cell lung cancer (NSCLC) to display a unique tumor microenvironment (TME) and metabolic profile.**

AUTHOR(S)

Abdul R. Naqash, Charalampos S. Floudas, Asaf Maoz, Joanne Xiu, Yasmine Baca, Jia Zeng, Chul Kim, Julia Judd, Luis E. Raez, Gilberto Lopes, Jorge J. Nieva, Hossein Borghaei, Wolfgang M. Korn, Naoko Takebe, Stephen V. Liu, Hirva Mamdani

ABSTRACT

9087

Chemo-immunotherapy outcomes of KRAS-G12C mutant lung cancer compared to other molecular subtypes of KRAS-mutant lung cancer.

AUTHOR(S)

Kathryn C. Arbour, Biagio Ricciuti, Hira Rizvi, Matthew D. Hellmann, Helena A. Yu, Marc Ladanyi, Mark G. Kris, Maria E. Arcila, Charles M. Rudin, Piro Lito, Mark M. Awad, Gregory J. Riely

ABSTRACT

9088

Safety and efficacy of pralsetinib in patients with advanced *RET* fusion-positive non-small cell lung cancer: Update from the ARROW trial.

AUTHOR(S)

Giuseppe Curigliano, Justin F. Gainor, Frank Griesinger, Michael Thomas, Vivek Subbiah, Christina S. Baik, Daniel S. Tan, Dae Ho Lee, Daniel Misch, Elena Garraalda, Dong-Wan Kim, Luis G. Paz-Ares, Julien Mazieres, Stephen V. Liu, Gregory P. Kalemkerian, Yariv Houvras, Daniel W. Bowles, Aaron S. Mansfield, Alena Zalutskaya, Anthonie J. van der Wekken

ABSTRACT

9089

Association between improvements in survival of metastatic NSCLC patients and targeted- and immuno-therapy.

AUTHOR(S)

Sreeram Ramagopalan, Thomas P. Leahy, Joshua Ray, Samantha Wilkinson, Cormac J. Sammon, Vivek Subbiah

ABSTRACT

9090

First-line pembrolizumab monotherapy for PD-L1-positive (TPS $\geq$ 50%) advanced non-small cell lung cancer (aNSCLC) in the real world: A national French bispective multicentric cohort—ESCKEYP trial (GFPC 05-2018).

AUTHOR(S)

Renaud Descourt, Laurent Greillier, Maurice Perol, Charles Ricordel, Jean-Bernard Auliac, Lionel Falchero, Pierre Demontrond, Remi Veillon, Sabine Vieillot, Florian Guisier, Marie Marcq, Gregoire Justeau, Laurence Bigay Game, Marie Bernardi, Pierre Fournel, Helene Doubre, Julian Pinsolle, Karim Amrane, Christos Chouaid, Chantal Decroisette

ABSTRACT

9091

Beyond steroids: Immunosuppressants in steroid-refractory/resistant immune related adverse events.

AUTHOR(S)

Jia Luo, Jason Beattie, Paige Fuentes, Hira Rizvi, Jacklynn V. Egger, Jeffrey Kern, Donald Y. Leung, Mario E. Lacouture, Mark G. Kris, Maya Gambarin, Bianca Santomaso, David M. Faleck, Matthew D. Hellmann

ABSTRACT

9092

CNS activity of poziotinib in NSCLC with exon 20 insertion mutations.

AUTHOR(S)

Xiuning Le, Marina C. Garassino, Robin Cornelissen, Mark A. Socinski, Nishan Tchekekyan, Julian R. Molina, Christina S. Baik, Sharon Leu, Lyndah Dreiling, Francois M. Lebel, Jeffrey M. Clarke

ABSTRACT

9093

Impact of rapid multigene assays with short turnaround time (TAT) on the development of precision medicine for non-small cell lung cancer (NSCLC).

AUTHOR(S)

Shingo Matsumoto, Takaya Ikeda, Kiyotaka Yoh, Akira Sugimoto, Terufumi Kato, Kei Kunimasa, Atsushi Nakamura, Ichiro Nakachi, Shoichi Kuyama, Jun Sakakibara-Konishi, Haruko Daga, Eiji Iwama, Kageaki Taima, Naoki Furuya, Kaname Nosaki, Hiroki Izumi, Yoshitaka Zenke, Koichi Goto

ABSTRACT

9094

Maintenance targeted therapy compared to standard of care (SoC) in patients (pts) with metastatic non-small cell lung cancer (NSCLC): Results from the phase II randomized UNICANCER/IFCT1301- SAFIR02-LUNG intergroup trial.

AUTHOR(S)

Benjamin Besse, Maryam Karimi, Pascale Tomasini, Henri Janicot, Judith Raimbourg, Clarisse Audigier-Valette, Anne Madroszyk, Francois Chomy, Eric Dansin, Julien Mazieres, Alexis Cortot, Ivan Bieche, Ludovic Lacroix, Sandrine Boyault, Isabelle Soubeyran, Alain Morel, Alicia Tran-Dien, Alexandra Jacquet, Jean-Charles Soria, Fabrice Barlesi

ABSTRACT

9095

Time-dependent efficacy of checkpoint inhibitor nivolumab in metastatic lung cancer patients.

AUTHOR(S)

Abdoulaye Karaboué, Thierry Collon, Ida Pavese, Viviane Bodiguel, Elda Zakine, Pasquale Innominato, Mohamed Bouchahda, René Adam, Francis Levi

ABSTRACT

9096

Optimal next-generation sequencing (NGS) panel for estimating tumor mutation burden (TMB) and its clinical implication for non-small cell lung cancer (NSCLC).

AUTHOR(S)

Takaya Ikeda, Hajime Oi, Kiyotaka Yoh, Shingo Matsumoto, Terufumi Kato, Kazumi Nishino, Atsushi Nakamura, Ichiro Nakachi, Jun Sakakibara-Konishi, Haruko Daga, Naoki Furuya, Kageaki Taima, Eiji Iwama, Noriyuki Ebi, Yuji Shibata, Hiroki Izumi, Kaname Nosaki, Yoshitaka Zenke, Koichi Goto

ABSTRACT

9097

Real-world response and outcomes in NSCLC patients with EGFR exon 20 insertion mutations.

AUTHOR(S)

Sai-Hong I. Ou, Huamao M. Lin, Jin-Liern Hong, Yu Yin, Shu Jin, Jianchang Lin, Minal Mehta, Danny Nguyen, Joel W. Neal

ABSTRACT

9098

Impact of immune checkpoint inhibitor (CPI) and EGFR tyrosine kinase inhibitor (TKI) sequence on time to treatment failure (TTF) among EGFR plus NSCLC treated in a community-based cancer research network.

AUTHOR(S)

Carissa Jones, Rebecca Lachs, Emma Sturgill, Amanda Misch, Caressa Lietman, Suzanne F. Jones, Melissa L. Johnson, David R. Spigel, Andrew J. McKenzie

ABSTRACT

9099

Interim results of viagenpumatulcel-L (HS-110) plus nivolumab in previously treated patients (pts) with advanced non-small cell lung cancer (NSCLC) in two treatment settings.

AUTHOR(S)

Roger B. Cohen, George E. Peoples, Toana Kawashima, Bill Arana, Xiaoxing Cui, Lyudmila Bazhenova, Rachel E. Sanborn, Wael A. Harb, Nathan A. Pennell, Daniel Morgensztern

ABSTRACT

9100

Incidence and heterogeneity of C797S and other EGFR resistance mutations on routine comprehensive genomic profiling (CGP).

AUTHOR(S)

Pasi A. Janne, Jessica K. Lee, Russell Madison, Jeffrey M. Venstrom, Alexa B. Schrock, Geoffrey R. Oxnard

ABSTRACT

9101

RATIONALE-307: Tislelizumab plus chemotherapy versus chemotherapy alone as first-line treatment for advanced squamous NSCLC in patients aged ≥ 65 .

AUTHOR(S)

Jie Wang, Shun Lu, Xinmin Yu, Yanping Hu, Yuping Sun, Zhijie Wang, Jun Zhao, Yan Yu, Chunhong Hu, Kunyu Yang, Guosheng Feng, Kejing Ying, Wu Zhuang, Jianying Zhou, Jingxun Wu, Shiang Jiin Leaw, Jing Zhang, Xiao Lin, Nong Yang

ABSTRACT

9102

Chronic immune checkpoint inhibitor (ICI) pneumonitis in patients (pts) with non-small cell lung cancer (NSCLC).

AUTHOR(S)

Jessica Stuart, Biagio Ricciuti, Joao Victor M. Alessi, Mizuki Nishino, Mark M. Awad

ABSTRACT

9103

Genomic markers associated with hyperprogression in patients with lung cancer treated with immune checkpoint inhibitors.

AUTHOR(S)

Eyob a. Tadesse, Kayla Heslin, Mohamed Hendawi, Luke Peterson, Frank M. Wolf, Thomas D. Brown, Michael A. Thompson

ABSTRACT

9105

Impact of *STK11* mutation on first-line immune checkpoint inhibitor (ICI) outcomes in a real-world KRAS G12C mutant lung adenocarcinoma cohort.

AUTHOR(S)

Rebecca S. Heist, Junhua Yu, Elifnur Y. Donderici, Nicole Zhang, Carin R. Espenschied, Kathryn Lang, Beata Korytowsky, Andrew S. Chi, James G. Christensen

ABSTRACT

9106

Association of concomitant NSAID and immunotherapy on outcomes in patients with non-small cell lung cancer: Analysis of the National Veterans Health Administration Database.

AUTHOR(S)

Drew Moghanaki, William A. Stokes, Madhusmita Behera, Renjian Jiang, David Gutman, Felipe Giuste, Abigail Burns, Nikhil Sebastian, Selvi Ramalingam, Vidula Sukhatme, Michael C. Lowe, Suresh S. Ramalingam, Vikas Sukhatme

ABSTRACT

9107

Genomic landscape differences in patients with advanced non-small cell lung cancer by sex and age.

AUTHOR(S)

ErinMarie Kimbrough, Hiba I. Dada, Leylah Drusbosky, Yujie Zhao, Rami Manochakian, Yanyan Lou

ABSTRACT

9108

Long-term efficacy and safety of larotrectinib in patients with TRK fusion-positive lung cancer.

AUTHOR(S)

Jessica J. Lin, Shivaani Kummar, Daniel S. Tan, Ulrik N. Lassen, Serge Leyvraz, Yongmei Liu, Victor Moreno, Jyoti D. Patel, Lee S. Rosen, Benjamin M. Solomon, Ricarda Norenberg, Laura Dima, Nicoletta Brega, Lin Shen, Alexander E. Drilon

ABSTRACT

9109

Ph I/II study of oral selective AXL inhibitor bemcentinib (BGB324) in combination with erlotinib in patients with advanced EGFRm NSCLC: End of trial update.

AUTHOR(S)

Lauren A. Byers, Kathryn A. Gold, Julio A. Peguero, Melissa L. Johnson, Jorge J. Nieva, Wael A. Harb, Alberto Chiappori, Igor I. Rybkin, James F. Strauss, David E. Gerber

ABSTRACT

9110

Capmatinib efficacy in patients with NSCLC identified as *MET*ex14 using an NGS-based liquid biopsy assay: Results from the GEOMETRY mono-1 study.

AUTHOR(S)

Rebecca S. Heist, Edward B. Garon, Daniel S. Tan, Harry J. Groen, Takashi Seto, Egbert F. Smit, Mike R. Zou, Yiqun Yang, Ying Li, Andrea Chassot-Agostinho, Juergen Wolf

ABSTRACT

9111

Interim results of a phase II single arm trial combining afatinib with cetuximab in patients with EGFRex20ins positive NSCLC.

AUTHOR(S)

Bianca van Veggel, Anthonie J. van der Wekken, Marthe Paats, Sayed M. Hashemi, Lizza Hendriks, Karolina Sikorska, Daan van den Broek, Kim Monkhorst, Egbert F. Smit, Joop De Langen

ABSTRACT

9112

***DNMT3A* mutation to identify a subset of non-small cell lung cancers with increased sensitivity to PD-(L)1 blockade.**

AUTHOR(S)

Biagio Ricciuti, Joao Victor M. Alessi, Yvonne Y. Li, Marissa N. Lawrence, Hersh Gupta, Mizuki Nishino, Andrew D. Cherniack, Lynette M. Sholl, Mark M. Awad

ABSTRACT

9113

Nitroglycerin (NTG) plus whole intracranial radiotherapy for brain metastases (BM) in non-small cell cancer patient (NSCLC): A randomized open label, phase II clinical trial.

AUTHOR(S)

Oscar Gerardo Arrieta Rodriguez, Norma Hernández-Pedro, Federico Maldonado, Maritza Ramos, Masao Yamamoto-Ramos, Diego López, Francisco Lozano, Zyanya L. Zatarain-Barron, Graciela Cruz-Rico, Pedro Barrios-Bernal, Mario Orozco-Morales, Bernardo Cacho, Diana Flores-Estrada, Andres Felipe Cardona Zorrilla, Christian D. Rolfo

ABSTRACT

9114

Stereotactic body radiation therapy and in situ oncolytic virus therapy followed by immunotherapy in metastatic non-small cell lung cancer.

AUTHOR(S)

Carlo Guerrero, Joe E. Ensor Jr., Kai Sun, Andrew M. Farach, Sindhu Nair, Jun Zhang, Monisha Singh, Jorge G. Darcourt, Priya V. Ramshesh, Edward B. Butler, Bin S. Teh, Mark Sultenfuss, Nakul Gupta, Helen E. Heslop, Jaime A. Mejia, Jenny C. Chang, Eric Bernicker

ABSTRACT

9115

Genomic landscape of non-small cell lung cancer (NSCLC) with methylthioadenosine phosphorylase (*MTAP*) deletion.

AUTHOR(S)

Stephen L. Graziano, Dean C. Pavlick, Ethan Sokol, Shakti H. Ramkissoon, Eric A. Severson, Richard S. Huang, Douglas A. Mata, Brennan Decker, Kimberly McGregor, Natalie Danziger, Jeffrey S. Ross

ABSTRACT

9116

Superior overall survival (OS), progression-free survival (PFS), and clinical response (CR) predictions for patients with non-small cell lung cancer (NSCLC) using Cellworks Singula: myCare-022-05.

AUTHOR(S)

Vamsidhar Velcheti, Michael Castro, Drew Watson, Shweta Kapoor, Anuj Tyagi, Mohammed Sauban, Aftab Alam, Kunal G. Roy, Swaminathan Rajagopalan, Shruthi Kulkarni, Nirjhar Mundkur, Jim Christie, Rakhi P. Suseela, Adity Ghosh, Kabya Basu, Diwyanshu Sahu, Yashaswini Ullal, Prashant Nair, Manmeet S. Ahluwalia

ABSTRACT

9117

Use of brain radiotherapy as part of first course of treatment for NSCLC with de novo brain metastasis.

AUTHOR(S)

Rafael Arteta-Bulos, Nadeem Bilani, Leah Elson, Elizabeth B. Elimimian, Diana Saravia, Mihir Naik, Zeina A. Nahleh, Evan W. Alley

ABSTRACT

9118

Clinicopathologic, genomic, and tumor microenvironment correlates of aneuploidy and immunotherapy outcomes in NSCLC.

AUTHOR(S)

Joao Victor M. Alessi, Biagio Ricciuti, Yvonne Y. Li, Hersh Gupta, Giuseppe Lamberti, Gonzalo Recondo, Deepti Venkatraman, Mizuki Nishino, Andrew D. Cherniack, James Lindsay, Bijaya Sharma, Kathleen L. Pfaff, Kristen Felt, Lynette M. Sholl, Scott J. Rodig, Mark M. Awad

ABSTRACT

9119

Population-based impacts of new therapies on outcomes for stage IV non-small cell lung cancer.

AUTHOR(S)

Rebekah Rittberg, Oliver Bucher, Lin Xue, Zeb Aurangzeb, Shantanu O. Banerji, David Dawe

ABSTRACT

9120

Clinicopathologic and genomic correlates of tumor-infiltrating immune cells and immunotherapy efficacy in NSCLC.

AUTHOR(S)

Joao Victor M. Alessi, Biagio Ricciuti, Mizuki Nishino, Jason L. Weirather, Ann-Elisabeth Le, James Lindsay, Bijaya Sharma, Kristen Felt, Lynette M. Sholl, Scott J. Rodig, Mark M. Awad

ABSTRACT

9121

Patterns of survival in NSCLC with de novo brain metastasis: SRS, WBRT, and no radiotherapy cohorts.

AUTHOR(S)

Diana Saravia, Nadeem Bilani, Leah Elson, Elizabeth B. Elimimian, Evan W. Alley, Mihir Naik, Zeina A. Nahleh, Rafael Arteta-Bulos

ABSTRACT

9122

Analysis of patterns of care and benefit of thoracic radiotherapy for patients with stage IV NSCLC in the immunotherapy-era from a national hospital-based registry.

AUTHOR(S)

Michael Kharouta, Andrew J. Gross, Kevin Kelley, Serah Choi, Tithi Biswas

ABSTRACT

9123

Effect of continuing osimertinib with chemotherapy in the post-progression setting on progression-free survival among patients with metastatic epidermal growth factor receptor (EGFR) positive non-small cell lung cancer.

AUTHOR(S)

Tejas Patil, David Chun Cheong Tsui, Andrew Nicklawsky, Erin L. Schenk, William T. Purcell, Paul A. Bunn Jr., Jose M. Pacheco, D. R. Camidge

ABSTRACT

9124

Lung cancer in HIV versus non-HIV population: Nationwide analysis of mortality, morbidity, demographics, and healthcare utilization.

AUTHOR(S)

Muhammad J. Tariq, Shweta Gupta

ABSTRACT

9125

Trial in progress: Blood-based biomarker analysis in high PD-L1 expressing NSCLC treated with PD-1/PD-L1 based therapy with or without the addition of platinum-based chemotherapy.

AUTHOR(S)

Mary J. Fidler, Victoria M. Villaflor, Amol Rao, Balazs Halmos, Erin M. Bertino, Raymond U. Osarogiagbon, David P. Carbone

ABSTRACT

TPS9126

A randomized, phase 3 study of datopotamab deruxtecan (Dato-DXd; DS-1062) versus docetaxel in previously treated advanced or metastatic non-small cell lung cancer (NSCLC) without actionable genomic alterations (TROPION-Lung01).

AUTHOR(S)

Kiyotaka Yoh, Yasushi Goto, Michael Thomas, Alexander I. Spira, Jacob Sands, Melissa L. Johnson, Jonathan Greenberg, Adam M. Petrich, Ferdinand M. Guevara, Penny Phillips, Ekaterine Alexandris, Wen Gu, Yong Zhang, Dale E. Shuster, Aaron E. Lisberg

ABSTRACT

TPS9127

AdvanTIG-302: Anti-TIGIT monoclonal antibody (mAb) ociperlimab (OCI) plus tislelizumab (TIS) versus pembrolizumab (PEM) in programmed death ligand-1 (PD-L1) selected, previously untreated, locally advanced, unresectable or metastatic non-small cell lung cancer (NSCLC).

AUTHOR(S)

Mark A. Socinski, Alexander I. Spira, Luis G. Paz-Ares, Martin Reck, Shun Lu, Makoto Nishio, Jiang Li, Yunfei Zhou, Joon Whan Rhee, Sandra Chica Duque, Xinmin Yu

ABSTRACT

TPS9128

KRYSTAL-12: A randomized phase 3 study of adagrasib (MRTX849) versus docetaxel in patients (pts) with previously treated non-small-cell lung cancer (NSCLC) with KRAS^{G12C} mutation.

AUTHOR(S)

Tony S. Mok, William E. Lawler, Merrill K. Shum, Shaker R. Dakhil, Alexander I. Spira, Fabrice Barlesi, Martin Reck, Marina C. Garassino, David R. Spigel, Delia Alvarez, Thian Kheoh, William Paxton, Richard C. Chao, Enriqueta Felip

ABSTRACT

TPS9129

Camrelizumab monotherapy or in combination with apatinib for PD-L1-positive advanced pulmonary sarcomatoid carcinoma: A multicenter, open-label, single-arm, phase II study.

AUTHOR(S)

Mingfang Zhao, Tao Han

ABSTRACT

TPS9130

A multicenter, randomized, double-blind study of gefitinib in combination with anlotinib or placebo in previously untreated patients with EGFR mutation-positive advanced non-small cell lung cancer (FL-ALTER).

AUTHOR(S)

Li Zhang, Wenfeng Fang, Yunpeng Yang, Qitao Yu, Di Wu, Yingcheng Lin, Hua Zhang, Junfei Zhu, Guowu Wu, Bin Lan, Zeqiang Zhou, Zibing WANG, Xiaolin Lei, Haifeng Lin, Xiaohua HU, Suming Pan

ABSTRACT

TPS9131

CHRYSLIS-2: A phase 1/1b study of lazertinib as monotherapy and in combination with amivantamab in patients with EGFR-mutant NSCLC.

AUTHOR(S)

Catherine A. Shu, Koichi Goto, Byoung Chul Cho, Frank Griesinger, James Chih-Hsin Yang, Enriqueta Felip, John Xie, Jun Chen, Janine Mahoney, Meena Thayu, Roland E. Knoblauch, Leonardo Trani, Joshua Bauml

ABSTRACT

TPS9132

CONTACT-01: A phase III, randomized study of atezolizumab plus cabozantinib versus docetaxel in patients with metastatic non-small cell lung cancer (mNSCLC) previously treated with PD-L1/PD-1 inhibitors and platinum-containing chemotherapy.

AUTHOR(S)

Joel W. Neal, Palak Kundu, Tomohiro Tanaka, Ida Enquist, Sid Patel, Alessia Balestrini, Jin Wang, Thomas Newsom-Davis, Yasushi Goto, Nick Pavlakis, Sang-We Kim

ABSTRACT

TPS9134

Phase I trial of *in situ* vaccination with autologous CCL21-modified dendritic cells (CCL21-DC) combined with pembrolizumab for advanced NSCLC.

AUTHOR(S)

Aaron E. Lisberg, Bin Liu, Ramin Salehi-Rad, Jay M. Lee, Linh Tran, Kostyantyn Krysan, Raymond Lim, Camelia Dumitras, Zhe Jiang, Fereidoun Abtin, Robert Suh, Scott Genshaft, Gregory Fishbein, Anita Kaul, Kanwarpal Kahlon, Shay Ashouri, Jonathan W. Goldman, David Elashoff, Edward B. Garon, Steven M. Dubinett

ABSTRACT

TPS9135

Phase II two-arm study of tepotinib plus osimertinib in patients with *EGFR*-mutant NSCLC and acquired resistance to first-line osimertinib due to *MET* amplification: INSIGHT 2.

AUTHOR(S)

Viola W. Zhu, Christine M. Bestvina, Gilberto Lopes, John T. Hamm, Melissa L. Johnson, Philip E. Lammers, Xiuning Le, Omkar Marathe, Luis E. Raez, Suman Rao, Joshua K. Sabari, Ronald J. Scheff, Umit Tapan, Jonathan R. Thompson, Niki Karachaliou, Barbara Ellers-Lenz, Sabine Brutlach, Egbert F. Smit, Yi-Long Wu

ABSTRACT

TPS9136

Phase 2 study of PD-1 inhibitor JTX-4014 alone and in combination with vopratelimab, an ICOS agonist, in biomarker-selected subjects with metastatic NSCLC after one prior platinum-containing regimen (SELECT).

AUTHOR(S)

Oleh Kobziev, Iurie Bulat, Yuriy Ostapenko, Zanete Zvirbule, Grygorii Ursol, Vasyl Boyko, Viktor Paramonov, Yasmin Hashambhoy-Ramsay, Courtney Hart, Christopher Harvey, Ashley Graca, Lidya Le, Weidong Zhang, Bo Chao, Judy Jimenez, Krithi Bala, Sarah Maxwell, Haley Laken, Johan Baeck, Ellen M. Hooper

ABSTRACT

TPS9137

An open-label, multicenter phase I/IIa study evaluating the safety and clinical activity of clonal neoantigen reactive T cells in patients with advanced non-small cell lung cancer (CHIRON).

AUTHOR(S)

Mariam Jamal-Hanjani, Alastair Greystoke, Fiona Thistlethwaite, Yvonne J. Summers, Jennifer Allison, Judith Cave, Kim Orchard, Christian Ottensmeier, Gary Middleton, Leila Khoja, Michael Grant, Shreenal Patel, Jane Robertson, Karl Peggs, Martin Forster

ABSTRACT

TPS9138

HERTHENA-Lung01: A randomized phase 2 study of patritumab deruxtecan (HER3-DXd) in previously treated metastatic *EGFR*-mutated NSCLC.

AUTHOR(S)

Pasi A. Janne, Melissa L. Johnson, Yasushi Goto, James Chih-Hsin Yang, Michele Vigliotti, Qian Dong, Yang Qiu, Channing Yu, Helena A. Yu

ABSTRACT

TPS9139

Melanoma/Skin Cancers

[Back to Program](#)

Showing 72 Presentations

<https://meetinglibrary.asco.org/session/13663>

Improved pyrexia-related outcomes associated with an adapted pyrexia adverse event (AE) management algorithm in patients (pts) treated with adjuvant dabrafenib + trametinib (dab + tram): Primary results of COMBI-APlus.

AUTHOR(S)

Victoria Atkinson, Caroline Robert, Jean-Jacques Grob, Helen Gogas, Caroline Dutriaux, Lev V. Demidov, Avinash Gupta, Alexander M. Menzies, Bettina Ryll, Flora Miranda, Hiya Banerjee, Mike R. Lau, Michele Del Vecchio

ABSTRACT

9525

Overall survival in patients who received checkpoint inhibitors after completing tebentafusp in a phase 3 randomized trial of first-line metastatic uveal melanoma.

AUTHOR(S)

Marlana Orloff, Richard D. Carvajal, Alexander N. Shoushtari, Joseph J. Sacco, Max Schlaak, Claire Watkins, Shaad E. Abdullah, Howard Goodall, Marcus O. Butler

ABSTRACT

9526

Co-primary endpoint of overall survival for tebentafusp (tebe)-induced rash in a phase 3 randomized trial comparing tebe versus investigator's choice (IC) in first-line metastatic uveal melanoma.

AUTHOR(S)

Jessica C. Hassel, Piotr Rutkowski, Jean-Francois Baurain, Marcus O. Butler, Max Schlaak, Ryan Sullivan, Sebastian Ochsenreither, Reinhard Dummer, John M. Kirkwood, Anthony M. Joshua, Joseph J. Sacco, Alexander N. Shoushtari, Marlana Orloff, Richard D. Carvajal, Omid Hamid, Shaad E. Abdullah, Chris Holland, Howard Goodall, Paul Nathan, Sophie Piperno-Neumann

ABSTRACT

9527

Results of phase II randomized study of intermittent versus continuous schedule of vemurafenib plus cobimetinib in BRAF-mutated advanced melanoma.

AUTHOR(S)

Maria Gonzalez-Cao, Clara Mayo de las Casas, Juana Oramas, Miguel-Angel Berciano-Guerrero, Luis De la Cruz, Pablo Cerezuela-Fuentes, Ana M. Arance, Eva Muñoz-Couselo, Enrique Espinosa, Teresa Puértolas, Robert Diaz Beveridge, Sebastian Ochendusko, Maria Jose Villanueva Silva, Laura Basterretxea, Lorena Bellido, Delvys Rodriguez-Abreu, Ana Drozdowskyj, Miguel Angel Molina Vila, Jose A. Lopez-Martin, Alfonso Berrocal

ABSTRACT

9528

A phase 2 clinical trial on trametinib and low-dose dabrafenib in advanced pretreated *BRAF*^{V600}/*NRAS*^{Q61R/K/L} wild-type melanoma (TraMel-WT): Interim efficacy and safety results.

AUTHOR(S)

Gil Awada, Julia K. Schwarze, Jens Tijtgat, Giuseppe Fasolino, Hendrik Everaert, Bart Neyns

ABSTRACT

9529

Discrepancies in response and immune-related adverse events (irAE) of anti-PD-1 monotherapy between races and primary sites in patients (pts) with advanced nonacral cutaneous melanoma (NACM).

AUTHOR(S)

Xue Bai, Alexander N. Shoushtari, Allison Betof Warner, Henry Quach, Christopher G. Cann, Michael Zhang, Lalit Pallan, Catriona Harvey, Lu Si, Bixia Tang, Chuanliang Cui, Michelle S. Kim, Tatyana Sharova, Keith Flaherty, Georgina V. Long, Alexander M. Menzies, Ryan J. Sullivan, Genevieve M. Boland, Douglas B. Johnson, Jun Guo

ABSTRACT

9530

Characterization of cytokine release syndrome (CRS) following treatment with tebentafusp in patients (pts) with previously treated (2L+) metastatic uveal melanoma (mUM).

AUTHOR(S)

Richard D. Carvajal, Takami Sato, Marcus O. Butler, Joseph J. Sacco, Alexander N. Shoushtari, Jessica C. Hassel, Alexandra Ikeguchi, Leonel F. Hernandez-Aya, Matthew Rioth, Omid Hamid, Josep M. Piulats, Jason J. Luke, Douglas B. Johnson, Serge Leyvraz, Enrique Espinosa, Laura Collins, Michelle L. McCully, Sarah Lockwood, Shaad E. Abdullah, Paul Nathan

ABSTRACT

9531

Triplet therapy with pembrolizumab (PEM), encorafenib (ENC) and binimetinib (BIN) in advanced, BRAF V600 mutant melanoma: Final results from the dose-finding phase I part of the IMMU-Target trial.

AUTHOR(S)

Lisa Zimmer, Angela Krackhardt, Erwin S. Schultz, Daniela Goeppner, Chalid Assaf, Dietrich Trebing, Elisabeth Livingstone, Dirk Schadendorf

ABSTRACT

9532

Patterns and management of progression on first-line ipilimumab combined with anti-PD-1 (IPI+PD1) in metastatic melanoma (MM) patients.

AUTHOR(S)

Ines Pires Da Silva, Judith M. Versluis, Tasnia Ahmed, Douglas B. Johnson, Jennifer Soon, Clara Allayous, Camille L. Gerard, Joanna Mangana, Oliver Klein, Lisa Zimmer, Caroline Robert, Maria G. Vitale, Hui-Ling Yeoh, Olivier Michielin, Celeste Lebbe, Shahneen K. Sandhu, Christian U. Blank, Matteo S. Carlino, Alexander M. Menzies, Georgina V. Long

ABSTRACT

9533

Characteristics and probability of survival for patients with advanced melanoma who live five or more years after initial treatment with immune checkpoint blockade (ICB).

AUTHOR(S)

Kimberly Loo, Debra A. Goldman, Katherine Panageas, Margaret K. Callahan, Paul B. Chapman, Parisa Momtaz, Alexander N. Shoushtari, Jedd D. Wolchok, Michael A. Postow, Allison Betof Warner

ABSTRACT

9534

Clinical characteristics of SF3B1 mutant (mut) uveal melanoma (UM) and response to immune checkpoint inhibition (ICI).

AUTHOR(S)

Joe M. Grimes, Alexander N. Shoushtari, Marlana Orloff, Shaheer Khan, Cody Chiuza, Susan J. Hsiao, Diana McDonnell, Brian P. Marr, Richard D. Carvajal

ABSTRACT

9535

Pembrolizumab and all-trans retinoic acid combination treatment of advanced melanoma.

AUTHOR(S)

Martin McCarter, Richard P. Tobin, Dasha T. Cogswell, Victoria M. Vorwald, Dana Davis, Robert J. Van Gulick, Kasey L. Coutts, Kimberly R. Jordan, Victoria Nuanes, Dexiang Gao, Theresa M. Medina, Karl D. Lewis, Rene Gonzalez, Ross W. McFarland, William A. Robinson

ABSTRACT

9536

Safety and efficacy of lifileucel (LN-144), an autologous, tumor infiltrating lymphocyte cell therapy in combination with pembrolizumab for immune checkpoint inhibitor naïve patients with advanced melanoma.

AUTHOR(S)

Sajeve S. Thomas, Gino K. In, Bernard Doger, Simon Haefliger, Juan Martin-Liberal, Zelanna Goldberg, Alex Cacovean, Rana Fiaz, Guang Chen, Madan H. Jagasia, Friedrich Graf Finckenstein, Maria Fardis, Antonio Jimeno

ABSTRACT

9537

The use of cryoablation to overcome resistance to PD-1 blockade in unresectable melanoma.

AUTHOR(S)

Meghan Mooradian, Florian J. Fintelmann, Howard E. Kaufman, Mari Mino-Kenudson, Jaimie L. Barth, Aleigha Lawless, Tatyana Sharova, Riley Fadden, Krista M. Rubin, Donald P. Lawrence, Dennie T. Frederick, Moshe Sade-Feldman, Ryan J. Sullivan

ABSTRACT

9538

Apatinib in combination with camrelizumab, a humanized immunoglobulin G4 monoclonal antibody against programmed cell death-1, in patients with metastatic acral melanoma.

AUTHOR(S)

Xuan Wang, Chuanliang Cui, Bin Lian, Lu Si, Zhihong Chi, Xinan Sheng, Yan Kong, Lili Mao, Xue Bai, Bixia Tang, Xieqiao Yan, Siming Li, Li Zhou, Jun Guo

ABSTRACT

9539

Predictors of overall survival (OS) in patients (pts) with melanoma brain metastasis (MBM) in the modern era.

AUTHOR(S)

Merve Hasanov, Denai R. Milton, Alicia B. Davies, Elizabeth Sirmans, Chantal M. Saberian, Eliza Posada, Jeffrey E. Gershenwald, Carlos A. Torres-Cabala, Jason T. Huse, Hussein A. Tawbi, Isabella C. Glitza, Jing Li, Caroline Chung, Debra Yeboa, Sylvia Opusunju, Betty Y. Kim, Frederick F. Lang, Lauren E. Haydu, Michael A. Davies, Sherise D. Ferguson

ABSTRACT

9540

KEYNOTE-555 Cohort B: Efficacy, safety, and PK of pembrolizumab (pembro) 400 mg every 6 weeks (Q6W) as 1L therapy for advanced melanoma.

AUTHOR(S)

Conrad R. Jacobs, Bernardo L. Rapoport, Sze Wai Chan, Paul Ruff, Ana M. Arance, Karmele Mujika, James R. Anderson, Mallika Lala, Lokesh Jain, Omobolaji O. Akala, Elliot Chartash, Graham L. Cohen

ABSTRACT

9541

Comparing the clinical efficacies of anti-PD-1 antibody monotherapy and anti-PD-1 and anti-CTLA-4 combination therapy as first-line immunotherapy in Japanese advanced acral melanoma: A retrospective, multicenter study (JAMP-neo study).

AUTHOR(S)

Yasuhiro Nakamura, Yukiko Kiniwa, Hiroshi Kato, Osamu Yamasaki, Takeo Maekawa, Shigeto Matsushita, Tatsuya Takenouchi, Takashi Inozume, Yasuo Nakai, Satoshi Fukushima, Shintaro Saito, Atsushi Otsuka, Noriki Fujimoto, Taiki Isei, Natsuki Baba, Taisuke Matsuya, Ryo Tanaka, Takahide Kaneko, Masazumi Onishi, Shusuke Yoshikawa

ABSTRACT

9542

Durability of response to immune checkpoint inhibitors (ICI) in metastatic Merkel cell carcinoma (mMCC) after treatment cessation.

AUTHOR(S)

Alison M. Weppler, Laetitia Da Meda, Ines Silva, Wen Xu, Giovanni Grignani, Alexander M. Menzies, Matteo S. Carlino, Georgina V. Long, Ina Nordman, Christopher Steer, Megan Lyle, Claudia Trojaniello, Paolo A. Ascierto, Celeste Lebbe, Shahneen K. Sandhu

ABSTRACT

9543

Toxicity, response, and survival in older adults with metastatic melanoma treated with checkpoint inhibitors.

AUTHOR(S)

Nienke A. De Glas, Esther Bastiaannet, Frederiek van den Bos, Simon Mooijaart, Astrid A. Van Der Veldt, Karijn Suijkerbuijk, Maureen J. Aarts, Franchette van den Berkmoortel, Christian U. Blank, Marye Boers-Sonderen, Alfonsus J. van den Eertwegh, Jan Willem de Groot, Geke Hospers, John B. Haanen, Djura Piersma, Rozemarijn Van Rijn, A. J. Ten Tije, Michel W. Wouters, Johanna E. Portielje, Ellen Kapiteijn

ABSTRACT

9544

Results from the phase Ib of the SENSITIZE trial combining domatinostat with pembrolizumab in advanced melanoma patients refractory to prior checkpoint inhibitor therapy.

AUTHOR(S)

Jessica C. Hassel, Carola Berking, Max Schlaak, Thomas Eigentler, Ralf Gutzmer, Paolo A. Ascierto, Bastian Schilling, Svetlana Hamm, Frank Hermann, Philip G. Reimann, Dirk Schadendorf

ABSTRACT

9545

KEYNOTE-629: Health-related quality of life (HRQoL) with pembrolizumab (pembro) in patients (pts) with locally advanced (LA) or recurrent or metastatic (R/M) cutaneous squamous cell carcinoma (cSCC).

AUTHOR(S)

Åse Bratland, Eva Muñoz-Couselo, Laurent Mortier, Osama Roshdy, Rene Gonzalez, Jacob Schachter, Ana M. Arance, Florent Grange, Nicolas Meyer, Abhishek J. Joshi, Salem Billan, Brett G. Hughes, Jean-Jacques Grob, Karthik Ramakrishnan, Eric (Pingye) Zhang, Burak Gumuscu, Ramona F. Swaby, Ralf Gutzmer

ABSTRACT

9546

Checkpoint inhibition in immunosuppressed or immunocompromised patients with advanced cutaneous squamous cell carcinoma (CSCC): Data from prospective CemiplimAb-rwlc Survivorship and Epidemiology (C.A.S.E.) study.

AUTHOR(S)

Guilherme Rabinowits, Soo J. Park, David M. Ellison, Francis P. Worden, Rhonda W. Gentry, John Strasswimmer, Suraj S. Venna, Michael R. Migden, Sunandana Chandra, Emily S. Ruiz, Nikita Mehta, Haixin R. Zhang, Jennifer McGinniss, Jigar Desai

ABSTRACT

9547

The influence of harvest method on dendritic cell function and clinical outcomes in a randomized trial of a dendritic cell vaccine to prevent recurrences in high-risk melanoma.

AUTHOR(S)

Alexandra M. Adams, G. T. Clifton, Timothy J. Vreeland, Anne E. O'Shea, Patrick M. McCarthy, Robert C. Chick, Phillip M. Kemp Bohan, Annelies Hickerson, Diane F. Hale, John R. Hyngstrom, Adam C. Berger, James W. Jakub, Jeffrey J. Sussman, Montaser F. Shaheen, Thomas Wagner, Mark B. Faries, George E. Peoples

ABSTRACT

9548

Survival outcomes associated with fewer combination ipilimumab/nivolumab doses in advanced-stage melanoma.

AUTHOR(S)

Vincent T. Ma, Yilun Sun, Merna Sitto, Jessica Waninger, Leslie A. Fecher, Michael Green, Christopher D. Lao

ABSTRACT

9549

Complete responders to checkpoint inhibitors in advanced melanoma: Relapse risk factors, and patients' outcomes.

AUTHOR(S)

Amelie Dutheil, Djaouida Belkadi, Marine Antigny, Severine Roy, Jeremy Lupu, Anaïs Vallet, Emilie Routier, Caroline Robert

ABSTRACT

9550

The risk and tropism of central nervous system metastases (CNS) in patients with stage II cutaneous melanoma.

AUTHOR(S)

Paul Johannet, Min Jae Kim, Melissa Call, Nicholas Gulati, Judy Zhong, Janice M. Mehnert, Iman Osman

ABSTRACT

9551

Impact of systemic therapy sequencing on overall survival for patients with advanced BRAF-mutated melanoma.

AUTHOR(S)

B. Adi Kartolo, Jasna Deluce, Wilma M. Hopman, Linda Liu, Tara D. Baetz, D. S. Ernst, John G. Lenehan

ABSTRACT

9552

IL-6 blockade for prophylaxis and management of immune-related adverse events (irAEs) with anti-PD-1 based immunotherapy.

AUTHOR(S)

Florentia Dimitriou, Sabrina A. Hogan, Phil F. Cheng, Reinhard Dummer, Alexander M. Menzies, Georgina V. Long

ABSTRACT

9553

Safety and efficacy of HX008: A humanized immunoglobulin G4 monoclonal antibody in patients with locally advanced or metastatic melanoma—A single-arm, multicenter, phase II study.

AUTHOR(S)

Bin Lian, Yu Chen, Di Wu, Zhiguo Luo, Zhengyun Zou, Yu Jiang, Hongming Pan, Qingxia Fan, Jianfu Zhao, Qing Xu, Renbing Jiang, Chuanliang Cui, Xuan Wang, Fang Lou, Zhen Guo, Lu Si, Zhihong Chi, Xinan Sheng, Jun Guo

ABSTRACT

9554

Encorafenib plus Binimetinib in patients with locally advanced, unresectable or metastatic BRAF^{V600}-mutant melanoma: First data of the multicenter, multinational, prospective, non-interventional longitudinal study BERING^{MELANOMA}.

AUTHOR(S)

Erika Richtig, Ralf Gutzmer, Carmen Loquai, Jochen Utikal, Christoph Hoeller, Rudolf Stadler, Andrea Forschner, Jessica C. Hassel, Daniela Goeppner, Michael Fluck, Sebastian Haferkamp, Martin Kaatz, Manfred Welslau, Reinhard Dummer, Roger A. Von Moos, Andrea Schmidt, Laura Milde, Olivier Michielin, Dirk Schadendorf

ABSTRACT

9555

Plasma thymidine kinase activity (TKa) as a novel prognostic biomarker in metastatic melanoma.

AUTHOR(S)

Hildur Helgadóttir, Fernanda C. Svedman, Marie Jalsenius, Veronica Hoiom, Samuel Rotstein, Suzanne E. Brage, Vitali Grozman, Fabian Söderdahl, Lars Ny, Mattias Bergqvist

ABSTRACT

9556

Outcomes of non-treatment naive melanoma patients with central nervous system relapse.

AUTHOR(S)

Thiago Pimentel Muniz, Hadee Lone, Diana P. Arteaga, Diana Gray, Maysa T. Silveira Vilbert Pereira, Luke Mantle, Raviya Singh, Sofia Genta, Samuel Saibil, David Hogg, Anna Spreafico, Marcus O. Butler

ABSTRACT

9557

***BRAF* and *NRAS* mutation status and response to checkpoint inhibition in advanced melanoma.**

AUTHOR(S)

Olivier J. van Not, Alfonsus J. van den Eertwegh, John B. Haanen, Christian U. Blank, Maureen J. Aarts, Franchette van den Berkmortel, Jan Willem de Groot, Geke Hospers, Ellen Kapiteijn, Djura Piersma, Rozemarijn Van Rijn, Marion Stevense, Astrid A. Van Der Veldt, Gerard Vreugdenhil, Marye Boers-Sonderen, Han J. Bonenkamp, Anne M. Jansen, Willeke Blokk, Michel W. Wouters, Karijn Suijkerbuijk

ABSTRACT

9558

A phase 1b clinical trial of anti-PD-1 ab (Toripalimab) plus intralesional injection of OrienX010 in stage IV melanoma with liver metastases.

AUTHOR(S)

Jun Guo, Chuanliang Cui, Xuan Wang, Bin Lian, Shanshan Yin, Yue Cong, Zhihong Chi, Lu Si, Xinan Sheng, Bixia Tang, Lili Mao, Xue Bai, Xieqiao Yan, Siming Li, Li Zhou

ABSTRACT

9559

Pyrexia-related outcomes upon application of an adapted pyrexia management algorithm in patients (pts) with *BRAF* V600: Mutant unresectable or metastatic melanoma treated with dabrafenib plus trametinib (DabTram) in the COMBI-i trial.

AUTHOR(S)

Paolo A. Ascierto, Caroline Robert, Paul D. Nathan, Reinhard Dummer, Hussein A. Tawbi, Keith T. Flaherty, Antoni Ribas, Dirk Schadendorf, Steven Green, Lali Sandalic, Mike R. Lau, Tonatiuh Romero, Georgina V. Long

ABSTRACT

9560

Treatment outcomes in patients (pts) with melanoma brain metastases (MBM) treated with systemic therapy: A systematic literature review (SLR) and meta-analysis.

AUTHOR(S)

Hussein A. Tawbi, Georgina V. Long, Nicolas Meyer, Boris Breznen, Charmy Vyas, Lisa Leung, Andriy Moshyk, Divya Pushkarna, Pratik K. Thakkar, Mir Sohail Fazeli, SRIVIDYA KOTAPATI, Dirk Schadendorf

ABSTRACT

9561

Efficacy of cetuximab after immunotherapy (IO) in advanced cutaneous squamous cell carcinoma (CSCC).

AUTHOR(S)

Julian A. Marin-Acevedo, Bethany Withycombe, Youngchul Kim, Zeynep Eroglu, Joseph Markowitz, Andrew S. Brohl, Ahmad A. Tarhini, Kenneth Y. Tsai, Nikhil I. Khushalani

ABSTRACT

9562

External validation of a Dutch predictive nomogram for complete response to T-VEC in an independent American patient cohort.

AUTHOR(S)

Emma H. Stahlie, Michael Carr, Jonathan S. Zager, Alexander C. Van Akkooi

ABSTRACT

9563

Outcomes of BRAF mutant metastatic melanoma (MM) patients (pts) after cessation of targeted therapy (TT) with BRAF or BRAF/MEK inhibitor(i).

AUTHOR(S)

Natalie Jackson, Theresa Rodgers, Ida John, Denai R. Milton, Lauren E. Haydu, Rodabe N. Amaria, Adi Diab, Jennifer L. McQuade, Sapna P. Patel, Hussein A. Tawbi, Michael K. Wong, Michael A. Davies, Isabella C. Glitza

ABSTRACT

9564

Multicentre retrospective assessment of toxicity and response to immunotherapy in elderly patients with metastatic melanoma.

AUTHOR(S)

Shivanshan Pathmanathan, Hari S. Babu, Robert Mason, Saw Htut, Zulfiquer A. Otty, Megan Lyle, Marcin R. Dzienis

ABSTRACT

9565

Health-related quality of life (HRQoL) in patients (pts) with locally advanced basal cell carcinoma (laBCC) treated with cemiplimab: Analysis of a phase II, open-label clinical trial.

AUTHOR(S)

Alexander J. Stratigos, Chieh-I Chen, Cristina Ivanescu, Karl D. Lewis, Ketty Peris, Oliver E. Bechter, James Harnett, Vera Mastey, Matthew Reaney, Christina Daskalopoulou, Patrick R. LaFontaine, Gerasimos Konidaris, Denise Bury, Suk-Young Yoo, Kosalai K. Mohan, Ebony Coates, Timothy G. Bowler, Matthew G. Fury, Aleksandar Sekulic

ABSTRACT

9566

Pathology of durable stable disease in melanoma patients treated with ipilimumab, nivolumab, or ipilimumab, and nivolumab combination therapy.

AUTHOR(S)

Elizabeth I. Buchbinder, Kathleen L. Pfaff, Michael P. Manos, Olivia Ouyang, Patrick A. Ott, Scott J. Rodig, F. S. Hodi

ABSTRACT

9567

Tumor PD-L1 expression and gene panel mutational profile as outcome predictors of PD-1-based checkpoint inhibition therapy in metastatic melanoma: A prospective multicenter DeCOG study.

AUTHOR(S)

Selma Ugurel, Klaus Griewank, Susanne Horn, Rudolf Herbst, Patrick Terheyden, Jochen Utikal, Claudia Pföhler, Jens Ulrich, Alexander Kreuter, Peter Mohr, Ralf Gutzmer, Friedegund E. Meier, Edgar Dippel, Antje Sucker, Jan-Malte Placke, Eva Hadaschik, Jürgen C. Becker, Michael Weichenthal, Dirk Schadendorf

ABSTRACT

9568

Analysis of patients (pts) with in-transit metastases treated with nivolumab (NIVO) or ipilimumab (IPI) in CheckMate 238.

AUTHOR(S)

James Larkin, Helen Gogas, Michele Del Vecchio, Michele Maio, Petr Arenberger, Ana M. Arance, Jean-Jacques Grob, Vanna Chiarion-Sileni, Karl D. Lewis, Laurent Mortier, Patrick A. Ott, Georgina V. Long, Alfonsus Van Den Eertwegh, C. L. Cowey, Michael Schenker, Marcus O. Butler, Maurice Lobo, Margarita Askelson, Paolo A. Ascierto, Jeffrey S. Weber

ABSTRACT

9569

A phase Ib clinical trial of neoadjuvant OrienX010, an oncolytic virus, in combination with toripalimab in patients with resectable stage IIIb to stage IVM1a acral melanoma.

AUTHOR(S)

Xuan Wang, Chuanliang Cui, Lu Si, Caili Li, Jie Dai, Lili Mao, Xue Bai, Zhihong Chi, Xinan Sheng, Yan Kong, Bin Lian, Bixia Tang, Xieqiao Yan, Li Zhou, Siming Li, Robert H. Andtbacka, Jun Guo

ABSTRACT

9570

Management of resected stage III/IV melanoma with adjuvant immunotherapy.

AUTHOR(S)

Rebecca Johnson, Victoria Atkinson, Prachi Bhave, Alison M. Wepler, Geoffrey D. Peters, Afaf Abed, Megan Lyle, Muhammad A. Khattak, Andrew M. Haydon, Matteo S. Carlino, Shahneen K. Sandhu, Georgina V. Long, Alexander M. Menzies

ABSTRACT

9571

Propensity weighted indirect treatment comparison of nivolumab (NIVO) versus placebo (PBO) as adjuvant therapy for resected melanoma: A number needed to treat and overall survival analysis.

AUTHOR(S)

Jeffrey S. Weber, Tayla Poretta, Brian Stwalley, Leon Sakkal, Ella X. Du, Travis Wang, Yan Chen, Yan Wang, Keith A. Betts, Alexander N. Shoushtari

ABSTRACT

9572

Adjuvant anti-PD-1 ab (Toripalimab) versus high-dose IFN-a2b in resected mucosal melanoma: A phase II randomized trial.

AUTHOR(S)

Chuanliang Cui, Bin Lian, Lu Si, Zhihong Chi, Xinan Sheng, Yan Kong, Xuan Wang, Hui Tian, Lili Mao, Xue Bai, Bixia Tang, Xieqiao Yan, Siming Li, Li Zhou, Jun Guo

ABSTRACT

9573

Association of health-related quality of life (HRQoL) and treatment safety with nivolumab (NIVO) in patients (pts) with resected stage IIIB/C or IV melanoma: Analysis of CheckMate 238 four-year follow-up (FU) data.

AUTHOR(S)

Jeffrey S. Weber, Helen Gogas, Xiaowu Sun, Christine Yip, Fiona Taylor, Julia Braverman, Maurice Lobo, Pratik K. Thakkar, Andriy Moshkyk, James Larkin, Paolo A. Ascierto

ABSTRACT

9574

Postoperative radiotherapy in Merkel cell carcinoma (MCC).

AUTHOR(S)

Sonja Levy, Stephanie Blankenstein, Dirk J. Grunhagen, Mathilde Jalving, Olga Hamming-Vrieze, Lukas B. Been, Lisa Tans, Alexander C. Van Akkooi, Margot E. Tesselaar

ABSTRACT

9575

Isolated same-basin lymph node recurrence after precision lymph node excision for clinically evident melanoma metastasis.

AUTHOR(S)

Kevin Lynch, Yinin Hu, Norma Farrow, Yun Song, Max Meneveau, Minyoung Kwak, Michael C. Lowe, Edmund Bartlett, Georgia Beasley, Giorgos Karakousis, Craig L. Slingluff Jr.

ABSTRACT

9576

Evaluation of patients with surgically resected high-risk melanoma receiving adjuvant therapy in routine clinical practice in the United States.

AUTHOR(S)

Michael B. Atkins, Cristina Julian, Matthew H. Secrest, Janet Lee, Ana Maria Abajo Guijarro, Edward F. Mckenna Jr.

ABSTRACT

9577

Efficacy of adjuvant radiotherapy in recurrent melanoma after adjuvant immunotherapy.

AUTHOR(S)

Prachi Bhawe, Angela M. Hong, Rebecca Johnson, Alexander M. Menzies, Georgina V. Long, Joanna Mangana, Douglas B. Johnson, Zeynep Eroglu, Ozgecan Dulgar, Hui-Ling Yeoh, Andrew M. Haydon, Georg Lodde, Elisabeth Livingstone, Muhammad A. Khattak, Katharina C. Kähler, Axel Hauschild, Wei Wang, Matteo S. Carlino

ABSTRACT

9578

The prognostic value of the interferon-gamma (IFN γ) signature in patients with macroscopic stage III melanoma treated with and without adjuvant systemic therapy.

AUTHOR(S)

Judith M. Versluis, Stephanie Blankenstein, Petros Dimitriadis, Joyce Sanders, Willem Hoefakker, Annegien Broeks, Winan J. van Houdt, Yvonne M. Schrage, Michel W. Wouters, Alexander C. Van Akkooi, Christian U. Blank

ABSTRACT

9579

Incidence, timing, and predictors of CNS metastasis in patients (Pts) with clinically localized cutaneous melanoma (CM).

AUTHOR(S)

Merve Hasanov, Denai R. Milton, Sapna P. Patel, Hussein A. Tawbi, Isabella C. Glitza, Sherise D. Ferguson, Debora A. Ledesma, Carlos A. Torres-Cabala, Alexander J. Lazar, Elizabeth M. Burton, Jeffrey E. Gershenwald, Lauren E. Haydu, Michael A. Davies

ABSTRACT

9580

Genome-wide association study to reveal novel germline markers of melanoma survival.

AUTHOR(S)

Vylyny Chat, Robert Ferguson, Leah Morales, Una Moran, Min Jae Kim, Matija Snuderl, Iman Osman, Jeffrey S. Weber, Tomas Kirchhoff

ABSTRACT

9581

Granulomatous and sarcoid-like immune related adverse events (irAEs) in melanoma patients following CTLA4 blockade adjuvant therapy: An analysis of 1670 high-risk patients.

AUTHOR(S)

Arish Noor, Ibrahim Yassine, Sandra J. Lee, Megan Othus, James Moon, John M. Kirkwood, Vernon K. Sondak, Antoni Ribas, Kenneth F. Grossmann, Ahmad A. Tarhini

ABSTRACT

9582

Adjuvant nivolumab in high-risk stage IIb/IIc melanoma patients: Results from investigator initiated clinical trial.

AUTHOR(S)

Melissa Wilson, Larisa J. Geskin, Richard D. Carvajal, Janice M. Mehnert, Cody Chiuzan, Benjamin Leiby, Katherine Senter, Lynn M. Schuchter, Ryan M. Weight, Michael J. Mastrangelo, Adam C. Berger

ABSTRACT

9583

Increased risk of immune-related hepatitis among adolescent and young adults (AYAs) with melanoma during immunotherapy with checkpoint inhibitors (ICIs).

AUTHOR(S)

Alicia Darwin, Damon R. Reed, Tawee Tanvetyanon

ABSTRACT

9584

S1801: A randomized trial of adjuvant versus neoadjuvant pembrolizumab for melanoma.

AUTHOR(S)

Sapna P. Patel, Megan Othus, James Moon, Michael Tetzlaff, Elizabeth I. Buchbinder, Vernon K. Sondak, Michael C. Lowe, Catrina Mireles, Elad Sharon, Larissa A. Korde, Samantha Guild, William E. Carson III, Antoni Ribas, Kenneth F. Grossmann

ABSTRACT

TPS9585

Combination of radiomic and biomarker signatures as exploratory objective in a phase II trial with intratumoral BO-112 plus pembrolizumab for advanced melanoma.

AUTHOR(S)

Ivan Marquez-Rodas, Stéphane Dalle, Eduardo Castanon, Miguel F. Sanmamed, Ana M. Arance, Pablo Cerezuela-Fuentes, Roberto Martin Huertas, Juan F. Rodríguez-Moreno, Maria Gonzalez-Cao, Eva Muñoz-Couselo, Juan Martin-Liberal, Delvys Rodríguez-Abreu, Ángel Alberich-Bayarri, Irene Mayorga-Ruiz, Miguel Angel Molina Vila, Ruth Román, Marya F. Chaney, Javier Sánchez López, Sonia Maciá, Marisol Quintero

ABSTRACT

TPS9586

CActUS: A parallel arm, biomarker driven, phase II feasibility trial to determine the role of circulating tumor DNA in guiding a switch between targeted therapy and immune therapy in patients with advanced cutaneous melanoma.

AUTHOR(S)

Rebecca Lee, Dominic G. Rothwell, Shien Chow, Heather M. Shaw, Samra Turajlic, Nigel Smith, Alexandra Clipson, Harry Clarke, Noel Kelso, Jackie Mitchell, Chris Sutton, Gema Sylvestre, Paul D. Nathan, James Larkin, Philippa G. Corrie, Elizabeth R. Plummer, Richard Marais, Caroline Dive, Paul Lorigan

ABSTRACT

TPS9587

Clinical trial in progress: Phase II trial of defactinib (VS-6063) combined with VS-6766 (CH5126766) in patients with metastatic uveal melanoma.

AUTHOR(S)

Rino S. Seedor, Marlana Orloff, J. Silvio Gutkind, Andrew E. Aplin, Mizue Terai, Erin Sharpe-Mills, Haley Klose, Michael J. Mastrangelo, Takami Sato

ABSTRACT

TPS9588

Ipilimumab, nivolumab and tocilizumab as first-line therapy for advanced melanoma.

AUTHOR(S)

Inderjit Mehmi, Omid Hamid, F. S. Hodi, Melinda Vassalo, Saundra Malatyali, Swathi Krishnarajapet, Nan O'Donnell, Angeli Castrence, Eunice Lim, Jill Gormley, Jeffrey S. Weber

ABSTRACT

TPS9589

NCT04552223: A phase II study of nivolumab plus BMS-986016 (relatlimab) in patients with metastatic uveal melanoma (UM) (CA224-094).

AUTHOR(S)

Jose Lutzky, Lynn G. Feun, Norma Magallanes, Deukwoo Kwon, J. William Harbour

ABSTRACT

TPS9590

Phase I/II trial of intratumoral administration of hu14.18-IL2, with local radiation, nivolumab, and ipilimumab in subjects with advanced melanoma.

AUTHOR(S)

Mark R. Albertini, Zachary S. Morris, Jacquelyn A. Hank, Erik Ranheim, Cindy L. Zuleger, Kimberly McDowell, Renae M. Quale, Molly Monson, Erin Clements, Tamara Koehn, Heather B. Neuman, Sharon M. Weber, Jennifer Racz, Mary Beth Henry, Emily Reinstad, KyungMann Kim, Stephen D. Gillies, Paul M. Sondel

ABSTRACT

TPS9591

A phase II, open-label study to investigate the efficacy and safety of domatinostat in combination with avelumab in patients with advanced unresectable/metastatic Merkel cell carcinoma progressing on anti-PD-(L)1 antibody therapy: The MERKLIN 2 study.

AUTHOR(S)

Alexander C. Van Akkooi, Paolo A. Ascierto, Paul D. Nathan, Paul Nghiem, Philip Reimann, Frank Hermann, Jürgen C. Becker

ABSTRACT

TPS9592

Winship 4851-19: A pilot study of neoadjuvant and adjuvant cemiplimab for high-risk cutaneous squamous cell carcinoma.

AUTHOR(S)

Michael C. Lowe, Melinda L. Yushak, Keith A. Delman, Monica Rizzo, Caroline Claar, Allyson Schmidt, Jeffrey M. Switchenko, David H. Lawson, Ragini R. Kudchadkar

ABSTRACT

TPS9593

Phase II study of binimetinib with imatinib in patients with unresectable KIT-mutant melanoma.

AUTHOR(S)

Katy K. Tsai, Iwei Yeh, Adil Daud, Ari Oglesby

ABSTRACT

TPS9594

Phase Ib/randomized phase II study combining hepatic percutaneous perfusion with ipilimumab plus nivolumab in advanced uveal melanoma: The CHOPIN trial.

AUTHOR(S)

Thaïs M. Tong, Mark C. Burgmans, Monique Van der Kooij, Frank M. Speetjens, Arian R. van Erkel, Rutger W. van der Meer, Shelley van den Bosch, Mare A. Jonker, Inge C. Roozen, Jacob Lutjeboer, Fenna Rijksen, Els L. van Persijn-van Meerten, Chris H. Martini, Remco W. Zoethout, Fred G. Tijl, Christian U. Blank, Ellen Kapiteijn

ABSTRACT

TPS9595

Multicenter phase I/II trial of encorafenib with and without binimetinib in combination with nivolumab and low-dose ipilimumab in metastatic BRAF-mutant melanoma.

AUTHOR(S)

Max Jameson-Lee, Patrick A. Ott, Jason J. Luke, Michael A. Postow, Andrew S. Poklepovic

ABSTRACT

TPS9596

Pediatric Oncology

[Back to Program](#)

Showing 27 Presentations

<https://meetinglibrary.asco.org/session/13665>

Resolving driver events in MLL-r negative high-risk infant ALL.

AUTHOR(S)

Jennifer Seelisch, Matthew Zatzman, Federico Comitani, Fabio Fuligni, Ledia Brunga, Patrick A. Brown, Adam Shlien, Sumit Gupta

ABSTRACT

10030

Forecasting asparaginase quantity required to treat pediatric ALL in LMICs using ACCESS FORxECAST.

AUTHOR(S)

Terence M. Hughes, Brianna Empringham, Sumit Gupta, Zachary J. Ward, Jennifer Yeh, Anita K. Wagner, Lewis B. Silverman, Lindsay L. Frazier, Avram Denburg

ABSTRACT

10031

Correlation of ex vivo drug sensitivity with clinical response in pediatric AML.

AUTHOR(S)

Ryosuke Kita, Michelle A. Richardson, Erica K. Anderson, Debbie C. Strachan, Raushan Rashid, Maci Terrell, Andrea N. Marcogliese, Marianne T. Santaguida, Alexandra M. Stevens

ABSTRACT

10032

Preclinical evaluation of the ETS inhibitor TK216 against relapsed and refractory childhood leukemia.

AUTHOR(S)

Ritul Sharma, Satbir Thakur, Mohit Jain, Chunfen Zhang, Anne-Marie Langevin, Aru Narendran

ABSTRACT

10033

Novel methods to assess cell-free circulating tumor DNA in acute lymphoblastic leukemia.

AUTHOR(S)

Meghan G. Haney, Shilpa Sampathi, Yelena Chernyavskaya, Henry Moore, Tom C. Badgett, Jessica S. Blackburn

ABSTRACT

10034

Discovery and validation of a cross-platform 21-gene prognostic signature in neuroblastoma.

AUTHOR(S)

Mehul Gupta, Sunand N. Kannappan, Aru Narendran, Pinaki Bose

ABSTRACT

10035

Racial and ethnic disparities in risk and survival in children with neuroblastoma: An updated analysis.

AUTHOR(S)

Caileigh Pudela, Mark A. Applebaum, Sang Mee Lee, Arlene Naranjo, Julie R. Park, Samuel L. Volchenboum, Tara O. Henderson, Susan L. Cohn, Ami V. Desai

ABSTRACT

10036

Testing of B7-H3 targeting antibody-drug conjugate (ADC) MGC018 in models of pediatric solid tumors by the Pediatric Preclinical Testing Consortium (PPTC).

AUTHOR(S)

Raushan Kurmasheva, Yael P. Mosse, Vanessa Del Pozo, Eric J. Earley, Stephen W. Erickson, David Groff, E. A. Kolb, Kateryna Krytska, Malcolm A. Smith, Matthew Tsang, Beverly A. Teicher, Richard G. Gorlick, John M. Maris, Peter Houghton

ABSTRACT

10037

Late health outcomes in survivors of Wilms tumor: A report from the St. Jude Lifetime (SJLIFE) cohort study.

AUTHOR(S)

Kayla L. Foster, Daniel M. Green, Sedigheh Mirzaei Salehabadi, Mengqi Xing, Kirsten K. Ness, Kevin R. Krull, Tara M. Brinkman, Matthew J. Ehrhardt, Wassim Chemaitilly, Stephanie B. Dixon, Nickhill Bhakta, Rachel C. Brennan, Matthew J. Krasin, Andrew M. Davidoff, Leslie L. Robison, Melissa M. Hudson, Daniel A. Mulrooney

ABSTRACT

10038

Predicting response to chemotherapy in neuroblastoma using deep learning: A report from the International Neuroblastoma Risk Group.

AUTHOR(S)

Siddhi Ramesh, Diana Michael, Liu Liu, Nicholas Feinberg, Meaghan Granger, Arlene Naranjo, Susan L. Cohn, Samuel L. Volchenbourn, Anoop Mayampurath, Mark A. Applebaum

ABSTRACT

10039

Preclinical evaluation of an engineered oncolytic herpes simplex virus for pediatric osteosarcoma.

AUTHOR(S)

Sara Hutchins, Raoud Marayati, Laura V. Bownes, Colin H. Quinn, Jerry E. Stewart, Gregory K. Friedman, Jennifer M. Coleman, G. Y. Gillespie, James M. Markert, Elizabeth A. Beierle

ABSTRACT

10040

Nonhematologic neoplasia in biallelic BRCA2 mutated Fanconi anemia.

AUTHOR(S)

Vasant Chinnabhandar, Todd E. DeFor, Rebecca Tryon, John E. Wagner, Margaret L. MacMillan

ABSTRACT

10041

Health-related quality of life (HRQoL) among pediatric patients with neurofibromatosis type 1 (NF1) and plexiform neurofibroma (PN) in the United States (U.S.).

AUTHOR(S)

Xiaoqin Yang, Hyun Kyoo Yoo, Suvina Amin, Wendy Y. Cheng, Heather Sipsma, Sanjana Sundaresan, Lujia Zhang, Mei S. Duh

ABSTRACT

10042

Predicting decreased health-related quality of life (HRQL) in adult survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).

AUTHOR(S)

Fiona Schulte, Yan Chen, Yutaka Yasui, Wendy M. Leisenring, Todd M. Gibson, Paul C. Nathan, Kevin C. Oeffinger, Melissa M. Hudson, Gregory T. Armstrong, Leslie L. Robison, Kevin R. Krull, I-Chan Huang

ABSTRACT

10043

Late morbidity and mortality among survivors of neuroblastoma treated with contemporary therapy: A report from the Childhood Cancer Survivor Study.

AUTHOR(S)

Danielle N. Friedman, Pamela J. Goodman, Wendy M. Leisenring, Lisa Diller, Susan L. Cohn, Emily S. Tonorezos, Rebecca M. Howell, Susan A. Smith, Suzanne L. Wolden, Joseph P. Neglia, Kirsten K. Ness, Todd M. Gibson, Paul C. Nathan, Leslie L. Robison, Kevin C. Oeffinger, Gregory T. Armstrong, Charles A. Sklar, Tara O. Henderson

ABSTRACT

10044

Accelerated aging and mortality in long-term survivors of childhood cancer: A report from the St. Jude Lifetime Cohort (SJLIFE).

AUTHOR(S)

AnnaLynn M. Williams, Jeanne S. Mandelblatt, Mingjuan Wang, Kirsten K. Ness, Gregory T. Armstrong, Nickhill Bhakta, Tara M. Brinkman, Wassim Chemaitilly, Matthew J. Ehrhardt, Daniel A. Mulrooney, Brent Small, Zhaoming Wang, Yutaka Yasui, Deokumar Srivastava, Melissa M. Hudson, Leslie L. Robison, Kevin R. Krull

ABSTRACT

10045

Determinants of symptom clusters and associations with health outcomes in childhood cancer survivors: A report from the St. Jude Lifetime Cohort (SJLIFE).

AUTHOR(S)

Hyewon Shin, William N. Dudley, Robin Bartlett, Yutaka Yasui, Deokumar Srivastava, Kirsten K. Ness, Kevin R. Krull, Leslie L. Robison, Melissa M. Hudson, I-Chan Huang

ABSTRACT

10046

Development and validation of a prediction model for kidney failure in long-term survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).

AUTHOR(S)

Natalie L. Wu, Yan Chen, Bryan V. Dieffenbach, Nan Li, Matthew J. Ehrhardt, Daniel M. Green, Sangeeta Hingorani, Rebecca M. Howell, John L. Jefferies, Daniel A. Mulrooney, Kevin C. Oeffinger, Leslie L. Robison, Brent R. Weil, Yan Yuan, Yutaka Yasui, Melissa M. Hudson, Wendy M. Leisenring, Gregory T. Armstrong, Eric J. Chow

ABSTRACT

10047

Health-related unemployment trends among survivors of childhood cancer: A report from the Childhood Cancer Survivor Study (CCSS).

AUTHOR(S)

Neel S. Bhatt, Pamela Goodman, Wendy M. Leisenring, Gregory T. Armstrong, Eric J. Chow, Melissa M. Hudson, Kevin R. Krull, Paul C. Nathan, Kevin C. Oeffinger, Leslie L. Robison, Anne C. Kirchhoff, Daniel A. Mulrooney

ABSTRACT

10048

Accelerated cognitive decline in adult survivors of pediatric central nervous system (CNS) tumors: A report from the Childhood Cancer Survivor Study (CCSS).

AUTHOR(S)

Nicholas S. Phillips, Kayla Stratton, AnnaLynn M. Williams, Wei Liu, Tim Ahles, Kirsten K. Ness, Todd M. Gibson, Pia Banerjee, Yutaka Yasui, Kevin C. Oeffinger, Eric J. Chow, Rebecca M. Howell, Leslie L. Robison, Gregory T. Armstrong, Wendy M. Leisenring, Kevin R. Krull

ABSTRACT

10049

Psychosocial impacts of the COVID-19 pandemic on young adult cancer survivors and parents of children with cancer.

AUTHOR(S)

Stephanie M. Smith, Dhanya Kumar, Catherine Benedict, Lauren C. Heathcote, Catherine Aftandilian, Melissa Bondy, Lidia Schapira

ABSTRACT

10050

Standardization of fertility preservation discussion amongst pediatric oncology and bone marrow transplant patients.

AUTHOR(S)

Chandni Dargan, Sarah Mc Dermott, Shelby Chesbro, Joy M. Fulbright

ABSTRACT

10051

Integration and feasibility of symptom burden assessment and early palliative care into an adolescent and young adult leukemia clinic.

AUTHOR(S)

Amy Y. Wang, Karen S. Hoehn, Collin Hanson, Sarah Monick, Fay J. Hlubocky, Jennifer L. McNeer, Tara O. Henderson, Wendy Stock, Christopher Daugherty

ABSTRACT

10052

Assessment of physician perceptions of pediatric palliative care for children with cancer in Latin America.

AUTHOR(S)

Michael McNeil, Bella Ehrlich, Marisol Bustamante, Veronica Dussel, Paola Friedrich, Ximena Garcia Quintero, Wendy Cristhyna Gomez Garcia, Dylan E. Graetz, Erica Kaye, Monika Metzger, Carla V. Sabato Danon, Justin N. Baker, Asya Agulnik

ABSTRACT

10053

Lessons from COVID-19, challenges of remote learning for childhood cancer survivors.

AUTHOR(S)

Kathy Ruble, Lisa Carey, Juliana Pare-Blagoev, Kimberly Milla, Sydney Henegan, Katrina Cork, Clifton Thornton, Lisa Jacobson

ABSTRACT

10054

Phase II study of nivolumab and ipilimumab in children and young adults with INI1-negative cancers.

AUTHOR(S)

Suzanne J. Forrest, Joanna Yi, Cassie Kline, Thomas Cash, Alyssa T. Reddy, Gregory M. Cote, Priscilla Merriam, Jeffrey Czaplinski, Ketki Bhushan, Steven G. DuBois, Katherine A. Janeway, Pei-Chi Kao, Wendy B. London, Susan N. Chi, Natalie B. Collins

ABSTRACT

TPS10055

FIREFLY-1: A phase 2 study of the pan-RAF inhibitor DAY101 in pediatric patients with low-grade glioma.

AUTHOR(S)

Lindsay B. Kilburn, Nada Jabado, Andrea Franson, Susan N. Chi, Michael J. Fisher, Darren R. Hargrave, Jordan R. Hansford, David S. Ziegler, Daniel Landi, Hyoung Jin Kang, Nicolas U. Gerber, Michal Yalon-Oren, Izzy Cornelio, Samuel C. Blackman, Michael C. Cox, Olaf Witt, Michael Prados, Sabine Mueller

ABSTRACT

TPS10056

Sarcoma

[Back to Program](#)

Showing 58 Presentations

<https://meetinglibrary.asco.org/session/13681>

Giant cell tumor of bone: Effect of longer dosing intervals of denosumab on tumor control and bone related complications.

AUTHOR(S)

Cindy Jiang, Lili Zhao, Scott Schuetze, Rashmi Chugh

ABSTRACT

11525

Efficacy and safety of JMT103 in patients with giant cell tumor of bone: A multicenter, single-arm, open-label, phase Ib/II study.

AUTHOR(S)

Xiaohui Niu, Feng Wei, Chongqi Tu, Gang Huang, Wenzhi Bi, Jianmin Li, Weitao Yao, Xiaojing Zhang, Jingnan Shen, Guochuan Zhang, Wangjun Yan, Jilong Yang, Jianhua Lin, Zhaoming Ye, Dong Wang, Zheng Guo, Zhichao Tong, Yuhong Zhou, Hairong Xu, Tao Li

ABSTRACT

11526

ABCB1/P-glycoprotein (Pgp) expression as stratification factor for treatment of patients with non-metastatic extremity high-grade osteosarcoma: A merged analysis of an Italian (ISG) and a Spanish (GEIS) sarcoma groups' multicentric prospective trials.

AUTHOR(S)

Emanuela Palmerini, Catalina Marquez, Cristina Meazza, Angela Tamburini, Gianni Bisogno, Francisco José Bautista Sirvent, Virginia Ferraresi, Sebastian D. Asafei, Giuseppe M. Milano, Roberto Luksch, Adela Canete, Aizpea Echebarria, Víctor Quintero, Cristina Mata, Rossella Bertulli, Alessandra Longhi, Piero Picci, Franca Fagioli, Nadia Hindi, Stefano Ferrari

ABSTRACT

11527

Activity of erlotinib in patients (pts) with advanced chordoma: A retrospective study.

AUTHOR(S)

Olivier Mir, Sylvain Briand, Thierry Lazure, Julien Adam, Rastilav Bahleda, Jean-Yves Blay, Andrea Cavalcanti, Ali N. Chamseddine, Aurélie Dutour, Matthieu Faron, Leila Haddag, Clemence Henon, Cecile Le Pechoux, Antonin Levy, Carine Ngo, Benjamin Verret, Charles Honoré, Charles Court, Axel Le Cesne

ABSTRACT

11528

GEIS 39: Phase II trial of nabpaclitaxel for the treatment of patient with multiply relapsed/refractory desmoplastic small round cell tumor (DSRCT) and Ewing sarcoma (EwS).

AUTHOR(S)

Jaume Mora, Mariona Suñol, Nadia Hindi, Alicia Castañeda, Andrés Redondo, Francisco José Bautista Sirvent, Robert Diaz Beveridge, Antonio Lopez-Pousa, Jose A. Lopez-Martin, Javier Martin Broto

ABSTRACT

11529

Outcome of patients with recurrent/refractory osteosarcoma enrolled in three recent phase II trials: A report from the Children's Oncology Group.

AUTHOR(S)

Seema Rao, Ruxu Han, Mark D. Krailo, Allen Buxton, Pooja Hingorani, Alexander J. Chou, Richard G. Gorlick, Damon R. Reed, Katherine A. Janeway, Lisa M. Kopp, Brenda Weigel, Michael Isakoff

ABSTRACT

11530

Comparison of treatment effect and long-term outcomes for pediatric and adult Ewing sarcoma patients in British Columbia, Canada.

AUTHOR(S)

Omar Hajjaj, Lauren Corke, Caron Strahlendorf, Christine E. Simmons

ABSTRACT

11531

Genomic alterations and associated pathway abnormalities in Ewing sarcoma.

AUTHOR(S)

Adam Rock, Warren A. Chow, An Uche, Sherri Z. Millis

ABSTRACT

11532

Accumulation of genome-wide somatic loss of heterozygosity (LOH) as a prominent feature of advanced malignant soft tissue tumors and association

with the BRCAness status, suppression of immune responses, and lower survival rates.

AUTHOR(S)

Katsuhito Takahashi, Yasutomo Miyaji, Ryotaro Ohkuma, Hajime Higuchi, Yoshihiro Komohara, Shinsuke Aida, Jun Yashima, Hiromasa Yamamoto, Ken Suzawa, Yuko Takahashi, Shinichi Toyooka, Hiroya Ashimine, Yu Oyama, Hiroyuki Narahara, Junko Yotsumoto, Hiroo Ishida, Takuya Tsunoda, Yasutsuna Sasaki, Yasuo Ono, Satoshi Teraoka

ABSTRACT

11533

A phase Ib/II study of selinexor in combination with imatinib in patients with advanced gastrointestinal stromal tumor (GIST): SeliGIST/GEIS-41 trial.

AUTHOR(S)

Cesar Serrano, Claudia Valverde, Josefina Cruz Jurado, Javier Martinez-Trufero, Xavier Guri, Martina Giuppi, Andrés Redondo, Beatriz Suarez-Paniagua, Cleofe Romagosa, Virginia Martinez

ABSTRACT

11534

Chromosomal complexity as a biomarker to de-escalate adjuvant imatinib treatment in high-risk gastrointestinal stromal tumor.

AUTHOR(S)

Kjetil Boye, Ludmila Gorunova, Ioannis Panagopoulos, Ivar Hompland, Bodil Bjerkehaugen, Jeanne-Marie Berner, Sverre Heim, Toto Hølmekj, Francesca Micci

ABSTRACT

11535

Intra-patient dose escalation (IPDE) of ripretinib after disease progression in patients with advanced gastrointestinal stromal tumor (GIST): Analyses from the phase 3 INVICTUS study.

AUTHOR(S)

John R. Zalcberg, Michael C. Heinrich, Suzanne George, Sebastian Bauer, Patrick Schoffski, Cesar Serrano, Robin L. Jones, Hans Gelderblom, Steven Attia, Gina Z. D'Amato, Ping Chi, Peter Reichardt, Neeta Somaiah, Julie N. Meade, Vienna L. Reichert, Kelvin Shi, Matthew L. Sherman, Rodrigo Ruiz-Soto, Margaret von Mehren, Jean-Yves Blay

ABSTRACT

11536

Next generation sequencing of sarcomas: Response to crizotinib in two cases with MET amplification.

AUTHOR(S)

Adrienne I. Victor, Olga Alvarez, Megan A. Baumgart, Gaurav Goyal, Deepak M. Sahasrabudhe

ABSTRACT

11538

Deciphering the molecular landscape and the tumor microenvironment of perivascular epitheloid cell neoplasma (PEComa).

AUTHOR(S)

Andreas Seeber, Lea Holzer, Andrew Elliott, Dietmer Dammerer, Vaia Florou, Roman Groisberg, Benjamin Henninger, Wolfgang M. Korn, Johannes Lanbach, Margaret von Mehren, Jaime Modiano, Steven O`Day, Alexander Perathoner, Andrew Rosenberg, Katja Schmitz, Anton Schwabegger, Martin Thaler, Jonathan C. Trent, Kai Zimmer, Florian Kocher

ABSTRACT

11539

Whole-genome sequencing to improve sarcoma diagnosis and patient care.

AUTHOR(S)

Luuk J. Schipper, Kim Monkhurst, Kris Samsom, Petur Snaebjornsson, Hester Van Boven, Paul Roepman, Lizet Van Der Kolk, Linda J. Bosch, Winan J. van Houdt, Winette T. Van Der Graaf, Gerrit A. Meijer, Emile E. Voest

ABSTRACT

11540

The sarcoma microbiome as a diagnostic and therapeutic target.

AUTHOR(S)

Gabriel Tinoco, Marium Husain, Rebecca Hoyd, Malvenderjit Jagjit Singh, YunZhou Liu, Xiaokui Mo, James L. Chen, David A. Liebner, Daniel Spakowicz

ABSTRACT

11541

Phase 1 trial of autologous dendritic cell vaccination with imiquimod immunomodulation in children and adults with refractory sarcoma.

AUTHOR(S)

Aditi Dhiri, Tulay Koru-Sengul, James Grosso, Gina Z. D'Amato, Matteo M. Trucco, Andrew Rosenberg, Eli Gilboa, John M. Goldberg, Jonathan C. Trent, Breelyn A. Wilky

ABSTRACT

11542

Results of NC-6300 (nanoparticle epirubicin) in an expansion cohort of patients with angiosarcoma.

AUTHOR(S)

Richard F. Riedel, Victoria S. Chua, Ted Kim, Jonathan Dang, Kitty Zheng, Ania Moradkhani, Atsushi Osada, Sant P. Chawla

ABSTRACT

11543

Long-term evaluation of the novel radioenhancer NBTXR3 plus radiotherapy in patients with locally advanced soft tissue sarcoma treated in the phase II/III Act.In.Sarc trial.

AUTHOR(S)

Sylvie Bonvalot, Piotr Rutkowski, Juliette Thariat, Sebastien Carrère, Anne Ducassou, Sunyach Marie, Peter Agoston, Angela M. Hong, Augustin Mervoyer, Marco Rastrelli, Cecile Le Pechoux, Victor Moreno, Rubi K. Li, Béatrice Tiangco, Zsuzsanna Papai

ABSTRACT

11544

Efficacy and safety of nivolumab and trabectedin in pretreated patients with advanced soft tissue sarcomas (STS): Preliminary results of a phase II trial of the German Interdisciplinary Sarcoma Group (GISG-15, NitraSarc) for the non-L sarcoma cohort.

AUTHOR(S)

Daniel Pink, Dimosthenis Andreou, Anne Flörcken, Alexander Golf, Stephan Richter, Torsten Kessler, Martin Kortüm, Christian A. Schmidt, Bernd Kasper, Eva Wardelmann, Jeanette Bahr, Daniel W. Mueller, Disorn Sookthai, Salah-Eddin Al-Batran, Peter Reichardt

ABSTRACT

11545

Recurrence and disease-specific survival after 10-year disease-free interval in patients with primary retroperitoneal liposarcoma: Implications for long-term surveillance.

AUTHOR(S)

Mark A. Eckardt, Danielle S. Graham, Brian E. Kadera, Kyle D. Klingbeil, Scott D. Nelson, Sarah M. Dry, Anusha Kalbasi, Arun S. Singh, Bartosz Chmielowski, Frederick R. Eilber, Joseph G. Crompton, Frederick C. Eilber

ABSTRACT

11546

Efficacy and safety of anlotinib plus TQB2450 in patients with advanced soft tissue sarcoma: A multicenter, single armed, phase 1b trial.

AUTHOR(S)

Jiayong Liu, Zhengfu Fan, Wei Guo, Tian Gao, Shu Li, Jie Xu, Chujie Bai, Ruifeng Xue, Lu Zhang, Lu Xie, Zhichao Tan

ABSTRACT

11547

The impact of multimodality therapies in marginally inoperable soft tissue sarcomas (STS): The Toronto Sarcoma Program (TSP) experience.

AUTHOR(S)

Olga Vornicova, Jay Wunder, Peter W. Chung, Abha A. Gupta, Rebecca A. Gladdy, Charles N. Catton, Samer Salah, Peter C. Ferguson, Kim Tsoi, David B. Shultz, Savtaj S. Brar, Philip Wong, Carol J. Swallow, Albiruni R. Abdul Razak, Esmail M. Al-Ezzi

ABSTRACT

11548

A phase 1b study of avelumab plus DCC-3014, a potent and selective inhibitor of colony stimulating factor 1 receptor (CSF1R), in patients with advanced high-grade sarcoma.

AUTHOR(S)

Evan Rosenbaum, Sujana Movva, Ciara M. Kelly, Mark A. Dickson, Mary Louise Keohan, Mrinal M. Gounder, Katherine A. Thornton, Ping Chi, Jason E. Chan, Benjamin Nacev, Viswatej Avutu, Matthew Biniakewitz, Olivia R. McKennan, Haley Phelan, Silvia Perez, Sinchun Hwang, Samuel Singer, Li-Xuan Qin, William D. Tap, Sandra P. D'Angelo

ABSTRACT

11549

Preliminary results of phase 2 trial of preoperative image guided intensity modulated proton radiation therapy (IMPT) with simultaneously integrated boost (SIB) to the high-risk margin for retroperitoneal sarcomas (RPS).

AUTHOR(S)

Thomas F. DeLaney, John T. Mullen, Yen-Lin Chen, Ivy A. Petersen, Andrew J. Bishop, Sam S. Yoon, Alex B. Haynes, Christina L. Roland, Sonia Cohen, Edwin Choy, Gregory M. Cote, Gunnlaugur Nielsen, Christopher Lescinskas, Katherine E. Santoro, Dian Wang, Beow Y. Yeap

ABSTRACT

11550

Durvalumab and pazopanib in patients with advanced soft tissue sarcoma: A single-center, single-arm, phase 2 trial.

AUTHOR(S)

Hyo Song Kim, Hee Jin Cho, Kum-Hee Yun, Young Han Lee, Sung Hyun Kim, Wooyeol Baek, Min Kyung Jeon

ABSTRACT

11551

Immune-desert tumor microenvironment in SMARCA4-deficient thoracic sarcomas with limited efficacy of immune checkpoint inhibitors.

AUTHOR(S)

Justine Gantzer, Guillaume Davidson, Bujamin Vokshi, Noëlle Weingertner, Antoine Bougoüin, Marco Moreira, Veronique Lindner, Guillaume Lacroix, Celine Mascaux, Marie Pierre Chenard, Irwin Davidson, Jean Emmanuel Kurtz, Catherine Sautes-Fridman, Wolf-Herman Fridman, Gabriel Malouf

ABSTRACT

11552

ESMO Magnitude of Clinical Benefit Scale (MCBS): An evaluation of systemic treatment trials for soft tissue sarcomas (STS).

AUTHOR(S)

Abdulazeez Salawu, Christopher Lemieux, Albiruni R. Abdul Razak

ABSTRACT

11553

First-in-human administration of CEB-01, a novel drug delivery implant matrix, in patients with recurrent or locally advanced retroperitoneal soft tissue sarcoma (RPS) after surgery: Preliminary safety and pharmacokinetics report.

AUTHOR(S)

José A. Gonzalez, Ana Sebio, Paula Cerdà, Francesc Cano, José A. Tornero, Luc Marti, Jaume Mora, Lucas Krauel, Antonio Lopez-Pousa

ABSTRACT

11554

Multiomic analysis reveals distinct molecular profiles of uterine and nonuterine leiomyosarcoma.

AUTHOR(S)

Tabitha Copeland, Roman Groisberg, Don S. Dizon, Andrew Elliott, Galina Lagos, Andreas Seeber, Margaret von Mehren, Kenneth Cardona, Michael J. Demeure, Richard F. Riedel, Vaia Florou, Alexander J. Chou, Abhijeet Kumar, Jaime Modiano, Moh'd M. Khushman, Gina Z. D'Amato, Andrea P. Espejo Freire, W. M. Korn, Jonathan C. Trent

ABSTRACT

11555

The efficacy and safety of anlotinib in refractory/recurrent/advanced pediatric solid tumors: A retrospective study.

AUTHOR(S)

Suying Lu, Ye Hong, Huimou Chen, Liuhong Wu, Jia Zhu, Juan Wang, Feifei Sun, Zijun Zhen, Yi Que, Lian Zhang, Xiaofei Sun, Junting Huang, Yizhuo Zhang

ABSTRACT

11556

Early results of Intratumoral INT230-6 alone or in combination with ipilimumab in subjects with advanced sarcomas.

AUTHOR(S)

Matthew Ingham, James S. Hu, Giles F. Whalen, Jacob S. Thomas, Anthony B. El-Khoueiry, Diana L. Hanna, Anthony J. Olszanski, Christian F. Meyer, Nilofer S. Azad, Syed Mahmood, Lewis H. Bender, Ian B. Walters, Albiruni R. Abdul Razak, Lillian L. Siu

ABSTRACT

11557

Regorafenib (R) in advanced solitary fibrous tumor (SFT): Results from an exploratory phase II clinical study.

AUTHOR(S)

Silvia Stacchiotti, Giacomo G. Baldi, Salvatore Lo Vullo, Carlo Morosi, Francesca G. Greco, Paola Collini, Marta Barisella, Gianpaolo Dagrada, Nadia Zaffaroni, Alessandro Gronchi, Noemi Simeone, Luigi Mariani, Anna Maria Frezza, Paolo G. Casali

ABSTRACT

11558

A pilot study of the feasibility and utility of a fitness tracker to correlate activity level with patient reported outcomes (PROs) in sarcoma patients undergoing systemic therapy.

AUTHOR(S)

Elizabeth J. Davis, G. D. Ayers, Deborah Wallace, Elizabeth Kaiser, Vicki L. Keedy, Rajiv Agarwal

ABSTRACT

11559

A patient reported outcomes of treatments for desmoid tumors: An international natural history study.

AUTHOR(S)

Danielle Braggio, Amanda Lucas, Lynne Hernandez, Kelly Mercier

ABSTRACT

11560

Treatment patterns, and survival of patients with metastatic undifferentiated pleomorphic sarcoma: A National Cancer Database (NCDB) study.

AUTHOR(S)

Hussain I. Rangoonwala, Mary E. Dahl, Jonathan Gootee, Sai Giridhar Gundepalli, Sarah J. Aurit, Peter T. Silberstein

ABSTRACT

11561

A phase 2 study using ipilimumab, nivolumab, and trabectedin for previously untreated metastatic soft tissue sarcoma.

AUTHOR(S)

Erlinda M. Gordon, Victoria S. Chua, Ted T. Kim, Neal S. Chawla, Don A. Bringham, Ishrat Bhuiyan, Mark Agulnik, Warren A. Chow, Sant P. Chawla

ABSTRACT

11562

Results of the phase 1b soft-tissue sarcoma (STS) portion of the global randomized, double-blind, placebo-controlled study of tazemetostat (TAZ) plus doxorubicin (DOX) as frontline therapy for advanced epithelioid sarcoma (ES).

AUTHOR(S)

Sant P. Chawla, Gerald S. Falchook, Melissa A. Burgess, James L. Chen, Robin L. Jones, Victoria S. Chua, Coya Tapia, Jessica Ainscough, Anthony Hamlett, Melinda S. Merchant, Rashmi Chugh

ABSTRACT

11563

Retrospective world-wide registry on the efficacy of immune checkpoint inhibitors in alveolar soft part sarcoma: Updated results from sixty patients.

AUTHOR(S)

Nadia Hindi, Evan Rosenbaum, Emily Jonczak, Rainer Hamacher, Piotr Rutkowski, Anthony Skryd, Elizabeth Connolly, Jean-Yves Blay, Antonio Gutierrez, Carolina Bogefors, Hans Gelderblom, Kjetil Boye, Clemence Henon, Javier Martinez-Trufero, Jose A. Lopez-Martin, Andrés Redondo, Claudia Valverde, Bruno Vincenzi, William D. Tap, Javier Martin Broto

ABSTRACT

11564

Palbociclib (P) in patients (pts) with soft tissue sarcoma (STS) with *CDK4* amplification: Results from the Targeted Agent and Profiling Utilization Registry (TAPUR) study.

AUTHOR(S)

Scott Schuetze, Michael Roth, Pam K. Mangat, Liz Garrett-Mayer, Funda Meric-Bernstam, Laura C. Farrington, Carmen Calfa, Stacy D. D'Andre, Michael B. Livingston, Ramya Thota, Alissa S. Marr, Margaret von Mehren, Kristopher Wentzel, Richard L. Schilsky

ABSTRACT

11565

Critical impact of radiotherapy protocol compliance and quality in the treatment of retroperitoneal sarcomas: Results from the 62092-22092 STRASS trial.

AUTHOR(S)

Rick L. Haas, Jean-Jacques Stelmes, Facundo Zaffaroni, Enrico Clementel, Raquel Bar Deroma, Cecile Le Pechoux, Saskia Litiere, Sandrine Marreaud, Najlaa Alyamani, Nicolaus Andratschke, Claudia Sangalli, Peter W. Chung, Aisha Miah, Coen Hurkmans, Alessandro Gronchi, Judith V. Bovée, Hans Gelderblom, Bernd Kasper, Damien Weber, Sylvie Bonvalot

ABSTRACT

11566

A phase 2 study of talimogene laherparepvec, nivolumab, and trabectedin (TNT) in advanced sarcoma.

AUTHOR(S)

Neal S. Chawla, Ted Kim, Travis Sherman, Jonathan Dang, Victoria S. Chua, Ania Moradkhani, Ishrat Bhuiyan, Nathalie Krkryan, Mitchel Fernando, Emma Colletti, William Feske, Kitty Zheng, Warren A. Chow, Mark Agulnik, Doris Quon, Sant P. Chawla, Erlinda M. Gordon, Arun S. Singh

ABSTRACT

11567

Evaluation of homologous recombination deficiency (HRD) score and immuno-tumor microenvironment (iTME) as biomarkers of soft tissue sarcoma (STS) survival and response to immune checkpoint inhibitor therapy.

AUTHOR(S)

Chenlu Zhang, Xi Guo, Fei Xu, Yang You, Zhiming Wang, Rongyuan Zhuang, Wenshuai Liu, Li-Jie Ma, Hanxing Tong, Yong Zhang, Weiqi Lu, Jun Liu, Yuhong Zhou

ABSTRACT

11568

Prospective cohort study of Kaposi sarcoma treated under real-world conditions in Malawi.

AUTHOR(S)

Edwards Kasonkanji, Yolanda Gondwe, Morgan Dewey, Joe Gumulira, Matthew Painschab, Mina Hosseinipour, Dirk Dittmer

ABSTRACT

11569

Active surveillance in primary desmoid tumor (DT): A prospective observational study.

AUTHOR(S)

Chiara Colombo, Salvatore Lo Vullo, Marco Fiore, Giovanni Grignani, Francesco Tolomeo, Alessandra Merlini, Elena Palassini, Paola Collini, Silvia Stacchiotti, Paolo G. Casali, Federica Perrone, Luigi Mariani, Alessandro Gronchi

ABSTRACT

11570

Growth rate and site of pulmonary metastasis to predict lung relapse and overall survival in patients affected by bone and soft tissue sarcomas (B-STs).

AUTHOR(S)

Lorenzo D'ambrosio, Francesco Tolomeo, Maria Cristina Bruna, Sandra Aliberti, Alessandra Merlini, Giulia Manessi, Andrea Mogavero, Alessandro Minelli, Tiziana Robba, Delia Campanella, Alberto Pisacane, Elena Maldi, Raimondo Piana, Enrico Ruffini, Claudio Mossetti, Bruno Vincenzi, Giovanni Grignani

ABSTRACT

11571

Immune contexture in high-risk soft tissue sarcomas (STS): A planned analysis of the ISG-STs-1001 randomized trial.

AUTHOR(S)

Sandro Pasquali, Chiara Castelli, Paola Collini, Marta Barisella, Cleofe Romagosa, Silvia Bague, Jean Michel Coindre, Paolo De Tos, Luca Braglia, Emanuela Palmerini, Vittorio Quagliuolo, Javier Martin Broto, Antonio Lopez-Pousa, Giovanni Grignani, Jean-Yves Blay, Robert Diaz Beveridge, Domenico F. Merlo, Silvia Stacchiotti, Paolo G. Casali, Alessandro Gronchi

ABSTRACT

11572

VAC temporization pending final margins after suprafascial myxofibrosarcoma excision to reduce the rate of local recurrence.

AUTHOR(S)

Mitchell S. Fourman, Duncan C. Ramsey, Justin Kleiner, Anser Daud, Erik T. Newman, Joseph H. Schwab, Yen-Lin Chen, Thomas F. DeLaney, John T. Mullen, Kevin Raskin, Santiago Lozano-Calderon

ABSTRACT

11573

Patient reported outcomes in patients with desmoid type fibromatosis.

AUTHOR(S)

Vikas Garg, Sameer Rastogi, Adarsh Barwad, Rambha Panday, Sandeep K. Bhorwal, Ekta Dhamija

ABSTRACT

11574

Phase II trial of olaparib in combination with ceralasertib in patients with recurrent osteosarcoma.

AUTHOR(S)

Suzanne J. Forrest, Michael D. Kinnaman, J Andrew A. Livingston, Kieuhoa T. Vo, Priscilla Merriam, Catherine Clinton, Kylene Desmith, Kerri Cavanaugh, Brunella Felicetti, Simon Smith, Emma Dean, Pei-Chi Kao, Wendy B. London, E. A. Sweet-Cordero, Katherine A. Janeway

ABSTRACT

TPS11575

REGOSTA: A randomized, placebo-controlled, double-blinded, multicenter study evaluating the efficacy and safety of regorafenib (REGO) as maintenance therapy after first-line treatment in patients (pts) with osteosarcoma (OS) and non-osteosarcomas (non-OS) of bone (non-Ewing, non-chondrosarcomas and non-chordomas).

AUTHOR(S)

Florence Duffaud, Sylvie Chabaud, Julien Gautier, Celine Ferlay, Séraphine Vizoso, Mehdi Brahmi, Sarah Benezech, Armelle Dufresne, Perrine Marec-Berard, Isabelle L. Ray-Coquard, Elsa Kalbacher, Olivier Collard, Nicolas Penel, Maria Rios, Emmanuelle Bompas, Christine Chevreau, Olivier Mir, Pascaline Boudou-Rouquette, Jean-Yves Blay, Sophie Piperno-Neumann

ABSTRACT

TPS11576

Phase 1 expansion trial of the LSD1 inhibitor seclidemstat (SP-2577) with and without topotecan and cyclophosphamide (TC) in patients (pts) with relapsed or refractory Ewing sarcoma (ES) and select sarcomas.

AUTHOR(S)

Damon R. Reed, Sant P. Chawla, Bhuvana Setty, Leo Mascarenhas, Paul A. Meyers, Jonathan Metts, Douglas J. Harrison, Stephen L. Lessnick, Brian D. Crompton, David Loeb, David D. Stenehjem, David S. Wages, Daniela Y. Santiesteban, Nadeem Q. Mirza, Steven G. DuBois

ABSTRACT

TPS11577

A phase 2 study of belinostat and SGI-110 (guadecitabine) for the treatment of unresectable and metastatic conventional chondrosarcoma.

AUTHOR(S)

Jay Oza, Shing M. Lee, Mia C. Weiss, Brittany L. Siontis, Benjamin C. Powers, Warren A. Chow, Wendy Magana, Tahir Sheikh, Richard Piekarz, Gary K. Schwartz, Matthew Ingham

ABSTRACT

TPS11578

A multicenter, open-label, uncontrolled phase II study of ONO-4538 for cutaneous angiosarcoma (Angio Check study).

AUTHOR(S)

Yasuhiro Fujisawa, Koji Yoshino, Taiki Isei, Kenjiro Namikawa, Taku Fujimura, Masahito Yasuda, Yuki Yamamoto, Hiroshi Uchi, Teruki Yanagi, Hiroshi Kato, Atsushi Otsuka

ABSTRACT

TPS11579

A randomized phase II trial of second-line treatment for advanced soft tissue sarcoma comparing trabectedin, eribulin and pazopanib (2ND-STEP, JCOG1802).

AUTHOR(S)

Makoto Endo, Kazuhiro Tanaka, Yoshihiro Matsumoto, Hiroaki Hiraga, Shintaro Iwata, Satoshi Tsukushi, Munenori Watanuki, Toru Akiyama, Tsukasa Yonemoto, Robert Nakayama, Keisuke Ae, Hiroyuki Kawashima, Hiroyuki Tsuchiya, Hirohisa Katagiri, Akihito Nagano, Satoshi Takenaka, Tomoko Kataoka, Ryunosuke Machida, Haruhiko Fukuda, Toshifumi Ozaki

ABSTRACT

TPS11580

ENVASARC: A pivotal trial of envafolimab, and envafolimab in combination with ipilimumab, in patients with advanced or metastatic undifferentiated pleomorphic sarcoma or myxofibrosarcoma who have progressed on prior chemotherapy.

AUTHOR(S)

Sandra P. D'Angelo, Steven I. Robinson, Joelle Lam, Bonne J. Adams, James L. Freddo, Charles P. Theuer, Robert G. Maki

ABSTRACT

TPS11581

IGNYTE-ESO: A master protocol to assess safety and activity of letetresgene autoleucel (lete-cel; GSK3377794) in HLA-A*02+ patients with synovial sarcoma or myxoid/round cell liposarcoma (Substudies 1 and 2).

AUTHOR(S)

Sandra P. D'Angelo, Jonathan C. Noujaim, Fiona Thistlethwaite, Albiruni R. Abdul Razak, Silvia Stacchiotti, Warren A. Chow, John B. Haanen, Anna W. Chalmers, Steven I. Robinson, Brian A. Van Tine, Kristen N. Ganjoo, Melissa L. Johnson, Victoria L. Chiou, Thomas H. Faitg, Mary Woessner, Laura Pearce, Aiman Shalabi, Jean-Yves Blay, George Demetri

ABSTRACT

TPS11582

A randomized phase II trial of cabozantinib combined with PD-1 and CTLA-4 inhibition in metastatic soft tissue sarcoma.

AUTHOR(S)

Vanessa A. Eulo, Breelyn A. Wilky, Jingqin Luo, Angela C. Hirbe, Mia C. Weiss, Peter J. Oppelt, Sarah Abaricia, Jacqui Toeniskoetter, Tyler Ruff, Robert G. Maki, Brian A. Van Tine

ABSTRACT

TPS11583